
<html lang="en"     class="pb-page"  data-request-id="25e11d76-3c57-4d64-822d-5639ed8e526c"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";article:article:10.1021/acs.jmedchem.0c01561;issue:issue:10.1021/jmcmar.2020.63.issue-24;requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;wgroup:string:ACHS website Group;website:website:acspubs;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="citation_journal_title" content="Journal of Medicinal Chemistry" /></meta><meta name="dc.Title" content="Design, Synthesis, and Biological Evaluation of a Series of Oxazolone Carboxamides as a Novel Class of Acid Ceramidase Inhibitors" /></meta><meta name="dc.Creator" content="Samantha  Caputo" /></meta><meta name="dc.Creator" content="Simona  Di Martino" /></meta><meta name="dc.Creator" content="Vincenzo  Cilibrasi" /></meta><meta name="dc.Creator" content="Piero  Tardia" /></meta><meta name="dc.Creator" content="Marco  Mazzonna" /></meta><meta name="dc.Creator" content="Debora  Russo" /></meta><meta name="dc.Creator" content="Ilaria  Penna" /></meta><meta name="dc.Creator" content="Maria  Summa" /></meta><meta name="dc.Creator" content="Sine Mandrup  Bertozzi" /></meta><meta name="dc.Creator" content="Natalia  Realini" /></meta><meta name="dc.Creator" content="Natasha  Margaroli" /></meta><meta name="dc.Creator" content="Marco  Migliore" /></meta><meta name="dc.Creator" content="Giuliana  Ottonello" /></meta><meta name="dc.Creator" content="Min  Liu" /></meta><meta name="dc.Creator" content="Peter  Lansbury" /></meta><meta name="dc.Creator" content="Andrea  Armirotti" /></meta><meta name="dc.Creator" content="Rosalia  Bertorelli" /></meta><meta name="dc.Creator" content="Soumya S.  Ray" /></meta><meta name="dc.Creator" content="Renato  Skerlj" /></meta><meta name="dc.Creator" content="Rita  Scarpelli" /></meta><meta name="dc.Description" content="Acid ceramidase (AC) is a cysteine hydrolase that plays a crucial role in the metabolism of lysosomal ceramides, important members of the sphingolipid family, a diversified class of bioactive molec..." /></meta><meta name="Description" content="Acid ceramidase (AC) is a cysteine hydrolase that plays a crucial role in the metabolism of lysosomal ceramides, important members of the sphingolipid family, a diversified class of bioactive molec..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="December 8, 2020" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.0c01561" /></meta><meta name="dc.Language" content="en" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="© 2020 American Chemical Society" /></meta><meta name="citation_fulltext_world_readable" content=""/></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.0c01561" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.0c01561" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.0c01561" /></link>
        
    
    

<title>Design, Synthesis, and Biological Evaluation of a Series of Oxazolone Carboxamides as a Novel Class of Acid Ceramidase Inhibitors | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.0c01561" /></meta><meta property="og:title" content="Design, Synthesis, and Biological Evaluation of a Series of Oxazolone Carboxamides as a Novel Class of Acid Ceramidase Inhibitors" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01561/20201218/images/large/jm0c01561_0023.jpeg" /></meta><meta property="og:description" content="Acid ceramidase (AC) is a cysteine hydrolase that plays a crucial role in the metabolism of lysosomal ceramides, important members of the sphingolipid family, a diversified class of bioactive molecules that mediate many biological processes ranging from cell structural integrity, signaling, and cell proliferation to cell death. In the effort to expand the structural diversity of the existing collection of AC inhibitors, a novel class of substituted oxazol-2-one-3-carboxamides were designed and synthesized. Herein, we present the chemical optimization of our initial hits, 2-oxo-4-phenyl-N-(4-phenylbutyl)oxazole-3-carboxamide 8a and 2-oxo-5-phenyl-N-(4-phenylbutyl)oxazole-3-carboxamide 12a, which resulted in the identification of 5-[4-fluoro-2-(1-methyl-4-piperidyl)phenyl]-2-oxo-N-pentyl-oxazole-3-carboxamide 32b as a potent AC inhibitor with optimal physicochemical and metabolic properties, showing target engagement in human neuroblastoma SH-SY5Y cells and a desirable pharmacokinetic profile in mice, following intravenous and oral administration. 32b enriches the arsenal of promising lead compounds that may therefore act as useful pharmacological tools for investigating the potential therapeutic effects of AC inhibition in relevant sphingolipid-mediated disorders." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.0c01561"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c01561">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-15/achre4.2021.54.issue-15/20210803/achre4.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-30/aamick.2021.13.issue-30/20210804/aamick.2021.13.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-15/acncdm.2021.12.issue-15/20210804/acncdm.2021.12.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-8/amlcef.2021.3.issue-8/20210802/amlcef.2021.3.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-30/acsodf.2021.6.issue-30/20210803/acsodf.2021.6.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-30/ascecg.2021.9.issue-30/20210802/ascecg.2021.9.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-30/ancham.2021.93.issue-30/20210803/ancham.2021.93.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-30/bichaw.2021.60.issue-30/20210803/bichaw.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-28/cgeabj.2021.99.issue-28/20210802/cgeabj.2021.99.issue-28.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-8/cgdefu.2021.21.issue-8/20210804/cgdefu.2021.21.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-15/esthag.2021.55.issue-15/20210803/esthag.2021.55.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-30/iecred.2021.60.issue-30/20210804/iecred.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-15/inocaj.2021.60.issue-15/20210802/inocaj.2021.60.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-30/jafcau.2021.69.issue-30/20210804/jafcau.2021.69.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-30/jacsat.2021.143.issue-30/20210804/jacsat.2021.143.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-8/jamsef.2021.32.issue-8/20210804/jamsef.2021.32.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-30/langd5.2021.37.issue-30/20210803/langd5.2021.37.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-8/mpohbp.2021.18.issue-8/20210802/mpohbp.2021.18.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.0c01561&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.0c01561&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.0c01561&amp;href=/doi/10.1021/acs.jmedchem.0c01561" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2020</span><span class="cit-fg-volume">, 63</span><span class="cit-fg-issue">, 24</span><span class="cit-fg-pageRange">, 15821-15851</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/63/24" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.0c01535" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/acs.jmedchem.0c01573" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Design, Synthesis, and Biological Evaluation of a Series of Oxazolone Carboxamides as a Novel Class of Acid Ceramidase Inhibitors</span></h1><ul class="loa"><li><span><span class="hlFld-ContribAuthor">Samantha Caputo</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Samantha Caputo</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Fondazione Istituto Italiano di Tecnologia, Via Morego 30, I-16163 Genova, Italy</div><div class="loa-info-affiliations-info">Drug Discovery and Development (D3)-Validation, Via Morego 30, I-16163 Genova, Italy</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Samantha++Caputo">Samantha Caputo</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Simona Di Martino</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Simona Di Martino</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Fondazione Istituto Italiano di Tecnologia, Via Morego 30, I-16163 Genova, Italy</div><div class="loa-info-affiliations-info">Drug Discovery and Development (D3)-Validation, Via Morego 30, I-16163 Genova, Italy</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Simona++Di+Martino">Simona Di Martino</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-5817-751X" title="Orcid link">http://orcid.org/0000-0001-5817-751X</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Vincenzo Cilibrasi</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Vincenzo Cilibrasi</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Fondazione Istituto Italiano di Tecnologia, Via Morego 30, I-16163 Genova, Italy</div><div class="loa-info-affiliations-info">Drug Discovery and Development (D3)-Validation, Via Morego 30, I-16163 Genova, Italy</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Vincenzo++Cilibrasi">Vincenzo Cilibrasi</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Piero Tardia</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Piero Tardia</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Fondazione Istituto Italiano di Tecnologia, Via Morego 30, I-16163 Genova, Italy</div><div class="loa-info-affiliations-info">Drug Discovery and Development (D3)-Validation, Via Morego 30, I-16163 Genova, Italy</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Piero++Tardia">Piero Tardia</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Marco Mazzonna</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Marco Mazzonna</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Fondazione Istituto Italiano di Tecnologia, Via Morego 30, I-16163 Genova, Italy</div><div class="loa-info-affiliations-info">Drug Discovery and Development (D3)-Validation, Via Morego 30, I-16163 Genova, Italy</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Marco++Mazzonna">Marco Mazzonna</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Debora Russo</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Debora Russo</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Fondazione Istituto Italiano di Tecnologia, Via Morego 30, I-16163 Genova, Italy</div><div class="loa-info-affiliations-info">D3-Pharma Chemistry, Via Morego 30, I-16163 Genova, Italy</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Debora++Russo">Debora Russo</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Ilaria Penna</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Ilaria Penna</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Fondazione Istituto Italiano di Tecnologia, Via Morego 30, I-16163 Genova, Italy</div><div class="loa-info-affiliations-info">D3-Pharma Chemistry, Via Morego 30, I-16163 Genova, Italy</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Ilaria++Penna">Ilaria Penna</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Maria Summa</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Maria Summa</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Fondazione Istituto Italiano di Tecnologia, Via Morego 30, I-16163 Genova, Italy</div><div class="loa-info-affiliations-info">Analytical Chemistry and Translational Pharmacology, Via Morego 30, I-16163 Genova, Italy</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Maria++Summa">Maria Summa</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Sine Mandrup Bertozzi</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Sine Mandrup Bertozzi</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Fondazione Istituto Italiano di Tecnologia, Via Morego 30, I-16163 Genova, Italy</div><div class="loa-info-affiliations-info">Analytical Chemistry and Translational Pharmacology, Via Morego 30, I-16163 Genova, Italy</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Sine+Mandrup++Bertozzi">Sine Mandrup Bertozzi</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Natalia Realini</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Natalia Realini</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Fondazione Istituto Italiano di Tecnologia, Via Morego 30, I-16163 Genova, Italy</div><div class="loa-info-affiliations-info">Drug Discovery and Development (D3)-Validation, Via Morego 30, I-16163 Genova, Italy</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Natalia++Realini">Natalia Realini</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Natasha Margaroli</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Natasha Margaroli</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Fondazione Istituto Italiano di Tecnologia, Via Morego 30, I-16163 Genova, Italy</div><div class="loa-info-affiliations-info">Drug Discovery and Development (D3)-Validation, Via Morego 30, I-16163 Genova, Italy</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Natasha++Margaroli">Natasha Margaroli</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Marco Migliore</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Marco Migliore</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Fondazione Istituto Italiano di Tecnologia, Via Morego 30, I-16163 Genova, Italy</div><div class="loa-info-affiliations-info">Drug Discovery and Development (D3)-Validation, Via Morego 30, I-16163 Genova, Italy</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Marco++Migliore">Marco Migliore</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Giuliana Ottonello</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Giuliana Ottonello</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Fondazione Istituto Italiano di Tecnologia, Via Morego 30, I-16163 Genova, Italy</div><div class="loa-info-affiliations-info">Analytical Chemistry and Translational Pharmacology, Via Morego 30, I-16163 Genova, Italy</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Giuliana++Ottonello">Giuliana Ottonello</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Min Liu</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Min Liu</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Lysosomal Therapeutics Inc., 19 Blackstone Street, Cambridge, Massachusetts 02139, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Min++Liu">Min Liu</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Peter Lansbury</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Peter Lansbury</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Lysosomal Therapeutics Inc., 19 Blackstone Street, Cambridge, Massachusetts 02139, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Peter++Lansbury">Peter Lansbury</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Andrea Armirotti</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Andrea Armirotti</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Fondazione Istituto Italiano di Tecnologia, Via Morego 30, I-16163 Genova, Italy</div><div class="loa-info-affiliations-info">Analytical Chemistry and Translational Pharmacology, Via Morego 30, I-16163 Genova, Italy</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Andrea++Armirotti">Andrea Armirotti</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-3766-8755" title="Orcid link">http://orcid.org/0000-0002-3766-8755</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Rosalia Bertorelli</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Rosalia Bertorelli</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Fondazione Istituto Italiano di Tecnologia, Via Morego 30, I-16163 Genova, Italy</div><div class="loa-info-affiliations-info">Analytical Chemistry and Translational Pharmacology, Via Morego 30, I-16163 Genova, Italy</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Rosalia++Bertorelli">Rosalia Bertorelli</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Soumya S. Ray</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Soumya S. Ray</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Lysosomal Therapeutics Inc., 19 Blackstone Street, Cambridge, Massachusetts 02139, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Soumya+S.++Ray">Soumya S. Ray</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Renato Skerlj</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Renato Skerlj</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Lysosomal Therapeutics Inc., 19 Blackstone Street, Cambridge, Massachusetts 02139, United States</div></div><span class="conrtib-corresp"><strong>*</strong>Email: <a href="/cdn-cgi/l/email-protection#1664737877627938657d73647a7c566e22667e77647b773875797b"><span class="__cf_email__" data-cfemail="9ae8fff4fbeef5b4e9f1ffe8f6f0dae2aeeaf2fbe8f7fbb4f9f5f7">[email protected]</span></a>. Phone: +1 617 610 8624.</span><span class="conrtib-corresp"></span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Renato++Skerlj">Renato Skerlj</a></span></div></div></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor">Rita Scarpelli</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Rita Scarpelli</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Fondazione Istituto Italiano di Tecnologia, Via Morego 30, I-16163 Genova, Italy</div><div class="loa-info-affiliations-info">Drug Discovery and Development (D3)-Validation, Via Morego 30, I-16163 Genova, Italy</div></div><span class="conrtib-corresp"><strong>*</strong>Email: <a href="/cdn-cgi/l/email-protection#4e3c273a2f603d2d2f3c3e2b2222270e27273a60273a"><span class="__cf_email__" data-cfemail="89fbe0fde8a7faeae8fbf9ece5e5e0c9e0e0fda7e0fd">[email protected]</span></a>. Phone: +39 010 2896233.</span><span class="conrtib-corresp"></span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Rita++Scarpelli">Rita Scarpelli</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-2623-306X" title="Orcid link">http://orcid.org/0000-0002-2623-306X</a></div></div></span></li><span class="comma-separator"></span></ul><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.0c01561&amp;href=/doi/10.1021%2Facs.jmedchem.0c01561" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2020</span></span><span class="cit-volume">, 63</span><span class="cit-issue">, 24</span><span class="cit-pageRange">, 15821–15851</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">December 8, 2020</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>7 September 2020</li><li><span class="item_label"><b>Published</b> online</span>8 December 2020</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 24 December 2020</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.0c01561" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c01561</a></div><div class="article_header-article-copyright"><strong>Copyright © 2020 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/page/rightslinkno.jsp">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"><a href="/page/policy/authorchoice/index.html"><img src="/pb-assets/images/programsLogos/OA_Icons_Ac-1612971054130.svg" alt="ACS AuthorChoice" /></img><span>ACS AuthorChoice</span></a><span class="article_header-cc-by text">with CC-BY<a href="/page/policy/authorchoice_ccby_termsofuse.html" title="License">license</a></span></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.0c01561"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">2506</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val">-</div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.0c01561" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Design, Synthesis, and Biological Evaluation of a Series of Oxazolone Carboxamides as a Novel Class of Acid Ceramidase Inhibitors&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Samantha&quot;,&quot;last_name&quot;:&quot;Caputo&quot;},{&quot;first_name&quot;:&quot;Simona&quot;,&quot;last_name&quot;:&quot;Di Martino&quot;},{&quot;first_name&quot;:&quot;Vincenzo&quot;,&quot;last_name&quot;:&quot;Cilibrasi&quot;},{&quot;first_name&quot;:&quot;Piero&quot;,&quot;last_name&quot;:&quot;Tardia&quot;},{&quot;first_name&quot;:&quot;Marco&quot;,&quot;last_name&quot;:&quot;Mazzonna&quot;},{&quot;first_name&quot;:&quot;Debora&quot;,&quot;last_name&quot;:&quot;Russo&quot;},{&quot;first_name&quot;:&quot;Ilaria&quot;,&quot;last_name&quot;:&quot;Penna&quot;},{&quot;first_name&quot;:&quot;Maria&quot;,&quot;last_name&quot;:&quot;Summa&quot;},{&quot;first_name&quot;:&quot;Sine&quot;,&quot;last_name&quot;:&quot;Mandrup Bertozzi&quot;},{&quot;first_name&quot;:&quot;Natalia&quot;,&quot;last_name&quot;:&quot;Realini&quot;},{&quot;first_name&quot;:&quot;Natasha&quot;,&quot;last_name&quot;:&quot;Margaroli&quot;},{&quot;first_name&quot;:&quot;Marco&quot;,&quot;last_name&quot;:&quot;Migliore&quot;},{&quot;first_name&quot;:&quot;Giuliana&quot;,&quot;last_name&quot;:&quot;Ottonello&quot;},{&quot;first_name&quot;:&quot;Min&quot;,&quot;last_name&quot;:&quot;Liu&quot;},{&quot;first_name&quot;:&quot;Peter&quot;,&quot;last_name&quot;:&quot;Lansbury&quot;},{&quot;first_name&quot;:&quot;Andrea&quot;,&quot;last_name&quot;:&quot;Armirotti&quot;},{&quot;first_name&quot;:&quot;Rosalia&quot;,&quot;last_name&quot;:&quot;Bertorelli&quot;},{&quot;first_name&quot;:&quot;Soumya&quot;,&quot;last_name&quot;:&quot;S. Ray&quot;},{&quot;first_name&quot;:&quot;Renato&quot;,&quot;last_name&quot;:&quot;Skerlj&quot;},{&quot;first_name&quot;:&quot;Rita&quot;,&quot;last_name&quot;:&quot;Scarpelli&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2020&quot;,&quot;month&quot;:&quot;12&quot;,&quot;day&quot;:&quot;08&quot;,&quot;issue&quot;:&quot;24&quot;,&quot;volume&quot;:&quot;63&quot;,&quot;pages&quot;:&quot;15821-15851&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.0c01561&quot;},&quot;abstract&quot;:&quot;Acid ceramidase (AC) is a cysteine hydrolase that plays a crucial role in the metabolism of lysosomal ceramides, important members of the sphingolipid family, a diversified class of bioactive molecules that mediate many biological processes ranging from cell structural integrity, signaling, and cell proliferation to cell death. In the effort to expand the structural diversity of the existing collection of AC inhibitors, a novel class of substituted oxazol-2-one-3-carboxamides were designed and synthesized. Herein, we present the chemical optimization of our initial hits, 2-oxo-4-phenyl-N-(4-phenylbutyl)oxazole-3-carboxamide 8a and 2-oxo-5-phenyl-N-(4-phenylbutyl)oxazole-3-carboxamide 12a, which resulted in the identification of 5-[4-fluoro-2-(1-methyl-4-piperidyl)phenyl]-2-oxo-N-pentyl-oxazole-3-carboxamide 32b as a potent AC inhibitor with optimal physicochemical and metabolic properties, showing target engagement in human neuroblastoma SH-SY5Y cells and a desirable pharmacokinetic profile in mice, following&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c01561&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c01561" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c01561&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c01561" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c01561&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c01561" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.0c01561&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c01561&amp;href=/doi/10.1021/acs.jmedchem.0c01561" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.0c01561" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.0c01561" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (4 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c01561&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.0c01561%26sid%3Dliteratum%253Aachs%26pmid%3D33290061%26genre%3Darticle%26aulast%3DCaputo%26date%3D2020%26atitle%3DDesign%252C%2BSynthesis%252C%2Band%2BBiological%2BEvaluation%2Bof%2Ba%2BSeries%2Bof%2BOxazolone%2BCarboxamides%2Bas%2Ba%2BNovel%2BClass%2Bof%2BAcid%2BCeramidase%2BInhibitors%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D63%26issue%3D24%26spage%3D15821%26epage%3D15851%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (2)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=291241" title="Phenyls">Phenyls</a>,</li><li><a href="/action/doSearch?ConceptID=292464" title="Rodent models">Rodent models</a>,</li><li><a href="/action/doSearch?ConceptID=292528" title="Inhibitors">Inhibitors</a>,</li><li><a href="/action/doSearch?ConceptID=291793" title="Inhibition">Inhibition</a>,</li><li><a href="/action/doSearch?ConceptID=291454" title="Solubility">Solubility</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/63/24" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/jmcmar.2020.63.issue-24/20201224/jmcmar.2020.63.issue-24.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="_i1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01561/20201218/images/medium/jm0c01561_0023.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01561/20201218/images/large/jm0c01561_0023.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01561&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">Acid ceramidase (AC) is a cysteine hydrolase that plays a crucial role in the metabolism of lysosomal ceramides, important members of the sphingolipid family, a diversified class of bioactive molecules that mediate many biological processes ranging from cell structural integrity, signaling, and cell proliferation to cell death. In the effort to expand the structural diversity of the existing collection of AC inhibitors, a novel class of substituted oxazol-2-one-3-carboxamides were designed and synthesized. Herein, we present the chemical optimization of our initial hits, 2-oxo-4-phenyl-<i>N</i>-(4-phenylbutyl)oxazole-3-carboxamide <b>8a</b> and 2-oxo-5-phenyl-<i>N</i>-(4-phenylbutyl)oxazole-3-carboxamide <b>12a</b>, which resulted in the identification of 5-[4-fluoro-2-(1-methyl-4-piperidyl)phenyl]-2-oxo-<i>N</i>-pentyl-oxazole-3-carboxamide <b>32b</b> as a potent AC inhibitor with optimal physicochemical and metabolic properties, showing target engagement in human neuroblastoma SH-SY5Y cells and a desirable pharmacokinetic profile in mice, following intravenous and oral administration. <b>32b</b> enriches the arsenal of promising lead compounds that may therefore act as useful pharmacological tools for investigating the potential therapeutic effects of AC inhibition in relevant sphingolipid-mediated disorders.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_45222" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_45222" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Ceramides (Cer) and their metabolites are members of the sphingolipid (SL) family that play important roles as integral components of the eukaryotic cell membranes and signaling molecules in apoptosis, cell growth, differentiation, senescence, diabetes, insulin resistance, inflammation, neurodegenerative disorders, and atherosclerosis.<a onclick="showRef(event, 'ref1 ref2 ref3 ref4'); return false;" href="javascript:void(0);" class="ref ref1 ref2 ref3 ref4">(1−4)</a> The proper regulation of ceramide biosynthesis and metabolism is controlled by a complex, highly compartmentalized, and interconnected network of enzymatic pathways essential to maintaining the cellular homeostasis and development.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> Although a detailed analysis of this complex network is beyond the scope of this paper, a simplified representation of the ceramide metabolism is shown in <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>. Cer are the centerpiece of the SL metabolism, produced in response to stressful stimuli via two major pathways: the <i>de novo</i> pathway from serine and palmitoyl-CoA in the endoplasmic reticulum and the <i>salvage</i> pathway from the recycling of sphingosine (So), bypassing the formation of dihydroceramide. The generated Cer can be transported to distinct cellular compartments and further modified to more complex SLs, for example, glycosylated to hexosylceramides (HexCer) and, in turn, to more complex glycosylceramides; metabolized into sphingomyelin (SM) and ceramide-1-phosphate (Cer-1P); and catabolized to produce So, which is further phosphorylated to sphingosine-1-phosphate (So-1P). Cellular Cer can also be generated through <i>catabolic</i> pathways in distinct sub-cellular compartments. In the lysosomes, for example, SM and HexCer (glucosylceramide and galactosylceramide) participate in distinct degradative pathways that contribute to the formation of lysosomal Cer. In the same compartment, HexCer can be hydrolyzed through distinct pathways to generate the corresponding lysosomal glycosylsphingosines.<a onclick="showRef(event, 'ref5'); return false;" href="javascript:void(0);" class="ref ref5">(5)</a> Evidence to date suggests that imbalances in this complex network because of an altered expression and/or regulation of SL-modifying enzymes can lead to dysregulated cell signaling responses that contribute to the initiation and progression of several SL-related disorders.<a onclick="showRef(event, 'ref3 ref4'); return false;" href="javascript:void(0);" class="ref ref3 ref4">(3,4)</a> During the past years, aided by the impressive advances of the modern biological and analytical technologies, the scientific community has focused much attention on improving the understanding of the functional roles of some basic components of this metabolic network, under physiological and pathological conditions.<a onclick="showRef(event, 'ref6'); return false;" href="javascript:void(0);" class="ref ref6">(6)</a></div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01561/20201218/images/medium/jm0c01561_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01561/20201218/images/large/jm0c01561_0002.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Overview of the ceramide metabolism and some related enzymes.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01561/20201218/images/large/jm0c01561_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01561&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Ceramidases (CDases) have attracted particular attention as key SL-metabolizing enzymes that regulate the levels and functions of different bioactive lipids, especially, Cer and So.<a onclick="showRef(event, 'ref7'); return false;" href="javascript:void(0);" class="ref ref7">(7)</a> Thus far, five human CDases (<i>h</i>CDase) have been identified, which can be characterized by their different optimal pH for catalytic activity and localization in cells: acid ceramidase (AC), neutral ceramidase (NC), alkaline ceramidase 1 (ACER1), alkaline ceramidase 2 (ACER2), and alkaline ceramidase 3 (ACER3).<a onclick="showRef(event, 'ref7 ref8'); return false;" href="javascript:void(0);" class="ref ref7 ref8">(7,8)</a> Because of differences in tissue distribution and expression level, cellular localization, optimum pH, and substrate specificity, these CDases appear to play distinct physiological roles in cellular responses.<a onclick="showRef(event, 'ref8'); return false;" href="javascript:void(0);" class="ref ref8">(8)</a> The overexpression of NC has been implicated in colon carcinogenesis<a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a> and, therefore, it has emerged as a potential new therapeutic target for cancer therapy.<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a> Recent reports have shown the implication of ACER1 in keratinocyte differentiation<a onclick="showRef(event, 'ref11 ref12'); return false;" href="javascript:void(0);" class="ref ref11 ref12">(11,12)</a> and that of ACER2 in programmed cell death in response to DNA damage.<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a> ACER3 has been reported to control both cell proliferation and apoptosis<a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a> and to be involved in motor coordination-associated Purkinje cell degeneration.<a onclick="showRef(event, 'ref15 ref16'); return false;" href="javascript:void(0);" class="ref ref15 ref16">(15,16)</a> Despite these fundamental studies on the functional roles of NC and ACER1-3 in certain biological processes, further investigations are still on going to better clarify their implications in human diseases.<a onclick="showRef(event, 'ref8'); return false;" href="javascript:void(0);" class="ref ref8">(8)</a> By contrast, a growing body of evidence describes the important role of AC in the development and progression of different human pathological conditions, suggesting human AC (<i>h</i>AC) as a potential target for promising therapeutic applications. <i>h</i>AC (also known as <i>N</i>-acylsphingosine amidohydrolase-1, ASAH-1) is a lysosomal cysteine amidase that, at an optimal pH of 4.5, hydrolyzes Cer into So and fatty acids (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>).<a onclick="showRef(event, 'ref17 ref18'); return false;" href="javascript:void(0);" class="ref ref17 ref18">(17,18)</a> Because the phosphorylation of So is the only pathway for the formation of So-1P, cellular So-1P is highly dependent on the availability of So; hence, <i>h</i>AC is a critical enzyme in regulating not only the hydrolysis of Cer but also the generation of both So and So-1P in cells. Cer and So-1P have opposing effects in the control of cell fate.<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a> While Cer favor cell-cycle arrest<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> and apoptosis,<a onclick="showRef(event, 'ref21 ref22'); return false;" href="javascript:void(0);" class="ref ref21 ref22">(21,22)</a> So-1P promotes angiogenesis, cell survival, and proliferation.<a onclick="showRef(event, 'ref23 ref24 ref25 ref26'); return false;" href="javascript:void(0);" class="ref ref23 ref24 ref25 ref26">(23−26)</a> Hence, the altered Cer/So balance determines the shifting of cell fate toward apoptosis and proliferation, respectively, and contributes to the pathogenesis of some human diseases. For example, various common diseases, including inflammation, pain, and several pulmonary disorders, have been associated with aberrant <i>h</i>AC activities.<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a><i>h</i>AC is also deficient in two rare inherited disorders: spinal muscular atrophy with myoclonic epilepsy and Farber’s disease.<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a> By contrast, collected evidence has shown that <i>h</i>AC is abnormally expressed in various types of human cancer, for example, prostate,<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a> melanoma,<a onclick="showRef(event, 'ref30'); return false;" href="javascript:void(0);" class="ref ref30">(30)</a> head and neck,<a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(31)</a> colon,<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a> and glioblastoma.<a onclick="showRef(event, 'ref33'); return false;" href="javascript:void(0);" class="ref ref33">(33)</a> It has been observed that the overexpression of <i>h</i>AC renders the cells more resistant to pharmacological induction of apoptosis.<a onclick="showRef(event, 'ref29 ref34'); return false;" href="javascript:void(0);" class="ref ref29 ref34">(29,34)</a> Therefore, the inhibition of <i>h</i>AC has been proposed as a potential strategy to enhance the therapeutic efficacy of standard antineoplastic agents and radiation.<a onclick="showRef(event, 'ref34 ref35'); return false;" href="javascript:void(0);" class="ref ref34 ref35">(34,35)</a> Relevant evidence has shown that Alzheimer’s disease (AD) brains exhibit elevated level and activity of <i>h</i>AC, suggesting a potential role of AC in controlling neuronal apoptosis and in the molecular mechanism of AD.<a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(36)</a> Notably, recent reports are proposing the role of <i>h</i>AC inhibition as an emerging strategy for treating some types of rare inherited metabolic disorders called lysosomal storage diseases (LSDs),<a onclick="showRef(event, 'ref37 ref38 ref39'); return false;" href="javascript:void(0);" class="ref ref37 ref38 ref39">(37−39)</a> in particular, some severe neuropathic conditions related to Gaucher’s<a onclick="showRef(event, 'ref40'); return false;" href="javascript:void(0);" class="ref ref40">(40)</a> disease (GD) and Krabbe’s<a onclick="showRef(event, 'ref41'); return false;" href="javascript:void(0);" class="ref ref41">(41)</a> disease (KD). GD and KD are caused by the defective functions of some specific lysosomal proteins, acid β-glucocerebrosidase (GCase, β-glucosyl ceramidase) for GD and β-galactocerebrosidase (GALCase, β-galactosyl ceramidase) for KD. In GD patients, recent evidence suggests an active role of <i>h</i>AC in the catabolism of the lysosomal glucosylceramide, which is responsible for the accumulation of toxic glucosylsphingosine (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>).<a onclick="showRef(event, 'ref42'); return false;" href="javascript:void(0);" class="ref ref42">(42)</a> In KD patients, deficiency of GALCase activity results in the buildup of the galactosylceramide and the galactosylsphingosine (psychosine) in nervous tissues, especially in the brain. Notably, a recent report suggests that genetic ablation or pharmacological inhibition of AC could eliminate the accumulation of the neurotoxic psychosine and prolong the life span of the KD mouse model.<a onclick="showRef(event, 'ref43'); return false;" href="javascript:void(0);" class="ref ref43">(43)</a> There are no approved treatments for neuropathic GD and KD; targeting the inhibition of <i>h</i>AC may provide an innovative approach for treating these severe diseases.</div><div class="NLM_p">Although many efforts in the past decade have been made to identify new classes of <i>h</i>AC inhibitors, to date, these activities have resulted in limited success and a very limited number of suitable candidates for in vivo experiments are currently available. In a recent study, Gebai and co-workers reported the crystal structure analysis of mammalian AC (PDB code: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5U7Z">5U7Z</a>),<a onclick="showRef(event, 'ref44'); return false;" href="javascript:void(0);" class="ref ref44">(44)</a> which may assist future structure-guided drug discovery programs. First generation <i>h</i>AC inhibitors were designed on the basis of substrate (Cer)-based structures, for example, <i>N</i>-oleoylethanolamine (OEA, median inhibitory concentration (IC<sub>50</sub>) ∼ 500 μM,<a onclick="showRef(event, 'ref45'); return false;" href="javascript:void(0);" class="ref ref45">(45)</a><a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>). Despite being the first Cer-mimicking inhibitor to be described, the ability of OEA to inhibit <i>h</i>AC was not always reproducible.<a onclick="showRef(event, 'ref45 ref46 ref47'); return false;" href="javascript:void(0);" class="ref ref45 ref46 ref47">(45−47)</a> Further representative examples are <span class="smallcaps smallerCapital">d</span>-<i>erithro</i>-2-(<i>N</i>-myristoylamino)-1-phenyl-1-propanol (<span class="smallcaps smallerCapital">d</span>-<i>e</i>-MAPP, IC<sub>50</sub> > 500 μM in HL-60 cell lysates<a onclick="showRef(event, 'ref45'); return false;" href="javascript:void(0);" class="ref ref45">(45)</a> and IC<sub>50</sub> = 500 μM in HaCaT cell lysates,<a onclick="showRef(event, 'ref48'); return false;" href="javascript:void(0);" class="ref ref48">(48)</a><a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>) and its more water soluble derivative <i>N</i>-NMAPPD (B13, IC<sub>50</sub> ∼ 10 μM in HaCaT cell lysates,<a onclick="showRef(event, 'ref48'); return false;" href="javascript:void(0);" class="ref ref48">(48)</a><a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>). Efforts to ameliorate these Cer-mimicking molecules led to several structurally varied analogues of B13, as compounds DP24a (IC<sub>50</sub> = 1.287 μM,<a onclick="showRef(event, 'ref49'); return false;" href="javascript:void(0);" class="ref ref49">(49)</a><a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>) and the potent irreversible AC inhibitor SABRAC (IC<sub>50</sub> = 0.052 μM,<a onclick="showRef(event, 'ref50 ref51'); return false;" href="javascript:void(0);" class="ref ref50 ref51">(50,51)</a><a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>). By contrast, the quinolinone-based compounds, Ceranib-1 and its optimized analogue Ceranib-2, represent the first class of non-Cer-mimicking inhibitors of <i>h</i>CDase identified by Draper and co-workers by screening a chemical library (<i>h</i>CDase IC<sub>50</sub> = 55 μM and 28 μM in SKOV3 cells, respectively,<a onclick="showRef(event, 'ref52'); return false;" href="javascript:void(0);" class="ref ref52">(52)</a><a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>). In another study by Yildiz-Oze and co-workers, Ceranib-2 was found to inhibit <i>h</i>AC activity by 44% at 25 μM in H460 cells.<a onclick="showRef(event, 'ref53'); return false;" href="javascript:void(0);" class="ref ref53">(53)</a> More recently, Cho and co-workers reported the identification of the hit compound [1,1′-biphenyl]-4-yl-2-(4-guanidinophenyl)acetate (E2, IC<sub>50</sub> = 52 μM,<a onclick="showRef(event, 'ref54'); return false;" href="javascript:void(0);" class="ref ref54">(54)</a><a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>) from 68 guanidine-based derivatives tested for the discovery of new antiangiogenic inhibitors and determined the role of <i>h</i>AC as the E2-binding protein. Although a comparative analysis of the AC inhibitory activities of these different molecules is limited by the fact that the reported pharmacological data have been collected using different assay conditions and protein sources (<a href="/doi/suppl/10.1021/acs.jmedchem.0c01561/suppl_file/jm0c01561_si_001.pdf" class="ext-link">Table S1</a>),<a onclick="showRef(event, 'ref45 ref46 ref47 ref48 ref49 ref50 ref52 ref53 ref54'); return false;" href="javascript:void(0);" class="ref ref45 ref46 ref47 ref48 ref49 ref50 ref52 ref53 ref54">(45−50,52−54)</a> overall, these AC inhibitors are characterized by low inhibitory potency (as those with IC<sub>50</sub> values in the μM range)<a onclick="showRef(event, 'ref45 ref46 ref47 ref48 ref49 ref52 ref53 ref54'); return false;" href="javascript:void(0);" class="ref ref45 ref46 ref47 ref48 ref49 ref52 ref53 ref54">(45−49,52−54)</a> and poor drug-likeness (as those with, e.g., long lipophilic carbon chains).<a onclick="showRef(event, 'ref45 ref46 ref47 ref48 ref49 ref50'); return false;" href="javascript:void(0);" class="ref ref45 ref46 ref47 ref48 ref49 ref50">(45−50)</a></div><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01561/20201218/images/medium/jm0c01561_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01561/20201218/images/large/jm0c01561_0003.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Representative known and structurally diversified AC inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01561/20201218/images/large/jm0c01561_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01561&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">A significant breakthrough was made by Realini and co-workers with the identification of carmofur [rat AC (<i>r</i>AC) IC<sub>50</sub> = 29 nM,<a onclick="showRef(event, 'ref55'); return false;" href="javascript:void(0);" class="ref ref55">(55)</a><a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a> and <a href="/doi/suppl/10.1021/acs.jmedchem.0c01561/suppl_file/jm0c01561_si_001.pdf" class="ext-link">Table S1</a>] and some close uracil analogues, for example, compounds <b>1a–d</b>, as nanomolar inhibitors of AC activity (<b>1a</b>, <i>r</i>AC IC<sub>50</sub> = 67 nM;<a onclick="showRef(event, 'ref55'); return false;" href="javascript:void(0);" class="ref ref55">(55)</a><b>1b</b>, <i>r</i>AC IC<sub>50</sub> = 12 nM;<a onclick="showRef(event, 'ref55'); return false;" href="javascript:void(0);" class="ref ref55">(55)</a><b>1c</b>, <i>r</i>AC IC<sub>50</sub> = 16 nM<a onclick="showRef(event, 'ref56'); return false;" href="javascript:void(0);" class="ref ref56">(56)</a> and <i>h</i>AC IC<sub>50</sub> = 7.7 nM;<a onclick="showRef(event, 'ref30'); return false;" href="javascript:void(0);" class="ref ref30">(30)</a> and <b>1d</b>, <i>h</i>AC IC<sub>50</sub> = 12.8 nM,<a onclick="showRef(event, 'ref30'); return false;" href="javascript:void(0);" class="ref ref30">(30)</a><a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a> and <a href="/doi/suppl/10.1021/acs.jmedchem.0c01561/suppl_file/jm0c01561_si_001.pdf" class="ext-link">Table S1</a>). Despite being potent AC inhibitors with some potential applications as chemo-sensitizing agents, the uracil derivatives showed low chemical and metabolic stability. Successively, using a ligand-based virtual screening approach, with carmofur as the template, Diamanti and co-workers identified a new class of potent <i>h</i>AC inhibitors, exemplified by the pyrazole carboxamide <b>2</b> (IC<sub>50</sub> = 14 nM,<a onclick="showRef(event, 'ref57'); return false;" href="javascript:void(0);" class="ref ref57">(57)</a><a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a> and <a href="/doi/suppl/10.1021/acs.jmedchem.0c01561/suppl_file/jm0c01561_si_001.pdf" class="ext-link">Table S1</a>). However, these molecules exhibited low metabolic stability (<b>2</b>, mouse plasma half-life, <i>t</i><sub>1/2</sub> = 9 min),<a onclick="showRef(event, 'ref57'); return false;" href="javascript:void(0);" class="ref ref57">(57)</a> limiting their therapeutic potential. Through a systematic computational investigation, Ortega and co-workers reported the identification of benzimidazole derivatives <b>3a–d</b> (<b>3a</b>, IC<sub>50</sub> = 2.5 nM; <b>3b</b>, IC<sub>50</sub> = 13.9 nM; <b>3c</b>, IC<sub>50</sub> = 22.5 nM; and <b>3d</b>, IC<sub>50</sub> = 14.8 nM,<a onclick="showRef(event, 'ref58'); return false;" href="javascript:void(0);" class="ref ref58">(58)</a><a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a> and <a href="/doi/suppl/10.1021/acs.jmedchem.0c01561/suppl_file/jm0c01561_si_001.pdf" class="ext-link">Table S1</a>) with promising AC inhibitory activity in different melanoma cell lines.<a onclick="showRef(event, 'ref58'); return false;" href="javascript:void(0);" class="ref ref58">(58)</a> A screening campaign of a small compound library was exploited by Pizzirani and co-workers resulting in the identification of the benzoxazolone (abbreviated as BOA, hereafter) carboxamide series, exemplified by the initial hit <b>4a</b> (IC<sub>50</sub> = 64 nM,<a onclick="showRef(event, 'ref59'); return false;" href="javascript:void(0);" class="ref ref59">(59)</a><a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a> and <a href="/doi/suppl/10.1021/acs.jmedchem.0c01561/suppl_file/jm0c01561_si_001.pdf" class="ext-link">Table S1</a>).<a onclick="showRef(event, 'ref59'); return false;" href="javascript:void(0);" class="ref ref59">(59)</a> Preliminary studies led to the more advanced and systematically active analogues <b>4b</b> (IC<sub>50</sub> = 79 nM,<a onclick="showRef(event, 'ref59'); return false;" href="javascript:void(0);" class="ref ref59">(59)</a><a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a> and <a href="/doi/suppl/10.1021/acs.jmedchem.0c01561/suppl_file/jm0c01561_si_001.pdf" class="ext-link">Table S1</a>) and <b>4c</b> (IC<sub>50</sub> = 33 nM,<a onclick="showRef(event, 'ref60'); return false;" href="javascript:void(0);" class="ref ref60">(60)</a><a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a> and <a href="/doi/suppl/10.1021/acs.jmedchem.0c01561/suppl_file/jm0c01561_si_001.pdf" class="ext-link">Table S1</a>).<a onclick="showRef(event, 'ref59 ref60'); return false;" href="javascript:void(0);" class="ref ref59 ref60">(59,60)</a> Although these molecules showed potent inhibitory effects on <i>h</i>AC activity, they generally suffered from low aqueous solubility and moderate metabolic stability, which impede their further development as oral drugs. During recent years, we directed the scope of our research work to solve these limitations. As part of our continued efforts in the optimization of the BOA carboxamide series, we recently reported the discovery of the piperidine <b>4d</b> (IC<sub>50</sub> = 166 nM,<a onclick="showRef(event, 'ref61'); return false;" href="javascript:void(0);" class="ref ref61">(61)</a><a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a> and <a href="/doi/suppl/10.1021/acs.jmedchem.0c01561/suppl_file/jm0c01561_si_001.pdf" class="ext-link">Table S1</a>) as a lead compound with good oral bioavailability, excellent brain penetration, and target engagement in two animal models of neuropathic GD and KD.<a onclick="showRef(event, 'ref61'); return false;" href="javascript:void(0);" class="ref ref61">(61)</a> As an extension of this work while adopting a different strategy, we started an exploratory drug discovery program directed to the search for a novel class of <i>h</i>AC inhibitors with optimal drug-like properties, suitable for investigational studies in cellular and in vivo model systems. In the present study, we describe our strategies for the design and synthesis of a novel chemotype of <i>h</i>AC inhibitors (general structure, compound <b>5</b>, <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>). The disruption of the molecular planarity of the fused bicyclic BOA moiety resulted in the identification of two initial hits, 2-oxo-4-phenyl-<i>N</i>-(4-phenylbutyl)oxazole-3-carboxamide <b>8a</b> and 2-oxo-5-phenyl-<i>N</i>-(4-phenylbutyl)oxazole-3-carboxamide <b>12a</b> (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>). Herein, we present the structure–activity relationship (SAR) exploration of this novel series of substituted oxazol-2-one-3-carboxamides and the chemical optimization which resulted in the identification of 5-[4-fluoro-2-(1-methyl-4-piperidyl)phenyl]-2-oxo-<i>N</i>-pentyl-oxazole-3-carboxamide <b>32b</b> as a potent and drug-like <i>h</i>AC inhibitor—structurally differentiated from previously reported series.</div><figure id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01561/20201218/images/medium/jm0c01561_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01561/20201218/images/large/jm0c01561_0004.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Rational design of the novel class of AC inhibitors and hit identification.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01561/20201218/images/large/jm0c01561_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01561&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i3">Chemistry</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_45726" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_45726" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">The synthetic routes for the preparation of all target compounds are described in <a class="ref internalNav" href="#sch1" aria-label="Schemes 1">Schemes 1</a>–<named-content content-type="anchor" rid="sch2" type="simple"></named-content><named-content content-type="anchor" rid="sch3" type="simple"></named-content><named-content content-type="anchor" rid="sch4" type="simple"></named-content><named-content content-type="anchor" rid="sch5" type="simple"></named-content><a class="ref internalNav" href="#sch6" aria-label="6">6</a>. We introduced different substituents at the C(4)- and C(5)-positions of the 2-oxazolone core scaffold by exploring the synthetic pathways depicted in <a class="ref internalNav" href="#sch1" aria-label="Schemes 1">Schemes 1</a> and <a class="ref internalNav" href="#sch2" aria-label="2">2</a>. The substituted 4-phenyl-oxazol-2-one derivatives <b>7a–c</b> were obtained starting from the corresponding α-hydroxy ketones <b>6a–c</b>, through the condensation reaction with potassium cyanate and in situ intramolecular cyclization under acidic conditions (<a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>).<a onclick="showRef(event, 'ref62'); return false;" href="javascript:void(0);" class="ref ref62">(62)</a> A series of substituted 5-phenyl- and 5-heteroaryl-oxazol-2-one derivatives <b>11a–q</b> were synthesized starting from the commercially available α-bromo ketones <b>9a–q</b> by condensation with 2,4-thiazolidinedione (TZD), followed by intramolecular cyclization of the intermediates <b>10a–q</b> under basic conditions (LiOH or <i>t</i>-BuOK) (<a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a>).<a onclick="showRef(event, 'ref63'); return false;" href="javascript:void(0);" class="ref ref63">(63)</a> We introduced the carboxamide functionalities using standard conditions, by reacting intermediates <b>7a–c</b> or <b>11a–q</b> with the corresponding commercially available isocyanates, as in the synthesis of <b>8a–d</b> (<a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>) or <b>12a–b</b>, <b>g–w</b> (<a class="ref internalNav" href="#sch3" aria-label="Scheme 3">Scheme 3</a>). Alternatively, the isocyanates were generated in situ, through the activation of the corresponding amines by reaction with Boc<sub>2</sub>O in the presence of 4-(dimethylamino)-pyridine (DMAP)<a onclick="showRef(event, 'ref64'); return false;" href="javascript:void(0);" class="ref ref64">(64)</a> (<b>12c–d</b>, <a class="ref internalNav" href="#sch3" aria-label="Scheme 3">Scheme 3</a>) or by reaction with triphosgene in the presence of <i>N</i>,<i>N</i>-diisopropylethylamine (DIPEA) or Et<sub>3</sub>N<a onclick="showRef(event, 'ref65'); return false;" href="javascript:void(0);" class="ref ref65">(65)</a> (<b>12e–f</b>, <a class="ref internalNav" href="#sch3" aria-label="Scheme 3">Scheme 3</a>). The <i>N</i>-methylated analogue <b>13a</b> and the carbamate <b>13b</b> were prepared upon the activation of <b>11a</b> with triphosgene in the presence of DIPEA, followed by the addition of <i>N</i>-methyl-4-phenylbutylamine and 4-phenyl-1-butanol, respectively (<a class="ref internalNav" href="#sch3" aria-label="Scheme 3">Scheme 3</a>). On the other hand, <b>11a</b> was converted to the corresponding amide <b>13c</b> by reaction with the corresponding freshly prepared 6-phenylhexanoic chloride. The oxazolidin-2-one analogues <b>15a–b</b> were prepared starting from the commercially available chiral (4<i>S</i>)-<b>14a</b>- and (4<i>R</i>)-<b>14b</b>-phenyl-oxazolidin-2-ones by carboxamide formation under standard conditions (<a class="ref internalNav" href="#sch4" aria-label="Scheme 4">Scheme 4</a>A). A similar synthetic strategy was adopted for the preparation of analogues <b>18a–b</b> upon the formation of the enantiomers (5<i>S</i>)-<b>17a</b>- and (5<i>R</i>)-<b>17b</b>-phenyl-oxazolidin-2-ones starting from the enantiomerically pure 2-amino-1-phenylethanols <b>16a–b</b> via 1,1′-carbonyldiimidazole (CDI)-mediated intramolecular cyclization (<a class="ref internalNav" href="#sch4" aria-label="Scheme 4">Scheme 4</a>B).</div><figure id="sch1" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01561/20201218/images/medium/jm0c01561_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01561/20201218/images/large/jm0c01561_0011.jpeg" id="gr10" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of <b>8a–d</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01561/20201218/images/large/jm0c01561_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01561&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) KNCO, AcOH, and <i>i</i>-PrOH, 70 °C, 3 h (36–53%) and (b) RNCO and DMAP, CH<sub>3</sub>CN, rt, 3–16 h (15–82%).</p></p></figure><figure id="sch2" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01561/20201218/images/medium/jm0c01561_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01561/20201218/images/large/jm0c01561_0012.jpeg" id="gr11" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Synthesis of <b>11a–q</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01561/20201218/images/large/jm0c01561_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01561&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) TZD, K<sub>2</sub>CO<sub>3</sub>, and DMF, rt, 1–2 h. (b) LiOH and THF, rt, 30 min–1 h (6%- quant. over two steps for <b>11a</b>, <b>11c–p</b>) or <i>t</i>-BuOK and THF, rt, 30 min (for <b>11b</b> and <b>11q</b>: 10 and 38% over two steps; respectively).</p></p></figure><figure id="sch3" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01561/20201218/images/medium/jm0c01561_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01561/20201218/images/large/jm0c01561_0013.jpeg" id="gr12" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Synthesis of <b>12a–y</b> and <b>13a–c</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01561/20201218/images/large/jm0c01561_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01561&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) RNCO and DMAP (10–83% for <b>12a–b</b>, <b>h–w</b>) or Et<sub>3</sub>N (78% for <b>12g</b>) and CH<sub>3</sub>CN, rt, 3–16 h or RNH<sub>2</sub>, Boc<sub>2</sub>O, DMAP and CH<sub>3</sub>CN, rt, 1–3 h (48–80% for <b>12c–d</b>) or RNH<sub>2</sub>, triphosgene, and DIPEA (76% for <b>12e</b>) or Et<sub>3</sub>N (24% for <b>12f</b>) and DCM, rt, 3–12 h; (b) 4 M HCl, 1,4-dioxane, rt, 2 h; (c) HCHO, AcOH, NaBH(OAc)<sub>3</sub>, and CH<sub>3</sub>CN, rt, 1 h (34% over two steps); (d) for <b>13a</b>: <i>N</i>-methyl-4-phenylbutylamine, triphosgene, DIPEA, and DCM, 0 °C to rt, 3 h (98%); for <b>13b</b>: 4-phenyl-1-butanol, triphosgene, DIPEA, and DCM, 0 °C to rt, 3 h (53%); for <b>13c</b>: 6-phenylhexanoic acid, SOCl<sub>2</sub>, and DCM, rt, 6 h; then <b>11a</b>, Et<sub>3</sub>N and THF, 0 °C to rt, 16 h (55%).</p></p></figure><figure id="sch4" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01561/20201218/images/medium/jm0c01561_0014.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01561/20201218/images/large/jm0c01561_0014.jpeg" id="gr13" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 4. Synthesis of <b>15a–b</b> and <b>18a–b</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01561/20201218/images/large/jm0c01561_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01561&amp;id=sch4"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: for the synthesis of <b>15a–b</b>: (a) 4-phenylbutyl isocyanate, DMAP, DMF, 50 °C, 2 h, (47–81%); for the synthesis of <b>18a–b</b>: (a′) CDI, imidazole, DCM, rt, 16 h (86–92%); (b′) 4-phenylbutyl isocyanate, DMAP, DMF, 50 °C, 4 h (68–79%).</p></p></figure><figure id="sch5" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Scheme 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01561/20201218/images/medium/jm0c01561_0015.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01561/20201218/images/large/jm0c01561_0015.jpeg" id="gr14" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 5. Synthesis of <b>25c–f</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01561/20201218/images/large/jm0c01561_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01561&amp;id=sch5"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) Pd(PPh<sub>3</sub>)<sub>4</sub>, 2 M Na<sub>2</sub>CO<sub>3</sub>, and 1,4-dioxane, reflux, 16 h (77–87%); (b) 10% Pd/C, cyclohexene, and EtOH, 60 °C, 24 h (65%); (c) TMSOTf, Et<sub>3</sub>N, and THF, −78 to −50 °C, 4 h; then, NBS and THF, −40 to −20 °C, 30 min; (d) TZD, K<sub>2</sub>CO<sub>3</sub>, and DMF, rt, 1–2 h (93% over three steps for <b>23b</b>); (e) <i>t</i>-BuOK and THF, rt, 1 h (29% over 4 steps for <b>24a</b>) or LiOH and THF, rt, 30 min (72% for <b>24b</b>); (f) 4-phenylbutyl isocyanate, DMAP, and pyridine, rt, 16 h (69%); (g) 4 M HCl and 1,4-dioxane, rt, 2 h (46%); (h) HCHO, AcOH, NaBH(OAc)<sub>3</sub>, and CH<sub>3</sub>CN, rt, 1 h (60%) (i) 4 M HCl and 1,4-dioxane, rt, 2 h; (j) HCHO, AcOH, NaBH(OAc)<sub>3</sub>, and CH<sub>3</sub>CN, rt, 1 h (71% over two steps); and (k) RNCO, DMAP, and pyridine, rt, 16 h (25–36% for <b>25d–e</b>) or <i>i</i>-BuNH<sub>2</sub>, triphosgene, Et<sub>3</sub>N, and DCM, rt, 3 h (82% for <b>25f</b>).</p></p></figure><figure id="sch6" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Scheme 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01561/20201218/images/medium/jm0c01561_0016.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01561/20201218/images/large/jm0c01561_0016.jpeg" id="gr15" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 6. Synthesis of <b>32a–c</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01561/20201218/images/large/jm0c01561_0016.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01561&amp;id=sch6"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) Pd(PPh<sub>3</sub>)<sub>4</sub>, 2 M Na<sub>2</sub>CO<sub>3</sub>, and 1,4-dioxane, reflux, 16 h (85%); (b) HCO<sub>2</sub>NH<sub>4</sub>, 20% Pd(OH)<sub>2</sub>, and MeOH, 60 °C, 4 h (69%); (c) TMSOTf, Et<sub>3</sub>N, and THF, −78 to −50 °C, 4 h; then, NBS and THF, −40 to −20 °C, 30 min; (d) TZD, K<sub>2</sub>CO<sub>3</sub>, and DMF, rt, 2 h (66% over three steps); (e) <i>t</i>-BuOK and THF, rt, 30 min (67%); (f) 4 M HCl and 1,4-dioxane, rt, 2 h; (g) HCHO, AcOH, NaBH(OAc)<sub>3</sub>, and CH<sub>3</sub>CN, rt, 1 h and (h) RNCO, DMAP, and pyridine, rt, 16 h (62% for <b>32a</b>; 64% for <b>32b</b>) or <i>i</i>-BuNH<sub>2</sub>, triphosgene, Et<sub>3</sub>N, and DCM, rt, 3 h (20% for <b>32c</b>).</p></p></figure><div class="NLM_p last">Similar procedures were exploited for the preparation of the targeted oxazolone carboxamides <b>25c–f</b> and <b>32a–c</b>, bearing a 4-methylpiperidine moiety at the C(3′)- and C(2′)-positions of the phenyl ring, respectively (<a class="ref internalNav" href="#sch5" aria-label="Schemes 5">Schemes 5</a> and <a class="ref internalNav" href="#sch6" aria-label="6">6</a>). The methyl ketones <b>22a–b</b> and <b>28</b> were prepared in two steps, starting from the corresponding bromophenyls <b>20a–b</b> and <b>26</b>, using Pd-catalyzed cross-coupling reactions, in the presence of the commercially available boronic pinacol ester <b>19</b>, followed by hydrogenation in EtOH at 60 °C in the presence of 10% Pd/C and cyclohexene (as in the synthesis of <b>22a–b</b>), or using Pd(OH)<sub>2</sub> and ammonium formate in MeOH at reflux (as in the synthesis of <b>28</b>). The resulting methyl ketones <b>22a–b</b> and <b>28</b> were transformed into the corresponding α-bromo ketones <b>22c–d</b> and <b>29</b>, through a slightly modified reported procedure,<a onclick="showRef(event, 'ref66'); return false;" href="javascript:void(0);" class="ref ref66">(66)</a> consisting of an in situ addition of <i>N</i>-bromosuccinimide (NBS) to the corresponding silyl enol ethers in the presence of Et<sub>3</sub>N at a controlled low temperature (<a class="ref internalNav" href="#sch5" aria-label="Schemes 5">Schemes 5</a> and <a class="ref internalNav" href="#sch6" aria-label="6">6</a>). The α-bromo ketones <b>22c–d</b> and <b>29</b> were directly reacted with TZD to afford the corresponding intermediates <b>23a–b</b> and <b>30</b> and then converted, through an intramolecular cyclization, to the 2-oxazolones <b>24a–b</b> and <b>31a</b>, respectively, as described above. Standard reaction conditions were exploited to convert the piperidines <b>24b</b> and <b>31a</b> to the corresponding 4-methylpiperidines <b>24d</b> and <b>31c</b>, which involved <i>N</i>-Boc removal and reductive amination in the presence of NaBH(OAc)<sub>3</sub> and 37% aqueous solution of HCHO. Alternatively, as in the synthesis of <b>25c</b>, these synthetic steps were performed on the corresponding carboxamide derivative <b>25a</b>, obtained by reacting <b>24a</b> with 4-phenylbutyl isocyanate (<a class="ref internalNav" href="#sch5" aria-label="Scheme 5">Scheme 5</a>). Finally, the carboxamide functionality of the targeted compounds <b>25d–f</b> and <b>32a–c</b> was introduced using standard reaction conditions, as described above.</div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i10">Results and Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_64180" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_64180" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">A common characteristic of some classes of known AC inhibitors is the presence of a cysteine (Cys)-targeting warhead as the α-bromo acetyl moiety or the urea-like functionality that can undergo a chemical reaction with the thiol group of the catalytic Cys143 of <i>h</i>AC to produce a covalent bond,<a onclick="showRef(event, 'ref44'); return false;" href="javascript:void(0);" class="ref ref44">(44)</a> as reported for 2-bromoacetamide SABRAC<a onclick="showRef(event, 'ref51'); return false;" href="javascript:void(0);" class="ref ref51">(51)</a> and the carboxamides <b>3a–b</b><a onclick="showRef(event, 'ref58'); return false;" href="javascript:void(0);" class="ref ref58">(58)</a> and <b>4a</b><a onclick="showRef(event, 'ref59'); return false;" href="javascript:void(0);" class="ref ref59">(59)</a> (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>). This evidence has been supported by recent studies, reported by Dementiev and co-workers, on the crystal structure analysis of carmofur covalently bound to Cys143 at a 2.7 Å resolution.<a onclick="showRef(event, 'ref67'); return false;" href="javascript:void(0);" class="ref ref67">(67)</a> While potent and, in certain cases, systemically active, for example, analogues <b>4b–c</b>,<a onclick="showRef(event, 'ref59 ref60'); return false;" href="javascript:void(0);" class="ref ref59 ref60">(59,60)</a> these potent <i>h</i>AC inhibitors share two characteristics that hamper their applications as oral drugs. First, the chemical warheads which, on the one hand, are responsible for the covalent binding mechanisms of these inhibitors and, on the other hand, can contribute to the poor chemical and plasma stability of these molecules (e.g., carmofur, <b>1a–d</b> and <b>2</b>);<a onclick="showRef(event, 'ref56 ref57'); return false;" href="javascript:void(0);" class="ref ref56 ref57">(56,57)</a> second, the hydrophobic linear side-chains, although fundamental for target recognition and some degree of specificity, negatively affect the drug-like properties of these molecules (e.g., SABRAC and <b>4a</b>).<a onclick="showRef(event, 'ref51 ref59'); return false;" href="javascript:void(0);" class="ref ref51 ref59">(51,59)</a> Thus, there is a strong need for novel and optimized <i>h</i>AC inhibitors. In this respect, our continued efforts dedicated to the chemical optimization of the BOA carboxamide series, exemplified by <b>4a–c</b>,<a onclick="showRef(event, 'ref59 ref60'); return false;" href="javascript:void(0);" class="ref ref59 ref60">(59,60)</a> have recently led to the identification of the lead <b>4d</b> as a potent and orally bioavailable <i>h</i>AC inhibitor with excellent brain penetration in mice and target engagement in two animal models of LSDs (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>).<a onclick="showRef(event, 'ref61'); return false;" href="javascript:void(0);" class="ref ref61">(61)</a> As part of our more exploratory research program, our medicinal chemistry strategies were also focused on expanding the chemical diversity of the existing <i>h</i>AC inhibitors for the identification of new chemotypes with optimal physicochemical and metabolic properties suitable for cellular and in vivo studies. In this regard, by the disruption of the molecular planarity of the fused bicyclic aromatic BOA system, we designed a series of compounds with the general structure <b>5</b> and synthesized a few initial molecules, for example, the 2-oxo-4-phenyl-<i>N</i>-(4-phenylbutyl)oxazole-3-carboxamide <b>8a</b> and 2-oxo-5-phenyl-<i>N</i>-(4-phenylbutyl)oxazole-3-carboxamide <b>12a</b> (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>). In particular, we were interested in studying the substituted-oxazolone ring system as a potential and attractive strategy for the BOA bioisosteric replacement. In addition, we envisaged that the insertion of this relatively unexplored heterocycle system, by reducing the molecular planarity of the core scaffold and, therefore, varying the nature of the leaving group at the reactive electrophilic functionality, might be a valuable strategy for the subsequent optimization of our targeted molecules.<a onclick="showRef(event, 'ref68'); return false;" href="javascript:void(0);" class="ref ref68">(68)</a> By contrast, in order to somehow preserve the <i>h</i>AC recognition, we initially designed scaffolds that bear a lipophilic group on the lateral chain of the urea-like functionality, as the butyl phenyl group of <b>8a</b> and <b>12a</b>, already described in other series of known inhibitors (e.g., <b>3a–b</b> and <b>4a–c</b>, <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>) to be suitable for chemical optimization. Compounds <b>8a</b> and <b>12a</b> were screened against <i>h</i>AC using a fluorogenic assay and were able to inhibit the enzymatic activity with IC<sub>50</sub> values equal to 0.007 and 0.090 μM, respectively (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>). These initial results encouraged us to start a preliminary SAR exploration around these new scaffolds in the three main <i>Regions A</i>, <i>B</i>, and <i>C</i>, as depicted in <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>, with the objective of identifying the pharmacophore necessary for target inhibition.</div><figure id="fig4" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01561/20201218/images/medium/jm0c01561_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01561/20201218/images/large/jm0c01561_0005.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Planned SAR exploration.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01561/20201218/images/large/jm0c01561_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01561&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. Inhibitory Potencies of Compounds <b>8a–d</b> and <b>12a–n</b> and <b>12y</b> on the Activity of <i>h</i>AC</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01561/20201218/images/medium/jm0c01561_0017.gif" alt="" id="GRAPHIC-d7e1885-autogenerated" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01561/20201218/images/medium/jm0c01561_0018.gif" alt="" id="gr16" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup><sup>a</sup></sup><p class="last">IC<sub>50</sub> values are the mean of at least three independent experiments performed in three technical replicates.</p></div><div class="footnote" id="t1fn2"><sup><sup>b</sup></sup><p class="last">IC<sub>50</sub> values were not determined for compounds showing less than 50% inhibition at concentrations of 10 μM for <i>h</i>AC.</p></div><div class="footnote" id="t1fn3"><sup><sup>c</sup></sup><p class="last">Partial degradation was observed in the 10 mM DMSO solution.</p></div></div><div></div></div><div class="NLM_p">In this regard, to first validate our initial hits, we prepared a set of representative analogues around the 4-phenyl-oxazol-2-one (4-POA) and 5-phenyl-oxazol-2-one (5-POA) carboxamide compounds <b>8a</b> and <b>12a</b> (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>). Interestingly, in the 4-POA carboxamide series, although a slight drop in potency was detected with the removal of the terminal aromatic ring, as in the <i>n</i>-pentyl analogue <b>8b</b> (<i>h</i>AC IC<sub>50</sub> = 0.025 μM), the insertion of a Cl atom at the <i>para</i> phenyl position was tolerated, with compound <b>8d</b> (<i>h</i>AC IC<sub>50</sub> = 0.005 μM) being equipotent to the parent <b>8a</b> (<i>h</i>AC IC<sub>50</sub> = 0.007 μM) (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>). In contrast, the insertion of a methyl group on the C(5)-position of the oxazolone ring, as in the di-substituted analogue <b>8c</b>, resulted in a 6-fold loss of potency (<i>h</i>AC IC<sub>50</sub> = 0.042 μM). A slightly different trend was observed in the 5-POA carboxamide series; the removal of the terminal phenyl ring, as in the <i>n</i>-pentyl analogue <b>12b</b> (<i>h</i>AC IC<sub>50</sub> = 0.039 μM), resulted in a weak improvement in potency compared to the parent compound <b>12a</b> (<i>h</i>AC IC<sub>50</sub> = 0.090 μM). Both the insertion of a Cl atom at the <i>para</i> phenyl position, as in <b>12i</b>, and the insertion of a methyl group at the C(4)-position of the oxazolone ring, as in <b>12h</b>, afforded analogues (<i>h</i>AC IC<sub>50</sub> = 0.083 and 0.069 μM, respectively) with similar potency compared to <b>12a</b> (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>).</div><div class="NLM_p">These encouraging preliminary results confirmed that both the 4- and 5-(POA) carboxamide series were promising scaffolds and warranted further exploration. Nevertheless, a head-to-head comparison of the two hit series directed future investigations toward the 5-POA carboxamide series. Specifically, although being very potent <i>h</i>AC inhibitors, the 4-POA carboxamide series suffered from significantly poorer chemical stability compared to the 5-POA carboxamide series, as measured by performing the stability assay in aqueous media [<b>8a</b>, <i>t</i><sub>1/2</sub> = 10 min, in phosphate buffered saline (PBS), pH 7.4; <b>12a</b>, <i>t</i><sub>1/2</sub> = >12 h, in PBS, pH 7.4].</div><div class="NLM_p">First, we demonstrated the importance of the reactive carboxamide functionality of <b>12a</b> because the corresponding unsubstituted analogue <b>11a</b> was not active against <i>h</i>AC at the concentrations tested (<a class="ref internalNav" href="#sch3" aria-label="Scheme 3">Scheme 3</a> and <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>A), suggesting that inhibition by <b>12a</b> could occur through covalent AC modification. Preliminary kinetic studies on <i>h</i>AC-enriched lysates showed that <b>12a</b> causes a concentration-dependent reduction in the maximal catalytic velocity of AC (<i>V</i><sub>max</sub>) without influencing the Michaelis–Menten constant (<i>K</i><sub>M</sub>) (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>B and <a href="/doi/suppl/10.1021/acs.jmedchem.0c01561/suppl_file/jm0c01561_si_001.pdf" class="ext-link">Table S2</a>) supporting irreversible binding. In addition, the replacement of the <i>N</i>–H of the urea-like functionality of <b>12a</b> with a <i>N</i>–Me (<b>13a</b>), with an oxygen (<b>13b</b>) or with a methylene (<b>13c</b>) were detrimental to activity (<a class="ref internalNav" href="#sch3" aria-label="Scheme 3">Scheme 3</a>), as these analogues were not active against <i>h</i>AC at the concentrations tested (1 and 10 μM). Moreover, we demonstrated that the presence of the oxazol-2-one ring of <b>12a</b> was essential to maintaining inhibitory potency, since the corresponding chiral 1,3-oxazolidinone carboxamide analogues <b>18a–b</b> were not active against <i>h</i>AC at the concentrations tested (1 and 10 μM) (<a class="ref internalNav" href="#sch3" aria-label="Scheme 3">Scheme 3</a>). A similar outcome was also observed with the chiral 1,3-oxazolidinone carboxamide analogues of the more potent <b>8a</b>, compounds <b>15a–b</b> (<a class="ref internalNav" href="#sch3" aria-label="Scheme 3">Scheme 3</a>).<a onclick="showRef(event, 'ref57'); return false;" href="javascript:void(0);" class="ref ref57">(57)</a></div><figure id="fig5" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01561/20201218/images/medium/jm0c01561_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01561/20201218/images/large/jm0c01561_0006.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. (A) Concentration–response curve for the inhibition of <i>h</i>AC activity by <b>11a</b> and <b>12a</b>; (B) Michaelis–Menten analysis of the reaction of <i>h</i>AC in the presence of vehicle (DMSO 1%, ●) or <b>12a</b> (25 nM, ▲; 100 nM, ■). Rbm14-12: fluorogenic substrate of <i>h</i>AC. The graph is representative of two independent experiments, each performed in three technical replicates.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01561/20201218/images/large/jm0c01561_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01561&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Therefore, based on these results, we continued with a more focused SAR exploration, by targeting additional analogues bearing small linear and branched alkyl substituents on the side-chain at the <i>N</i>-terminal urea moiety of <b>12a</b> series (<i>Region C</i>, <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>). Replacement of one methylene unit with an oxygen in the <i>n</i>-pentyl chain of <b>12b</b> (as ethers <b>12c–d</b>) significantly affected the inhibitory potency; specifically, <b>12c</b> showed an <i>h</i>AC IC<sub>50</sub> = 2.04 μM, while a complete loss in potency was observed for <b>12d</b> (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>). These results suggested that the lipophilic side-chains at <i>region C</i> were very likely occupying a hydrophobic channel of the enzyme. Our SAR exploration continued with the insertion of branched alkyl groups, the <i>i</i>-butyl <b>12e</b> inhibited AC with an IC<sub>50</sub> of 1.70 μM, while the <i>s</i>-butyl analogue <b>12f</b> was not active up to 10 μM. No improvement was also observed with the aryl urea <b>12g</b>.</div><div class="NLM_p">In parallel, our medicinal chemistry efforts were also focused on the exploration of <i>region A</i> by introducing different substituents on the phenyl ring of the <b>12a</b> series. Besides, the <i>p</i>-Cl atom of <b>12i</b>, both electron-withdrawing (F) and electron-donating (OCH<sub>3</sub>) groups at different positions of the phenyl ring were tolerated, resulting in compounds, such as <b>12j</b> (<i>p</i>-F) and <b>12k–m</b> (<i>p</i>-, <i>m</i>- and <i>o</i>-OCH<sub>3</sub>), with <i>h</i>AC IC<sub>50</sub> values in the submicromolar ranges (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>). In addition, the di-substituted derivative <b>12n</b> (<i>p</i>-F, <i>m</i>-OCH<sub>3</sub>) was almost equipotent (<i>h</i>AC IC<sub>50</sub> = 0.080 μM) to <b>12a</b>.</div><div class="NLM_p">With these results in hand, we explored the replacement of the substituted phenyl rings at the C(5)-position of the oxazol-2-one moiety with a series of heteroaryl groups by preparing compounds <b>12o–v</b> (<a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>). Different 5- and 6-membered-, 6 + 5-, and 6 + 6-fused heteroaryl groups were introduced on <i>Region A</i>. Interestingly, we identified potent AC inhibitors, for example, the 2- and 4-pyridyl analogues <b>12o</b> and <b>12q</b>, showing <i>h</i>AC IC<sub>50</sub> = 0.025 and 0.018 μM, respectively; whereas, the 3-pyridyl isomer <b>12p</b> (<i>h</i>AC IC<sub>50</sub> = 0.070 μM) was almost equipotent to <b>12a</b> (<a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>). A similar improvement of inhibitory potency was also observed with other nitrogen containing heteroaryl derivatives, for example, the pyrazine (<b>12r</b>) and quinoxaline (<b>12s</b>) analogues (<i>h</i>AC IC<sub>50</sub> = 0.032 and 0.037 μM, respectively). On the other hand, while the thiazole isomers <b>12u</b> and <b>12v</b> showed a moderately improved inhibitory activity (<i>h</i>AC IC<sub>50</sub> = 0.059 and 0.044 μM, respectively), the 1-methylindazole <b>12t</b> (<i>h</i>AC IC<sub>50</sub> = 0.092 μM) was equipotent to the parent <b>12a</b>.</div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. Inhibitory Potencies of Compounds <b>12o–v</b> on the Activity of <i>h</i>AC</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01561/20201218/images/medium/jm0c01561_0019.gif" alt="" id="GRAPHIC-d7e2393-autogenerated" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01561/20201218/images/medium/jm0c01561_0020.gif" alt="" id="gr17" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t2fn1"><div class="footnote" id="t2fn1"><sup><sup>a</sup></sup><p class="last">IC<sub>50</sub> values are the mean of at least three independent experiments performed in three technical replicates.</p></div></div><div></div></div><div class="NLM_p">A comparison of several of these analogues in terms of aqueous kinetic solubility (PBS, pH 7.4) and in vitro metabolism (<i>t</i><sub>1/2</sub> in mouse plasma and mouse liver microsomes) underlined some important differences (<a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a>), which informed the next steps of the SAR exploration. In general, these compounds showed poor aqueous solubility, which was not ameliorated by the removal of the terminal lipophilic phenyl group (e.g., <i>n</i>-pentyl analogue <b>12b</b>), or by the introduction of more polar groups, such as an oxygen atom on the lateral chain (<b>12c</b>) or heteroaryl rings at the C(5)-position of the oxazol-2-one moiety (e.g., the pyridines <b>12o–q</b> and the pyrazine <b>12r</b>) (<a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a>). On the contrary, more pronounced differences were observed by comparing the mouse plasma and mouse liver microsomal stability properties of these analogues. In general, except for the parent <b>12a</b> and the heteroaryls <b>12o</b> and <b>12q–r</b>, the selected compounds showed good mouse plasma stability. In contrast, poor mouse microsomal stabilities were observed within the phenyl derivatives, except when a F-atom was inserted in the phenyl ring, for example, <i>p</i>-F analogues <b>12j</b> (<i>m</i>-liver microsomal <i>t</i><sub>1/2</sub> = 60 min) and <b>12n</b> (<i>m</i>-liver microsomal <i>t</i><sub>1/2</sub> > 60 min, 74% compound remaining at 1 h). An improvement of the mouse microsomal stability was also detected with the <i>i</i>-butyl analogue <b>12e</b> (<i>m</i>-liver microsomal <i>t</i><sub>1/2</sub> = 50 min). A similar effect of the F-atom was shown by some nitrogen containing heteroaryl analogues, bearing an “aza”-group in the phenyl ring, for example, the 4-pyridyl <b>12q</b> (<i>m</i>-liver microsomal <i>t</i><sub>1/2</sub> > 60 min, 75% compound remaining at 1 h) and the pyrazine <b>12r</b> (<i>m</i>-liver microsomal <i>t</i><sub>1/2</sub> = 60 min) (<a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a>).</div><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. Aqueous Kinetic Solubility and In Vitro Metabolism of Some Selected Compounds</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compound</th><th class="colsep0 rowsep0" align="center">solubility (μM)<a class="ref internalNav" href="#t3fn1" aria-label="a">a</a> (PBS, pH 7.4)</th><th class="colsep0 rowsep0" align="center"><i>m</i>-plasma<a class="ref internalNav" href="#t3fn2" aria-label="b">b</a><i>t</i><sub>1/2</sub> (min) [% at 120 min]</th><th class="colsep0 rowsep0" align="center"><i>m</i>-LM<a class="ref internalNav" href="#t3fn3" aria-label="c">c</a><i>t</i><sub>1/2</sub> (min) [% at 60 min]</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>12a</b></td><td class="colsep0 rowsep0" align="left"><1</td><td class="colsep0 rowsep0" align="left"><5</td><td class="colsep0 rowsep0" align="left">40</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>12b</b></td><td class="colsep0 rowsep0" align="left"><1</td><td class="colsep0 rowsep0" align="left">>120 [60%]</td><td class="colsep0 rowsep0" align="left"><5</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>12c</b></td><td class="colsep0 rowsep0" align="left">20</td><td class="colsep0 rowsep0" align="left">80</td><td class="colsep0 rowsep0" align="left"><5</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>12e</b></td><td class="colsep0 rowsep0" align="left"><1</td><td class="colsep0 rowsep0" align="left">>120 [70%]</td><td class="colsep0 rowsep0" align="left">50</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>12j</b></td><td class="colsep0 rowsep0" align="left"><1</td><td class="colsep0 rowsep0" align="left">90</td><td class="colsep0 rowsep0" align="left">60</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>12l</b></td><td class="colsep0 rowsep0" align="left"><1</td><td class="colsep0 rowsep0" align="left">>120 [64%]</td><td class="colsep0 rowsep0" align="left">30</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>12n</b></td><td class="colsep0 rowsep0" align="left"><1</td><td class="colsep0 rowsep0" align="left">>120 [64%]</td><td class="colsep0 rowsep0" align="left">>60 [74%]</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>12o</b></td><td class="colsep0 rowsep0" align="left"><1</td><td class="colsep0 rowsep0" align="left">40</td><td class="colsep0 rowsep0" align="left">10</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>12p</b></td><td class="colsep0 rowsep0" align="left"><1</td><td class="colsep0 rowsep0" align="left">60</td><td class="colsep0 rowsep0" align="left">>60 [55%]</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>12q</b></td><td class="colsep0 rowsep0" align="left"><1</td><td class="colsep0 rowsep0" align="left">30</td><td class="colsep0 rowsep0" align="left">>60 [75%]</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>12r</b></td><td class="colsep0 rowsep0" align="left"><1</td><td class="colsep0 rowsep0" align="left">40</td><td class="colsep0 rowsep0" align="left">60</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t3fn1"><div class="footnote" id="t3fn1"><sup><sup>a</sup></sup><p class="last">Aqueous kinetic solubility in PBS.</p></div><div class="footnote" id="t3fn2"><sup><sup>b</sup></sup><p class="last">Mouse plasma.</p></div><div class="footnote" id="t3fn3"><sup><sup>c</sup></sup><p class="last">Mouse liver microsomes. <sup>a,b,c</sup>Values are reported as the mean of at least two independent experiments performed in two technical replicates.</p></div></div></div><div class="NLM_p">Based on these results, we continued the SAR exploration by modifying the scaffold with the insertion of some potential solubilizing groups. We specifically focused our attention on <i>regions A</i> and <i>B</i> due to the fact that, as mentioned above, our SAR study suggested <i>region C</i> to be more involved in lipophilic interactions with <i>h</i>AC (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>). In this respect, our preliminary exploration of this series showed that the insertion of an hydrophilic group, such as the <i>N</i>-methyl-piperidine ring at the C(5)-position of the oxazol-2-one moiety (<b>12y</b>, <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>), although detrimental for the inhibitory potency (<i>h</i>AC IC<sub>50</sub> = 1.40 μM), was essential for significantly improving the aqueous solubility (<b>12y</b>, kinetic solubility = 248 μM). As a consequence, we decided to investigate the effect of inserting the <i>N</i>-methyl-piperidine group directly at the C(3′)- position of the phenyl ring of the 5-POA carboxamide series by preparing analogues <b>25c</b> and <b>25d</b> (<a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a></a>). Although a similar decrease in potency (<i>h</i>AC IC<sub>50</sub> = 0.153 and 0.341 μM, respectively) was observed compared to the corresponding parent compounds <b>12a</b> and <b>12j</b>, we were pleased to notice that, overall, these structural modifications were tolerated. Moreover, a similar trend was observed when the <i>N</i>-methyl-piperidine ring was moved to the C(2′)- position of the phenyl ring, with <b>32a</b> (<i>h</i>AC IC<sub>50</sub> = 0.337 μM) being equipotent to <b>25d</b>. Notably, we observed that these targeted compounds showed moderately improved solubility (kinetic solubility > 30 μM, <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">Table <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a></a>) compared to the parent compounds <b>12a</b> and <b>12j</b>.</div><div class="NLM_table-wrap" id="tbl4"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 4. Inhibitory Potencies of Compounds <b>25c–f</b> and <b>32a–c</b> on the Activity of <i>h</i>AC</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01561/20201218/images/medium/jm0c01561_0021.gif" alt="" id="GRAPHIC-d7e2849-autogenerated" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01561/20201218/images/medium/jm0c01561_0022.gif" alt="" id="gr18" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t4fn1"><div class="footnote" id="t4fn1"><sup><sup>a</sup></sup><p class="last">IC<sub>50</sub> values are the mean of at least three independent experiments performed in three technical replicates.</p></div><div class="footnote" id="t4fn2"><sup><sup>b</sup></sup><p class="last">IC<sub>50</sub> values were not determined for compounds showing less than 50% inhibition at concentrations of 10 μM for <i>h</i>AC.</p></div></div><div></div></div><div class="NLM_table-wrap" id="tbl5"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 5. Aqueous Kinetic Solubility and In Vitro Metabolism of Some Selected Compounds</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compound</th><th class="colsep0 rowsep0" align="center">solubility (μM)<a class="ref internalNav" href="#t5fn1" aria-label="a">a</a> (PBS,pH 7.4)</th><th class="colsep0 rowsep0" align="center"><i>m</i>-plasma<a class="ref internalNav" href="#t5fn2" aria-label="b">b</a><i>t</i><sub>1/2</sub> (min) [% at 120 min]</th><th class="colsep0 rowsep0" align="center"><i>m</i>-LM<a class="ref internalNav" href="#t5fn3" aria-label="c">c</a><i>t</i><sub>1/2</sub> (min) [% at 60 min]</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>25c</b></td><td class="colsep0 rowsep0" align="left">70</td><td class="colsep0 rowsep0" align="left">>120 [73%]</td><td class="colsep0 rowsep0" align="left">30</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>25d</b></td><td class="colsep0 rowsep0" align="left">30</td><td class="colsep0 rowsep0" align="left">>120 [80%]</td><td class="colsep0 rowsep0" align="left">>60 [70%]</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>32a</b></td><td class="colsep0 rowsep0" align="left">60</td><td class="colsep0 rowsep0" align="left">>120 [54%]</td><td class="colsep0 rowsep0" align="left">>60 [51%]</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>32b</b></td><td class="colsep0 rowsep0" align="left">>250</td><td class="colsep0 rowsep0" align="left">110</td><td class="colsep0 rowsep0" align="left">>60 [74%]</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t5fn1"><div class="footnote" id="t5fn1"><sup><sup>a</sup></sup><p class="last">Aqueous kinetic solubility in PBS.</p></div><div class="footnote" id="t5fn2"><sup><sup>b</sup></sup><p class="last">Mouse plasma.</p></div><div class="footnote" id="t5fn3"><sup><sup>c</sup></sup><p class="last">Mouse liver microsomes. <sup>a,b,c</sup>Values are reported as the mean of at least two independent experiments performed in two technical replicates.</p></div></div></div><div class="NLM_p">These results prompted us to continue a more focused SAR study on the lateral chains of <b>25d</b> and <b>32a</b> scaffolds, selecting the optimal moieties previously identified in the exploration of <i>region C</i> (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Tables <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a> and <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a>) and, hence, synthetizing the corresponding <i>n</i>-pentyl analogues <b>25e</b> and <b>32b</b> and the <i>i</i>-butyl analogues <b>25f</b> and <b>32c</b>. Although, a complete loss in potency was observed with both <i>i</i>-butyl analogues <b>25f</b> and <b>32c</b>, the <i>n</i>-pentyl derivatives <b>25e</b> and <b>32b</b> gave unexpected results. While <b>25e</b> showed a <i>h</i>AC IC<sub>50</sub> of 1.9 μM, surprisingly, compound <b>32b</b> inhibited <i>h</i>AC with an IC<sub>50</sub> equal to 0.129 μM. In addition, compound <b>32b</b>, bearing both the <i>N</i>-methyl piperidine ring and the small linear alkyl chain, showed a high solubility value (kinetic solubility > 250 μM) (<a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">Table <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a></a>). Finally, the most promising compounds were evaluated for in vitro metabolism (<a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">Table <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a></a>). In general, we were pleased to observe that the selected compounds exhibited good mouse plasma stabilities with <i>t</i><sub>1/2</sub> values ≥2 h. On the other hand, the poor mouse liver microsomal stability observed for <b>25c</b> was ameliorated by the insertion of a F-atom at the <i>para</i>-position of the phenyl ring (<b>25d</b>, <i>m</i>-liver microsomal <i>t</i><sub>1/2</sub> > 60 min, 70% compound remaining at 1 h). A similar trend was observed with the other fluorinated analogues, compound <b>32a–b</b>. Furthermore, additional in vitro metabolism studies were performed on <b>32b</b> which showed acceptable <i>h</i>-plasma (<i>t</i><sub>1/2</sub> = 40 min) and good <i>h</i>-liver microsomal stability (<i>t</i><sub>1/2</sub> > 60 min, 80% compound remaining at 1 h).</div><div class="NLM_p">Based on its inhibitory potency and good overall drug-like properties, compound <b>32b</b> was selected for further biological and pharmacological characterizations. As previously anticipated for the initial hit <b>12a</b> and based on our previous work with <b>4d</b>,<a onclick="showRef(event, 'ref61'); return false;" href="javascript:void(0);" class="ref ref61">(61)</a> the mechanism of inhibition of <b>32b</b> occurs through covalent <i>h</i>AC modification. This was further supported by the corresponding analogue <b>31c</b>, lacking the reactive urea-like functionality of <b>32b</b>, which was not active against <i>h</i>AC (<named-content content-type="anchor" rid="fig6" type="simple"></named-content><named-content content-type="anchor" rid="fig7" type="simple"></named-content><a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>A). Based on these considerations, we prioritized the selectivity evaluation of <b>32b</b> against human <i>N</i>-acylethanolamine acid amidase (<i>h</i>NAAA), a lysosomal cysteine amidase that shares 33–34% sequence identity and a very similar reactive site with <i>h</i>AC.<a onclick="showRef(event, 'ref69'); return false;" href="javascript:void(0);" class="ref ref69">(69)</a> Notably, <b>32b</b> showed no effect at up to 125 μM against <i>h</i>NAAA under our assay conditions. In an effort to gain insights into the structural bases of these biological results, we then performed molecular modeling and docking studies using the X-ray crystal structures of <i>h</i>AC (PDB code: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6MHM">6MHM</a>)<a onclick="showRef(event, 'ref67'); return false;" href="javascript:void(0);" class="ref ref67">(67)</a> and <i>h</i>NAAA (PDB code: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6DXX">6DXX</a>).<a onclick="showRef(event, 'ref69'); return false;" href="javascript:void(0);" class="ref ref69">(69)</a> The protein (<i>h</i>AC)–ligand (targeted compound) binding site was prepared by adding hydrogen atoms, optimizing hydrogen bonds, and verifying the protonation states of His, Gln, and Asn. The energy minimization was carried out using a default constraint of 0.3 Å rmsd and OPLS 3e force field. The SiteMap tool was used to identify binding pockets of <i>h</i>AC. The docking calculation on the SAR series was carried out using Schrödinger covalent docking program CovDock. The docking procedure used the distance cutoffs (8 Å Cβ to the ligand, 5 Å to the ligand reactive carbonyl group) to decide if the covalent reaction can indeed happen or a molecule pose should be kept for further consideration. Cys143 was used as the reactive nucleophile in the calculations. While under experimental conditions, the leaving group would in fact cleave from the molecule and only a part of the molecule would remain attached to Cys143; the docking calculation actually captures the binding pose quality of the tetrahedral intermediate (reaction intermediate). The binding strength and quality of the pose for this is likely to have an impact on the overall ligand potency. A series of compounds from the described SAR studies were analyzed using this docking model. We observed that, while the docking model could account for the large changes in potency and the scores were well correlated with the experimental potency, it was hard to account for the smaller incremental changes in the SAR data. Nevertheless, these computational analyses gave useful insights in our experimental results. In particular, in silico docking studies of <b>32b</b> to <i>h</i>AC suggests a binding mode of the corresponding tetrahedral intermediate (reaction intermediate, docking score = −7.3), as depicted in <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>B. The docking pose suggests the alkyl side-chain (<i>n</i>-pentyl) of <b>32b</b> sharing the same binding mode of the <i>n</i>-hexyl chain of carmofur (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>) within the <i>h</i>AC binding pocket,<a onclick="showRef(event, 'ref67'); return false;" href="javascript:void(0);" class="ref ref67">(67)</a> where lipophilic residues, such as Phe163, Tyr137, Leu211, and Meth161, are localized. In addition, hydrogen bonding interaction stabilizes the transition state around the catalytic Cys143 residue between the side-chain carboxyl group of Glu225 (2.77 Å) and the hydroxy group (tetrahedral intermediate) on the alpha carbon of the reaction center. The ligand pose itself is stabilized by a cation–pi interaction between the protonated <i>N</i>-methyl amino group of the piperidine ring and Trp395 and a second edge to face the pi–pi interaction between the fluorophenyl group of the ligand and Phe165 (4.56 and 3.43 Å). It is conceivable that the electron-withdrawing nature of the fluorophenyl might promote the strength of the pi–pi interaction.</div><figure id="fig6" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01561/20201218/images/medium/jm0c01561_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01561/20201218/images/large/jm0c01561_0007.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Concentration dependence of the effects of <b>32b</b> in SH-SY5Y cells on <i>h</i>AC activity after a 3 h incubation (A) and SL levels (B–F). GraphPad Prism software (GraphPad Software, Inc., USA) was used for statistical analysis. Data were analyzed using the Student <i>t</i>-test or 1-way ANOVA followed by the Bonferroni post hoc test for multiple comparisons. Differences between groups were considered statistically significant at values of <i>p</i> < 0.05. Values are expressed as means SEM of at least six determinations. Experiments were repeated twice with similar results.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01561/20201218/images/large/jm0c01561_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01561&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="fig7" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01561/20201218/images/medium/jm0c01561_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01561/20201218/images/large/jm0c01561_0008.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Time course of the effects of <b>32b</b> (10 μM) in SH-SY5Y cells on <i>h</i>AC activity (A) and SL levels (B–F). GraphPad Prism software (GraphPad Software, Inc., USA) was used for statistical analysis. Data were analyzed using the Student <i>t</i>-test or 1-way ANOVA followed by the Bonferroni post hoc test for multiple comparisons. Differences between groups were considered statistically significant at values of <i>p</i> < 0.05. Values are expressed as means SEM of at least six determinations. Experiments were repeated twice with similar results.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01561/20201218/images/large/jm0c01561_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01561&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="fig8" data-index="14" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01561/20201218/images/medium/jm0c01561_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01561/20201218/images/large/jm0c01561_0009.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Concentration–response curve for the inhibition of <i>h</i>AC activity by <b>31c</b> and <b>32b</b> (A) and putative docking pose of compound <b>32b</b> in <i>h</i>AC (PDB code: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6MHM">6MHM</a>) (B).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01561/20201218/images/large/jm0c01561_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01561&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Analysis of <b>32b</b> in the anti-target <i>h</i>NAAA suggests that the binding site of the two enzymes share over 90% similarity in their amino acid composition. However, when compound <b>32b</b> is docked into <i>h</i>NAAA,<a onclick="showRef(event, 'ref69'); return false;" href="javascript:void(0);" class="ref ref69">(69)</a> the resultant equivalent pose has a very low score. Careful examination of the docking poses (modeling details in <a class="ref internalNav" href="#sec5" aria-label="Experimental Section">Experimental Section</a>) show that there is a critical difference between <i>h</i>AC and <i>h</i>NAAA around residue 182 in the binding site. While <i>h</i>AC has Leu at position 182, the equivalent position is occupied by much larger Trp181 in <i>h</i>NAAA. The <i>n</i>-pentyl side-chain on the compound <b>32b</b> easily fits in the wider pocket of <i>h</i>AC (<a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">9</a></a>A), but it causes steric clashes, as seen in the <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">9</a></a>B, in the case of <i>h</i>NAAA because of the much bulkier Trp181 side-chain. We believe this to be one of key reasons for selectivity observed in <b>32b</b> that might be further exploited in future drug design programs.</div><figure id="fig9" data-index="15" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01561/20201218/images/medium/jm0c01561_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01561/20201218/images/large/jm0c01561_0010.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. Putative docking poses of compound <b>32b</b> in <i>h</i>AC (PDB code: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6MHM">6MHM</a>) (A) and in <i>h</i>NAAA (PDB code: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6DXX">6DXX</a>) (B).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01561/20201218/images/large/jm0c01561_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01561&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Because of the overall property profile of <b>32b</b>, this compound was selected for additional pharmacological studies with the aim of testing its ability to inhibit <i>h</i>AC in intact cells. In particular, we examined the effects of compound <b>32b</b> treatment using human neuroblastoma SH-SY5Y cells, which are a well-characterized and widely used in vitro cell model.<a onclick="showRef(event, 'ref70 ref71'); return false;" href="javascript:void(0);" class="ref ref70 ref71">(70,71)</a> Notably, Kyriakou and co-workers recently established and characterized a stable AC knockdown human neuroblastoma SH-SY5Y cell line, as a human in vitro cell model for studying the effects of AC deficiency.<a onclick="showRef(event, 'ref72'); return false;" href="javascript:void(0);" class="ref ref72">(72)</a> Human neuroblastoma SH-SY5Y cells were incubated in the presence of <b>32b</b> at different concentrations for 3 h (1, 2.5, 5, and 10 μM, <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>) and in the presence of <b>32b</b> (10 μM) at different incubation times (1, 3, and 6 h, <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>). <i>h</i>AC activity was measured and SL levels were identified and quantified with a liquid chromatography/mass spectrometry (LC/MS)-based activity assay, as previously described.<a onclick="showRef(event, 'ref55 ref56 ref61'); return false;" href="javascript:void(0);" class="ref ref55 ref56 ref61">(55,56,61)</a> We indeed demonstrated that <b>32b</b> is effectively able to engage <i>h</i>AC in the complex cellular environment under our experimental conditions, causing the expected changes in the cellular levels of SL. Treatment of SH-SY5Y cell cultures with <b>32b</b> caused a concentration (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>A) and time-dependent reduction of <i>h</i>AC activity (<a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>A). After 3 h incubation, we observed an intracellular accumulation of various Cer species, including Cer (d18:0/16:0) and Cer (d18:1/16:0) (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>B,C), and a corresponding decrease in So levels in a concentration-dependent manner (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>D). Conversely, no major variations were observed in the levels of SM (d18:1/16:0) (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>E) and HexCer (d18:1/16:0) (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>F). The effect of <b>32b</b> (10 μM) on the inhibition of <i>h</i>AC activity and the intracellular SL levels is reported in <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>A–F. Specifically, we observed that <b>32b</b> inhibits <i>h</i>AC in SH-SY5Y cells leading to an increased Cer (d18:0/16:0) and Cer (d18:1/16:0) (<a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>B,C) and decreased So levels (<a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>D), which persisted up to 6 h. No major variations were observed in the levels of SM (d18:1/16:0) (<a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>E) and HexCer (d18:1/16:0) (<a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>F).</div><div class="NLM_p">Finally, we then took <b>32b</b> for pharmacokinetic (PK) studies in C57BL/6 mice, following intravenous (i.v.) and oral administration (p.o.). The relevant PK parameters are reported in <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">Table <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">6</a></a>. Values of plasma clearance (Cl<sub>p</sub>), volume of distribution (<i>V</i><sub>dss</sub>), and plasma elimination half-life (<i>t</i><sub>1/2</sub>) were calculated after i.v. administration of <b>32b</b> at 3 mg/kg. Cl<sub>p</sub> was relatively low (72 mL/min/kg) with acceptable plasma <i>t</i><sub>1/2</sub> (119 min) and high <i>V</i><sub>dss</sub> (12426 mL/kg), indicating that <b>32b</b> is well distributed out of the circulating mouse plasma compartment. Compound <b>32b</b> is an orally bioavailable <i>h</i>AC inhibitor at 10 mg/kg (oral bioavailability, <i>F</i> = 40%) and is rapidly adsorbed in the plasma compartment (<i>t</i><sub>max</sub> = 30 min), with a maximal plasma concentration (C<sub>max</sub>) of 278 ng/mL and acceptable plasma <i>t</i><sub>1/2</sub> (147 min). Moreover, <b>32b</b> shows significant exposures in mouse plasma, after both i.v. and p.o. doses (AUC = 31978 and 42525 min × ng/mL, respectively).</div><div class="NLM_table-wrap" id="tbl6"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 6. PK Properties of <b>32b</b> after Intravenous (3 mg/kg) and Oral Administration (10 mg/kg) in C57BL/6 Mice</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">parameters<a class="ref internalNav" href="#t6fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center">(3 mg/kg, i.v.)</th><th class="colsep0 rowsep0" align="center" char=".">(10 mg/kg, p.o.)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>t</i><sub>max</sub> (min)</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="char" char=".">30</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>C</i><sub>max</sub> (ng/mL)</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="char" char=".">278</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>t</i><sub>1/2</sub> (min)</td><td class="colsep0 rowsep0" align="left">119</td><td class="colsep0 rowsep0" align="char" char=".">147</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Cl (mL/min/kg)</td><td class="colsep0 rowsep0" align="left">72</td><td class="colsep0 rowsep0" align="char" char=".">155</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>V</i><sub>dss</sub> (mL/kg)</td><td class="colsep0 rowsep0" align="left">12 426</td><td class="colsep0 rowsep0" align="char" char=".">32 877</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">AUC (min × ng/mL)</td><td class="colsep0 rowsep0" align="left">31 978</td><td class="colsep0 rowsep0" align="char" char=".">42 525</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>F</i> (%)</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="char" char=".">40</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t6fn1"><div class="footnote" id="t6fn1"><sup><sup>a</sup></sup><p class="last">PK parameters were calculated using PK solutions.</p></div></div></div><div class="NLM_p last">Taking into account its overall profile, <b>32b</b> was selected for further development studies aimed to elucidate the potential therapeutic applications of AC inhibition in cellular and in vivo model systems of relevant SL-mediated disorders, which will be described elsewhere in due course.</div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i17">Conclusions</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_72038" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_72038" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p last">Although <i>h</i>AC inhibition has been the focus of intense discovery in the last decade, only a very limited number of valuable candidates for in vivo experiments are available. The scope of this work was directed to solve this limitation. The design and synthesis of a series of substituted oxazol-2-one-3-carboxamide derivatives were presented, resulting in the identification of two initial hits, <b>8a</b> and <b>12a</b> as a novel and versatile class of <i>h</i>AC inhibitors. Preliminary results of the hit expansion around these new scaffolds in the three main <i>Regions A</i>, <i>B</i>, and <i>C</i> contributed to the definition of the pharmacophore necessary for target inhibition and directed the strategies for chemical optimization. Our medicinal chemistry efforts around the most promising 5-substituted oxazol-2-one-3-carboxamide series led to the identification of 5-[4-fluoro-2-(1-methyl-4-piperidyl)phenyl]-2-oxo-<i>N</i>-pentyl-oxazole-3-carboxamide (<b>32b</b>) as an optimized <i>h</i>AC inhibitor, structurally distinct from previous reported inhibitors, with good drug-like properties. Furthermore, <b>32b</b> showed target engagement in human neuroblastoma SH-SY5Y cells and desirable PK properties in mice, with good <i>F</i> % and significant exposures in plasma, after intravenous and oral administrations. Compound <b>32b</b> is a valuable lead that increases the arsenal of suitable <i>h</i>AC-targeting molecules, which can directly probe the link of <i>h</i>AC function to distinct physiological processes and investigate how the inhibition of its activity can provide health benefits under severe pathological conditions. The identification of novel <i>h</i>AC-modulating compounds, targeting active Cys143 with optimal drug-like properties, remains a challenging task and can be only achieved by a critical and balanced modulation of different parameters, whose objectives often clash during the chemical optimization process. Utilizing the recently reported crystal structures, we were able to dock our covalent inhibitors into the reactive site highlighting the basis for selectivity observed with <b>32b</b> for <i>h</i>AC compared to <i>h</i>NAAA. In addition, the modeling that was undertaken can guide future optimization of this lead series accelerating the field of research and contributing to the identification of additional novel and efficacious <i>h</i>AC inhibitors.</div></div><div id="sec5" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i18">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_74881" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_74881" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec5_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i19" class="anchor-spacer"></div><h3 class="article-section__title" id="_i19"> Chemicals, Materials, and Methods</h3><div class="NLM_p last">Solvents and reagents were obtained from commercial suppliers and were used without further purification. Automated column chromatography purifications were done using a Teledyne ISCO apparatus (CombiFlash Rf) with pre-packed silica gel or neutral alumina columns of different sizes (from 4 g until 120 g). Mixtures of increasing polarity of Cy and EtOAc or dichloromethane (DCM) and MeOH were used as eluents. Thin-layer chromatography (TLC) analyses were performed using Supelco silica gel on TLC Al foils 0.2 mm with a fluorescence indicator 254 nm. NMR experiments of all the intermediates and final compounds were run on a Bruker AVANCE III 400 system (400.13 MHz for <sup>1</sup>H, and 100.62 MHz for <sup>13</sup>C), equipped with a BBI probe and <i>Z</i>-gradient coil. Spectra were acquired at 300 K using DMSO-<i>d</i><sub>6</sub> or CDCl<sub>3</sub> as solvents. Chemical shifts for <sup>1</sup>H and <sup>13</sup>C spectra were recorded in parts per million (ppm) using the residual nondeuterated solvent as the internal standard (for DMSO-<i>d</i><sub>6</sub>: 2.50 ppm, <sup>1</sup>H; 39.52 ppm, <sup>13</sup>C; for CDCl<sub>3</sub>: 7.26 ppm, <sup>1</sup>H and 77.16 ppm, <sup>13</sup>C). Data are reported as follows: chemical shift (ppm), multiplicity (indicated as: bs, broad singlet; s, singlet; d, doublet; t, triplet; q, quartet; p, quintet, sx, sextet; m, multiplet; and combinations thereof), coupling constants (<i>J</i>) in Hertz (Hz), and integrated intensity. Quantitative <sup>1</sup>H NMR analyses of the freshly prepared 10 mM DMSO-<i>d</i><sub>6</sub> stock solutions (used for biological screenings) of the final compounds were performed using the PULCON method (pulse length-based concentration determination, Bruker software, topspin 3.0. References: (a) Wider, G.; Reires, L. <i>J. Am. Chem. Soc.</i><b>2006,</b><i>128</i> (8)<i>,</i> 2571–2576; (b) Burton, I. W.; Quilliam, M. A.; Valter, J. A. <i>Anal. Chem.</i><b>2005,</b><i>77,</i> 3123–3131). UPLC/MS analyses of all the intermediates and final compounds were performed on a Waters Acquity UPLC/MS system consisting of single quadrupole detection (SQD) mass spectrometry (MS) equipped with an electrospray ionization (ESI) interface and a photodiode array (PDA) detector. The PDA range was 210–400 nm. Analyses were performed on an Acquity UPLC BEH C18 column (50 × 2.1 mm ID, particle size 1.7 μm) with a VanGuard BEH C18 pre-column (5 × 2.1 mm ID, particle size 1.7 μm). The mobile phase was 10 mM NH<sub>4</sub>OAc in H<sub>2</sub>O at pH 5 adjusted with AcOH (A) and 10 mM NH<sub>4</sub>OAc in CH<sub>3</sub>CN/H<sub>2</sub>O (95:5) at pH 5 (B). ESI in both positive and negative modes was used in the mass scan range 100–650 Da. Analyses were performed with <i>method A</i>, <i>B</i>, <i>C</i>, or <i>D</i>. <i>Method A</i>: Gradient: 5–95% B over 2.5 min. Flow rate 0.5 mL/min. Temperature 40 °C. <i>Method B</i>: Gradient: 50–100% B over 2.5 min. Flow rate 0.5 mL/min. Temperature 40 °C. <i>Method C</i>: Gradient: 0–100% B over 2.5 min. Flow rate 0.5 mL/min. Temperature 40 °C. <i>Method D</i>: Isocratic 55% B over 5 min. Flow rate 0.5 mL/min. Temperature 40 °C. UPLC/MS analyses of freshly prepared 10 mM DMSO-<i>d</i><sub>6</sub> stock solutions (used for biological screenings) of the final compounds were performed with <i>method E</i> or <i>method F</i>. DMSO-<i>d</i><sub>6</sub> stock solution (10 μL, 10 mM) was diluted 20-fold or 100-fold with a 1:1 CH<sub>3</sub>CN/H<sub>2</sub>O solution and directly analyzed. An Acquity UPLC BEH C18 (100 × 2.1 mm ID, particle size 1.7 μm) with a VanGuard BEH C18 pre-column (5 × 2.1 mm ID, particle size 1.7 μm). The mobile phase was either 10 mM NH<sub>4</sub>OAc in H<sub>2</sub>O at pH 5 adjusted with AcOH (A) and 10 mM NH<sub>4</sub>OAc in CH<sub>3</sub>CN/H<sub>2</sub>O (95:5) at pH 5 (B). ESI in positive and negative modes was applied in the mass scan range 100–650 Da. <i>Method E</i>: Gradient: 10–90% B over 6 min. Flow rate 0.5 mL/min. Temperature 40 °C. <i>Method F</i>: Gradient: 50–100% B over 6 min. Flow rate 0.5 mL/min. Temperature 40 °C. The detection wavelength (λ) was set at 215 nm for relative purity determination. <i>R</i><sub><i>t</i></sub> of the final compounds under <i>method E</i> or <i>F</i> UPLC/MS analytical conditions are reported in <a href="/doi/suppl/10.1021/acs.jmedchem.0c01561/suppl_file/jm0c01561_si_001.pdf" class="ext-link">Table S3</a>. Optical rotations were measured on a Rudolf Research Analytical Autopol II Automatic polarimeter using a sodium lamp (589 nm) as the light source, concentrations are expressed in g/100 mL using CHCl<sub>3</sub> as a solvent and a 1 dm cell. Accurate mass measurements were performed on a Synapt G2 Quadrupole-ToF Instrument (Waters, USA), equipped with an ESI ion source; the compounds were diluted to 50 μM in CH<sub>3</sub>CN/H<sub>2</sub>O and analyzed. Leucine Enkephalin (2 ng/mL) was used as the lock mass reference compound for spectra recalibration. All final compounds displayed ≥95% purity as determined by NMR and UPLC/MS analysis.</div></div><div id="sec5_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i20" class="anchor-spacer"></div><h3 class="article-section__title" id="_i20"> General Procedure for the Synthesis of 4-Substituted-oxazol-2-ones (Procedure A)</h3><div class="NLM_p last">To a mixture of the appropriate α-hydroxy ketone (1.0 equiv) and KNCO (2.0 equiv) in i-PrOH (0.2 M) was added dropwise AcOH (2.0 equiv) with stirring. The resulting suspension was heated at 70 °C for 3 h, then poured into an ice/H<sub>2</sub>O bath, and extracted with DCM or EtOAc. The organic phase was dried over Na<sub>2</sub>SO<sub>4</sub> and concentrated under reduced pressure. The crude was purified by column chromatography (SiO<sub>2</sub>), eluting with Cy/EtOAc or used as crude in the next step without further purification.</div></div><div id="sec5_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i21" class="anchor-spacer"></div><h3 class="article-section__title" id="_i21"> General Procedure for the Synthesis of 5-Substituted-oxazol-2-ones (Procedure B)</h3><div class="NLM_p last">Step 1: to a stirred solution of the appropriate α-bromoketone (1.0 equiv) and TZD (1.2 equiv) in DMF (0.1–1 M) was added K<sub>2</sub>CO<sub>3</sub> (1.5 equiv). The resulting mixture was stirred at rt for 1–2 h and then poured into an ice/H<sub>2</sub>O bath. In some cases, the resulting solid was filtered off and washed with H<sub>2</sub>O. In other cases, the aq phase was extracted with EtOAc, and the organic layer was washed with 5% aq LiCl and brine and dried over Na<sub>2</sub>SO<sub>4</sub>. After evaporation of the solvent, the crude was purified by flash chromatography (SiO<sub>2</sub>) eluting with Cy/EtOAc or used as a crude in the next step without further purification, as indicated in each case. Step 2: the corresponding intermediate from step 1 was dissolved in THF (0.1 M) and treated with LiOH (4.0 equiv) or <i>t</i>-BuOK (2.0–4.0 equiv) as indicated in each case. The resulting mixture was stirred at rt for 30–60 min and then poured into a cold aq AcOH solution (5.0–10.0 equiv). In some cases, the resulting solid was filtered off, washed with H<sub>2</sub>O, and used in the next step without further purification. Alternatively, the aq phase was extracted with EtOAc and the organic phase was dried over Na<sub>2</sub>SO<sub>4</sub>. After evaporation of the solvent, the crude was purified by flash chromatography (SiO<sub>2</sub> or Al<sub>2</sub>O<sub>3</sub>) eluting with Cy/EtOAc or DCM/MeOH or DCM/EtOH or used as a crude in the next step without further purification, as indicated in each case.</div></div><div id="sec5_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i22" class="anchor-spacer"></div><h3 class="article-section__title" id="_i22"> General Procedure for the Synthesis of 5-Phenyl-oxazolidin-2-ones (Procedure C)</h3><div class="NLM_p last">To a solution of (<i>S</i>) or (<i>R</i>)-2-amino-1-phenylethanol (1.0 equiv) in DCM (0.1 M) was added imidazole (0.5 equiv) followed by the addition of CDI (1.1 equiv). The reaction mixture was stirred at rt 16 h, then washed with H<sub>2</sub>O, and dried over Na<sub>2</sub>SO<sub>4</sub>. After evaporation of the solvent, the crude was purified by flash chromatography (SiO<sub>2</sub>) eluting with DCM/MeOH, as indicated in each case.</div></div><div id="sec5_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i23" class="anchor-spacer"></div><h3 class="article-section__title" id="_i23"> General Procedure for the Synthesis of Carboxamides (Procedure D)</h3><div class="NLM_p last"><i>Method A</i>: to a stirred solution of the appropriate oxazol-2-one, or oxazolidin-2-one, (1.0 equiv) in CH<sub>3</sub>CN, or pyridine, or DMF (0.2 M) were added DMAP (0.1–1.1 equiv), or Et<sub>3</sub>N (4.0 equiv), and the appropriate isocyanate (1.1–2.0 equiv). The resulting solution was stirred at rt (or at 50 °C, as indicated in each case) for 3–16 h, then diluted with EtOAc, washed with sat. aq NH<sub>4</sub>Cl solution and brine, and dried over Na<sub>2</sub>SO<sub>4</sub>. After evaporation of the solvent, the crude was purified by column chromatography (SiO<sub>2</sub> or Al<sub>2</sub>O<sub>3</sub>), eluting with Cy/EtOAc or DCM/MeOH, as indicated in each case. <i>Method B</i>: To a stirred solution of Boc<sub>2</sub>O (2.0 equiv) in CH<sub>3</sub>CN (0.4 M) were added DMAP (2.0 equiv) and the appropriate amine (1.1–2.0 equiv). The resulting solution was stirred at rt for 10 min then the appropriate oxazol-2-one derivative (1.0 equiv) was added, and the mixture was stirred at rt for 1–3 h. After evaporation of the solvent, the crude was purified by flash chromatography (SiO<sub>2</sub>) eluting with Cy/EtOAc or DCM/MeOH, as indicated in each case. <i>Method C</i>: To a stirred solution of triphosgene (0.33 equiv) in dry DCM (0.2 M), a solution of the appropriate amine (1.0 equiv) and Et<sub>3</sub>N, or DIPEA, (2.0 equiv) in DCM (0.2 M) was added at −15 °C. The resulting mixture was stirred at rt for 30 min under a N<sub>2</sub> atmosphere and then added to a solution of the appropriate oxazol-2-one (0.33 equiv) and Et<sub>3</sub>N, or DIPEA, (1.0 equiv) in DCM (0.2 M). The reaction mixture was stirred under a N<sub>2</sub> atmosphere at rt for 3–12 h, then diluted with DCM, washed with sat. aq NH<sub>4</sub>Cl solution and brine, and dried over Na<sub>2</sub>SO<sub>4</sub>. After evaporation of the solvent, the crude was purified by column chromatography (SiO<sub>2</sub>), eluting with Cy/EtOAc, or DCM/MeOH, as indicated in each case.</div></div><div id="sec5_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i24" class="anchor-spacer"></div><h3 class="article-section__title" id="_i24"> General Procedure for Palladium-Catalyzed Cross-Coupling Reaction (Procedure E)</h3><div class="NLM_p last">To a solution of the appropriate phenyl bromide (1.0 equiv) in dry 1,4-dioxane (0.1 M, previously degassed under a nitrogen atmosphere), <b>19</b> (1.1 equiv) was added followed by the addition of Pd(PPh<sub>3</sub>)<sub>4</sub> (0.05 equiv) and Na<sub>2</sub>CO<sub>3</sub> (2.2 equiv, 2 M aq solution). The suspension was stirred at reflux on, cooled to rt, and then diluted with EtOAc and filtered through a pad of celite. The filtrate was concentrated under reduced pressure, diluted with EtOAc, washed with sat. aq NH<sub>4</sub>Cl solution and brine, and dried over Na<sub>2</sub>SO<sub>4</sub>. After evaporation of the solvent, the crude was purified by flash chromatography (SiO<sub>2</sub>), eluting with Cy/EtOAc, as indicated in each case.</div></div><div id="sec5_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i25" class="anchor-spacer"></div><h3 class="article-section__title" id="_i25"> General Procedure for Catalytic Hydrogenation Reaction (Procedure F)</h3><div class="NLM_p last"><i>Method A</i>: To a suspension of the appropriate unsaturated intermediate (1.0 equiv) in EtOH (0.1 M) were added 10% Pd/C (0.1 equiv) and cyclohexene (20.0 equiv,) and the mixture was stirred at 60 °C until disappearance of the starting material, as indicated by UPLC/MS analysis. The suspension was filtered through a pad of celite, and the filtrate was quickly evaporated under reduced pressure. The crude was purified by flash chromatography (SiO<sub>2</sub>), eluting with Cy/EtOAc or used in the next step without further purification, as indicated in each case. <i>Method B</i>: To a suspension of the appropriate unsaturated intermediate (1.0 equiv) in MeOH (0.1 M) were added 20% Pd(OH)<sub>2</sub> on carbon (10% wt) and HCO<sub>2</sub>NH<sub>4</sub> (7.0 equiv), and the mixture was stirred at 60 °C for 4 h. The suspension was filtered through a pad of celite, and the filtrate was quickly evaporated under reduced pressure. The crude was purified by flash chromatography (SiO<sub>2</sub>), eluting with Cy/EtOAc, or used in the next step without further purification, as indicated in each case.</div></div><div id="sec5_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i26" class="anchor-spacer"></div><h3 class="article-section__title" id="_i26"> General Procedure for <i>N</i>-Boc Removal (Procedure G)</h3><div class="NLM_p last">To a suspension of the appropriate <i>N</i>-Boc protected intermediate (1.0 equiv) in 1,4-dioxane (0.1 M) was added HCl (30.0 equiv, 4 M in 1,4-dioxane), and the reaction mixture was stirred at rt for 2 h. After evaporation of the solvent, the crude was triturated with Et<sub>2</sub>O, or used as a crude, in the next step without further purification.</div></div><div id="sec5_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i27" class="anchor-spacer"></div><h3 class="article-section__title" id="_i27"> General Procedure for Reductive Amination Reaction (Procedure H)</h3><div class="NLM_p">To a solution of the appropriate substituted piperidine intermediate (1.0 equiv) in CH<sub>3</sub>CN (0.1 M) were added 37% aq solutions of HCHO (2.0–5.0 equiv), AcOH (2.0 equiv), and NaBH(OAc)<sub>3</sub> (3.0 equiv). The mixture was stirred at rt for 1 h. Then, the reaction mixture was poured into a saturated aqueous NaHCO<sub>3</sub> solution and extracted with EtOAc. The organic phase was washed with brine and dried over Na<sub>2</sub>SO<sub>4</sub>. After evaporation of the solvent, the crude was purified by flash chromatography (SiO<sub>2</sub>) eluting with DCM/MeOH, or used as a crude, in the next step without further purification, as indicated in each case.</div><div id="sec5_9_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i28" class="anchor-spacer"></div><h4 class="article-section__title" id="_i28"> Synthesis of 4-Phenyl-3<i>H</i>-oxazol-2-one (<b>7a</b>)</h4><div class="NLM_p last">Compound <b>7a</b> was prepared according to general procedure A using <b>6a</b> (1.360 g, 10.00 mmol). The crude was purified by column chromatography (SiO<sub>2</sub>), eluting with Cy/EtOAc (4:1) to afford <b>7a</b> as a yellow solid (0.858 g, 53%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 11.34 (bs, 1H), 7.68 (d, <i>J</i> = 1.2 Hz, 1H), 7.62–7.53 (m, 2H), 7.49–7.40 (m, 2H), 7.39–7.29 (m, 1H). UPLC/MS (<i>method A</i>): <i>R</i><sub><i>t</i></sub> 1.48 min. MS (ES): C<sub>9</sub>H<sub>7</sub>NO<sub>2</sub> requires, 161; found, 162 [M + H]<sup>+</sup>, 160 [M – H]<sup>−</sup>.</div></div><div id="sec5_9_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i29" class="anchor-spacer"></div><h4 class="article-section__title" id="_i29"> Synthesis of 5-Methyl-4-phenyl-3<i>H</i>-oxazol-2-one (<b>7b</b>)</h4><div class="NLM_p last">Compound <b>7b</b> was prepared according to general procedure A using <b>6b</b> (0.350 g, 2.33 mmol). The crude was used in the next step without further purification. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 9.39 (bs, 1H), 7.48–7.41 (m, 2H), 7.40–7.32 (m, 3H), 2.32 (s, 3H). UPLC/MS (<i>method A</i>): <i>R</i><sub><i>t</i></sub> 1.84 min. MS (ES): C<sub>10</sub>H<sub>9</sub>NO<sub>2</sub> requires, 175; found, 176 [M + H]<sup>+</sup>, 174 [M – H]<sup>−</sup>.</div></div><div id="sec5_9_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i30" class="anchor-spacer"></div><h4 class="article-section__title" id="_i30"> Synthesis of 4-(4-Chlorophenyl)-3<i>H</i>-oxazol-2-one (<b>7c</b>)</h4><div class="NLM_p last">Compound <b>7c</b> was prepared according to general procedure A using <b>6c</b> (0.241 g, 1.41 mmol). The crude was purified by column chromatography (SiO<sub>2</sub>), eluting with Cy/EtOAc (9:1), to afford <b>7c</b> as a yellow solid (0.10 g, 36%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 9.61 (bs, 1H), 7.42 (d, <i>J</i> = 8.5 Hz, 2H), 7.33 (d, <i>J</i> = 8.5 Hz, 2H), 7.11–7.08 (m, 1H). UPLC/MS (<i>method A</i>): <i>R</i><sub><i>t</i></sub> 1.71 min. MS (ES): C<sub>9</sub>H<sub>6</sub>ClNO<sub>2</sub> requires, 195; found, 196 [M + H]<sup>+</sup>, 194 [M – H]<sup>−</sup>.</div></div><div id="sec5_9_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i31" class="anchor-spacer"></div><h4 class="article-section__title" id="_i31"> Synthesis of 2-Oxo-4-phenyl-<i>N</i>-(4-phenylbutyl)oxazole-3-carboxamide (<b>8a</b>)</h4><div class="NLM_p last">Compound <b>8a</b> was prepared according to general procedure D (<i>method A</i>) using <b>7a</b> (0.161 g, 1.00 mmol), DMAP (0.012 g, 0.10 mmol), and 4-phenylbutyl isocyanate (0.350 g, 2.00 mmol) in CH<sub>3</sub>CN. The crude was purified by column chromatography (SiO<sub>2</sub>), eluting with Cy/EtOAc (9:1), to afford <b>8a</b> as a white solid (0.243 g, 72%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 8.10 (bs, 1H), 7.56–7.34 (m, 5H), 7.34–7.27 (m, overlapped with CDCl<sub>3</sub> signal, 2H), 7.26–7.11 (m, 3H), 6.75 (s, 1H), 3.42–3.26 (m, 2H), 2.63 (t, <i>J</i> = 7.2 Hz, 2H), 1.78–1.60 (m, 4H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>): δ 154.57, 148.99, 142.09, 129.36, 129.00, 128.85, 128.53, 128.50, 128.14, 127.43, 125.99 (2C), 40.28, 35.57, 29.12, 28.68. UPLC/MS (<i>method A</i>): <i>R</i><sub><i>t</i></sub> 2.55 min. MS (ES): C<sub>20</sub>H<sub>20</sub>N<sub>2</sub>O<sub>3</sub> requires, 336; found, 337 [M + H]<sup>+</sup>. HRMS: C<sub>20</sub>H<sub>20</sub>N<sub>2</sub>O<sub>3</sub> [M + H]<sup>+</sup> calcd 337.1552; measured, 337.1549, Δppm −0.9.</div></div><div id="sec5_9_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i32" class="anchor-spacer"></div><h4 class="article-section__title" id="_i32"> Synthesis of 2-Oxo-<i>N</i>-pentyl-4-phenyl-oxazole-3-carboxamide (<b>8b</b>)</h4><div class="NLM_p last">Compound <b>8b</b> was prepared according to general procedure D (<i>method A</i>) using <b>7a</b> (0.161 g, 1.00 mmol), DMAP (0.012 g, 0.10 mmol), and <i>n</i>-pentyl isocyanate (0.170 g, 1.50 mmol) in CH<sub>3</sub>CN. The crude was purified by column chromatography (SiO<sub>2</sub>), eluting with Cy/EtOAc (9:1), to afford <b>8b</b> as yellow oil (0.225 g, 82%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 8.09 (bs, 1H), 7.45–7.32 (m, 5H), 6.74 (s, 1H), 3.34–3.23 (m, 2H), 1.64–1.49 (m, overlapped with a H<sub>2</sub>O signal, 2H), 1.40–1.23 (m, 4H), 0.91 (t, <i>J</i> = 6.8 Hz, 3H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>): δ 154.57, 148.94, 129.33, 128.97, 128.85, 128.12, 127.45, 125.80, 40.45, 29.16, 29.08, 22.42, 14.09. UPLC/MS (<i>method A</i>): <i>R</i><sub><i>t</i></sub> 2.40 min. MS (ES): C<sub>15</sub>H<sub>18</sub>N<sub>2</sub>O<sub>3</sub> requires, 274; found, 275 [M + H]<sup>+</sup>. HRMS: C<sub>15</sub>H<sub>18</sub>N<sub>2</sub>O<sub>3</sub>Na [M + Na]<sup>+</sup> calcd 297.1215; measured, 297.1210, Δppm −1.7.</div></div><div id="sec5_9_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i33" class="anchor-spacer"></div><h4 class="article-section__title" id="_i33"> Synthesis of 5-Methyl-2-oxo-4-phenyl-<i>N</i>-(4-phenylbutyl)oxazole-3-carboxamide (<b>8c</b>)</h4><div class="NLM_p last">Compound <b>8c</b> was prepared according to general procedure D (<i>method A</i>) using <b>7b</b> (0.130 g, 0.74 mmol), DMAP (0.099 g, 0.81 mmol), and 4-phenylbutyl isocyanate (0.142 g, 0.81 mmol) in pyridine. The crude was purified by column chromatography (SiO<sub>2</sub>), eluting with Cy/EtOAc (4:1), to afford <b>8c</b> as a white solid (0.040 g, 15%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 8.09 (t, <i>J</i> = 4.4 Hz, 1H), 7.42–7.37 (m, 3H), 7.33–7.24 (m, overlapped with CDCl<sub>3</sub> signal, 4H), 7.21–7.12 (m, 3H), 3.34–3.23 (m, 2H), 2.61 (t, <i>J</i> = 7.4 Hz, 2H), 2.05 (s, 3H), 1.71–1.56 (m, overlapped with H<sub>2</sub>O signal, 4H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>): δ 149.26, 142.13, 135.35, 131.21, 129.77, 129.14, 128.87, 128.53, 128.47, 128.11, 126.59, 125.95, 40.16, 35.58, 29.16, 28.69, 10.19. UPLC/MS (<i>method A</i>): <i>R</i><sub><i>t</i></sub> 2.71 min. MS (ES): C<sub>21</sub>H<sub>22</sub>N<sub>2</sub>O<sub>3</sub> requires, 350; found, 351 [M + H]<sup>+</sup>. HRMS: C<sub>21</sub>H<sub>22</sub>N<sub>2</sub>O<sub>3</sub>Na [M + Na]<sup>+</sup> calcd 373.1528; measured, 373.1523, Δppm −1.3.</div></div><div id="sec5_9_7" class="NLM_sec NLM_sec_level_3"><div id="ac_i34" class="anchor-spacer"></div><h4 class="article-section__title" id="_i34"> Synthesis of 4-(4-Chlorophenyl)-2-oxo-<i>N</i>-(4-phenylbutyl)oxazole-3-carboxamide (<b>8d</b>)</h4><div class="NLM_p last">Compound <b>8d</b> was prepared according to general procedure D (<i>method A</i>) using <b>7c</b> (0.100 g, 0.51 mmol), DMAP (0.068 g, 0.56 mmol), and 4-phenylbutyl isocyanate (0.098 g, 0.56 mmol) in pyridine. The crude was purified by column chromatography (SiO<sub>2</sub>), eluting with Cy/EtOAc (95:5), to afford <b>8d</b> as yellow oil (0.040 g, 21%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 8.10 (t, <i>J</i> = 5.2 Hz, 1H), 7.40–7.34 (m, 2H), 7.32–7.26 (m, overlapped with CDCl<sub>3</sub> signal, 4H), 7.22–7.12 (m, 3H), 6.75 (s, 1H), 3.41–3.23 (m, 2H), 2.63 (t, <i>J</i> = 7.3 Hz, 2H), 1.90–1.49 (m, 4H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>): δ 154.33, 148.93, 142.02, 135.54, 130.32, 128.50 (2C), 128.43 (3C), 126.00, 125.88, 40.29, 35.54, 29.07, 28.65. UPLC/MS (<i>method A</i>): <i>R</i><sub><i>t</i></sub> 2.71 min. MS (ES): C<sub>20</sub>H<sub>19</sub>ClN<sub>2</sub>O<sub>3</sub> requires, 370; found, 371 [M + H]<sup>+</sup>. HRMS: C<sub>20</sub>H<sub>19</sub>ClN<sub>2</sub>O<sub>3</sub> [M + Na]<sup>+</sup> calcd 393.0982; measured, 393.0973, Δppm −2.3.</div></div><div id="sec5_9_8" class="NLM_sec NLM_sec_level_3"><div id="ac_i35" class="anchor-spacer"></div><h4 class="article-section__title" id="_i35"> Synthesis of 3-Phenacylthiazolidine-2,4-dione (<b>10a</b>)</h4><div class="NLM_p last">Compound <b>10a</b> was prepared according to general procedure B, Step 1, using <b>9a</b> (1.990 g, 10.00 mmol). The crude was used in Step 2 without further purification. UPLC/MS (<i>method A</i>): <i>R</i><sub><i>t</i></sub> 1.69 min. MS (ES): C<sub>11</sub>H<sub>9</sub>NO<sub>3</sub>S requires, 235; found, 234 [M – H]<sup>−</sup>.</div></div><div id="sec5_9_9" class="NLM_sec NLM_sec_level_3"><div id="ac_i36" class="anchor-spacer"></div><h4 class="article-section__title" id="_i36"> Synthesis of 3-(1-Methyl-2-oxo-2-phenyl-ethyl)thiazolidine-2,4-dione (<b>10b</b>)</h4><div class="NLM_p last">Compound <b>10b</b> was prepared according to general procedure B, Step 1, using <b>9b</b> (0.500 g, 2.35 mmol). The crude was purified by column chromatography (SiO<sub>2</sub>), eluting with Cy/EtOAc (4:1), to afford <b>10b</b> as a white solid (0.550 g, 94%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 7.75–7.68 (m, 2H), 7.58–7.52 (m, 1H), 7.47–7.41 (m, 2H), 5.55 (q, <i>J</i> = 7.0 Hz, 1H), 3.90 (d, <i>J</i> = 17.5 Hz, 1H), 3.82 (d, <i>J</i> = 17.5 Hz, 1H), 1.65 (d, <i>J</i> = 7.0 Hz, 3H). UPLC/MS (<i>method A</i>): <i>R</i><sub><i>t</i></sub> 1.83 min. MS (ES): C<sub>12</sub>H<sub>11</sub>NO<sub>3</sub>S requires, 249; found, 250 [M + H]<sup>+</sup>.</div></div><div id="sec5_9_10" class="NLM_sec NLM_sec_level_3"><div id="ac_i37" class="anchor-spacer"></div><h4 class="article-section__title" id="_i37"> Synthesis of 3-[2-(4-Chlorophenyl)-2-oxo-ethyl]thiazolidine-2,4-dione (<b>10c</b>)</h4><div class="NLM_p last">Compound <b>10c</b> was prepared according to general procedure B, Step 1, using <b>9c</b> (1.170 g, 5.00 mmol). The crude was used in Step 2 without further purification. UPLC/MS (<i>method A</i>): <i>R</i><sub><i>t</i></sub> 2.01 min. MS (ES): C<sub>11</sub>H<sub>8</sub>ClNO<sub>3</sub>S requires, 269; found, 268 [M – H]<sup>−</sup>.</div></div><div id="sec5_9_11" class="NLM_sec NLM_sec_level_3"><div id="ac_i38" class="anchor-spacer"></div><h4 class="article-section__title" id="_i38"> Synthesis of 3-[2-(4-Fluorophenyl)-2-oxo-ethyl]thiazolidine-2,4-dione (<b>10d</b>)</h4><div class="NLM_p last">Compound <b>10d</b> was prepared according to general procedure B, Step 1, using <b>9d</b> (2.170 g, 10.00 mmol). The crude was used in Step 2 without further purification. UPLC/MS (<i>method A</i>): <i>R</i><sub><i>t</i></sub> 1.81 min. MS (ES): C<sub>11</sub>H<sub>8</sub>FNO<sub>3</sub>S requires, 253; found, 254 [M + H]<sup>+</sup>, 252 [M – H]<sup>−</sup>.</div></div><div id="sec5_9_12" class="NLM_sec NLM_sec_level_3"><div id="ac_i39" class="anchor-spacer"></div><h4 class="article-section__title" id="_i39"> Synthesis of 3-[2-(4-Methoxyphenyl)-2-oxo-ethyl]thiazolidine-2,4-dione (<b>10e</b>)</h4><div class="NLM_p last">Compound <b>10e</b> was prepared according to general procedure B, Step 1, using <b>9e</b> (2.290 g, 10.00 mmol). The crude was used in Step 2 without further purification. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 8.13–7.92 (m, 2H), 7.14–7.05 (m, 2H), 5.06 (s, 2H), 4.39 (s, 2H), 3.87 (s, 3H). UPLC/MS (<i>method A</i>): <i>R</i><sub><i>t</i></sub> 1.78 min. MS (ES): C<sub>12</sub>H<sub>11</sub>NO<sub>4</sub>S requires, 265; found, 266 [M + H]<sup>+</sup>, 264 [M – H]<sup>−</sup>.</div></div><div id="sec5_9_13" class="NLM_sec NLM_sec_level_3"><div id="ac_i40" class="anchor-spacer"></div><h4 class="article-section__title" id="_i40"> Synthesis of 3-[2-(3-Methoxyphenyl)-2-oxo-ethyl]thiazolidine-2,4-dione (<b>10f</b>)</h4><div class="NLM_p last">Compound <b>10f</b> was prepared according to general procedure B, Step 1, using <b>9f</b> (1.260 g, 5.50 mmol). The crude was used in Step 2 without further purification. UPLC/MS (<i>method A</i>): <i>R</i><sub><i>t</i></sub> 1.83 min. MS (ES): C<sub>12</sub>H<sub>11</sub>NO<sub>4</sub>S requires, 265; found, 266 [M + H]<sup>+</sup>, 264 [M – H]<sup>−</sup>.</div></div><div id="sec5_9_14" class="NLM_sec NLM_sec_level_3"><div id="ac_i41" class="anchor-spacer"></div><h4 class="article-section__title" id="_i41"> Synthesis 3-[2-(2-Methoxyphenyl)-2-oxo-ethyl]thiazolidine-2,4-dione (<b>10g</b>)</h4><div class="NLM_p last">Compound <b>10g</b> was prepared according to general procedure B, Step 1, using <b>9g</b> (0.500 g, 2.18 mmol). The crude was used in Step 2 without further purification. UPLC/MS (<i>method A</i>): <i>R</i><sub><i>t</i></sub> 1.85 min. MS (ES): C<sub>12</sub>H<sub>11</sub>NO<sub>4</sub>S requires, 265; found, 266 [M + H]<sup>+</sup>, 264 [M – H]<sup>−</sup>.</div></div><div id="sec5_9_15" class="NLM_sec NLM_sec_level_3"><div id="ac_i42" class="anchor-spacer"></div><h4 class="article-section__title" id="_i42"> Synthesis of 3-[2-(4-Fluoro-3-methoxy-phenyl)-2-oxo-ethyl]thiazolidine-2,4-dione (<b>10h</b>)</h4><div class="NLM_p last">Compound <b>10h</b> was prepared according to general procedure B, Step 1, using <b>9h</b> (0.250 g, 1.01 mmol). The crude was used in Step 2 without further purification. UPLC/MS (<i>method A</i>): <i>R</i><sub><i>t</i></sub> 1.85 min. MS (ES): C<sub>12</sub>H<sub>10</sub>FNO<sub>4</sub>S requires, 283; found, 284 [M + H]<sup>+</sup>, 282 [M – H]<sup>−</sup>.</div></div><div id="sec5_9_16" class="NLM_sec NLM_sec_level_3"><div id="ac_i43" class="anchor-spacer"></div><h4 class="article-section__title" id="_i43"> Synthesis of 3-[2-Oxo-2-(2-pyridyl)ethyl]thiazolidine-2,4-dione (<b>10i</b>)</h4><div class="NLM_p last">Compound <b>10i</b> was prepared according to general procedure B, Step 1, using <b>9i</b> (0.400 g, 2.00 mmol). The crude was used in Step 2 without further purification. UPLC/MS (<i>method A</i>): <i>R</i><sub><i>t</i></sub> 1.38 min. MS (ES): C<sub>10</sub>H<sub>8</sub>N<sub>2</sub>O<sub>3</sub>S requires, 236; found, 237 [M + H]<sup>+</sup>.</div></div><div id="sec5_9_17" class="NLM_sec NLM_sec_level_3"><div id="ac_i44" class="anchor-spacer"></div><h4 class="article-section__title" id="_i44"> Synthesis of 3-[2-Oxo-2-(3-pyridyl)ethyl]thiazolidine-2,4-dione (<b>10j</b>)</h4><div class="NLM_p last">Compound <b>10j</b> was prepared according to general procedure B, Step 1, using <b>9j</b> (2.000 g, 10.00 mmol). The crude was used in Step 2 without further purification. UPLC/MS (<i>method A</i>): <i>R</i><sub><i>t</i></sub> 1.21 min. MS (ES): C<sub>10</sub>H<sub>8</sub>N<sub>2</sub>O<sub>3</sub>S requires, 236; found, 237 [M + H]<sup>+</sup>.</div></div><div id="sec5_9_18" class="NLM_sec NLM_sec_level_3"><div id="ac_i45" class="anchor-spacer"></div><h4 class="article-section__title" id="_i45"> Synthesis of 3-[2-Oxo-2-(4-pyridyl)ethyl]thiazolidine-2,4-dione (<b>10k</b>)</h4><div class="NLM_p last">Compound <b>10k</b> was prepared according to general procedure B, Step 1, using <b>9k</b> (1.000 g, 5.00 mmol). The crude was used in Step 2 without further purification. UPLC/MS (<i>method A</i>): <i>R</i><sub><i>t</i></sub> 1.15 min. MS (ES): C<sub>10</sub>H<sub>8</sub>N<sub>2</sub>O<sub>3</sub>S requires, 236; found, 237 [M + H]<sup>+</sup>.</div></div><div id="sec5_9_19" class="NLM_sec NLM_sec_level_3"><div id="ac_i46" class="anchor-spacer"></div><h4 class="article-section__title" id="_i46"> Synthesis of 3-(2-Oxo-2-pyrazin-2-yl-ethyl)thiazolidine-2,4-dione (<b>10l</b>)</h4><div class="NLM_p last">Compound <b>10l</b> was prepared according to general procedure B, Step 1, using <b>9l</b> (0.600 g, 2.99 mmol). The crude was used in Step 2 without further purification. UPLC/MS (<i>method A</i>): <i>R</i><sub><i>t</i></sub> 1.25 min. MS (ES): C<sub>9</sub>H<sub>7</sub>N<sub>3</sub>O<sub>3</sub>S requires, 237; found, 238 [M + H]<sup>+</sup>.</div></div><div id="sec5_9_20" class="NLM_sec NLM_sec_level_3"><div id="ac_i47" class="anchor-spacer"></div><h4 class="article-section__title" id="_i47"> Synthesis of 3-(2-Oxo-2-quinoxalin-2-yl-ethyl)thiazolidine-2,4-dione (<b>10m</b>)</h4><div class="NLM_p last">Compound <b>10m</b> was prepared according to general procedure B, Step 1, using <b>9m</b> (0.200 g, 0.80 mmol). The crude was used in Step 2 without further purification. UPLC/MS (<i>method A</i>): <i>R</i><sub><i>t</i></sub> 1.76 min. MS (ES): C<sub>13</sub>H<sub>9</sub>N<sub>3</sub>O<sub>3</sub>S requires, 287; found, 288 [M + H]<sup>+</sup>.</div></div><div id="sec5_9_21" class="NLM_sec NLM_sec_level_3"><div id="ac_i48" class="anchor-spacer"></div><h4 class="article-section__title" id="_i48"> Synthesis of 3-[2-(1-Methylindazol-3-yl)-2-oxo-ethyl]thiazolidine-2,4-dione (<b>10n</b>)</h4><div class="NLM_p last">Compound <b>10n</b> was prepared according to general procedure B, Step 1, using <b>9n</b> (0.120 g, 0.47 mmol). The crude was used in Step 2 without further purification. UPLC/MS (<i>method D</i>): <i>R</i><sub><i>t</i></sub> 1.08 min. MS (ES): C<sub>13</sub>H<sub>11</sub>N<sub>3</sub>O<sub>3</sub>S requires, 289; found, 290 [M + H]<sup>+</sup>, 288 [M – H]<sup>−</sup>.</div></div><div id="sec5_9_22" class="NLM_sec NLM_sec_level_3"><div id="ac_i49" class="anchor-spacer"></div><h4 class="article-section__title" id="_i49"> Synthesis of 3-(2-Oxo-2-thiazol-2-yl-ethyl)thiazolidine-2,4-dione (<b>10o</b>)</h4><div class="NLM_p last">Compound <b>10o</b> was prepared according to general procedure B, Step 1, using <b>9o</b> (0.500 g, 2.43 mmol). The crude was used in Step 2 without further purification. UPLC/MS (<i>method A</i>): <i>R</i><sub><i>t</i></sub> 1.47 min. MS (ES): C<sub>8</sub>H<sub>6</sub>N<sub>2</sub>O<sub>3</sub>S<sub>2</sub> requires, 242; found, 243 [M + H]<sup>+</sup>, 241 [M – H]<sup>−</sup>.</div></div><div id="sec5_9_23" class="NLM_sec NLM_sec_level_3"><div id="ac_i50" class="anchor-spacer"></div><h4 class="article-section__title" id="_i50"> Synthesis of 3-(2-Oxo-2-thiazol-4-yl-ethyl)thiazolidine-2,4-dione (<b>10p</b>)</h4><div class="NLM_p last">Compound <b>10p</b> was prepared according to general procedure B, Step 1, using <b>9p</b> (0.130 g, 0.63 mmol). The crude was used in Step 2 without further purification. UPLC/MS (<i>method A</i>): <i>R</i><sub><i>t</i></sub> 1.27 min. MS (ES): C<sub>8</sub>H<sub>6</sub>N<sub>2</sub>O<sub>3</sub>S<sub>2</sub> requires, 242; found, 243 [M + H]<sup>+</sup>, 241 [M – H]<sup>−</sup>.</div></div><div id="sec5_9_24" class="NLM_sec NLM_sec_level_3"><div id="ac_i51" class="anchor-spacer"></div><h4 class="article-section__title" id="_i51"> Synthesis of <i>tert</i>-Butyl 4-[2-(2,4-Dioxothiazolidin-3-yl)acetyl]piperidine-1-carboxylate (<b>10q</b>)</h4><div class="NLM_p last">Compound <b>10q</b> was prepared according to general procedure B, Step 1, using <b>9q</b> (0.310 g, 1.00 mmol). The crude was used in Step 2 without further purification. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 4.46 (s, 2H), 4.17–4.06 (m, 2H), 4.03 (s, 2H), 2.89–2.77 (m, 2H), 2.61 (tt, <i>J</i> = 11.2, 3.8 Hz, 1H), 1.92–1.81 (m, 2H), 1.61 (qd, <i>J</i> = 11.9, 4.3 Hz, 1H), 1.45 (s, 9H). UPLC/MS (<i>method A</i>): <i>R</i><sub><i>t</i></sub> 1.98 min. MS (ES): C<sub>15</sub>H<sub>22</sub>N<sub>2</sub>O<sub>5</sub>S requires, 342; found, 343 [M + H]<sup>+</sup>.</div></div><div id="sec5_9_25" class="NLM_sec NLM_sec_level_3"><div id="ac_i52" class="anchor-spacer"></div><h4 class="article-section__title" id="_i52"> Synthesis of 5-Phenyl-3<i>H</i>-oxazol-2-one (<b>11a</b>)</h4><div class="NLM_p last">Compound <b>11a</b> was prepared using <b>10a</b> (2.350 g, 10.00 mmol) and LiOH (0.960 g, 40.00 mmol), according to general procedure B, Step 2. After aq. work-up, the resulting solid was collected by filtration to afford <b>11a</b> as a white solid (1.20 g, 74%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 10.83 (bs, 1H), 7.53–7.46 (m, 3H), 7.44–7.36 (m, 2H), 7.31–7.23 (m, 1H). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>): δ 155.16, 138.51, 128.82, 128.80, 127.90, 127.43, 122.30, 122.27, 109.05. UPLC/MS (<i>method A</i>): <i>R</i><sub><i>t</i></sub> 1.50 min. MS (ES): C<sub>9</sub>H<sub>7</sub>NO<sub>2</sub> requires, 161; found, 162 [M + H]<sup>+</sup>, 160 [M – H]<sup>−</sup>. HRMS: C<sub>9</sub>H<sub>8</sub>NO<sub>2</sub> [M + H]<sup>+</sup> calcd 162.0555; measured, 162.0546, Δppm −5.0.</div></div><div id="sec5_9_26" class="NLM_sec NLM_sec_level_3"><div id="ac_i53" class="anchor-spacer"></div><h4 class="article-section__title" id="_i53"> Synthesis of 4-Methyl-5-phenyl-3<i>H</i>-oxazol-2-one (<b>11b</b>)</h4><div class="NLM_p last">Compound <b>11b</b> was prepared using <b>10b</b> (0.150 g, 0.60 mmol) and <i>t</i>-BuOK (0.130 g, 1.20 mmol), according to general procedure B, Step 2. The crude was purified by column chromatography (Al<sub>2</sub>O<sub>3</sub>), eluting with DCM/EtOH (9:1 to 6:4), to afford <b>11b</b> as a white solid (0.010 g, 10%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 9.30 (bs, 1H), 7.50–7.45 (m, 2H), 7.43–7.37 (m, 2H), 7.32–7.26 (m, overlapped with CDCl<sub>3</sub> signal, 1H), 2.31 (s, 3H). UPLC/MS (<i>method A</i>): <i>R</i><sub><i>t</i></sub> 1.61 min. MS (ES): C<sub>10</sub>H<sub>9</sub>NO<sub>2</sub> requires, 175; found, 176 [M + H]<sup>+</sup>, 174 [M – H]<sup>−</sup>.</div></div><div id="sec5_9_27" class="NLM_sec NLM_sec_level_3"><div id="ac_i54" class="anchor-spacer"></div><h4 class="article-section__title" id="_i54"> Synthesis of 5-(4-Chlorophenyl)-3<i>H</i>-oxazol-2-one (<b>11c</b>)</h4><div class="NLM_p last">Compound <b>11c</b> was prepared using <b>10c</b> (1.345 g, 5.00 mmol) and LiOH (0.479 g, 20.00 mmol), according to general procedure B, Step 2. After aq work-up, the resulting solid was collected by filtration to afford <b>11c</b> as a pink solid (0.975 g, quant.). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 10.82 (bs, 1H), 7.55 (s, 1H), 7.53–7.43 (m, 4H). UPLC/MS (<i>method A</i>): <i>R</i><sub><i>t</i></sub> 1.79 min. MS (ES): C<sub>9</sub>H<sub>6</sub>ClNO<sub>2</sub> requires, 195; found, 196 [M + H]<sup>+</sup>, 194 [M – H]<sup>−</sup></div></div><div id="sec5_9_28" class="NLM_sec NLM_sec_level_3"><div id="ac_i55" class="anchor-spacer"></div><h4 class="article-section__title" id="_i55"> Synthesis of 5-(4-Fluorophenyl)-3<i>H</i>-oxazol-2-one (<b>11d</b>)</h4><div class="NLM_p last">Compound <b>11d</b> was prepared using <b>10d</b> (2.530 g, 10.00 mmol) and LiOH (0.958 g, 40.00 mmol), according to general procedure B, Step 2. After aq work-up, the resulting solid was collected by filtration to afford <b>11d</b> as a white solid (0.300 g, 17%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 10.84 (bs, 1H), 7.59–7.49 (m, 2H), 7.46 (s, 1H), 7.30–7.20 (m, 2H). UPLC/MS (<i>method A</i>): <i>R</i><sub><i>t</i></sub> 1.60 min. MS (ES): C<sub>9</sub>H<sub>6</sub>FNO<sub>2</sub> requires, 179; found, 180 [M + H]<sup>+</sup>, 178 [M – H]<sup>−</sup>.</div></div><div id="sec5_9_29" class="NLM_sec NLM_sec_level_3"><div id="ac_i56" class="anchor-spacer"></div><h4 class="article-section__title" id="_i56"> Synthesis of 5-(4-Methoxyphenyl)-3<i>H</i>-oxazol-2-one (<b>11e</b>)</h4><div class="NLM_p last">Compound <b>11e</b> was prepared using <b>10e</b> (2.650 g, 10.00 mmol) and LiOH (0.958 g, 40.00 mmol), according to general procedure B, Step 2. After aq work-up, the resulting solid was collected by filtration to afford <b>11e</b> as a white solid (1.040 g, 54%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 10.62 (bs, 1H), 7.48–7.39 (m, 2H), 7.30 (s, 1H), 7.03–6.91 (m, 2H), 3.77 (s, 3H). UPLC/MS (<i>method A</i>): <i>R</i><sub><i>t</i></sub> 1.55 min. MS (ES): C<sub>10</sub>H<sub>9</sub>NO<sub>3</sub> requires, 191; found, 192 [M + H]<sup>+</sup>, 190 [M – H]<sup>−</sup>.</div></div><div id="sec5_9_30" class="NLM_sec NLM_sec_level_3"><div id="ac_i57" class="anchor-spacer"></div><h4 class="article-section__title" id="_i57"> Synthesis of 5-(3-Methoxyphenyl)-3<i>H</i>-oxazol-2-one (<b>11f</b>)</h4><div class="NLM_p last">Compound <b>11f</b> was prepared using <b>10f</b> (1.458 g, 5.50 mmol) and LiOH (0.527 g, 22.00 mmol), according to general procedure B, Step 2. After aq work-up, the resulting solid was collected by filtration to afford <b>11f</b> as a white solid (0.627 g, 60%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 10.85 (bs, 1H), 7.52 (s, 1H), 7.31 (t, <i>J</i> = 8.0 Hz, 1H), 7.19–6.95 (m, 2H), 6.85 (ddd, <i>J</i> = 8.4, 2.6, 0.9 Hz, 1H), 3.78 (s, 3H). UPLC/MS (<i>method A</i>): <i>R</i><sub><i>t</i></sub> 1.59 min. MS (ES): C<sub>10</sub>H<sub>9</sub>NO<sub>3</sub> requires, 191; found, 192 [M + H]<sup>+</sup>, 190 [M – H]<sup>−</sup>.</div></div><div id="sec5_9_31" class="NLM_sec NLM_sec_level_3"><div id="ac_i58" class="anchor-spacer"></div><h4 class="article-section__title" id="_i58"> Synthesis of 5-(2-Methoxyphenyl)-3<i>H</i>-oxazol-2-one (<b>11g</b>)</h4><div class="NLM_p last">Compound <b>11g</b> was prepared using <b>10g</b> (0.578 g, 2.18 mmol) and LiOH (0.210 g, 8.72 mmol), according to general procedure B, Step 2. After aq work-up, the resulting solid was collected by filtration to afford <b>11g</b> as a white solid (0.250 g, 60%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 9.56 (bs, 1H), 7.66 (dd, <i>J</i> = 7.7, 1.6 Hz, 1H), 7.31–7.21 (m, overlapped with CDCl<sub>3</sub> signal, 1H), 7.11 (d, <i>J</i> = 1.9 Hz, 1H), 7.02 (t, <i>J</i> = 7.6 Hz, 1H), 6.93 (d, <i>J</i> = 8.3 Hz, 1H), 3.93 (s, 3H). UPLC/MS (<i>method A</i>): <i>R</i><sub><i>t</i></sub> 1.65 min. MS (ES): C<sub>10</sub>H<sub>9</sub>NO<sub>3</sub> requires, 191; found, 192 [M + H]<sup>+</sup>, 190 [M – H]<sup>−</sup>.</div></div><div id="sec5_9_32" class="NLM_sec NLM_sec_level_3"><div id="ac_i59" class="anchor-spacer"></div><h4 class="article-section__title" id="_i59"> Synthesis of 5-(4-Fluoro-3-methoxy-phenyl)-3<i>H</i>-oxazol-2-one (<b>11h</b>)</h4><div class="NLM_p last">Compound <b>11h</b> was prepared using <b>10h</b> (0.286 g, 1.01 mmol) and LiOH (0.097 g, 4.04 mmol), according to general procedure B, Step 2. The crude was purified by flash chromatography (SiO<sub>2</sub>), eluting with DCM/MeOH (95:5), to afford <b>11h</b> as a yellow solid (0.055 g, 26%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 8.67 (bs, 1H), 7.13–7.04 (m, 2H), 7.04–6.97 (m, 1H), 6.78 (s, 1H), 3.93 (s, 3H). UPLC/MS (<i>method A</i>): <i>R</i><sub><i>t</i></sub> 1.61 min. MS (ES): C<sub>10</sub>H<sub>8</sub>FNO<sub>3</sub> requires, 209; found, 210 [M + H]<sup>+</sup>, 208 [M – H]<sup>−</sup>.</div></div><div id="sec5_9_33" class="NLM_sec NLM_sec_level_3"><div id="ac_i60" class="anchor-spacer"></div><h4 class="article-section__title" id="_i60"> Synthesis of 5-(2-Pyridyl)-3<i>H</i>-oxazol-2-one (<b>11i</b>)</h4><div class="NLM_p last">Compound <b>11i</b> was prepared using <b>10i</b> (0.472 g, 2.00 mmol) and LiOH (0.192 g, 8.00 mmol), according to general procedure B, Step 2. After aq work-up, the resulting solid was collected by filtration to afford <b>11i</b> as an orange solid (0.308 g, 93%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 8.56–8.49 (m, 1H), 7.82 (td, <i>J</i> = 7.8, 1.8 Hz, 1H), 7.55 (s, 1H), 7.47–7.42 (m, 1H), 7.34–7.19 (m, 1H). UPLC/MS (<i>method A</i>): <i>R</i><sub><i>t</i></sub> 1.02 min. MS (ES): C<sub>8</sub>H<sub>6</sub>N<sub>2</sub>O<sub>2</sub> requires, 162; found, 163 [M + H]<sup>+</sup>, 161 [M – H]<sup>−</sup>.</div></div><div id="sec5_9_34" class="NLM_sec NLM_sec_level_3"><div id="ac_i61" class="anchor-spacer"></div><h4 class="article-section__title" id="_i61"> Synthesis of 5-(3-Pyridyl)-3<i>H</i>-oxazol-2-one (<b>11j</b>)</h4><div class="NLM_p last">Compound <b>11j</b> was prepared using <b>10j</b> (2.360 g, 10.00 mmol) and LiOH (0.958 g, 40.00 mmol), according to general procedure B, Step 2. The crude was purified by flash chromatography (SiO<sub>2</sub>), eluting with DCM/MeOH (95:5), to afford <b>11j</b> as an orange solid (0.375 g, 23%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 8.78–8.74 (m, 1H), 8.55 (dd, <i>J</i> = 4.9, 1.7 Hz, 1H), 7.79 (dt, <i>J</i> = 8.0, 2.0 Hz, 1H), 7.34 (ddd, <i>J</i> = 8.2, 5.0, 0.8 Hz, 1H), 6.93 (d, <i>J</i> = 2.1 Hz, 1H). UPLC/MS (<i>method A</i>): <i>R</i><sub><i>t</i></sub> 1.00 min. MS (ES): C<sub>8</sub>H<sub>6</sub>N<sub>2</sub>O<sub>2</sub> requires, 162; found, 163 [M + H]<sup>+</sup>, 161 [M – H]<sup>−</sup>.</div></div><div id="sec5_9_35" class="NLM_sec NLM_sec_level_3"><div id="ac_i62" class="anchor-spacer"></div><h4 class="article-section__title" id="_i62"> Synthesis of 5-(4-Pyridyl)-3<i>H</i>-oxazol-2-one (<b>11k</b>)</h4><div class="NLM_p last">Compound <b>11k</b> was prepared using <b>10k</b> (1.180 g, 5.00 mmol) and LiOH (0.479 g, 20.00 mmol), according to general procedure B, Step 2. The crude was purified by flash chromatography (SiO<sub>2</sub>), eluting with DCM/MeOH (95:5), to afford <b>11k</b> as an orange solid (0.122 g, 15%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 11.18 (bs, 1H), 8.60–8.52 (m, 2H), 7.85 (s, 1H), 7.49–7.40 (m, 2H). UPLC/MS (<i>method A</i>): <i>R</i><sub><i>t</i></sub> 0.83 min. MS (ES): C<sub>8</sub>H<sub>6</sub>N<sub>2</sub>O<sub>2</sub> requires, 162; found, 163 [M + H]<sup>+</sup>, 161 [M – H]<sup>−</sup>.</div></div><div id="sec5_9_36" class="NLM_sec NLM_sec_level_3"><div id="ac_i63" class="anchor-spacer"></div><h4 class="article-section__title" id="_i63"> Synthesis of 5-Pyrazin-2-yl-3<i>H</i>-oxazol-2-one (<b>11l</b>)</h4><div class="NLM_p last">Compound <b>11l</b> was prepared using <b>10l</b> (0.709 g, 2.99 mmol) and LiOH (0.958 g, 40.00 mmol), according to general procedure B, Step 2. The crude was purified by flash chromatography (SiO<sub>2</sub>), eluting with DCM/MeOH (95:5), to afford <b>11l</b> as a brown solid (0.030 g, 6%). UPLC/MS (<i>method A</i>): <i>R</i><sub><i>t</i></sub> 0.86 min. MS (ES): C<sub>7</sub>H<sub>5</sub>N<sub>3</sub>O<sub>2</sub> requires, 163; found, 162 [M – H]<sup>−</sup>. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 8.94–8.88 (m, 1H), 8.64–8.60 (m, 1H), 8.55–8.52 (m, 1H), 8.27–7.87 (m, 1H).</div></div><div id="sec5_9_37" class="NLM_sec NLM_sec_level_3"><div id="ac_i64" class="anchor-spacer"></div><h4 class="article-section__title" id="_i64"> Synthesis of 5-Quinoxalin-2-yl-3<i>H</i>-oxazol-2-one (<b>11m</b>)</h4><div class="NLM_p last">Compound <b>11m</b> was prepared using <b>10m</b> (0.230 g, 0.80 mmol) and LiOH (0.077 g, 3.20 mmol), according to general procedure B, Step 2. After aq work-up, the resulting solid was collected by filtration to afford <b>11m</b> as an orange solid (0.158 g, 93%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 11.46 (bs, 1H), 9.17 (s, 1H), 8.18 (d, <i>J</i> = 2.3 Hz, 1H), 8.12–7.99 (m, 2H), 7.90–7.65 (m, 2H). UPLC/MS (<i>method A</i>): <i>R</i><sub><i>t</i></sub> 1.29 min. MS (ES): C<sub>11</sub>H<sub>7</sub>N<sub>3</sub>O<sub>2</sub> requires, 213; found, 214 [M + H]<sup>+</sup>, 212 [M – H]<sup>−</sup>.</div></div><div id="sec5_9_38" class="NLM_sec NLM_sec_level_3"><div id="ac_i65" class="anchor-spacer"></div><h4 class="article-section__title" id="_i65"> Synthesis of 5-(1-Methylindazol-3-yl)-3<i>H</i>-oxazol-2-one (<b>11n</b>)</h4><div class="NLM_p last">Compound <b>11n</b> was prepared using <b>10n</b> (0.136 g, 0.47 mmol) and LiOH (0.045 g, 1.88 mmol), according to general procedure B, Step 2. The crude was purified by flash chromatography (SiO<sub>2</sub>), eluting with DCM/MeOH (8:2), to afford <b>11n</b> as a yellow solid (0.050 g, 49%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 10.97 (bs, 1H), 7.97–7.92 (m, 1H), 7.70–7.64 (m, 1H), 7.59 (d, <i>J</i> = 2.2 Hz, 1H), 7.49–7.43 (m, 1H), 7.25–7.19 (m, 1H), 4.06 (s, 3H). UPLC/MS (<i>method D</i>): <i>R</i><sub><i>t</i></sub> 0.49 min. MS (ES): C<sub>11</sub>H<sub>9</sub>N<sub>3</sub>O<sub>2</sub> requires, 215; found, 216 [M + H]<sup>+</sup>, 214 [M – H]<sup>−</sup>.</div></div><div id="sec5_9_39" class="NLM_sec NLM_sec_level_3"><div id="ac_i66" class="anchor-spacer"></div><h4 class="article-section__title" id="_i66"> Synthesis of 5-Thiazol-2-yl-3<i>H</i>-oxazol-2-one (<b>11o</b>)</h4><div class="NLM_p last">Compound <b>11o</b> was prepared using <b>10o</b> (0.588 g, 2.43 mmol) and LiOH (0.233 g, 9.72 mmol), according to general procedure B, Step 2. After aq work-up, the resulting solid was collected by filtration to afford <b>11o</b> as a yellow solid (0.200 g, 49%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 11.29 (bs, 1H), 7.86 (d, <i>J</i> = 3.2 Hz, 1H), 7.73 (d, <i>J</i> = 3.2 Hz, 1H), 7.72–7.68 (m, 1H). UPLC/MS (<i>method A</i>): <i>R</i><sub><i>t</i></sub> 1.09 min. MS (ES): C<sub>6</sub>H<sub>4</sub>N<sub>2</sub>O<sub>2</sub>S requires, 168; found, 169 [M + H]<sup>+</sup>, 167 [M – H]<sup>−</sup>.</div></div><div id="sec5_9_40" class="NLM_sec NLM_sec_level_3"><div id="ac_i67" class="anchor-spacer"></div><h4 class="article-section__title" id="_i67"> Synthesis of 5-Thiazol-4-yl-3<i>H</i>-oxazol-2-one (<b>11p</b>)</h4><div class="NLM_p last">Compound <b>11p</b> was prepared using <b>10p</b> (0.152 g, 0.63 mmol) and LiOH (0.060 g, 2.52 mmol), according to general procedure B, Step 2. After aq work-up, the resulting solid was collected by filtration to afford <b>11p</b> as a brown solid (0.100 g, 94%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 10.92 (bs, 1H), 9.16 (d, <i>J</i> = 1.9 Hz, 1H), 7.68 (d, <i>J</i> = 1.9 Hz, 1H), 7.32 (s, 1H). UPLC/MS (<i>method A</i>): <i>R</i><sub><i>t</i></sub> 1.09 min. MS (ES): C<sub>6</sub>H<sub>4</sub>N<sub>2</sub>O<sub>2</sub>S requires, 168; found, 169 [M + H]<sup>+</sup>, 167 [M – H]<sup>−</sup>.</div></div><div id="sec5_9_41" class="NLM_sec NLM_sec_level_3"><div id="ac_i68" class="anchor-spacer"></div><h4 class="article-section__title" id="_i68"> Synthesis of <i>tert</i>-Butyl 4-(2-Oxo-3H-oxazol-5-yl)piperidine-1-carboxylate (<b>11q</b>)</h4><div class="NLM_p last">Compound <b>11q</b> was prepared using <b>10q</b> (0.300 g, 0.88 mmol) and <i>t</i>-BuOK (0.197 g, 1.75 mmol) in THF, according to general procedure B, Step 2. The crude was purified by column chromatography (SiO<sub>2</sub>), eluting with DCM/EtOAc (3:7 to 0:10), to afford <b>11q</b> as a pale yellow solid (0.091 g, 38%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 10.27 (bs, 1H), 6.58 (d, <i>J</i> = 1.4 Hz, 1H), 4.02–3.79 (m, 2H), 2.97–2.68 (m, 2H), 2.63–2.52 (m, overlapped with DMSO signal, 1H), 1.86–1.73 (m, 2H), 1.39 (s, 9H), 1.28 (qd, <i>J</i> = 12.1, 4.3 Hz, 2H). UPLC/MS (<i>method A</i>): <i>R</i><sub><i>t</i></sub> 1.72 min. MS (ES): C<sub>13</sub>H<sub>20</sub>N<sub>2</sub>O<sub>4</sub> requires, 268; found, 267 [M – H]<sup>−</sup>.</div></div><div id="sec5_9_42" class="NLM_sec NLM_sec_level_3"><div id="ac_i69" class="anchor-spacer"></div><h4 class="article-section__title" id="_i69"> Synthesis of 2-Oxo-5-phenyl-<i>N</i>-(4-phenylbutyl)oxazole-3-carboxamide (<b>12a</b>)</h4><div class="NLM_p last">Compound <b>12a</b> was prepared according to general procedure D (<i>method A</i>) using <b>11a</b> (0.161 g, 1.00 mmol), DMAP (0.012 g, 0.10 mmol), and 4-phenylbutyl isocyanate (0.350 g, 2.00 mmol) in CH<sub>3</sub>CN. The crude was purified by column chromatography (SiO<sub>2</sub>), eluting with Cy/EtOAc (9:1), to afford <b>12a</b> as a white solid (0.276 g, 82%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 7.95 (t, <i>J</i> = 5.7 Hz, 1H), 757–7.49 (m, 2H), 7.46 (s, 1H), 7.45–7.32 (m, 3H), 7.32–7.25 (m, overlapped with CDCl<sub>3</sub> signal, 2H), 7.22–7.15 (m, 3H), 3.49–3.35 (m, 2H), 2.67 (t, <i>J</i> = 7.2 Hz, 2H), 1.79–1.60 (m, 4H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>): δ 152.83, 148.59, 142.01, 139.77, 129.29, 129.12 (2C), 128.53, 126.41, 126.03, 123.72, 106.08, 40.44, 35.58, 29.21, 28.65. UPLC/MS (<i>method A</i>): <i>R</i><sub><i>t</i></sub> 2.74 min. MS (ES): C<sub>20</sub>H<sub>20</sub>N<sub>2</sub>O<sub>3</sub> requires, 336; found, 337 [M + H]<sup>+</sup>. HRMS: C<sub>20</sub>H<sub>20</sub>N<sub>2</sub>O<sub>3</sub>Na [M + Na]<sup>+</sup> calcd 359.1372; measured, 359.1366, Δppm −0.6.</div></div><div id="sec5_9_43" class="NLM_sec NLM_sec_level_3"><div id="ac_i70" class="anchor-spacer"></div><h4 class="article-section__title" id="_i70"> Synthesis of 2-Oxo-<i>N</i>-pentyl-5-phenyl-oxazole-3-carboxamide (<b>12b</b>)</h4><div class="NLM_p last">Compound <b>12b</b> was prepared according to general procedure D (<i>method B</i>) using <b>11a</b> (0.100 g, 0.62 mmol) and <i>n</i>-pentyl amine (0.059 g, 0.68 mmol). The crude was purified by column chromatography (SiO<sub>2</sub>), eluting with Cy/EtOAc (9:1), to afford <b>12b</b> as a white solid (0.107 g, 63%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 7.94 (bs, 1H), 7.56–7.49 (m, 2H), 7.47 (s, 1H), 7.45–7.38 (m, 2H), 7.38–7.32 (m, 1H), 3.45–3.33 (m, 2H), 1.68–1.51 (m, overlapped with H<sub>2</sub>O signal, 2H), 1.43–1.29 (m, 4H), 0.99–0.86 (m, 3H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>): δ 152.52, 148.24, 139.39, 128.92, 128.77, 126.11, 123.37, 105.79, 40.29, 28.96, 28.73, 22.11, 13.75. UPLC/MS (<i>method A</i>): <i>R</i><sub><i>t</i></sub> 2.62 min. MS (ES): C<sub>15</sub>H<sub>18</sub>N<sub>2</sub>O<sub>3</sub> requires, 274; found, 275 [M + H]<sup>+</sup>, 160 [M–CONH(CH<sub>2</sub>)<sub>4</sub>CH<sub>3</sub>]<sup>−</sup>. HRMS: C<sub>15</sub>H<sub>18</sub>N<sub>2</sub>O<sub>3</sub>Na [M + Na]<sup>+</sup> calcd 297.1215; measured, 297.1207, Δppm −2.7.</div></div><div id="sec5_9_44" class="NLM_sec NLM_sec_level_3"><div id="ac_i71" class="anchor-spacer"></div><h4 class="article-section__title" id="_i71"> Synthesis of <i>N</i>-(2-Ethoxyethyl)-2-oxo-5-phenyl-oxazole-3-carboxamide (<b>12c</b>)</h4><div class="NLM_p last">Compound <b>12c</b> was prepared according to general procedure D (<i>method B</i>) using <b>11a</b> (0.161 g, 1.00 mmol) and 2-ethoxyethyl amine (0.178 g, 2.00 mmol). The crude was purified by column chromatography (SiO<sub>2</sub>), eluting with Cy/EtOAc (8:2), to afford <b>12c</b> as a white solid (0.222 g, 80%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 8.21 (bs, 1H), 7.56–7.49 (m, 2H), 7.46 (s, 1H), 7.45–7.38 (m, 2H), 7.38–7.32 (m, 1H), 3.62–3.59 (m, 4H), 3.54 (q, <i>J</i> = 7.0 Hz, 2H), 1.23 (t, <i>J</i> = 7.0 Hz, 3H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>): δ 152.66, 148.72, 139.77, 129.27, 129.10, 126.41, 123.71, 106.03, 68.63, 66.78, 40.56, 15.23. UPLC/MS (<i>method A</i>): <i>R</i><sub><i>t</i></sub> 2.19 min. MS (ES): C<sub>14</sub>H<sub>16</sub>N<sub>2</sub>O<sub>4</sub> requires, 276; found, 277 [M + H]<sup>+</sup>, 275 [M – H]<sup>−</sup>, 160 [M–CONH(CH<sub>2</sub>)<sub>2</sub>OCH<sub>2</sub>CH<sub>3</sub>]<sup>−</sup>. HRMS: C<sub>14</sub>H<sub>16</sub>N<sub>2</sub>O<sub>4</sub> [M + H]<sup>+</sup> calcd 277.1188; measured, 277.1187, Δppm −0.4.</div></div><div id="sec5_9_45" class="NLM_sec NLM_sec_level_3"><div id="ac_i72" class="anchor-spacer"></div><h4 class="article-section__title" id="_i72"> Synthesis of <i>N</i>-(3-Methoxypropyl)-2-oxo-5-phenyl-oxazole-3-carboxamide (<b>12d</b>)</h4><div class="NLM_p last">Compound <b>12d</b> was prepared according to general procedure D (<i>method B</i>) using <b>11a</b> (0.100 g, 0.62 mmol) and 3-methoxypropyl amine (0.061 g, 0.68 mmol). The crude was purified by column chromatography (SiO<sub>2</sub>), eluting with DCM/MeOH (8:2), to afford <b>12d</b> as a white solid (0.082 g, 48%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 8.24 (bs, 1H), 7.56–7.49 (m, 2H), 7.46 (s, 1H), 7.45–7.38 (m, 2H), 7.38–7.32 (m, 1H), 3.56–3.47 (m, 4H), 3.38 (s, 3H), 1.89 (p, <i>J</i> = 6.2 Hz, 2H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>): δ 152.71, 148.59, 129.24, 129.11, 128.44, 126.48, 123.71, 106.13, 70.86, 58.94, 38.70, 29.29. UPLC/MS (<i>method A</i>): <i>R</i><sub><i>t</i></sub> 2.11 min. MS (ES): C<sub>14</sub>H<sub>16</sub>N<sub>2</sub>O<sub>4</sub> requires, 276; found, 277 [M + H]<sup>+</sup>, 160 [M–CONH(CH<sub>2</sub>)<sub>3</sub>OCH<sub>3</sub>]<sup>−</sup>. HRMS: C<sub>14</sub>H<sub>16</sub>N<sub>2</sub>O<sub>4</sub> [M + H]<sup>+</sup> calcd 277.1188; measured, 277.1183, Δppm −1.8.</div></div><div id="sec5_9_46" class="NLM_sec NLM_sec_level_3"><div id="ac_i73" class="anchor-spacer"></div><h4 class="article-section__title" id="_i73"> Synthesis of <i>N</i>-Isobutyl-2-oxo-5-phenyl-oxazole-3-carboxamide (<b>12e</b>)</h4><div class="NLM_p last">Compound <b>12e</b> was prepared according to general procedure D (<i>method C</i>) using <b>11a</b> (0.050 g, 0.31 mmol), 2-methylpropan-1-amine (0.069 g, 0.94 mmol), and DIPEA (0.243 g, 1.88 mmol). The crude was purified by column chromatography (SiO<sub>2</sub>), eluting with Cy/EtOAc (95:5), to afford <b>12e</b> as a white solid (0.061 g, 76%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 8.01 (t, <i>J</i> = 6.0 Hz, 1H), 7.55–7.49 (m, 2H), 7.47 (s, 1H), 7.45–7.38 (m, 2H), 7.38–7.32 (m, 1H), 3.23 (t, <i>J</i> = 6.4 Hz, 2H), 1.97–1.82 (m, 1H), 0.98 (d, <i>J</i> = 6.7 Hz, 6H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>): δ 152.87, 148.69, 139.71, 129.24, 129.08, 126.43, 123.69, 106.14, 47.87, 28.61, 20.10. UPLC/MS (<i>method A</i>): <i>R</i><sub><i>t</i></sub> 2.42 min. MS (ES): C<sub>14</sub>H<sub>16</sub>N<sub>2</sub>O<sub>3</sub> requires, 260; found, 261 [M + H]<sup>+</sup>, 160 [M–CONHCH<sub>2</sub>CH(CH<sub>3</sub>)<sub>2</sub>]<sup>−</sup>. HRMS: C<sub>14</sub>H<sub>16</sub>N<sub>2</sub>O<sub>3</sub>Na [M + Na]<sup>+</sup> calcd 283.1059; measured, 283.1049, Δppm −3.5.</div></div><div id="sec5_9_47" class="NLM_sec NLM_sec_level_3"><div id="ac_i74" class="anchor-spacer"></div><h4 class="article-section__title" id="_i74"> Synthesis of (±) 2-Oxo-5-phenyl-<i>N</i>-<i>s</i>-butyl-oxazole-3-carboxamide (<b>12f</b>)</h4><div class="NLM_p last">Compound <b>12f</b> was prepared according to general procedure D (<i>method B</i>) using <b>11a</b> (0.161 g, 1.00 mmol) and butan-2-amine (0.110 g, 1.50 mmol). The crude was purified by column chromatography (SiO<sub>2</sub>), eluting with Cy/EtOAc (95:5), to afford <b>12f</b> as a white solid (0.062 g, 24%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 7.78 (d, <i>J</i> = 7.5 Hz, 1H), 7.58–7.49 (m, 2H), 7.46 (s, 1H), 7.45–7.38 (m, 2H), 7.38–7.32 (m, 1H), 4.02–3.85 (m, 1H), 1.60 (q, <i>J</i> = 7.3 Hz, overlapped with H<sub>2</sub>O signal, 2H), 1.25 (d, <i>J</i> = 6.6 Hz, 3H), 0.97 (t, <i>J</i> = 7.4 Hz, 3H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>): δ 152.86, 148.00, 139.67, 129.24, 129.11, 126.48, 123.71, 106.13, 48.44, 29.63, 20.50, 10.40. UPLC/MS (<i>method A</i>): <i>R</i><sub><i>t</i></sub> 2.44 min. MS (ES): C<sub>14</sub>H<sub>16</sub>N<sub>2</sub>O<sub>3</sub> requires, 260; found, 261 [M + H]<sup>+</sup>. HRMS: C<sub>14</sub>H<sub>16</sub>N<sub>2</sub>O<sub>3</sub>Na [M + Na]<sup>+</sup> calcd 283.1059; measured, 283.1059, Δppm 0.0.</div></div><div id="sec5_9_48" class="NLM_sec NLM_sec_level_3"><div id="ac_i75" class="anchor-spacer"></div><h4 class="article-section__title" id="_i75"> Synthesis of 2-Oxo-<i>N</i>,5-diphenyl-oxazole-3-carboxamide (<b>12g</b>)</h4><div class="NLM_p last">Compound <b>12g</b> was prepared according to general procedure D (<i>method A</i>) using <b>11a</b> (0.050 g, 0.31 mmol), Et<sub>3</sub>N (0.125 g, 1.24 mmol), and phenyl isocyanate (0.046 g, 0.34 mmol) in CH<sub>3</sub>CN. The crude was purified by column chromatography (SiO<sub>2</sub>), eluting with Cy/EtOAc (95:5), to afford <b>12g</b> as a white solid (0.068 g, 78%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 9.95 (bs, 1H), 7.63–7.52 (m, 5H), 7.49–7.34 (m, 5H), 7.22–7.15 (m, 1H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>): δ 152.87, 145.86, 140.24, 136.43, 129.54, 129.39, 129.18, 126.17, 125.23, 123.85, 120.41, 105.83. UPLC/MS (<i>method B</i>): <i>R</i><sub><i>t</i></sub> 2.48 min. MS (ES): C<sub>16</sub>H<sub>12</sub>N<sub>2</sub>O<sub>3</sub> requires, 280; found, 160 [M–CONHPh]<sup>−</sup>. HRMS: C<sub>16</sub>H<sub>13</sub>N<sub>2</sub>O<sub>2</sub> [M + H]<sup>+</sup> calcd 281.0923; measured, 281.0926, Δppm 0.</div></div><div id="sec5_9_49" class="NLM_sec NLM_sec_level_3"><div id="ac_i76" class="anchor-spacer"></div><h4 class="article-section__title" id="_i76"> Synthesis of 4-Methyl-2-oxo-5-phenyl-<i>N</i>-(4-phenylbutyl)oxazole-3-carboxamide (<b>12h</b>)</h4><div class="NLM_p last">Compound <b>12h</b> was prepared according to general procedure D (<i>method A</i>) using <b>11b</b> (0.010 g, 0.057 mmol), DMAP (0.008 g, 0.06 mmol), and 4-phenylbutyl isocyanate (0.011 g, 0.06 mmol) in CH<sub>3</sub>CN. The crude was purified by column chromatography (Al<sub>2</sub>O<sub>3</sub>), eluting with Cy, to afford <b>12h</b> as a white solid (0.007 g, 35%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 8.33 (t, <i>J</i> = 5.3 Hz, 1H), 7.52–7.47 (m, 2H), 7.47–7.41 (m, 2H), 7.40–7.34 (m, 1H), 7.32–7.26 (m, 2H, overlapped with CDCl<sub>3</sub> signal), 7.22–7.15 (m, 3H), 3.38 (td, <i>J</i> = 6.8, 5.6 Hz, 2H), 2.67 (t, <i>J</i> = 7.3 Hz, 2H), 2.58 (s, 3H), 1.78–1.56 (m, overlapped with H<sub>2</sub>O signal, 4H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>): δ 154.02, 150.34, 142.12, 135.72, 128.92, 128.86, 128.56, 128.51, 127.12, 126.68, 126.00, 119.54, 40.17, 35.61, 29.16, 28.74, 12.16. UPLC/MS (<i>method B</i>): <i>R</i><sub><i>t</i></sub> 1.97 min. MS (ES): C<sub>21</sub>H<sub>22</sub>N<sub>2</sub>O<sub>3</sub> requires, 350; found, 351 [M + H]<sup>+</sup>, 174 [M–CONH(CH<sub>2</sub>)<sub>4</sub>Ph]<sup>−</sup>. HRMS: C<sub>21</sub>H<sub>22</sub>N<sub>2</sub>O<sub>3</sub> [M + H]<sup>+</sup> calcd 351.1709; measured, 351.1714, Δppm 1.4.</div></div><div id="sec5_9_50" class="NLM_sec NLM_sec_level_3"><div id="ac_i77" class="anchor-spacer"></div><h4 class="article-section__title" id="_i77"> Synthesis of 5-(4-Chlorophenyl)-2-oxo-<i>N</i>-(4-phenylbutyl)oxazole-3-carboxamide (<b>12i</b>)</h4><div class="NLM_p last">Compound <b>12i</b> was prepared according to general procedure D (<i>method A</i>) using <b>11c</b> (0.100 g, 0.51 mmol), DMAP (0.006 g, 0.05 mmol), and 4-phenylbutyl isocyanate (0.135 g, 0.77 mmol) in CH<sub>3</sub>CN. The precipitate was collected by filtration to afford <b>12i</b> as a white solid (0.055 g, 29%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 7.91 (t, <i>J</i> = 5.9 Hz, 1H), 7.50–7.42 (m, 3H), 7.41–7.36 (m, 2H), 7.33–7.24 (m, overlapped with CDCl<sub>3</sub> signal, 2H), 7.22–7.15 (m, 3H), 3.51–3.34 (m, 2H), 2.67 (t, <i>J</i> = 7.2 Hz, 2H), 1.78–1.61 (m, 4H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>): δ 152.61, 148.43, 141.98, 138.81, 135.18, 129.45, 128.53 (2C), 126.04, 124.96, 124.91, 106.51, 40.48, 35.57, 29.19, 28.63. UPLC/MS (<i>method B</i>): <i>R</i><sub><i>t</i></sub> 2.08 min. MS (ES): C<sub>20</sub>H<sub>19</sub>ClN<sub>2</sub>O<sub>3</sub> requires, 370; found, 369 [M – H]<sup>−</sup> and 194 [M–CONH(CH<sub>2</sub>)<sub>4</sub>Ph]<sup>−</sup>. HRMS: C<sub>20</sub>H<sub>19</sub>ClN<sub>2</sub>O<sub>3</sub> [M + H]<sup>+</sup> calcd 371.1184; measured, 371.1168, Δppm 1.6.</div></div><div id="sec5_9_51" class="NLM_sec NLM_sec_level_3"><div id="ac_i78" class="anchor-spacer"></div><h4 class="article-section__title" id="_i78"> Synthesis of 5-(4-Fluorophenyl)-2-oxo-<i>N</i>-(4-phenylbutyl)oxazole-3-carboxamide (<b>12j</b>)</h4><div class="NLM_p last">Compound <b>12j</b> was prepared according to general procedure D (<i>method A</i>) using <b>11d</b> (0.150 g, 0.84 mmol), DMAP (0.112 g, 0.92 mmol), and 4-phenylbutyl isocyanate (0.161 g, 0.92 mmol) in pyridine. The crude was purified by column chromatography (SiO<sub>2</sub>), eluting with Cy/EtOAc (8:2), to afford <b>12j</b> as a white solid (0.180 g, 59%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 7.92 (t, <i>J</i> = 5.9 Hz, 1H), 7.54–7.46 (m, 2H), 7.41 (s, 1H), 7.32–7.24 (m, overlapped with CDCl<sub>3</sub>, signal 2H), 7.23–7.15 (m, 3H), 7.15–7.08 (m, 2H), 3.46–3.37 (m, 2H), 2.67 (t, <i>J</i> = 7.2 Hz, 2H), 1.78–1.61 (m, 4H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>): δ 163.16 (d, <i>J</i><sub>C–F</sub> = 250.4 Hz), 152.70, 148.51, 141.99, 138.97, 128.52 (2C), 125.77 (d, <i>J</i><sub>C–F</sub> = 8.2 Hz, ×2), 122.69, 116.38 (d, <i>J</i><sub>C–F</sub> = 22.1 Hz), 105.78, 40.45, 35.56, 29.19, 28.63. UPLC/MS (<i>method A</i>): <i>R</i><sub><i>t</i></sub> 2.76 min. MS (ES): C<sub>20</sub>H<sub>19</sub>FN<sub>2</sub>O<sub>3</sub> requires, 354; found, 353 [M – H]<sup>−</sup> and 178 [M–CONH(CH<sub>2</sub>)<sub>4</sub>Ph]<sup>−</sup>. HRMS: C<sub>20</sub>H<sub>19</sub>FN<sub>2</sub>O<sub>3</sub> [M + H]<sup>+</sup> calcd 355.1458; measured, 355.1451, Δppm 1.1.</div></div><div id="sec5_9_52" class="NLM_sec NLM_sec_level_3"><div id="ac_i79" class="anchor-spacer"></div><h4 class="article-section__title" id="_i79"> Synthesis of 5-(4-Methoxyphenyl)-2-oxo-<i>N</i>-(4-phenylbutyl)oxazole-3-carboxamide (<b>12k</b>)</h4><div class="NLM_p last">Compound <b>12k</b> was prepared according to general procedure D (<i>method A</i>) using <b>11e</b> (0.150 g, 0.84 mmol), DMAP (0.105 g, 0.86 mmol), and 4-phenylbutyl isocyanate (0.150 g, 0.86 mmol) in pyridine. The crude was purified by column chromatography (SiO<sub>2</sub>), eluting with Cy/EtOAc (8:2), to afford <b>12k</b> as a yellow solid (0.187 g, 65%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 7.95 (t, <i>J</i> = 5.9 Hz, 1H), 7.48–7.41 (m, 2H), 7.32 (s, 1H), 7.31–7.24 (m, overlapped with CDCl<sub>3</sub> signal, 2H), 7.22–7.14 (m, 3H), 6.98–6.89 (m, 2H), 3.84 (s, 3H), 3.47–3.35 (m, 2H), 2.67 (t, <i>J</i> = 7.3 Hz, 2H), 1.78–1.60 (m, 4H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>): δ 160.46, 152.91, 148.71, 142.02, 139.86, 128.53, 128.50, 126.00, 125.34, 119.05, 114.59, 104.39, 55.51, 40.38, 35.56, 29.20, 28.62. UPLC/MS (<i>method A</i>): <i>R</i><sub><i>t</i></sub> 2.72 min. MS (ES): C<sub>21</sub>H<sub>22</sub>N<sub>2</sub>O<sub>4</sub> requires, 366; found, 190 [M–CONH(CH<sub>2</sub>)<sub>4</sub>Ph]<sup>−</sup>. HRMS: C<sub>21</sub>H<sub>22</sub>N<sub>2</sub>O<sub>4</sub> [M + H]<sup>+</sup> calcd 367.1658; measured, 367.1646, Δppm −1.2.</div></div><div id="sec5_9_53" class="NLM_sec NLM_sec_level_3"><div id="ac_i80" class="anchor-spacer"></div><h4 class="article-section__title" id="_i80"> Synthesis of 5-(3-Methoxyphenyl)-2-oxo-<i>N</i>-(4-phenylbutyl)oxazole-3-carboxamide (<b>12l</b>)</h4><div class="NLM_p last">Compound <b>12l</b> was prepared according to general procedure D (<i>method A</i>) using <b>11f</b> (0.191 g, 1.00 mmol), DMAP (0.012 g, 0.10 mmol), and 4-phenylbutyl isocyanate (0.350 g, 2.00 mmol) in CH<sub>3</sub>CN. The precipitate was collected by filtration to afford <b>12l</b> as a white solid (0.150 g, 41%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 7.94 (t, <i>J</i> = 5.8 Hz, 1H), 7.46 (s, 1H), 7.36–7.24 (m, overlapped with CDCl<sub>3</sub> signal, 3H), 7.22–7.15 (m, 3H), 7.11 (dt, <i>J</i> = 7.7, 1.2 Hz, 1H), 7.06–7.02 (m, 1H), 6.92–6.87 (m, 1H), 3.84 (s, 3H), 3.45–3.38 (m, 2H), 2.67 (t, <i>J</i> = 7.3 Hz, 2H), 1.78–1.60 (m, 4H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>): δ 160.15, 152.77, 148.55, 142.01, 139.63, 130.27, 128.54, 127.61, 126.03, 116.12, 115.34, 108.94, 106.35, 104.88, 55.54, 40.45, 35.58, 29.21, 28.65. UPLC/MS (<i>method A</i>): <i>R</i><sub><i>t</i></sub> 2.73 min. MS (ES): C<sub>21</sub>H<sub>22</sub>N<sub>2</sub>O<sub>4</sub> requires, 366; found, 367 [M + H]<sup>+</sup>, 190 [M–CONH(CH<sub>2</sub>)<sub>4</sub>Ph]<sup>−</sup>. HRMS: C<sub>21</sub>H<sub>22</sub>N<sub>2</sub>O<sub>4</sub> [M + H]<sup>+</sup> calcd 367.1658; measured, 367.1654, Δppm −1.1.</div></div><div id="sec5_9_54" class="NLM_sec NLM_sec_level_3"><div id="ac_i81" class="anchor-spacer"></div><h4 class="article-section__title" id="_i81"> Synthesis of 5-(2-Methoxyphenyl)-2-oxo-<i>N</i>-(4-phenylbutyl)oxazole-3-carboxamide (<b>12m</b>)</h4><div class="NLM_p last">Compound <b>12m</b> was prepared according to general procedure D (<i>method A</i>) using <b>11g</b> (0.120 g, 0.63 mmol), DMAP (0.084 g, 0.69 mmol), and 4-phenylbutyl isocyanate (0.121 g, 0.69 mmol) in pyridine. The crude was purified by column chromatography (SiO<sub>2</sub>), eluting with Cy/EtOAc (8:2), to afford <b>12m</b> as a yellow solid (0.060 g, 26%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 8.01 (t, <i>J</i> = 5.2 Hz, 1H), 7.65 (s, 1H), 7.63 (dd, <i>J</i> = 7.8, 1.6 Hz, 1H), 7.35–7.25 (m, overlapped with CDCl<sub>3</sub> signal, 3H), 7.23–7.12 (m, 3H), 7.03 (td, <i>J</i> = 7.7, 0.8 Hz, 1H), 6.99–6.93 (m, 1H), 3.95 (s, 3H), 3.46–3.37 (m, 2H), 2.67 (t, <i>J</i> = 7.3 Hz, 2H), 1.78–1.60 (m, 4H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>): δ 155.98, 152.63, 148.84, 142.05, 136.36, 129.69, 128.55, 128.51, 126.00, 125.53, 120.93, 115.43, 110.73, 110.35, 55.59, 40.38, 35.59, 29.23, 28.66. UPLC/MS (<i>method A</i>): <i>R</i><sub><i>t</i></sub> 2.79 min. MS (ES): C<sub>21</sub>H<sub>22</sub>N<sub>2</sub>O<sub>4</sub> requires, 366; found, 367 [M + H]<sup>+</sup>, 190 [M–CONH(CH<sub>2</sub>)<sub>4</sub>Ph]<sup>−</sup>. HRMS: C<sub>21</sub>H<sub>22</sub>N<sub>2</sub>O<sub>4</sub> [M + H]<sup>+</sup> calcd 367.1658; measured, 367.1655, Δppm −1.0.</div></div><div id="sec5_9_55" class="NLM_sec NLM_sec_level_3"><div id="ac_i82" class="anchor-spacer"></div><h4 class="article-section__title" id="_i82"> Synthesis of 5-(4-Fluoro-3-methoxy-phenyl)-2-oxo-<i>N</i>-(4-phenylbutyl)oxazole-3-carboxamide (<b>12n</b>)</h4><div class="NLM_p last">Compound <b>12n</b> was prepared according to general procedure D (<i>method A</i>) using <b>11h</b> (0.055 g, 0.26 mmol), DMAP (0.035 g, 0.29 mmol), and 4-phenylbutyl isocyanate (0.051 g, 0.29 mmol) in pyridine. The crude was purified by column chromatography (SiO<sub>2</sub>), eluting with DCM/MeOH (9:1), and then was triturated with pentane to afford <b>12n</b> as a white solid (0.045 g, 45%). <sup>1</sup>H NMR (400 MHz CDCl<sub>3</sub>): δ 7.91 (t, <i>J</i> = 5.2 Hz, 1H), 7.41 (s, 1H), 7.32–7.24 (m, overlapped with CDCl<sub>3</sub> signal, 2H), 7.23–7.15 (m, 3H), 7.15–7.03 (m, 3H), 3.93 (s, 3H), 3.47–3.37 (m, 2H), 2.67 (t, <i>J</i> = 7.0 Hz, 2H), 1.77–1.60 (m, 4H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>): δ 154.13, 152.89 (d, <i>J</i><sub>C–F</sub> = 250.1 Hz), 152.65, 148.47, 141.99, 138.98, 128.53 (2C), 126.04, 122.93 (d, <i>J</i><sub>C–F</sub> = 3.9 Hz), 116.91 (d, <i>J</i><sub>C–F</sub> = 19.5 Hz), 116.51 (d, <i>J</i><sub>C–F</sub> = 7.1 Hz), 108.86, 105.92, 56.47, 40.46, 35.56, 29.18, 28.64. UPLC/MS (<i>method A</i>): <i>R</i><sub><i>t</i></sub> 2.70 min. MS (ES): C<sub>21</sub>H<sub>21</sub>FN<sub>2</sub>O<sub>4</sub> requires, 384; found, 385 [M + H]<sup>+</sup>, 208 [M–CONH(CH<sub>2</sub>)<sub>4</sub>Ph]<sup>−</sup>. HRMS: C<sub>21</sub>H<sub>21</sub>FN<sub>2</sub>O<sub>4</sub> [M + H]<sup>+</sup> calcd 385.1564; measured, 385.1566, Δppm 0.5.</div></div><div id="sec5_9_56" class="NLM_sec NLM_sec_level_3"><div id="ac_i83" class="anchor-spacer"></div><h4 class="article-section__title" id="_i83"> Synthesis of 2-Oxo-<i>N</i>-(4-phenylbutyl)-5-(2-pyridyl)oxazole-3-carboxamide (<b>12o</b>)</h4><div class="NLM_p last">Compound <b>12o</b> was prepared according to general procedure D (<i>method A</i>) using <b>11i</b> (0.280 g, 1.73 mmol), DMAP (0.232 g, 1.90 mmol), and 4-phenylbutyl isocyanate (0.333 g, 1.90 mmol) in pyridine. The crude was purified by column chromatography (SiO<sub>2</sub>), eluting with DCM/MeOH (9:1), to afford <b>12o</b> as a white solid (0.058 g, 10%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 8.60 (ddd, <i>J</i> = 4.8, 1.7, 0.9 Hz, 1H), 7.92 (t, <i>J</i> = 4.8 Hz, 1H), 7.86 (s, 1H), 7.76 (td, <i>J</i> = 7.8, 1.7 Hz, 1H), 7.55–7.48 (m, 1H), 7.31–7.22 (m, overlapped with CDCl<sub>3</sub> signal, 3H), 7.21–7.15 (m, 3H), 3.48–3.36 (m, 2H), 2.67 (t, <i>J</i> = 7.2 Hz, 2H), 1.79–1.60 (m, 4H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>): δ 152.66, 150.17, 148.31, 145.92, 142.01, 139.13, 137.10, 128.54 (2C), 126.03, 123.56, 118.81, 109.78, 40.50, 35.57, 29.18, 28.64. UPLC/MS (<i>method A</i>): <i>R</i><sub><i>t</i></sub> 2.38 min. MS (ES): C<sub>19</sub>H<sub>19</sub>N<sub>3</sub>O<sub>3</sub> requires, 337; found, 338 [M + H]<sup>+</sup>, 161 [M–CONH(CH<sub>2</sub>)<sub>4</sub>Ph]<sup>−</sup>. HRMS: C<sub>19</sub>H<sub>19</sub>N<sub>3</sub>O<sub>3</sub> [M + H]<sup>+</sup> calcd 338.1505; measured, 338.1497, Δppm −2.4.</div></div><div id="sec5_9_57" class="NLM_sec NLM_sec_level_3"><div id="ac_i84" class="anchor-spacer"></div><h4 class="article-section__title" id="_i84"> Synthesis of 2-Oxo-<i>N</i>-(4-phenylbutyl)-5-(3-pyridyl)oxazole-3-carboxamide (<b>12p</b>)</h4><div class="NLM_p last">Compound <b>12p</b> was prepared according to general procedure D (<i>method A</i>) using <b>11j</b> (0.200 g, 1.23 mmol), DMAP (0.165 g, 1.35 mmol), and 4-phenylbutyl isocyanate (0.236 g, 1.35 mmol) in pyridine. The crude was purified by column chromatography (SiO<sub>2</sub>), eluting with DCM/MeOH (9:1), to afford <b>12p</b> as a white solid (0.187 g, 45%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 8.85–8.79 (m, 1H), 8.60 (dd, <i>J</i> = 4.9, 1.5 Hz, 1H), 7.89 (t, <i>J</i> = 5.0 Hz, 1H), 7.83 (dt, <i>J</i> = 8.0, 1.8 Hz, 1H), 7.59 (s, 1H), 7.39 (ddd, <i>J</i> = 8.0, 4.9, 0.7 Hz, 1H), 7.32–7.24 (m, overlapped with CDCl<sub>3</sub> signal, 2H), 7.22–7.15 (m, 3H), 3.51–3.35 (m, 2H), 2.67 (t, <i>J</i> = 7.2 Hz, 2H), 1.92–1.60 (m, overlapped with H<sub>2</sub>O signal, 4H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>): δ 152.52, 149.90, 148.26, 144.99, 141.97, 137.06, 131.08, 128.55 (2C), 126.07, 123.89, 122.98, 107.73, 40.54, 35.57, 29.17, 28.62. UPLC/MS (<i>method A</i>): <i>R</i><sub><i>t</i></sub> 2.34 min. MS (ES): C<sub>19</sub>H<sub>19</sub>N<sub>3</sub>O<sub>3</sub> requires, 337; found, 338 [M + H]<sup>+</sup>, 161 [M–CONH(CH<sub>2</sub>)<sub>4</sub>Ph]<sup>−</sup>. HRMS: C<sub>19</sub>H<sub>19</sub>N<sub>3</sub>O<sub>3</sub> [M + H]<sup>+</sup> calcd 338.1505; measured, 338.1497, Δppm −2.4.</div></div><div id="sec5_9_58" class="NLM_sec NLM_sec_level_3"><div id="ac_i85" class="anchor-spacer"></div><h4 class="article-section__title" id="_i85"> Synthesis of 2-Oxo-<i>N</i>-(4-phenylbutyl)-5-(4-pyridyl)oxazole-3-carboxamide Hydrochloride (<b>12q</b>)</h4><div class="NLM_p last">Compound <b>12q</b> was prepared according to general procedure D (<i>method A</i>) using <b>11k</b> (0.120 g, 0.74 mmol), DMAP (0.099 g, 0.81 mmol), and 4-phenylbutyl isocyanate (0.142 g, 0.81 mmol) in pyridine. The crude was purified by column chromatography (SiO<sub>2</sub>), eluting with DCM/MeOH (9:1), to afford the free base of <b>12q</b>. The free base of <b>12q</b> was then dissolved in 1.0 mL of 1,4-dioxane and 4.0 M HCl solution (3.7 mL, 14.8 mmol, 20.0 equiv) was added. The evaporation of solvents afforded <b>12q</b> as a white solid (0.120 g, 43%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 8.84–8.78 (m, 2H), 8.72 (s, 1H), 8.08 (t, <i>J</i> = 5.9 Hz, 1H), 8.03–7.97 (m, 2H), 7.32–7.24 (m, 2H), 7.22–7.12 (m, 3H), 3.43–3.24 (m, overlapped with H<sub>2</sub>O signal, 2H), 2.61 (t, <i>J</i> = 7.2 Hz, 2H), 1.68–1.49 (m, 4H). <sup>13</sup>C NMR (101 MHz, DMSO): δ 151.14, 147.38, 144.25, 141.99, 134.41, 128.28, 128.22, 125.67, 118.87, 116.84, 40.35 (overlapped with DMSO signal), 34.70, 28.51, 28.05. UPLC/MS (<i>method A</i>): <i>R</i><sub><i>t</i></sub> 2.26 min. MS (ES): C<sub>19</sub>H<sub>19</sub>N<sub>3</sub>O<sub>3</sub> requires, 337; found, 338 [M + H]<sup>+</sup>, 161 [M–CONH(CH<sub>2</sub>)<sub>4</sub>Ph]<sup>−</sup>. HRMS: C<sub>19</sub>H<sub>19</sub>N<sub>3</sub>O<sub>3</sub> [M + H]<sup>+</sup> calcd 338.1505; measured, 338.1503, Δppm −0.6.</div></div><div id="sec5_9_59" class="NLM_sec NLM_sec_level_3"><div id="ac_i86" class="anchor-spacer"></div><h4 class="article-section__title" id="_i86"> Synthesis of 2-Oxo-<i>N</i>-(4-phenylbutyl)-5-pyrazin-2-yl-oxazole-3-carboxamide (<b>12r</b>)</h4><div class="NLM_p last">Compound <b>12r</b> was prepared according to general procedure D (<i>method A</i>) using <b>11l</b> (0.027 g, 0.16 mmol), DMAP (0.022 g, 0.18 mmol), and 4-phenylbutyl isocyanate (0.033 g, 0.18 mmol) in pyridine. The crude was purified by column chromatography (SiO<sub>2</sub>), eluting with DCM/MeOH (9:1), to afford <b>12r</b> as a white solid (0.045 g, 83%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 8.83–8.77 (m, 1H), 8.59–8.50 (m, 2H), 7.92 (s, 1H), 7.89 (bs, 1H), 7.33–7.24 (m, overlapped with CDCl<sub>3</sub> signal, 2H), 7.22–7.15 (m, 3H), 3.49–3.38 (m, 2H), 2.67 (t, <i>J</i> = 7.2 Hz, 2H), 1.80–1.58 (m, 4H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>): δ 152.28, 147.97, 144.62, 144.40, 141.91, 140.07, 136.89, 128.50 (2C), 126.02, 111.67, 40.55, 35.52, 29.11, 28.58. UPLC/MS (<i>method A</i>): <i>R</i><sub><i>t</i></sub> 2.28 min. MS (ES): C<sub>18</sub>H<sub>18</sub>N<sub>4</sub>O<sub>3</sub> requires, 338; found, 339 [M + H]<sup>+</sup>, 162 [M–CONH(CH<sub>2</sub>)<sub>4</sub>Ph]<sup>−</sup>. HRMS: C<sub>18</sub>H<sub>18</sub>N<sub>4</sub>O<sub>3</sub> [M + H]<sup>+</sup> calcd 339.1457; measured, 339.1455, Δppm −0.6.</div></div><div id="sec5_9_60" class="NLM_sec NLM_sec_level_3"><div id="ac_i87" class="anchor-spacer"></div><h4 class="article-section__title" id="_i87"> 2-Oxo-<i>N</i>-(4-phenylbutyl)-5-quinoxalin-2-yl-oxazole-3-carboxamide (<b>12s</b>)</h4><div class="NLM_p last">Compound <b>12s</b> was prepared according to general procedure D (<i>method A</i>) using <b>11m</b> (0.081 g, 0.38 mmol), DMAP (0.051 g, 0.42 mmol), and 4-phenylbutyl isocyanate (0.074 g, 0.42 mmol) in pyridine. The crude was purified by column chromatography (SiO<sub>2</sub>), eluting with DCM/MeOH (9:1), to afford <b>12s</b> as a white solid (0.063 g, 43%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 9.08 (s, 1H), 8.16–8.06 (m, 3H), 7.93 (t, <i>J</i> = 5.3 Hz, 1H), 7.86–7.74 (m, 2H), 7.32–7.25 (m, overlapped with CDCl<sub>3</sub> signal, 2H), 7.23–7.15 (m, 3H), 3.45–3.40 (m, 2H), 2.68 (t, <i>J</i> = 7.2 Hz, 2H), 1.80–1.61 (m, 4H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>): δ 152.37, 148.02, 142.23, 142.10, 141.96, 140.84, 140.49, 137.53, 131.23, 130.65, 129.61, 129.48, 128.56 (2C), 126.08, 112.35, 40.64, 35.57, 29.15, 28.64. UPLC/MS (<i>method A</i>): <i>R</i><sub><i>t</i></sub> 2.49 min. MS (ES): C<sub>22</sub>H<sub>20</sub>N<sub>4</sub>O<sub>3</sub> requires, 388; found, 389 [M + H]<sup>+</sup>, 212 [M–CONH(CH<sub>2</sub>)<sub>4</sub>Ph]<sup>−</sup>. HRMS: C<sub>22</sub>H<sub>20</sub>N<sub>4</sub>O<sub>3</sub> [M + H]<sup>+</sup> calcd 389.1614; measured, 389.1611, Δppm −0.8.</div></div><div id="sec5_9_61" class="NLM_sec NLM_sec_level_3"><div id="ac_i88" class="anchor-spacer"></div><h4 class="article-section__title" id="_i88"> Synthesis of 5-(1-Methylindazol-3-yl)-2-oxo-<i>N</i>-(4-phenylbutyl)oxazole-3-carboxamide (<b>12t</b>)</h4><div class="NLM_p last">Compound <b>12t</b> was prepared according to general procedure D (<i>method A</i>) using <b>11n</b> (0.041 g, 0.19 mmol), DMAP (0.026 g, 0.21 mmol), and 4-phenylbutyl isocyanate (0.037 g, 0.21 mmol) in pyridine. The crude was purified by column chromatography (SiO<sub>2</sub>), eluting with DCM/MeOH (9:1), and, then, triturated with pentane to afford <b>12t</b> as a white solid (0.040 g, 54%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 7.99 (t, <i>J</i> = 5.2 Hz, 1H), 7.91 (d, <i>J</i> = 8.2 Hz, 1H), 7.65 (s, 1H), 7.50–7.40 (m, 2H), 7.34–7.23 (m, overlapped with CDCl<sub>3</sub> signal, 3H), 7.23–7.14 (m, 3H), 4.12 (s, 3H), 3.50–3.38 (m, 2H), 2.67 (t, <i>J</i> = 7.2 Hz, 2H), 1.80–1.59 (m, 4H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>): δ 152.64, 148.56, 142.02, 140.96, 135.22, 131.42, 128.55, 128.52, 127.27, 126.02, 122.10, 120.94, 120.82, 109.62, 107.28, 40.47, 36.07, 35.58, 29.20, 28.66. UPLC/MS (<i>method A</i>): <i>R</i><sub><i>t</i></sub> 2.63 min. MS (ES): C<sub>22</sub>H<sub>22</sub>N<sub>4</sub>O<sub>3</sub> requires, 390; found, 391 [M + H]<sup>+</sup>, 214 [M–CONH(CH<sub>2</sub>)<sub>4</sub>Ph]<sup>−</sup>.</div></div><div id="sec5_9_62" class="NLM_sec NLM_sec_level_3"><div id="ac_i89" class="anchor-spacer"></div><h4 class="article-section__title" id="_i89"> Synthesis of 2-Oxo-<i>N</i>-(4-phenylbutyl)-5-thiazol-2-yl-oxazole-3-carboxamide (<b>12u</b>)</h4><div class="NLM_p last">Compound <b>12u</b> was prepared according to general procedure D (<i>method A</i>) using <b>11o</b> (0.100 g, 0.59 mmol), DMAP (0.079 g, 0.65 mmol), and 4-phenylbutyl isocyanate (0.114 g, 0.65 mmol) in pyridine. The crude was purified by column chromatography (SiO<sub>2</sub>), eluting with Cy/EtOAc (8:2), to afford <b>12u</b> as a white solid (0.150 g, 73%). <sup>1</sup>H NMR (400 MHz CDCl<sub>3</sub>): δ 7.89 (d, <i>J</i> = 3.2 Hz, 1H), 7.86 (t, <i>J</i> = 5.4 Hz, 1H), 7.80 (s, 1H), 7.42 (d, <i>J</i> = 3.2 Hz, 1H), 7.34–7.24 (m, overlapped with CDCl<sub>3</sub> signal, 2H), 7.23–7.12 (m, 3H), 3.47–3.35 (m, 2H), 2.66 (t, <i>J</i> = 7.2 Hz, 2H), 1.77–1.60 (m, overlapped with H<sub>2</sub>O signal, 4H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>): δ 151.81, 147.95, 144.46, 144.42, 141.94, 140.61, 128.53 (2C), 126.05, 119.74, 109.26, 40.58, 35.54, 29.11, 28.61. UPLC/MS (<i>method A</i>): <i>R</i><sub><i>t</i></sub> 2.41 min. MS (ES): C<sub>17</sub>H<sub>17</sub>N<sub>3</sub>O<sub>3</sub>S requires, 343; found, 344 [M + H]<sup>+</sup>, 167 [M–CONH(CH<sub>2</sub>)<sub>4</sub>Ph]<sup>−</sup>. HRMS: C<sub>17</sub>H<sub>17</sub>N<sub>3</sub>O<sub>3</sub>S [M + H]<sup>+</sup> calcd 344.1069; measured, 344.1054, Δppm −4.4.</div></div><div id="sec5_9_63" class="NLM_sec NLM_sec_level_3"><div id="ac_i90" class="anchor-spacer"></div><h4 class="article-section__title" id="_i90"> Synthesis of 2-Oxo-<i>N</i>-(4-phenylbutyl)-5-thiazol-4-yl-oxazole-3-carboxamide (<b>12v</b>)</h4><div class="NLM_p last">Compound <b>12v</b> was prepared according to general procedure D (<i>method A</i>) using <b>11p</b> (0.120 g, 0.71 mmol), DMAP (0.100 g, 0.78 mmol). and 4-phenylbutyl isocyanate (0.140 g, 0.78 mmol) in pyridine. The crude was purified by column chromatography (SiO<sub>2</sub>), eluting with Cy/EtOAc (8:2), to afford <b>12v</b> as a white solid (0.122 g, 50%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 7.90 (d, <i>J</i> = 3.2 Hz, 1H), 7.86 (t, <i>J</i> = 4.8 Hz, 1H), 7.83 (s, 1H), 7.42 (d, <i>J</i> = 3.2 Hz, 1H), 7.33–7.25 (m, overlapped with CDCl<sub>3</sub> signal, 2H), 7.22–7.15 (m, 3H), 3.47–3.36 (m, 2H), 2.66 (t, <i>J</i> = 7.2 Hz, 2H), 1.76–1.59 (m, 4H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>): δ 153.82, 151.80, 147.15, 144.36, 141.94, 138.47, 128.57 (2C), 126.05, 119.76, 109.41, 40.59, 35.55, 29.12, 28.62. UPLC/MS (<i>method A</i>): <i>R</i><sub><i>t</i></sub> 2.41 min. MS (ES): C<sub>17</sub>H<sub>17</sub>N<sub>3</sub>O<sub>3</sub>S requires, 343; found, 344 [M + H]<sup>+</sup>, 167 [M–CONH(CH<sub>2</sub>)<sub>4</sub>Ph]<sup>−</sup>. HRMS: C<sub>17</sub>H<sub>17</sub>N<sub>3</sub>O<sub>3</sub>S [M + H]<sup>+</sup> calcd 344.1069; measured, 344.1061, Δppm −2.3.</div></div><div id="sec5_9_64" class="NLM_sec NLM_sec_level_3"><div id="ac_i91" class="anchor-spacer"></div><h4 class="article-section__title" id="_i91"> Synthesis of <i>tert</i>-Butyl 4-[2-Oxo-3-(4-phenylbutylcarbamoyl)oxazol-5-yl]piperidine-1-carboxylate (<b>12w</b>)</h4><div class="NLM_p last">Compound <b>12w</b> was prepared according to general procedure D (<i>method A</i>) using <b>11q</b> (0.090 g, 0.34 mmol), DMAP (0.045 g, 0.37 mmol). and 4-phenylbutyl isocyanate (0.065 g, 0.37 mmol) in CH<sub>3</sub>CN. The crude was purified by column chromatography (SiO<sub>2</sub>), eluting with Cy/EtOAc (65:35), to afford <b>12w</b> as a white solid (0.025 g, 17%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 7.88 (t, <i>J</i> = 5.7 Hz, 1H), 7.32–7.26 (m, overlapped with CDCl<sub>3</sub> signal, 2H), 7.21–7.12 (m, 3H), 6.87 (d, <i>J</i> = 1.4 Hz, 1H), 4.23–4.05 (m, 2H), 3.37 (q, <i>J</i> = 6.5 Hz, 2H), 2.90–2.75 (m, 2H), 2.65 (t, <i>J</i> = 7.3 Hz, 2H), 2.62–2.53 (m, 1H), 1.95–1.85 (m, 2H), 1.77–1.49 (m, 6H), 1.46 (s, 9H). UPLC/MS (<i>method B</i>): <i>R</i><sub><i>t</i></sub> 1.91 min. MS (ES): C<sub>24</sub>H<sub>33</sub>N<sub>3</sub>O<sub>5</sub> requires, 443; found, 444 [M + H]<sup>+</sup>.</div></div><div id="sec5_9_65" class="NLM_sec NLM_sec_level_3"><div id="ac_i92" class="anchor-spacer"></div><h4 class="article-section__title" id="_i92"> Synthesis of 2-Oxo-<i>N</i>-(4-phenylbutyl)-5-(4-piperidyl)oxazole-3-carboxamide Hydrochloride (<b>12x</b>)</h4><div class="NLM_p last">Compound <b>12x</b> was prepared according to general procedure G using <b>12w</b> (0.025 g, 0.06 mmol). The crude was used in the next step without further purification. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 8.79 (bs, 2H), 7.98 (t, <i>J</i> = 5.9 Hz, 1H), 7.30–7.23 (m, 2H), 7.22–7.12 (m, 4H), 3.33–3.17 (m, overlapped with H<sub>2</sub>O signal, 4H), 2.94 (td, <i>J</i> = 12.2, 3.1 Hz, 2H), 2.88–2.77 (m, 1H), 2.59 (t, <i>J</i> = 7.3 Hz, 2H), 2.04–1.94 (m, 2H), 1.78–1.64 (m, 2H), 1.62–1.44 (m, 4H). UPLC/MS (<i>method A</i>): <i>R</i><sub><i>t</i></sub> 1.89 min. MS (ES): C<sub>19</sub>H<sub>25</sub>N<sub>3</sub>O<sub>3</sub> requires, 343; found, 344 [M + H]<sup>+</sup>.</div></div><div id="sec5_9_66" class="NLM_sec NLM_sec_level_3"><div id="ac_i93" class="anchor-spacer"></div><h4 class="article-section__title" id="_i93"> Synthesis of 5-(1-Methyl-4-piperidyl)-2-oxo-<i>N</i>-(4-phenylbutyl)oxazole-3-carboxamide (<b>12y</b>)</h4><div class="NLM_p last">Compound <b>12y</b> was prepared according to general procedure H using <b>12x</b> (0.022 g, 0.06 mmol) and 37% aq solution of HCHO (0.023 g, 0.022 mL, 0.29 mmol). The crude was purified by column chromatography (SiO<sub>2</sub>), eluting with DCM/MeOH (88:12), to afford <b>12y</b> as a white solid (0.007 g, 34%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 7.97 (t, <i>J</i> = 5.9 Hz, 1H), 7.30–7.23 (m, 2H), 7.21–7.13 (m, 3H), 7.05 (d, <i>J</i> = 1.5 Hz, 1H), 3.26 (q, <i>J</i> = 6.4 Hz, 2H), 2.74 (dt, <i>J</i> = 11.7, 3.6 Hz, 2H), 2.58 (t, <i>J</i> = 7.3 Hz, 2H), 2.44–2.33 (m, 1H), 2.15 (s, 3H), 1.91 (td, <i>J</i> = 11.6, 2.5 Hz, 2H), 1.84–1.74 (m, 2H), 1.63–1.42 (m, 6H). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>): δ 152.30, 148.08, 144.06, 142.00, 128.27, 128.21, 125.65, 106.25, 54.32 (2C), 46.06, 39.77 (overlapped with DMSO signal), 34.69, 31.87, 28.58, 28.09. UPLC/MS (<i>method A</i>): <i>R</i><sub><i>t</i></sub> 1.90 min. MS (ES): C<sub>20</sub>H<sub>27</sub>N<sub>3</sub>O<sub>3</sub> requires, 357; found, 358 [M + H]<sup>+</sup>. HRMS: C<sub>20</sub>H<sub>27</sub>N<sub>3</sub>O<sub>3</sub> [M + H]<sup>+</sup> calcd 358.2131; measured, 358.2121, Δppm −2.8.</div></div><div id="sec5_9_67" class="NLM_sec NLM_sec_level_3"><div id="ac_i94" class="anchor-spacer"></div><h4 class="article-section__title" id="_i94"> Synthesis of <i>N</i>-Methyl-2-oxo-5-phenyl-<i>N</i>-(4-phenylbutyl)oxazole-3-carboxamide (<b>13a</b>)</h4><div class="NLM_p last">Compound <b>13a</b> was prepared according to general procedure D (<i>method C</i>) using <b>11a</b> (0.155 g, 0.96 mmol, 1.0 equiv), <i>N</i>-methyl-4-phenylbutylamine hydrochloride (0.061 g, 0.32 mmol, 0.33 equiv), and DIPEA (0.496 g, 0.668 mL, 3.84 mmol, 4.0 equiv). The crude was purified by column chromatography (SiO<sub>2</sub>), eluting with Cy/EtOAc (91:9), to afford <b>13a</b> as yellow oil (0.109 g, 98%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 7.82 (s, 1H), 7.62–7.56 (m, 2H), 7.50–7.42 (m, 2H), 7.40–7.32 (m, 1H), 7.30–7.23 (m, 2H), 7.22–7.14 (m, 3H), 3.46–3.37 (m, 2H), 3.00 (s, 3H), 2.65–2.56 (m, 2H), 1.65–1.51 (m, 4H). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>): δ 150.11, 149.58, 141.88, 139.14, 128.93, 128.52, 128.23 (2C), 126.66, 125.67, 122.99, 110.18, 49.52, 36.47, 34.69, 27.69 (×2). UPLC/MS (<i>method B</i>): <i>R</i><sub><i>t</i></sub> 1.56 min. MS (ES): C<sub>21</sub>H<sub>22</sub>N<sub>2</sub>O<sub>3</sub> requires, 350; found, 351 [M + H]<sup>+</sup>. HRMS: C<sub>21</sub>H<sub>22</sub>N<sub>2</sub>O<sub>3</sub> [M + H]<sup>+</sup> calcd 351.1704; measured, 351.1709, Δppm −1.4.</div></div><div id="sec5_9_68" class="NLM_sec NLM_sec_level_3"><div id="ac_i95" class="anchor-spacer"></div><h4 class="article-section__title" id="_i95"> Synthesis of 4-Phenylbutyl-2-oxo-5-phenyl-oxazole-3-carboxylate (<b>13b</b>)</h4><div class="NLM_p last">Compound <b>13b</b> was prepared according to general procedure D (<i>method C</i>) using <b>11a</b> (0.160 g, 1.00 mmol), 4-phenyl-1-butanol (0.050 g, 0.051 mL, 0.33 mmol, 0.33 equiv), and DIPEA (0.260 g, 0.350 mL, 2.01 mmol). The crude was purified by column chromatography (SiO<sub>2</sub>), eluting with Cy/EtOAc (94:6), to afford <b>13b</b> as a white solid (0.059 g, 53%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 7.58–7.50 (m, 2H), 7.49–7.37 (m, 3H), 7.33–7.24 (m, overlapped with CDCl<sub>3</sub> signal, 2H), 7.24–7.14 (m, 4H), 4.42 (t, <i>J</i> = 6.1 Hz, 2H), 2.70 (t, <i>J</i> = 7.1 Hz, 2H), 1.90–1.71 (m, 4H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>): δ 149.39, 148.73, 141.80, 140.13, 129.56, 129.12, 128.57 (2C), 126.26, 126.12, 123.91, 105.95, 68.52, 35.43, 28.16, 27.45. UPLC/MS (<i>method B</i>): <i>R</i><sub><i>t</i></sub> 2.48 min. MS (ES): C<sub>20</sub>H<sub>19</sub>NO<sub>4</sub> requires, 337; found, 338 [M + H]<sup>+</sup>. HRMS: C<sub>20</sub>H<sub>19</sub>NO<sub>4</sub>Na [M + Na]<sup>+</sup> calcd 360.1212; measured, 360.1207, Δppm −1.4.</div></div><div id="sec5_9_69" class="NLM_sec NLM_sec_level_3"><div id="ac_i96" class="anchor-spacer"></div><h4 class="article-section__title" id="_i96"> Synthesis of 5-Phenyl-3-(6-phenylhexanoyl)oxazol-2-one (<b>13c</b>)</h4><div class="NLM_p last">To a solution of 6-phenylhexanoic acid (0.086 g, 0.45 mmol, 1.2 equiv) in dry DCM (7.5 mL, 0.06 M) was added slowly SOCl<sub>2</sub> (0.169 g, 0.104 mL, 0.53 mmol, 1.5 equiv) at 0 °C. The mixture was stirred at rt for 6 h and, then, the solvent was evaporated. The residue was taken up in dry THF (1.0 mL) and added dropwise over 10 min to a solution of <b>11a</b> (0.060 g, 0.37 mmol, 1.0 equiv) and Et<sub>3</sub>N (0.163 g, 0.225 mL, 1.61 mmol, 4.3 equiv) in dry THF (0.37 M) at 0 °C. The reaction mixture was stirred, and then, sat. aq NH<sub>4</sub>Cl was added and extracted with DCM. The combined organic layers were dried over Na<sub>2</sub>SO<sub>4</sub>. After the evaporation of the solvent, the crude was purified by column chromatography (SiO<sub>2</sub>), eluting with Cy/EtOAc (97:3), to afford <b>13c</b> as a white solid (0.069 g, 55%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 8.06 (s, 1H), 7.71–7.63 (m, 2H), 7.50–7.42 (m, 2H), 7.42–7.35 (m, 1H), 7.30–7.23 (m, 2H), 7.22–7.13 (m, 3H), 2.94 (t, <i>J</i> = 7.3 Hz, 2H), 2.58 (t, <i>J</i> = 7.7 Hz, 2H), 1.71–1.52 (m, 4H), 1.44–1.30 (m, 2H). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>): δ 170.12, 150.51, 142.16, 139.35, 128.98, 128.96, 128.25, 128.19, 126.25, 125.59, 123.49, 106.70, 34.97, 34.65, 30.70, 27.97, 23.06. UPLC/MS (<i>method B</i>): <i>R</i><sub><i>t</i></sub> 2.16 min. MS (ES): C<sub>21</sub>H<sub>21</sub>NO<sub>3</sub> requires, 335; found, 336 [M + H]<sup>+</sup>, 334 [M – H]<sup>−</sup>. HRMS: C<sub>21</sub>H<sub>21</sub>NO<sub>3</sub>Na [M + Na]<sup>+</sup> calcd 358.1419; measured, 358.1416, Δppm −0.8.</div></div><div id="sec5_9_70" class="NLM_sec NLM_sec_level_3"><div id="ac_i97" class="anchor-spacer"></div><h4 class="article-section__title" id="_i97"> Synthesis of (4<i>S</i>)-(+)-2-Oxo-4-phenyl-<i>N</i>-(4-phenylbutyl)oxazolidine-3-carboxamide (<b>15a</b>)</h4><div class="NLM_p last">Compound <b>15a</b> was prepared according to general procedure D (<i>method A</i>) at 50 °C using <b>14a</b> (0.250 g, 1.53 mmol), DMAP (0.206 g, 0.17 mmol), and 4-phenylbutyl isocyanate (0.279 g, 1.70 mmol) in DMF. The crude was purified by column chromatography (SiO<sub>2</sub>), eluting with Cy/EtOAc (85:15), to afford <b>15a</b> as a white solid (0.420 g, 81%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 7.81 (bs, 1H), 7.42–7.23 (m, overlapped with CDCl<sub>3</sub> signal, 7H), 7.21–7.10 (m, 3H), 5.43 (dd, <i>J</i> = 8.9, 3.8 Hz, 1H), 4.71 (t, <i>J</i> = 8.9 Hz, 1H), 4.28 (dd, <i>J</i> = 8.8, 3.8 Hz, 1H), 3.37–3.12 (m, 2H), 2.61 (t, <i>J</i> = 7.5 Hz, 2H), 1.70–1.44 (m, overlapped with H<sub>2</sub>O signal, 4H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>): δ 156.01, 151.05, 142.17, 139.70, 129.32, 128.80, 128.50, 128.45, 125.95, 125.91, 70.47, 57.72, 40.05, 35.56, 29.31, 28.65. [α]<sub class="stack">D</sub><sup class="stack">30</sup> +71.8 (<i>c</i> 0.1, CHCl<sub>3</sub>). UPLC/MS (<i>method A</i>): <i>R</i><sub><i>t</i></sub> 2.48 min. MS (ES): C<sub>20</sub>H<sub>22</sub>N<sub>2</sub>O<sub>3</sub> requires, 338; found, 339 [M + H]<sup>+</sup>. HRMS: C<sub>20</sub>H<sub>22</sub>N<sub>2</sub>O<sub>3</sub> [M + H]<sup>+</sup> calcd 339.1709; measured, 339.1697, Δppm −1.2.</div></div><div id="sec5_9_71" class="NLM_sec NLM_sec_level_3"><div id="ac_i98" class="anchor-spacer"></div><h4 class="article-section__title" id="_i98"> Synthesis of (4<i>R</i>)-(−)-2-Oxo-4-phenyl-<i>N</i>-(4-phenylbutyl)oxazolidine-3-carboxamide (<b>15b</b>)</h4><div class="NLM_p last">Compound <b>15b</b> was prepared according to general procedure D (<i>method A</i>) using <b>14b</b> (0.326 g, 2.00 mmol), DMAP (0.268 g, 2.20 mmol), and 4-phenylbutyl isocyanate (0.385 g, 2.20 mmol) in pyridine. The crude was purified by column chromatography (SiO<sub>2</sub>), eluting with Cy/EtOAc (85:15), to afford <b>15b</b> as a white solid (0.320 g, 47%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) 7.81 (bs, 1H), 7.42–7.23 (m, overlapped with CDCl<sub>3</sub> signal, 7H), 7.21–7.10 (m, 3H), 5.43 (dd, <i>J</i> = 8.9, 3.8 Hz, 1H), 4.71 (t, <i>J</i> = 8.9 Hz, 1H), 4.28 (dd, <i>J</i> = 8.8, 3.8 Hz, 1H), 3.37–3.12 (m, 2H), 2.61 (t, <i>J</i> = 7.5 Hz, 2H), 1.70–1.44 (m, overlapped with H<sub>2</sub>O signal, 4H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>): δ 155.92, 150.96, 142.08, 139.65, 129.20, 128.67, 128.41, 128.35, 125.85, 125.82, 70.36, 57.59, 39.92, 35.45, 29.21, 28.55. [α]<sub class="stack">D</sub><sup class="stack">30</sup> −39.8 (<i>c</i> 0.1, CHCl<sub>3</sub>). UPLC/MS (<i>method A</i>): <i>R</i><sub><i>t</i></sub> 2.48 min. MS (ES): C<sub>20</sub>H<sub>22</sub>N<sub>2</sub>O<sub>3</sub> requires, 338; found, 339 [M + H]<sup>+</sup>. HRMS: C<sub>20</sub>H<sub>22</sub>N<sub>2</sub>O<sub>3</sub> [M + H]<sup>+</sup> calcd 339.1709; measured, 339.1714, Δppm 0.5.</div></div><div id="sec5_9_72" class="NLM_sec NLM_sec_level_3"><div id="ac_i99" class="anchor-spacer"></div><h4 class="article-section__title" id="_i99"> Synthesis of (5<i>S</i>)-(+)-5-Phenyloxazolidin-2-one (<b>17a</b>)</h4><div class="NLM_p last">Compound <b>17a</b> was prepared according to general procedure C using <b>16a</b> (0.100 g, 0.73 mmol). The crude was purified by column chromatography (SiO<sub>2</sub>), eluting with DCM/MeOH (8:2), to afford <b>17a</b> as a white solid (0.103 g, 86%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 7.49–7.31 (m, 5H), 5.72–5.49 (m, 2H), 3.98 (t, <i>J</i> = 8.6 Hz, 1H), 3.58–3.51 (m, 1H). [α]<sub class="stack">D</sub><sup class="stack">30</sup> +28.3 (<i>c</i> 0.6, EtOH), consistent with data reported in the literature (lit:<a onclick="showRef(event, 'ref73'); return false;" href="javascript:void(0);" class="ref ref73">(73)</a> [α]<sub class="stack">D</sub><sup class="stack">30</sup> +26.1 (<i>c</i> 0.88, EtOH)). UPLC/MS (<i>method A</i>): <i>R</i><sub><i>t</i></sub> 1.41 min. MS (ES): C<sub>9</sub>H<sub>9</sub>NO<sub>2</sub> requires, 163; found, 164 [M + H]<sup>+</sup>.</div></div><div id="sec5_9_73" class="NLM_sec NLM_sec_level_3"><div id="ac_i100" class="anchor-spacer"></div><h4 class="article-section__title" id="_i100"> Synthesis of (5<i>R</i>)-(−)-5-Phenyloxazolidin-2-one (<b>17b</b>)</h4><div class="NLM_p last">Compound <b>17b</b> was prepared according to general procedure C using <b>16b</b> (0.100 g, 0.73 mmol). The crude was purified by column chromatography (SiO<sub>2</sub>), eluting with DCM/MeOH (9:1), to afford <b>17b</b> as a whitish solid (0.109 g, 92%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 7.49–7.31 (m, 5H), 5.63 (t, <i>J</i> = 8.1 Hz, 1H), 5.35 (bs, 1H), 4.02–3.95 (m, 1H), 3.58–3.51 (m, 1H). [α]<sub class="stack">D</sub><sup class="stack">30</sup> −26.0 (<i>c</i> 0.5, EtOH), consistent with data reported in the literature (lit:<a onclick="showRef(event, 'ref74'); return false;" href="javascript:void(0);" class="ref ref74">(74)</a> [α]<sub class="stack">D</sub><sup class="stack">22</sup> −24.6° (<i>c</i> 0.045, EtOH)). UPLC/MS (<i>method A</i>): <i>R</i><sub><i>t</i></sub> 1.41 min. MS (ES): C<sub>9</sub>H<sub>9</sub>NO<sub>2</sub> requires, 163; found, 164 [M + H]<sup>+</sup>.</div></div><div id="sec5_9_74" class="NLM_sec NLM_sec_level_3"><div id="ac_i101" class="anchor-spacer"></div><h4 class="article-section__title" id="_i101"> Synthesis of (5<i>S</i>)-(−)-2-Oxo-5-phenyl-<i>N</i>-(4-phenylbutyl)oxazolidine-3-carboxamide (<b>18a</b>)</h4><div class="NLM_p last">Compound <b>18a</b> was prepared according to general procedure D (<i>method A</i>) at 50 °C using compound <b>17a</b> (0.103 g, 0.63 mmol), DMAP (0.084 g, 0.69 mmol), and 4-phenylbutyl isocyanate (0.122 g, 0.69 mmol) in DMF. The crude was purified by column chromatography (SiO<sub>2</sub>), eluting with DCM/MeOH (97:3), to afford <b>18a</b> as colorless oil (0.146 g, 68%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 7.80 (bs, 1H), 7.47–7.39 (m, 3H), 7.39–7.34 (m, 2H), 7.31–7.24 (m, overlapped with CDCl<sub>3</sub> signal, 2H), 7.22–7.14 (m, 3H), 5.58 (t, <i>J</i> = 8.3 Hz, 1H), 4.43 (dd, <i>J</i> = 10.5, 8.9 Hz, 1H), 3.96 (dd, <i>J</i> = 10.5, 7.7 Hz, 1H), 3.40–3.26 (m, 2H), 2.65 (t, <i>J</i> = 7.4 Hz, 2H), 1.77–1.57 (m, 4H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>): δ 155.35, 151.61, 142.17, 137.15, 129.54, 129.24, 128.55, 128.49, 125.96, 125.89, 75.45, 49.86, 40.18, 35.62, 29.38, 28.71. [α]<sub class="stack">D</sub><sup class="stack">30</sup> −8.70 (<i>c</i> 0.1, CHCl<sub>3</sub>). UPLC/MS (<i>method B</i>): <i>R</i><sub><i>t</i></sub> 1.50 min. MS (ES): C<sub>20</sub>H<sub>22</sub>N<sub>2</sub>O<sub>3</sub> requires, 338; found, 339 [M + H]<sup>+</sup>. HRMS: C<sub>20</sub>H<sub>22</sub>N<sub>2</sub>O<sub>3</sub> [M + H]<sup>+</sup> calcd 339.1709; measured, 339.1703, Δppm −1.8.</div></div><div id="sec5_9_75" class="NLM_sec NLM_sec_level_3"><div id="ac_i102" class="anchor-spacer"></div><h4 class="article-section__title" id="_i102"> Synthesis of (5<i>R</i>)-(+)-2-Oxo-5-phenyl-<i>N</i>-(4-phenylbutyl)oxazolidine-3-carboxamide (<b>18b</b>)</h4><div class="NLM_p last">Compound <b>18b</b> was prepared according to general procedure D (<i>method A</i>) using <b>17b</b> (0.109 g, 0.67 mmol), DMAP (0.084 g, 0.74 mmol), and 4-phenylbutyl isocyanate (0.130 g, 0.74 mmol) in pyridine. The crude was purified by column chromatography (SiO<sub>2</sub>), eluting with Cy/EtOAc (9:1), to afford <b>18b</b> as colorless oil (0.180 g, 79%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 7.80 (bs, 1H), 7.47–7.39 (m, 3H), 7.39–7.34 (m, 2H), 7.31–7.24 (m, overlapped with CDCl<sub>3</sub> signal, 2H), 7.22–7.14 (m, 3H), 5.58 (t, <i>J</i> = 8.3 Hz, 1H), 4.43 (dd, <i>J</i> = 10.5, 8.9 Hz, 1H), 3.96 (dd, <i>J</i> = 10.5, 7.7 Hz, 1H), 3.40–3.26 (m, 2H), 2.65 (t, <i>J</i> = 7.4 Hz, 2H), 1.77–1.57 (m, 4H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>): δ 155.35, 151.61, 142.17, 137.15, 129.54, 129.24, 128.55, 128.49, 125.96, 125.89, 75.45, 49.86, 40.18, 35.62, 29.38, 28.71. [α]<sub class="stack">D</sub><sup class="stack">30</sup> +18.9 (<i>c</i> 0.1, CHCl<sub>3</sub>). UPLC/MS (<i>method B</i>): <i>R</i><sub><i>t</i></sub> 1.50 min. MS (ES): C<sub>20</sub>H<sub>22</sub>N<sub>2</sub>O<sub>3</sub> requires, 338; found, 339 [M + H]<sup>+</sup>. HRMS: C<sub>20</sub>H<sub>22</sub>N<sub>2</sub>O<sub>3</sub> [M + H]<sup>+</sup> calcd 339.1709; measured, 339.1704, Δppm −1.5.</div></div><div id="sec5_9_76" class="NLM_sec NLM_sec_level_3"><div id="ac_i103" class="anchor-spacer"></div><h4 class="article-section__title" id="_i103"> Synthesis of <i>tert</i>-Butyl 4-(3-Acetylphenyl)-3,6-dihydro-2<i>H</i>-pyridine-1-carboxylate (<b>21a</b>)</h4><div class="NLM_p last">Compound <b>21a</b> was prepared according to general procedure E using <b>20a</b> (0.500 g, 2.50 mmol) and <b>19</b> (0.850 g, 2.75 mmol). The crude was purified by column chromatography (SiO<sub>2</sub>), eluting with Cy/EtOAc (8:2), to afford <b>21a</b> as yellowish oil (0.580 g, 77%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 7.99–7.94 (m, 1H), 7.87–7.81 (m, 1H), 7.60–7.54 (m, 1H), 7.43 (t, <i>J</i> = 7.7 Hz, 1H), 6.15–6.08 (m, 1H), 4.12–4.07 (m, 2H), 3.66 (t, <i>J</i> = 5.7 Hz, 2H), 2.62 (s, 3H), 2.59–2.52 (m, 2H), 1.50 (s, 9H). UPLC/MS (<i>method A</i>): <i>R</i><sub><i>t</i></sub> 2.42 min. MS (ES): C<sub>18</sub>H<sub>23</sub>NO<sub>3</sub> requires, 301; found, 302 [M + H]<sup>+</sup>.</div></div><div id="sec5_9_77" class="NLM_sec NLM_sec_level_3"><div id="ac_i104" class="anchor-spacer"></div><h4 class="article-section__title" id="_i104"> Synthesis of <i>tert</i>-Butyl 4-(5-Acetyl-2-fluoro-phenyl)-3,6-dihydro-2<i>H</i>-pyridine-1-carboxylate (<b>21b</b>)</h4><div class="NLM_p last">Compound <b>21b</b> was prepared according to general procedure E using <b>20b</b> (1.000 g, 4.61 mmol) and <b>19</b> (1.568 g, 5.07 mmol). The crude was purified by column chromatography (SiO<sub>2</sub>), eluting with Cy/EtOAc (9:1), to afford <b>20b</b> as colorless oil (1.280 g, 87%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 7.91–7.81 (m, 2H), 7.11 (dd, <i>J</i> = 10.4, 8.5 Hz, 1H), 6.04–5.94 (m, 1H), 4.11–4.06 (m, 2H), 3.63 (t, <i>J</i> = 5.7 Hz, 2H), 2.59 (s, 3H), 2.54–2.49 (m, 2H), 1.50 (s, 9H). UPLC/MS (<i>method A</i>): <i>R</i><sub><i>t</i></sub> 2.56 min. MS (ES): C<sub>18</sub>H<sub>22</sub>FNO<sub>3</sub> requires, 319; found, 320 [M + H]<sup>+</sup>.</div></div><div id="sec5_9_78" class="NLM_sec NLM_sec_level_3"><div id="ac_i105" class="anchor-spacer"></div><h4 class="article-section__title" id="_i105"> Synthesis of <i>tert</i>-Butyl 4-(3-Acetylphenyl)piperidine-1-carboxylate (<b>22a</b>)</h4><div class="NLM_p last">Compound <b>22a</b> was prepared according to general procedure F (<i>method A</i>) using <b>21a</b> (0.510 g, 1.69 mmol). The crude was used in the next step without further purification. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 7.88–7.76 (m, 2H), 7.44–7.38 (m, 2H), 4.32–4.21 (m, 2H), 2.81 (td, <i>J</i> = 13.0, 2.7 Hz, 2H), 2.72 (tt, <i>J</i> = 12.1, 3.7 Hz, 1H), 2.60 (s, 3H), 1.89–1.78 (m, 2H), 1.65 (qd, <i>J</i> = 12.7, 4.5 Hz, 2H), 1.49 (s, 9H). UPLC/MS (<i>method A</i>): <i>R</i><sub><i>t</i></sub> 2.43 min. MS (ES): C<sub>18</sub>H<sub>25</sub>NO<sub>3</sub> requires, 303; found, 304 [M + H]<sup>+</sup>.</div></div><div id="sec5_9_79" class="NLM_sec NLM_sec_level_3"><div id="ac_i106" class="anchor-spacer"></div><h4 class="article-section__title" id="_i106"> Synthesis of <i>tert</i>-Butyl 4-(5-Acetyl-2-fluoro-phenyl)piperidine-1-carboxylate (<b>22b</b>)</h4><div class="NLM_p last">Compound <b>22b</b> was prepared according to general procedure F (<i>method A</i>) using <b>21b</b> (1.000 g, 3.13 mmol). The crude was purified by column chromatography (SiO<sub>2</sub>), eluting with Cy/EtOAc (9:1), to afford <b>21b</b> as colorless oil (0.650 g, 65%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 7.87–7.84 (m, 1H), 7.84–7.78 (m, 1H), 7.09 (dd, <i>J</i> = 9.9, 8.5 Hz, 1H), 4.34–4.22 (m, 2H), 3.02 (tt, <i>J</i> = 12.1, 3.6 Hz, 1H), 2.83 (td, <i>J</i> = 13.2, 2.7 Hz, 2H), 2.58 (s, 3H), 1.86–1.78 (m, 2H), 1.68 (qd, <i>J</i> = 12.6, 4.1 Hz, 2H), 1.48 (s, 9H). UPLC/MS (<i>method A</i>): <i>R</i><sub><i>t</i></sub> 2.54 min. MS (ES): C<sub>18</sub>H<sub>24</sub>FNO<sub>3</sub> requires, 321; found, 322 [M + H]<sup>+</sup>.</div></div><div id="sec5_9_80" class="NLM_sec NLM_sec_level_3"><div id="ac_i107" class="anchor-spacer"></div><h4 class="article-section__title" id="_i107"> Synthesis of <i>tert</i>-Butyl 4-[3-(2-Bromoacetyl)phenyl]piperidine-1-carboxylate (<b>22c</b>)</h4><div class="NLM_p last">To a solution of <b>22a</b> (0.370 g, 1.22 mmol, 1.0 equiv) in dry THF (12 mL, 0.1 M), Et<sub>3</sub>N (0.494 g, 0.68 mL, 4.88 mmol, 4.0 equiv) was added at 0 °C under a N<sub>2</sub> atmosphere. After 30 min, TMSOTf (0.425 g, 0.35 mL, 1.92 mmol, 1.5 equiv) was added dropwise at −78 °C. The mixture was stirred at −50 °C for 4 h and then quenched with cold 5% aq NaHCO<sub>3</sub> solution and extracted with cold EtOAc (3 times). The combined organic layer was dried over Na<sub>2</sub>SO<sub>4</sub>. After evaporation of the solvent, the crude was dissolved in dry THF (12 mL, 0.1 M) and NBS (0.230 g, 1.28 mmol, 1.0 equiv) was added at −40 °C, and the mixture was stirred at −20 °C for additional 30 min. The reaction was diluted with H<sub>2</sub>O and extracted with EtOAc. The combined organic layer was washed with brine and dried over Na<sub>2</sub>SO<sub>4</sub>. After evaporation of the solvent, <b>22c</b> was used in the next step without further purification. UPLC/MS (<i>method A</i>): <i>R</i><sub><i>t</i></sub> 2.66 min. MS (ES): C<sub>18</sub>H<sub>24</sub>BrNO<sub>3</sub> requires, 381; found, 382 [M + H]<sup>+</sup>.</div></div><div id="sec5_9_81" class="NLM_sec NLM_sec_level_3"><div id="ac_i108" class="anchor-spacer"></div><h4 class="article-section__title" id="_i108"> Synthesis of <i>tert</i>-Butyl 4-[5-(2-Bromoacetyl)-2-fluoro-phenyl]piperidine-1-carboxylate (<b>22d</b>)</h4><div class="NLM_p last">To a solution of <b>22b</b> (0.450 g, 1.40 mmol, 1.0 equiv) in dry THF (14 mL, 0.1 M), Et<sub>3</sub>N (0.570 g, 0.780 mL, 5.60 mmol, 4.0 equiv) was added at 0 °C under a N<sub>2</sub> atmosphere. After 30 min, TMSOTf (0.470 g, 0.380 mL, 2.10 mmol, 1.5 equiv) was added dropwise at −78 °C. The mixture was stirred at −50 °C for 4 h. Then, the mixture was quenched with cold 5% aq NaHCO<sub>3</sub> solution and extracted with cold EtOAc (3 times). The combined organic layer was dried over Na<sub>2</sub>SO<sub>4</sub> and the solvent was removed under vacuum. The crude was dissolved in dry THF (14 mL, 0.1 M) and NBS (0.230 g, 1.28 mmol, 1.0 equiv) was added at −40 °C, and the mixture was stirred at −20 °C for an additional 30 min. The reaction was diluted with H<sub>2</sub>O and extracted with EtOAc. The combined organic layer was washed with brine and dried over Na<sub>2</sub>SO<sub>4</sub>. After evaporation of the solvent, <b>22d</b> was used as the crude in the next step without further purification. UPLC/MS (<i>method B</i>): <i>R</i><sub><i>t</i></sub> 1.68 min. MS (ES): C<sub>18</sub>H<sub>23</sub>BrFNO<sub>3</sub> requires, 399; found, 400 [M + H]<sup>+</sup>.</div></div><div id="sec5_9_82" class="NLM_sec NLM_sec_level_3"><div id="ac_i109" class="anchor-spacer"></div><h4 class="article-section__title" id="_i109"> Synthesis of <i>tert</i>-Butyl 4-[3-[2-(2,4-Dioxothiazolidin-3-yl)acetyl]phenyl]piperidine-1-carboxylate (<b>23a</b>)</h4><div class="NLM_p last">Compound <b>23a</b> was prepared according to general procedure B, Step 1, using <b>22c</b> (0.466 g, 1.22 mmol). The crude was used in Step 2 without further purification. UPLC/MS (<i>method A</i>): <i>R</i><sub><i>t</i></sub> 2.46 min. MS (ES): C<sub>21</sub>H<sub>26</sub>N<sub>2</sub>O<sub>5</sub>S requires, 418; found, 419 [M + H]<sup>+</sup>, 417 [M – H]<sup>−</sup>.</div></div><div id="sec5_9_83" class="NLM_sec NLM_sec_level_3"><div id="ac_i110" class="anchor-spacer"></div><h4 class="article-section__title" id="_i110"> Synthesis of <i>tert</i>-Butyl 4-[5-[2-(2,4-Dioxothiazolidin-3-yl)acetyl]-2-fluoro-phenyl]piperidine-1-carboxylate (<b>23b</b>)</h4><div class="NLM_p last">Compound <b>23b</b> was prepared according to general procedure B, Step 1, using <b>22d</b> (0.560 g, 1.40 mmol, 1.0 equiv). The crude was purified by column chromatography (SiO<sub>2</sub>), eluting with Cy/EtOAc (9:1), to afford <b>23b</b> as a white solid (0.570 g, 93%). <sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>): δ 7.87–7.80 (m, 2H), 7.15 (dd, <i>J</i> = 9.8, 8.4 Hz, 1H), 5.00 (s, 2H), 4.32–4.24 (m, 2H), 4.10 (s, 2H), 3.04 (tt, <i>J</i> = 12.2, 3.5 Hz, 1H), 2.83 (td, <i>J</i> = 13.1, 2.6 Hz, 2H), 1.86–1.78 (m, 2H), 1.67 (qd, <i>J</i> = 12.8, 4.4 Hz, 2H), 1.48 (s, 9H). UPLC/MS (<i>method A</i>): <i>R</i><sub><i>t</i></sub> 2.50 min. MS (ES): C<sub>21</sub>H<sub>25</sub>FN<sub>2</sub>O<sub>5</sub>S requires, 436; found, 437 [M + H]<sup>+</sup>.</div></div><div id="sec5_9_84" class="NLM_sec NLM_sec_level_3"><div id="ac_i111" class="anchor-spacer"></div><h4 class="article-section__title" id="_i111"> Synthesis of <i>tert</i>-Butyl 4-[3-(2-Oxo-3<i>H</i>-oxazol-5-yl)phenyl]piperidine-1-carboxylate (<b>24a</b>)</h4><div class="NLM_p last">Compound <b>24a</b> was prepared using <b>23a</b> (0.509 g, 1.22 mmol) and LiOH (0.117 g, 4.88 mmol), according to general procedure B, Step 2. The crude was purified by flash chromatography (SiO<sub>2</sub>), eluting with Cy/EtOAc (9:1), to afford <b>24a</b> as colorless oil (0.120 g, 29%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 7.43–7.39 (m, 2H), 7.34–7.31 (m, 1H), 7.29–7.24 (m, overlapped with CDCl<sub>3</sub> signal, 1H), 6.95 (s, 1H), 4.29–4.19 (m, 2H), 2.94 (tt, <i>J</i> = 11.8, 3.3 Hz, 1H), 2.84–2.73 (m, 2H), 1.83–1.75 (m, 2H), 1.70–1.60 (m, overlapped with H<sub>2</sub>O signal, 2H), 1.48 (s, 9H). UPLC/MS (<i>method A</i>): <i>R</i><sub><i>t</i></sub> 2.83 min. MS (ES): C<sub>19</sub>H<sub>24</sub>N<sub>2</sub>O<sub>4</sub> requires, 344; found, 345 [M + H]<sup>+</sup>.</div></div><div id="sec5_9_85" class="NLM_sec NLM_sec_level_3"><div id="ac_i112" class="anchor-spacer"></div><h4 class="article-section__title" id="_i112"> Synthesis of <i>tert</i>-Butyl 4-[2-Fluoro-5-(2-oxo-3<i>H</i>-oxazol-5-yl)phenyl]piperidine-1-carboxylate (<b>24b</b>)</h4><div class="NLM_p last">Compound <b>24b</b> was prepared using <b>23b</b> (0.560 g, 1.30 mmol) and <i>t</i>-BuOK (0.586 g, 5.22 mmol, 4.0 equiv), according to general procedure B, Step 2. The crude was purified by flash chromatography (SiO<sub>2</sub>), eluting with Cy/EtOAc (6:4), to afford <b>24b</b> as an orange solid (0.340 g, 72%). <sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>): δ 9.22–9.12 (m, 1H), 7.36–7.29 (m, 2H), 7.04 (dd, <i>J</i> = 9.9, 8.5 Hz, 1H), 6.79–6.76 (m, 1H), 4.35–4.20 (m, 2H), 3.01 (tt, <i>J</i> = 12.2, 3.5 Hz, 1H), 2.87–2.76 (m, 2H), 1.84–1.75 (m, 2H), 1.66 (qd, <i>J</i> = 12.7, 4.4 Hz, 2H), 1.48 (s, 9H). UPLC/MS (<i>method A</i>): <i>R</i><sub><i>t</i></sub> 2.30 min. MS (ES): C<sub>19</sub>H<sub>23</sub>FN<sub>2</sub>O<sub>4</sub> requires, 362; found, 363 [M + H]<sup>+</sup>, 361 [M – H]<sup>−</sup>.</div></div><div id="sec5_9_86" class="NLM_sec NLM_sec_level_3"><div id="ac_i113" class="anchor-spacer"></div><h4 class="article-section__title" id="_i113"> Synthesis of 5-[4-Fluoro-3-(4-piperidyl)phenyl]-3<i>H</i>-oxazol-2-one Hydrochloride (<b>24c</b>)</h4><div class="NLM_p last">Compound <b>24c</b> was prepared according to general procedure G using <b>24b</b> (0.150 g, 0.41 mmol). The crude was used in the next step without further purification. UPLC/MS (<i>method A</i>): <i>R</i><sub><i>t</i></sub> 1.22 min. MS (ES): C<sub>14</sub>H<sub>15</sub>FN<sub>2</sub>O<sub>2</sub> requires, 262; found, 263 [M + H]<sup>+</sup>,261 [M – H]<sup>−</sup>.</div></div><div id="sec5_9_87" class="NLM_sec NLM_sec_level_3"><div id="ac_i114" class="anchor-spacer"></div><h4 class="article-section__title" id="_i114"> Synthesis of 5-[4-Fluoro-3-(1-methyl-4-piperidyl)phenyl]-3<i>H</i>-oxazol-2-one (<b>24d</b>)</h4><div class="NLM_p last">Compound <b>24d</b> was prepared according to general procedure H using <b>24c</b> (0.123 g, 0.41 mmol) and 37% aq. solution of HCHO (0.066 g, 0.061 mL, 0.82 mmol). The crude was purified by trituration with Et<sub>2</sub>O to afford <b>24d</b> as a white solid (0.080 g, 71%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 7.48–7.41 (m, 1H), 7.38–7.31 (m, 1H), 7.08–6.99 (m, 1H), 6.91 (s, 1H), 3.48–3.36 (m, 2H), 3.10–2.98 (m, 1H), 2.67 (s, 3H), 2.66–2.53 (m, 2H), 2.37–2.20 (m, 2H), 2.02–1.91 (m, 2H). UPLC/MS (<i>method A</i>): <i>R</i><sub><i>t</i></sub> 1.23 min. MS (ES): C<sub>15</sub>H<sub>17</sub>FN<sub>2</sub>O<sub>2</sub> requires, 276; found, 277 [M + H]<sup>+</sup>, 275 [M – H]<sup>−</sup>.</div></div><div id="sec5_9_88" class="NLM_sec NLM_sec_level_3"><div id="ac_i115" class="anchor-spacer"></div><h4 class="article-section__title" id="_i115"> Synthesis of <i>tert</i>-Butyl 4-[3-[2-Oxo-3-(4-phenylbutylcarbamoyl)oxazol-5-yl]phenyl]piperidine-1-carboxylate (<b>25a</b>)</h4><div class="NLM_p last">Compound <b>25a</b> was prepared according to general procedure D (<i>method A</i>) using <b>24a</b> (0.120 g, 0.35 mmol), DMAP (0.047 g, 0.39 mmol) and 4-phenylbutyl isocyanate (0.068 g, 0.067 mL, 0.39 mmol) in pyridine. The crude was purified by column chromatography (SiO<sub>2</sub>), eluting with Cy/EtOAc (9:1), to afford <b>25a</b> as yellowish oil (0.125 g, 69%). UPLC/MS (<i>method B</i>): <i>R</i><sub><i>t</i></sub> 2.46 min. MS (ES): C<sub>30</sub>H<sub>37</sub>N<sub>3</sub>O<sub>5</sub> requires, 519; found, 520 [M + H]<sup>+</sup>.</div></div><div id="sec5_9_89" class="NLM_sec NLM_sec_level_3"><div id="ac_i116" class="anchor-spacer"></div><h4 class="article-section__title" id="_i116"> Synthesis of 2-Oxo-<i>N</i>-(4-phenylbutyl)-5-[3-(4-piperidyl)phenyl]oxazole-3-carboxamide Hydrochloride (<b>25b</b>)</h4><div class="NLM_p last">Compound <b>25b</b> was prepared according to general procedure G using <b>25a</b> (0.125 g, 0.24 mmol). The crude was purified by trituration with Et<sub>2</sub>O to afford <b>25b</b> as a white solid (0.046 g, 46%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 8.66 (bs, 2H), 8.12 (t, <i>J</i> = 5.9 Hz, 1H), 7.57 (s, 1H), 7.52–7.45 (m, 2H), 7.39–7.32 (m, 2H), 7.31–7.24 (m, 2H), 7.24–7.11 (m, 3H), 3.43–3.26 (m, overlapped with H<sub>2</sub>O signal, 4H), 3.24–3.13 (m, 1H), 3.09–2.90 (m, 1H), 2.61 (t, <i>J</i> = 7.2 Hz, 2H), 1.95–1.77 (m, 4H), 1.68–1.48 (m, 4H). UPLC/MS (<i>method B</i>): <i>R</i><sub><i>t</i></sub> 1.72 min. MS (ES): C<sub>25</sub>H<sub>29</sub>N<sub>3</sub>O<sub>3</sub> requires, 419; found, 420 [M + H]<sup>+</sup>, 418 [M – H]<sup>−</sup>.</div></div><div id="sec5_9_90" class="NLM_sec NLM_sec_level_3"><div id="ac_i117" class="anchor-spacer"></div><h4 class="article-section__title" id="_i117"> Synthesis of 5-[3-(1-Methyl-4-piperidyl)phenyl]-2-oxo-<i>N</i>-(4-phenylbutyl)oxazole-3-carboxamide (<b>25c</b>)</h4><div class="NLM_p last">Compound <b>25c</b> was prepared according to general procedure H using <b>25b</b> (0.046 g, 0.01 mmol) and 37% aq solution of HCHO (0.016 g, 0.015 mL, 0.19 mmol). The crude was purified by trituration with Et<sub>2</sub>O to afford <b>25c</b> as a white solid (0.025 g, 60%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 7.99 (t, <i>J</i> = 5.9 Hz, 1H), 7.48–7.37 (m, 3H), 7.34–7.22 (m, overlapped with CDCl<sub>3</sub> signal, 4H), 7.25–7.16 (m, 3H), 3.48–3.39 (m, 2H), 3.11–2.98 (m, 2H), 2.80 (tt, <i>J</i> = 11.9, 3.8 Hz, 1H), 2.67 (t, <i>J</i> = 7.2 Hz, 2H), 2.38 (s, 3H), 2.23–2.09 (m, 2H), 2.03–1.87 (m, 2H), 1.86–1.78 (m, 2H), 1.78–1.60 (m, overlapped with H<sub>2</sub>O signal, 4H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>): δ 152.89, 148.67, 144.41, 141.99, 139.54, 130.49, 129.13, 128.53 (2C), 127.01, 126.68, 126.04, 125.01, 108.93, 56.16, 46.11, 40.44, 38.30, 35.57, 32.89, 29.22, 28.65. UPLC/MS (<i>method B</i>): <i>R</i><sub><i>t</i></sub> 1.10 min. MS (ES): C<sub>26</sub>H<sub>31</sub>N<sub>3</sub>O<sub>3</sub> requires, 433; found, 434 [M + H]<sup>+</sup>, 257 [M–CONH(CH<sub>2</sub>)<sub>4</sub>Ph]<sup>−</sup>. HRMS: C<sub>26</sub>H<sub>31</sub>N<sub>3</sub>O<sub>3</sub> [M + H]<sup>+</sup> calcd 434.2444; measured, 434.2450, Δppm 1.4.</div></div><div id="sec5_9_91" class="NLM_sec NLM_sec_level_3"><div id="ac_i118" class="anchor-spacer"></div><h4 class="article-section__title" id="_i118"> Synthesis of 5-[4-Fluoro-3-(1-methyl-4-piperidyl)phenyl]-2-oxo-<i>N</i>-(4-phenylbutyl)oxazole-3-carboxamide (<b>25d</b>)</h4><div class="NLM_p last">Compound <b>25d</b> was prepared according to general procedure D (<i>method A</i>) using <b>24d</b> (0.075 g, 0.27 mmol), DMAP (0.037 g, 0.30 mmol), and 4-phenylbutyl isocyanate (0.095 g, 0.092 mL, 0.54 mmol) in pyridine at 50 °C. The crude was purified by column chromatography (SiO<sub>2</sub>), eluting with DCM/MeOH (92:8), to afford <b>25d</b> as a white solid (0.030 g, 25%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 7.92 (t, <i>J</i> = 5.8 Hz, 1H), 7.41 (dd, <i>J</i> = 6.9, 2.3 Hz, 1H), 7.38 (s, 1H), 7.34 (ddd, <i>J</i> = 8.5, 4.8, 2.3 Hz, 1H), 7.31–7.26 (m, overlapped with CDCl<sub>3</sub> signal, 2H), 7.22–7.13 (m, 3H), 7.06 (dd, <i>J</i> = 9.9, 8.5 Hz, 1H), 3.45–3.36 (m, 2H), 3.14–3.00 (m, 2H), 2.94–2.81 (m, 1H), 2.66 (t, <i>J</i> = 7.2 Hz, 2H), 2.40 (s, 3H), 2.26–2.13 (m, 2H), 2.01–1.80 (m, 4H), 1.77–1.60 (m, 4H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>): δ 152.70, 148.52, 142.02, 139.03, 128.56, 128.53, 126.03, 123.38, 122.98, 116.42 (d, <i>J</i><sub>C–F</sub> = 24.2 Hz), 105.90, 55.80, 45.60, 40.46, 35.57, 34.37, 30.85, 29.20, 28.64. UPLC/MS (<i>method A</i>): <i>R</i><sub><i>t</i></sub> 2.30 min. MS (ES): C<sub>26</sub>H<sub>30</sub>FN<sub>3</sub>O<sub>3</sub> requires, 451; found, 452 [M + H]<sup>+</sup>, 275 [M–CONH(CH<sub>2</sub>)<sub>4</sub>Ph]<sup>−</sup>. HRMS: C<sub>26</sub>H<sub>30</sub>FN<sub>3</sub>O<sub>3</sub> [M + H]<sup>+</sup> calcd 452.2349; measured, 452.2340, Δppm −2.0.</div></div><div id="sec5_9_92" class="NLM_sec NLM_sec_level_3"><div id="ac_i119" class="anchor-spacer"></div><h4 class="article-section__title" id="_i119"> Synthesis of 5-[4-Fluoro-3-(1-methyl-4-piperidyl)phenyl]-2-oxo-<i>N</i>-pentyl-oxazole-3-carboxamide (<b>25e</b>)</h4><div class="NLM_p last">Compound <b>25e</b> was prepared according to general procedure D (<i>method A</i>), using <b>24d</b> (0.070 g, 0.25 mmol), Et<sub>3</sub>N (0.050 g, 0.070 mL, 0.05 mmol) and pentyl isocyanate (0.034 g, 0.038 mL, 0.30 mmol) in CH<sub>3</sub>CN at 50 °C. The crude was purified by column chromatography (SiO<sub>2</sub>), eluting with DCM/MeOH (9:1), to afford <b>25e</b> as a white solid (0.035 g, 36%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 8.09 (s, 1H), 8.01 (t, <i>J</i> = 5.8 Hz, 1H), 7.68–7.62 (m, 1H), 7.55–7.49 (m, 1H), 7.23 (dd, <i>J</i> = 10.3, 8.7 Hz, 1H), 3.33–3.22 (m, overlapped with H<sub>2</sub>O signal, 2H), 3.02–2.89 (m, 2H), 2.79 (tt, <i>J</i> = 11.7, 3.5 Hz, 1H), 2.28 (s, 3H), 2.20–2.02 (m, 2H), 1.82 (qd, <i>J</i> = 12.4, 3.3 Hz, 2H), 1.75–1.66 (m, 2H), 1.53 (p, <i>J</i> = 7.2 Hz, 2H), 1.37–1.21 (m, 4H), 0.88 (t, <i>J</i> = 6.8 Hz, 3H). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>): δ 159.96 (d, <i>J</i><sub>C–F</sub> = 246.6 Hz), 151.80, 147.92, 142.44, 137.69, 132.80, 123.23, 123.15 (d, <i>J</i><sub>C–F</sub> = 3.1 Hz), 116.08 (d, <i>J</i> = 24.1 Hz), 107.61, 54.89, 44.95, 40.11 (overlapped with DMSO signal), 33.82, 30.38, 28.61, 28.34, 21.76, 13.85. UPLC/MS (<i>method A</i>): <i>R</i><sub><i>t</i></sub> 2.12 min. MS (ES): C<sub>21</sub>H<sub>28</sub>FN<sub>3</sub>O<sub>3</sub> requires, 389; found, 390 [M + H]<sup>+</sup>, 275 [M–CONH(CH<sub>2</sub>)<sub>4</sub>CH<sub>3</sub>]<sup>−</sup>. HRMS: C<sub>21</sub>H<sub>28</sub>FN<sub>3</sub>O<sub>3</sub> [M + H]<sup>+</sup> calcd 390.2193; measured, 390.2195, Δppm 0.5.</div></div><div id="sec5_9_93" class="NLM_sec NLM_sec_level_3"><div id="ac_i120" class="anchor-spacer"></div><h4 class="article-section__title" id="_i120"> Synthesis of 5-[4-Fluoro-3-(1-methyl-4-piperidyl)phenyl]-<i>N</i>-isobutyl-2-oxo-oxazole-3-carboxamide (<b>25f</b>)</h4><div class="NLM_p last">Compound <b>25f</b> was prepared according to general procedure D (<i>method C</i>) using <b>24d</b> (0.035 g, 0.13 mmol), 2-methylpropan-1-amine (0.028 g, 0.030 mL, 0.39 mmol), and Et<sub>3</sub>N (0.079 g, 0.109 mL, 0.78 mmol). The crude was purified by column chromatography (SiO<sub>2</sub>), eluting with DCM/MeOH (9:1), to afford <b>25f</b> as a white solid (0.040 g, 82%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 7.98 (t, <i>J</i> = 4.9 Hz, 1H), 7.45–7.41 (m, 1H), 7.41 (s, 1H), 7.35 (ddd, <i>J</i> = 8.6, 4.8, 2.2 Hz, 1H), 7.07 (dd, <i>J</i> = 10.0, 8.5 Hz, 1H), 3.23 (t, <i>J</i> = 6.4 Hz, 2H), 3.20–3.11 (m, 2H), 2.92 (tt, <i>J</i> = 11.5, 2.9 Hz, 1H), 2.47 (s, 3H), 2.40–2.25 (m, 2H), 2.11–1.96 (m, 2H), 1.95–1.82 (m, 3H), 0.98 (d, <i>J</i> = 6.7 Hz, 6H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>): δ 161.07 (d, <i>J</i><sub>C–F</sub> = 249.2 Hz), 152.75, 148.63, 139.04, 133.22 (d, <i>J</i> = 15.4 Hz), 123.45, 123.40, 122.93 (d, <i>J</i><sub>C–F</sub> = 3.5 Hz), 116.38 (d, <i>J</i><sub>C–F</sub> = 24.2 Hz), 105.86 (d, <i>J</i><sub>C–F</sub> = 2.1 Hz), 55.93, 47.89, 45.88, 34.56, 31.19, 28.61, 20.11. UPLC/MS (<i>method A</i>): <i>R</i><sub><i>t</i></sub> 1.96 min. MS (ES): C<sub>20</sub>H<sub>26</sub>FN<sub>3</sub>O<sub>3</sub> requires, 375; found, 376 [M + H]<sup>+</sup>, 275 [M–CONHCH<sub>2</sub>CH(CH<sub>3</sub>)<sub>2</sub>]<sup>−</sup>. HRMS: C<sub>20</sub>H<sub>26</sub>FN<sub>3</sub>O<sub>3</sub> [M + H]<sup>+</sup> calcd 376.2036 measured 376.2028, Δppm −2.1.</div></div><div id="sec5_9_94" class="NLM_sec NLM_sec_level_3"><div id="ac_i121" class="anchor-spacer"></div><h4 class="article-section__title" id="_i121"> Synthesis of <i>tert</i>-Butyl 4-(2-Acetyl-5-fluoro-phenyl)-3,6-dihydro-2<i>H</i>-pyridine-1-carboxylate (<b>27</b>)</h4><div class="NLM_p last">Compound <b>27</b> was prepared according to general procedure E using <b>26</b> (2.000 g, 9.22 mmol) and <b>19</b> (3.990 g, 12.90 mmol). The crude was purified by column chromatography (SiO<sub>2</sub>), eluting with Cy/EtOAc (9:1), to afford <b>27</b> as yellow oil (2.530 g, 85%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 7.60 (dd, <i>J</i> = 8.6, 5.7 Hz, 1H), 7.05–6.99 (m, 1H), 6.92 (dd, <i>J</i> = 9.5, 2.6 Hz, 1H), 5.60–5.51 (m, 1H), 4.02 (q, <i>J</i> = 2.8 Hz, 2H), 3.65 (t, <i>J</i> = 5.6 Hz, 2H), 2.46 (s, 3H), 2.40–2.32 (m, 2H), 1.49 (s, 9H). UPLC/MS (<i>method B</i>): <i>R</i><sub><i>t</i></sub> 1.40 min. MS (ES): C<sub>18</sub>H<sub>22</sub>FNO<sub>3</sub> requires, 319; found, 320 [M + H]<sup>+</sup>.</div></div><div id="sec5_9_95" class="NLM_sec NLM_sec_level_3"><div id="ac_i122" class="anchor-spacer"></div><h4 class="article-section__title" id="_i122"> Synthesis of <i>tert</i>-Butyl 4-(2-Acetyl-5-fluoro-phenyl)piperidine-1-carboxylate (<b>28</b>)</h4><div class="NLM_p last">Compound <b>28</b> was prepared according to general procedure F (<i>method B</i>) using <b>27</b> (1.500 g, 4.70 mmol). The crude was purified by column chromatography (SiO<sub>2</sub>), eluting with Cy/EtOAc (9:1), to afford <b>28</b> as colorless oil (1.040 g, 69%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 7.65 (dd, <i>J</i> = 8.6, 5.9 Hz, 1H), 7.05 (dd, <i>J</i> = 10.6, 2.6 Hz, 1H), 6.98–6.92 (m, 1H), 4.31–4.16 (m, 2H), 3.43 (dddd, <i>J</i> = 10.0, 8.6, 3.7, 1.6 Hz, 1H), 2.81 (t, <i>J</i> = 12.8 Hz, 2H), 2.58 (s, 3H), 1.85–1.75 (m, 2H), 1.61–1.52 (m, overlapped with H<sub>2</sub>O signal, 2H), 1.48 (s, 9H). UPLC/MS (<i>method B</i>): <i>R</i><sub><i>t</i></sub> 1.51 min. MS (ES): C<sub>18</sub>H<sub>24</sub>FNO<sub>3</sub> requires, 321; found, 322 [M + H]<sup>+</sup>.</div></div><div id="sec5_9_96" class="NLM_sec NLM_sec_level_3"><div id="ac_i123" class="anchor-spacer"></div><h4 class="article-section__title" id="_i123"> Synthesis of <i>tert</i>-Butyl 4-[2-(2-Bromoacetyl)-5-fluoro-phenyl]piperidine-1-carboxylate (<b>29</b>)</h4><div class="NLM_p last">To a solution of <b>28</b> (0.410 g, 1.28 mmol, 1.0 equiv) in dry THF (13 mL, 0.1 M), and Et<sub>3</sub>N (0.516 g, 0.710 mL, 5.10 mmol, 4.0 equiv) was added at 0 °C under a N<sub>2</sub> atmosphere. After 30 min, TMSOTf (0.425 g, 0.346 mL, 1.92 mmol, 1.5 equiv) was added dropwise at −78 °C. The mixture was stirred at −50 °C for 4 h. Then, the mixture was quenched with cold 5% aq NaHCO<sub>3</sub> solution and extracted with cold EtOAc (3 times). The combined organic layer was washed with brine and dried over Na<sub>2</sub>SO<sub>4</sub>. After evaporation of the solvent, the crude was dissolved in dry THF (13 mL, 0.1 M), NBS (0.227 g, 1.28 mmol, 1.0 equiv) was added at −40 °C, and the mixture was stirred at −20 °C for additional 30 min. The reaction was diluted with H<sub>2</sub>O and extracted with EtOAc. The combined organic layer was washed with brine and dried over Na<sub>2</sub>SO<sub>4</sub>. After evaporation of the solvent, the crude of <b>29</b> was used in the next step without further purification. UPLC/MS (<i>method B</i>): <i>R</i><sub><i>t</i></sub> 1.70 min. MS (ES): C<sub>18</sub>H<sub>23</sub>BrFNO<sub>3</sub> requires, 399; found, 400 [M + H]<sup>+</sup>, 398 [M – H]<sup>−</sup>.</div></div><div id="sec5_9_97" class="NLM_sec NLM_sec_level_3"><div id="ac_i124" class="anchor-spacer"></div><h4 class="article-section__title" id="_i124"> Synthesis of <i>tert</i>-Butyl 4-[2-[2-(2,4-Dioxothiazolidin-3-yl)acetyl]-5-fluoro-phenyl]piperidine-1-carboxylate (<b>30</b>)</h4><div class="NLM_p last">Compound <b>30</b> was prepared according to general procedure B, Step 1, using <b>29</b> (0.512 g, 1.28 mmol). The crude was purified by column chromatography (SiO<sub>2</sub>), eluting with Cy/EtOAc (8:2), to afford <b>30</b> as colorless oil (0.366 g, 66%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 7.67 (dd, <i>J</i> = 8.7, 5.6 Hz, 1H), 7.10 (dd, <i>J</i> = 10.5, 2.6 Hz, 1H), 7.05–6.98 (m, 1H), 4.85 (s, 2H), 4.27–4.16 (m, 2H), 4.10 (s, 2H), 3.36–3.25 (m, 1H), 2.81 (td, <i>J</i> = 13.4, 13.0, 2.5 Hz, 2H), 1.84–1.74 (m, 2H), 1.58–1.51 (m, overlapped with H<sub>2</sub>O signal, 2H), 1.47 (s, 9H). UPLC/MS (<i>method B</i>): <i>R</i><sub><i>t</i></sub> 1.42 min. MS (ES): C<sub>21</sub>H<sub>25</sub>FN<sub>2</sub>O<sub>5</sub>S requires, 436; found, 437 [M + H]<sup>+</sup>, 435 [M – H]<sup>−</sup>.</div></div><div id="sec5_9_98" class="NLM_sec NLM_sec_level_3"><div id="ac_i125" class="anchor-spacer"></div><h4 class="article-section__title" id="_i125"> Synthesis of <i>tert</i>-Butyl 4-[5-Fluoro-2-(2-oxo-3<i>H</i>-oxazol-5-yl)phenyl]piperidine-1-carboxylate (<b>31a</b>)</h4><div class="NLM_p last">Compound <b>31a</b> was prepared using <b>30</b> (0.366 g, 0.84 mmol) and <i>t</i>-BuOK (0.376 g, 3.35 mmol), according to general procedure B, Step 2. The crude was purified by flash chromatography (SiO<sub>2</sub>), eluting with DCM/MeOH (95:5), to afford <b>31a</b> as yellow foam (0.204 g, 67%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 9.14 (bs, 1H), 7.39 (dd, <i>J</i> = 8.6, 5.8 Hz, 1H), 7.02 (dd, <i>J</i> = 10.3, 2.6 Hz, 1H), 6.99–6.92 (m, 1H), 6.59 (d, <i>J</i> = 1.9 Hz, 1H), 4.41–4.14 (m, 2H), 3.05–2.90 (m, 1H), 2.89–2.70 (m, 2H), 1.84–1.75 (m, 2H), 1.71–1.53 (m, overlapped with H<sub>2</sub>O signal, 2H), 1.48 (s, 9H). UPLC/MS (<i>method A</i>): <i>R</i><sub><i>t</i></sub> 2.25 min. MS (ES): C<sub>19</sub>H<sub>23</sub>FN<sub>2</sub>O<sub>4</sub> requires, 362; found, 363 [M + H]<sup>+</sup>, 361 [M – H]<sup>−</sup>.</div></div><div id="sec5_9_99" class="NLM_sec NLM_sec_level_3"><div id="ac_i126" class="anchor-spacer"></div><h4 class="article-section__title" id="_i126"> Synthesis of 5-[4-Fluoro-2-(4-piperidyl)phenyl]-3<i>H</i>-oxazol-2-one Hydrochloride (<b>31b</b>)</h4><div class="NLM_p last">Compound <b>31b</b> was prepared according to general procedure G using <b>31a</b> (0.150 g, 0.41 mmol). The crude was used in the next step without further purification. UPLC/MS (<i>method A</i>): <i>R</i><sub><i>t</i></sub> 1.27 min. MS (ES): C<sub>14</sub>H<sub>15</sub>FN<sub>2</sub>O<sub>2</sub> requires, 262; found, 263 [M + H]<sup>+</sup>, 261 [M – H]<sup>−</sup>.</div></div><div id="sec5_9_100" class="NLM_sec NLM_sec_level_3"><div id="ac_i127" class="anchor-spacer"></div><h4 class="article-section__title" id="_i127"> Synthesis of 5-[4-Fluoro-2-(1-methyl-4-piperidyl)phenyl]-3<i>H</i>-oxazol-2-one (<b>31c</b>)</h4><div class="NLM_p last">Compound <b>31c</b> was prepared according to general procedure H using <b>31b</b> (0.123 g, 0.41 mmol) and 37% aq solution of HCHO (0.165 g, 0.150 mL, 2.05 mmol). The crude was used in the next step without further purification. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 10.85 (bs, 1H), 7.43 (dd, <i>J</i> = 8.7, 6.1 Hz, 1H), 7.21 (dd, <i>J</i> = 10.8, 2.7 Hz, 1H), 7.11 (td, <i>J</i> = 8.4, 2.7 Hz, 1H), 7.06 (s, 1H), 2.94–2.84 (m, 2H), 2.83–2.73 (m, 1H), 2.23 (s, 3H), 2.10–1.96 (m, 2H), 1.78–1.62 (m, 4H). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>): δ 163.57, 161.12, 155.27, 146.81, 137.06, 130.53, 123.11, 113.52, 113.38, 113.30, 113.17, 55.42, 45.73, 37.72, 32.11. UPLC/MS (<i>method A</i>): <i>R</i><sub><i>t</i></sub> 1.27 min. MS (ES): C<sub>15</sub>H<sub>17</sub>FN<sub>2</sub>O<sub>2</sub> requires, 276; found, 277 [M + H]<sup>+</sup>, 275 [M – H]<sup>−</sup>. HRMS: C<sub>15</sub>H<sub>18</sub>FN<sub>2</sub>O<sub>2</sub> [M + H]<sup>+</sup> calcd 277.1352; measured, 277.1354, Δppm 0.7.</div></div><div id="sec5_9_101" class="NLM_sec NLM_sec_level_3"><div id="ac_i128" class="anchor-spacer"></div><h4 class="article-section__title" id="_i128"> Synthesis of 5-[4-Fluoro-2-(1-methyl-4-piperidyl)phenyl]-2-oxo-<i>N</i>-(4-phenylbutyl)oxazole-3-carboxamide (<b>32a</b>)</h4><div class="NLM_p last">Compound <b>32a</b> was prepared according to general procedure D (<i>method A</i>) using <b>31c</b> (0.048 g, 0.174 mmol), DMAP (0.023 g, 0.19 mmol), and 4-phenylbutyl isocyanate (0.033 g, 0.033 mL, 0.19 mmol) in DMF at 50 °C. The crude was purified by column chromatography (SiO<sub>2</sub>), eluting with DCM/MeOH (95:5), to afford <b>32a</b> as a white solid (0.050 g, 62%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 8.06 (t, <i>J</i> = 5.9 Hz, 1H), 7.51 (dd, <i>J</i> = 8.6, 6.0 Hz, 1H), 7.45 (s, 1H), 7.31–7.24 (m, 3H), 7.23–7.11 (m, 4H), 3.36–3.22 (m, overlapped with H<sub>2</sub>O signal, 2H), 2.92–2.82 (m, 2H), 2.82–2.71 (m, 1H), 2.61 (t, <i>J</i> = 7.2 Hz, 2H), 2.19 (s, 3H), 1.96 (td, <i>J</i> = 11.1, 3.9 Hz, 2H), 1.79–1.51 (m, 8H). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>): δ 163.03 (d, <i>J</i><sub>C–F</sub> = 247.8 Hz), 151.80, 148.00, 147.96, 141.98, 137.25, 131.49 (d, <i>J</i><sub>C–F</sub> = 8.6 Hz), 128.27, 128.21, 125.65, 121.58 (d, <i>J</i><sub>C–F</sub> = 3.2 Hz) 113.76, 113.42 (d, <i>J</i><sub>C–F</sub> = 22.3 Hz), 109.67, 55.52 (2C), 46.02, 40.01 (overlapped with DMSO signal), 38.03, 34.71, 32.42 (2C), 28.61, 28.12. UPLC/MS (<i>method A</i>): <i>R</i><sub><i>t</i></sub> 2.27 min. MS (ES): C<sub>26</sub>H<sub>30</sub>FN<sub>3</sub>O<sub>3</sub> requires, 451; found, 452 [M + H]<sup>+</sup>, 275 [M–CONH(CH<sub>2</sub>)<sub>4</sub>Ph]<sup>−</sup>. HRMS: C<sub>26</sub>H<sub>30</sub>FN<sub>3</sub>O<sub>3</sub> [M + H]<sup>+</sup> calcd 452.2349; measured, 452.2358, Δppm 2.0.</div></div><div id="sec5_9_102" class="NLM_sec NLM_sec_level_3"><div id="ac_i129" class="anchor-spacer"></div><h4 class="article-section__title" id="_i129"> Synthesis of 5-[4-Fluoro-2-(1-methyl-4-piperidyl)phenyl]-2-oxo-<i>N</i>-pentyl-oxazole-3-carboxamide (<b>32b</b>)</h4><div class="NLM_p last">Compound <b>32b</b> was prepared according to general procedure D (<i>method A</i>) using <b>31c</b> (0.040 g, 0.14 mmol), DMAP (0.020 g, 0.17 mmol), and <i>n</i>-pentyl isocyanate (0.019 g, 0.022 mL, 0.17 mmol) in CH<sub>3</sub>CN at 50 °C. The crude was purified by column chromatography (SiO<sub>2</sub>), eluting with DCM/MeOH (9:1), to afford <b>32b</b> as a white solid (0.035 g, 64%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 8.04 (t, <i>J</i> = 5.8 Hz, 1H), 7.51 (dd, <i>J</i> = 8.7, 6.0 Hz, 1H), 7.45 (s, 1H), 7.26 (dd, <i>J</i> = 10.7, 2.7 Hz, 1H), 7.15 (td, <i>J</i> = 8.4, 2.7 Hz, 1H), 3.31–3.23 (m, overlapped with H<sub>2</sub>O signal, 2H), 2.90–2.82 (m, 2H), 2.81–2.70 (m, 1H), 2.18 (s, 3H), 1.94 (td, <i>J</i> = 11.0, 3.8 Hz, 2H), 1.78–1.62 (m, 4H), 1.54–1.48 (m, 2H), 1.36–1.25 (m, 4H), 0.88 (t, <i>J</i> = 6.8 Hz, 3H). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>): δ 151.85, 148.13, 147.95, 137.28, 131.50 (d, <i>J</i><sub>C–F</sub> = 9.0 Hz), 121.60, 113.78, 113.43 (d, <i>J</i><sub>C–F</sub> = 23.0 Hz), 109.67, 55.56, 46.08, 40.15 (overlapped with DMSO signal), 38.09, 32.47, 28.61, 28.35, 21.76, 13.85. UPLC/MS (<i>method A</i>): <i>R</i><sub><i>t</i></sub> 2.12 min. MS (ES): C<sub>21</sub>H<sub>28</sub>FN<sub>3</sub>O<sub>3</sub> requires, 389; found, 390 [M + H]<sup>+</sup>, 275 [M–CONH(CH<sub>2</sub>)<sub>4</sub>CH<sub>3</sub>]<sup>−</sup>. HRMS: C<sub>21</sub>H<sub>28</sub>FN<sub>3</sub>O<sub>3</sub> [M + H]<sup>+</sup> calcd 390.2193; measured, 390.2204, Δppm 2.8.</div></div><div id="sec5_9_103" class="NLM_sec NLM_sec_level_3"><div id="ac_i130" class="anchor-spacer"></div><h4 class="article-section__title" id="_i130"> Synthesis of 5-[4-Fluoro-2-(1-methyl-4-piperidyl)phenyl]-<i>N</i>-isobutyl-2-oxo-oxazole-3-carboxamide Hydrochloride (<b>32c</b>)</h4><div class="NLM_p last">Compound <b>32c</b> was prepared according to general procedure D (<i>method C</i>) using <b>31c</b> (0.034 g, 0.12 mmol), 2-methylpropan-1-amine (0.027 g, 0.029 mL, 0.37 mmol), and Et<sub>3</sub>N (0.075 g, 0.104 mL, 0.74 mmol). The crude was purified by column chromatography (SiO<sub>2</sub>), eluting with DCM/MeOH (95:5), to afford the free base of <b>32c</b> (44%, 0.020 g, 0.053 mmol). The free base of <b>32c</b> (0.020 g, 0.05 mmol) was then dissolved in 0.5 mL of 1,4-dioxane and 4.0 M HCl solution (0.27 mL, 1.06 mmol, 20.0 equiv) was added. After evaporation of the solvent, the residue was triturated with Et<sub>2</sub>O to afford <b>32c</b> as a white solid (0.009 g, 20%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 12.88 (bs, 1H), 7.96 (t, <i>J</i> = 5.9 Hz, 1H), 7.39 (dd, <i>J</i> = 8.6, 5.6 Hz, 1H), 7.29–7.21 (m, overlapped with CDCl<sub>3</sub> signal, 2H), 7.05–6.97 (m, 1H), 3.67–3.55 (m, 2H), 3.24 (dd, <i>J</i> = 6.8, 5.9 Hz, 2H), 3.05 (tt, <i>J</i> = 12.0, 2.7 Hz, 2H), 2.91–2.77 (m, 5H), 2.69–2.52 (m, 2H), 2.07–1.97 (m, 2H), 1.96–1.84 (m, 1H), 0.99 (d, <i>J</i> = 6.7 Hz, 6H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>): δ 165.58, 152.78, 149.42, 148.51, 144.71, 138.82, 131.80 (d, <i>J</i><sub>C–F</sub> = 8.7 Hz), 115.01 (d, <i>J</i><sub>C–F</sub> = 22.0 Hz), 114.91, 109.29, 55.10, 47.96, 44.00, 36.67, 29.99, 28.64, 20.11. UPLC/MS (<i>method A</i>): <i>R</i><sub><i>t</i></sub> 1.93 min. MS (ES): C<sub>20</sub>H<sub>26</sub>FN<sub>3</sub>O<sub>3</sub> requires, 375; found, 376 [M + H]<sup>+</sup>, 275 [M–CONHCH<sub>2</sub>(CH<sub>3</sub>)<sub>2</sub>]<sup>−</sup>. HRMS: C<sub>20</sub>H<sub>26</sub>FN<sub>3</sub>O<sub>3</sub> [M + H]<sup>+</sup> calcd 376.2031; measured, 376.2036, Δppm −1.3.</div></div></div></div><div id="sec6" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i131">Molecular Modeling and Docking Studies</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_00668" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_00668" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec6_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i132" class="anchor-spacer"></div><h3 class="article-section__title" id="_i132"> Covalent Docking</h3><div class="NLM_p last">To carry out the covalent docking, we used docking modules available in a Schrodinger platform: CovDoc in Schrodinger 2018-4 version. These covalent docking tools require that the ligand set must be a series of compounds all of which should react with the receptor at the same site and by the same mechanism. The first step is the regular noncovalent docking of the ligands having the potential to form a covalent bond with the reactive residue of the receptor. Then, the program allows for the different conformations of the side-chain of the reactive residue, which is temporarily mutated to alanine at this stage. The reason for this temporary mutation is only to avoid the bias toward the particular ligand conformation if the side-chain of the reactive residue is present. After the noncovalent docking, the original side-chain of the reactive residue is replaced with the cysteine and the covalent bond is formed. The ligands where the covalent bond lengths between the reactive center of the ligand and the reactive residue of the receptor are longer compared to the standard chemical bonds are discarded. After the bond formation between the potential covalent ligand and the receptor, the complex is minimized using the Prime module of Schrodinger suite. Finally, the docked poses of the covalently linked ligands are to be visualized and rank ordered by energy and the docked score. The reaction site of ligands was determined using a SMART2 search pattern implemented in the covalent docking program. After determining the reactive sites from both the ligands and the receptor, a 12 A3 grid box was generated making sure that Cys143 would be in that grid box. The docked poses and the energetics were analyzed and 43 covalent inhibitors were showing good docking poses with lower complex energies and having docking scores ≥6.0. Some of the ligands lacked the proper SMARTS for the reaction and were rejected from the calculations. Docking calculations for <i>h</i>NAAA were carried out under identical conditions using the X-ray structure (PDB code: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6DXX">6DXX</a>). Compound <b>32b</b> did not natively dock into this receptor using the standard CovDock protocol. To understand the binding mode in greater details, each step of the docking run was analyzed and the raw unrefined poses were examined. It was clear that Trp181 was occluding binding of the <i>n</i>-pentyl side-chain of compound <b>32b</b> leading to a docking score >10,000 (indicate no binding affinity to NAAA). The compound was thus modeled using a flexible ligand overlay using the AC docking pose for the purpose of generating a figure.</div></div></div><div id="sec7" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i133">In Vitro Pharmacological Assay</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_16064" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_16064" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec7_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i134" class="anchor-spacer"></div><h3 class="article-section__title" id="_i134"> In Vitro <i>h</i>AC Fluorescent Assay</h3><div id="sec7_1_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i135" class="anchor-spacer"></div><h4 class="article-section__title" id="_i135"> Cell Culture Conditions and Preparation of the <i>h</i>AC-Enriched Lysate</h4><div class="NLM_p last">HEK293 cells stably expressing <i>h</i>AC (HEK293-<i>h</i>AC) were generated in our laboratory using a protocol, as previously described.<a onclick="showRef(event, 'ref30'); return false;" href="javascript:void(0);" class="ref ref30">(30)</a> Briefly, <i>h</i>AC (variant 1 coding sequence, NM_177924) cDNA was purchased from Open Biosystems (clone ID 3923451) and subcloned in the mammalian expression vector pCDNA3.1, containing the neomycin resistance gene. HEK293 cells were transfected with the <i>h</i>AC-pCDNA3.1 construct using a JetPEI reagent (Polyplus Transfection, Illkirch-Graffenstaden, France) and following the manufacturer’s instructions. A stable cell line was generated by selection with G418 (1 mg/mL), and cell clones were derived by limited dilution plating. HEK293-<i>h</i>AC were grown in Dulbecco’s modified Eagle medium (DMEM) containing 10% fetal bovine serum (FBS), 1% glutamine, 1 mM sodium pyruvate, and 500 μg/mL G418. Cells were harvested and pellets were stored at −80 °C until lysosomal-enriched lysate preparation. Cells were suspended in 20 mM Tris HCl (pH 7.5) with 0.32 M sucrose, sonicated, and centrifuged at 800 × <i>g</i> for 30 min at 4 °C. Supernatants were then centrifuged at 12 000 × <i>g</i> for 30 min at 4 °C. Pellets were re-suspended in PBS (pH 7.4) and subjected to three freeze–thaw cycles at −80 °C. The suspension was finally centrifuged at 105 000 × <i>g</i> for 1 h at 4 °C, and protein concentration was measured in the supernatant with a bicinchoninic acid based protein assay. This <i>h</i>AC-enriched preparation allowed us to further optimize the enzymatic assay and to use small amounts of lysate (2 μg/well) at the 5 μM substrate (Rbm14-12) around its <i>K</i><sub>M</sub> (<i>K</i><sub>M</sub> = 5.0 μM).</div></div><div id="sec7_1_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i136" class="anchor-spacer"></div><h4 class="article-section__title" id="_i136"> Fluorogenic <i>h</i>AC Assay</h4><div class="NLM_p last">The assay was performed in Optiplate 96-wells black plates, with each reaction well containing a mixture of 25 mM NaOAc buffer (pH 4.5) and a fixed amount of protein (2 μg) in a volume of 85 μL. After 10 min of pre-incubation with the test compounds (diluted 20× from DMSO stock solutions at different concentrations), the fluorogenic probe was added (diluted 40× from EtOH stock solution, final concentration 5 μM). After 3 h incubation at 37 °C, reactions were stopped with 50 μL of MeOH and 100 μL of a 2.5 mg/mL NaIO<sub>4</sub> fresh solution in 100 mM glycine/NaOH buffer (pH 10.6). The plates were further incubated for 2 h at 37 °C in the dark and fluorescence intensities were measured at excitation/emission wavelengths of 355/460 nm. Negative control samples consisted of the same incubation mixture in the absence of protein-enriched extracts. Data were plotted as a function of compound concentrations. IC<sub>50</sub> values were calculated by nonlinear regression analysis using GraphPad Prism 5 (GraphPad Software Inc., CA, USA) applying a standard slope curve fitting. The reported IC<sub>50</sub> values are the mean of at least three independent experiments performed in three technical replicates.</div></div></div></div><div id="sec8" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i137">Kinetic Studies</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_35140" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_35140" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec8_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i138" class="anchor-spacer"></div><h3 class="article-section__title" id="_i138"> Michaelis–Menten Analysis</h3><div class="NLM_p last">Assay conditions for the kinetic studies were the same as those described for the fluorogenic <i>h</i>AC assay. The enzyme-enriched lysate (2 μg) was incubated with the following concentrations of substrate Rbm14-12: 0.25, 0.5, 1, 2.5, 5, 10, 12.5, 15 μM. Compound <b>12a</b> was used at a final concentration of 25 and 100 nM. Initial velocities (<i>V</i><sub>0</sub>) were determined and automatically fitted to the Michaelis–Menten equation to obtain kinetic parameters (<i>K</i><sub>M</sub> and <i>V</i><sub>max</sub>). The graph is representative of two independent experiments, each performed in three technical replicates. Graphs and data analysis were performed using GraphPad Prism 5 software (GraphPad Software Inc., CA, USA).</div></div><div id="sec8_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i139" class="anchor-spacer"></div><h3 class="article-section__title" id="_i139"> In Vitro <i>h</i>NAAA Fluorescent Assay</h3><div id="sec8_2_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i140" class="anchor-spacer"></div><h4 class="article-section__title" id="_i140"> Cell Culture and Preparation of the <i>h</i>NAAA-Enriched Lysate</h4><div class="NLM_p last">HEK-293 cells stably transfected with the <i>h</i>NAAA coding sequence cloned from a human spleen cDNA library (catalog no. 639124, Clontech, Mountain View, CA, USA) were used as the enzyme source. Cells were grown in DMEM containing 10% FBS, 1% glutamine, 1 mM sodium pyruvate, and 500 μg/mL G418. Cells were harvested and pellets were stored at −80 °C until lysosomal-enriched lysate preparation. Cells were suspended in 20 mM Tris HCl (pH 7.4) with 0.32 M sucrose, sonicated, and centrifuged at 800 × <i>g</i> for 30 min at 4 °C. Supernatants were then ultracentrifuged at 12 000 × <i>g</i> for 30 min at 4 °C. Pellets were re-suspended in PBS buffer (pH 7.4) and subjected to three freeze–thaw cycles at −80 °C. The suspension was finally ultracentrifuged at 105 000 × <i>g</i> for 1 h at 4 °C, supernatants were collected, protein concentration was measured, and samples aliquoted and stored at −80 °C until use.</div></div><div id="sec8_2_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i141" class="anchor-spacer"></div><h4 class="article-section__title" id="_i141"> Fluorogenic <i>h</i>NAAA Assay</h4><div class="NLM_p last">The assay was run in 96-well microplates (Black OptiPlate-96 F; PerkinElmer, Massachusetts, USA) in a total reaction volume of 200 μL. <i>h</i>NAAA protein preparation (4.0 μg) was pre-incubated for 30 min with various concentrations of test compounds or vehicle control (DMSO 5%) in 100 mM citrate/phosphate buffer (pH 4.5) containing 3.0 mM dithiothreitol (DTT), 0.1% NP40 0.1%, 0.05% bovine serum albumin, and 150 mM NaCl. <i>N</i>-(4-Methyl-2-oxo-chromen-7-yl)-hexadecanamide (PAMCA) was used as a substrate (2.0 μM) and the reaction carried out for 50 min at 37 °C. Fluorescence was measured with an EnVision 2014 Multilabel Reader (PerkinElmer, Massachusetts, USA) using an excitation wavelength of 355 nm and emission 460 nm. IC<sub>50</sub> values were calculated by nonlinear regression analysis of log[concentration]/inhibition curves using GraphPad Prism 5 (GraphPad Software Inc., CA, USA) applying a standard slope curve fitting. The values are the mean of at least three independent experiments performed in three technical replicates.</div></div></div></div><div id="sec9" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i142">Cell Culture and Treatments</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_03656" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_03656" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">SH-SY5Y cells were purchased from Sigma Aldrich (Italy) and cultured in DMEM containing 10% FBS at 37 °C and 5% CO<sub>2</sub>. Drugs were dissolved in DMSO (10 mM) and diluted in cell culture medium with reduced serum (1%) for cell treatments.</div><div id="sec9_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i143" class="anchor-spacer"></div><h3 class="article-section__title" id="_i143"> <i>h</i>AC LC/MS-Based Activity Assay</h3><div class="NLM_p last"><i>h</i>AC activity measurement was performed as previously described.<a onclick="showRef(event, 'ref59 ref61'); return false;" href="javascript:void(0);" class="ref ref59 ref61">(59,61)</a> Total lysates from cells were diluted in assay buffer (100 mM sodium phosphate, 0.1% Nonidet P-40, 150 mM NaCl, 3 mM DTT, 100 mM sodium citrate, pH 4.5). Reactions were started by the addition of 50 μM <i>N</i>-lauroyl ceramide (Nu-Chek Prep, Elysian, MN) and carried out for 1 h at 37 °C. Reactions were stopped by the addition of a mixture of CHCl<sub>3</sub>/MeOH (2:1) spike with 11-lauroleic acid (1.0 nmol, NuChek Prep). The organic phases were collected, dried under N<sub>2</sub>, and analyzed by UPLC/MS (Acquity, Waters) in the negative-ion mode monitoring the reaction product (lauric acid, <i>m</i>/<i>z</i>: 199) using 11-lauroleic acid as the internal standard. Lipids were eluted on an Acquity UPLC BEH C18 column (50 mm length, 2.1 mm ID, 1.7 μm pore size, Waters) column at 0.5 mL/min for 1.5 min with a gradient of CH<sub>3</sub>CN and H<sub>2</sub>O, both containing 0.25% AcOH and 5 mM NH<sub>4</sub>OAc (70–100% CH<sub>3</sub>CN in 0.5 min, 100% CH<sub>3</sub>CN for 0.5 min, 70% CH<sub>3</sub>CN for 0.4 min). The column temperature was 40 °C. ESI was in the negative mode, capillary voltage was 1 kV, and cone voltage was 50 V. N<sub>2</sub> was used as a drying gas at a flow rate of 500 L/h and at a temperature of 400 °C. The [M – H]<sup>−</sup> ion was monitored in the selected-ion monitoring mode (<i>m</i>/<i>z</i> values: lauric acid 199, 11-lauroleic acid 197.35). Calibration curves were generated with authentic lauric acid (Nu Check Prep).</div></div><div id="sec9_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i144" class="anchor-spacer"></div><h3 class="article-section__title" id="_i144"> Lipid Extraction and Ceramide Analysis</h3><div class="NLM_p last">Lipid extraction and SL measurements were performed as previously described.<a onclick="showRef(event, 'ref59 ref61 ref75'); return false;" href="javascript:void(0);" class="ref ref59 ref61 ref75">(59,61,75)</a> Lipids were extracted with a CHCl<sub>3</sub>/MeOH mixture (2:1, 3 mL) spike with internal standards. The organic phase was collected, dried under N<sub>2</sub>, and dissolved in CHCl<sub>3</sub>/MeOH (1:3) for LC/MS analyses. Ceramides and sphingosine were analyzed by LC/MS/MS, using a Waters Acquity UPLC coupled to a Waters Xevo triple quadrupole mass spectrometer (TQMS) and interfaced with an ESI ion source. Separation was performed on a Waters Acquity BEH C18 1.7 μm column (2.1 × 50 mm) at 60 °C. A linear gradient of 0.1% HCOOH in CH<sub>3</sub>CN/<i>i</i>-PrOH (20:80) as solvent B in 0.1% HCOOH in CH<sub>3</sub>CN/H<sub>2</sub>O (20:80) as solvent A and was applied at a flow rate of 0.4 mL/min. The detection of SLs was performed in positive ion mode. Capillary voltage was 3.5 kV and cone voltage was 25 V. The source temperature and desolvation temperatures were set at 120 and 600 °C, respectively. Desolvation gas and cone gas (N<sub>2</sub>) flows were 800 and 20 L/h, respectively. Ceramides were identified by comparison of their LC retention times and MS/MS fragmentation patterns with those of authentic standards (Avanti Polar Lipids). Multiple reaction monitoring (MRM) ion chromatograms were used to quantify dihydroceramide (Cer(d18:0/16:0), <i>R</i><sub><i>t</i></sub> = 4.6 min, <i>m</i>/<i>z</i>: 540.5 > 522.5), palmitoyl ceramide (Cer(d18:1/16:0), <i>R</i><sub><i>t</i></sub> = 4.5 min, <i>m</i>/<i>z</i>: 520.3 > 264.2) sphingosine (So(d18:1), <i>R</i><sub><i>t</i></sub> = 2.6 min, <i>m</i>/<i>z</i>: 300.2 > 282.2), sphingomyelin (SM(d18:1/16:0), <i>R</i><sub><i>t</i></sub> = 4.2 min, <i>m</i>/<i>z</i>: 703.2 > 184.1) and hexosylceramide (HexCer (d18:1/16:0), 4.3 min, <i>m</i>/<i>z</i>: 682.2 > 264.2). Detection and analysis were controlled by Waters MassLynx software version 4.1. Calibration curves were prepared for every experiment.</div></div><div id="sec9_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i145" class="anchor-spacer"></div><h3 class="article-section__title" id="_i145"> Statistics</h3><div class="NLM_p last">GraphPad Prism software (GraphPad Software, Inc., USA) was used for statistical analysis. Data were analyzed using the Student <i>t</i>-test or 1-way ANOVA followed by Bonferroni post hoc test for multiple comparisons. Differences between groups were considered statistically significant at values of <i>p</i> < 0.05. Results are expressed as mean ± SEM.</div></div></div><div id="sec10" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i146">In Vitro Physicochemical and Metabolic Stability Assay</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_67057" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_67057" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec10_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i147" class="anchor-spacer"></div><h3 class="article-section__title" id="_i147"> Aqueous Kinetic Solubility Assay</h3><div class="NLM_p last">The aqueous kinetic solubility was determined from a 10 mM CH<sub>3</sub>CN stock solution of the test compound in PBS at pH 7.4. The study was performed by the incubation of an aliquot of 10 mM CH<sub>3</sub>CN stock solution in PBS (pH 7.4) at a target concentration of 250 μM. The incubation was carried out under shaking at 25 °C for 1 h, followed by centrifugation at 21 100 × <i>g</i> for 30 min. The supernatant was analyzed by UPLC/MS for the quantification of the dissolved compound (in μM) by UV at a specific wavelength (215 nm). The aqueous kinetic solubility (in μM) was calculated by dividing the peak area of the dissolved test compound (supernatant) by the peak area of the test compound in the reference (250 μM in CH<sub>3</sub>CN) and further multiplied by the target concentration and dilution factor. The UPLC/MS analyses were performed on a Waters Acquity UPLC/MS system consisting of SQDMS equipped with an ESI interface and a PDA detector. The PDA range was 210–400 nm. ESI in positive mode was used in the mass scan range 100–650 Da. The analyses were run on an Acquity UPLC BEH C18 column (50 × 2.1 mm ID, particle size 1.7 μm) with a VanGuard BEH C18 pre-column (5 × 2.1 mm ID, particle size 1.7 μm), using 10 mM NH<sub>4</sub>OAc in H<sub>2</sub>O at pH 5 adjusted with AcOH (A) and 10 mM NH<sub>4</sub>OAc in CH<sub>3</sub>CN/H<sub>2</sub>O (95:5) at pH 5 (B) as the mobile phase. The values are the mean of at least two independent experiments performed in two technical replicates.</div></div><div id="sec10_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i148" class="anchor-spacer"></div><h3 class="article-section__title" id="_i148"> Chemical Stability Assay</h3><div class="NLM_p last">Chemical stability of the selected compounds was evaluated under physiological pH conditions (0.01 M PBS, pH 7.4) for up to 8 h. The buffer was added with 10% of CH<sub>3</sub>CN. Stock solutions of each compound (10 mM) were freshly prepared in CH<sub>3</sub>CN. Each compound was incubated at a final concentration of 1 μM in pre-heated buffer (37 °C). The sample solutions were divided into aliquots in glass vials (preheated at 37 °C) for each time point. The samples were maintained at 37 °C in an UPLC/MS autosampler during the study (no shaking). A reference solution of each compound (final concentration: 1 μM) in preheated CH<sub>3</sub>CN was prepared from the stock solutions and maintained at 37 °C in the UPLC/MS autosampler during the study. For each time point, the samples were analyzed directly by LC/MS without any further sample preparation. The samples were analyzed by integrating the corresponding MRM peak areas. The relative compound concentration was calculated by dividing the peak area at each time point by the peak area at <i>t</i> = 0 min. The reference solution was analyzed at the beginning (<i>t</i> = 0 min) and at the end of the study (<i>t</i> = 8 h). The apparent half-life (<i>t</i><sub>1/2</sub>) of the disappearance of the compound was calculated using the best fitting equation by GraphPad Prism (GraphPad Software, Inc., USA). The analyses were performed on a Waters Acquity UPLC/MS triple quadrupole detection (TQD) system consisting of TQD MS equipped with an ESI interface and a PDA detector. The analyses were run on an Acquity UPLC BEH C18 1.7 μm 2.1 × 50 mm column with a VanGuard BEH C18 1.7 μm pre-column at 40 °C. For each compound, the appropriate mobile phase was chosen. ESI was applied in positive mode. The values are the mean of at least two independent experiments performed in two technical replicates.</div></div><div id="sec10_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i149" class="anchor-spacer"></div><h3 class="article-section__title" id="_i149"> In Vitro Plasma Stability Study</h3><div class="NLM_p last">Freshly prepared 10 mM CH<sub>3</sub>CN stock solution of the test compound was diluted 50-fold with DMSO/H<sub>2</sub>O (1:1) and incubated at 37 °C for 2 h with mouse/human plasma added 5% DMSO (preheated at 37 °C for 10 min). The final concentration was 2 μM. At each time point (0, 5, 15, 30, 60, and 120 min), 50 μL of the incubation mixture was diluted with 200 μL of cold CH<sub>3</sub>CN spiked with 200 nM of the internal standard, followed by centrifugation at 3300 × <i>g</i> for 20 min. The supernatant was further diluted with H<sub>2</sub>O (1:1) for analysis. The concentration of the test compound was quantified by LC/MS–MS on a Waters Acquity UPLC/MS TQD system consisting of TQD MS equipped with an ESI interface. The analyses were run on an Acquity UPLC BEH C18 (50 × 2.1 mm ID, particle size 1.7 μm) with a VanGuard BEH C18 pre-column (5 × 2.1 mm ID, particle size 1.7 μm) at 40 °C. For each compound, the appropriate mobile phase was chosen. ESI was applied in positive mode. The response factors, calculated on the basis of the internal standard peak area, were plotted over time. When possible, response versus time profiles were fitted with Prism (GraphPad Software, Inc., USA) to estimate compounds <i>t</i><sub>1/2</sub> in the plasma. The values are the mean of at least two independent experiments performed in two technical replicates.</div></div><div id="sec10_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i150" class="anchor-spacer"></div><h3 class="article-section__title" id="_i150"> In Vitro Microsomal Stability Study</h3><div class="NLM_p last">Freshly prepared 10 mM CH<sub>3</sub>CN stock solution of the test compound was pre-incubated at 37 °C for 15 min with mouse/human liver microsomes added 0.1 M Tris-HCl buffer (pH 7.4). The final concentration was 4.6 μM. After pre-incubation, the cofactors (NADPH, G6P, G6PDH, and MgCl<sub>2</sub> pre-dissolved in 0.1 M Tris-HCl) were added to the incubation mixture and the incubation was continued at 37 °C for 1 h. At each time point (0, 5, 15, 30, and 60 min), 30 μL of the incubation mixture was diluted with 200 μL of cold CH<sub>3</sub>CN spiked with 200 nM of the internal standard, followed by centrifugation at 3300<i>g</i> for 15 min. The supernatant was further diluted with H<sub>2</sub>O (1:1) for analysis. The concentration of the test compound was quantified by LC/MS–MS on a Waters Acquity UPLC/MS TQD system consisting of TQD MS equipped with an ESI interface. The analyses were run on an Acquity UPLC BEH C18 (50 × 2.1 mm ID, particle size 1.7 μm) with a VanGuard BEH C18 pre-column (5 × 2.1 mm ID, particle size 1.7 μm) at 40 °C. For each compound, the appropriate mobile phase was chosen. ESI was applied in positive mode. The percentage of the test compound remaining at each time point relative to <i>t</i> = 0 was calculated. The <i>t</i><sub>1/2</sub> were determined by a one-phase decay equation using a nonlinear regression of the compound concentration versus time. The values are the mean of at least two independent experiments performed in two technical replicates.</div></div></div><div id="sec11" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i151">Animal Models</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_15532" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_15532" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec11_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i152" class="anchor-spacer"></div><h3 class="article-section__title" id="_i152"> In Vivo PK Study</h3><div class="NLM_p last">C57 B6/J male mice, 8 weeks old (22–24 g), were used (Charles River, Calco). All procedures were performed in accordance with the Ethical Guidelines of European Communities Council (Directive 2010/63/EU of 22 September 2010) and accepted by the Italian Ministry of Health. All efforts were made to minimize animal suffering and to use the minimal number of animals required to produce reliable results, according to the “3Rs rules”. Animals were group-housed in ventilated cages and had free access to food and water. They were maintained under a 12 h light/dark cycle (lights on at 8:00 am) at a controlled temperature (21 ± 1 °C) and relative humidity (55 ± 10%). <b>32b</b> was administrated intravenously (i.v.) at 3 mg/kg/5 mL, vehicle: PEG400/Tween 80/saline solution (10/10/80% in volume, respectively) via tail vein injection and via oral administration (p.o.) at 10 mg/kg/10 mL, vehicle: PEG400/Tween 80/saline solution (10/10/80% in volume, respectively) by an oral gavage. <i>Sample collection</i>. Samples were collected at 5 min, 15 min, 30 min, 1 h, 2 h, and 4 h (i.v. administration) and at 15 min, 30 min, 1 h, 2 h, 4 h, and 6 h (p.o. administration). <i>N</i> = 3 animals per dose time point were treated. Plasma samples were centrifuged at 21,100<i>g</i> for 15 min at 4 °C. An aliquot of each sample was extracted (1:3) with cold CH<sub>3</sub>CN containing 200 nM of an appropriate internal standard being a close analogue of compound <b>32b</b>. A calibration curve was prepared in blank mouse plasma over a 1 nM–10 μM range. Three quality controls were prepared by spiking compound <b>32b</b> in the blank mouse plasma to 20, 200, and 2000 nM as final concentrations. The calibrators and quality controls were extracted (1:3) with the same extraction solution as the plasma samples. The plasma samples, the calibrators, and quality controls were centrifuged at 3270 × <i>g</i> for 15 min at 4 °C. The supernatants were further diluted (1:1) with H<sub>2</sub>O and analyzed by LC/MS–MS on a Waters Acquity UPLC/MS TQD system consisting of TQD) MS equipped with an ESI interface and a PDA detector. ESI was applied in positive mode. Compound-dependent parameters such as MRM transitions and collision energy were developed for compound <b>32b</b> and the internal standard. The analyses were run on an Acquity UPLC BEH C18 (50 × 2.1 mm ID, particle size 1.7 μm) with a VanGuard BEH C18 pre-column (5 × 2.1 mm ID, particle size 1.7 μm) at 40 °C. For plasma samples, the mobile phase was H<sub>2</sub>O + 0.1% HCOOH (A) and CH<sub>3</sub>CN + 0.1% HCOOH (B) at a flow rate = 0.5 mL/min. A linear gradient was applied starting at 20% B with an initial hold for 0.2 min, then 20–100% B in 2 min. All samples (plasma samples, calibrators, and quality controls) were quantified by a MRM peak area response factor in order to determine the levels of compound <b>32b</b> in the plasma. The concentrations versus time were plotted and the profiles were fitted using PK Solutions Excel Application (Summit Research Service, USA) in order to determine the PK parameters.</div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i153"><a href="/doi/suppl/10.1021/acs.jmedchem.0c01561" class="ext-link">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_05220" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_05220" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge at <a href="/doi/10.1021/acs.jmedchem.0c01561?goto=supporting-info" class="ext-link">https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c01561</a>.<ul class="NLM_list-list_type-label" id="silist"><li><p class="inline">AC inhibitory activity data and assay methods for selected literature compounds; <i>V</i><sub>max</sub> and <i>K</i><sub>M</sub> determinations; <sup>1</sup>H NMR and <sup>13</sup>C NMR spectra of the final compounds; retention times and UPLC analytical methods of the final compounds; and UPLC traces of the final compounds (<a href="/doi/suppl/10.1021/acs.jmedchem.0c01561/suppl_file/jm0c01561_si_001.pdf" class="ext-link">PDF</a>)</p></li><li><p class="inline">Molecular formula strings (<a href="/doi/suppl/10.1021/acs.jmedchem.0c01561/suppl_file/jm0c01561_si_002.csv" class="ext-link">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c01561/suppl_file/jm0c01561_si_001.pdf">jm0c01561_si_001.pdf (9.72 MB)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c01561/suppl_file/jm0c01561_si_002.csv">jm0c01561_si_002.csv (2.86 kb)</a></li></ul></div></div></div><div class="testing" data-doi="10.1021/acs.jmedchem.0c01561" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_16213" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_16213" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Renato Skerlj</span> - <span class="hlFld-Affiliation affiliation">Lysosomal
Therapeutics Inc., 19 Blackstone Street, Cambridge, Massachusetts 02139, United States</span>; 
    <span>Present Address:
                        X4 Pharmaceuticals, 955 Massachusetts Avenue, 4th Floor, Cambridge, MA 02139</span>; 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#2f5d4a414e5b40015c444a5d43456f571b5f474e5d424e014c4042"><span class="__cf_email__" data-cfemail="b1c3d4dfd0c5de9fc2dad4c3dddbf1c985c1d9d0c3dcd09fd2dedc">[email protected]</span></a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Rita Scarpelli</span> - <span class="hlFld-Affiliation affiliation">Fondazione
Istituto Italiano di Tecnologia, Via Morego 30, I-16163 Genova, Italy</span>; 
    <span class="hlFld-Affiliation affiliation">Drug
Discovery and Development (D3)-Validation, Via Morego 30, I-16163 Genova, Italy</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-2623-306X" title="Orcid link">http://orcid.org/0000-0002-2623-306X</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#65170c11044b16060417150009090c250c0c114b0c11"><span class="__cf_email__" data-cfemail="1b69726f7a3568787a696b7e7777725b72726f35726f">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Samantha Caputo</span> - <span class="hlFld-Affiliation affiliation">Fondazione
Istituto Italiano di Tecnologia, Via Morego 30, I-16163 Genova, Italy</span>; 
    <span class="hlFld-Affiliation affiliation">Drug
Discovery and Development (D3)-Validation, Via Morego 30, I-16163 Genova, Italy</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Simona Di Martino</span> - <span class="hlFld-Affiliation affiliation">Fondazione
Istituto Italiano di Tecnologia, Via Morego 30, I-16163 Genova, Italy</span>; 
    <span class="hlFld-Affiliation affiliation">Drug
Discovery and Development (D3)-Validation, Via Morego 30, I-16163 Genova, Italy</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-5817-751X" title="Orcid link">http://orcid.org/0000-0001-5817-751X</a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Vincenzo Cilibrasi</span> - <span class="hlFld-Affiliation affiliation">Fondazione
Istituto Italiano di Tecnologia, Via Morego 30, I-16163 Genova, Italy</span>; 
    <span class="hlFld-Affiliation affiliation">Drug
Discovery and Development (D3)-Validation, Via Morego 30, I-16163 Genova, Italy</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Piero Tardia</span> - <span class="hlFld-Affiliation affiliation">Fondazione
Istituto Italiano di Tecnologia, Via Morego 30, I-16163 Genova, Italy</span>; 
    <span class="hlFld-Affiliation affiliation">Drug
Discovery and Development (D3)-Validation, Via Morego 30, I-16163 Genova, Italy</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Marco Mazzonna</span> - <span class="hlFld-Affiliation affiliation">Fondazione
Istituto Italiano di Tecnologia, Via Morego 30, I-16163 Genova, Italy</span>; 
    <span class="hlFld-Affiliation affiliation">Drug
Discovery and Development (D3)-Validation, Via Morego 30, I-16163 Genova, Italy</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Debora Russo</span> - <span class="hlFld-Affiliation affiliation">Fondazione
Istituto Italiano di Tecnologia, Via Morego 30, I-16163 Genova, Italy</span>; 
    <span class="hlFld-Affiliation affiliation">D3-Pharma
Chemistry, Via Morego
30, I-16163 Genova, Italy</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Ilaria Penna</span> - <span class="hlFld-Affiliation affiliation">Fondazione
Istituto Italiano di Tecnologia, Via Morego 30, I-16163 Genova, Italy</span>; 
    <span class="hlFld-Affiliation affiliation">D3-Pharma
Chemistry, Via Morego
30, I-16163 Genova, Italy</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Maria Summa</span> - <span class="hlFld-Affiliation affiliation">Fondazione
Istituto Italiano di Tecnologia, Via Morego 30, I-16163 Genova, Italy</span>; 
    <span class="hlFld-Affiliation affiliation">Analytical
Chemistry and Translational Pharmacology, Via Morego 30, I-16163 Genova, Italy</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Sine Mandrup Bertozzi</span> - <span class="hlFld-Affiliation affiliation">Fondazione
Istituto Italiano di Tecnologia, Via Morego 30, I-16163 Genova, Italy</span>; 
    <span class="hlFld-Affiliation affiliation">Analytical
Chemistry and Translational Pharmacology, Via Morego 30, I-16163 Genova, Italy</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Natalia Realini</span> - <span class="hlFld-Affiliation affiliation">Fondazione
Istituto Italiano di Tecnologia, Via Morego 30, I-16163 Genova, Italy</span>; 
    <span class="hlFld-Affiliation affiliation">Drug
Discovery and Development (D3)-Validation, Via Morego 30, I-16163 Genova, Italy</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Natasha Margaroli</span> - <span class="hlFld-Affiliation affiliation">Fondazione
Istituto Italiano di Tecnologia, Via Morego 30, I-16163 Genova, Italy</span>; 
    <span class="hlFld-Affiliation affiliation">Drug
Discovery and Development (D3)-Validation, Via Morego 30, I-16163 Genova, Italy</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Marco Migliore</span> - <span class="hlFld-Affiliation affiliation">Fondazione
Istituto Italiano di Tecnologia, Via Morego 30, I-16163 Genova, Italy</span>; 
    <span class="hlFld-Affiliation affiliation">Drug
Discovery and Development (D3)-Validation, Via Morego 30, I-16163 Genova, Italy</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Giuliana Ottonello</span> - <span class="hlFld-Affiliation affiliation">Fondazione
Istituto Italiano di Tecnologia, Via Morego 30, I-16163 Genova, Italy</span>; 
    <span class="hlFld-Affiliation affiliation">Analytical
Chemistry and Translational Pharmacology, Via Morego 30, I-16163 Genova, Italy</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Min Liu</span> - <span class="hlFld-Affiliation affiliation">Lysosomal
Therapeutics Inc., 19 Blackstone Street, Cambridge, Massachusetts 02139, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Peter Lansbury</span> - <span class="hlFld-Affiliation affiliation">Lysosomal
Therapeutics Inc., 19 Blackstone Street, Cambridge, Massachusetts 02139, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Andrea Armirotti</span> - <span class="hlFld-Affiliation affiliation">Fondazione
Istituto Italiano di Tecnologia, Via Morego 30, I-16163 Genova, Italy</span>; 
    <span class="hlFld-Affiliation affiliation">Analytical
Chemistry and Translational Pharmacology, Via Morego 30, I-16163 Genova, Italy</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-3766-8755" title="Orcid link">http://orcid.org/0000-0002-3766-8755</a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Rosalia Bertorelli</span> - <span class="hlFld-Affiliation affiliation">Fondazione
Istituto Italiano di Tecnologia, Via Morego 30, I-16163 Genova, Italy</span>; 
    <span class="hlFld-Affiliation affiliation">Analytical
Chemistry and Translational Pharmacology, Via Morego 30, I-16163 Genova, Italy</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Soumya S. Ray</span> - <span class="hlFld-Affiliation affiliation">Lysosomal
Therapeutics Inc., 19 Blackstone Street, Cambridge, Massachusetts 02139, United States</span></div></li></ul></li><li><span class="author-information-subsection-header">Author Contributions</span><p>S.C. and S.D.M. contributed equally. All the authors have given approval to the final version of the manuscript.</p></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare the following competing financial interest(s): All the work in the manuscript was funded by Lysosomal Therapeutics Inc. A Sponsored Research Agreement was signed between Fondazione Istituto Italiano di Tecnologia, Drug Discovery and Development (D3)-Validation and Lysosomal Therapeutics Inc.<br /></br></div></li></ul></div><div class="ack" id="ack1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i156">Acknowledgments</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_02710" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_02710" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The authors thank Silvia Venzano, Luca Goldoni and Marina Veronesi for their technical support.</p></div><table summary="" class="NLM_def-list" id="dl1"><tr><td colspan="2" class="NLM_title">Abbreviations</td></tr><tr><td class="NLM_term">AC</td><td class="NLM_def"><p class="first last">acid ceramidase</p></td></tr><tr><td class="NLM_term">ASM</td><td class="NLM_def"><p class="first last">acid sphingomyelinase</p></td></tr><tr><td class="NLM_term">Cer</td><td class="NLM_def"><p class="first last">ceramide</p></td></tr><tr><td class="NLM_term">dh-CerDES</td><td class="NLM_def"><p class="first last">dihydro-ceramide desaturase</p></td></tr><tr><td class="NLM_term">CerS</td><td class="NLM_def"><p class="first last">ceramide synthase</p></td></tr><tr><td class="NLM_term">CerK</td><td class="NLM_def"><p class="first last">ceramide kinase</p></td></tr><tr><td class="NLM_term">CerPPase</td><td class="NLM_def"><p class="first last">ceramide phosphate phosphatase</p></td></tr><tr><td class="NLM_term">diGalCer</td><td class="NLM_def"><p class="first last">di-galactosylceramide</p></td></tr><tr><td class="NLM_term">GALCase</td><td class="NLM_def"><p class="first last">β-galactosyl ceramidase</p></td></tr><tr><td class="NLM_term">GD</td><td class="NLM_def"><p class="first last">Gaucher’s disease</p></td></tr><tr><td class="NLM_term">GCase</td><td class="NLM_def"><p class="first last">β-glucosyl ceramidase</p></td></tr><tr><td class="NLM_term">GalCer</td><td class="NLM_def"><p class="first last">galactosylceramide</p></td></tr><tr><td class="NLM_term">GluCer</td><td class="NLM_def"><p class="first last">glucosylceramide</p></td></tr><tr><td class="NLM_term">CGALT</td><td class="NLM_def"><p class="first last">ceramide galactosyl transferase</p></td></tr><tr><td class="NLM_term">CGT</td><td class="NLM_def"><p class="first last">ceramide glucosyl transferase</p></td></tr><tr><td class="NLM_term">LacCer</td><td class="NLM_def"><p class="first last">lactosylceramide</p></td></tr><tr><td class="NLM_term">LSD</td><td class="NLM_def"><p class="first last">lysosomal storage disease</p></td></tr><tr><td class="NLM_term">KD</td><td class="NLM_def"><p class="first last">Krabbe’s disease</p></td></tr><tr><td class="NLM_term">SL</td><td class="NLM_def"><p class="first last">sphingolipid</p></td></tr><tr><td class="NLM_term">So</td><td class="NLM_def"><p class="first last">sphingosine</p></td></tr><tr><td class="NLM_term">So-1P</td><td class="NLM_def"><p class="first last">sphingosine 1-phosphate</p></td></tr><tr><td class="NLM_term">SK</td><td class="NLM_def"><p class="first last">sphingosine kinase</p></td></tr><tr><td class="NLM_term">SMase</td><td class="NLM_def"><p class="first last">sphingomyelinase</p></td></tr><tr><td class="NLM_term">SPPase</td><td class="NLM_def"><p class="first last">sphingosine phosphate phosphatase</p></td></tr><tr><td class="NLM_term">SMS</td><td class="NLM_def"><p class="first last">sphingomyelin synthase</p></td></tr><tr><td class="NLM_term">AcOH</td><td class="NLM_def"><p class="first last">acetic acid</p></td></tr><tr><td class="NLM_term">Al<sub>2</sub>O<sub>3</sub></td><td class="NLM_def"><p class="first last">alumina</p></td></tr><tr><td class="NLM_term">CH<sub>3</sub>CN</td><td class="NLM_def"><p class="first last">acetonitrile</p></td></tr><tr><td class="NLM_term">NH<sub>4</sub>OAc</td><td class="NLM_def"><p class="first last">ammonium acetate</p></td></tr><tr><td class="NLM_term">NH<sub>4</sub>Cl</td><td class="NLM_def"><p class="first last">ammonium chloride</p></td></tr><tr><td class="NLM_term">HCO<sub>2</sub>NH<sub>4</sub></td><td class="NLM_def"><p class="first last">ammonium formate</p></td></tr><tr><td class="NLM_term">aq</td><td class="NLM_def"><p class="first last">aqueous</p></td></tr><tr><td class="NLM_term">NBS</td><td class="NLM_def"><p class="first last"><i>N</i>-bromosuccinimide</p></td></tr><tr><td class="NLM_term">CDI</td><td class="NLM_def"><p class="first last">1,1′-carbonyldiimidazole</p></td></tr><tr><td class="NLM_term">CHCl<sub>3</sub></td><td class="NLM_def"><p class="first last">chloroform</p></td></tr><tr><td class="NLM_term">Cy</td><td class="NLM_def"><p class="first last">cyclohexane</p></td></tr><tr><td class="NLM_term">celite</td><td class="NLM_def"><p class="first last">diatomaceous earth</p></td></tr><tr><td class="NLM_term">DCM</td><td class="NLM_def"><p class="first last">dichloromethane</p></td></tr><tr><td class="NLM_term">Et<sub>2</sub>O</td><td class="NLM_def"><p class="first last">diethyl ether</p></td></tr><tr><td class="NLM_term">DIPEA</td><td class="NLM_def"><p class="first last"><i>N</i>,<i>N</i>-diisopropylethylamine</p></td></tr><tr><td class="NLM_term">DMAP</td><td class="NLM_def"><p class="first last">4-(dimethylamino)-pyridine</p></td></tr><tr><td class="NLM_term">DMF</td><td class="NLM_def"><p class="first last"><i>N</i>,<i>N</i>-dimethylformamide</p></td></tr><tr><td class="NLM_term">DMSO</td><td class="NLM_def"><p class="first last">dimethylsulfoxide</p></td></tr><tr><td class="NLM_term">Boc<sub>2</sub>O</td><td class="NLM_def"><p class="first last">di-<i>tert</i>-butyl dicarbonate</p></td></tr><tr><td class="NLM_term">equiv</td><td class="NLM_def"><p class="first last">equivalent</p></td></tr><tr><td class="NLM_term">EtOH</td><td class="NLM_def"><p class="first last">ethanol</p></td></tr><tr><td class="NLM_term">EtOAc</td><td class="NLM_def"><p class="first last">ethyl acetate</p></td></tr><tr><td class="NLM_term">HCHO</td><td class="NLM_def"><p class="first last">formaldehyde</p></td></tr><tr><td class="NLM_term">HCOOH</td><td class="NLM_def"><p class="first last">formic acid</p></td></tr><tr><td class="NLM_term">HCl</td><td class="NLM_def"><p class="first last">hydrochloric acid</p></td></tr><tr><td class="NLM_term">LiCl</td><td class="NLM_def"><p class="first last">lithium chloride</p></td></tr><tr><td class="NLM_term">LiOH</td><td class="NLM_def"><p class="first last">lithium hydroxide</p></td></tr><tr><td class="NLM_term">MeOH</td><td class="NLM_def"><p class="first last">methanol</p></td></tr><tr><td class="NLM_term">N<sub>2</sub></td><td class="NLM_def"><p class="first last">nitrogen</p></td></tr><tr><td class="NLM_term">on</td><td class="NLM_def"><p class="first last">overnight</p></td></tr><tr><td class="NLM_term">Pd(OH)<sub>2</sub></td><td class="NLM_def"><p class="first last">palladium hydroxide</p></td></tr><tr><td class="NLM_term">Pd/C</td><td class="NLM_def"><p class="first last">palladium on carbon</p></td></tr><tr><td class="NLM_term">K<sub>2</sub>CO<sub>3</sub></td><td class="NLM_def"><p class="first last">potassium carbonate</p></td></tr><tr><td class="NLM_term">KNCO</td><td class="NLM_def"><p class="first last">potassium cyanate</p></td></tr><tr><td class="NLM_term"><i>t</i>-BuOK</td><td class="NLM_def"><p class="first last">potassium <i>tert</i>-butoxide</p></td></tr><tr><td class="NLM_term"><i>i</i>-PrOH</td><td class="NLM_def"><p class="first last">2-propanol</p></td></tr><tr><td class="NLM_term"><i>R</i><sub><i>t</i></sub></td><td class="NLM_def"><p class="first last">retention time</p></td></tr><tr><td class="NLM_term">rt</td><td class="NLM_def"><p class="first last">room temperature</p></td></tr><tr><td class="NLM_term">sat.</td><td class="NLM_def"><p class="first last">saturated</p></td></tr><tr><td class="NLM_term">SiO<sub>2</sub></td><td class="NLM_def"><p class="first last">silica gel</p></td></tr><tr><td class="NLM_term">NaOAc</td><td class="NLM_def"><p class="first last">sodium acetate</p></td></tr><tr><td class="NLM_term">NaHCO<sub>3</sub></td><td class="NLM_def"><p class="first last">sodium bicarbonate</p></td></tr><tr><td class="NLM_term">Na<sub>2</sub>CO<sub>3</sub></td><td class="NLM_def"><p class="first last">sodium carbonate</p></td></tr><tr><td class="NLM_term">NaCl</td><td class="NLM_def"><p class="first last">sodium chloride</p></td></tr><tr><td class="NLM_term">Na<sub>2</sub>SO<sub>4</sub></td><td class="NLM_def"><p class="first last">sodium sulfate</p></td></tr><tr><td class="NLM_term">NaBH(OAc)<sub>3</sub></td><td class="NLM_def"><p class="first last">sodium triacetoxyborohydride</p></td></tr><tr><td class="NLM_term">THF</td><td class="NLM_def"><p class="first last">tetrahydrofuran</p></td></tr><tr><td class="NLM_term">Pd(PPh<sub>3</sub>)<sub>4</sub></td><td class="NLM_def"><p class="first last">tetrakis(triphenylphosphine) palladium(0)</p></td></tr><tr><td class="NLM_term">TZD</td><td class="NLM_def"><p class="first last">2,4-thiazolidinedione</p></td></tr><tr><td class="NLM_term">SOCl<sub>2</sub></td><td class="NLM_def"><p class="first last">thionyl chloride</p></td></tr><tr><td class="NLM_term">Et<sub>3</sub>N</td><td class="NLM_def"><p class="first last">trimethylamine</p></td></tr><tr><td class="NLM_term">TMSOTf</td><td class="NLM_def"><p class="first last">trimethylsilyl trifluoromethanesulfonate</p></td></tr><tr><td class="NLM_term">H<sub>2</sub>O</td><td class="NLM_def"><p class="first last">water</p></td></tr><tr><td class="NLM_term">wt</td><td class="NLM_def"><p class="first last">weight</p></td></tr></table><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i158">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_25058" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_25058" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 75 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hannun, Y. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Obeid, L. M.</span></span> <span> </span><span class="NLM_article-title">Many ceramides</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>286</i></span>,  <span class="NLM_fpage">27855</span>– <span class="NLM_lpage">27862</span>, <span class="refDoi"> DOI: 10.1074/jbc.r111.254359</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01561&amp;key=10.1074%2Fjbc.R111.254359" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01561&amp;key=21693702" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01561&amp;key=1%3ACAS%3A528%3ADC%252BC3MXpsl2ntbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=286&publication_year=2011&pages=27855-27862&author=Y.+A.+Hannunauthor=L.+M.+Obeid&title=Many+ceramides&doi=10.1074%2Fjbc.r111.254359"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Many Ceramides</span></div><div class="casAuthors">Hannun, Yusuf A.; Obeid, Lina M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">286</span>
        (<span class="NLM_cas:issue">32</span>),
    <span class="NLM_cas:pages">27855-27862</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">A review.  Intensive research over the past 2 decades has implicated ceramide in the regulation of several cell responses.  However, emerging evidence points to dramatic complexities in ceramide metab. and structure that defy the prevailing unifying hypothesis on ceramide function that is based on the understanding of ceramide as a single entity.  Here, we develop the concept that "ceramide" constitutes a family of closely related mols., subject to metab. by >28 enzymes and with >200 structurally distinct mammalian ceramides distinguished by specific structural modifications.  These ceramides are synthesized in a combinatorial fashion with distinct enzymes responsible for the specific modifications.  These multiple pathways of ceramide generation led to the hypothesis that individual ceramide mol. species are regulated by specific biochem. pathways in distinct subcellular compartments and execute distinct functions.  In this minireview, we describe the "many ceramides" paradigm, along with the rationale, supporting evidence, and implications for our understanding of bioactive sphingolipids and approaches for unraveling these pathways.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrwtYXUgk_GdbVg90H21EOLACvtfcHk0lg9Eq3ddxEPgA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXpsl2ntbo%253D&md5=7a11bcd01d3bc56c1e1b833438dc1fbd</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1074%2Fjbc.R111.254359&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.R111.254359%26sid%3Dliteratum%253Aachs%26aulast%3DHannun%26aufirst%3DY.%2BA.%26aulast%3DObeid%26aufirst%3DL.%2BM.%26atitle%3DMany%2520ceramides%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2011%26volume%3D286%26spage%3D27855%26epage%3D27862%26doi%3D10.1074%2Fjbc.r111.254359" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gomez-Muñoz, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Presa, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gomez-Larrauri, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rivera, I.-G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trueba, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ordoñez, M.</span></span> <span> </span><span class="NLM_article-title">Control of inflammatory responses by ceramide, sphingosine 1-phosphate and ceramide 1-phosphate</span>. <i>Prog. Lipid Res.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">51</span>– <span class="NLM_lpage">62</span>, <span class="refDoi"> DOI: 10.1016/j.plipres.2015.09.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01561&amp;key=10.1016%2Fj.plipres.2015.09.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01561&amp;key=26703189" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01561&amp;key=1%3ACAS%3A528%3ADC%252BC2MXitVGhtrnP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2016&pages=51-62&author=A.+Gomez-Mu%C3%B1ozauthor=N.+Presaauthor=A.+Gomez-Larrauriauthor=I.-G.+Riveraauthor=M.+Truebaauthor=M.+Ordo%C3%B1ez&title=Control+of+inflammatory+responses+by+ceramide%2C+sphingosine+1-phosphate+and+ceramide+1-phosphate&doi=10.1016%2Fj.plipres.2015.09.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Control of inflammatory responses by ceramide, sphingosine 1-phosphate and ceramide 1-phosphate</span></div><div class="casAuthors">Gomez-Munoz, Antonio; Presa, Natalia; Gomez-Larrauri, Ana; Rivera, Io-Guane; Trueba, Miguel; Ordonez, Marta</div><div class="citationInfo"><span class="NLM_cas:title">Progress in Lipid Research</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">51-62</span>CODEN:
                <span class="NLM_cas:coden">PLIRDW</span>;
        ISSN:<span class="NLM_cas:issn">0163-7827</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Inflammation is a network of complex processes involving a variety of metabolic and signaling pathways aiming at healing and repairing damage tissue, or fighting infection.  However, inflammation can be detrimental when it becomes out of control.  Inflammatory mediators involve cytokines, bioactive lipids and lipid-derived metabolites.  In particular, the simple sphingolipids ceramides, sphingosine 1-phosphate, and ceramide 1-phosphate have been widely implicated in inflammation.  However, although ceramide 1-phosphate was first described as pro-inflammatory, recent studies show that it has anti-inflammatory properties when produced in specific cell types or tissues.  The biol. functions of ceramides and sphingosine 1-phosphate have been extensively studied.  These sphingolipids have opposing effects with ceramides being potent inducers of cell cycle arrest and apoptosis, and sphingosine 1-phosphate promoting cell growth and survival.  However, the biol. actions of ceramide 1-phosphate have only been partially described.  Ceramide 1-phosphate is mitogenic and anti-apoptotic, and more recently, it has been demonstrated to be key regulator of cell migration.  Both sphingosine 1-phosphate and ceramide 1-phosphate are also implicated in tumor growth and dissemination.  The present review highlights new aspects on the control of inflammation and cell migration by simple sphingolipids, with special emphasis to the role played by ceramide 1-phosphate in controlling these actions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoZ0ndilncuqbVg90H21EOLACvtfcHk0lj-k8Gs9DIUlw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXitVGhtrnP&md5=8a3a4a52943303e535f26fe9ca386192</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1016%2Fj.plipres.2015.09.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.plipres.2015.09.002%26sid%3Dliteratum%253Aachs%26aulast%3DGomez-Mu%25C3%25B1oz%26aufirst%3DA.%26aulast%3DPresa%26aufirst%3DN.%26aulast%3DGomez-Larrauri%26aufirst%3DA.%26aulast%3DRivera%26aufirst%3DI.-G.%26aulast%3DTrueba%26aufirst%3DM.%26aulast%3DOrdo%25C3%25B1ez%26aufirst%3DM.%26atitle%3DControl%2520of%2520inflammatory%2520responses%2520by%2520ceramide%252C%2520sphingosine%25201-phosphate%2520and%2520ceramide%25201-phosphate%26jtitle%3DProg.%2520Lipid%2520Res.%26date%3D2016%26volume%3D61%26spage%3D51%26epage%3D62%26doi%3D10.1016%2Fj.plipres.2015.09.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hannun, Y. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Obeid, L. M.</span></span> <span> </span><span class="NLM_article-title">Sphingolipids and their metabolism in physiology and disease</span>. <i>Nat. Rev. Mol. Cell Biol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">175</span>– <span class="NLM_lpage">191</span>, <span class="refDoi"> DOI: 10.1038/nrm.2017.107</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01561&amp;key=10.1038%2Fnrm.2017.107" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01561&amp;key=29165427" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01561&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhvVKqt7fE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2018&pages=175-191&author=Y.+A.+Hannunauthor=L.+M.+Obeid&title=Sphingolipids+and+their+metabolism+in+physiology+and+disease&doi=10.1038%2Fnrm.2017.107"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Sphingolipids and their metabolism in physiology and disease</span></div><div class="casAuthors">Hannun, Yusuf A.; Obeid, Lina M.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Molecular Cell Biology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">175-191</span>CODEN:
                <span class="NLM_cas:coden">NRMCBP</span>;
        ISSN:<span class="NLM_cas:issn">1471-0072</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">A review.  Studies of bioactive lipids in general and sphingolipids in particular have intensified over the past several years, revealing an unprecedented and unanticipated complexity of the lipidome and its many functions, which rivals, if not exceeds, that of the genome or proteome.  These results highlight crit. roles for bioactive sphingolipids in most, if not all, major cell biol. responses, including all major cell signalling pathways, and they link sphingolipid metab. to key human diseases.  Nevertheless, the fairly nascent field of bioactive sphingolipids still faces challenges in its biochem. and mol. underpinnings, including defining the mol. mechanisms of pathway and enzyme regulation, the study of lipid-protein interactions and the development of cellular probes, suitable biomarkers and therapeutic approaches.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrl9A-uh9uFPrVg90H21EOLACvtfcHk0lj-k8Gs9DIUlw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhvVKqt7fE&md5=81409d71ab1c29c9dea5f060105032be</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1038%2Fnrm.2017.107&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrm.2017.107%26sid%3Dliteratum%253Aachs%26aulast%3DHannun%26aufirst%3DY.%2BA.%26aulast%3DObeid%26aufirst%3DL.%2BM.%26atitle%3DSphingolipids%2520and%2520their%2520metabolism%2520in%2520physiology%2520and%2520disease%26jtitle%3DNat.%2520Rev.%2520Mol.%2520Cell%2520Biol.%26date%3D2018%26volume%3D19%26spage%3D175%26epage%3D191%26doi%3D10.1038%2Fnrm.2017.107" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kurz, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parnham, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Geisslinger, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schiffmann, S.</span></span> <span> </span><span class="NLM_article-title">Ceramides as novel disease biomarkers</span>. <i>Trends Mol. Med.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">20</span>– <span class="NLM_lpage">32</span>, <span class="refDoi"> DOI: 10.1016/j.molmed.2018.10.009</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01561&amp;key=10.1016%2Fj.molmed.2018.10.009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01561&amp;key=30477968" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01561&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitFyhtLbP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2019&pages=20-32&author=J.+Kurzauthor=M.+J.+Parnhamauthor=G.+Geisslingerauthor=S.+Schiffmann&title=Ceramides+as+novel+disease+biomarkers&doi=10.1016%2Fj.molmed.2018.10.009"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Ceramides as Novel Disease Biomarkers</span></div><div class="casAuthors">Kurz, Jennifer; Parnham, Michael J.; Geisslinger, Gerd; Schiffmann, Susanne</div><div class="citationInfo"><span class="NLM_cas:title">Trends in Molecular Medicine</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">20-32</span>CODEN:
                <span class="NLM_cas:coden">TMMRCY</span>;
        ISSN:<span class="NLM_cas:issn">1471-4914</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Ceramides are sphingolipids and integral components of the eukaryotic cell membrane.  Apart from providing structural integrity, ceramides have also been shown to act as second messengers in cell signaling processes.  In recent publications, ceramide modulation has been reported in pathol. conditions such as cancer, diabetes, Alzheimer's disease (AD), coronary artery disease (CAD), multiple sclerosis (MS), as well as depression.  Ceramides or ceramide panel combinations have been proposed as specific disease biomarkers that could be detected in diseased tissue, synovial fluid, cerebrospinal fluid (CSF), and blood.  This article reviews ceramide modulation in a selection of different diseases and the potential use of ceramides as biomarkers in diagnostics, detn. of disease stage and personalized medicine.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqOKsisq3HF1LVg90H21EOLACvtfcHk0lj-k8Gs9DIUlw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitFyhtLbP&md5=f3079e8ebc71c2ab23cc1afa621e273a</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1016%2Fj.molmed.2018.10.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.molmed.2018.10.009%26sid%3Dliteratum%253Aachs%26aulast%3DKurz%26aufirst%3DJ.%26aulast%3DParnham%26aufirst%3DM.%2BJ.%26aulast%3DGeisslinger%26aufirst%3DG.%26aulast%3DSchiffmann%26aufirst%3DS.%26atitle%3DCeramides%2520as%2520novel%2520disease%2520biomarkers%26jtitle%3DTrends%2520Mol.%2520Med.%26date%3D2019%26volume%3D25%26spage%3D20%26epage%3D32%26doi%3D10.1016%2Fj.molmed.2018.10.009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">van
Eijk, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferraz, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boot, R. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aerts, J. M. F. G.</span></span> <span> </span><span class="NLM_article-title">Lyso-glycosphingolipids: presence and consequences</span>. <i>Essays Biochem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>64</i></span>,  <span class="NLM_fpage">565</span>, <span class="refDoi"> DOI: 10.1042/EBC20190090</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01561&amp;key=10.1042%2FEBC20190090" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01561&amp;key=32808655" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01561&amp;key=1%3ACAS%3A528%3ADC%252BB3cXitFaqtbjL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=64&publication_year=2020&pages=565&author=M.+van%0AEijkauthor=M.+J.+Ferrazauthor=R.+G.+Bootauthor=J.+M.+F.+G.+Aerts&title=Lyso-glycosphingolipids%3A+presence+and+consequences&doi=10.1042%2FEBC20190090"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Lyso-glycosphingolipids: presence and consequences</span></div><div class="casAuthors">van Eijk, Marco; Ferraz, Maria J.; Boot, Rolf G.; Aerts, Johannes M. F. G.</div><div class="citationInfo"><span class="NLM_cas:title">Essays in Biochemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">64</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">565-578</span>CODEN:
                <span class="NLM_cas:coden">ESBIAV</span>;
        ISSN:<span class="NLM_cas:issn">1744-1358</span>.
    
            (<span class="NLM_cas:orgname">Portland Press Ltd.</span>)
        </div><div class="casAbstract">Lyso-glycosphingolipids are generated in excess in glycosphingolipid storage disorders.  In the course of these pathologies glycosylated sphingolipid species accumulate within lysosomes due to flaws in the resp. lipid degrading machinery.  Deacylation of accumulating glycosphingolipids drives the formation of lyso-glycosphingolipids.  In lysosomal storage diseases such as Gaucher Disease, Fabry Disease, Krabbe disease, GM1- and GM2 gangliosidosis, Niemann Pick type C and Metachromatic leukodystrophy massive intra-lysosomal glycosphingolipid accumulation occurs.  The lysosomal enzyme acid ceramidase generates the deacylated lyso-glycosphingolipid species.  This review discusses how the various lyso-glycosphingolipids are synthesized, how they may contribute to abnormal immunity in glycosphingolipid storing lysosomal diseases and what therapeutic opportunities exist.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrw9yRedbOINbVg90H21EOLACvtfcHk0lgqRbgl60DWXQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXitFaqtbjL&md5=18a11c134a2ed76adc52c4a0c5a27418</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1042%2FEBC20190090&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1042%252FEBC20190090%26sid%3Dliteratum%253Aachs%26aulast%3Dvan%2BEijk%26aufirst%3DM.%26aulast%3DFerraz%26aufirst%3DM.%2BJ.%26aulast%3DBoot%26aufirst%3DR.%2BG.%26aulast%3DAerts%26aufirst%3DJ.%2BM.%2BF.%2BG.%26atitle%3DLyso-glycosphingolipids%253A%2520presence%2520and%2520consequences%26jtitle%3DEssays%2520Biochem.%26date%3D2020%26volume%3D64%26spage%3D565%26doi%3D10.1042%2FEBC20190090" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sahu, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hannun, Y. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yao, N.</span></span> <span> </span><span class="NLM_article-title">Emergence of membrane sphingolipids as a potential therapeutic target</span>. <i>Biochimie</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>158</i></span>,  <span class="NLM_fpage">257</span>– <span class="NLM_lpage">264</span>, <span class="refDoi"> DOI: 10.1016/j.biochi.2019.01.018</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01561&amp;key=10.1016%2Fj.biochi.2019.01.018" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01561&amp;key=30703477" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01561&amp;key=1%3ACAS%3A528%3ADC%252BC1MXisFWmt7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=158&publication_year=2019&pages=257-264&author=S.+K.+Sahuauthor=Y.+A.+Hannunauthor=N.+Yao&title=Emergence+of+membrane+sphingolipids+as+a+potential+therapeutic+target&doi=10.1016%2Fj.biochi.2019.01.018"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Emergence of membrane sphingolipids as a potential therapeutic target</span></div><div class="casAuthors">Sahu, Sunil Kumar; Hannun, Yusuf A.; Yao, Nan</div><div class="citationInfo"><span class="NLM_cas:title">Biochimie</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">158</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">257-264</span>CODEN:
                <span class="NLM_cas:coden">BICMBE</span>;
        ISSN:<span class="NLM_cas:issn">0300-9084</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Though sphingolipids are ubiquitously present in eukaryotic cells, but until the last decade, they were merely considered as a structural component of the plasma membrane with limited function.  However, over the last decade, numerous functions have been ascribed to sphingolipids after the seminal discoveries on the bioactivities of several sphingolipids.  Sphingolipids are now well-recognized signals for fundamental cellular processes.  Here we discussed about the advent of several sphingolipids components as potential therapeutic target for both human and plants.  Sphingolipid contents and/or sphingolipid-metabolizing enzyme expression/activity often get impaired during pathophysiol. conditions, and hence manipulation of this signaling pathway may be beneficial in disease diagnosis, and the plasma concns. can serve as an important prognostic and diagnostic marker for the disease.  Sphingolipids are emerging as a goldmine for new therapeutic drug targets with promising new applications (cosmeceutical and nutraceutical), thereby opening new avenues for pharmaceuticals and nutraceutical industries.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqmUxzI4fnNurVg90H21EOLACvtfcHk0lgqRbgl60DWXQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXisFWmt7w%253D&md5=6855bfbe3633b819a87f27b6b6f70898</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1016%2Fj.biochi.2019.01.018&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.biochi.2019.01.018%26sid%3Dliteratum%253Aachs%26aulast%3DSahu%26aufirst%3DS.%2BK.%26aulast%3DHannun%26aufirst%3DY.%2BA.%26aulast%3DYao%26aufirst%3DN.%26atitle%3DEmergence%2520of%2520membrane%2520sphingolipids%2520as%2520a%2520potential%2520therapeutic%2520target%26jtitle%3DBiochimie%26date%3D2019%26volume%3D158%26spage%3D257%26epage%3D264%26doi%3D10.1016%2Fj.biochi.2019.01.018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Coant, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sakamoto, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mao, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hannun, Y. A.</span></span> <span> </span><span class="NLM_article-title">Ceramidases, roles in sphingolipid metabolism and in health and disease</span>. <i>Adv. Biol. Regul.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>63</i></span>,  <span class="NLM_fpage">122</span>– <span class="NLM_lpage">131</span>, <span class="refDoi"> DOI: 10.1016/j.jbior.2016.10.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01561&amp;key=10.1016%2Fj.jbior.2016.10.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01561&amp;key=27771292" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01561&amp;key=1%3ACAS%3A528%3ADC%252BC28XhslSqsbvK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2017&pages=122-131&author=N.+Coantauthor=W.+Sakamotoauthor=C.+Maoauthor=Y.+A.+Hannun&title=Ceramidases%2C+roles+in+sphingolipid+metabolism+and+in+health+and+disease&doi=10.1016%2Fj.jbior.2016.10.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Ceramidases, roles in sphingolipid metabolism and in health and disease</span></div><div class="casAuthors">Coant, Nicolas; Sakamoto, Wataru; Mao, Cungui; Hannun, Yusuf A.</div><div class="citationInfo"><span class="NLM_cas:title">Advances in Biological Regulation</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">122-131</span>CODEN:
                <span class="NLM_cas:coden">ABRDE5</span>;
        ISSN:<span class="NLM_cas:issn">2212-4934</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Over the past three decades, extensive research has been able to det. the biol. functions for the main bioactive sphingolipids, namely ceramide, sphingosine, and sphingosine 1-phosphate (S1P) (Hannun, 1996; Hannun et al., 1986; Okazaki et al., 1989).  These studies have managed to define the metab., regulation, and function of these bioactive sphingolipids.  This emerging body of literature has also implicated bioactive sphingolipids, particularly S1P and ceramide, as key regulators of cellular homeostasis.  Ceramidases have the important role of cleaving fatty acid from ceramide and producing sphingosine, thereby controlling the interconversion of these two lipids.  Thus far, five human ceramidases encoded by five different genes have been identified: acid ceramidase (AC), neutral ceramidase (NC), alk. ceramidase 1 (ACER1), alk. ceramidase 2 (ACER2), and alk. ceramidase 3 (ACER3).  These ceramidases are classified according to their optimal pH for catalytic activity.  AC, which is localized to the lysosomal compartment, has been assocd. with Farber's disease and is involved in the regulation of cell viability.  Neutral ceramidase, which is localized to the plasma membrane and primarily expressed in the small intestine and colon, is involved in digestion, and has been implicated in colon carcinogenesis.  ACER1 which can be found in the endoplasmic reticulum and is highly expressed in the skin, plays an important role in keratinocyte differentiation.  ACER2, localized to the Golgi complex and highly expressed in the placenta, is involved in programed cell death in response to DNA damage.  ACER3, also localized to the endoplasmic reticulum and the Golgi complex, is ubiquitously expressed, and is involved in motor coordination-assocd. Purkinje cell degeneration.  This review seeks to consolidate the current knowledge regarding these key cellular players.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGowWeoXuPUgXrVg90H21EOLACvtfcHk0linBUzE9ndwyw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhslSqsbvK&md5=84e937e947b7a38256761a6ab60a7353</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1016%2Fj.jbior.2016.10.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jbior.2016.10.002%26sid%3Dliteratum%253Aachs%26aulast%3DCoant%26aufirst%3DN.%26aulast%3DSakamoto%26aufirst%3DW.%26aulast%3DMao%26aufirst%3DC.%26aulast%3DHannun%26aufirst%3DY.%2BA.%26atitle%3DCeramidases%252C%2520roles%2520in%2520sphingolipid%2520metabolism%2520and%2520in%2520health%2520and%2520disease%26jtitle%3DAdv.%2520Biol.%2520Regul.%26date%3D2017%26volume%3D63%26spage%3D122%26epage%3D131%26doi%3D10.1016%2Fj.jbior.2016.10.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Parveen, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bender, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Law, S.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mishra, V. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, C.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ke, L.-Y.</span></span> <span> </span><span class="NLM_article-title">Role of ceramidases in sphingolipid metabolism and human diseases</span>. <i>Cells</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">1573</span>– <span class="NLM_lpage">1592</span>, <span class="refDoi"> DOI: 10.3390/cells8121573</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01561&amp;key=10.3390%2Fcells8121573" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01561&amp;key=1%3ACAS%3A528%3ADC%252BB3cXptVSqtL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2019&pages=1573-1592&author=F.+Parveenauthor=D.+Benderauthor=S.-H.+Lawauthor=V.+K.+Mishraauthor=C.-C.+Chenauthor=L.-Y.+Ke&title=Role+of+ceramidases+in+sphingolipid+metabolism+and+human+diseases&doi=10.3390%2Fcells8121573"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Role of ceramidases in sphingolipid metabolism and human diseases</span></div><div class="casAuthors">Parveen, Farzana; Bender, Daniel; Law, Shi-Hui; Mishra, Vineet Kumar; Chen, Chih-Chieh; Ke, Liang-Yin</div><div class="citationInfo"><span class="NLM_cas:title">Cells</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1573</span>CODEN:
                <span class="NLM_cas:coden">CELLC6</span>;
        ISSN:<span class="NLM_cas:issn">2073-4409</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">Human pathologies such as Alzheimer's disease, type 2 diabetes-induced insulin resistance, cancer, and cardiovascular diseases have altered lipid homeostasis.  Among these imbalanced lipids, the bioactive sphingolipids ceramide and sphingosine-1 phosphate (S1P) are pivotal in the pathophysiol. of these diseases.  Several enzymes within the sphingolipid pathway contribute to the homeostasis of ceramide and S1P.  Ceramidase is key in the degrdn. of ceramide into sphingosine and free fatty acids.  In humans, five different ceramidases are known-acid ceramidase, neutral ceramidase, and alk. ceramidase 1, 2, and 3-which are encoded by five different genes (ASAH1, ASAH2, ACER1, ACER2, and ACER3, resp.).  Notably, the neutral ceramidase N-acylsphingosine amidohydrolase 2 (ASAH2) shows considerable differences between humans and animals in terms of tissue expression levels.  Besides, the subcellular localization of ASAH2 remains controversial.  In this review, we sum up the results obtained for identifying gene divergence, structure, subcellular localization, and manipulating factors and address the role of ASAH2 along with other ceramidases in human diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGol2bCWkWONUbVg90H21EOLACvtfcHk0linBUzE9ndwyw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXptVSqtL4%253D&md5=4ff578971ab07c327e0291add9c311e4</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.3390%2Fcells8121573&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fcells8121573%26sid%3Dliteratum%253Aachs%26aulast%3DParveen%26aufirst%3DF.%26aulast%3DBender%26aufirst%3DD.%26aulast%3DLaw%26aufirst%3DS.-H.%26aulast%3DMishra%26aufirst%3DV.%2BK.%26aulast%3DChen%26aufirst%3DC.-C.%26aulast%3DKe%26aufirst%3DL.-Y.%26atitle%3DRole%2520of%2520ceramidases%2520in%2520sphingolipid%2520metabolism%2520and%2520human%2520diseases%26jtitle%3DCells%26date%3D2019%26volume%3D8%26spage%3D1573%26epage%3D1592%26doi%3D10.3390%2Fcells8121573" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">García-Barros, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coant, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kawamori, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wada, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Snider, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Truman, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, B. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Furuya, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clarke, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bialkowska, A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghaleb, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, V. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Obeid, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hannun, Y. A.</span></span> <span> </span><span class="NLM_article-title">Role of neutral ceramidase in colon cancer</span>. <i>FASEB J.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>30</i></span>,  <span class="NLM_fpage">4159</span>– <span class="NLM_lpage">4171</span>, <span class="refDoi"> DOI: 10.1096/fj.201600611R</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01561&amp;key=10.1096%2Ffj.201600611R" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01561&amp;key=27609772" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01561&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsFKrs7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2016&pages=4159-4171&author=M.+Garc%C3%ADa-Barrosauthor=N.+Coantauthor=T.+Kawamoriauthor=M.+Wadaauthor=A.+J.+Sniderauthor=J.+P.+Trumanauthor=B.+X.+Wuauthor=H.+Furuyaauthor=C.+J.+Clarkeauthor=A.+B.+Bialkowskaauthor=A.+Ghalebauthor=V.+W.+Yangauthor=L.+M.+Obeidauthor=Y.+A.+Hannun&title=Role+of+neutral+ceramidase+in+colon+cancer&doi=10.1096%2Ffj.201600611R"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Role of neutral ceramidase in colon cancer</span></div><div class="casAuthors">Garcia-Barros, Monica; Coant, Nicolas; Kawamori, Toshihiko; Wada, Masayuki; Snider, Ashley J.; Truman, Jean-Philip; Wu, Bill X.; Furuya, Hideki; Clarke, Christopher J.; Bialkowska, Agnieszka B.; Ghaleb, Amr; Yang, Vincent W.; Obeid, Lina M.; Hannun, Yusuf A.</div><div class="citationInfo"><span class="NLM_cas:title">FASEB Journal</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">4159-4171</span>CODEN:
                <span class="NLM_cas:coden">FAJOEC</span>;
        ISSN:<span class="NLM_cas:issn">0892-6638</span>.
    
            (<span class="NLM_cas:orgname">Federation of American Societies for Experimental Biology</span>)
        </div><div class="casAbstract">Alterations in sphingolipid metab., esp. ceramide and sphingosine 1-phosphate, have been linked to colon cancer, suggesting that enzymes of sphingolipid metab. may emerge as novel regulators and targets in colon cancer.  Neutral ceramidase (nCDase), a key enzyme in sphingolipid metab. that hydrolyzes ceramide into sphingosine, is highly expressed in the intestine; however, its role in colon cancer has not been defined.  Here we show that mol. and pharmacol. inhibition of nCDase in colon cancer cells increases ceramide, and this is accompanied by decreased cell survival and increased apoptosis and autophagy, with minimal effects on noncancerous cells.  Inhibition of nCDase resultedinloss of β-catenin and inhibition of ERK, components of pathways relevant for colon cancer development.  Furthermore, inhibition of nCDase in a xenograft model delayed tumor growth and increased ceramide while decreasing proliferation.  It is noteworthy that mice lacking nCDase treated with azoxymethane were protected fromtumor formation.  Taken together, these studies show that nCDase is pivotal for regulating initiation and development of colon cancer, and these data suggest that this enzyme is a suitable and novel target for colon cancer therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrjFMZMfHdb-bVg90H21EOLACvtfcHk0linBUzE9ndwyw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsFKrs7Y%253D&md5=408b6c905c1a504d00ca89f2ec955d9e</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1096%2Ffj.201600611R&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1096%252Ffj.201600611R%26sid%3Dliteratum%253Aachs%26aulast%3DGarc%25C3%25ADa-Barros%26aufirst%3DM.%26aulast%3DCoant%26aufirst%3DN.%26aulast%3DKawamori%26aufirst%3DT.%26aulast%3DWada%26aufirst%3DM.%26aulast%3DSnider%26aufirst%3DA.%2BJ.%26aulast%3DTruman%26aufirst%3DJ.%2BP.%26aulast%3DWu%26aufirst%3DB.%2BX.%26aulast%3DFuruya%26aufirst%3DH.%26aulast%3DClarke%26aufirst%3DC.%2BJ.%26aulast%3DBialkowska%26aufirst%3DA.%2BB.%26aulast%3DGhaleb%26aufirst%3DA.%26aulast%3DYang%26aufirst%3DV.%2BW.%26aulast%3DObeid%26aufirst%3DL.%2BM.%26aulast%3DHannun%26aufirst%3DY.%2BA.%26atitle%3DRole%2520of%2520neutral%2520ceramidase%2520in%2520colon%2520cancer%26jtitle%3DFASEB%2520J.%26date%3D2016%26volume%3D30%26spage%3D4159%26epage%3D4171%26doi%3D10.1096%2Ffj.201600611R" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Coant, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hannun, Y. A.</span></span> <span> </span><span class="NLM_article-title">Neutral ceramidase: advances in mechanisms, cell regulation, and roles in cancer</span>. <i>Adv. Biol. Regul.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>71</i></span>,  <span class="NLM_fpage">141</span>– <span class="NLM_lpage">146</span>, <span class="refDoi"> DOI: 10.1016/j.jbior.2018.10.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01561&amp;key=10.1016%2Fj.jbior.2018.10.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01561&amp;key=30389354" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01561&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitVCktr%252FN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=71&publication_year=2019&pages=141-146&author=N.+Coantauthor=Y.+A.+Hannun&title=Neutral+ceramidase%3A+advances+in+mechanisms%2C+cell+regulation%2C+and+roles+in+cancer&doi=10.1016%2Fj.jbior.2018.10.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Neutral ceramidase: Advances in mechanisms, cell regulation, and roles in cancer</span></div><div class="casAuthors">Coant, Nicolas; Hannun, Yusuf A.</div><div class="citationInfo"><span class="NLM_cas:title">Advances in Biological Regulation</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">71</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">141-146</span>CODEN:
                <span class="NLM_cas:coden">ABRDE5</span>;
        ISSN:<span class="NLM_cas:issn">2212-4934</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Extensive research conducted in the last three decades has identified the roles for the main bioactive sphingolipids, namely ceramide, sphingosine, and sphingosine 1-phosphate (S1P) as key regulators of cellular homeostasis, growth and death.  One of the major groups of enzymes in the ceramide pathway, ceramidases, converts ceramide into sphingosine and fatty acids, with sphingosine being further metabolized to S1P.  Thus, these enzymes play important roles in the network controlling the functions assocd. with these bioactive sphingolipids.  Among the family of ceramidases, neutral ceramidase (nCDase), which is named according to its optimal pH for catalytic activity, has received increased attention in the last decade.  The goal of this review is to provide a brief background on bioactive sphingolipids and the ceramidases.  We then describe more recent advances on nCDase, specifically the resoln. of its crystal structure and understanding its roles in cell biol. and physiol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoHkDx4Pq8957Vg90H21EOLACvtfcHk0ljMyrCdnLwYQw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitVCktr%252FN&md5=89677c27d48978f5f7821a0920541e7e</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1016%2Fj.jbior.2018.10.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jbior.2018.10.005%26sid%3Dliteratum%253Aachs%26aulast%3DCoant%26aufirst%3DN.%26aulast%3DHannun%26aufirst%3DY.%2BA.%26atitle%3DNeutral%2520ceramidase%253A%2520advances%2520in%2520mechanisms%252C%2520cell%2520regulation%252C%2520and%2520roles%2520in%2520cancer%26jtitle%3DAdv.%2520Biol.%2520Regul.%26date%3D2019%26volume%3D71%26spage%3D141%26epage%3D146%26doi%3D10.1016%2Fj.jbior.2018.10.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liakath-Ali, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vancollie, V. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lelliott, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Speak, A. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lafont, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Protheroe, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ingvorsen, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galli, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Green, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gleeson, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ryder, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Glover, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vizcay-Barrena, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karp, N. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arends, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brenn, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spiegel, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adams, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watt, F. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van der Weyden, L.</span></span> <span> </span><span class="NLM_article-title">Alkaline ceramidase 1 is essential for mammalian skin homeostasis and regulating whole-body energy expenditure</span>. <i>J. Pathol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>239</i></span>,  <span class="NLM_fpage">374</span>– <span class="NLM_lpage">383</span>, <span class="refDoi"> DOI: 10.1002/path.4737</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01561&amp;key=10.1002%2Fpath.4737" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01561&amp;key=27126290" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01561&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtVWmu7vF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=239&publication_year=2016&pages=374-383&author=K.+Liakath-Aliauthor=V.+E.+Vancollieauthor=C.+J.+Lelliottauthor=A.+O.+Speakauthor=D.+Lafontauthor=H.+J.+Protheroeauthor=C.+Ingvorsenauthor=A.+Galliauthor=A.+Greenauthor=D.+Gleesonauthor=E.+Ryderauthor=L.+Gloverauthor=G.+Vizcay-Barrenaauthor=N.+A.+Karpauthor=M.+J.+Arendsauthor=T.+Brennauthor=S.+Spiegelauthor=D.+J.+Adamsauthor=F.+M.+Wattauthor=L.+van+der+Weyden&title=Alkaline+ceramidase+1+is+essential+for+mammalian+skin+homeostasis+and+regulating+whole-body+energy+expenditure&doi=10.1002%2Fpath.4737"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Alkaline ceramidase 1 is essential for mammalian skin homeostasis and regulating whole-body energy expenditure</span></div><div class="casAuthors">Liakath-Ali, Kifayathullah; Vancollie, Valerie E.; Lelliott, Christopher J.; Speak, Anneliese O.; Lafont, David; Protheroe, Hayley J.; Ingvorsen, Camilla; Galli, Antonella; Green, Angela; Gleeson, Diane; Ryder, Ed; Glover, Leanne; Vizcay-Barrena, Gema; Karp, Natasha A.; Arends, Mark J.; Brenn, Thomas; Spiegel, Sarah; Adams, David J.; Watt, Fiona M.; van der Weyden, Louise</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pathology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">239</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">374-383</span>CODEN:
                <span class="NLM_cas:coden">JPTLAS</span>;
        ISSN:<span class="NLM_cas:issn">1096-9896</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons Ltd.</span>)
        </div><div class="casAbstract">The epidermis is the outermost layer of skin that acts as a barrier to protect the body from the external environment and to control water and heat loss.  This barrier function is established through the multistage differentiation of keratinocytes and the presence of bioactive sphingolipids such as ceramides, the levels of which are tightly regulated by a balance of ceramide synthase and ceramidase activities.  Here we reveal the essential role of alk. ceramidase 1 (Acer1) in the skin.  Acer1-deficient (Acer1-/-) mice showed elevated levels of ceramide in the skin, aberrant hair shaft cuticle formation and cyclic alopecia.  We demonstrate that Acer1 is specifically expressed in differentiated interfollicular epidermis, infundibulum and sebaceous glands and consequently Acer1-/- mice have significant alterations in infundibulum and sebaceous gland architecture.  Acer1-/- skin also shows perturbed hair follicle stem cell compartments.  These alterations result in Acer1-/- mice showing increased transepidermal water loss and a hypermetabolism phenotype with assocd. redn. of fat content with age.  We conclude that Acer1 is indispensable for mammalian skin homeostasis and whole-body energy homeostasis. © 2016 The Authors.  The Journal of Pathol. published by John Wiley & Sons Ltd on behalf of Pathol. Society of Great Britain and Ireland.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpGes66APLUrLVg90H21EOLACvtfcHk0ljMyrCdnLwYQw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtVWmu7vF&md5=c297e027f36783fec5de3a86a3e98983</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1002%2Fpath.4737&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fpath.4737%26sid%3Dliteratum%253Aachs%26aulast%3DLiakath-Ali%26aufirst%3DK.%26aulast%3DVancollie%26aufirst%3DV.%2BE.%26aulast%3DLelliott%26aufirst%3DC.%2BJ.%26aulast%3DSpeak%26aufirst%3DA.%2BO.%26aulast%3DLafont%26aufirst%3DD.%26aulast%3DProtheroe%26aufirst%3DH.%2BJ.%26aulast%3DIngvorsen%26aufirst%3DC.%26aulast%3DGalli%26aufirst%3DA.%26aulast%3DGreen%26aufirst%3DA.%26aulast%3DGleeson%26aufirst%3DD.%26aulast%3DRyder%26aufirst%3DE.%26aulast%3DGlover%26aufirst%3DL.%26aulast%3DVizcay-Barrena%26aufirst%3DG.%26aulast%3DKarp%26aufirst%3DN.%2BA.%26aulast%3DArends%26aufirst%3DM.%2BJ.%26aulast%3DBrenn%26aufirst%3DT.%26aulast%3DSpiegel%26aufirst%3DS.%26aulast%3DAdams%26aufirst%3DD.%2BJ.%26aulast%3DWatt%26aufirst%3DF.%2BM.%26aulast%3Dvan%2Bder%2BWeyden%26aufirst%3DL.%26atitle%3DAlkaline%2520ceramidase%25201%2520is%2520essential%2520for%2520mammalian%2520skin%2520homeostasis%2520and%2520regulating%2520whole-body%2520energy%2520expenditure%26jtitle%3DJ.%2520Pathol.%26date%3D2016%26volume%3D239%26spage%3D374%26epage%3D383%26doi%3D10.1002%2Fpath.4737" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sun, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crellin, H. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bielawski, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Szulc, Z. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thiers, B. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Obeid, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mao, C.</span></span> <span> </span><span class="NLM_article-title">Upregulation of the human alkaline ceramidase 1 and acid ceramidase mediates calcium-induced differentiation of epidermal keratinocytes</span>. <i>J. Invest. Dermatol.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>128</i></span>,  <span class="NLM_fpage">389</span>– <span class="NLM_lpage">397</span>, <span class="refDoi"> DOI: 10.1038/sj.jid.5701025</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01561&amp;key=10.1038%2Fsj.jid.5701025" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01561&amp;key=17713573" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01561&amp;key=1%3ACAS%3A528%3ADC%252BD1cXmsV2ltg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=128&publication_year=2008&pages=389-397&author=W.+Sunauthor=R.+Xuauthor=W.+Huauthor=J.+Jinauthor=H.+A.+Crellinauthor=J.+Bielawskiauthor=Z.+M.+Szulcauthor=B.+H.+Thiersauthor=L.+M.+Obeidauthor=C.+Mao&title=Upregulation+of+the+human+alkaline+ceramidase+1+and+acid+ceramidase+mediates+calcium-induced+differentiation+of+epidermal+keratinocytes&doi=10.1038%2Fsj.jid.5701025"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Upregulation of the Human Alkaline Ceramidase 1 and Acid Ceramidase Mediates Calcium-Induced Differentiation of Epidermal Keratinocytes</span></div><div class="casAuthors">Sun, Wei; Xu, Ruijuan; Hu, Wei; Jin, Junfei; Crellin, Heather A.; Bielawski, Jacek; Szulc, Zdzislaw M.; Thiers, Bruce H.; Obeid, Lina M.; Mao, Cungui</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Investigative Dermatology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">128</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">389-397</span>CODEN:
                <span class="NLM_cas:coden">JIDEAE</span>;
        ISSN:<span class="NLM_cas:issn">0022-202X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Extracellular calcium (Ca2+o) potently induces the growth arrest and differentiation of human epidermal keratinocytes (HEKs).  We report that Ca2+o markedly upregulates the human alk. ceramidase 1 (haCER1) in HEKs; and its upregulation mediates the Ca2+o-induced growth arrest and differentiation of HEKs.  HaCER1 is the human ortholog of mouse alk. ceramidase 1 that we previously identified.  HaCER1 catalyzed the hydrolysis of very long-chain ceramides to generate sphingosine (SPH).  This in vitro activity required Ca2+.  Ectopic expression of haCER1 in HEKs decreased the levels of D-e-C24:1-ceramide and D-e-C24:0-ceramide but elevated the levels of both SPH and its phosphate (S1P), whereas RNA interference-mediated knockdown of haCER1 caused the opposite effects on the levels of these sphingolipids in HEKs.  Similar to haCER1 overexpression, Ca2+o increased the levels of SPH and S1P, and this was attenuated by haCER1 knockdown. haCER1 knockdown also inhibited the Ca2+o-induced growth arrest of HEKs and the Ca2+o-induced expression of keratin 1 and involucrin in HEKs.  In addn., the acid ceramidase (AC) was also upregulated by Ca2+o; and its knockdown attenuated the Ca2+o-induced expression of keratin 1 and involucrin in HEKs.  These results strongly suggest that upregulation of haCER1 and AC mediates the Ca2+o-induced growth arrest and differentiation of HEKs by generating SPH and S1P.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqVoiEV5ww6obVg90H21EOLACvtfcHk0ljMyrCdnLwYQw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXmsV2ltg%253D%253D&md5=8b2831c9327084efd1a3260a2c942fa8</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1038%2Fsj.jid.5701025&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.jid.5701025%26sid%3Dliteratum%253Aachs%26aulast%3DSun%26aufirst%3DW.%26aulast%3DXu%26aufirst%3DR.%26aulast%3DHu%26aufirst%3DW.%26aulast%3DJin%26aufirst%3DJ.%26aulast%3DCrellin%26aufirst%3DH.%2BA.%26aulast%3DBielawski%26aufirst%3DJ.%26aulast%3DSzulc%26aufirst%3DZ.%2BM.%26aulast%3DThiers%26aufirst%3DB.%2BH.%26aulast%3DObeid%26aufirst%3DL.%2BM.%26aulast%3DMao%26aufirst%3DC.%26atitle%3DUpregulation%2520of%2520the%2520human%2520alkaline%2520ceramidase%25201%2520and%2520acid%2520ceramidase%2520mediates%2520calcium-induced%2520differentiation%2520of%2520epidermal%2520keratinocytes%26jtitle%3DJ.%2520Invest.%2520Dermatol.%26date%3D2008%26volume%3D128%26spage%3D389%26epage%3D397%26doi%3D10.1038%2Fsj.jid.5701025" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xu, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mileva, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hannun, Y. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Obeid, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mao, C.</span></span> <span> </span><span class="NLM_article-title">Alkaline ceramidase 2 and its bioactive product sphingosine are novel regulators of the DNA damage response</span>. <i>Oncotarget</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">18440</span>– <span class="NLM_lpage">18457</span>, <span class="refDoi"> DOI: 10.18632/oncotarget.7825</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01561&amp;key=10.18632%2Foncotarget.7825" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01561&amp;key=26943039" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01561&amp;key=1%3ACAS%3A280%3ADC%252BC28jmvV2lsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2016&pages=18440-18457&author=R.+Xuauthor=K.+Wangauthor=I.+Milevaauthor=Y.+A.+Hannunauthor=L.+M.+Obeidauthor=C.+Mao&title=Alkaline+ceramidase+2+and+its+bioactive+product+sphingosine+are+novel+regulators+of+the+DNA+damage+response&doi=10.18632%2Foncotarget.7825"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Alkaline ceramidase 2 and its bioactive product sphingosine are novel regulators of the DNA damage response</span></div><div class="casAuthors">Xu Ruijuan; Wang Kai; Hannun Yusuf A; Obeid Lina M; Mao Cungui; Xu Ruijuan; Wang Kai; Hannun Yusuf A; Obeid Lina M; Mao Cungui; Mileva Izolda; Obeid Lina M</div><div class="citationInfo"><span class="NLM_cas:title">Oncotarget</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">18440-57</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Human cells respond to DNA damage by elevating sphingosine, a bioactive sphingolipid that induces programmed cell death (PCD) in response to various forms of stress, but its regulation and role in the DNA damage response remain obscure.  Herein we demonstrate that DNA damage increases sphingosine levels in tumor cells by upregulating alkaline ceramidase 2 (ACER2) and that the upregulation of the ACER2/sphingosine pathway induces PCD in response to DNA damage by increasing the production of reactive oxygen species (ROS).  Treatment with the DNA damaging agent doxorubicin increased both ACER2 expression and sphingosine levels in HCT116 cells in a dose-dependent manner.  ACER2 overexpression increased sphingosine in HeLa cells whereas knocking down ACER2 inhibited the doxorubicin-induced increase in sphingosine in HCT116 cells, suggesting that DNA damage elevates sphingosine by upregulating ACER2.  Knocking down ACER2 inhibited an increase in the apoptotic and necrotic cell population and the cleavage of poly ADP ribose polymerase (PARP) in HCT116 cells in response to doxorubicin as well as doxorubicin-induced release of lactate dehydrogenase (LDH) from these cells.  Similar to treatment with doxorubicin, ACER2 overexpression induced an increase in the apoptotic and necrotic cell population and PARP cleavage in HeLa cells and LDH release from cells, suggesting that ACER2 upregulation mediates PCD in response to DNA damage through sphingosine.  Mechanistic studies demonstrated that the upregulation of the ACER2/sphingosine pathway induces PCD by increasing ROS levels.  Taken together, these results suggest that the ACER2/sphingosine pathway mediates PCD in response to DNA damage through ROS production.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRCO-JaxZbqSpdYoSR9eyvsfW6udTcc2eYhdibhyocAWbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC28jmvV2lsw%253D%253D&md5=baf9847bfe0128f958d8de5ed003ebd4</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.18632%2Foncotarget.7825&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18632%252Foncotarget.7825%26sid%3Dliteratum%253Aachs%26aulast%3DXu%26aufirst%3DR.%26aulast%3DWang%26aufirst%3DK.%26aulast%3DMileva%26aufirst%3DI.%26aulast%3DHannun%26aufirst%3DY.%2BA.%26aulast%3DObeid%26aufirst%3DL.%2BM.%26aulast%3DMao%26aufirst%3DC.%26atitle%3DAlkaline%2520ceramidase%25202%2520and%2520its%2520bioactive%2520product%2520sphingosine%2520are%2520novel%2520regulators%2520of%2520the%2520DNA%2520damage%2520response%26jtitle%3DOncotarget%26date%3D2016%26volume%3D7%26spage%3D18440%26epage%3D18457%26doi%3D10.18632%2Foncotarget.7825" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Szulc, Z. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bielawski, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Obeid, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mao, C.</span></span> <span> </span><span class="NLM_article-title">Alkaline ceramidase 3 (ACER3) hydrolyzes unsaturated long-chain ceramides, and its down-regulation inhibits both cell proliferation and apoptosis</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>285</i></span>,  <span class="NLM_fpage">7964</span>– <span class="NLM_lpage">7976</span>, <span class="refDoi"> DOI: 10.1074/jbc.m109.063586</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01561&amp;key=10.1074%2Fjbc.M109.063586" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01561&amp;key=20068046" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01561&amp;key=1%3ACAS%3A528%3ADC%252BC3cXislyqtLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=285&publication_year=2010&pages=7964-7976&author=W.+Huauthor=R.+Xuauthor=W.+Sunauthor=Z.+M.+Szulcauthor=J.+Bielawskiauthor=L.+M.+Obeidauthor=C.+Mao&title=Alkaline+ceramidase+3+%28ACER3%29+hydrolyzes+unsaturated+long-chain+ceramides%2C+and+its+down-regulation+inhibits+both+cell+proliferation+and+apoptosis&doi=10.1074%2Fjbc.m109.063586"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Alkaline Ceramidase 3 (ACER3) Hydrolyzes Unsaturated Long-chain Ceramides, and Its Down-regulation Inhibits Both Cell Proliferation and Apoptosis</span></div><div class="casAuthors">Hu, Wei; Xu, Ruijuan; Sun, Wei; Szulc, Zdzislaw M.; Bielawski, Jacek; Obeid, Lina M.; Mao, Cungui</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">285</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">7964-7976</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">Ceramides with different fatty acyl chains may vary in their physiol. or pathol. roles; however, it remains unclear how cellular levels of individual ceramide species are regulated.  Here, we demonstrate that our previously cloned human alk. ceramidase 3 (ACER3) specifically controls the hydrolysis of ceramides carrying unsatd. long acyl chains, unsatd. long-chain (ULC) ceramides.  In vitro, ACER3 only hydrolyzed C18:1-, C20:1-, C20:4-ceramides, dihydroceramides, and phytoceramides.  In cells, ACER3 overexpression decreased C18:1- and C20:1-ceramides and dihydroceramides, whereas ACER3 knockdown by RNA interference had the opposite effect, suggesting that ACER3 controls the catabolism of ULC ceramides and dihydroceramides.  ACER3 knockdown inhibited cell proliferation and up-regulated the cyclin-dependent kinase inhibitor p21CIP1/WAF1.  Blocking p21CIP1/WAF1 up-regulation attenuated the inhibitory effect of ACER3 knockdown on cell proliferation, suggesting that ACER3 knockdown inhibits cell proliferation because of p21CIP1/WAF1 up-regulation.  ACER3 knockdown inhibited cell apoptosis in response to serum deprivation.  ACER3 knockdown up-regulated the expression of the alk. ceramidase 2 (ACER2), and the ACER2 up-regulation decreased non-ULC ceramide species while increasing both sphingosine and its phosphate.  Collectively, these data suggest that ACER3 catalyzes the hydrolysis of ULC ceramides and dihydroceramides and that ACER3 coordinates with ACER2 to regulate cell proliferation and survival.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpCiCEwa7GRxLVg90H21EOLACvtfcHk0lgulGAvxy7dig"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXislyqtLk%253D&md5=24778e515470e14507c49f98f8fae8c8</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M109.063586&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M109.063586%26sid%3Dliteratum%253Aachs%26aulast%3DHu%26aufirst%3DW.%26aulast%3DXu%26aufirst%3DR.%26aulast%3DSun%26aufirst%3DW.%26aulast%3DSzulc%26aufirst%3DZ.%2BM.%26aulast%3DBielawski%26aufirst%3DJ.%26aulast%3DObeid%26aufirst%3DL.%2BM.%26aulast%3DMao%26aufirst%3DC.%26atitle%3DAlkaline%2520ceramidase%25203%2520%2528ACER3%2529%2520hydrolyzes%2520unsaturated%2520long-chain%2520ceramides%252C%2520and%2520its%2520down-regulation%2520inhibits%2520both%2520cell%2520proliferation%2520and%2520apoptosis%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2010%26volume%3D285%26spage%3D7964%26epage%3D7976%26doi%3D10.1074%2Fjbc.m109.063586" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schrandt, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shah, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gong, Y. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Preston, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yi, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, C.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spyropoulos, D. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rhee, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ge, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Snider, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hannun, Y. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Obeid, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mao, C.</span></span> <span> </span><span class="NLM_article-title">Alkaline ceramidase 3 deficiency results in purkinje cell degeneration and cerebellar ataxia due to dyshomeostasis of sphingolipids in the brain</span>. <i>PLoS Genet.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">e1005591</span>– <span class="NLM_lpage">e1005622</span>, <span class="refDoi"> DOI: 10.1371/journal.pgen.1005591</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01561&amp;key=10.1371%2Fjournal.pgen.1005591" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01561&amp;key=26474409" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01561&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtFelsrfN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2015&pages=e1005591-e1005622&author=K.+Wangauthor=R.+Xuauthor=J.+Schrandtauthor=P.+Shahauthor=Y.+Z.+Gongauthor=C.+Prestonauthor=L.+Wangauthor=J.+K.+Yiauthor=C.-L.+Linauthor=W.+Sunauthor=D.+D.+Spyropoulosauthor=S.+Rheeauthor=M.+Liauthor=J.+Zhouauthor=S.+Geauthor=G.+Zhangauthor=A.+J.+Sniderauthor=Y.+A.+Hannunauthor=L.+M.+Obeidauthor=C.+Mao&title=Alkaline+ceramidase+3+deficiency+results+in+purkinje+cell+degeneration+and+cerebellar+ataxia+due+to+dyshomeostasis+of+sphingolipids+in+the+brain&doi=10.1371%2Fjournal.pgen.1005591"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Alkaline ceramidase 3 deficiency results in Purkinje cell degeneration and cerebellar ataxia due to dyshomeostasis of sphingolipids in the brain</span></div><div class="casAuthors">Wang, Kai; Xu, Ruijuan; Schrandt, Jennifer; Shah, Prithvi; Gong, Yong Z.; Preston, Chet; Wang, Louis; Yi, Jae Kyo; Lin, Chih-Li; Sun, Wei; Spyropoulos, Demetri D.; Rhee, Soyoung; Li, Mingsong; Zhou, Jie; Ge, Shaoyu; Zhang, Guofeng; Snider, Ashley J.; Hannun, Yusuf A.; Obeid, Lina M.; Mao, Cungui</div><div class="citationInfo"><span class="NLM_cas:title">PLoS Genetics</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">e1005591/1-e1005591/31</span>CODEN:
                <span class="NLM_cas:coden">PGLEB5</span>;
        ISSN:<span class="NLM_cas:issn">1553-7404</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">Dyshomeostasis of both ceramides and sphingosine-1-phosphate (S1P) in the brain has been implicated in aging-assocd. neurodegenerative disorders in humans.  However, mechanisms that maintain the homeostasis of these bioactive sphingolipids in the brain remain unclear.  Mouse alk. ceramidase 3 (Acer3), which preferentially catalyzes the hydrolysis of C18:1-ceramide, a major unsatd. long-chain ceramide species in the brain, is upregulated with age in the mouse brain.  Acer3 knockout causes an age-dependent accumulation of various ceramides and C18:1-monohexosylceramide and abolishes the age-related increase in the levels of sphingosine and S1P in the brain; thereby resulting in Purkinje cell degeneration in the cerebellum and deficits in motor coordination and balance.  Our results indicate that Acer3 plays critically protective roles in controlling the homeostasis of various sphingolipids, including ceramides, sphingosine, S1P, and certain complex sphingolipids in the brain and protects Purkinje cells from premature degeneration.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGquK9k-H7uHI7Vg90H21EOLACvtfcHk0lgulGAvxy7dig"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtFelsrfN&md5=d4df63930a9c02e142dc5761a1908ee3</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pgen.1005591&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pgen.1005591%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DK.%26aulast%3DXu%26aufirst%3DR.%26aulast%3DSchrandt%26aufirst%3DJ.%26aulast%3DShah%26aufirst%3DP.%26aulast%3DGong%26aufirst%3DY.%2BZ.%26aulast%3DPreston%26aufirst%3DC.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DYi%26aufirst%3DJ.%2BK.%26aulast%3DLin%26aufirst%3DC.-L.%26aulast%3DSun%26aufirst%3DW.%26aulast%3DSpyropoulos%26aufirst%3DD.%2BD.%26aulast%3DRhee%26aufirst%3DS.%26aulast%3DLi%26aufirst%3DM.%26aulast%3DZhou%26aufirst%3DJ.%26aulast%3DGe%26aufirst%3DS.%26aulast%3DZhang%26aufirst%3DG.%26aulast%3DSnider%26aufirst%3DA.%2BJ.%26aulast%3DHannun%26aufirst%3DY.%2BA.%26aulast%3DObeid%26aufirst%3DL.%2BM.%26aulast%3DMao%26aufirst%3DC.%26atitle%3DAlkaline%2520ceramidase%25203%2520deficiency%2520results%2520in%2520purkinje%2520cell%2520degeneration%2520and%2520cerebellar%2520ataxia%2520due%2520to%2520dyshomeostasis%2520of%2520sphingolipids%2520in%2520the%2520brain%26jtitle%3DPLoS%2520Genet.%26date%3D2015%26volume%3D11%26spage%3De1005591%26epage%3De1005622%26doi%3D10.1371%2Fjournal.pgen.1005591" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Edvardson, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yi, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jalas, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Webb, B. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Snider, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fedick, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kleinman, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Treff, N. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mao, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elpeleg, O.</span></span> <span> </span><span class="NLM_article-title">Deficiency of the alkaline ceramidase ACER3 manifests in early childhood by progressive leukodystrophy</span>. <i>J. Med. Genet.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>53</i></span>,  <span class="NLM_fpage">389</span>– <span class="NLM_lpage">396</span>, <span class="refDoi"> DOI: 10.1136/jmedgenet-2015-103457</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01561&amp;key=10.1136%2Fjmedgenet-2015-103457" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01561&amp;key=26792856" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01561&amp;key=1%3ACAS%3A528%3ADC%252BC1cXkvFKjsLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2016&pages=389-396&author=S.+Edvardsonauthor=J.+K.+Yiauthor=C.+Jalasauthor=R.+Xuauthor=B.+D.+Webbauthor=J.+Sniderauthor=A.+Fedickauthor=E.+Kleinmanauthor=N.+R.+Treffauthor=C.+Maoauthor=O.+Elpeleg&title=Deficiency+of+the+alkaline+ceramidase+ACER3+manifests+in+early+childhood+by+progressive+leukodystrophy&doi=10.1136%2Fjmedgenet-2015-103457"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Deficiency of the alkaline ceramidase ACER3 manifests in early childhood by progressive leukodystrophy</span></div><div class="casAuthors">Edvardson, Simon; Yi, Jae Kyo; Jalas, Chaim; Xu, Ruijuan; Webb, Bryn D.; Snider, Justin; Fedick, Anastasia; Kleinman, Elisheva; Treff, Nathan R.; Mao, Cungui; Elpeleg, Orly</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medical Genetics</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">389-396</span>CODEN:
                <span class="NLM_cas:coden">JMDGAE</span>;
        ISSN:<span class="NLM_cas:issn">0022-2593</span>.
    
            (<span class="NLM_cas:orgname">BMJ Publishing Group</span>)
        </div><div class="casAbstract">Background/aims Leukodystrophies due to abnormal prodn. of myelin cause extensive morbidity in early life; their genetic background is still largely unknown.  We aimed at reaching a mol. diagnosis in Ashkenazi-Jewish patients who suffered from developmental regression at 6-13 mo, leukodystrophy and peripheral neuropathy.  Methods Exome anal., detn. of alk. ceramidase activity catalyzing the conversion of C18:1- ceramide to sphingosine and D-ribo-C12-N-(7-nitrobenz-2- oxa-1,3-diazol-4-yl) (NBD)-phytoceramide to NBD-C12- fatty acid using liq. chromatog.-tandem mass spectrometry (LC-MS/MS) and thin layer chromatog., resp., and sphingolipid anal. in patients' blood by LC-MS/MS.  Results The patients were homozygous for p.E33G in the ACER3, which encodes a C18:1-alk. ceramidase and C20:1-alk. ceramidase.  The mutation abolished ACER3 catalytic activity in the patients' cells and failed to restore alk. ceramidase activity in yeast mutant strain.  The levels of ACER3 substrates, C18:1-ceramides and dihydroceramides and C20:1-ceramides and dihydroceramides and other long-chain ceramides and dihydroceramides were markedly increased in the patients' plasma, along with that of complex sphingolipids, including monohexosylceramides and lactosylceramides.  Conclusions Homozygosity for the p.E33G mutation in the ACER3 gene results in inactivation of ACER3, leading to the accumulation of various sphingolipids in blood and probably in brain, likely accounting for this new form of childhood leukodystroph.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrehSzH5J9uSrVg90H21EOLACvtfcHk0livAnQgx-qRuw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXkvFKjsLY%253D&md5=cada68b70a98e6b78509e9935b58d5db</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1136%2Fjmedgenet-2015-103457&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1136%252Fjmedgenet-2015-103457%26sid%3Dliteratum%253Aachs%26aulast%3DEdvardson%26aufirst%3DS.%26aulast%3DYi%26aufirst%3DJ.%2BK.%26aulast%3DJalas%26aufirst%3DC.%26aulast%3DXu%26aufirst%3DR.%26aulast%3DWebb%26aufirst%3DB.%2BD.%26aulast%3DSnider%26aufirst%3DJ.%26aulast%3DFedick%26aufirst%3DA.%26aulast%3DKleinman%26aufirst%3DE.%26aulast%3DTreff%26aufirst%3DN.%2BR.%26aulast%3DMao%26aufirst%3DC.%26aulast%3DElpeleg%26aufirst%3DO.%26atitle%3DDeficiency%2520of%2520the%2520alkaline%2520ceramidase%2520ACER3%2520manifests%2520in%2520early%2520childhood%2520by%2520progressive%2520leukodystrophy%26jtitle%3DJ.%2520Med.%2520Genet.%26date%3D2016%26volume%3D53%26spage%3D389%26epage%3D396%26doi%3D10.1136%2Fjmedgenet-2015-103457" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bernardo, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hurwitz, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zenk, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Desnick, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferlinz, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schuchman, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sandhoff, K.</span></span> <span> </span><span class="NLM_article-title">Purification, characterization, and biosynthesis of human acid ceramidase</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1995</span>,  <span class="NLM_volume"><i>270</i></span>,  <span class="NLM_fpage">11098</span>– <span class="NLM_lpage">11102</span>, <span class="refDoi"> DOI: 10.1074/jbc.270.19.11098</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01561&amp;key=10.1074%2Fjbc.270.19.11098" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01561&amp;key=7744740" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01561&amp;key=1%3ACAS%3A528%3ADyaK2MXls1ejtb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=270&publication_year=1995&pages=11098-11102&author=K.+Bernardoauthor=R.+Hurwitzauthor=T.+Zenkauthor=R.+Desnickauthor=K.+Ferlinzauthor=E.+Schuchmanauthor=K.+Sandhoff&title=Purification%2C+characterization%2C+and+biosynthesis+of+human+acid+ceramidase&doi=10.1074%2Fjbc.270.19.11098"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Purification, characterization, and biosynthesis of human acid ceramidase</span></div><div class="casAuthors">Bernardo, Katussevani; Hurwitz, Robert; Zenk, Thomas; Desnick, Robert J.; Ferlinz, Klaus; Schuchman, Edward H.; Sandhoff, Konrad</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">1995</span>),
    <span class="NLM_cas:volume">270</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">11098-102</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">Acid ceramidase (N-acylsphingosine deacylase, EC 3.5.1.23) (I) is the lysosomal enzyme catalyzing the hydrolysis of ceramide to sphingosine and free fatty acid.  Its inherited deficiency causes ceramide accumulation in inherited deficiency causes ceramide accumulation in Faber's disease.  I was purified to apparent homogeneity from human urine by sequential chromatog. on octyl-Sepharose, Con A-Sepharose, Blue-Sepharose, and DEAE-cellulose.  The final prepn., which was enriched ∼4450-fold over the starting material, resulted in a polypeptide of ∼50 kDa and could be reduced into 2 subunits of ∼13 (α) and ∼40 (β) kDa.  Treatment of purified I with endoglycosidase H or peptide N-glycanase F reduced the mol. wt. of the β subunit to ∼30-35 and ∼27 kDa, resp.  In contrast, the mol. wt. of the α subunit was unchanged.  Purified I had an apparent Km of 149 μM and a Vmax of 136 nmol/mg/h using N-lauroylsphingosine as substrate.  Polyclonal antibodies were raised against the purified urinary enzyme and used to investigate the biosynthesis of I.  Immunopptn. studies on metabolically labeled skin fibroblasts indicated that both subunits arise from a single precursor of ∼55 kDa.  A minor protein of newly synthesized I was secreted into the medium as a monomeric 47-kDa protein, indicating that generation of the mature heterodimeric enzyme occurs in endosomal and/or lysosomal compartments.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpm-1pFxhqHCLVg90H21EOLACvtfcHk0livAnQgx-qRuw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2MXls1ejtb4%253D&md5=d8f667c773db8a01ca5d22e49dd36123</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1074%2Fjbc.270.19.11098&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.270.19.11098%26sid%3Dliteratum%253Aachs%26aulast%3DBernardo%26aufirst%3DK.%26aulast%3DHurwitz%26aufirst%3DR.%26aulast%3DZenk%26aufirst%3DT.%26aulast%3DDesnick%26aufirst%3DR.%26aulast%3DFerlinz%26aufirst%3DK.%26aulast%3DSchuchman%26aufirst%3DE.%26aulast%3DSandhoff%26aufirst%3DK.%26atitle%3DPurification%252C%2520characterization%252C%2520and%2520biosynthesis%2520of%2520human%2520acid%2520ceramidase%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D1995%26volume%3D270%26spage%3D11098%26epage%3D11102%26doi%3D10.1074%2Fjbc.270.19.11098" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ferlinz, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kopal, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bernardo, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Linke, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bär, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Breiden, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neumann, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lang, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schuchman, E. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sandhoff, K.</span></span> <span> </span><span class="NLM_article-title">Human acid ceramidase. Processing, glycosylation, and lysosomal targeting</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>276</i></span>,  <span class="NLM_fpage">35352</span>– <span class="NLM_lpage">35360</span>, <span class="refDoi"> DOI: 10.1074/jbc.m103066200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01561&amp;key=10.1074%2Fjbc.M103066200" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01561&amp;key=11451951" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01561&amp;key=1%3ACAS%3A528%3ADC%252BD3MXntFaiu74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=276&publication_year=2001&pages=35352-35360&author=K.+Ferlinzauthor=G.+Kopalauthor=K.+Bernardoauthor=T.+Linkeauthor=J.+B%C3%A4rauthor=B.+Breidenauthor=U.+Neumannauthor=F.+Langauthor=E.+H.+Schuchmanauthor=K.+Sandhoff&title=Human+acid+ceramidase.+Processing%2C+glycosylation%2C+and+lysosomal+targeting&doi=10.1074%2Fjbc.m103066200"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Human acid ceramidase. Processing, glycosylation, and lysosomal targeting</span></div><div class="casAuthors">Ferlinz, Klaus; Kopal, Guido; Bernardo, Katussevani; Linke, Thomas; Bar, Julia; Breiden, Bernadette; Neumann, Ulrich; Lang, Florian; Schuchman, Edward H.; Sandhoff, Konrad</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">276</span>
        (<span class="NLM_cas:issue">38</span>),
    <span class="NLM_cas:pages">35352-35360</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">The biosynthesis of human acid ceramidase (hAC) starts with the expression of a single precursor polypeptide of ∼53-55 kDa, which is subsequently processed to the mature, heterodimeric enzyme (40 + 13 kDa) in the endosomes/lysosomes.  Secretion of hAC by either fibroblasts or acid ceramidase cDNA-transfected COS cells is extraordinarily low.  Both lysosomal targeting and endocytosis critically depend on a functional mannose 6-phosphate receptor as judged by the following criteria: (i) hAC-precursor secretion by NH4Cl-treated fibroblasts and I-cell disease fibroblasts, (ii) inhibition of the formation of mature heterodimeric hAC in NH4Cl-treated fibroblasts or in I-cell disease fibroblasts, and (iii) blocked endocytosis of hAC precursor by mannose 6-phosphate receptor-deficient fibroblasts or the addn. of mannose 6-phosphate.  The influence of the six individual potential N-glycosylation sites of human acid ceramidase on targeting, processing, and catalytic activity was detd. by site-directed mutagenesis.  Five glycosylation sites (sites 1-5 from the N terminus) are used.  The elimination of sites 2, 4, and 6 has no influence on lysosomal processing or enzymic activity of recombinant ceramidase.  The removal of sites 1, 3, and 5 inhibits the formation of the heterodimeric enzyme form.  None of the mutant ceramidases gave rise to an increased rate of secretion, suggesting that lysosomal targeting does not depend on one single carbohydrate chain.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGphqd4zG5xUarVg90H21EOLACvtfcHk0livAnQgx-qRuw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXntFaiu74%253D&md5=ed5f3b1df1fde010beeba41678f61fcc</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M103066200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M103066200%26sid%3Dliteratum%253Aachs%26aulast%3DFerlinz%26aufirst%3DK.%26aulast%3DKopal%26aufirst%3DG.%26aulast%3DBernardo%26aufirst%3DK.%26aulast%3DLinke%26aufirst%3DT.%26aulast%3DB%25C3%25A4r%26aufirst%3DJ.%26aulast%3DBreiden%26aufirst%3DB.%26aulast%3DNeumann%26aufirst%3DU.%26aulast%3DLang%26aufirst%3DF.%26aulast%3DSchuchman%26aufirst%3DE.%2BH.%26aulast%3DSandhoff%26aufirst%3DK.%26atitle%3DHuman%2520acid%2520ceramidase.%2520Processing%252C%2520glycosylation%252C%2520and%2520lysosomal%2520targeting%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2001%26volume%3D276%26spage%3D35352%26epage%3D35360%26doi%3D10.1074%2Fjbc.m103066200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Newton, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lima, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maceyka, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spiegel, S.</span></span> <span> </span><span class="NLM_article-title">Revisiting the sphingolipid rheostat: Evolving concepts in cancer therapy</span>. <i>Exp. Cell Res.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>333</i></span>,  <span class="NLM_fpage">195</span>– <span class="NLM_lpage">200</span>, <span class="refDoi"> DOI: 10.1016/j.yexcr.2015.02.025</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01561&amp;key=10.1016%2Fj.yexcr.2015.02.025" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01561&amp;key=25770011" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01561&amp;key=1%3ACAS%3A528%3ADC%252BC2MXksFWis7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=333&publication_year=2015&pages=195-200&author=J.+Newtonauthor=S.+Limaauthor=M.+Maceykaauthor=S.+Spiegel&title=Revisiting+the+sphingolipid+rheostat%3A+Evolving+concepts+in+cancer+therapy&doi=10.1016%2Fj.yexcr.2015.02.025"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Revisiting the sphingolipid rheostat- evolving concepts in cancer therapy</span></div><div class="casAuthors">Newton, Jason; Lima, Santiago; Maceyka, Michael; Spiegel, Sarah</div><div class="citationInfo"><span class="NLM_cas:title">Experimental Cell Research</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">333</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">195-200</span>CODEN:
                <span class="NLM_cas:coden">ECREAL</span>;
        ISSN:<span class="NLM_cas:issn">0014-4827</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  This article discusses about role of sphingolipid metabolites such as ceramide and sphingosine-1-phosphate in cell fate along with effects of targeting sphingosine-1-phosphate metabolic enzymes in modulation of progression and drug resistance of cancer in human.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrGeaW9kxBn-LVg90H21EOLACvtfcHk0liENGiRREuRpA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXksFWis7s%253D&md5=0c70739b9f3c002817f82203d832500a</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1016%2Fj.yexcr.2015.02.025&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.yexcr.2015.02.025%26sid%3Dliteratum%253Aachs%26aulast%3DNewton%26aufirst%3DJ.%26aulast%3DLima%26aufirst%3DS.%26aulast%3DMaceyka%26aufirst%3DM.%26aulast%3DSpiegel%26aufirst%3DS.%26atitle%3DRevisiting%2520the%2520sphingolipid%2520rheostat%253A%2520Evolving%2520concepts%2520in%2520cancer%2520therapy%26jtitle%3DExp.%2520Cell%2520Res.%26date%3D2015%26volume%3D333%26spage%3D195%26epage%3D200%26doi%3D10.1016%2Fj.yexcr.2015.02.025" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Huang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Withers, B. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dickson, R. C.</span></span> <span> </span><span class="NLM_article-title">Sphingolipids and lifespan regulation</span>. <i>Biochim. Biophys. Acta, Mol. Cell Biol. Lipids</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>1841</i></span>,  <span class="NLM_fpage">657</span>– <span class="NLM_lpage">664</span>, <span class="refDoi"> DOI: 10.1016/j.bbalip.2013.08.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01561&amp;key=10.1016%2Fj.bbalip.2013.08.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01561&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtlGqs7vN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1841&publication_year=2014&pages=657-664&author=X.+Huangauthor=B.+R.+Withersauthor=R.+C.+Dickson&title=Sphingolipids+and+lifespan+regulation&doi=10.1016%2Fj.bbalip.2013.08.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Sphingolipids and lifespan regulation</span></div><div class="casAuthors">Huang, Xinhe; Withers, Bradley R.; Dickson, Robert C.</div><div class="citationInfo"><span class="NLM_cas:title">Biochimica et Biophysica Acta, Molecular and Cell Biology of Lipids</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">1841</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">657-664</span>CODEN:
                <span class="NLM_cas:coden">BBMLFG</span>;
        ISSN:<span class="NLM_cas:issn">1388-1981</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B. V.</span>)
        </div><div class="casAbstract">A review.  Diseases including cancer, type 2 diabetes, cardiovascular and immune dysfunction and neurodegeneration become more prevalent as we age, and combined with the increase in av. human lifespan, place an ever increasing burden on the health care system.  In this chapter we focus on finding ways of modulating sphingolipids to prevent the development of age-assocd. diseases or delay their onset, both of which could improve health in elderly, fragile people.  Reducing the incidence of or delaying the onset of diseases of aging has blossomed in the past decade because of advances in understanding signal transduction pathways and cellular processes, esp. in model organisms, that are largely conserved in most eukaryotes and that can be modulated to reduce signs of aging and increase health span.  In model organisms such interventions must also increase lifespan to be considered significant, but this is not a requirement for use in humans.  The most encouraging interventions in model organisms involve lowering the concn. of one or more sphingolipids so as to reduce the activity of key signaling pathways, one of the most promising being the Target of Rapamycin Complex 1 (TORC1) protein kinase pathway.  Other potential ways in which modulating sphingolipids may contribute to improving the health profile of the elderly is by reducing oxidative stresses, inflammatory responses and growth factor signaling.  Lastly, perhaps the most interesting way to modulate sphingolipids and promote longevity is by lowering the activity of serine palmitoyltransferase, the first enzyme in the de novo sphingolipid biosynthesis pathway.  Available data in yeasts and rodents are encouraging and as we gain insights into mol. mechanisms the strategies for improving human health by modulating sphingolipids will become more apparent.  This article is part of a Special Issue entitled New Frontiers in Sphingolipid Biol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr-1RgynOoylLVg90H21EOLACvtfcHk0liENGiRREuRpA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtlGqs7vN&md5=43c74eeb2e56fcd45233c75fde965851</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1016%2Fj.bbalip.2013.08.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bbalip.2013.08.006%26sid%3Dliteratum%253Aachs%26aulast%3DHuang%26aufirst%3DX.%26aulast%3DWithers%26aufirst%3DB.%2BR.%26aulast%3DDickson%26aufirst%3DR.%2BC.%26atitle%3DSphingolipids%2520and%2520lifespan%2520regulation%26jtitle%3DBiochim.%2520Biophys.%2520Acta%252C%2520Mol.%2520Cell%2520Biol.%2520Lipids%26date%3D2014%26volume%3D1841%26spage%3D657%26epage%3D664%26doi%3D10.1016%2Fj.bbalip.2013.08.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pettus, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chalfant, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hannun, Y. A.</span></span> <span> </span><span class="NLM_article-title">Ceramide in apoptosis: an overview and current perspectives</span>. <i>Biochim. Biophys. Acta, Mol. Cell Biol. Lipids</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>1585</i></span>,  <span class="NLM_fpage">114</span>– <span class="NLM_lpage">125</span>, <span class="refDoi"> DOI: 10.1016/s1388-1981(02)00331-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01561&amp;key=10.1016%2FS1388-1981%2802%2900331-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01561&amp;key=12531544" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01561&amp;key=1%3ACAS%3A528%3ADC%252BD3sXivVOqtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1585&publication_year=2002&pages=114-125&author=B.+J.+Pettusauthor=C.+E.+Chalfantauthor=Y.+A.+Hannun&title=Ceramide+in+apoptosis%3A+an+overview+and+current+perspectives&doi=10.1016%2Fs1388-1981%2802%2900331-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Ceramide in apoptosis: an overview and current perspectives</span></div><div class="casAuthors">Pettus, Benjamin J.; Chalfant, Charles E.; Hannun, Yusuf A.</div><div class="citationInfo"><span class="NLM_cas:title">Biochimica et Biophysica Acta, Molecular and Cell Biology of Lipids</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">1585</span>
        (<span class="NLM_cas:issue">2-3</span>),
    <span class="NLM_cas:pages">114-125</span>CODEN:
                <span class="NLM_cas:coden">BBMLFG</span>;
        ISSN:<span class="NLM_cas:issn">1388-1981</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Recent years have witnessed significant advances in the understanding of the role of ceramide in apoptosis.  This review summarizes these recent findings and discusses insights from studies of ceramide metab., topol., and effector actions.  The recent identification of several genes for enzymes of ceramide metab., the development of mass spectrometric methods for ceramide anal., and the increasing mol. and pharmacol. tools to probe ceramide metab. and function promise an accelerated phase in defining the mol. and biochem. details of the role of ceramide in apoptosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoXIUeERO-epbVg90H21EOLACvtfcHk0liENGiRREuRpA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXivVOqtg%253D%253D&md5=e1cc8bcdf206d5417e085bdd0d6f0096</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1016%2FS1388-1981%2802%2900331-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1388-1981%252802%252900331-1%26sid%3Dliteratum%253Aachs%26aulast%3DPettus%26aufirst%3DB.%2BJ.%26aulast%3DChalfant%26aufirst%3DC.%2BE.%26aulast%3DHannun%26aufirst%3DY.%2BA.%26atitle%3DCeramide%2520in%2520apoptosis%253A%2520an%2520overview%2520and%2520current%2520perspectives%26jtitle%3DBiochim.%2520Biophys.%2520Acta%252C%2520Mol.%2520Cell%2520Biol.%2520Lipids%26date%3D2002%26volume%3D1585%26spage%3D114%26epage%3D125%26doi%3D10.1016%2Fs1388-1981%2802%2900331-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Morales, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goñi, F. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kolesnick, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fernandez-Checa, J. C.</span></span> <span> </span><span class="NLM_article-title">Sphingolipids and cell death</span>. <i>Apoptosis</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">923</span>– <span class="NLM_lpage">939</span>, <span class="refDoi"> DOI: 10.1007/s10495-007-0721-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01561&amp;key=10.1007%2Fs10495-007-0721-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01561&amp;key=17294080" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01561&amp;key=1%3ACAS%3A528%3ADC%252BD2sXksFamtr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2007&pages=923-939&author=A.+Moralesauthor=H.+Leeauthor=F.+M.+Go%C3%B1iauthor=R.+Kolesnickauthor=J.+C.+Fernandez-Checa&title=Sphingolipids+and+cell+death&doi=10.1007%2Fs10495-007-0721-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Sphingolipids and cell death</span></div><div class="casAuthors">Morales, Albert; Lee, Hyunmi; Goni, Felix M.; Kolesnick, Richard; Fernandez-Checa, Jose C.</div><div class="citationInfo"><span class="NLM_cas:title">Apoptosis</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">923-939</span>CODEN:
                <span class="NLM_cas:coden">APOPFN</span>;
        ISSN:<span class="NLM_cas:issn">1360-8185</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">A review.  Sphingolipids (SLs) have been considered for many years as predominant building blocks of biol. membranes with key structural functions and little relevance in cellular signaling.  However, this view has changed dramatically in recent years with the recognition that certain SLs such as ceramide, sphingosine 1-phosphate and gangliosides, participate actively in signal transduction pathways, regulating many different cell functions such as proliferation, differentiation, adhesion and cell death.  In particular, ceramide has attracted considerable attention in cell biol. and biophysics due to its key role in the modulation of membrane phys. properties, signaling and cell death regulation.  This latter function is largely exerted by the ability of ceramide to activate the major pathways governing cell death such as the endoplasmic reticulum and mitochondria.  Overall, the evidence so far indicates a key function of SLs in disease pathogenesis and hence their regulation may be of potential therapeutic relevance in different pathologies including liver diseases, neurodegeneration and cancer biol. and therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoO8HgnKrzkeLVg90H21EOLACvtfcHk0lgihvAH8BncsQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXksFamtr4%253D&md5=5f7e22e3f90eaab152197336d1f0a37b</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1007%2Fs10495-007-0721-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10495-007-0721-0%26sid%3Dliteratum%253Aachs%26aulast%3DMorales%26aufirst%3DA.%26aulast%3DLee%26aufirst%3DH.%26aulast%3DGo%25C3%25B1i%26aufirst%3DF.%2BM.%26aulast%3DKolesnick%26aufirst%3DR.%26aulast%3DFernandez-Checa%26aufirst%3DJ.%2BC.%26atitle%3DSphingolipids%2520and%2520cell%2520death%26jtitle%3DApoptosis%26date%3D2007%26volume%3D12%26spage%3D923%26epage%3D939%26doi%3D10.1007%2Fs10495-007-0721-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Desai, N. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olivera, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seki, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brooker, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spiegel, S.</span></span> <span> </span><span class="NLM_article-title">Sphingosine-1-phosphate, a novel lipid, involved in cellular proliferation</span>. <i>J. Cell Biol.</i> <span class="NLM_year" style="font-weight: bold;">1991</span>,  <span class="NLM_volume"><i>114</i></span>,  <span class="NLM_fpage">155</span>– <span class="NLM_lpage">167</span>, <span class="refDoi"> DOI: 10.1083/jcb.114.1.155</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01561&amp;key=10.1083%2Fjcb.114.1.155" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01561&amp;key=2050740" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01561&amp;key=1%3ACAS%3A528%3ADyaK3MXksVKku7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=114&publication_year=1991&pages=155-167&author=H.+Zhangauthor=N.+N.+Desaiauthor=A.+Oliveraauthor=T.+Sekiauthor=G.+Brookerauthor=S.+Spiegel&title=Sphingosine-1-phosphate%2C+a+novel+lipid%2C+involved+in+cellular+proliferation&doi=10.1083%2Fjcb.114.1.155"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Sphingosine-1-phosphate, a novel lipid, involved in cellular proliferation</span></div><div class="casAuthors">Zhang, Hong; Desai, Naishadh N.; Olivera, Ana; Seki, Takashi; Brooker, Gary; Spiegel, Sarah</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Cell Biology</span>
        (<span class="NLM_cas:date">1991</span>),
    <span class="NLM_cas:volume">114</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">155-67</span>CODEN:
                <span class="NLM_cas:coden">JCLBA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9525</span>.
    </div><div class="casAbstract">The rapid increase in 32P-labeled sphingosine-1-phosphate levels induced by sphingosine was concn. dependent and correlated with its effect on DNA synthesis.  Similar to the mitogenic effects of sphingosine, low concns. of sphingosine-1-phosphate stimulated DNA synthesis and induced pronounced morphol. alterations.  Both sphingosine and sphingosine-1-phosphate stimulated DNA synthesis in cells made protein kinase C deficient by prolonged treatment with phorbol ester and sphingosine still elicited similar increases in sphingosine-1-phosphate levels in these cells.  Although both sphingosine and sphingosine-1-phosphate acted synergistically with a wide variety of growth factors, there was no additive or synergistic effect in response to a combination of sphingosine and sphingosine-1-phosphate.  Using a digital imaging system for measurement of Ca changes, it was obsd. that both sphingosine and sphingosine-1-phosphate are potent Ca-mobilizing agonists in viable 3T3 fibroblasts.  The rapid rise in cytosolic free Ca was independent of the presence of Ca in the external medium, indicating that the response is due to the mobilization of Ca from internal stores.  Sphingosine-1-phosphate may be a component of the intracellular 2nd messenger system that is involved in Ca release and the regulation of cell growth induced by sphingosine.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoNmAVbQBZTs7Vg90H21EOLACvtfcHk0lgihvAH8BncsQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3MXksVKku7c%253D&md5=f5991020e4dd2971ef810f20022b8f23</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1083%2Fjcb.114.1.155&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1083%252Fjcb.114.1.155%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DDesai%26aufirst%3DN.%2BN.%26aulast%3DOlivera%26aufirst%3DA.%26aulast%3DSeki%26aufirst%3DT.%26aulast%3DBrooker%26aufirst%3DG.%26aulast%3DSpiegel%26aufirst%3DS.%26atitle%3DSphingosine-1-phosphate%252C%2520a%2520novel%2520lipid%252C%2520involved%2520in%2520cellular%2520proliferation%26jtitle%3DJ.%2520Cell%2520Biol.%26date%3D1991%26volume%3D114%26spage%3D155%26epage%3D167%26doi%3D10.1083%2Fjcb.114.1.155" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Payne, S. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Milstien, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spiegel, S.</span></span> <span> </span><span class="NLM_article-title">Sphingosine-1-phosphate: dual messenger functions</span>. <i>FEBS Lett.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>531</i></span>,  <span class="NLM_fpage">54</span>– <span class="NLM_lpage">57</span>, <span class="refDoi"> DOI: 10.1016/s0014-5793(02)03480-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01561&amp;key=10.1016%2Fs0014-5793%2802%2903480-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01561&amp;key=12401202" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01561&amp;key=1%3ACAS%3A528%3ADC%252BD38XotVOjtLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=531&publication_year=2002&pages=54-57&author=S.+G.+Payneauthor=S.+Milstienauthor=S.+Spiegel&title=Sphingosine-1-phosphate%3A+dual+messenger+functions&doi=10.1016%2Fs0014-5793%2802%2903480-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Sphingosine-1-phosphate: dual messenger functions</span></div><div class="casAuthors">Payne, Shawn G.; Milstien, Sheldon; Spiegel, Sarah</div><div class="citationInfo"><span class="NLM_cas:title">FEBS Letters</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">531</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">54-57</span>CODEN:
                <span class="NLM_cas:coden">FEBLAL</span>;
        ISSN:<span class="NLM_cas:issn">0014-5793</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science B.V.</span>)
        </div><div class="casAbstract">A review.  The sphingolipid metabolite, sphingosine-1-phosphate (S1P), is a serum-borne lipid that regulates many vital cellular processes.  S1P is the ligand of a family of 5 specific G protein-coupled receptors that are differentially expressed in different tissues and regulate diverse cellular actions.  Much less is known of the intracellular actions of S1P.  It has been suggested that S1P may also function as an intracellular 2nd messenger to regulate Ca2+ mobilization, cell growth, and suppression of apoptosis in response to a variety of extracellular stimuli.  Dissecting the dual actions and identification of intracellular targets of S1P has been challenging, but there is ample evidence to suggest that the balance between S1P and ceramide and/or sphingosine levels in cells is an important determinant of cell fate.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo76yT7OtSBfLVg90H21EOLACvtfcHk0lgihvAH8BncsQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XotVOjtLg%253D&md5=ba8373675f89dc1cdea56cd3a3ad9cd3</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1016%2Fs0014-5793%2802%2903480-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fs0014-5793%252802%252903480-4%26sid%3Dliteratum%253Aachs%26aulast%3DPayne%26aufirst%3DS.%2BG.%26aulast%3DMilstien%26aufirst%3DS.%26aulast%3DSpiegel%26aufirst%3DS.%26atitle%3DSphingosine-1-phosphate%253A%2520dual%2520messenger%2520functions%26jtitle%3DFEBS%2520Lett.%26date%3D2002%26volume%3D531%26spage%3D54%26epage%3D57%26doi%3D10.1016%2Fs0014-5793%2802%2903480-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Spiegel, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Milstien, S.</span></span> <span> </span><span class="NLM_article-title">Sphingosine-1-phosphate: an enigmatic signalling lipid</span>. <i>Nat. Rev. Mol. Cell Biol.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">397</span>– <span class="NLM_lpage">407</span>, <span class="refDoi"> DOI: 10.1038/nrm1103</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01561&amp;key=10.1038%2Fnrm1103" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01561&amp;key=12728273" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01561&amp;key=1%3ACAS%3A528%3ADC%252BD3sXjtlalt7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2003&pages=397-407&author=S.+Spiegelauthor=S.+Milstien&title=Sphingosine-1-phosphate%3A+an+enigmatic+signalling+lipid&doi=10.1038%2Fnrm1103"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Sphingosine-1-phosphate: an enigmatic signalling lipid</span></div><div class="casAuthors">Spiegel, Sarah; Milstien, Sheldon</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Molecular Cell Biology</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">397-407</span>CODEN:
                <span class="NLM_cas:coden">NRMCBP</span>;
        ISSN:<span class="NLM_cas:issn">1471-0072</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The evolutionarily conserved actions of the sphingolipid metabolite, sphingosine-1-phosphate (S1P), in yeast, plants, and mammals have shown that it has important functions.  In higher eukaryotes, S1P is the ligand for a family of 5 G protein-coupled receptors.  These S1P receptors are differentially expressed, coupled to various G proteins, and regulate angiogenesis, vascular maturation, cardiac development, and immunity, and are important for directed cell movement.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGos0XUAxYZwqLVg90H21EOLACvtfcHk0ljMrMMBL4pQbA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXjtlalt7o%253D&md5=689a33cfeb4bae72637b64cd90e6c910</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1038%2Fnrm1103&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrm1103%26sid%3Dliteratum%253Aachs%26aulast%3DSpiegel%26aufirst%3DS.%26aulast%3DMilstien%26aufirst%3DS.%26atitle%3DSphingosine-1-phosphate%253A%2520an%2520enigmatic%2520signalling%2520lipid%26jtitle%3DNat.%2520Rev.%2520Mol.%2520Cell%2520Biol.%26date%3D2003%26volume%3D4%26spage%3D397%26epage%3D407%26doi%3D10.1038%2Fnrm1103" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Takabe, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spiegel, S.</span></span> <span> </span><span class="NLM_article-title">Export of sphingosine-1-phosphate and cancer progression</span>. <i>J. Lipid Res.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">1839</span>– <span class="NLM_lpage">1846</span>, <span class="refDoi"> DOI: 10.1194/jlr.r046656</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01561&amp;key=10.1194%2Fjlr.R046656" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01561&amp;key=24474820" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01561&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsVGjurnN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2014&pages=1839-1846&author=K.+Takabeauthor=S.+Spiegel&title=Export+of+sphingosine-1-phosphate+and+cancer+progression&doi=10.1194%2Fjlr.r046656"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Export of sphingosine-1-phosphate and cancer progression</span></div><div class="casAuthors">Takabe, Kazuaki; Spiegel, Sarah</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Lipid Research</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1839-1846</span>CODEN:
                <span class="NLM_cas:coden">JLPRAW</span>;
        ISSN:<span class="NLM_cas:issn">0022-2275</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology, Inc.</span>)
        </div><div class="casAbstract">A review.  Sphingosine-1-phosphate (S1P) is a bioactive lipid mediator that promotes cell survival, proliferation, migration, angiogenesis, lymphangiogenesis, and immune response; all are crit. processes of cancer progression.  Although some important roles of intracellular S1P have recently been uncovered, the majority of its biol. effects are known to be mediated via activation of five specific G protein-coupled receptors [S1P receptor (S1PR)1-S1PR5] located on the cell surface.  Secretion of S1P produced inside cells by sphingosine kinases can then signal through these receptors in autocrine, paracrine, and/or endocrine manners, coined "inside-out" signaling of S1P.  Numerous studies suggest that secreted S1P plays important roles in cancer progression; thus, understanding the mechanism by which S1P is exported out of cells, particularly cancer cells, is both interesting and important.  Here we will review the current understanding of the transport of S1P out of cancer cells and its potential roles in the tumor microenvironment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrpbPqJSPEIt7Vg90H21EOLACvtfcHk0ljMrMMBL4pQbA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsVGjurnN&md5=2371f977febf54b94ccfc91cd00cb0c2</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1194%2Fjlr.R046656&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1194%252Fjlr.R046656%26sid%3Dliteratum%253Aachs%26aulast%3DTakabe%26aufirst%3DK.%26aulast%3DSpiegel%26aufirst%3DS.%26atitle%3DExport%2520of%2520sphingosine-1-phosphate%2520and%2520cancer%2520progression%26jtitle%3DJ.%2520Lipid%2520Res.%26date%3D2014%26volume%3D55%26spage%3D1839%26epage%3D1846%26doi%3D10.1194%2Fjlr.r046656" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schuchman, E. H.</span></span> <span> </span><span class="NLM_article-title">Acid ceramidase and the treatment of ceramide diseases: the expanding role of enzyme replacement therapy</span>. <i>Biochim. Biophys. Acta, Mol. Basis Dis.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>1862</i></span>,  <span class="NLM_fpage">1459</span>– <span class="NLM_lpage">1471</span>, <span class="refDoi"> DOI: 10.1016/j.bbadis.2016.05.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01561&amp;key=10.1016%2Fj.bbadis.2016.05.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01561&amp;key=27155573" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01561&amp;key=1%3ACAS%3A528%3ADC%252BC28XnsV2gsL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1862&publication_year=2016&pages=1459-1471&author=E.+H.+Schuchman&title=Acid+ceramidase+and+the+treatment+of+ceramide+diseases%3A+the+expanding+role+of+enzyme+replacement+therapy&doi=10.1016%2Fj.bbadis.2016.05.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Acid ceramidase and the treatment of ceramide diseases: The expanding role of enzyme replacement therapy</span></div><div class="casAuthors">Schuchman, Edward H.</div><div class="citationInfo"><span class="NLM_cas:title">Biochimica et Biophysica Acta, Molecular Basis of Disease</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">1862</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1459-1471</span>CODEN:
                <span class="NLM_cas:coden">BBADEX</span>;
        ISSN:<span class="NLM_cas:issn">0925-4439</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B. V.</span>)
        </div><div class="casAbstract">Ceramides are a diverse group of sphingolipids that play important roles in many biol. processes.  Acid ceramidase (AC) is one key enzyme that regulates ceramide metab.  Early research on AC focused on the fact that it is the enzyme deficient in the rare genetic disorder, Farber Lipogranulomatosis.  Recent research has revealed that deficiency of the same enzyme is responsible for a rare form of spinal muscular atrophy assocd. with myoclonic epilepsy (SMA-PME).  Due to their diverse role in biol., accumulation of ceramides also has been implicated in the pathobiol. of many other common diseases, including infectious lung diseases, diabetes, cancers and others.  This has revealed the potential of AC as a therapy for many of these diseases.  This review will focus on the biol. of AC and the potential role of this enzyme in the treatment of human disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqxHxbePZKk7rVg90H21EOLACvtfcHk0ljMrMMBL4pQbA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XnsV2gsL0%253D&md5=b44a07178d44b3de2ef72da888931fbe</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1016%2Fj.bbadis.2016.05.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bbadis.2016.05.001%26sid%3Dliteratum%253Aachs%26aulast%3DSchuchman%26aufirst%3DE.%2BH.%26atitle%3DAcid%2520ceramidase%2520and%2520the%2520treatment%2520of%2520ceramide%2520diseases%253A%2520the%2520expanding%2520role%2520of%2520enzyme%2520replacement%2520therapy%26jtitle%3DBiochim.%2520Biophys.%2520Acta%252C%2520Mol.%2520Basis%2520Dis.%26date%3D2016%26volume%3D1862%26spage%3D1459%26epage%3D1471%26doi%3D10.1016%2Fj.bbadis.2016.05.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yu, F. P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Medin, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amintas, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levade, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levade, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Medin, J. A.</span></span> <span> </span><span class="NLM_article-title">Acid ceramidase deficiency: Farber disease and SMA-PME</span>. <i>Orphanet J. Rare Dis.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">121</span>– <span class="NLM_lpage">140</span>, <span class="refDoi"> DOI: 10.1186/s13023-018-0845-z</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01561&amp;key=10.1186%2Fs13023-018-0845-z" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01561&amp;key=30029679" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01561&amp;key=1%3ACAS%3A280%3ADC%252BB3c7gtleiug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2018&pages=121-140&author=F.+P.+S.+Yuauthor=J.+A.+Medinauthor=S.+Amintasauthor=T.+Levadeauthor=T.+Levadeauthor=J.+A.+Medin&title=Acid+ceramidase+deficiency%3A+Farber+disease+and+SMA-PME&doi=10.1186%2Fs13023-018-0845-z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Acid ceramidase deficiency: Farber disease and SMA-PME</span></div><div class="casAuthors">Yu Fabian P S; Medin Jeffrey A; Amintas Samuel; Levade Thierry; Levade Thierry; Medin Jeffrey A</div><div class="citationInfo"><span class="NLM_cas:title">Orphanet journal of rare diseases</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">121</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Acid ceramidase (ACDase) deficiency is a spectrum of disorders that includes a rare lysosomal storage disorder called Farber disease (FD) and a rare epileptic disorder called spinal muscular atrophy with progressive myoclonic epilepsy (SMA-PME).  Both disorders are caused by mutations in the ASAH1 gene that encodes the lysosomal hydrolase that breaks down the bioactive lipid ceramide.  To date, there have been fewer than 200 reported cases of FD and SMA-PME in the literature.  Typical textbook manifestations of classical FD include the formation of subcutaneous nodules, accumulation of joint contractures, and development of a hoarse voice.  In reality, however, the clinical presentation is much broader.  Patients may develop severe pathologies leading to death in infancy or may develop attenuated forms of the disorder wherein they are often misdiagnosed or not diagnosed until adulthood.  A clinical variability also exists for SMA-PME, in which patients develop progressive muscle weakness and seizures.  Currently, there is no known cure for FD or for SMA-PME.  The main treatment is symptom management.  In rare cases, treatment may include surgery or hematopoietic stem cell transplantation.  Research using disease models has provided insights into the pathology as well as the role of ACDase in the development of these conditions.  Recent studies have highlighted possible biomarkers for an effective diagnosis of ACDase deficiency.  Ongoing work is being conducted to evaluate the use of recombinant human ACDase (rhACDase) for the treatment of FD.  Finally, gene therapy strategies for the treatment of ACDase deficiency are actively being pursued.  This review highlights the broad clinical definition and outlines key studies that have improved our understanding of inherited ACDase deficiency-related conditions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSjSNsollUD2zMsgLhIoICsfW6udTcc2eYxgq2-WhG2GLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3c7gtleiug%253D%253D&md5=c24c1f6d0a92e846fd3e36620b160e4e</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1186%2Fs13023-018-0845-z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs13023-018-0845-z%26sid%3Dliteratum%253Aachs%26aulast%3DYu%26aufirst%3DF.%2BP.%2BS.%26aulast%3DMedin%26aufirst%3DJ.%2BA.%26aulast%3DAmintas%26aufirst%3DS.%26aulast%3DLevade%26aufirst%3DT.%26aulast%3DLevade%26aufirst%3DT.%26aulast%3DMedin%26aufirst%3DJ.%2BA.%26atitle%3DAcid%2520ceramidase%2520deficiency%253A%2520Farber%2520disease%2520and%2520SMA-PME%26jtitle%3DOrphanet%2520J.%2520Rare%2520Dis.%26date%3D2018%26volume%3D13%26spage%3D121%26epage%3D140%26doi%3D10.1186%2Fs13023-018-0845-z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Seelan, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qian, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yokomizo, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bostwick, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, D. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, W.</span></span> <span> </span><span class="NLM_article-title">Human acid ceramidase is overexpressed but not mutated in prostate cancer</span>. <i>Genes, Chromosomes Cancer</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>29</i></span>,  <span class="NLM_fpage">137</span>– <span class="NLM_lpage">146</span>, <span class="refDoi"> DOI: 10.1002/1098-2264(2000)9999:9999<::aid-gcc1018>3.0.co;2-e</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01561&amp;key=10.1002%2F1098-2264%282000%299999%3A9999%3C%3A%3AAID-GCC1018%3E3.0.CO%3B2-E" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01561&amp;key=10959093" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01561&amp;key=1%3ACAS%3A528%3ADC%252BD3cXntVWiurg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2000&pages=137-146&author=R.+S.+Seelanauthor=C.+Qianauthor=A.+Yokomizoauthor=D.+G.+Bostwickauthor=D.+I.+Smithauthor=W.+Liu&title=Human+acid+ceramidase+is+overexpressed+but+not+mutated+in+prostate+cancer&doi=10.1002%2F1098-2264%282000%299999%3A9999%3C%3A%3Aaid-gcc1018%3E3.0.co%3B2-e"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Human acid ceramidase is overexpressed but not mutated in prostate cancer</span></div><div class="casAuthors">Seelan, Ratnam S.; Qian, Chiping; Yokomizo, Akira; Bostwick, David G.; Smith, David I.; Liu, Wanguo</div><div class="citationInfo"><span class="NLM_cas:title">Genes, Chromosomes & Cancer</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">137-146</span>CODEN:
                <span class="NLM_cas:coden">GCCAES</span>;
        ISSN:<span class="NLM_cas:issn">1045-2257</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Liss, Inc.</span>)
        </div><div class="casAbstract">The human acid ceramidase gene, that causes Farber disease, is located in 8p22, a region frequently altered in several cancers, including prostate cancer.  Acid ceramidase catalyzes the hydrolysis of ceramide, a potent lipid second messenger mol. that promotes apoptosis and inhibits cellular proliferation.  It is not known whether this gene, or its expression, is altered in prostate cancer.  Here, the authors report the structural organization of the human gene, its expression in human tissues, and the identification of several single nucleotide polymorphisms.  No cancer-related mutations were found in the gene in a panel of prostate tumor DNAs analyzed, but increased expression was obsd. in prostate tumor tissues when compared with matched normals.  This increase was obsd. in all three prostate tumor cell lines tested (DU145, LnCAP, and PC3) when compared to a BPH (benign prostatic hyperplasia) cell line and 15/36 prostate tumors.  These results suggest that acid ceramidase may play an important role in prostate carcinogenesis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo2Y-_n5vjRdbVg90H21EOLACvtfcHk0lijWm0PNLDbWw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXntVWiurg%253D&md5=9c690947f4f44a446d83608ffda02c54</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1002%2F1098-2264%282000%299999%3A9999%3C%3A%3AAID-GCC1018%3E3.0.CO%3B2-E&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252F1098-2264%25282000%25299999%253A9999%253C%253A%253AAID-GCC1018%253E3.0.CO%253B2-E%26sid%3Dliteratum%253Aachs%26aulast%3DSeelan%26aufirst%3DR.%2BS.%26aulast%3DQian%26aufirst%3DC.%26aulast%3DYokomizo%26aufirst%3DA.%26aulast%3DBostwick%26aufirst%3DD.%2BG.%26aulast%3DSmith%26aufirst%3DD.%2BI.%26aulast%3DLiu%26aufirst%3DW.%26atitle%3DHuman%2520acid%2520ceramidase%2520is%2520overexpressed%2520but%2520not%2520mutated%2520in%2520prostate%2520cancer%26jtitle%3DGenes%252C%2520Chromosomes%2520Cancer%26date%3D2000%26volume%3D29%26spage%3D137%26epage%3D146%26doi%3D10.1002%2F1098-2264%282000%299999%3A9999%3C%3A%3Aaid-gcc1018%3E3.0.co%3B2-e" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Realini, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palese, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pizzirani, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pontis, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Basit, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bach, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ganesan, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Piomelli, D.</span></span> <span> </span><span class="NLM_article-title">Acid ceramidase in melanoma: expression, localization, and effects of pharmacological inhibition</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>291</i></span>,  <span class="NLM_fpage">2422</span>– <span class="NLM_lpage">2434</span>, <span class="refDoi"> DOI: 10.1074/jbc.m115.666909</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01561&amp;key=10.1074%2Fjbc.M115.666909" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01561&amp;key=26553872" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01561&amp;key=1%3ACAS%3A528%3ADC%252BC28Xhs1Cqsbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=291&publication_year=2016&pages=2422-2434&author=N.+Realiniauthor=F.+Paleseauthor=D.+Pizziraniauthor=S.+Pontisauthor=A.+Basitauthor=A.+Bachauthor=A.+Ganesanauthor=D.+Piomelli&title=Acid+ceramidase+in+melanoma%3A+expression%2C+localization%2C+and+effects+of+pharmacological+inhibition&doi=10.1074%2Fjbc.m115.666909"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Acid Ceramidase in Melanoma. Expression, location, and effects of pharmacological inhibitors</span></div><div class="casAuthors">Realini, Natalia; Palese, Francesca; Pizzirani, Daniela; Pontis, Silvia; Basit, Abdul; Bach, Anders; Ganesan, Anand; Piomelli, Daniele</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">291</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">2422-2434</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">Acid ceramidase (AC) is a lysosomal cysteine amidase that controls sphingolipid signaling by lowering the levels of ceramides and concomitantly increasing those of sphingosine and its bioactive metabolite, sphingosine 1-phosphate.  In the present study, we evaluated the role of AC-regulated sphingolipid signaling in melanoma.  We found that AC expression is markedly elevated in normal human melanocytes and proliferative melanoma cell lines, compared with other skin cells (keratinocytes and fibroblasts) and non-melanoma cancer cells.  High AC expression was also obsd. in biopsies from human subjects with Stage II melanoma.  Immunofluorescence studies revealed that the subcellular localization of AC differs between melanocytes (where it is found in both cytosol and nucleus) and melanoma cells (where it is primarily localized to cytosol).  In addn. to having high AC levels, melanoma cells generate lower amts. of ceramides than normal melanocytes do.  This down-regulation in ceramide prodn. appears to result from suppression of the de novo biosynthesis pathway.  To test whether AC might contribute to melanoma cell proliferation, we blocked AC activity using a new potent (IC50 = 12 nm) and stable inhibitor.  AC inhibition increased cellular ceramide levels, decreased sphingosine 1-phosphate levels, and acted synergistically with several, albeit not all, antitumoral agents.  The results suggest that AC-controlled sphingolipid metab. may play an important role in the control of melanoma proliferation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpQ1pGRTPNfObVg90H21EOLACvtfcHk0lijWm0PNLDbWw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xhs1Cqsbo%253D&md5=40dd33dee5301d0b79ee77c54b3b3fe3</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M115.666909&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M115.666909%26sid%3Dliteratum%253Aachs%26aulast%3DRealini%26aufirst%3DN.%26aulast%3DPalese%26aufirst%3DF.%26aulast%3DPizzirani%26aufirst%3DD.%26aulast%3DPontis%26aufirst%3DS.%26aulast%3DBasit%26aufirst%3DA.%26aulast%3DBach%26aufirst%3DA.%26aulast%3DGanesan%26aufirst%3DA.%26aulast%3DPiomelli%26aufirst%3DD.%26atitle%3DAcid%2520ceramidase%2520in%2520melanoma%253A%2520expression%252C%2520localization%252C%2520and%2520effects%2520of%2520pharmacological%2520inhibition%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2016%26volume%3D291%26spage%3D2422%26epage%3D2434%26doi%3D10.1074%2Fjbc.m115.666909" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Roh, J.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, J. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, E. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jang, H. J.</span></span> <span> </span><span class="NLM_article-title">Targeting acid ceramidase sensitises head and neck cancer to cisplatin</span>. <i>Eur. J. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>52</i></span>,  <span class="NLM_fpage">163</span>– <span class="NLM_lpage">172</span>, <span class="refDoi"> DOI: 10.1016/j.ejca.2015.10.056</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01561&amp;key=10.1016%2Fj.ejca.2015.10.056" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01561&amp;key=26687835" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01561&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvFems7zF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2016&pages=163-172&author=J.-L.+Rohauthor=J.+Y.+Parkauthor=E.+H.+Kimauthor=H.+J.+Jang&title=Targeting+acid+ceramidase+sensitises+head+and+neck+cancer+to+cisplatin&doi=10.1016%2Fj.ejca.2015.10.056"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting acid ceramidase sensitises head and neck cancer to cisplatin</span></div><div class="casAuthors">Roh, Jong-Lyel; Park, Jin Young; Kim, Eun Hye; Jang, Hye Jin</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Cancer</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">163-172</span>CODEN:
                <span class="NLM_cas:coden">EJCAEL</span>;
        ISSN:<span class="NLM_cas:issn">0959-8049</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Acid ceramidase (AC), a key enzyme in ceramide metab., plays a role in cancer progression and resistance to therapy.  However, the role of AC in head and neck cancer (HNC) has not been addressed.  Here, we investigate the effect of AC inhibition on the response to cisplatin-based chemotherapy for HNC.AC protein and mRNA (mRNA) expression were examd. in primary tumors and paired normal tissues, and in HNC cell lines.  The effects of genetic and pharmacol. AC inhibition using small hairpin RNA (shRNA) and N-oleoyl-ethanolamine (NOE), alone and in combination with cisplatin, were assessed in human HNC cells by measuring cell viability, cell cycle progression, apoptosis, mRNA, and protein expression, and in preclin. tumor xenograft mouse models.AC overexpression was obsd. in four of six primary tumor tissues and six of nine HNC cell lines.  Cisplatin sensitivity was significantly decreased by AC overexpression and significantly increased by AC downregulation in HNC cells (P < 0.01).  NOE or AC shRNA-mediated AC inhibition enhanced cisplatin-induced HNC cell death by increasing ceramide prodn. and activating pro-apoptotic proteins, and these effects were abrogated by PUMA small interfering RNA transfection.  AC inhibition promoted cisplatin-induced apoptosis of HNC cells in vitro and in vivo.AC overexpression is assocd. with cisplatin sensitivity, suggesting its potential role as a chemotherapeutic target for HNC.  Genetic or pharmacol. AC inhibition promotes cisplatin cytotoxicity in HNC cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGomDQBsoYn4e7Vg90H21EOLACvtfcHk0lhaPbUc6cYrww"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvFems7zF&md5=21cc9a783fabe8e2147577e80841a660</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1016%2Fj.ejca.2015.10.056&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejca.2015.10.056%26sid%3Dliteratum%253Aachs%26aulast%3DRoh%26aufirst%3DJ.-L.%26aulast%3DPark%26aufirst%3DJ.%2BY.%26aulast%3DKim%26aufirst%3DE.%2BH.%26aulast%3DJang%26aufirst%3DH.%2BJ.%26atitle%3DTargeting%2520acid%2520ceramidase%2520sensitises%2520head%2520and%2520neck%2520cancer%2520to%2520cisplatin%26jtitle%3DEur.%2520J.%2520Cancer%26date%3D2016%26volume%3D52%26spage%3D163%26epage%3D172%26doi%3D10.1016%2Fj.ejca.2015.10.056" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Klobučar, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grbčić, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pavelić, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jonjić, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Visentin, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sedić, M.</span></span> <span> </span><span class="NLM_article-title">Acid ceramidase inhibition sensitizes human colon cancer cells to oxaliplatin through downregulation of transglutaminase 2 and beta1 integrin/FAK-mediated signalling</span>. <i>Biochem. Biophys. Res. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>503</i></span>,  <span class="NLM_fpage">843</span>– <span class="NLM_lpage">848</span>, <span class="refDoi"> DOI: 10.1016/j.bbrc.2018.06.085</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01561&amp;key=10.1016%2Fj.bbrc.2018.06.085" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01561&amp;key=29920241" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01561&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtFymsr%252FE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=503&publication_year=2018&pages=843-848&author=M.+Klobu%C4%8Darauthor=P.+Grb%C4%8Di%C4%87author=S.+K.+Paveli%C4%87author=N.+Jonji%C4%87author=S.+Visentinauthor=M.+Sedi%C4%87&title=Acid+ceramidase+inhibition+sensitizes+human+colon+cancer+cells+to+oxaliplatin+through+downregulation+of+transglutaminase+2+and+beta1+integrin%2FFAK-mediated+signalling&doi=10.1016%2Fj.bbrc.2018.06.085"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Acid ceramidase inhibition sensitizes human colon cancer cells to oxaliplatin through downregulation of transglutaminase 2 and β1 integrin/FAK-mediated signalling</span></div><div class="casAuthors">Klobucar, Marko; Grbcic, Petra; Pavelic, Sandra Kraljevic; Jonjic, Nives; Visentin, Sarah; Sedic, Mirela</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical and Biophysical Research Communications</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">503</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">843-848</span>CODEN:
                <span class="NLM_cas:coden">BBRCA9</span>;
        ISSN:<span class="NLM_cas:issn">0006-291X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Acid ceramidase (ASAH1) has been implicated in the progression and chemoresistance in different cancers.  Its role in colon cancer biol. and response to std. chemotherapy has been poorly addressed so far.  Here, we have investigated ASAH1 expression at the protein level in human colon cancer cell lines and tissues from colon cancer patients, and have examd. in vitro the possible link between ASAH1 expression and functional activity of p53 protein whose inactivation is assocd. with the progression from adenoma to malignant tumor in colon cancer.  Finally, we have explored the role of ASAH1 in response and resistance mechanisms to oxaliplatin (OXA) in HCT 116 colon cancer cells.  We have demonstrated that human colon cancer cells and colorectal adenocarcinoma tissues constitutively express ASAH1, and that its expression is higher in tumor tissues than in normal colonic mucosa.  Furthermore, we found an inverse correlation between ASAH1 expression and p53 functional activity.  Obtained data revealed that ASAH1 was involved in HCT 116 cell response to OXA and that anti-proliferative, pro-apoptotic, anti-migratory and anti-clonogenic effects of OXA could be significantly increased by combination treatment with ASAH1 inhibitor carmofur.  Increased OXA sensitivity was assocd. with downregulation of signalling involved in acquired resistance to OXA in colon cancer, in particular transglutaminase 2 and β1 integrin/FAK, which resulted in the suppression of NF-κB and Akt.  Thus, combination of OXA with ASAH1 inhibitors could be a promising strategy to counter chemoresistance and improve treatment outcome in advanced colon cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoUqtsO2v4hpLVg90H21EOLACvtfcHk0lhaPbUc6cYrww"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtFymsr%252FE&md5=dd13faabb73a822e616fef8e37a769bd</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1016%2Fj.bbrc.2018.06.085&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bbrc.2018.06.085%26sid%3Dliteratum%253Aachs%26aulast%3DKlobu%25C4%258Dar%26aufirst%3DM.%26aulast%3DGrb%25C4%258Di%25C4%2587%26aufirst%3DP.%26aulast%3DPaveli%25C4%2587%26aufirst%3DS.%2BK.%26aulast%3DJonji%25C4%2587%26aufirst%3DN.%26aulast%3DVisentin%26aufirst%3DS.%26aulast%3DSedi%25C4%2587%26aufirst%3DM.%26atitle%3DAcid%2520ceramidase%2520inhibition%2520sensitizes%2520human%2520colon%2520cancer%2520cells%2520to%2520oxaliplatin%2520through%2520downregulation%2520of%2520transglutaminase%25202%2520and%2520beta1%2520integrin%252FFAK-mediated%2520signalling%26jtitle%3DBiochem.%2520Biophys.%2520Res.%2520Commun.%26date%3D2018%26volume%3D503%26spage%3D843%26epage%3D848%26doi%3D10.1016%2Fj.bbrc.2018.06.085" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Doan, N. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alhajala, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Al-Gizawiy, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mueller, W. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rand, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Connelly, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cochran, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chitambar, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clark, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmainda, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mirza, S. P.</span></span> <span> </span><span class="NLM_article-title">Acid ceramidase and its inhibitors: a de novo drug target and a new class of drugs for killing glioblastoma cancer stem cells with high efficiency</span>. <i>Oncotarget</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">112662</span>– <span class="NLM_lpage">112674</span>, <span class="refDoi"> DOI: 10.18632/oncotarget.22637</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01561&amp;key=10.18632%2Foncotarget.22637" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01561&amp;key=29348854" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01561&amp;key=1%3ACAS%3A280%3ADC%252BC1Mvit1SrtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=112662-112674&author=N.+B.+Doanauthor=H.+Alhajalaauthor=M.+M.+Al-Gizawiyauthor=W.+M.+Muellerauthor=S.+D.+Randauthor=J.+M.+Connellyauthor=E.+J.+Cochranauthor=C.+R.+Chitambarauthor=P.+Clarkauthor=J.+Kuoauthor=K.+M.+Schmaindaauthor=S.+P.+Mirza&title=Acid+ceramidase+and+its+inhibitors%3A+a+de+novo+drug+target+and+a+new+class+of+drugs+for+killing+glioblastoma+cancer+stem+cells+with+high+efficiency&doi=10.18632%2Foncotarget.22637"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Acid ceramidase and its inhibitors: a de novo drug target and a new class of drugs for killing glioblastoma cancer stem cells with high efficiency</span></div><div class="casAuthors">Doan Ninh B; Mirza Shama P; Doan Ninh B; Mueller Wade M; Alhajala Hisham; Chitambar Christopher R; Schmainda Kathleen M; Al-Gizawiy Mona M; Rand Scott D; Connelly Jennifer M; Cochran Elizabeth J; Clark Paul; Kuo John; Schmainda Kathleen M; Mirza Shama P; Mirza Shama P</div><div class="citationInfo"><span class="NLM_cas:title">Oncotarget</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">68</span>),
    <span class="NLM_cas:pages">112662-112674</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Glioblastoma remains the most common, malignant primary cancer of the central nervous system with a low life expectancy and an overall survival of less than 1.5 years.  The treatment options are limited and there is no cure.  Moreover, almost all patients develop recurrent tumors, which typically are more aggressive.  Therapeutically resistant glioblastoma or glioblastoma stem-like cells (GSCs) are hypothesized to cause this inevitable recurrence.  Identifying prognostic biomarkers of glioblastoma will potentially advance knowledge about glioblastoma tumorigenesis and enable discovery of more effective therapies.  Proteomic analysis of more than 600 glioblastoma-specific proteins revealed, for the first time, that expression of acid ceramidase (ASAH1) is associated with poor glioblastoma survival.  CD133+ GSCs express significantly higher ASAH1 compared to CD133- GSCs and serum-cultured glioblastoma cell lines, such as U87MG.  These findings implicate ASAH1 as a plausible independent prognostic marker, providing a target for a therapy tailored toward GSCs.  We further demonstrate that ASAH1 inhibition increases cellular ceramide level and induces apoptosis.  Strikingly, U87MG cells, and three different patient-derived glioblastoma stem-like cancer cell lines were efficiently killed, through apoptosis, by three different known ASAH1 inhibitors with IC50's ranging from 11-104 μM.  In comparison, the standard glioblastoma chemotherapy agent, temozolomide, had minimal GSC-targeted effects at comparable or even higher concentrations (IC50 > 750 μM against GSCs).  ASAH1 is identified as a de novo glioblastoma drug target, and ASAH1 inhibitors, such as carmofur, are shown to be highly effective and to specifically target glioblastoma GSCs.  Carmofur is an ASAH1 inhibitor that crosses the blood-brain barrier, a major bottleneck in glioblastoma treatment.  It has been approved in Japan since 1981 for colorectal cancer therapy.  Therefore, it is poised for repurposing and translation to glioblastoma clinical trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTkPFERLjQD2MrRqEXsZufAfW6udTcc2eawWR6TQT0sb7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1Mvit1SrtQ%253D%253D&md5=cf2b957e6c9b8664b919941d4a1eeddb</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.18632%2Foncotarget.22637&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18632%252Foncotarget.22637%26sid%3Dliteratum%253Aachs%26aulast%3DDoan%26aufirst%3DN.%2BB.%26aulast%3DAlhajala%26aufirst%3DH.%26aulast%3DAl-Gizawiy%26aufirst%3DM.%2BM.%26aulast%3DMueller%26aufirst%3DW.%2BM.%26aulast%3DRand%26aufirst%3DS.%2BD.%26aulast%3DConnelly%26aufirst%3DJ.%2BM.%26aulast%3DCochran%26aufirst%3DE.%2BJ.%26aulast%3DChitambar%26aufirst%3DC.%2BR.%26aulast%3DClark%26aufirst%3DP.%26aulast%3DKuo%26aufirst%3DJ.%26aulast%3DSchmainda%26aufirst%3DK.%2BM.%26aulast%3DMirza%26aufirst%3DS.%2BP.%26atitle%3DAcid%2520ceramidase%2520and%2520its%2520inhibitors%253A%2520a%2520de%2520novo%2520drug%2520target%2520and%2520a%2520new%2520class%2520of%2520drugs%2520for%2520killing%2520glioblastoma%2520cancer%2520stem%2520cells%2520with%2520high%2520efficiency%26jtitle%3DOncotarget%26date%3D2017%26volume%3D8%26spage%3D112662%26epage%3D112674%26doi%3D10.18632%2Foncotarget.22637" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mahdy, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elojeimy, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meacham, W. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Turner, L. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bai, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gault, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McPherson, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garcia, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beckham, T. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saad, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bielawska, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bielawski, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hannun, Y. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keane, T. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taha, M. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hammouda, H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Norris, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, X.</span></span> <span> </span><span class="NLM_article-title">Acid ceramidase upregulation in prostate cancer cells confers resistance to radiation: AC inhibition, a potential radiosensitizer</span>. <i>Mol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">430</span>– <span class="NLM_lpage">438</span>, <span class="refDoi"> DOI: 10.1038/mt.2008.281</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01561&amp;key=10.1038%2Fmt.2008.281" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01561&amp;key=19107118" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01561&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhsFart7fF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2009&pages=430-438&author=A.+E.+Mahdyauthor=J.+C.+Chengauthor=J.+Liauthor=S.+Elojeimyauthor=W.+D.+Meachamauthor=L.+S.+Turnerauthor=A.+Baiauthor=C.+R.+Gaultauthor=A.+S.+McPhersonauthor=N.+Garciaauthor=T.+H.+Beckhamauthor=A.+Saadauthor=A.+Bielawskaauthor=J.+Bielawskiauthor=Y.+A.+Hannunauthor=T.+E.+Keaneauthor=M.+I.+Tahaauthor=H.+M.+Hammoudaauthor=J.+S.+Norrisauthor=X.+Liu&title=Acid+ceramidase+upregulation+in+prostate+cancer+cells+confers+resistance+to+radiation%3A+AC+inhibition%2C+a+potential+radiosensitizer&doi=10.1038%2Fmt.2008.281"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Acid Ceramidase Upregulation in Prostate Cancer Cells Confers Resistance to Radiation: AC Inhibition, a Potential Radiosensitizer</span></div><div class="casAuthors">Mahdy, Ayman E. M.; Cheng, Joseph C.; Li, Jun; Elojeimy, Saeed; Meacham, William D.; Turner, Lorianne S.; Bai, Aiping; Gault, Christopher R.; McPherson, Alex S.; Garcia, Nicole; Beckham, Thomas H.; Saad, Antonio; Bielawska, Alicja; Bielawski, Jacek; Hannun, Yusuf A.; Keane, Thomas E.; Taha, Mohhammed I.; Hammouda, Hisham M.; Norris, James S.; Liu, Xiang</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Therapy</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">430-438</span>CODEN:
                <span class="NLM_cas:coden">MTOHCK</span>;
        ISSN:<span class="NLM_cas:issn">1525-0016</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Radiation resistance in a subset of prostate tumors remains a challenge to prostate cancer radiotherapy.  The current study on the effects of radiation on prostate cancer cells reveals that radiation programs an unpredicted resistance mechanism by upregulating acid ceramidase (AC).  Irradiated cells demonstrated limited changes of ceramide levels while elevating levels of sphingosine and sphingosine-1-phosphate.  By genetically downregulating AC with small interfering RNA (siRNA), we obsd. radiosensitization of cells using clonogenic and cytotoxicity assays.  Conversely, AC overexpression further decreased sensitivity to radiation.  We also obsd. that radiation-induced AC upregulation was sufficient to create cross-resistance to chemotherapy as demonstrated by decreased sensitivity to Taxol and C6 ceramide compared to controls.  Lower levels of caspase 3/7 activity were detected in cells pretreated with radiation, also indicating increased resistance.  Finally, utilization of the small mol. AC inhibitor, LCL385, sensitized PPC-1 cells to radiation and significantly decreased tumor xenograft growth.  These data suggest a new mechanism of cancer cell resistance to radiation, through upregulation of AC i.e., in part, mediated by application of the therapy itself.  An improved understanding of radiotherapy and the application of combination therapy achieved in this study offer new opportunities for the modulation of radiation effects in the treatment of cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqcfZKQJLJrLbVg90H21EOLACvtfcHk0lgviT2jehOagA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhsFart7fF&md5=96aa1d9b77ef926f93655a78e610e20a</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1038%2Fmt.2008.281&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fmt.2008.281%26sid%3Dliteratum%253Aachs%26aulast%3DMahdy%26aufirst%3DA.%2BE.%26aulast%3DCheng%26aufirst%3DJ.%2BC.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DElojeimy%26aufirst%3DS.%26aulast%3DMeacham%26aufirst%3DW.%2BD.%26aulast%3DTurner%26aufirst%3DL.%2BS.%26aulast%3DBai%26aufirst%3DA.%26aulast%3DGault%26aufirst%3DC.%2BR.%26aulast%3DMcPherson%26aufirst%3DA.%2BS.%26aulast%3DGarcia%26aufirst%3DN.%26aulast%3DBeckham%26aufirst%3DT.%2BH.%26aulast%3DSaad%26aufirst%3DA.%26aulast%3DBielawska%26aufirst%3DA.%26aulast%3DBielawski%26aufirst%3DJ.%26aulast%3DHannun%26aufirst%3DY.%2BA.%26aulast%3DKeane%26aufirst%3DT.%2BE.%26aulast%3DTaha%26aufirst%3DM.%2BI.%26aulast%3DHammouda%26aufirst%3DH.%2BM.%26aulast%3DNorris%26aufirst%3DJ.%2BS.%26aulast%3DLiu%26aufirst%3DX.%26atitle%3DAcid%2520ceramidase%2520upregulation%2520in%2520prostate%2520cancer%2520cells%2520confers%2520resistance%2520to%2520radiation%253A%2520AC%2520inhibition%252C%2520a%2520potential%2520radiosensitizer%26jtitle%3DMol.%2520Ther.%26date%3D2009%26volume%3D17%26spage%3D430%26epage%3D438%26doi%3D10.1038%2Fmt.2008.281" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Saad, A. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meacham, W. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bai, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anelli, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elojeimy, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mahdy, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Turner, L. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bielawska, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bielawski, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keane, T. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Obeid, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hannun, Y. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Norris, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, X.</span></span> <span> </span><span class="NLM_article-title">The functional effects of acid ceramidase overexpression in prostate cancer progression and resistance to chemotherapy</span>. <i>Cancer Biol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">1455</span>– <span class="NLM_lpage">1460</span>, <span class="refDoi"> DOI: 10.4161/cbt.6.9.4623</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01561&amp;key=10.4161%2Fcbt.6.9.4623" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01561&amp;key=17881906" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01561&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtlCitb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2007&pages=1455-1460&author=A.+F.+Saadauthor=W.+D.+Meachamauthor=A.+Baiauthor=V.+Anelliauthor=S.+Elojeimyauthor=A.+E.+Mahdyauthor=L.+S.+Turnerauthor=J.+Chengauthor=A.+Bielawskaauthor=J.+Bielawskiauthor=T.+E.+Keaneauthor=L.+M.+Obeidauthor=Y.+A.+Hannunauthor=J.+S.+Norrisauthor=X.+Liu&title=The+functional+effects+of+acid+ceramidase+overexpression+in+prostate+cancer+progression+and+resistance+to+chemotherapy&doi=10.4161%2Fcbt.6.9.4623"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">The functional effects of acid ceramidase overexpression in prostate cancer progression and resistance to chemotherapy</span></div><div class="casAuthors">Saad, Antonio F.; Meacham, William D.; Bai, Aiping; Anelli, Viviane; Elojeimy, Saeed; Mahdy, Ayman E. M.; Turner, Lorianne S.; Cheng, Joe; Bielawska, Alicja; Bielawski, Jacek; Keane, Thomas E.; Obeid, Lina M.; Hannun, Yusuf A.; Norris, James S.; Liu, Xiang</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Biology & Therapy</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1455-1460</span>CODEN:
                <span class="NLM_cas:coden">CBTAAO</span>;
        ISSN:<span class="NLM_cas:issn">1538-4047</span>.
    
            (<span class="NLM_cas:orgname">Landes Bioscience</span>)
        </div><div class="casAbstract">Among the many processes regulating cell death, ceramide signaling is a vital component.  We previously detd. that acid ceramidase (AC) is upregulated in 60% of primary prostate cancer (PCa) tissues, suggesting that AC may play a role in tumor development.  In order to det. the significance of AC elevation, stable clones of DU145 cells with AC overexpression (AC-EGFP) were generated.  Compared to controls (EGFP), AC-EGFP cells exhibited enhanced cell proliferation and migration.  S.c. injection of AC-EGFP cells into Nu/Nu mice resulted in larger tumor vols. compared to EGFP controls.  Moreover, using the MTS viability assay, AC-EGFP cells were more resistant to cell death induced by doxorubicin, cisplatin, etoposide, gemcitabine or C6-ceramide.  Conversely, knock down of AC using siRNA, sensitized AC-EGFP cells to these drugs.  In addn., mass spectroscopic anal. of sphingolipids indicated that long chain ceramide levels were decreased in AC-EGFP cells treated with either doxorubicin or etoposide.  In conclusion, this study implicates AC as a crit. regulator of PCa progression by affecting not only tumor cell proliferation and migration but also responses to drug therapy, suggesting AC as a potential therapeutic target in advanced PCa.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGraaHP0ax4FC7Vg90H21EOLACvtfcHk0lgviT2jehOagA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtlCitb8%253D&md5=6825c755b1ccad4ec808f1f6d64f5e6e</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.4161%2Fcbt.6.9.4623&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4161%252Fcbt.6.9.4623%26sid%3Dliteratum%253Aachs%26aulast%3DSaad%26aufirst%3DA.%2BF.%26aulast%3DMeacham%26aufirst%3DW.%2BD.%26aulast%3DBai%26aufirst%3DA.%26aulast%3DAnelli%26aufirst%3DV.%26aulast%3DElojeimy%26aufirst%3DS.%26aulast%3DMahdy%26aufirst%3DA.%2BE.%26aulast%3DTurner%26aufirst%3DL.%2BS.%26aulast%3DCheng%26aufirst%3DJ.%26aulast%3DBielawska%26aufirst%3DA.%26aulast%3DBielawski%26aufirst%3DJ.%26aulast%3DKeane%26aufirst%3DT.%2BE.%26aulast%3DObeid%26aufirst%3DL.%2BM.%26aulast%3DHannun%26aufirst%3DY.%2BA.%26aulast%3DNorris%26aufirst%3DJ.%2BS.%26aulast%3DLiu%26aufirst%3DX.%26atitle%3DThe%2520functional%2520effects%2520of%2520acid%2520ceramidase%2520overexpression%2520in%2520prostate%2520cancer%2520progression%2520and%2520resistance%2520to%2520chemotherapy%26jtitle%3DCancer%2520Biol.%2520Ther.%26date%3D2007%26volume%3D6%26spage%3D1455%26epage%3D1460%26doi%3D10.4161%2Fcbt.6.9.4623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tanimukai, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iqbal, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grundke-Iqbal, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gong, C.-X.</span></span> <span> </span><span class="NLM_article-title">Elevation of the level and activity of acid ceramidase in Alzheimer’s disease brain</span>. <i>Eur. J. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">3489</span>– <span class="NLM_lpage">3497</span>, <span class="refDoi"> DOI: 10.1111/j.1460-9568.2004.03852.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01561&amp;key=10.1111%2Fj.1460-9568.2004.03852.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01561&amp;key=15610181" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01561&amp;key=1%3ACAS%3A280%3ADC%252BD2cnjsVymsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2004&pages=3489-3497&author=Y.+Huangauthor=H.+Tanimukaiauthor=F.+Liuauthor=K.+Iqbalauthor=I.+Grundke-Iqbalauthor=C.-X.+Gong&title=Elevation+of+the+level+and+activity+of+acid+ceramidase+in+Alzheimer%E2%80%99s+disease+brain&doi=10.1111%2Fj.1460-9568.2004.03852.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Elevation of the level and activity of acid ceramidase in Alzheimer's disease brain</span></div><div class="casAuthors">Huang Yu; Tanimukai Hitoshi; Liu Fei; Iqbal Khalid; Grundke-Iqbal Inge; Gong Cheng-Xin</div><div class="citationInfo"><span class="NLM_cas:title">The European journal of neuroscience</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">3489-97</span>
        ISSN:<span class="NLM_cas:issn">0953-816X</span>.
    </div><div class="casAbstract">Protein glycosylation modifies the processing of several key proteins involved in the molecular pathogenesis of Alzheimer's disease (AD).  Aberrant glycosylation of tau and down-regulation of sialyltransferase in AD brain suggest a possible dysregulation of protein glycosylation that may play a role in AD.  We therefore isolated major glycoproteins from AD brain by using lectin-affinity chromatographies and ion-exchange chromatography and further separated them using SDS-polyacylamide gel electrophoresis.  Mass spectrometry analysis of 11 isolated glycoproteins led to their identification as: neuronal cell adhesion molecule, beta-globin, IgM heavy chain VH1 region precursor, contactin precursor, dipeptidylpeptidase VI, CD81 partner 3, prenylcysteine lyase, adipocyte plasma-associated protein, acid ceramidase and two novel proteins.  We found that the level and activity of acid ceramidase (AC), one of the major identified human brain glycoproteins, were significantly elevated in AD brain.  Immunohistochemical staining indicated that AC was located mainly in the cell bodies of neurons and colocalized with neurofibrillary tangles.  Our findings suggest that AC might play a role in controlling neuronal apoptosis and that AC-mediated signalling pathways might be involved in the molecular mechanism of AD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQSqqlZmYRDfrGbPKh4T9eAfW6udTcc2eYGD463SE6oQLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2cnjsVymsA%253D%253D&md5=80dbc51128110c4deeb4d8cf44bf133e</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1111%2Fj.1460-9568.2004.03852.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1460-9568.2004.03852.x%26sid%3Dliteratum%253Aachs%26aulast%3DHuang%26aufirst%3DY.%26aulast%3DTanimukai%26aufirst%3DH.%26aulast%3DLiu%26aufirst%3DF.%26aulast%3DIqbal%26aufirst%3DK.%26aulast%3DGrundke-Iqbal%26aufirst%3DI.%26aulast%3DGong%26aufirst%3DC.-X.%26atitle%3DElevation%2520of%2520the%2520level%2520and%2520activity%2520of%2520acid%2520ceramidase%2520in%2520Alzheimer%25E2%2580%2599s%2520disease%2520brain%26jtitle%3DEur.%2520J.%2520Neurosci.%26date%3D2004%26volume%3D20%26spage%3D3489%26epage%3D3497%26doi%3D10.1111%2Fj.1460-9568.2004.03852.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gieselmann, V.</span></span> <span> </span><span class="NLM_article-title">Lysosomal storage diseases</span>. <i>Biochim. Biophys. Acta, Mol. Basis Dis.</i> <span class="NLM_year" style="font-weight: bold;">1995</span>,  <span class="NLM_volume"><i>1270</i></span>,  <span class="NLM_fpage">103</span>– <span class="NLM_lpage">136</span>, <span class="refDoi"> DOI: 10.1016/0925-4439(94)00075-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01561&amp;key=10.1016%2F0925-4439%2894%2900075-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01561&amp;key=7727535" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01561&amp;key=1%3ACAS%3A528%3ADyaK2MXkvFGms7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1270&publication_year=1995&pages=103-136&author=V.+Gieselmann&title=Lysosomal+storage+diseases&doi=10.1016%2F0925-4439%2894%2900075-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Lysosomal storage diseases</span></div><div class="casAuthors">Gieselmann, Volkmar</div><div class="citationInfo"><span class="NLM_cas:title">Biochimica et Biophysica Acta, Molecular Basis of Disease</span>
        (<span class="NLM_cas:date">1995</span>),
    <span class="NLM_cas:volume">1270</span>
        (<span class="NLM_cas:issue">2-3</span>),
    <span class="NLM_cas:pages">103-36</span>CODEN:
                <span class="NLM_cas:coden">BBADEX</span>;
        ISSN:<span class="NLM_cas:issn">0925-4439</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review with 410 refs. on lipidoses, disorders of glycoprotein degrdn., and mucopolysaccharidoses.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrM-4LaaOM1orVg90H21EOLACvtfcHk0lgI0Paj2nVSJA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2MXkvFGms7o%253D&md5=533266b4fdac47258d9a924b0dd4a3b4</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1016%2F0925-4439%2894%2900075-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0925-4439%252894%252900075-2%26sid%3Dliteratum%253Aachs%26aulast%3DGieselmann%26aufirst%3DV.%26atitle%3DLysosomal%2520storage%2520diseases%26jtitle%3DBiochim.%2520Biophys.%2520Acta%252C%2520Mol.%2520Basis%2520Dis.%26date%3D1995%26volume%3D1270%26spage%3D103%26epage%3D136%26doi%3D10.1016%2F0925-4439%2894%2900075-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ballabio, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gieselmann, V.</span></span> <span> </span><span class="NLM_article-title">Lysosomal disorders: From storage to cellular damage</span>. <i>Biochim. Biophys. Acta, Mol. Cell Res.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>1793</i></span>,  <span class="NLM_fpage">684</span>– <span class="NLM_lpage">696</span>, <span class="refDoi"> DOI: 10.1016/j.bbamcr.2008.12.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01561&amp;key=10.1016%2Fj.bbamcr.2008.12.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01561&amp;key=19111581" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01561&amp;key=1%3ACAS%3A528%3ADC%252BD1MXjslOlsbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1793&publication_year=2009&pages=684-696&author=A.+Ballabioauthor=V.+Gieselmann&title=Lysosomal+disorders%3A+From+storage+to+cellular+damage&doi=10.1016%2Fj.bbamcr.2008.12.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Lysosomal disorders: From storage to cellular damage</span></div><div class="casAuthors">Ballabio, Andrea; Gieselmann, Volkmar</div><div class="citationInfo"><span class="NLM_cas:title">Biochimica et Biophysica Acta, Molecular Cell Research</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">1793</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">684-696</span>CODEN:
                <span class="NLM_cas:coden">BBAMCO</span>;
        ISSN:<span class="NLM_cas:issn">0167-4889</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Lysosomal storage diseases represent a group of about 50 genetic disorders caused by deficiencies of lysosomal and non-lysosomal proteins.  Patients accumulate compds. which are normally degraded in the lysosome.  In many diseases this accumulation affects various organs leading to severe symptoms and premature death.  The revelation of the mechanism by which stored compds. affect cellular function is the basis for understanding pathophysiol. underlying lysosomal storage diseases.  In the past years it has become clear that storage compds. interfere with various processes on the cellular level.  The spectrum covers e.g. receptor activation by non-physiol. ligands, modulation of receptor response and intracellular effectors of signal transduction cascades, impairment of autophagy, and others.  Importantly, many of these processes are assocd. with accumulation of storage material in non-lysosomal compartments.  Here we summarize current knowledge on the effects that storage material can elicit on the cellular level.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGphT4XBgFcs3rVg90H21EOLACvtfcHk0lgI0Paj2nVSJA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXjslOlsbk%253D&md5=618ababe4f0b39bd914c25d235c30693</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1016%2Fj.bbamcr.2008.12.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bbamcr.2008.12.001%26sid%3Dliteratum%253Aachs%26aulast%3DBallabio%26aufirst%3DA.%26aulast%3DGieselmann%26aufirst%3DV.%26atitle%3DLysosomal%2520disorders%253A%2520From%2520storage%2520to%2520cellular%2520damage%26jtitle%3DBiochim.%2520Biophys.%2520Acta%252C%2520Mol.%2520Cell%2520Res.%26date%3D2009%26volume%3D1793%26spage%3D684%26epage%3D696%26doi%3D10.1016%2Fj.bbamcr.2008.12.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="NLM_citation" id="cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cox, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cachón-González, M. B.</span></span> <span> </span><span class="NLM_article-title">The cellular pathology of lysosomal diseases</span>. <i>J. Pathol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>226</i></span>,  <span class="NLM_fpage">241</span>– <span class="NLM_lpage">254</span>, <span class="refDoi"> DOI: 10.1002/path.3021</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01561&amp;key=10.1002%2Fpath.3021" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01561&amp;key=21990005" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01561&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhsFCqsbvO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=226&publication_year=2012&pages=241-254&author=T.+M.+Coxauthor=M.+B.+Cach%C3%B3n-Gonz%C3%A1lez&title=The+cellular+pathology+of+lysosomal+diseases&doi=10.1002%2Fpath.3021"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">The cellular pathology of lysosomal diseases</span></div><div class="casAuthors">Cox, Timothy M.; Cachon-Gonzalez, M. Begona</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pathology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">226</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">241-254</span>CODEN:
                <span class="NLM_cas:coden">JPTLAS</span>;
        ISSN:<span class="NLM_cas:issn">0022-3417</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons Ltd.</span>)
        </div><div class="casAbstract">A review.  With a constitutive recycling function and the capacity to digest exogenous material as well as endogenous organelles in the process of autophagy, lysosomes are at the heart of the living cell.  Dynamic interactions with other cellular components ensure that the lysosomal compartment is a central point of convergence in countless diverse diseases.  Inborn lysosomal (storage) diseases represent about 70 genetically distinct conditions, with a combined birth frequency of about 1 in 7500.  Many are assocd. with macromol. storage, causing phys. disruption of the organelle and cognate structures; in neurons, ectopic dendritogenesis and axonal swelling due to distension with membraneous tubules and autophagic vacuoles are obsd.  Disordered autophagy is almost universal in lysosomal diseases but biochem. injury due to toxic metabolites such as lysosphingolipid mols., abnormal calcium homeostasis and endoplasmic reticulum stress responses and immune-inflammatory processes occur.  However, in no case have the mechanistic links between individual clinico-pathol. manifestations and the underlying mol. defect been precisely defined.  With access to the external fluid-phase and intracellular trafficking pathways, the lysosome and its diseases are a focus of pioneering investment in biotechnol.; this has generated innovative orphan drugs and, in the case of Gaucher's disease, effective treatment for the haematol. and visceral manifestations.  Given that two-thirds of lysosomal diseases have potentially devastating consequences in the nervous system, future therapeutic research will require an integrative understanding of the unitary steps in their neuro pathogenesis.  Informative genetic variants illustrated by patients with primary defects in this organelle offer unique insights into the central role of lysosomes in human health and disease.  We provide a conspectus of inborn lysosomal diseases and their pathobiol.; the cryptic evolution of events leading to irreversible changes may be dissocd. from the cellular storage phenotype, as revealed by the outcome of therapeutic gene transfer undertaken at different stages of disease.  Copyright © 2011 Pathol. Society of Great Britain and Ireland.  Published by John Wiley & Sons, Ltd.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqL5CDde9M4OLVg90H21EOLACvtfcHk0lgI0Paj2nVSJA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhsFCqsbvO&md5=d0675527595829b6e888182d8d0f9a76</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1002%2Fpath.3021&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fpath.3021%26sid%3Dliteratum%253Aachs%26aulast%3DCox%26aufirst%3DT.%2BM.%26aulast%3DCach%25C3%25B3n-Gonz%25C3%25A1lez%26aufirst%3DM.%2BB.%26atitle%3DThe%2520cellular%2520pathology%2520of%2520lysosomal%2520diseases%26jtitle%3DJ.%2520Pathol.%26date%3D2012%26volume%3D226%26spage%3D241%26epage%3D254%26doi%3D10.1002%2Fpath.3021" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref40"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref40'); return false;" data-citation="" class="refNumLink">40</a></strong><div class="NLM_citation" id="cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Stirnemann, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Belmatoug, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Camou, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Serratrice, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Froissart, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caillaud, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levade, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Astudillo, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Serratrice, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brassier, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rose, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Billette
de Villemeur, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berger, M.</span></span> <span> </span><span class="NLM_article-title">A review of gaucher disease pathophysiology, clinical presentation and treatments</span>. <i>Int. J. Mol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">441</span>– <span class="NLM_lpage">471</span>, <span class="refDoi"> DOI: 10.3390/ijms18020441</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01561&amp;key=10.3390%2Fijms18020441" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01561&amp;key=1%3ACAS%3A528%3ADC%252BC1cXkvVSju70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2017&pages=441-471&author=J.+Stirnemannauthor=N.+Belmatougauthor=F.+Camouauthor=C.+Serratriceauthor=R.+Froissartauthor=C.+Caillaudauthor=T.+Levadeauthor=L.+Astudilloauthor=J.+Serratriceauthor=A.+Brassierauthor=C.+Roseauthor=T.+Billette%0Ade+Villemeurauthor=M.+Berger&title=A+review+of+gaucher+disease+pathophysiology%2C+clinical+presentation+and+treatments&doi=10.3390%2Fijms18020441"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">A review of gaucher disease pathophysiology, clinical presentation and treatments</span></div><div class="casAuthors">Stirnemann, Jerome; Belmatoug, Nadia; Camou, Fabrice; Serratrice, Christine; Froissart, Roseline; Caillaud, Catherine; Levade, Thierry; Astudillo, Leonardo; Serratrice, Jacques; Brassier, Anais; Rose, Christian; Billette de Villemeur, Thierry; Berger, Marc G.</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Molecular Sciences</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">441/1-441/30</span>CODEN:
                <span class="NLM_cas:coden">IJMCFK</span>;
        ISSN:<span class="NLM_cas:issn">1422-0067</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">A review.  Gaucher disease (GD, ORPHA355) is a rare, autosomal recessive genetic disorder.  It is caused by a deficiency of the lysosomal enzyme, glucocerebrosidase, which leads to an accumulation of its substrate, glucosylceramide, in macrophages.  In the general population, its incidence is approx. 1/40,000 to 1/60,000 births, rising to 1/800 in Ashkenazi Jews.  The main cause of the cytopenia, splenomegaly, hepatomegaly, and bone lesions assocd. with the disease is considered to be the infiltration of the bone marrow, spleen, and liver by Gaucher cells.  Type-1 Gaucher disease, which affects the majority of patients (90% in Europe and USA, but less in other regions), is characterized by effects on the viscera, whereas types 2 and 3 are also assocd. with neurol. impairment, either severe in type 2 or variable in type 3.  A diagnosis of GD can be confirmed by demonstrating the deficiency of acid glucocerebrosidase activity in leukocytes.  Mutations in the GBA1 gene should be identified as they may be of prognostic value in some cases.  Patients with type-1 GD-but also carriers of GBA1 mutation-have been found to be predisposed to developing Parkinson's disease, and the risk of neoplasia assocd. with the disease is still subject to discussion.  Disease-specific treatment consists of i.v. enzyme replacement therapy (ERT) using one of the currently available mols. (imiglucerase, velaglucerase, or taliglucerase).  Orally administered inhibitors of glucosylceramide biosynthesis can also be used (miglustat or eliglustat).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqpeVOOYHDqyLVg90H21EOLACvtfcHk0lj7un4fXVYojA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXkvVSju70%253D&md5=38a4c125a4007d25177135c8996f7abe</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.3390%2Fijms18020441&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fijms18020441%26sid%3Dliteratum%253Aachs%26aulast%3DStirnemann%26aufirst%3DJ.%26aulast%3DBelmatoug%26aufirst%3DN.%26aulast%3DCamou%26aufirst%3DF.%26aulast%3DSerratrice%26aufirst%3DC.%26aulast%3DFroissart%26aufirst%3DR.%26aulast%3DCaillaud%26aufirst%3DC.%26aulast%3DLevade%26aufirst%3DT.%26aulast%3DAstudillo%26aufirst%3DL.%26aulast%3DSerratrice%26aufirst%3DJ.%26aulast%3DBrassier%26aufirst%3DA.%26aulast%3DRose%26aufirst%3DC.%26aulast%3DBillette%2Bde%2BVillemeur%26aufirst%3DT.%26aulast%3DBerger%26aufirst%3DM.%26atitle%3DA%2520review%2520of%2520gaucher%2520disease%2520pathophysiology%252C%2520clinical%2520presentation%2520and%2520treatments%26jtitle%3DInt.%2520J.%2520Mol.%2520Sci.%26date%3D2017%26volume%3D18%26spage%3D441%26epage%3D471%26doi%3D10.3390%2Fijms18020441" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref41"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref41'); return false;" data-citation="" class="refNumLink">41</a></strong><div class="NLM_citation" id="cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Won, J.-S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, I.</span></span> <span> </span><span class="NLM_article-title">Biochemical, cell biological, pathological, and therapeutic aspects of Krabbe’s disease</span>. <i>J. Neurosci. Res.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>94</i></span>,  <span class="NLM_fpage">990</span>– <span class="NLM_lpage">1006</span>, <span class="refDoi"> DOI: 10.1002/jnr.23873</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01561&amp;key=10.1002%2Fjnr.23873" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01561&amp;key=27638584" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01561&amp;key=1%3ACAS%3A528%3ADC%252BC28XhsFWltr3I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=94&publication_year=2016&pages=990-1006&author=J.-S.+Wonauthor=A.+K.+Singhauthor=I.+Singh&title=Biochemical%2C+cell+biological%2C+pathological%2C+and+therapeutic+aspects+of+Krabbe%E2%80%99s+disease&doi=10.1002%2Fjnr.23873"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Biochemical, cell biological, pathological, and therapeutic aspects of Krabbe's disease</span></div><div class="casAuthors">Won, Je-Seong; Singh, Avtar K.; Singh, Inderjit</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Neuroscience Research</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">94</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">990-1006</span>CODEN:
                <span class="NLM_cas:coden">JNREDK</span>;
        ISSN:<span class="NLM_cas:issn">0360-4012</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">A review.  Krabbe's disease (KD; also called globoid cell leukodystrophy) is a genetic disorder involving demyelination of the central (CNS) and peripheral (PNS) nervous systems.  The disease may be subdivided into three types, an infantile form, which is the most common and severe; a juvenile form; and a rare adult form.  KD is an autosomal recessive disorder caused by a deficiency of galactocerebrosidase activity in lysosomes, leading to accumulation of galactoceramide and neurotoxic galactosylsphingosine (psychosine [PSY]) in macrophages (globoid cells) as well as neural cells, esp. in oligodendrocytes and Schwann cells.  This ultimately results in damage to myelin in both CNS and PNS with assocd. morbidity and mortality.  Accumulation of PSY, a lysolipid with detergent-like properties, over a threshold level could trigger membrane destabilization, leading to cell lysis.  Moreover, subthreshold concns. of PSY trigger cell signaling pathways that induce oxidative stress, mitochondrial dysfunction, apoptosis, inflammation, endothelial/vascular dysfunctions, and neuronal and axonal damage.  From the time the "psychosine hypothesis" was proposed, considerable efforts have been made in search of an effective therapy for lowering PSY load with pharmacol., gene, and stem cell approaches to attenuate PSY-induced neurotoxicity.  This Review focuses on the recent advances and prospective research for understanding disease mechanisms and therapeutic approaches for KD. © 2016 Wiley Periodicals, Inc.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoyiXLjIgjfi7Vg90H21EOLACvtfcHk0lj7un4fXVYojA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhsFWltr3I&md5=4f5306516d90cf3abf8a9023172ac8dc</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1002%2Fjnr.23873&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjnr.23873%26sid%3Dliteratum%253Aachs%26aulast%3DWon%26aufirst%3DJ.-S.%26aulast%3DSingh%26aufirst%3DA.%2BK.%26aulast%3DSingh%26aufirst%3DI.%26atitle%3DBiochemical%252C%2520cell%2520biological%252C%2520pathological%252C%2520and%2520therapeutic%2520aspects%2520of%2520Krabbe%25E2%2580%2599s%2520disease%26jtitle%3DJ.%2520Neurosci.%2520Res.%26date%3D2016%26volume%3D94%26spage%3D990%26epage%3D1006%26doi%3D10.1002%2Fjnr.23873" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref42"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref42'); return false;" data-citation="" class="refNumLink">42</a></strong><div class="NLM_citation" id="cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ferraz, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marques, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verhoek, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strijland, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mirzaian, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scheij, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ouairy, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lahav, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wisse, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Overkleeft, H. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boot, R. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aerts, J. M.</span></span> <span> </span><span class="NLM_article-title">Lysosomal glycosphingolipid catabolism by acid ceramidase: formation of glycosphingoid bases during deficiency of glycosidases</span>. <i>FEBS Lett.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>590</i></span>,  <span class="NLM_fpage">716</span>– <span class="NLM_lpage">725</span>, <span class="refDoi"> DOI: 10.1002/1873-3468.12104</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01561&amp;key=10.1002%2F1873-3468.12104" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01561&amp;key=26898341" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01561&amp;key=1%3ACAS%3A528%3ADC%252BC28Xht1Krur7N" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=590&publication_year=2016&pages=716-725&author=M.+J.+Ferrazauthor=M.+D.+Marquesauthor=M.+Verhoekauthor=A.+Strijlandauthor=M.+Mirzaianauthor=S.+Scheijauthor=C.+M.+Ouairyauthor=D.+Lahavauthor=P.+Wisseauthor=H.+S.+Overkleeftauthor=R.+G.+Bootauthor=J.+M.+Aerts&title=Lysosomal+glycosphingolipid+catabolism+by+acid+ceramidase%3A+formation+of+glycosphingoid+bases+during+deficiency+of+glycosidases&doi=10.1002%2F1873-3468.12104"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Lysosomal glycosphingolipid catabolism by acid ceramidase: formation of glycosphingoid bases during deficiency of glycosidases</span></div><div class="casAuthors">Ferraz, Maria J.; Marques, Andre R. A.; Appelman, Monique D.; Verhoek, Marri; Strijland, Anneke; Mirzaian, Mina; Scheij, Saskia; Ouairy, Cecile M.; Lahav, Daniel; Wisse, Patrick; Overkleeft, Herman S.; Boot, Rolf G.; Aerts, Johannes M.</div><div class="citationInfo"><span class="NLM_cas:title">FEBS Letters</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">590</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">716-725</span>CODEN:
                <span class="NLM_cas:coden">FEBLAL</span>;
        ISSN:<span class="NLM_cas:issn">0014-5793</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Glycosphingoid bases are elevated in inherited lysosomal storage disorders with deficient activity of glycosphingolipid catabolizing glycosidases.  We investigated the mol. basis of the formation of glucosyl sphingosine and globotriaosyl sphingosine during deficiency of glucocerebrosidase (Gaucher disease) and α-galactosidase A (Fabry disease).  Independent genetic and pharmacol. evidence is presented pointing to an active role of acid ceramidase in both processes through deacylation of lysosomal glycosphingolipids.  The potential pathophysiol. relevance of elevated glycosphingoid bases generated through this alternative metab. in patients suffering from lysosomal glycosidase defects is discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqD3HCj2x7-AbVg90H21EOLACvtfcHk0ljF2voVErsCew"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xht1Krur7N&md5=ecfbbdaaf640b5e567ea771241262e09</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1002%2F1873-3468.12104&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252F1873-3468.12104%26sid%3Dliteratum%253Aachs%26aulast%3DFerraz%26aufirst%3DM.%2BJ.%26aulast%3DMarques%26aufirst%3DM.%2BD.%26aulast%3DVerhoek%26aufirst%3DM.%26aulast%3DStrijland%26aufirst%3DA.%26aulast%3DMirzaian%26aufirst%3DM.%26aulast%3DScheij%26aufirst%3DS.%26aulast%3DOuairy%26aufirst%3DC.%2BM.%26aulast%3DLahav%26aufirst%3DD.%26aulast%3DWisse%26aufirst%3DP.%26aulast%3DOverkleeft%26aufirst%3DH.%2BS.%26aulast%3DBoot%26aufirst%3DR.%2BG.%26aulast%3DAerts%26aufirst%3DJ.%2BM.%26atitle%3DLysosomal%2520glycosphingolipid%2520catabolism%2520by%2520acid%2520ceramidase%253A%2520formation%2520of%2520glycosphingoid%2520bases%2520during%2520deficiency%2520of%2520glycosidases%26jtitle%3DFEBS%2520Lett.%26date%3D2016%26volume%3D590%26spage%3D716%26epage%3D725%26doi%3D10.1002%2F1873-3468.12104" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref43"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref43'); return false;" data-citation="" class="refNumLink">43</a></strong><div class="NLM_citation" id="cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benitez, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagree, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dearborn, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guzman, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woloszynek, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giaramita, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yip, B. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elsbernd, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Babcock, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fowler, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wozniak, D. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vogler, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Medin, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crawford, B. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sands, M. S.</span></span> <span> </span><span class="NLM_article-title">Genetic ablation of acid ceramidase in Krabbe disease confirms the psychosine hypothesis and identifies a new therapeutic target</span>. <i>Proc. Natl. Acad. Sci. U.S.A.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>116</i></span>,  <span class="NLM_fpage">20097</span>– <span class="NLM_lpage">20103</span>, <span class="refDoi"> DOI: 10.1073/pnas.1912108116</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01561&amp;key=10.1073%2Fpnas.1912108116" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01561&amp;key=31527255" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01561&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhvFSitrfE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=116&publication_year=2019&pages=20097-20103&author=Y.+Liauthor=Y.+Xuauthor=B.+A.+Benitezauthor=M.+S.+Nagreeauthor=J.+T.+Dearbornauthor=X.+Jiangauthor=M.+A.+Guzmanauthor=J.+C.+Woloszynekauthor=A.+Giaramitaauthor=B.+K.+Yipauthor=J.+Elsberndauthor=M.+C.+Babcockauthor=M.+Loauthor=S.+C.+Fowlerauthor=D.+F.+Wozniakauthor=C.+A.+Voglerauthor=J.+A.+Medinauthor=B.+E.+Crawfordauthor=M.+S.+Sands&title=Genetic+ablation+of+acid+ceramidase+in+Krabbe+disease+confirms+the+psychosine+hypothesis+and+identifies+a+new+therapeutic+target&doi=10.1073%2Fpnas.1912108116"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">Genetic ablation of acid ceramidase in Krabbe disease confirms the psychosine hypothesis and identifies a new therapeutic target</span></div><div class="casAuthors">Li, Yedda; Xu, Yue; Benitez, Bruno A.; Nagree, Murtaza S.; Dearborn, Joshua T.; Jiang, Xuntian; Guzman, Miguel A.; Woloszynek, Josh C.; Giaramita, Alex; Yip, Bryan K.; Elsbernd, Joseph; Babcock, Michael C.; Lo, Melanie; Fowler, Stephen C.; Wozniak, David F.; Vogler, Carole A.; Medin, Jeffrey A.; Crawford, Brett E.; Sands, Mark S.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">116</span>
        (<span class="NLM_cas:issue">40</span>),
    <span class="NLM_cas:pages">20097-20103</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Infantile globoid cell leukodystrophy (GLD, Krabbe disease) is a fatal demyelinating disorder caused by a deficiency in the lysosomal enzyme galactosylceramidase (GALC).  GALC deficiency leads to the accumulation of the cytotoxic glycolipid, galactosylsphingosine (psychosine).  Complementary evidence suggested that psychosine is synthesized via an anabolic pathway.  Here, we show instead that psychosine is generated catabolically through the deacylation of galactosylceramide by acid ceramidase (ACDase).  This reaction uncouples GALC deficiency from psychosine accumulation, allowing us to test the long-standing "psychosine hypothesis".  We demonstrate that genetic loss of ACDase activity (Farber disease) in the GALC-deficient mouse model of human GLD (twitcher) eliminates psychosine accumulation and cures GLD.  These data suggest that ACDase could be a target for substrate redn. therapy (SRT) in Krabbe patients.  We show that pharmacol. inhibition of ACDase activity with carmofur significantly decreases psychosine accumulation in cells from a Krabbe patient and prolongs the life span of the twitcher (Twi) mouse.  Previous SRT expts. in the Twi mouse utilized L-cycloserine, which inhibits an enzyme several steps upstream of psychosine synthesis, thus altering the balance of other important lipids.  Drugs that directly inhibit ACDase may have a more acceptable safety profile due to their mechanistic proximity to psychosine biogenesis.  In total, these data clarify our understanding of psychosine synthesis, confirm the long-held psychosine hypothesis, and provide the impetus to discover safe and effective inhibitors of ACDase to treat Krabbe disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoMIjeCuiB29bVg90H21EOLACvtfcHk0lhNrCqhaAeLFQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhvFSitrfE&md5=921bc583ee05d71e2d55dd98a235fd1b</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1912108116&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1912108116%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DY.%26aulast%3DXu%26aufirst%3DY.%26aulast%3DBenitez%26aufirst%3DB.%2BA.%26aulast%3DNagree%26aufirst%3DM.%2BS.%26aulast%3DDearborn%26aufirst%3DJ.%2BT.%26aulast%3DJiang%26aufirst%3DX.%26aulast%3DGuzman%26aufirst%3DM.%2BA.%26aulast%3DWoloszynek%26aufirst%3DJ.%2BC.%26aulast%3DGiaramita%26aufirst%3DA.%26aulast%3DYip%26aufirst%3DB.%2BK.%26aulast%3DElsbernd%26aufirst%3DJ.%26aulast%3DBabcock%26aufirst%3DM.%2BC.%26aulast%3DLo%26aufirst%3DM.%26aulast%3DFowler%26aufirst%3DS.%2BC.%26aulast%3DWozniak%26aufirst%3DD.%2BF.%26aulast%3DVogler%26aufirst%3DC.%2BA.%26aulast%3DMedin%26aufirst%3DJ.%2BA.%26aulast%3DCrawford%26aufirst%3DB.%2BE.%26aulast%3DSands%26aufirst%3DM.%2BS.%26atitle%3DGenetic%2520ablation%2520of%2520acid%2520ceramidase%2520in%2520Krabbe%2520disease%2520confirms%2520the%2520psychosine%2520hypothesis%2520and%2520identifies%2520a%2520new%2520therapeutic%2520target%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2019%26volume%3D116%26spage%3D20097%26epage%3D20103%26doi%3D10.1073%2Fpnas.1912108116" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref44"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref44'); return false;" data-citation="" class="refNumLink">44</a></strong><div class="NLM_citation" id="cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gebai, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gorelik, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Illes, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagar, B.</span></span> <span> </span><span class="NLM_article-title">Structural basis for the activation of acid ceramidase</span>. <i>Nat. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">1621</span>, <span class="refDoi"> DOI: 10.1038/s41467-018-03844-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01561&amp;key=10.1038%2Fs41467-018-03844-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01561&amp;key=29692406" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01561&amp;key=1%3ACAS%3A280%3ADC%252BC1Mjmtl2rtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2018&pages=1621&author=A.+Gebaiauthor=A.+Gorelikauthor=Z.+Liauthor=K.+Illesauthor=B.+Nagar&title=Structural+basis+for+the+activation+of+acid+ceramidase&doi=10.1038%2Fs41467-018-03844-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">Structural basis for the activation of acid ceramidase</span></div><div class="casAuthors">Gebai Ahmad; Gorelik Alexei; Li Zixian; Illes Katalin; Nagar Bhushan</div><div class="citationInfo"><span class="NLM_cas:title">Nature communications</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">1621</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Acid ceramidase (aCDase, ASAH1) hydrolyzes lysosomal membrane ceramide into sphingosine, the backbone of all sphingolipids, to regulate many cellular processes.  Abnormal function of aCDase leads to Farber disease, spinal muscular atrophy with progressive myoclonic epilepsy, and is associated with Alzheimer's, diabetes, and cancer.  Here, we present crystal structures of mammalian aCDases in both proenzyme and autocleaved forms.  In the proenzyme, the catalytic center is buried and protected from solvent.  Autocleavage triggers a conformational change exposing a hydrophobic channel leading to the active site.  Substrate modeling suggests distinct catalytic mechanisms for substrate hydrolysis versus autocleavage.  A hydrophobic surface surrounding the substrate binding channel appears to be a site of membrane attachment where the enzyme accepts substrates facilitated by the accessory protein, saposin-D.  Structural mapping of disease mutations reveals that most would destabilize the protein fold.  These results will inform the rational design of aCDase inhibitors and recombinant aCDase for disease therapeutics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcT6RpR0JSKnbwHqQV89nF-2fW6udTcc2eZqXujbVRc1jrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1Mjmtl2rtg%253D%253D&md5=a7fb6f187dc50d25c9a14597053718c1</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1038%2Fs41467-018-03844-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41467-018-03844-2%26sid%3Dliteratum%253Aachs%26aulast%3DGebai%26aufirst%3DA.%26aulast%3DGorelik%26aufirst%3DA.%26aulast%3DLi%26aufirst%3DZ.%26aulast%3DIlles%26aufirst%3DK.%26aulast%3DNagar%26aufirst%3DB.%26atitle%3DStructural%2520basis%2520for%2520the%2520activation%2520of%2520acid%2520ceramidase%26jtitle%3DNat.%2520Commun.%26date%3D2018%26volume%3D9%26spage%3D1621%26doi%3D10.1038%2Fs41467-018-03844-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref45"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref45'); return false;" data-citation="" class="refNumLink">45</a></strong><div class="NLM_citation" id="cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bielawska, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greenberg, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perry, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jayadev, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shayman, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McKay, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hannun, Y. A.</span></span> <span> </span><span class="NLM_article-title">(1S,2R)-D-erythro-2-(N-myristoylamino)-1-phenyl-1-propanol as an inhibitor of ceramidase</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1996</span>,  <span class="NLM_volume"><i>271</i></span>,  <span class="NLM_fpage">12646</span>– <span class="NLM_lpage">12654</span>, <span class="refDoi"> DOI: 10.1074/jbc.271.21.12646</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01561&amp;key=10.1074%2Fjbc.271.21.12646" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01561&amp;key=8647877" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01561&amp;key=1%3ACAS%3A528%3ADyaK28XjtFantLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=271&publication_year=1996&pages=12646-12654&author=A.+Bielawskaauthor=M.+S.+Greenbergauthor=D.+Perryauthor=S.+Jayadevauthor=J.+A.+Shaymanauthor=C.+McKayauthor=Y.+A.+Hannun&title=%281S%2C2R%29-D-erythro-2-%28N-myristoylamino%29-1-phenyl-1-propanol+as+an+inhibitor+of+ceramidase&doi=10.1074%2Fjbc.271.21.12646"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">(1S,2R)-D-erythro-2-(N-myristoylamino)-1-phenyl-1-propanol as an inhibitor of ceramidase</span></div><div class="casAuthors">Bielawska, Alicja; Greenberg, Mathew S.; Perry, David; Jayadev, Supriya; Shayman, James A.; McKay, Charles; Hannun, Yusuf A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">271</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">12646-12654</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">The cellular and biochem. activities of the ceramide analog, (1S,2R)-D-erythro-2-(N-myristoylamino)-1-phenyl-1-propanol (D-e-MAPP), were examd.  The addn. of 5 μM D-e-MAPP to HL-60 human promyelocytic leukemia cells resulted in a concn.- and time-dependent growth suppression accompanied by an arrest in the G0/G1 phase of the cell cycle; thus mimicking the action of exogenous ceramides.  Its enantiomer, L-e-MAPP, was without effect.  Two lines of evidence suggested that D-e-MAPP may not function as a direct analog of ceramide.  First, D-e-MAPP possesses a stereochem. configuration opposite to that of D-erythro-ceramide.  Second, D-e-MAPP failed to activate ceramide-activated phosphoprotein phosphatase in vitro.  Therefore, the authors examd. if D-e-MAPP functioned indirectly by modulating endogenous ceramide levels.  The addn. of D-e-MAPP to cells, but not L-e-MAPP, caused a time- and concn.-dependent elevation in endogenous ceramide levels reaching >3-fold over baseline following 24 h of treatment.  Both D-e-MAPP and L-e-MAPP underwent similar uptake by HL-60 cells.  D-E-MAPP was poorly metabolized, and remained intact in cells, whereas L-e-MAPP underwent a time- and concn.-dependent metab., primarily through N-deacylation.  In vitro, L-e-MAPP was metabolized by alk. ceramidase to an extent similar to that seen with C16-ceramide.  D-E-MAPP was not metabolized.  Instead, D-e-MAPP inhibited alk. ceramidase activity in vitro with an IC50 of 1-5 μM.  D-E-MAPP did not modulate the activity of other ceramide-metabolizing enzymes in vitro or in cells, and it was a poor inhibitor of acid ceramidase (IC50 > 500 μM).  Finally, D-e-MAPP inhibited the metab. of L-e-MAPP in cells.  These studies demonstrate that D-e-MAPP functions as an inhibitor of alk. ceramidase in vitro and in cells resulting in elevation in endogenous levels of ceramide with the consequent biol. effects of growth suppression and cell cycle arrest.  These studies point to an important role for ceramidases in the regulation of endogenous levels of ceramide.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr7PyYHPPP3ebVg90H21EOLACvtfcHk0lhNrCqhaAeLFQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK28XjtFantLg%253D&md5=1ed01f1936e1d2a9dcbd9b4b137ebbaa</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1074%2Fjbc.271.21.12646&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.271.21.12646%26sid%3Dliteratum%253Aachs%26aulast%3DBielawska%26aufirst%3DA.%26aulast%3DGreenberg%26aufirst%3DM.%2BS.%26aulast%3DPerry%26aufirst%3DD.%26aulast%3DJayadev%26aufirst%3DS.%26aulast%3DShayman%26aufirst%3DJ.%2BA.%26aulast%3DMcKay%26aufirst%3DC.%26aulast%3DHannun%26aufirst%3DY.%2BA.%26atitle%3D%25281S%252C2R%2529-D-erythro-2-%2528N-myristoylamino%2529-1-phenyl-1-propanol%2520as%2520an%2520inhibitor%2520of%2520ceramidase%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D1996%26volume%3D271%26spage%3D12646%26epage%3D12654%26doi%3D10.1074%2Fjbc.271.21.12646" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref46"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref46'); return false;" data-citation="" class="refNumLink">46</a></strong><div class="NLM_citation" id="cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sugita, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moser, H. W.</span></span> <span> </span><span class="NLM_article-title">Ceramidase and ceramide synthesis in human kidney and cerebellum: description of a new alkaline ceramidase</span>. <i>Biochim. Biophys. Acta, Lipids Lipid Metab.</i> <span class="NLM_year" style="font-weight: bold;">1975</span>,  <span class="NLM_volume"><i>398</i></span>,  <span class="NLM_fpage">125</span>– <span class="NLM_lpage">131</span>, <span class="refDoi"> DOI: 10.1016/0005-2760(75)90176-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01561&amp;key=10.1016%2F0005-2760%2875%2990176-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01561&amp;key=238641" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01561&amp;key=1%3ACAS%3A528%3ADyaE2MXkvFChtb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=398&publication_year=1975&pages=125-131&author=M.+Sugitaauthor=J.+T.+Williamsauthor=H.+W.+Moser&title=Ceramidase+and+ceramide+synthesis+in+human+kidney+and+cerebellum%3A+description+of+a+new+alkaline+ceramidase&doi=10.1016%2F0005-2760%2875%2990176-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">Ceramidase and ceramide synthesis in human kidney and cerebellum.  Description of a new alkaline ceramidase</span></div><div class="casAuthors">Sugita, Mutsumi; Williams, Marcia; Dulaney, John T.; Moser, Hugo W.</div><div class="citationInfo"><span class="NLM_cas:title">Biochimica et Biophysica Acta, Lipids and Lipid Metabolism</span>
        (<span class="NLM_cas:date">1975</span>),
    <span class="NLM_cas:volume">398</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">125-31</span>CODEN:
                <span class="NLM_cas:coden">BBLLA6</span>;
        ISSN:<span class="NLM_cas:issn">0005-2760</span>.
    </div><div class="casAbstract">In normal cerebellum ceramide cleavage and the reverse reaction, free fatty acid-dependent ceramide synthesis, both occur not only at pH 4.0 but also at pH 9.0, although normal kidney exhibits these activities only at pH 4.0.  Both tissues are capable of synthesizing ceramide via an acyl-CoA-dependent pathway at neutral pH.  The synthetic analog of ceramide, N-oleoyl-ethanolamine, is a potent inhibitor of ceramidase.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp3dnZmqqVFYrVg90H21EOLACvtfcHk0ljzzpZsVndhwQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaE2MXkvFChtb4%253D&md5=a59f9b1a82754943c2da77f5c9deaf19</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1016%2F0005-2760%2875%2990176-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0005-2760%252875%252990176-9%26sid%3Dliteratum%253Aachs%26aulast%3DSugita%26aufirst%3DM.%26aulast%3DWilliams%26aufirst%3DJ.%2BT.%26aulast%3DMoser%26aufirst%3DH.%2BW.%26atitle%3DCeramidase%2520and%2520ceramide%2520synthesis%2520in%2520human%2520kidney%2520and%2520cerebellum%253A%2520description%2520of%2520a%2520new%2520alkaline%2520ceramidase%26jtitle%3DBiochim.%2520Biophys.%2520Acta%252C%2520Lipids%2520Lipid%2520Metab.%26date%3D1975%26volume%3D398%26spage%3D125%26epage%3D131%26doi%3D10.1016%2F0005-2760%2875%2990176-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref47"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref47'); return false;" data-citation="" class="refNumLink">47</a></strong><div class="NLM_citation" id="cit47"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Grijalvo, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bedia, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Triola, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Casas, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Llebaria, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Teixidó, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rabal, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levade, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Delgado, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fabriàs, G.</span></span> <span> </span><span class="NLM_article-title">Design, synthesis and activity as acid ceramidase inhibitors of 2-oxooctanoyl and N-oleoylethanolamine analogues</span>. <i>Chem. Phys. Lipids</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>144</i></span>,  <span class="NLM_fpage">69</span>– <span class="NLM_lpage">84</span>, <span class="refDoi"> DOI: 10.1016/j.chemphyslip.2006.07.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01561&amp;key=10.1016%2Fj.chemphyslip.2006.07.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01561&amp;key=16942762" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01561&amp;key=1%3ACAS%3A528%3ADC%252BD28XhtVygsLbE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=144&publication_year=2006&pages=69-84&author=S.+Grijalvoauthor=C.+Bediaauthor=G.+Triolaauthor=J.+Casasauthor=A.+Llebariaauthor=J.+Teixid%C3%B3author=O.+Rabalauthor=T.+Levadeauthor=A.+Delgadoauthor=G.+Fabri%C3%A0s&title=Design%2C+synthesis+and+activity+as+acid+ceramidase+inhibitors+of+2-oxooctanoyl+and+N-oleoylethanolamine+analogues&doi=10.1016%2Fj.chemphyslip.2006.07.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">Design, synthesis and activity as acid ceramidase inhibitors of 2-oxooctanoyl and N-oleoylethanolamine analogues</span></div><div class="casAuthors">Grijalvo, Santiago; Bedia, Carmen; Triola, Gemma; Casas, Josefina; Llebaria, Amadeu; Teixido, Jordi; Rabal, Obdulia; Levade, Thierry; Delgado, Antonio; Fabrias, Gemma</div><div class="citationInfo"><span class="NLM_cas:title">Chemistry and Physics of Lipids</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">144</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">69-84</span>CODEN:
                <span class="NLM_cas:coden">CPLIA4</span>;
        ISSN:<span class="NLM_cas:issn">0009-3084</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">The synthesis of novel N-acylethanolamines and their use as inhibitors of the aCDase is reported here.  The compds. are either 2-oxooctanamides or oleamides of sphingosine analogs featuring a 3-hydroxy-4,5-hexadecenyl tail replaced by ether or thioether moieties.  It appears that, within the 2-oxooctanamide family, the C3-OH group of the sphingosine mol. is required for inhibition both in vitro and in cultured cells.  Furthermore, although the (E)-4 double bond is not essential for inhibitory activity, the (E) configuration is required, since the analog with a (Z)-4 unsatn. was not inhibitory.  None of the oleamides inhibited the aCDase in vitro.  Conversely, with the exception of N-oleoylethanolamine and its analogs with S-decyl and S-hexadecyl substituents, all the synthesized oleamides inhibited the aCDase in cultured cells, although with a relatively low potency.  We conclude that novel aCDase inhibitors can evolve from N-acylation of sphingoid bases with electron deficient-acyl groups.  In contrast, chem. modification of the N-oleoylsphingosine backbone does not seem to offer an appropriate strategy to obtain aCDase inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpVLIJyKt70kbVg90H21EOLACvtfcHk0ljzzpZsVndhwQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhtVygsLbE&md5=2a5303057207a7f0aa16e56801ad0c47</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1016%2Fj.chemphyslip.2006.07.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.chemphyslip.2006.07.001%26sid%3Dliteratum%253Aachs%26aulast%3DGrijalvo%26aufirst%3DS.%26aulast%3DBedia%26aufirst%3DC.%26aulast%3DTriola%26aufirst%3DG.%26aulast%3DCasas%26aufirst%3DJ.%26aulast%3DLlebaria%26aufirst%3DA.%26aulast%3DTeixid%25C3%25B3%26aufirst%3DJ.%26aulast%3DRabal%26aufirst%3DO.%26aulast%3DLevade%26aufirst%3DT.%26aulast%3DDelgado%26aufirst%3DA.%26aulast%3DFabri%25C3%25A0s%26aufirst%3DG.%26atitle%3DDesign%252C%2520synthesis%2520and%2520activity%2520as%2520acid%2520ceramidase%2520inhibitors%2520of%25202-oxooctanoyl%2520and%2520N-oleoylethanolamine%2520analogues%26jtitle%3DChem.%2520Phys.%2520Lipids%26date%3D2006%26volume%3D144%26spage%3D69%26epage%3D84%26doi%3D10.1016%2Fj.chemphyslip.2006.07.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref48"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref48'); return false;" data-citation="" class="refNumLink">48</a></strong><div class="NLM_citation" id="cit48"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Raisova, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goltz, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bektas, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bielawska, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riebeling, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hossini, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eberle, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hannun, Y. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Orfanos, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Geilen, C. C.</span></span> <span> </span><span class="NLM_article-title">Bcl-2 overexpression prevents apoptosis induced by ceramidase inhibitors in malignant melanoma and HaCaT keratinocytes</span>. <i>FEBS Lett.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>516</i></span>,  <span class="NLM_fpage">47</span>– <span class="NLM_lpage">52</span>, <span class="refDoi"> DOI: 10.1016/s0014-5793(02)02472-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01561&amp;key=10.1016%2FS0014-5793%2802%2902472-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01561&amp;key=11959101" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01561&amp;key=1%3ACAS%3A528%3ADC%252BD38XivVaisbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=516&publication_year=2002&pages=47-52&author=M.+Raisovaauthor=G.+Goltzauthor=M.+Bektasauthor=A.+Bielawskaauthor=C.+Riebelingauthor=A.+M.+Hossiniauthor=J.+Eberleauthor=Y.+A.+Hannunauthor=C.+E.+Orfanosauthor=C.+C.+Geilen&title=Bcl-2+overexpression+prevents+apoptosis+induced+by+ceramidase+inhibitors+in+malignant+melanoma+and+HaCaT+keratinocytes&doi=10.1016%2Fs0014-5793%2802%2902472-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">Bcl-2 overexpression prevents apoptosis induced by ceramidase inhibitors in malignant melanoma and HaCaT keratinocytes</span></div><div class="casAuthors">Raisova, Monika; Goltz, Gerit; Bektas, Meryem; Bielawska, Alicja; Riebeling, Christian; Hossini, Amir M.; Eberle, Jurgen; Hannun, Yusuf A.; Orfanos, Constantin E.; Geilen, Christoph C.</div><div class="citationInfo"><span class="NLM_cas:title">FEBS Letters</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">516</span>
        (<span class="NLM_cas:issue">1-3</span>),
    <span class="NLM_cas:pages">47-52</span>CODEN:
                <span class="NLM_cas:coden">FEBLAL</span>;
        ISSN:<span class="NLM_cas:issn">0014-5793</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science B.V.</span>)
        </div><div class="casAbstract">The authors examd. the biol. effects of the ceramide analogs (1S,2R)-2-N-myristoylamino-1-phenyl-1-propanol (D-e-MAPP) and (1R,2R)-2-N-myristoylamino-1-(4-nitrophenyl)-1,3-propandiol (D-NMAPPD) on human HaCaT keratinocytes and human melanoma cells.  The authors could demonstrate that D-e-MAPP and D-NMAPPD are able to suppress acid ceramidase activity.  The elevation of the endogenous level of ceramide is followed by induction of apoptosis and suppression of proliferation in HaCaT keratinocytes.  Moreover, the authors recently identified a group of human melanoma cell populations which are heterogeneously susceptible to C2-ceramide-mediated apoptosis.  Studies with these melanoma cells revealed correlation between ceramide-mediated apoptosis and D-NMAPPD-induced apoptosis, confirming the effect of this inhibitor on ceramide signaling in human melanoma cells.  These findings suggest ceramidase inhibitors as a potential new therapeutical class of antiproliferative and cytostatic drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqHkVJsCkB4OLVg90H21EOLACvtfcHk0ljzzpZsVndhwQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XivVaisbk%253D&md5=b4fac80e2573fe62b6e90b5a518eff44</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1016%2FS0014-5793%2802%2902472-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0014-5793%252802%252902472-9%26sid%3Dliteratum%253Aachs%26aulast%3DRaisova%26aufirst%3DM.%26aulast%3DGoltz%26aufirst%3DG.%26aulast%3DBektas%26aufirst%3DM.%26aulast%3DBielawska%26aufirst%3DA.%26aulast%3DRiebeling%26aufirst%3DC.%26aulast%3DHossini%26aufirst%3DA.%2BM.%26aulast%3DEberle%26aufirst%3DJ.%26aulast%3DHannun%26aufirst%3DY.%2BA.%26aulast%3DOrfanos%26aufirst%3DC.%2BE.%26aulast%3DGeilen%26aufirst%3DC.%2BC.%26atitle%3DBcl-2%2520overexpression%2520prevents%2520apoptosis%2520induced%2520by%2520ceramidase%2520inhibitors%2520in%2520malignant%2520melanoma%2520and%2520HaCaT%2520keratinocytes%26jtitle%3DFEBS%2520Lett.%26date%3D2002%26volume%3D516%26spage%3D47%26epage%3D52%26doi%3D10.1016%2Fs0014-5793%2802%2902472-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref49"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref49'); return false;" data-citation="" class="refNumLink">49</a></strong><div class="NLM_citation" id="cit49"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Proksch, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klein, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arenz, C.</span></span> <span> </span><span class="NLM_article-title">Potent inhibition of acid ceramidase by novel B-13 analogues</span>. <i>J. Lipids</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>2011</i></span>,  <span class="NLM_fpage">971618</span>, <span class="refDoi"> DOI: 10.1155/2011/971618</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01561&amp;key=10.1155%2F2011%2F971618" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01561&amp;key=21490813" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01561&amp;key=1%3ACAS%3A280%3ADC%252BC3MvjsVKmsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2011&publication_year=2011&pages=971618&author=D.+Prokschauthor=J.+J.+Kleinauthor=C.+Arenz&title=Potent+inhibition+of+acid+ceramidase+by+novel+B-13+analogues&doi=10.1155%2F2011%2F971618"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">Potent inhibition of Acid ceramidase by novel B-13 analogues</span></div><div class="casAuthors">Proksch Denny; Klein Jan Jasper; Arenz Christoph</div><div class="citationInfo"><span class="NLM_cas:title">Journal of lipids</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">2011</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">971618</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The lipid-signalling molecule ceramide is known to induce apoptosis in a variety of cell types.  Inhibition of the lysosomal acid ceramidase can increase cellular ceramide levels and thus induce apoptosis.  Indeed, inhibitors of acid ceramidase have been reported to induce cell death and to display potentiating effects to classical radio- or chemo therapy in a number of in vitro and in vivo cancer models.  The most potent in vitro inhibitor of acid ceramidase, B-13, recently revealed to be virtually inactive towards lysosomal acid ceramidase in living cells.  In contrast, a number of weakly basic B-13 analogues have been shown to accumulate in the acidic compartments of living cells and to efficiently inhibit lysosomal acid ceramidase.  However, introduction of weakly basic groups at the ω-position of the fatty acid moiety of B-13 led to a significant reduction of potency towards acid ceramidase from cellular extracts.  Herein, we report a novel B-13-derived scaffold for more effective inhibitors of acid ceramidase.  Furthermore, we provide hints for an introduction of basic functional groups at an alternative site of the B-13 scaffold that do not interfere with acid ceramidase inhibition in vitro.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSBEW1u4DksqVVwdslNBF-tfW6udTcc2ebdsOYeDyW_iLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3MvjsVKmsg%253D%253D&md5=c1160708d814d43c68b3ba460b49874a</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1155%2F2011%2F971618&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1155%252F2011%252F971618%26sid%3Dliteratum%253Aachs%26aulast%3DProksch%26aufirst%3DD.%26aulast%3DKlein%26aufirst%3DJ.%2BJ.%26aulast%3DArenz%26aufirst%3DC.%26atitle%3DPotent%2520inhibition%2520of%2520acid%2520ceramidase%2520by%2520novel%2520B-13%2520analogues%26jtitle%3DJ.%2520Lipids%26date%3D2011%26volume%3D2011%26spage%3D971618%26doi%3D10.1155%2F2011%2F971618" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref50"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref50'); return false;" data-citation="" class="refNumLink">50</a></strong><div class="NLM_citation" id="cit50"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Camacho, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meca-Cortés, Ó.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abad, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">García, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rubio, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Díaz, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Celià-Terrassa, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cingolani, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bermudo, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fernández, P. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blanco, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Delgado, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Casas, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fabriàs, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomson, T. M.</span></span> <span> </span><span class="NLM_article-title">Acid ceramidase as a therapeutic target in metastatic prostate cancer</span>. <i>J. Lipid Res.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>54</i></span>,  <span class="NLM_fpage">1207</span>– <span class="NLM_lpage">1220</span>, <span class="refDoi"> DOI: 10.1194/jlr.m032375</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01561&amp;key=10.1194%2Fjlr.M032375" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01561&amp;key=23423838" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01561&amp;key=1%3ACAS%3A528%3ADC%252BC3sXlsFaruro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2013&pages=1207-1220&author=L.+Camachoauthor=%C3%93.+Meca-Cort%C3%A9sauthor=J.+L.+Abadauthor=S.+Garc%C3%ADaauthor=N.+Rubioauthor=A.+D%C3%ADazauthor=T.+Celi%C3%A0-Terrassaauthor=F.+Cingolaniauthor=R.+Bermudoauthor=P.+L.+Fern%C3%A1ndezauthor=J.+Blancoauthor=A.+Delgadoauthor=J.+Casasauthor=G.+Fabri%C3%A0sauthor=T.+M.+Thomson&title=Acid+ceramidase+as+a+therapeutic+target+in+metastatic+prostate+cancer&doi=10.1194%2Fjlr.m032375"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">Acid ceramidase as a therapeutic target in metastatic prostate cancer</span></div><div class="casAuthors">Camacho, Luz; Meca-Cortes, Oscar; Abad, Jose Luis; Garcia, Simon; Rubio, Nuria; Diaz, Alba; Celia-Terrassa, Toni; Cingolani, Francesca; Bermudo, Raquel; Fernandez, Pedro L.; Blanco, Jeronimo; Delgado, Antonio; Casas, Josefina; Fabrias, Gemma; Thomson, Timothy M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Lipid Research</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1207-1220</span>CODEN:
                <span class="NLM_cas:coden">JLPRAW</span>;
        ISSN:<span class="NLM_cas:issn">0022-2275</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology, Inc.</span>)
        </div><div class="casAbstract">Acid ceramidase (AC) catalyzes the hydrolysis of ceramide into sphingosine, in turn a substrate of sphingosine kinases that catalyze its conversion into the mitogenic sphingosine-1-phosphate.  AC is expressed at high levels in several tumor types and has been proposed as a cancer therapeutic target.  Using a model derived from PC-3 prostate cancer cells, the highly tumorigenic, metastatic, and chemoresistant clone PC-3/Mc expressed higher levels of the AC ASAH1 than the nonmetastatic clone PC-3/S.  Stable knockdown of ASAH1 in PC-3/Mc cells caused an accumulation of ceramides, inhibition of clonogenic potential, increased requirement for growth factors, and inhibition of tumorigenesis and lung metastases.  We developed de novo ASAH1 inhibitors, which also caused a dose-dependent accumulation of ceramides in PC-3/Mc cells and inhibited their growth and clonogenicity.  Finally, immunohistochem. anal. of primary prostate cancer samples showed that higher levels of ASAH1 were assocd. with more advanced stages of this neoplasia.  These observations confirm ASAH1 as a therapeutic target in advanced and chemoresistant forms of prostate cancer and suggest that our new potent and specific AC inhibitors could act by counteracting crit. growth properties of these highly aggressive tumor cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGprkd7ioZLP4bVg90H21EOLACvtfcHk0liQVijUJ2LmhA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXlsFaruro%253D&md5=581be45e3daf85648de6a281b7fcf3be</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1194%2Fjlr.M032375&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1194%252Fjlr.M032375%26sid%3Dliteratum%253Aachs%26aulast%3DCamacho%26aufirst%3DL.%26aulast%3DMeca-Cort%25C3%25A9s%26aufirst%3D%25C3%2593.%26aulast%3DAbad%26aufirst%3DJ.%2BL.%26aulast%3DGarc%25C3%25ADa%26aufirst%3DS.%26aulast%3DRubio%26aufirst%3DN.%26aulast%3DD%25C3%25ADaz%26aufirst%3DA.%26aulast%3DCeli%25C3%25A0-Terrassa%26aufirst%3DT.%26aulast%3DCingolani%26aufirst%3DF.%26aulast%3DBermudo%26aufirst%3DR.%26aulast%3DFern%25C3%25A1ndez%26aufirst%3DP.%2BL.%26aulast%3DBlanco%26aufirst%3DJ.%26aulast%3DDelgado%26aufirst%3DA.%26aulast%3DCasas%26aufirst%3DJ.%26aulast%3DFabri%25C3%25A0s%26aufirst%3DG.%26aulast%3DThomson%26aufirst%3DT.%2BM.%26atitle%3DAcid%2520ceramidase%2520as%2520a%2520therapeutic%2520target%2520in%2520metastatic%2520prostate%2520cancer%26jtitle%3DJ.%2520Lipid%2520Res.%26date%3D2013%26volume%3D54%26spage%3D1207%26epage%3D1220%26doi%3D10.1194%2Fjlr.m032375" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref51"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref51'); return false;" data-citation="" class="refNumLink">51</a></strong><div class="NLM_citation" id="cit51"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ordóñez, Y. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abad, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aseeri, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Casas, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garcia, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Casasampere, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schuchman, E. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levade, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Delgado, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Triola, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fabrias, G.</span></span> <span> </span><span class="NLM_article-title">Activity-based imaging of acid ceramidase in living cells</span>. <i>J. Am. Chem. Soc.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>141</i></span>,  <span class="NLM_fpage">7736</span>– <span class="NLM_lpage">7742</span>, <span class="refDoi"> DOI: 10.1021/jacs.8b11687</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jacs.8b11687" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01561&amp;key=1%3ACAS%3A528%3ADC%252BC1MXosVOhsb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=141&publication_year=2019&pages=7736-7742&author=Y.+F.+Ord%C3%B3%C3%B1ezauthor=J.+L.+Abadauthor=M.+Aseeriauthor=J.+Casasauthor=V.+Garciaauthor=M.+Casasampereauthor=E.+H.+Schuchmanauthor=T.+Levadeauthor=A.+Delgadoauthor=G.+Triolaauthor=G.+Fabrias&title=Activity-based+imaging+of+acid+ceramidase+in+living+cells&doi=10.1021%2Fjacs.8b11687"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit51R"><div class="casContent"><span class="casTitleNuber">51</span><div class="casTitle"><span class="NLM_cas:atitle">Activity-Based Imaging of Acid Ceramidase in Living Cells</span></div><div class="casAuthors">Ordonez, Yadira F.; Abad, Jose Luis; Aseeri, Mazen; Casas, Josefina; Garcia, Virginie; Casasampere, Mireia; Schuchman, Edward H.; Levade, Thierry; Delgado, Antonio; Triola, Gemma; Fabrias, Gemma</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">141</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">7736-7742</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Acid ceramidase (AC) hydrolyzes ceramides into sphingoid bases and fatty acids.  The enzyme is overexpressed in several types of cancer and Alzheimer's disease, and its genetic defect causes different incurable disorders.  The availability of a method for the specific visualization of catalytically active AC in intracellular compartments is crucial for diagnosis and follow-up of therapeutic strategies in diseases linked to altered AC activity.  This work was undertaken to develop activity-based probes for the detection of AC.  Several analogs of the AC inhibitor SABRAC were synthesized and found to act as very potent (two-digit nM range) irreversible AC inhibitors by reaction with the active site Cys143.  Detection of active AC in cell-free systems was achieved either by using fluorescent SABRAC analogs or by click chem. with an azide-substituted analog.  The compd. affording the best features allowed the unprecedented labeling of active AC in living cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqx2rO1y9xv5LVg90H21EOLACvtfcHk0ljhqaKLkpsv1A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXosVOhsb8%253D&md5=5c1fe4e82ef6c2268c69a3bd7f733227</span></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1021%2Fjacs.8b11687&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjacs.8b11687%26sid%3Dliteratum%253Aachs%26aulast%3DOrd%25C3%25B3%25C3%25B1ez%26aufirst%3DY.%2BF.%26aulast%3DAbad%26aufirst%3DJ.%2BL.%26aulast%3DAseeri%26aufirst%3DM.%26aulast%3DCasas%26aufirst%3DJ.%26aulast%3DGarcia%26aufirst%3DV.%26aulast%3DCasasampere%26aufirst%3DM.%26aulast%3DSchuchman%26aufirst%3DE.%2BH.%26aulast%3DLevade%26aufirst%3DT.%26aulast%3DDelgado%26aufirst%3DA.%26aulast%3DTriola%26aufirst%3DG.%26aulast%3DFabrias%26aufirst%3DG.%26atitle%3DActivity-based%2520imaging%2520of%2520acid%2520ceramidase%2520in%2520living%2520cells%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D2019%26volume%3D141%26spage%3D7736%26epage%3D7742%26doi%3D10.1021%2Fjacs.8b11687" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref52"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref52'); return false;" data-citation="" class="refNumLink">52</a></strong><div class="NLM_citation" id="cit52"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Draper, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xia, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhuang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, C. D.</span></span> <span> </span><span class="NLM_article-title">Discovery and evaluation of inhibitors of human ceramidase</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">2052</span>– <span class="NLM_lpage">2061</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.mct-11-0365</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01561&amp;key=10.1158%2F1535-7163.MCT-11-0365" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01561&amp;key=21885864" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01561&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhsVeltLbL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2011&pages=2052-2061&author=J.+M.+Draperauthor=Z.+Xiaauthor=R.+A.+Smithauthor=Y.+Zhuangauthor=W.+Wangauthor=C.+D.+Smith&title=Discovery+and+evaluation+of+inhibitors+of+human+ceramidase&doi=10.1158%2F1535-7163.mct-11-0365"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit52R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery and Evaluation of Inhibitors of Human Ceramidase</span></div><div class="casAuthors">Draper, Jeremiah M.; Xia, Zuping; Smith, Ryan A.; Zhuang, Yan; Wang, Wenxue; Smith, Charles D.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2052-2061</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The ceramide/sphingosine-1-phosphate (S1P) rheostat has been hypothesized to play a crit. role in regulating tumor cell fate, with elevated levels of ceramide inducing death and elevated levels of S1P leading to survival and proliferation.  Ceramidases are key enzymes that control this rheostat by hydrolyzing ceramide to produce sphingosine and may also confer resistance to drugs and radiation.  Therefore, ceramidase inhibitors have excellent potential for development as new anticancer drugs.  In this study, we identify a novel ceramidase inhibitor (Ceranib-1) by screening a small mol. library and describe the synthesis of a more potent analog (Ceranib-2).  In a cell-based assay, both compds. were found to inhibit cellular ceramidase activity toward an exogenous ceramide analog, induce the accumulation of multiple ceramide species, decrease levels of sphingosine and S1P, inhibit the proliferation of cells alone and in combination with paclitaxel, and induce cell-cycle arrest and cell death.  In vivo, Ceranib-2 was found to delay tumor growth in a syngeneic tumor model without hematol. suppression or overt signs of toxicity.  These data support the selection of ceramidases as suitable targets for anticancer drug development and provide the first nonlipid inhibitors of human ceramidase activity.  Mol Cancer Ther; 10(11); 2052-61.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpB2jpM4jQkMrVg90H21EOLACvtfcHk0ljhqaKLkpsv1A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhsVeltLbL&md5=0adf607e83b91dff2ed50d989cdeb34e</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-11-0365&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-11-0365%26sid%3Dliteratum%253Aachs%26aulast%3DDraper%26aufirst%3DJ.%2BM.%26aulast%3DXia%26aufirst%3DZ.%26aulast%3DSmith%26aufirst%3DR.%2BA.%26aulast%3DZhuang%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DW.%26aulast%3DSmith%26aufirst%3DC.%2BD.%26atitle%3DDiscovery%2520and%2520evaluation%2520of%2520inhibitors%2520of%2520human%2520ceramidase%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2011%26volume%3D10%26spage%3D2052%26epage%3D2061%26doi%3D10.1158%2F1535-7163.mct-11-0365" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref53"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref53'); return false;" data-citation="" class="refNumLink">53</a></strong><div class="NLM_citation" id="cit53"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yildiz-Ozer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oztopcu-Vatan, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kus, G.</span></span> <span> </span><span class="NLM_article-title">The investigation of ceranib-2 on apoptosis and drug interaction with carboplatin in human non small cell lung cancer cells in vitro</span>. <i>Cytotechnology</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>70</i></span>,  <span class="NLM_fpage">387</span>– <span class="NLM_lpage">396</span>, <span class="refDoi"> DOI: 10.1007/s10616-017-0154-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01561&amp;key=10.1007%2Fs10616-017-0154-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01561&amp;key=29230631" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01561&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhvFOmtLrM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=70&publication_year=2018&pages=387-396&author=M.+Yildiz-Ozerauthor=P.+Oztopcu-Vatanauthor=G.+Kus&title=The+investigation+of+ceranib-2+on+apoptosis+and+drug+interaction+with+carboplatin+in+human+non+small+cell+lung+cancer+cells+in+vitro&doi=10.1007%2Fs10616-017-0154-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit53R"><div class="casContent"><span class="casTitleNuber">53</span><div class="casTitle"><span class="NLM_cas:atitle">The investigation of ceranib-2 on apoptosis and drug interaction with carboplatin in human non small cell lung cancer cells in vitro</span></div><div class="casAuthors">Yildiz-Ozer, Merve; Oztopcu-Vatan, Pinar; Kus, Gokhan</div><div class="citationInfo"><span class="NLM_cas:title">Cytotechnology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">70</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">387-396</span>CODEN:
                <span class="NLM_cas:coden">CYTOER</span>;
        ISSN:<span class="NLM_cas:issn">0920-9069</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Ceramide is found to be involved in inhibition of cell division and induction of apoptosis in certain tumor cells.  Ceranib-2 is an agent that increases ceramide levels by inhibiting ceramidase in cancer cells.  Therefore, we aimed to investigate the effects of ceranib-2 on cell survival, apoptosis and interaction with carboplatin in human non-small cell lung cancer cells.  The cytotoxic effect of ceranib-2 (1-100μM) was detd. by MTT assay in human lung adenocarcinoma (A549) and large cell lung carcinoma (H460) cells.  Carboplatin (1-100μM) and lung bronchial epithelial cells (BEAS-2B) were used as pos. controls.  Morphol. and ultrastructural changes were analyzed by light microscope and TEM.  Apoptotic/necrotic cell death and acid ceramidase activity were analyzed by ELISA.  Combination effects of ceranib-2 and carboplatin were investigated by MTT.  The expression levels of CASP3, CASP9, BAX and BCL-2 were examd. by qRT-PCR.  The IC50 of ceranib-2 was detd. as 22μM in A549 cells and 8μM in H460 cells for 24 h.  Morphol. changes and induction of DNA fragmentation have revealed apoptotic effects of ceranib-2 in both cell lines.  Ceranib-2 and carboplatin has shown synergism in combined treatment at 10 and 25μM doses in H460 cells for 24 h.  Ceranib-2 inhibited acid ceramidase activity by 44% at 25μM in H460 cells.  Finally, CASP3, CASP9 and BAX expressions were increased while BCL-2 expression was reduced in both cells.  Our results obtained some preliminary results about the cytotoxic and apoptotic effects of ceranib-2 for the first time in NSCLC cell lines.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqDjZ_ufhN1cbVg90H21EOLACvtfcHk0ljhqaKLkpsv1A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhvFOmtLrM&md5=7f3de4445930da4a914fae8878a81965</span></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.1007%2Fs10616-017-0154-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10616-017-0154-8%26sid%3Dliteratum%253Aachs%26aulast%3DYildiz-Ozer%26aufirst%3DM.%26aulast%3DOztopcu-Vatan%26aufirst%3DP.%26aulast%3DKus%26aufirst%3DG.%26atitle%3DThe%2520investigation%2520of%2520ceranib-2%2520on%2520apoptosis%2520and%2520drug%2520interaction%2520with%2520carboplatin%2520in%2520human%2520non%2520small%2520cell%2520lung%2520cancer%2520cells%2520in%2520vitro%26jtitle%3DCytotechnology%26date%3D2018%26volume%3D70%26spage%3D387%26epage%3D396%26doi%3D10.1007%2Fs10616-017-0154-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref54"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref54'); return false;" data-citation="" class="refNumLink">54</a></strong><div class="NLM_citation" id="cit54"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cho, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, H. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, M.-W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kwon, H. J.</span></span> <span> </span><span class="NLM_article-title">A guanidine-based synthetic compound suppresses angiogenesis via inhibition of acid ceramidase</span>. <i>ACS Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">11</span>– <span class="NLM_lpage">19</span>, <span class="refDoi"> DOI: 10.1021/acschembio.8b00558</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acschembio.8b00558" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01561&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitlKmsbfI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2019&pages=11-19&author=S.+M.+Choauthor=H.+K.+Leeauthor=Q.+Liuauthor=M.-W.+Wangauthor=H.+J.+Kwon&title=A+guanidine-based+synthetic+compound+suppresses+angiogenesis+via+inhibition+of+acid+ceramidase&doi=10.1021%2Facschembio.8b00558"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit54R"><div class="casContent"><span class="casTitleNuber">54</span><div class="casTitle"><span class="NLM_cas:atitle">A Guanidine-Based Synthetic Compound Suppresses Angiogenesis via Inhibition of Acid Ceramidase</span></div><div class="casAuthors">Cho, Sung Min; Lee, Hyung Keun; Liu, Qing; Wang, Ming-Wei; Kwon, Ho Jeong</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Biology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">11-19</span>CODEN:
                <span class="NLM_cas:coden">ACBCCT</span>;
        ISSN:<span class="NLM_cas:issn">1554-8929</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Angiogenesis generates new blood vessels from pre-existing vessels.  Tumors induce the formation of new blood vessels to ensure sufficient oxygen and nutrients for their growth.  Normally, angiogenesis is induced by various pro-angiogenesis factors, including vascular endothelial growth factor (VEGF).  Inhibition of VEGF is a promising approach to cancer treatment.  A guanidine-based synthetic compd., E2, was identified as a potent hit from 68 guanidine-based derivs. by screening for angiogenesis inhibitors showing antiproliferative activity in human umbilical vein endothelial cells (HUVECs).  To explore the mode of action of E2(I), target proteins were investigated using phage display biopanning, and acid ceramidase 1 (ASAH1) was identified as an E2-binding protein.  Drug affinity responsive target stability (DARTS) and ASAH1 activity assays revealed the direct binding of E2 to ASAH1.  Moreover, siRNA knockdown of ASAH1 demonstrated its role as an angiogenesis factor.  Consequently, E2 inhibited chemoinvasion and tube formation of HUVECs in a dose-dependent manner.  E2 also potently suppressed neo-vascularization of chorioallantoic membranes in vivo.  Collectively, these data suggest that E2 is a novel angiogenesis inhibitor and ASAH1 is proposed to be a new antiangiogenesis target.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoNp2VCUdl057Vg90H21EOLACvtfcHk0ljhqaKLkpsv1A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitlKmsbfI&md5=8fe37e555f70ebc4cdd41431d10f48b5</span></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.1021%2Facschembio.8b00558&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facschembio.8b00558%26sid%3Dliteratum%253Aachs%26aulast%3DCho%26aufirst%3DS.%2BM.%26aulast%3DLee%26aufirst%3DH.%2BK.%26aulast%3DLiu%26aufirst%3DQ.%26aulast%3DWang%26aufirst%3DM.-W.%26aulast%3DKwon%26aufirst%3DH.%2BJ.%26atitle%3DA%2520guanidine-based%2520synthetic%2520compound%2520suppresses%2520angiogenesis%2520via%2520inhibition%2520of%2520acid%2520ceramidase%26jtitle%3DACS%2520Chem.%2520Biol.%26date%3D2019%26volume%3D14%26spage%3D11%26epage%3D19%26doi%3D10.1021%2Facschembio.8b00558" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref55"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref55'); return false;" data-citation="" class="refNumLink">55</a></strong><div class="NLM_citation" id="cit55"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Realini, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Solorzano, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pagliuca, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pizzirani, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Armirotti, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luciani, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Costi, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bandiera, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Piomelli, D.</span></span> <span> </span><span class="NLM_article-title">Discovery of highly potent acid ceramidase inhibitors with in vitro tumor chemosensitizing activity</span>. <i>Sci. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">1035</span>, <span class="refDoi"> DOI: 10.1038/srep01035</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01561&amp;key=10.1038%2Fsrep01035" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01561&amp;key=23301156" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01561&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtFaqt7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2013&pages=1035&author=N.+Realiniauthor=C.+Solorzanoauthor=C.+Pagliucaauthor=D.+Pizziraniauthor=A.+Armirottiauthor=R.+Lucianiauthor=M.+P.+Costiauthor=T.+Bandieraauthor=D.+Piomelli&title=Discovery+of+highly+potent+acid+ceramidase+inhibitors+with+in+vitro+tumor+chemosensitizing+activity&doi=10.1038%2Fsrep01035"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit55R"><div class="casContent"><span class="casTitleNuber">55</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of highly potent acid ceramidase inhibitors with in vitro tumor chemosensitizing activity</span></div><div class="casAuthors">Realini, Natalia; Solorzano, Carlos; Pagliuca, Chiara; Pizzirani, Daniela; Armirotti, Andrea; Luciani, Rosaria; Costi, Maria Paola; Bandiera, Tiziano; Piomelli, Daniele</div><div class="citationInfo"><span class="NLM_cas:title">Scientific Reports</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">srep01035, 7 pp.</span>CODEN:
                <span class="NLM_cas:coden">SRCEC3</span>;
        ISSN:<span class="NLM_cas:issn">2045-2322</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The expression of acid ceramidase (AC) - a cysteine amidase that hydrolyzes the proapoptotic lipid ceramide - is abnormally high in several human tumors, which is suggestive of a role in chemoresistance.  Available AC inhibitors lack, however, the potency and drug-likeness necessary to test this idea.  Here we show that the antineoplastic drug carmofur, which is used in the clinic to treat colorectal cancers, is a potent AC inhibitor and that this property is essential to its anti-proliferative effects.  Modifications in the chem. scaffold of carmofur yield new AC inhibitors that act synergistically with std. antitumoral drugs to prevent cancer cell proliferation.  These findings identify AC as an unexpected target for carmofur, and suggest that this mol. can be used as starting point for the design of novel chemosensitizing agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoknWbdLSLhRbVg90H21EOLACvtfcHk0ljUCGEngiSrqw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtFaqt7w%253D&md5=7ff74388fc2bea42c0e97fa8cbcfe61f</span></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.1038%2Fsrep01035&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsrep01035%26sid%3Dliteratum%253Aachs%26aulast%3DRealini%26aufirst%3DN.%26aulast%3DSolorzano%26aufirst%3DC.%26aulast%3DPagliuca%26aufirst%3DC.%26aulast%3DPizzirani%26aufirst%3DD.%26aulast%3DArmirotti%26aufirst%3DA.%26aulast%3DLuciani%26aufirst%3DR.%26aulast%3DCosti%26aufirst%3DM.%2BP.%26aulast%3DBandiera%26aufirst%3DT.%26aulast%3DPiomelli%26aufirst%3DD.%26atitle%3DDiscovery%2520of%2520highly%2520potent%2520acid%2520ceramidase%2520inhibitors%2520with%2520in%2520vitro%2520tumor%2520chemosensitizing%2520activity%26jtitle%3DSci.%2520Rep.%26date%3D2013%26volume%3D3%26spage%3D1035%26doi%3D10.1038%2Fsrep01035" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref56"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref56'); return false;" data-citation="" class="refNumLink">56</a></strong><div class="NLM_citation" id="cit56"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pizzirani, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pagliuca, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Realini, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Branduardi, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bottegoni, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mor, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bertozzi, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scarpelli, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Piomelli, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bandiera, T.</span></span> <span> </span><span class="NLM_article-title">Discovery of a new class of highly potent inhibitors of acid ceramidase: synthesis and structure–activity relationship (SAR)</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">3518</span>– <span class="NLM_lpage">3530</span>, <span class="refDoi"> DOI: 10.1021/jm301879g</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm301879g" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01561&amp;key=1%3ACAS%3A528%3ADC%252BC3sXms1Wjtbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=3518-3530&author=D.+Pizziraniauthor=C.+Pagliucaauthor=N.+Realiniauthor=D.+Branduardiauthor=G.+Bottegoniauthor=M.+Morauthor=F.+Bertozziauthor=R.+Scarpelliauthor=D.+Piomelliauthor=T.+Bandiera&title=Discovery+of+a+new+class+of+highly+potent+inhibitors+of+acid+ceramidase%3A+synthesis+and+structure%E2%80%93activity+relationship+%28SAR%29&doi=10.1021%2Fjm301879g"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit56R"><div class="casContent"><span class="casTitleNuber">56</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of a New Class of Highly Potent Inhibitors of Acid Ceramidase: Synthesis and Structure-Activity Relationship (SAR)</span></div><div class="casAuthors">Pizzirani, Daniela; Pagliuca, Chiara; Realini, Natalia; Branduardi, Davide; Bottegoni, Giovanni; Mor, Marco; Bertozzi, Fabio; Scarpelli, Rita; Piomelli, Daniele; Bandiera, Tiziano</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">3518-3530</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">1-(Alkylamino)-2,4-pyrimidinediones such as I [R = H, F, MeO, F3C, Ph; R1 = Me(CH2)nNH; R2 = H, Me, MeO2C; n = 5, 7] were prepd. as inhibitors of acid ceramidase for potential use as antitumor agents.  Uracils bearing an electron-withdrawing substituent at position 5, a substituent such as Me at position 3, and an alkylaminocarbonyl moiety with a six- to eight-carbon alkyl group at position 1 were the most effective inhibitors of acid ceramidase of the compds. tested.  The acid ceramidase inhibition and stability of an alkylaminopyrimidinedione was correlated with the stabilization of the antibonding orbital of its N1-carbonyl bond.  I (R = H, F, Ph; R2 = H, Me; n = 5, 7) inhibited a human cancer cell line (SW403) with IC50 values of 20-24 μM.  I (R = F, F3C, MeO; R2 = H, MeO2C; n = 5, 7) inhibited acid ceramidase with single digit-nanomolar IC50 values (IC50 = 4-7 nM).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrSG4lPgE1b1bVg90H21EOLACvtfcHk0ljUCGEngiSrqw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXms1Wjtbo%253D&md5=e8b1cb63aa40e8654de70985febc56dd</span></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=10.1021%2Fjm301879g&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm301879g%26sid%3Dliteratum%253Aachs%26aulast%3DPizzirani%26aufirst%3DD.%26aulast%3DPagliuca%26aufirst%3DC.%26aulast%3DRealini%26aufirst%3DN.%26aulast%3DBranduardi%26aufirst%3DD.%26aulast%3DBottegoni%26aufirst%3DG.%26aulast%3DMor%26aufirst%3DM.%26aulast%3DBertozzi%26aufirst%3DF.%26aulast%3DScarpelli%26aufirst%3DR.%26aulast%3DPiomelli%26aufirst%3DD.%26aulast%3DBandiera%26aufirst%3DT.%26atitle%3DDiscovery%2520of%2520a%2520new%2520class%2520of%2520highly%2520potent%2520inhibitors%2520of%2520acid%2520ceramidase%253A%2520synthesis%2520and%2520structure%25E2%2580%2593activity%2520relationship%2520%2528SAR%2529%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D3518%26epage%3D3530%26doi%3D10.1021%2Fjm301879g" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref57"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref57'); return false;" data-citation="" class="refNumLink">57</a></strong><div class="NLM_citation" id="cit57"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Diamanti, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bottegoni, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldoni, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Realini, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pagliuca, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bertozzi, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Piomelli, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pizzirani, D.</span></span> <span> </span><span class="NLM_article-title">Pyrazole-based acid ceramidase inhibitors: design, synthesis, and structure–activity relationships</span>. <i>Synthesis</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>48</i></span>,  <span class="NLM_fpage">2739</span>– <span class="NLM_lpage">2756</span>, <span class="refDoi"> DOI: 10.1055/s-0035-1561456</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01561&amp;key=10.1055%2Fs-0035-1561456" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01561&amp;key=1%3ACAS%3A528%3ADC%252BC28Xps1ahur0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2016&pages=2739-2756&author=E.+Diamantiauthor=G.+Bottegoniauthor=L.+Goldoniauthor=N.+Realiniauthor=C.+Pagliucaauthor=F.+Bertozziauthor=D.+Piomelliauthor=D.+Pizzirani&title=Pyrazole-based+acid+ceramidase+inhibitors%3A+design%2C+synthesis%2C+and+structure%E2%80%93activity+relationships&doi=10.1055%2Fs-0035-1561456"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit57R"><div class="casContent"><span class="casTitleNuber">57</span><div class="casTitle"><span class="NLM_cas:atitle">Pyrazole-Based Acid Ceramidase Inhibitors: Design, Synthesis, and Structure-Activity Relationships</span></div><div class="casAuthors">Diamanti, Eleonora; Bottegoni, Giovanni; Goldoni, Luca; Realini, Natalia; Pagliuca, Chiara; Bertozzi, Fabio; Piomelli, Daniele; Pizzirani, Daniela</div><div class="citationInfo"><span class="NLM_cas:title">Synthesis</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">48</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">2739-2756</span>CODEN:
                <span class="NLM_cas:coden">SYNTBF</span>;
        ISSN:<span class="NLM_cas:issn">1437-210X</span>.
    
            (<span class="NLM_cas:orgname">Georg Thieme Verlag</span>)
        </div><div class="casAbstract">Acid ceramidase (a.c.) is a lysosomal cysteine amidase responsible for the cleavage of ceramide into sphingosine, which is then phosphorylated to sphingosine 1-phosphate.  AC regulates the intracellular levels of ceramide and sphingosine, and a.c. inhibition may be useful in the treatment of disorders, such as cancer, in which ceramide-mediated signaling may be dysfunctional.  Despite their potential exptl. and therapeutic value, the no. of available small-mol. inhibitors of a.c. activity remains limited.  In the present study is described the discovery of a class of potent pyrazole carboxamide-based a.c. inhibitors, which were identified using the at. property field (APF) approach and developed through systematic SAR studies and in vitro pharmacol. characterization.  The best compd. of this series inhibits a.c. with nanomolar potency and causes ceramide accumulation and sphingosine depletion in intact G361 proliferative melanoma cells.  By expanding the current armamentarium of a.c. inhibitors, these results should facilitate future efforts to unravel the biol. of a.c. and the therapeutic potential of its inhibition.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpZ0V1BSSYCl7Vg90H21EOLACvtfcHk0ljQGGbmOmyNbA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xps1ahur0%253D&md5=3308bc4d0f16df0692358e6cc75235de</span></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=10.1055%2Fs-0035-1561456&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1055%252Fs-0035-1561456%26sid%3Dliteratum%253Aachs%26aulast%3DDiamanti%26aufirst%3DE.%26aulast%3DBottegoni%26aufirst%3DG.%26aulast%3DGoldoni%26aufirst%3DL.%26aulast%3DRealini%26aufirst%3DN.%26aulast%3DPagliuca%26aufirst%3DC.%26aulast%3DBertozzi%26aufirst%3DF.%26aulast%3DPiomelli%26aufirst%3DD.%26aulast%3DPizzirani%26aufirst%3DD.%26atitle%3DPyrazole-based%2520acid%2520ceramidase%2520inhibitors%253A%2520design%252C%2520synthesis%252C%2520and%2520structure%25E2%2580%2593activity%2520relationships%26jtitle%3DSynthesis%26date%3D2016%26volume%3D48%26spage%3D2739%26epage%3D2756%26doi%3D10.1055%2Fs-0035-1561456" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref58"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref58'); return false;" data-citation="" class="refNumLink">58</a></strong><div class="NLM_citation" id="cit58"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ortega, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arencibia, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">La Sala, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borgogno, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bauer, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bono, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Braccia, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Armirotti, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Girotto, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ganesan, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Vivo, M.</span></span> <span> </span><span class="NLM_article-title">Pharmacophore identification and scaffold exploration to discover novel, potent, and chemically stable inhibitors of acid ceramidase in melanoma cells</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">5800</span>– <span class="NLM_lpage">5815</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b00472</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b00472" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01561&amp;key=1%3ACAS%3A528%3ADC%252BC2sXpslSrsr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=5800-5815&author=J.+A.+Ortegaauthor=J.+M.+Arencibiaauthor=G.+La+Salaauthor=M.+Borgognoauthor=I.+Bauerauthor=L.+Bonoauthor=C.+Bracciaauthor=A.+Armirottiauthor=S.+Girottoauthor=A.+Ganesanauthor=M.+De+Vivo&title=Pharmacophore+identification+and+scaffold+exploration+to+discover+novel%2C+potent%2C+and+chemically+stable+inhibitors+of+acid+ceramidase+in+melanoma+cells&doi=10.1021%2Facs.jmedchem.7b00472"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit58R"><div class="casContent"><span class="casTitleNuber">58</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacophore Identification and Scaffold Exploration to Discover Novel, Potent, and Chemically Stable Inhibitors of Acid Ceramidase in Melanoma Cells</span></div><div class="casAuthors">Ortega, Jose Antonio; Arencibia, Jose M.; La Sala, Giuseppina; Borgogno, Marco; Bauer, Inga; Bono, Luca; Braccia, Clarissa; Armirotti, Andrea; Girotto, Stefania; Ganesan, Anand; De Vivo, Marco</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">5800-5815</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Acid ceramidase (AC) hydrolyzes ceramides, which are central lipid messengers for metab. and signaling of sphingolipids.  A growing body of evidence links deregulation of sphingolipids to several diseases, including cancer.  Indeed, AC expression is abnormally high in melanoma cells.  AC inhibition may thus be key to treating malignant melanoma.  Here, the authors have used a systematic scaffold exploration to design a general pharmacophore for AC inhibition.  This pharmacophore comprises a 6+5 fused ring heterocycle linked to an aliph. substituent via a urea moiety.  The authors have thus identified the novel benzimidazole derivs., which are highly potent AC inhibitors.  Their chem. and metabolic stability is comparable or superior to that of previously reported AC inhibitors.  Moreover, they are potent against endogenous AC in intact melanoma cells.  These novel inhibitors merit further characterization and can serve as a promising starting point for the discovery of new antimelanoma therapeutics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqsJbGrbc7g0bVg90H21EOLACvtfcHk0ljQGGbmOmyNbA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXpslSrsr4%253D&md5=9ad5f49ead19498e6080e7dbed47c5be</span></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b00472&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b00472%26sid%3Dliteratum%253Aachs%26aulast%3DOrtega%26aufirst%3DJ.%2BA.%26aulast%3DArencibia%26aufirst%3DJ.%2BM.%26aulast%3DLa%2BSala%26aufirst%3DG.%26aulast%3DBorgogno%26aufirst%3DM.%26aulast%3DBauer%26aufirst%3DI.%26aulast%3DBono%26aufirst%3DL.%26aulast%3DBraccia%26aufirst%3DC.%26aulast%3DArmirotti%26aufirst%3DA.%26aulast%3DGirotto%26aufirst%3DS.%26aulast%3DGanesan%26aufirst%3DA.%26aulast%3DDe%2BVivo%26aufirst%3DM.%26atitle%3DPharmacophore%2520identification%2520and%2520scaffold%2520exploration%2520to%2520discover%2520novel%252C%2520potent%252C%2520and%2520chemically%2520stable%2520inhibitors%2520of%2520acid%2520ceramidase%2520in%2520melanoma%2520cells%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26spage%3D5800%26epage%3D5815%26doi%3D10.1021%2Facs.jmedchem.7b00472" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref59"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref59'); return false;" data-citation="" class="refNumLink">59</a></strong><div class="NLM_citation" id="cit59"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pizzirani, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bach, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Realini, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Armirotti, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mengatto, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bauer, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Girotto, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pagliuca, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Vivo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Summa, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ribeiro, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Piomelli, D.</span></span> <span> </span><span class="NLM_article-title">Benzoxazolone carboxamides: potent and systemically active inhibitors of intracellular acid ceramidase</span>. <i>Angew. Chem., Int. Ed.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>127</i></span>,  <span class="NLM_fpage">495</span>– <span class="NLM_lpage">499</span>, <span class="refDoi"> DOI: 10.1002/ange.201409042</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01561&amp;key=10.1002%2Fange.201409042" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=127&publication_year=2015&pages=495-499&author=D.+Pizziraniauthor=A.+Bachauthor=N.+Realiniauthor=A.+Armirottiauthor=L.+Mengattoauthor=I.+Bauerauthor=S.+Girottoauthor=C.+Pagliucaauthor=M.+De+Vivoauthor=M.+Summaauthor=A.+Ribeiroauthor=D.+Piomelli&title=Benzoxazolone+carboxamides%3A+potent+and+systemically+active+inhibitors+of+intracellular+acid+ceramidase&doi=10.1002%2Fange.201409042"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=10.1002%2Fange.201409042&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fange.201409042%26sid%3Dliteratum%253Aachs%26aulast%3DPizzirani%26aufirst%3DD.%26aulast%3DBach%26aufirst%3DA.%26aulast%3DRealini%26aufirst%3DN.%26aulast%3DArmirotti%26aufirst%3DA.%26aulast%3DMengatto%26aufirst%3DL.%26aulast%3DBauer%26aufirst%3DI.%26aulast%3DGirotto%26aufirst%3DS.%26aulast%3DPagliuca%26aufirst%3DC.%26aulast%3DDe%2BVivo%26aufirst%3DM.%26aulast%3DSumma%26aufirst%3DM.%26aulast%3DRibeiro%26aufirst%3DA.%26aulast%3DPiomelli%26aufirst%3DD.%26atitle%3DBenzoxazolone%2520carboxamides%253A%2520potent%2520and%2520systemically%2520active%2520inhibitors%2520of%2520intracellular%2520acid%2520ceramidase%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2015%26volume%3D127%26spage%3D495%26epage%3D499%26doi%3D10.1002%2Fange.201409042" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref60"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref60'); return false;" data-citation="" class="refNumLink">60</a></strong><div class="NLM_citation" id="cit60"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bach, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pizzirani, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Realini, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vozella, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Russo, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Penna, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Melzig, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scarpelli, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Piomelli, D.</span></span> <span> </span><span class="NLM_article-title">Benzoxazolone carboxamides as potent acid ceramidase inhibitors: synthesis and structure–activity relationship (SAR) Studies</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">9258</span>– <span class="NLM_lpage">9272</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b01188</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b01188" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01561&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvVWnsbvI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=9258-9272&author=A.+Bachauthor=D.+Pizziraniauthor=N.+Realiniauthor=V.+Vozellaauthor=D.+Russoauthor=I.+Pennaauthor=L.+Melzigauthor=R.+Scarpelliauthor=D.+Piomelli&title=Benzoxazolone+carboxamides+as+potent+acid+ceramidase+inhibitors%3A+synthesis+and+structure%E2%80%93activity+relationship+%28SAR%29+Studies&doi=10.1021%2Facs.jmedchem.5b01188"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit60R"><div class="casContent"><span class="casTitleNuber">60</span><div class="casTitle"><span class="NLM_cas:atitle">Benzoxazolone Carboxamides as Potent Acid Ceramidase Inhibitors: Synthesis and Structure-Activity Relationship (SAR) Studies</span></div><div class="casAuthors">Bach, Anders; Pizzirani, Daniela; Realini, Natalia; Vozella, Valentina; Russo, Debora; Penna, Ilaria; Melzig, Laurin; Scarpelli, Rita; Piomelli, Daniele</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">9258-9272</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Ceramides are lipid-derived intracellular messengers involved in the control of senescence, inflammation, and apoptosis.  The cysteine amidase, acid ceramidase (AC), hydrolyzes these substances into sphingosine and fatty acid and, by doing so, regulates their signaling activity.  AC inhibitors may be useful in the treatment of pathol. conditions, such as cancer, in which ceramide levels are abnormally reduced.  Here, we present a systematic SAR investigation of the benzoxazolone carboxamides, a recently described class of AC inhibitors that display high potency and systemic activity in mice.  We examd. a diverse series of substitutions on both benzoxazolone ring and carboxamide side chain.  Several modifications enhanced potency and stability, and one key compd. with a balanced activity-stability profile I was found to inhibit AC activity in mouse lungs and cerebral cortex after systemic administration.  The results expand our arsenal of AC inhibitors, thereby facilitating the use of these compds. as pharmacol. tools and their potential development as drug leads.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoXKrFwyTWVt7Vg90H21EOLACvtfcHk0ljQGGbmOmyNbA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvVWnsbvI&md5=1b8de2b433b0e1b42299cf224d53e33a</span></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b01188&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b01188%26sid%3Dliteratum%253Aachs%26aulast%3DBach%26aufirst%3DA.%26aulast%3DPizzirani%26aufirst%3DD.%26aulast%3DRealini%26aufirst%3DN.%26aulast%3DVozella%26aufirst%3DV.%26aulast%3DRusso%26aufirst%3DD.%26aulast%3DPenna%26aufirst%3DI.%26aulast%3DMelzig%26aufirst%3DL.%26aulast%3DScarpelli%26aufirst%3DR.%26aulast%3DPiomelli%26aufirst%3DD.%26atitle%3DBenzoxazolone%2520carboxamides%2520as%2520potent%2520acid%2520ceramidase%2520inhibitors%253A%2520synthesis%2520and%2520structure%25E2%2580%2593activity%2520relationship%2520%2528SAR%2529%2520Studies%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D9258%26epage%3D9272%26doi%3D10.1021%2Facs.jmedchem.5b01188" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref61"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref61'); return false;" data-citation="" class="refNumLink">61</a></strong><div class="NLM_citation" id="cit61"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Di
Martino, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tardia, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cilibrasi, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caputo, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mazzonna, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Russo, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Penna, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Realini, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Margaroli, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Migliore, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pizzirani, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ottonello, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bertozzi, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Armirotti, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nguyen, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bongarzone, E. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lansbury, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Skerlj, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scarpelli, R.</span></span> <span> </span><span class="NLM_article-title">Lead optimization of benzoxazolone carboxamides as orally bioavailable and CNS penetrant acid ceramidase inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>63</i></span>,  <span class="NLM_fpage">3634</span>– <span class="NLM_lpage">3664</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.9b02004</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b02004" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01561&amp;key=1%3ACAS%3A528%3ADC%252BB3cXkvFyiur0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2020&pages=3634-3664&author=S.+Di%0AMartinoauthor=P.+Tardiaauthor=V.+Cilibrasiauthor=S.+Caputoauthor=M.+Mazzonnaauthor=D.+Russoauthor=I.+Pennaauthor=N.+Realiniauthor=N.+Margaroliauthor=M.+Miglioreauthor=D.+Pizziraniauthor=G.+Ottonelloauthor=S.+M.+Bertozziauthor=A.+Armirottiauthor=D.+Nguyenauthor=Y.+Sunauthor=E.+R.+Bongarzoneauthor=P.+Lansburyauthor=M.+Liuauthor=R.+Skerljauthor=R.+Scarpelli&title=Lead+optimization+of+benzoxazolone+carboxamides+as+orally+bioavailable+and+CNS+penetrant+acid+ceramidase+inhibitors&doi=10.1021%2Facs.jmedchem.9b02004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit61R"><div class="casContent"><span class="casTitleNuber">61</span><div class="casTitle"><span class="NLM_cas:atitle">Lead Optimization of Benzoxazolone Carboxamides as Orally Bioavailable and CNS Penetrant Acid Ceramidase Inhibitors</span></div><div class="casAuthors">Di Martino, Simona; Tardia, Piero; Cilibrasi, Vincenzo; Caputo, Samantha; Mazzonna, Marco; Russo, Debora; Penna, Ilaria; Realini, Natalia; Margaroli, Natasha; Migliore, Marco; Pizzirani, Daniela; Ottonello, Giuliana; Bertozzi, Sine Mandrup; Armirotti, Andrea; Nguyen, Duc; Sun, Ying; Bongarzone, Ernesto R.; Lansbury, Peter; Liu, Min; Skerlj, Renato; Scarpelli, Rita</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">3634-3664</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Sphingolipids (SphLs) are a diverse class of mols. that are regulated by a complex network of enzymic pathways.  A disturbance in these pathways leads to lipid accumulation and initiation of several SphL-related disorders.  Acid ceramidase is one of the key enzymes that regulate the metab. of ceramides and glycosphingolipids, which are important members of the SphL family.  Herein, we describe the lead optimization studies of benzoxazolone carboxamides resulting in piperidine 22m(), where we demonstrated target engagement in two animal models of neuropathic lysosomal storage diseases (LSDs), Gaucher's and Krabbe's diseases.  After daily i.p. administration at 90 mg kg-1, 22m significantly reduced the brain levels of the toxic lipids glucosylsphingosine (GluSph) in 4L;C* mice and galactosylsphingosine (GalSph) in Twitcher mice.  We believe that 22m is a lead mol. that can be further developed for the correction of severe neurol. LSDs where GluSph or GalSph play a significant role in disease pathogenesis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGocXf_shVZ0drVg90H21EOLACvtfcHk0liQGlmxK_rbhQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXkvFyiur0%253D&md5=ef0b0dbe54b610f1c28634d5337d5ce3</span></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b02004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b02004%26sid%3Dliteratum%253Aachs%26aulast%3DDi%2BMartino%26aufirst%3DS.%26aulast%3DTardia%26aufirst%3DP.%26aulast%3DCilibrasi%26aufirst%3DV.%26aulast%3DCaputo%26aufirst%3DS.%26aulast%3DMazzonna%26aufirst%3DM.%26aulast%3DRusso%26aufirst%3DD.%26aulast%3DPenna%26aufirst%3DI.%26aulast%3DRealini%26aufirst%3DN.%26aulast%3DMargaroli%26aufirst%3DN.%26aulast%3DMigliore%26aufirst%3DM.%26aulast%3DPizzirani%26aufirst%3DD.%26aulast%3DOttonello%26aufirst%3DG.%26aulast%3DBertozzi%26aufirst%3DS.%2BM.%26aulast%3DArmirotti%26aufirst%3DA.%26aulast%3DNguyen%26aufirst%3DD.%26aulast%3DSun%26aufirst%3DY.%26aulast%3DBongarzone%26aufirst%3DE.%2BR.%26aulast%3DLansbury%26aufirst%3DP.%26aulast%3DLiu%26aufirst%3DM.%26aulast%3DSkerlj%26aufirst%3DR.%26aulast%3DScarpelli%26aufirst%3DR.%26atitle%3DLead%2520optimization%2520of%2520benzoxazolone%2520carboxamides%2520as%2520orally%2520bioavailable%2520and%2520CNS%2520penetrant%2520acid%2520ceramidase%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2020%26volume%3D63%26spage%3D3634%26epage%3D3664%26doi%3D10.1021%2Facs.jmedchem.9b02004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref62"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref62'); return false;" data-citation="" class="refNumLink">62</a></strong><div class="NLM_citation" id="cit62"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dong, X.-Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X.</span></span> <span> </span><span class="NLM_article-title">New synthetic strategy for chiral 2-oxazolidinones derivatives via rhodium-catalyzed asymmetric hydrogenation</span>. <i>Tetrahedron Lett.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">658</span>– <span class="NLM_lpage">662</span>, <span class="refDoi"> DOI: 10.1016/j.tetlet.2015.12.105</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01561&amp;key=10.1016%2Fj.tetlet.2015.12.105" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01561&amp;key=1%3ACAS%3A528%3ADC%252BC28XnsF2gsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2016&pages=658-662&author=Q.+Wangauthor=X.+Tanauthor=Z.+Zhuauthor=X.-Q.+Dongauthor=X.+Zhang&title=New+synthetic+strategy+for+chiral+2-oxazolidinones+derivatives+via+rhodium-catalyzed+asymmetric+hydrogenation&doi=10.1016%2Fj.tetlet.2015.12.105"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit62R"><div class="casContent"><span class="casTitleNuber">62</span><div class="casTitle"><span class="NLM_cas:atitle">New synthetic strategy for chiral 2-oxazolidinones derivatives via rhodium-catalyzed asymmetric hydrogenation</span></div><div class="casAuthors">Wang, Qingli; Tan, Xuefeng; Zhu, Ziyue; Dong, Xiu-Qin; Zhang, Xumu</div><div class="citationInfo"><span class="NLM_cas:title">Tetrahedron Letters</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">658-662</span>CODEN:
                <span class="NLM_cas:coden">TELEAY</span>;
        ISSN:<span class="NLM_cas:issn">0040-4039</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Asym. hydrogenation of 4-substituted cyclic enamido esters catalyzed by a rhodium-TangPhos complex provides an efficient method for the synthesis of chiral 4-substituted oxazolinones with excellent yields and good enantioselectivities.  The products are valuable chiral building blocks and the applications as chiral auxiliaries and pharmaceuticals are well-known.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoqPTQAbbn24LVg90H21EOLACvtfcHk0liQGlmxK_rbhQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XnsF2gsg%253D%253D&md5=0ae31b529dbadfcb4202127e4d90a417</span></div><a href="/servlet/linkout?suffix=cit62&amp;dbid=16384&amp;doi=10.1016%2Fj.tetlet.2015.12.105&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tetlet.2015.12.105%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DQ.%26aulast%3DTan%26aufirst%3DX.%26aulast%3DZhu%26aufirst%3DZ.%26aulast%3DDong%26aufirst%3DX.-Q.%26aulast%3DZhang%26aufirst%3DX.%26atitle%3DNew%2520synthetic%2520strategy%2520for%2520chiral%25202-oxazolidinones%2520derivatives%2520via%2520rhodium-catalyzed%2520asymmetric%2520hydrogenation%26jtitle%3DTetrahedron%2520Lett.%26date%3D2016%26volume%3D57%26spage%3D658%26epage%3D662%26doi%3D10.1016%2Fj.tetlet.2015.12.105" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref63"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref63'); return false;" data-citation="" class="refNumLink">63</a></strong><div class="NLM_citation" id="cit63"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Brown, M. L.</span>; <span class="NLM_string-name">Cheung, M.</span>; <span class="NLM_string-name">Dickerson, S. H.</span>; <span class="NLM_string-name">Gauthier, C.</span>; <span class="NLM_string-name">Harris, P. A.</span>; <span class="NLM_string-name">Hunter, R. N.</span>; <span class="NLM_string-name">Pacofsky, G.</span>; <span class="NLM_string-name">Peel, M. R.</span>; <span class="NLM_string-name">Stafford, J. A.</span></span> <span> </span><span class="NLM_article-title">Chemical compounds</span>. <span class="NLM_patent">WO 2004032882 A2</span>, <span class="NLM_year">2004</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2004&author=M.+L.+Brown&author=M.+Cheung&author=S.+H.+Dickerson&author=C.+Gauthier&author=P.+A.+Harris&author=R.+N.+Hunter&author=G.+Pacofsky&author=M.+R.+Peel&author=J.+A.+Stafford&title=Chemical+compounds"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit63&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DBrown%26aufirst%3DM.%2BL.%26atitle%3DChemical%2520compounds%26date%3D2004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref64"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref64'); return false;" data-citation="" class="refNumLink">64</a></strong><div class="NLM_citation" id="cit64"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Knölker, H.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Braxmeier, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schlechtingen, G.</span></span> <span> </span><span class="NLM_article-title">A Novel method for the synthesis of isocyanates under mild conditions</span>. <i>Angew. Chem., Int. Ed.</i> <span class="NLM_year" style="font-weight: bold;">1995</span>,  <span class="NLM_volume"><i>34</i></span>,  <span class="NLM_fpage">2497</span>– <span class="NLM_lpage">2500</span>, <span class="refDoi"> DOI: 10.1002/anie.199524971</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01561&amp;key=10.1002%2Fanie.199524971" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=1995&pages=2497-2500&author=H.-J.+Kn%C3%B6lkerauthor=T.+Braxmeierauthor=G.+Schlechtingen&title=A+Novel+method+for+the+synthesis+of+isocyanates+under+mild+conditions&doi=10.1002%2Fanie.199524971"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit64&amp;dbid=16384&amp;doi=10.1002%2Fanie.199524971&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.199524971%26sid%3Dliteratum%253Aachs%26aulast%3DKn%25C3%25B6lker%26aufirst%3DH.-J.%26aulast%3DBraxmeier%26aufirst%3DT.%26aulast%3DSchlechtingen%26aufirst%3DG.%26atitle%3DA%2520Novel%2520method%2520for%2520the%2520synthesis%2520of%2520isocyanates%2520under%2520mild%2520conditions%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D1995%26volume%3D34%26spage%3D2497%26epage%3D2500%26doi%3D10.1002%2Fanie.199524971" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref65"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref65'); return false;" data-citation="" class="refNumLink">65</a></strong><div class="NLM_citation" id="cit65"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Eckert, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Forster, B.</span></span> <span> </span><span class="NLM_article-title">Triphosgene, a crystalline phosgene substitute</span>. <i>Angew. Chem., Int. Ed.</i> <span class="NLM_year" style="font-weight: bold;">1987</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">894</span>– <span class="NLM_lpage">895</span>, <span class="refDoi"> DOI: 10.1002/anie.198708941</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01561&amp;key=10.1002%2Fanie.198708941" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=1987&pages=894-895&author=H.+Eckertauthor=B.+Forster&title=Triphosgene%2C+a+crystalline+phosgene+substitute&doi=10.1002%2Fanie.198708941"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit65&amp;dbid=16384&amp;doi=10.1002%2Fanie.198708941&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.198708941%26sid%3Dliteratum%253Aachs%26aulast%3DEckert%26aufirst%3DH.%26aulast%3DForster%26aufirst%3DB.%26atitle%3DTriphosgene%252C%2520a%2520crystalline%2520phosgene%2520substitute%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D1987%26volume%3D26%26spage%3D894%26epage%3D895%26doi%3D10.1002%2Fanie.198708941" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref66"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref66'); return false;" data-citation="" class="refNumLink">66</a></strong><div class="NLM_citation" id="cit66"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Guha, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baik, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koo, S.</span></span> <span> </span><span class="NLM_article-title">TMS·OTf-catalyzed α-bromination of carbonyl compounds by N-bromosuccinimide</span>. <i>Tetrahedron Lett.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>47</i></span>,  <span class="NLM_fpage">291</span>– <span class="NLM_lpage">293</span>, <span class="refDoi"> DOI: 10.1016/j.tetlet.2005.11.023</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01561&amp;key=10.1016%2Fj.tetlet.2005.11.023" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01561&amp;key=1%3ACAS%3A528%3ADC%252BD2MXht12qsbrL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2006&pages=291-293&author=S.+K.+Guhaauthor=B.+Wuauthor=B.+S.+Kimauthor=W.+Baikauthor=S.+Koo&title=TMS%C2%B7OTf-catalyzed+%CE%B1-bromination+of+carbonyl+compounds+by+N-bromosuccinimide&doi=10.1016%2Fj.tetlet.2005.11.023"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit66R"><div class="casContent"><span class="casTitleNuber">66</span><div class="casTitle"><span class="NLM_cas:atitle">TMS·OTf-catalyzed α-bromination of carbonyl compounds by N-bromosuccinimide</span></div><div class="casAuthors">Guha, Samar Kumar; Wu, Bo; Kim, Beom Soo; Baik, Woonphil; Koo, Sangho</div><div class="citationInfo"><span class="NLM_cas:title">Tetrahedron Letters</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">47</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">291-293</span>CODEN:
                <span class="NLM_cas:coden">TELEAY</span>;
        ISSN:<span class="NLM_cas:issn">0040-4039</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Various carbonyl compds. undergo α-bromination reaction under a mild and practical condition utilizing N-bromosuccinimide (NBS), catalyzed by trimethylsilyl trifluoromethanesulfonate (TMS.OTf).  This method is also effective for the side-chain bromination of heteroarom. carbonyl compds. without the ring brominations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrU1RgBMEwTt7Vg90H21EOLACvtfcHk0ljSPwbp7x2o-w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXht12qsbrL&md5=53bcb50f555bd780cde04e6d513564dd</span></div><a href="/servlet/linkout?suffix=cit66&amp;dbid=16384&amp;doi=10.1016%2Fj.tetlet.2005.11.023&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tetlet.2005.11.023%26sid%3Dliteratum%253Aachs%26aulast%3DGuha%26aufirst%3DS.%2BK.%26aulast%3DWu%26aufirst%3DB.%26aulast%3DKim%26aufirst%3DB.%2BS.%26aulast%3DBaik%26aufirst%3DW.%26aulast%3DKoo%26aufirst%3DS.%26atitle%3DTMS%25C2%25B7OTf-catalyzed%2520%25CE%25B1-bromination%2520of%2520carbonyl%2520compounds%2520by%2520N-bromosuccinimide%26jtitle%3DTetrahedron%2520Lett.%26date%3D2006%26volume%3D47%26spage%3D291%26epage%3D293%26doi%3D10.1016%2Fj.tetlet.2005.11.023" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref67"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref67'); return false;" data-citation="" class="refNumLink">67</a></strong><div class="NLM_citation" id="cit67"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dementiev, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joachimiak, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nguyen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gorelik, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Illes, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shabani, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gelsomino, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahn, E.-Y. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagar, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doan, N.</span></span> <span> </span><span class="NLM_article-title">Molecular mechanism of inhibition of acid ceramidase by carmofur</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">987</span>– <span class="NLM_lpage">992</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b01723</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b01723" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01561&amp;key=1%3ACAS%3A528%3ADC%252BC1cXisVGnsLrE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=987-992&author=A.+Dementievauthor=A.+Joachimiakauthor=H.+Nguyenauthor=A.+Gorelikauthor=K.+Illesauthor=S.+Shabaniauthor=M.+Gelsominoauthor=E.-Y.+E.+Ahnauthor=B.+Nagarauthor=N.+Doan&title=Molecular+mechanism+of+inhibition+of+acid+ceramidase+by+carmofur&doi=10.1021%2Facs.jmedchem.8b01723"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit67R"><div class="casContent"><span class="casTitleNuber">67</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular mechanism of inhibition of acid ceramidase by carmofur</span></div><div class="casAuthors">Dementiev, Alexey; Joachimiak, Andrzej; Nguyen, Ha; Gorelik, Alexei; Illes, Katalin; Shabani, Saman; Gelsomino, Michael; Ahn, Eun-Young Erin; Nagar, Bhushan; Doan, Ninh</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">987-992</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Human acid ceramidase (AC) is a lysosomal cysteine amidase, which has received a great deal of interest in recent years as a potential target for the development of new therapeutics against melanoma and glioblastoma tumors.  Despite the strong interest in obtaining structural information, only the structures of the apo-AC enzyme in its zymogen and activated conformations are available.  In this work, the crystal structure of AC in complex with the covalent carmofur inhibitor is presented.  Carmofur (1-hexylcarbamoyl-5-fluorouracil) is an antineoplastic drug contg. an electrophilic carbonyl reactive group that targets the catalytic cysteine.  This novel structural data explains the basis of the AC inhibition, provides insights into the enzymic properties of the protein, and is a great aid toward the structure-based drug design of potent inhibitors for AC, providing the detailed mechanism, which has eluded the scientific community for more than 30 years, of carmofur's mysterious 5-fluorouracil-independent antitumor activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqLv97-NENYSbVg90H21EOLACvtfcHk0ljSPwbp7x2o-w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXisVGnsLrE&md5=b88fa5e1014bc879d160e210dd1c2dfa</span></div><a href="/servlet/linkout?suffix=cit67&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b01723&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b01723%26sid%3Dliteratum%253Aachs%26aulast%3DDementiev%26aufirst%3DA.%26aulast%3DJoachimiak%26aufirst%3DA.%26aulast%3DNguyen%26aufirst%3DH.%26aulast%3DGorelik%26aufirst%3DA.%26aulast%3DIlles%26aufirst%3DK.%26aulast%3DShabani%26aufirst%3DS.%26aulast%3DGelsomino%26aufirst%3DM.%26aulast%3DAhn%26aufirst%3DE.-Y.%2BE.%26aulast%3DNagar%26aufirst%3DB.%26aulast%3DDoan%26aufirst%3DN.%26atitle%3DMolecular%2520mechanism%2520of%2520inhibition%2520of%2520acid%2520ceramidase%2520by%2520carmofur%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26spage%3D987%26epage%3D992%26doi%3D10.1021%2Facs.jmedchem.8b01723" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref68"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref68'); return false;" data-citation="" class="refNumLink">68</a></strong><div class="NLM_citation" id="cit68"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ishikawa, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hashimoto, Y.</span></span> <span> </span><span class="NLM_article-title">Improvement in aqueous solubility in small molecule drug discovery programs by disruption of molecular planarity and symmetry</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>54</i></span>,  <span class="NLM_fpage">1539</span>– <span class="NLM_lpage">1554</span>, <span class="refDoi"> DOI: 10.1021/jm101356p</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm101356p" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01561&amp;key=1%3ACAS%3A528%3ADC%252BC3MXisVWltLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=1539-1554&author=M.+Ishikawaauthor=Y.+Hashimoto&title=Improvement+in+aqueous+solubility+in+small+molecule+drug+discovery+programs+by+disruption+of+molecular+planarity+and+symmetry&doi=10.1021%2Fjm101356p"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit68R"><div class="casContent"><span class="casTitleNuber">68</span><div class="casTitle"><span class="NLM_cas:atitle">Improvement in Aqueous Solubility in Small Molecule Drug Discovery Programs by Disruption of Molecular Planarity and Symmetry</span></div><div class="casAuthors">Ishikawa, Minoru; Hashimoto, Yuichi</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1539-1554</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpKbtbfvqKZjrVg90H21EOLACvtfcHk0ljSPwbp7x2o-w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXisVWltLw%253D&md5=a88804b3850625ef9c3f7424366acb91</span></div><a href="/servlet/linkout?suffix=cit68&amp;dbid=16384&amp;doi=10.1021%2Fjm101356p&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm101356p%26sid%3Dliteratum%253Aachs%26aulast%3DIshikawa%26aufirst%3DM.%26aulast%3DHashimoto%26aufirst%3DY.%26atitle%3DImprovement%2520in%2520aqueous%2520solubility%2520in%2520small%2520molecule%2520drug%2520discovery%2520programs%2520by%2520disruption%2520of%2520molecular%2520planarity%2520and%2520symmetry%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D1539%26epage%3D1554%26doi%3D10.1021%2Fjm101356p" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref69"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref69'); return false;" data-citation="" class="refNumLink">69</a></strong><div class="NLM_citation" id="cit69"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gorelik, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gebai, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Illes, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Piomelli, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagar, B.</span></span> <span> </span><span class="NLM_article-title">Molecular mechanism of activation of the immunoregulatory amidase NAAA</span>. <i>Proc. Natl. Acad. Sci. U.S.A.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>115</i></span>,  <span class="NLM_fpage">E10032</span>– <span class="NLM_lpage">E10040</span>, <span class="refDoi"> DOI: 10.1073/pnas.1811759115</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01561&amp;key=10.1073%2Fpnas.1811759115" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01561&amp;key=30301806" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01561&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitVyhsLvP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=115&publication_year=2018&pages=E10032-E10040&author=A.+Gorelikauthor=A.+Gebaiauthor=K.+Illesauthor=D.+Piomelliauthor=B.+Nagar&title=Molecular+mechanism+of+activation+of+the+immunoregulatory+amidase+NAAA&doi=10.1073%2Fpnas.1811759115"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit69R"><div class="casContent"><span class="casTitleNuber">69</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular mechanism of activation of the immunoregulatory amidase NAAA</span></div><div class="casAuthors">Gorelik, Alexei; Gebai, Ahmad; Illes, Katalin; Piomelli, Daniele; Nagar, Bhushan</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">115</span>
        (<span class="NLM_cas:issue">43</span>),
    <span class="NLM_cas:pages">E10032-E10040</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Palmitoylethanolamide is a bioactive lipid that strongly alleviates pain and inflammation in animal models and in humans.  Its signaling activity is terminated through degrdn. by N-acylethanolamine acid amidase (NAAA), a cysteine hydrolase expressed at high levels in immune cells.  Pharmacol. inhibitors of NAAA activity exert profound analgesic and antiinflammatory effects in rodent models, pointing to this protein as a potential target for therapeutic drug discovery.  To facilitate these efforts and to better understand the mol. mechanism of action of NAAA, we detd. crystal structures of this enzyme in various activation states and in complex with several ligands, including both a covalent and a reversible inhibitor.  Self-proteolysis exposes the otherwise buried active site of NAAA to allow catalysis.  Formation of a stable substrate- or inhibitor-binding site appears to be conformationally coupled to the interaction of a pair of hydrophobic helixes in the enzyme with lipid membranes, resulting in the creation of a linear hydrophobic cavity near the active site that accommodates the liganda's acyl chain.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpe4SyudaY7MrVg90H21EOLACvtfcHk0lh3gRWPaH23Cg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitVyhsLvP&md5=9debd68d3239a82bd60849c9cf98e8ae</span></div><a href="/servlet/linkout?suffix=cit69&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1811759115&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1811759115%26sid%3Dliteratum%253Aachs%26aulast%3DGorelik%26aufirst%3DA.%26aulast%3DGebai%26aufirst%3DA.%26aulast%3DIlles%26aufirst%3DK.%26aulast%3DPiomelli%26aufirst%3DD.%26aulast%3DNagar%26aufirst%3DB.%26atitle%3DMolecular%2520mechanism%2520of%2520activation%2520of%2520the%2520immunoregulatory%2520amidase%2520NAAA%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2018%26volume%3D115%26spage%3DE10032%26epage%3DE10040%26doi%3D10.1073%2Fpnas.1811759115" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref70"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref70'); return false;" data-citation="" class="refNumLink">70</a></strong><div class="NLM_citation" id="cit70"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kovalevich, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Langford, D.</span></span> <span> </span><span class="NLM_article-title">Considerations for the use of SH-SY5Y neuroblastoma cells in neurobiology</span>. <i>Methods Mol. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>1078</i></span>,  <span class="NLM_fpage">9</span>– <span class="NLM_lpage">21</span>, <span class="refDoi"> DOI: 10.1007/978-1-62703-640-5_2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01561&amp;key=10.1007%2F978-1-62703-640-5_2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01561&amp;key=23975817" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01561&amp;key=1%3ACAS%3A528%3ADC%252BC2MXjsFOhsb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1078&publication_year=2013&pages=9-21&author=J.+Kovalevichauthor=D.+Langford&title=Considerations+for+the+use+of+SH-SY5Y+neuroblastoma+cells+in+neurobiology&doi=10.1007%2F978-1-62703-640-5_2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit70R"><div class="casContent"><span class="casTitleNuber">70</span><div class="casTitle"><span class="NLM_cas:atitle">Considerations for the Use of SH - SY5Y Neuroblastoma Cells in Neurobiology</span></div><div class="casAuthors">Kovalevich, Jane; Langford, Dianne</div><div class="citationInfo"><span class="NLM_cas:title">Methods in Molecular Biology (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">1078</span>
        (<span class="NLM_cas:issue">Neuronal Cell Culture</span>),
    <span class="NLM_cas:pages">9-21</span>CODEN:
                <span class="NLM_cas:coden">MMBIED</span>;
        ISSN:<span class="NLM_cas:issn">1064-3745</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">The use of primary mammalian neurons derived from embryonic central nervous system tissue is limited by the fact that once terminally differentiated into mature neurons, the cells can no longer be propagated.  Transformed neuronal-like cell lines can be used in vitro to overcome this limitation.  However, several caveats exist when utilizing cells derived from malignant tumors.  In this context, the popular SH - SY5Y neuroblastoma cell line and its use in in vitro systems is described.  Originally derived from a metastatic bone tumor biopsy, SH - SY5Y (ATCC CRL-2266) cells are a subline of the parental line SK - N - SH (ATCC HTB-11).  SK-N-SH were subcloned three times; first to SH - SY , then to SH - SY5 , and finally to SH - SY5Y .  SH - SY5Y were deposited to the ATCC in 1970 by June L.  Biedler.Three important characteristics of SH - SY5Y cells should be considered when using these cells in in vitro studies.  First, cultures include both adherent and floating cells, both types of which are viable.  Few studies address the biol. significance of the adherent vs. floating phenotypes, but most reported studies utilize adherent populations and discard the floating cells during media changes.  Second, early studies by Biedler's group indicated that the parental differentiated SK - N - SH cells contained two morphol. distinct phenotypes: neuroblast-like cells and epithelial-like cells (Ross et al., J Nat Cancer Inst 71:741-747, 1983).  These two phenotypes may correspond to the "N" and "S" types described in later studies in SH - SY5Y by Encinas et al. (J Neurochem 75:991-1003, 2000).  Cells with neuroblast-like morphol. are pos. for tyrosine hydroxylase (TH) and dopamine-β-hydroxylase characteristic of catecholaminergic neurons, whereas the epithelial-like counterpart cells lacked these enzymic activities (Ross et al., J Nat Cancer Inst 71:741-747, 1983).  Third, SH - SY5Y cells can be differentiated to a more mature neuron-like phenotype that is characterized by neuronal markers.  There are several methods to differentiate SH - SY5Y cells and are mentioned below.  Retinoic acid is the most commonly used means for differentiation and will be addressed in detail.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrCVTav2R1Mr7Vg90H21EOLACvtfcHk0lh3gRWPaH23Cg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXjsFOhsb8%253D&md5=c4b1a3d107c070810b83efd461a2d0ec</span></div><a href="/servlet/linkout?suffix=cit70&amp;dbid=16384&amp;doi=10.1007%2F978-1-62703-640-5_2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252F978-1-62703-640-5_2%26sid%3Dliteratum%253Aachs%26aulast%3DKovalevich%26aufirst%3DJ.%26aulast%3DLangford%26aufirst%3DD.%26atitle%3DConsiderations%2520for%2520the%2520use%2520of%2520SH-SY5Y%2520neuroblastoma%2520cells%2520in%2520neurobiology%26jtitle%3DMethods%2520Mol.%2520Biol.%26date%3D2013%26volume%3D1078%26spage%3D9%26epage%3D21%26doi%3D10.1007%2F978-1-62703-640-5_2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref71"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref71'); return false;" data-citation="" class="refNumLink">71</a></strong><div class="NLM_citation" id="cit71"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xicoy, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wieringa, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martens, G. J.</span></span> <span> </span><span class="NLM_article-title">The SH-SY5Y cell line in Parkinson’s disease research: a systematic review</span>. <i>Mol. Neurodegener.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">10</span>– <span class="NLM_lpage">20</span>, <span class="refDoi"> DOI: 10.1186/s13024-017-0149-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01561&amp;key=10.1186%2Fs13024-017-0149-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01561&amp;key=28118852" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01561&amp;key=1%3ACAS%3A528%3ADC%252BC1cXjsFGitLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2017&pages=10-20&author=H.+Xicoyauthor=B.+Wieringaauthor=G.+J.+Martens&title=The+SH-SY5Y+cell+line+in+Parkinson%E2%80%99s+disease+research%3A+a+systematic+review&doi=10.1186%2Fs13024-017-0149-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit71R"><div class="casContent"><span class="casTitleNuber">71</span><div class="casTitle"><span class="NLM_cas:atitle">The SH-SY5Y cell line in Parkinson's disease research: a systematic review</span></div><div class="casAuthors">Xicoy, Helena; Wieringa, Be; Martens, Gerard J. M.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Neurodegeneration</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">10/1-10/11</span>CODEN:
                <span class="NLM_cas:coden">MNOEAZ</span>;
        ISSN:<span class="NLM_cas:issn">1750-1326</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">Parkinson's disease (PD) is a devastating and highly prevalent neurodegenerative disease for which only symptomatic treatment is available.  In order to develop a truly effective disease-modifying therapy, improvement of our current understanding of the mol. and cellular mechanisms underlying PD pathogenesis and progression is crucial.  For this purpose, standardization of research protocols and disease models is necessary.  As human dopaminergic neurons, the cells mainly affected in PD, are difficult to obtain and maintain as primary cells, current PD research is mostly performed with permanently established neuronal cell models, in particular the neuroblastoma SH-SY5Y lineage.  This cell line is frequently chosen because of its human origin, catecholaminergic (though not strictly dopaminergic) neuronal properties, and ease of maintenance.  However, there is no consensus on many fundamental aspects that are assocd. with its use, such as the effects of culture media compn. and of variations in differentiation protocols.  Here we present the outcome of a systematic review of scientific articles that have used SH-SY5Y cells to explore PD.  We describe the cell source, culture conditions, differentiation protocols, methods/approaches used to mimic PD and the preclin. validation of the SH-SY5Y findings by employing alternative cellular and animal models.  Thus, this overview may help to standardize the use of the SH-SY5Y cell line in PD research and serve as a future user's guide.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrZVJyPwUVS5LVg90H21EOLACvtfcHk0lh3gRWPaH23Cg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXjsFGitLs%253D&md5=829cd2918af329627c201c6c0fc859d4</span></div><a href="/servlet/linkout?suffix=cit71&amp;dbid=16384&amp;doi=10.1186%2Fs13024-017-0149-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs13024-017-0149-0%26sid%3Dliteratum%253Aachs%26aulast%3DXicoy%26aufirst%3DH.%26aulast%3DWieringa%26aufirst%3DB.%26aulast%3DMartens%26aufirst%3DG.%2BJ.%26atitle%3DThe%2520SH-SY5Y%2520cell%2520line%2520in%2520Parkinson%25E2%2580%2599s%2520disease%2520research%253A%2520a%2520systematic%2520review%26jtitle%3DMol.%2520Neurodegener.%26date%3D2017%26volume%3D12%26spage%3D10%26epage%3D20%26doi%3D10.1186%2Fs13024-017-0149-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref72"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref72'); return false;" data-citation="" class="refNumLink">72</a></strong><div class="NLM_citation" id="cit72"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kyriakou, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lederer, C. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kleanthous, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drousiotou, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Malekkou, A.</span></span> <span> </span><span class="NLM_article-title">Acid ceramidase depletion impairs neuronal survival and induces morphological defects in neurites associated with altered gene transcription and sphingolipid content</span>. <i>Int. J. Mol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">1607</span>– <span class="NLM_lpage">1631</span>, <span class="refDoi"> DOI: 10.3390/ijms21051607</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01561&amp;key=10.3390%2Fijms21051607" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01561&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhvVaqtLzP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2020&pages=1607-1631&author=K.+Kyriakouauthor=C.+W.+Ledererauthor=M.+Kleanthousauthor=A.+Drousiotouauthor=A.+Malekkou&title=Acid+ceramidase+depletion+impairs+neuronal+survival+and+induces+morphological+defects+in+neurites+associated+with+altered+gene+transcription+and+sphingolipid+content&doi=10.3390%2Fijms21051607"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit72R"><div class="casContent"><span class="casTitleNuber">72</span><div class="casTitle"><span class="NLM_cas:atitle">Acid ceramidase depletion impairs neuronal survival and induces morphological defects in neurites associated with altered gene transcription and sphingolipid content</span></div><div class="casAuthors">Kyriakou, Kalia; Lederer, Carsten W.; Kleanthous, Marina; Drousiotou, Anthi; Malekkou, Anna</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Molecular Sciences</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1607</span>CODEN:
                <span class="NLM_cas:coden">IJMCFK</span>;
        ISSN:<span class="NLM_cas:issn">1422-0067</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">The ASAH1 gene encodes acid ceramidase (AC), an enzyme that is implicated in the metab. of ceramide (Cer).  Mutations in the ASAH1 gene cause two different disorders, Farber disease (FD), a rare lysosomal storage disorder, and a rare form of spinal muscular atrophy combined with progressive myoclonic epilepsy (SMA-PME).  In the absence of human in vitro neuronal disease models and to gain mechanistic insights into pathol. effects of ASAH1 deficiency, we established and characterized a stable ASAH1 knockdown (ASAH1KD) SH-SY5Y cell line.  ASAH1KD cells displayed reduced proliferation due to elevated apoptosis and G1/S cell cycle arrest.  Distribution of LAMP1-pos. lysosomes towards the cell periphery and significantly shortened and less branched neurites upon differentiation, implicate AC for lysosome positioning and neuronal development, resp.  Lipidomic anal. revealed changes in the intracellular levels of distinct sphingolipid species, importantly without Cer accumulation, in line with altered gene transcription within the sphingolipid pathway.  Addnl., the transcript levels for Rho GTPases (RhoA, Rac1, and Cdc42), which are key regulators of axonal orientation, neurite branching and lysosome positioning were found to be dysregulated.  This study shows the crit. role of AC in neurons and suggests how AC depletion leads to defects seen in neuropathol. of SMA-PME and FD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrdFcJ08olUeLVg90H21EOLACvtfcHk0lh00dl1CD76ww"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhvVaqtLzP&md5=6eca7dad3eb3a0b15aaacc3589042f05</span></div><a href="/servlet/linkout?suffix=cit72&amp;dbid=16384&amp;doi=10.3390%2Fijms21051607&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fijms21051607%26sid%3Dliteratum%253Aachs%26aulast%3DKyriakou%26aufirst%3DK.%26aulast%3DLederer%26aufirst%3DC.%2BW.%26aulast%3DKleanthous%26aufirst%3DM.%26aulast%3DDrousiotou%26aufirst%3DA.%26aulast%3DMalekkou%26aufirst%3DA.%26atitle%3DAcid%2520ceramidase%2520depletion%2520impairs%2520neuronal%2520survival%2520and%2520induces%2520morphological%2520defects%2520in%2520neurites%2520associated%2520with%2520altered%2520gene%2520transcription%2520and%2520sphingolipid%2520content%26jtitle%3DInt.%2520J.%2520Mol.%2520Sci.%26date%3D2020%26volume%3D21%26spage%3D1607%26epage%3D1631%26doi%3D10.3390%2Fijms21051607" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref73"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref73'); return false;" data-citation="" class="refNumLink">73</a></strong><div class="NLM_citation" id="cit73"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yamanaka, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kondoh, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Terada, M.</span></span> <span> </span><span class="NLM_article-title">Kinetic resolution of racemic amino alcohols through intermolecular acetalization catalyzed by a chiral Bronsted acid</span>. <i>J. Am. Chem. Soc.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>137</i></span>,  <span class="NLM_fpage">1048</span>– <span class="NLM_lpage">1051</span>, <span class="refDoi"> DOI: 10.1021/ja512238n</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ja512238n" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01561&amp;key=1%3ACAS%3A528%3ADC%252BC2MXns12guw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=137&publication_year=2015&pages=1048-1051&author=T.+Yamanakaauthor=A.+Kondohauthor=M.+Terada&title=Kinetic+resolution+of+racemic+amino+alcohols+through+intermolecular+acetalization+catalyzed+by+a+chiral+Bronsted+acid&doi=10.1021%2Fja512238n"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit73R"><div class="casContent"><span class="casTitleNuber">73</span><div class="casTitle"><span class="NLM_cas:atitle">Kinetic Resolution of Racemic Amino Alcohols through Intermolecular Acetalization Catalyzed by a Chiral Bronsted Acid</span></div><div class="casAuthors">Yamanaka, Takuto; Kondoh, Azusa; Terada, Masahiro</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">137</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1048-1051</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">In the presence of nonracemic bis(triisopropylphenyl) binaphthylphosphoric or octahydrobinaphthylphosphoric acids, racemic (phenoxycarbonyl)amino alcs. such as RCH(OH)CH2NHCO2Ph [R = Ph, 2-naphthyl, 1,3-benzodioxol-5-yl, 2-thienyl, (E)-PhCH:CMe, i-Pr, cyclohexyl, t-Bu, TBSOCMe2, 2-hexyl-1,3-dithiane-2-yl] underwent enantioselective acetalization and kinetic resoln. with 2,3-dihydrofuran to yield nonracemic amino alcs. (R)-RCH(OH)CH2NHCO2Ph [R = Ph, 2-naphthyl, 1,3-benzodioxol-5-yl, 2-thienyl, (E)-PhCH:CMe, i-Pr, cyclohexyl, t-Bu, TBSOCMe2, 2-hexyl-1,3-dithiane-2-yl; TBS = tert-butyldimethylsilyl] and (S)-O-2-tetrahydrofuranylated amino alcs.; the alcs. were isolated in 32-50% recoveries and in 94-99% ee.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrvpCoP5D-airVg90H21EOLACvtfcHk0lh00dl1CD76ww"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXns12guw%253D%253D&md5=0131909d83e98eaf38ff64504b7e52dd</span></div><a href="/servlet/linkout?suffix=cit73&amp;dbid=16384&amp;doi=10.1021%2Fja512238n&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja512238n%26sid%3Dliteratum%253Aachs%26aulast%3DYamanaka%26aufirst%3DT.%26aulast%3DKondoh%26aufirst%3DA.%26aulast%3DTerada%26aufirst%3DM.%26atitle%3DKinetic%2520resolution%2520of%2520racemic%2520amino%2520alcohols%2520through%2520intermolecular%2520acetalization%2520catalyzed%2520by%2520a%2520chiral%2520Bronsted%2520acid%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D2015%26volume%3D137%26spage%3D1048%26epage%3D1051%26doi%3D10.1021%2Fja512238n" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref74"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref74'); return false;" data-citation="" class="refNumLink">74</a></strong><div class="NLM_citation" id="cit74"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dinsmore, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mercer, S. P.</span></span> <span> </span><span class="NLM_article-title">Carboxylation and Mitsunobu reaction of amines to give carbamates: retention vs inversion of configuration is substituent-dependent</span>. <i>Org. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">2885</span>– <span class="NLM_lpage">2888</span>, <span class="refDoi"> DOI: 10.1021/ol0491080</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ol0491080" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01561&amp;key=1%3ACAS%3A528%3ADC%252BD2cXlvFamsrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2004&pages=2885-2888&author=C.+J.+Dinsmoreauthor=S.+P.+Mercer&title=Carboxylation+and+Mitsunobu+reaction+of+amines+to+give+carbamates%3A+retention+vs+inversion+of+configuration+is+substituent-dependent&doi=10.1021%2Fol0491080"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit74R"><div class="casContent"><span class="casTitleNuber">74</span><div class="casTitle"><span class="NLM_cas:atitle">Carboxylation and Mitsunobu reaction of amines to give carbamates: Retention vs inversion of configuration is substituent-dependent</span></div><div class="casAuthors">Dinsmore, Christopher J.; Mercer, Swati P.</div><div class="citationInfo"><span class="NLM_cas:title">Organic Letters</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">2885-2888</span>CODEN:
                <span class="NLM_cas:coden">ORLEF7</span>;
        ISSN:<span class="NLM_cas:issn">1523-7060</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A mild method for the synthesis of carbamates from amino alcs. involved sequential carboxylation with carbon dioxide, followed by a Mitsunobu reaction.  Unexpectedly, the stereochem. course of the Mitsunobu reaction was dependent on whether the carbamic acid intermediate was N-substituted with hydrogen (retention) or carbon (inversion).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrAw4KyvNDZgbVg90H21EOLACvtfcHk0lh00dl1CD76ww"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXlvFamsrc%253D&md5=62ee852830c0b7f21dacbdc39529663e</span></div><a href="/servlet/linkout?suffix=cit74&amp;dbid=16384&amp;doi=10.1021%2Fol0491080&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fol0491080%26sid%3Dliteratum%253Aachs%26aulast%3DDinsmore%26aufirst%3DC.%2BJ.%26aulast%3DMercer%26aufirst%3DS.%2BP.%26atitle%3DCarboxylation%2520and%2520Mitsunobu%2520reaction%2520of%2520amines%2520to%2520give%2520carbamates%253A%2520retention%2520vs%2520inversion%2520of%2520configuration%2520is%2520substituent-dependent%26jtitle%3DOrg.%2520Lett.%26date%3D2004%26volume%3D6%26spage%3D2885%26epage%3D2888%26doi%3D10.1021%2Fol0491080" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref75"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref75'); return false;" data-citation="" class="refNumLink">75</a></strong><div class="NLM_citation" id="cit75"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Basit, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Piomelli, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Armirotti, A.</span></span> <span> </span><span class="NLM_article-title">Rapid evaluation of 25 key sphingolipids and phosphosphingolipids in human plasma by LC-MS/MS</span>. <i>Anal. Bioanal. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>407</i></span>,  <span class="NLM_fpage">5189</span>– <span class="NLM_lpage">5198</span>, <span class="refDoi"> DOI: 10.1007/s00216-015-8585-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01561&amp;key=10.1007%2Fs00216-015-8585-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01561&amp;key=25749796" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01561&amp;key=1%3ACAS%3A528%3ADC%252BC2MXktVKjtbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=407&publication_year=2015&pages=5189-5198&author=A.+Basitauthor=D.+Piomelliauthor=A.+Armirotti&title=Rapid+evaluation+of+25+key+sphingolipids+and+phosphosphingolipids+in+human+plasma+by+LC-MS%2FMS&doi=10.1007%2Fs00216-015-8585-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit75R"><div class="casContent"><span class="casTitleNuber">75</span><div class="casTitle"><span class="NLM_cas:atitle">Rapid evaluation of 25 key sphingolipids and phosphosphingolipids in human plasma by LC-MS/MS</span></div><div class="casAuthors">Basit, Abdul; Piomelli, Daniele; Armirotti, Andrea</div><div class="citationInfo"><span class="NLM_cas:title">Analytical and Bioanalytical Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">407</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">5189-5198</span>CODEN:
                <span class="NLM_cas:coden">ABCNBP</span>;
        ISSN:<span class="NLM_cas:issn">1618-2642</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">We report on a new, sensitive, and fast LC-MS/MS method for the simultaneous detn. of 25 key sphingolipid components in human plasma, including phosphorylated sphinganine and sphingosine, in a single 9-min run.  This method enables an effective and high-throughput coverage of the metabolic changes involving the sphingolipidome during physiol. or pathol. states.  The method is based on liq.-liq. extn. followed by reversed-phase LC-MS/MS.  Exogenous odd-chain lipids are used as cost-effective but reliable internal stds.  The method was fully validated in surrogate matrix and naive human plasma following FDA guidelines.  Sample stability and diln. integrity were also tested and verified.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqMk_mtifaXnLVg90H21EOLACvtfcHk0lg0JeGmu-rCtw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXktVKjtbo%253D&md5=57a06856ca08eea60fe0cd4a1ac3d2b8</span></div><a href="/servlet/linkout?suffix=cit75&amp;dbid=16384&amp;doi=10.1007%2Fs00216-015-8585-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00216-015-8585-6%26sid%3Dliteratum%253Aachs%26aulast%3DBasit%26aufirst%3DA.%26aulast%3DPiomelli%26aufirst%3DD.%26aulast%3DArmirotti%26aufirst%3DA.%26atitle%3DRapid%2520evaluation%2520of%252025%2520key%2520sphingolipids%2520and%2520phosphosphingolipids%2520in%2520human%2520plasma%2520by%2520LC-MS%252FMS%26jtitle%3DAnal.%2520Bioanal.%2520Chem.%26date%3D2015%26volume%3D407%26spage%3D5189%26epage%3D5198%26doi%3D10.1007%2Fs00216-015-8585-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36'],'ref37':['cit37'],'ref38':['cit38'],'ref39':['cit39'],'ref40':['cit40'],'ref41':['cit41'],'ref42':['cit42'],'ref43':['cit43'],'ref44':['cit44'],'ref45':['cit45'],'ref46':['cit46'],'ref47':['cit47'],'ref48':['cit48'],'ref49':['cit49'],'ref50':['cit50'],'ref51':['cit51'],'ref52':['cit52'],'ref53':['cit53'],'ref54':['cit54'],'ref55':['cit55'],'ref56':['cit56'],'ref57':['cit57'],'ref58':['cit58'],'ref59':['cit59'],'ref60':['cit60'],'ref61':['cit61'],'ref62':['cit62'],'ref63':['cit63'],'ref64':['cit64'],'ref65':['cit65'],'ref66':['cit66'],'ref67':['cit67'],'ref68':['cit68'],'ref69':['cit69'],'ref70':['cit70'],'ref71':['cit71'],'ref72':['cit72'],'ref73':['cit73'],'ref74':['cit74'],'ref75':['cit75']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article has not yet been cited by other publications.</p></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="_i1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01561/20201218/images/medium/jm0c01561_0023.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01561/20201218/images/large/jm0c01561_0023.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01561&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01561/20201218/images/medium/jm0c01561_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01561/20201218/images/large/jm0c01561_0002.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Overview of the ceramide metabolism and some related enzymes.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01561/20201218/images/large/jm0c01561_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01561&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01561/20201218/images/medium/jm0c01561_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01561/20201218/images/large/jm0c01561_0003.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Representative known and structurally diversified AC inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01561/20201218/images/large/jm0c01561_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01561&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01561/20201218/images/medium/jm0c01561_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01561/20201218/images/large/jm0c01561_0004.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Rational design of the novel class of AC inhibitors and hit identification.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01561/20201218/images/large/jm0c01561_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01561&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01561/20201218/images/medium/jm0c01561_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01561/20201218/images/large/jm0c01561_0011.jpeg" id="rightTab-gr10" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of <b>8a–d</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01561/20201218/images/large/jm0c01561_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01561&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) KNCO, AcOH, and <i>i</i>-PrOH, 70 °C, 3 h (36–53%) and (b) RNCO and DMAP, CH<sub>3</sub>CN, rt, 3–16 h (15–82%).</p></p></figure><figure data-id="sch2" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01561/20201218/images/medium/jm0c01561_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01561/20201218/images/large/jm0c01561_0012.jpeg" id="rightTab-gr11" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Synthesis of <b>11a–q</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01561/20201218/images/large/jm0c01561_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01561&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) TZD, K<sub>2</sub>CO<sub>3</sub>, and DMF, rt, 1–2 h. (b) LiOH and THF, rt, 30 min–1 h (6%- quant. over two steps for <b>11a</b>, <b>11c–p</b>) or <i>t</i>-BuOK and THF, rt, 30 min (for <b>11b</b> and <b>11q</b>: 10 and 38% over two steps; respectively).</p></p></figure><figure data-id="sch3" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01561/20201218/images/medium/jm0c01561_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01561/20201218/images/large/jm0c01561_0013.jpeg" id="rightTab-gr12" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Synthesis of <b>12a–y</b> and <b>13a–c</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01561/20201218/images/large/jm0c01561_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01561&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) RNCO and DMAP (10–83% for <b>12a–b</b>, <b>h–w</b>) or Et<sub>3</sub>N (78% for <b>12g</b>) and CH<sub>3</sub>CN, rt, 3–16 h or RNH<sub>2</sub>, Boc<sub>2</sub>O, DMAP and CH<sub>3</sub>CN, rt, 1–3 h (48–80% for <b>12c–d</b>) or RNH<sub>2</sub>, triphosgene, and DIPEA (76% for <b>12e</b>) or Et<sub>3</sub>N (24% for <b>12f</b>) and DCM, rt, 3–12 h; (b) 4 M HCl, 1,4-dioxane, rt, 2 h; (c) HCHO, AcOH, NaBH(OAc)<sub>3</sub>, and CH<sub>3</sub>CN, rt, 1 h (34% over two steps); (d) for <b>13a</b>: <i>N</i>-methyl-4-phenylbutylamine, triphosgene, DIPEA, and DCM, 0 °C to rt, 3 h (98%); for <b>13b</b>: 4-phenyl-1-butanol, triphosgene, DIPEA, and DCM, 0 °C to rt, 3 h (53%); for <b>13c</b>: 6-phenylhexanoic acid, SOCl<sub>2</sub>, and DCM, rt, 6 h; then <b>11a</b>, Et<sub>3</sub>N and THF, 0 °C to rt, 16 h (55%).</p></p></figure><figure data-id="sch4" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01561/20201218/images/medium/jm0c01561_0014.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01561/20201218/images/large/jm0c01561_0014.jpeg" id="rightTab-gr13" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 4. Synthesis of <b>15a–b</b> and <b>18a–b</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01561/20201218/images/large/jm0c01561_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01561&amp;id=sch4"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: for the synthesis of <b>15a–b</b>: (a) 4-phenylbutyl isocyanate, DMAP, DMF, 50 °C, 2 h, (47–81%); for the synthesis of <b>18a–b</b>: (a′) CDI, imidazole, DCM, rt, 16 h (86–92%); (b′) 4-phenylbutyl isocyanate, DMAP, DMF, 50 °C, 4 h (68–79%).</p></p></figure><figure data-id="sch5" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Scheme 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01561/20201218/images/medium/jm0c01561_0015.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01561/20201218/images/large/jm0c01561_0015.jpeg" id="rightTab-gr14" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 5. Synthesis of <b>25c–f</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01561/20201218/images/large/jm0c01561_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01561&amp;id=sch5"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) Pd(PPh<sub>3</sub>)<sub>4</sub>, 2 M Na<sub>2</sub>CO<sub>3</sub>, and 1,4-dioxane, reflux, 16 h (77–87%); (b) 10% Pd/C, cyclohexene, and EtOH, 60 °C, 24 h (65%); (c) TMSOTf, Et<sub>3</sub>N, and THF, −78 to −50 °C, 4 h; then, NBS and THF, −40 to −20 °C, 30 min; (d) TZD, K<sub>2</sub>CO<sub>3</sub>, and DMF, rt, 1–2 h (93% over three steps for <b>23b</b>); (e) <i>t</i>-BuOK and THF, rt, 1 h (29% over 4 steps for <b>24a</b>) or LiOH and THF, rt, 30 min (72% for <b>24b</b>); (f) 4-phenylbutyl isocyanate, DMAP, and pyridine, rt, 16 h (69%); (g) 4 M HCl and 1,4-dioxane, rt, 2 h (46%); (h) HCHO, AcOH, NaBH(OAc)<sub>3</sub>, and CH<sub>3</sub>CN, rt, 1 h (60%) (i) 4 M HCl and 1,4-dioxane, rt, 2 h; (j) HCHO, AcOH, NaBH(OAc)<sub>3</sub>, and CH<sub>3</sub>CN, rt, 1 h (71% over two steps); and (k) RNCO, DMAP, and pyridine, rt, 16 h (25–36% for <b>25d–e</b>) or <i>i</i>-BuNH<sub>2</sub>, triphosgene, Et<sub>3</sub>N, and DCM, rt, 3 h (82% for <b>25f</b>).</p></p></figure><figure data-id="sch6" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Scheme 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01561/20201218/images/medium/jm0c01561_0016.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01561/20201218/images/large/jm0c01561_0016.jpeg" id="rightTab-gr15" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 6. Synthesis of <b>32a–c</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01561/20201218/images/large/jm0c01561_0016.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01561&amp;id=sch6"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) Pd(PPh<sub>3</sub>)<sub>4</sub>, 2 M Na<sub>2</sub>CO<sub>3</sub>, and 1,4-dioxane, reflux, 16 h (85%); (b) HCO<sub>2</sub>NH<sub>4</sub>, 20% Pd(OH)<sub>2</sub>, and MeOH, 60 °C, 4 h (69%); (c) TMSOTf, Et<sub>3</sub>N, and THF, −78 to −50 °C, 4 h; then, NBS and THF, −40 to −20 °C, 30 min; (d) TZD, K<sub>2</sub>CO<sub>3</sub>, and DMF, rt, 2 h (66% over three steps); (e) <i>t</i>-BuOK and THF, rt, 30 min (67%); (f) 4 M HCl and 1,4-dioxane, rt, 2 h; (g) HCHO, AcOH, NaBH(OAc)<sub>3</sub>, and CH<sub>3</sub>CN, rt, 1 h and (h) RNCO, DMAP, and pyridine, rt, 16 h (62% for <b>32a</b>; 64% for <b>32b</b>) or <i>i</i>-BuNH<sub>2</sub>, triphosgene, Et<sub>3</sub>N, and DCM, rt, 3 h (20% for <b>32c</b>).</p></p></figure><figure data-id="fig4" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01561/20201218/images/medium/jm0c01561_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01561/20201218/images/large/jm0c01561_0005.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Planned SAR exploration.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01561/20201218/images/large/jm0c01561_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01561&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01561/20201218/images/medium/jm0c01561_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01561/20201218/images/large/jm0c01561_0006.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. (A) Concentration–response curve for the inhibition of <i>h</i>AC activity by <b>11a</b> and <b>12a</b>; (B) Michaelis–Menten analysis of the reaction of <i>h</i>AC in the presence of vehicle (DMSO 1%, ●) or <b>12a</b> (25 nM, ▲; 100 nM, ■). Rbm14-12: fluorogenic substrate of <i>h</i>AC. The graph is representative of two independent experiments, each performed in three technical replicates.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01561/20201218/images/large/jm0c01561_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01561&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig6" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01561/20201218/images/medium/jm0c01561_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01561/20201218/images/large/jm0c01561_0007.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Concentration dependence of the effects of <b>32b</b> in SH-SY5Y cells on <i>h</i>AC activity after a 3 h incubation (A) and SL levels (B–F). GraphPad Prism software (GraphPad Software, Inc., USA) was used for statistical analysis. Data were analyzed using the Student <i>t</i>-test or 1-way ANOVA followed by the Bonferroni post hoc test for multiple comparisons. Differences between groups were considered statistically significant at values of <i>p</i> < 0.05. Values are expressed as means SEM of at least six determinations. Experiments were repeated twice with similar results.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01561/20201218/images/large/jm0c01561_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01561&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig7" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01561/20201218/images/medium/jm0c01561_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01561/20201218/images/large/jm0c01561_0008.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Time course of the effects of <b>32b</b> (10 μM) in SH-SY5Y cells on <i>h</i>AC activity (A) and SL levels (B–F). GraphPad Prism software (GraphPad Software, Inc., USA) was used for statistical analysis. Data were analyzed using the Student <i>t</i>-test or 1-way ANOVA followed by the Bonferroni post hoc test for multiple comparisons. Differences between groups were considered statistically significant at values of <i>p</i> < 0.05. Values are expressed as means SEM of at least six determinations. Experiments were repeated twice with similar results.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01561/20201218/images/large/jm0c01561_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01561&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig8" data-index="14" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01561/20201218/images/medium/jm0c01561_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01561/20201218/images/large/jm0c01561_0009.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Concentration–response curve for the inhibition of <i>h</i>AC activity by <b>31c</b> and <b>32b</b> (A) and putative docking pose of compound <b>32b</b> in <i>h</i>AC (PDB code: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6MHM">6MHM</a>) (B).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01561/20201218/images/large/jm0c01561_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01561&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig9" data-index="15" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01561/20201218/images/medium/jm0c01561_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01561/20201218/images/large/jm0c01561_0010.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. Putative docking poses of compound <b>32b</b> in <i>h</i>AC (PDB code: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6MHM">6MHM</a>) (A) and in <i>h</i>NAAA (PDB code: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6DXX">6DXX</a>) (B).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01561/20201218/images/large/jm0c01561_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01561&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i158">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_65430" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_65430" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 75 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hannun, Y. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Obeid, L. M.</span></span> <span> </span><span class="NLM_article-title">Many ceramides</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>286</i></span>,  <span class="NLM_fpage">27855</span>– <span class="NLM_lpage">27862</span>, <span class="refDoi"> DOI: 10.1074/jbc.r111.254359</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01561&amp;key=10.1074%2Fjbc.R111.254359" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01561&amp;key=21693702" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01561&amp;key=1%3ACAS%3A528%3ADC%252BC3MXpsl2ntbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=286&publication_year=2011&pages=27855-27862&author=Y.+A.+Hannunauthor=L.+M.+Obeid&title=Many+ceramides&doi=10.1074%2Fjbc.r111.254359"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Many Ceramides</span></div><div class="casAuthors">Hannun, Yusuf A.; Obeid, Lina M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">286</span>
        (<span class="NLM_cas:issue">32</span>),
    <span class="NLM_cas:pages">27855-27862</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">A review.  Intensive research over the past 2 decades has implicated ceramide in the regulation of several cell responses.  However, emerging evidence points to dramatic complexities in ceramide metab. and structure that defy the prevailing unifying hypothesis on ceramide function that is based on the understanding of ceramide as a single entity.  Here, we develop the concept that "ceramide" constitutes a family of closely related mols., subject to metab. by >28 enzymes and with >200 structurally distinct mammalian ceramides distinguished by specific structural modifications.  These ceramides are synthesized in a combinatorial fashion with distinct enzymes responsible for the specific modifications.  These multiple pathways of ceramide generation led to the hypothesis that individual ceramide mol. species are regulated by specific biochem. pathways in distinct subcellular compartments and execute distinct functions.  In this minireview, we describe the "many ceramides" paradigm, along with the rationale, supporting evidence, and implications for our understanding of bioactive sphingolipids and approaches for unraveling these pathways.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrwtYXUgk_GdbVg90H21EOLACvtfcHk0lheyjMQeANMSw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXpsl2ntbo%253D&md5=7a11bcd01d3bc56c1e1b833438dc1fbd</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1074%2Fjbc.R111.254359&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.R111.254359%26sid%3Dliteratum%253Aachs%26aulast%3DHannun%26aufirst%3DY.%2BA.%26aulast%3DObeid%26aufirst%3DL.%2BM.%26atitle%3DMany%2520ceramides%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2011%26volume%3D286%26spage%3D27855%26epage%3D27862%26doi%3D10.1074%2Fjbc.r111.254359" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gomez-Muñoz, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Presa, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gomez-Larrauri, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rivera, I.-G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trueba, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ordoñez, M.</span></span> <span> </span><span class="NLM_article-title">Control of inflammatory responses by ceramide, sphingosine 1-phosphate and ceramide 1-phosphate</span>. <i>Prog. Lipid Res.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">51</span>– <span class="NLM_lpage">62</span>, <span class="refDoi"> DOI: 10.1016/j.plipres.2015.09.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01561&amp;key=10.1016%2Fj.plipres.2015.09.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01561&amp;key=26703189" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01561&amp;key=1%3ACAS%3A528%3ADC%252BC2MXitVGhtrnP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2016&pages=51-62&author=A.+Gomez-Mu%C3%B1ozauthor=N.+Presaauthor=A.+Gomez-Larrauriauthor=I.-G.+Riveraauthor=M.+Truebaauthor=M.+Ordo%C3%B1ez&title=Control+of+inflammatory+responses+by+ceramide%2C+sphingosine+1-phosphate+and+ceramide+1-phosphate&doi=10.1016%2Fj.plipres.2015.09.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Control of inflammatory responses by ceramide, sphingosine 1-phosphate and ceramide 1-phosphate</span></div><div class="casAuthors">Gomez-Munoz, Antonio; Presa, Natalia; Gomez-Larrauri, Ana; Rivera, Io-Guane; Trueba, Miguel; Ordonez, Marta</div><div class="citationInfo"><span class="NLM_cas:title">Progress in Lipid Research</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">51-62</span>CODEN:
                <span class="NLM_cas:coden">PLIRDW</span>;
        ISSN:<span class="NLM_cas:issn">0163-7827</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Inflammation is a network of complex processes involving a variety of metabolic and signaling pathways aiming at healing and repairing damage tissue, or fighting infection.  However, inflammation can be detrimental when it becomes out of control.  Inflammatory mediators involve cytokines, bioactive lipids and lipid-derived metabolites.  In particular, the simple sphingolipids ceramides, sphingosine 1-phosphate, and ceramide 1-phosphate have been widely implicated in inflammation.  However, although ceramide 1-phosphate was first described as pro-inflammatory, recent studies show that it has anti-inflammatory properties when produced in specific cell types or tissues.  The biol. functions of ceramides and sphingosine 1-phosphate have been extensively studied.  These sphingolipids have opposing effects with ceramides being potent inducers of cell cycle arrest and apoptosis, and sphingosine 1-phosphate promoting cell growth and survival.  However, the biol. actions of ceramide 1-phosphate have only been partially described.  Ceramide 1-phosphate is mitogenic and anti-apoptotic, and more recently, it has been demonstrated to be key regulator of cell migration.  Both sphingosine 1-phosphate and ceramide 1-phosphate are also implicated in tumor growth and dissemination.  The present review highlights new aspects on the control of inflammation and cell migration by simple sphingolipids, with special emphasis to the role played by ceramide 1-phosphate in controlling these actions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoZ0ndilncuqbVg90H21EOLACvtfcHk0lheyjMQeANMSw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXitVGhtrnP&md5=8a3a4a52943303e535f26fe9ca386192</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1016%2Fj.plipres.2015.09.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.plipres.2015.09.002%26sid%3Dliteratum%253Aachs%26aulast%3DGomez-Mu%25C3%25B1oz%26aufirst%3DA.%26aulast%3DPresa%26aufirst%3DN.%26aulast%3DGomez-Larrauri%26aufirst%3DA.%26aulast%3DRivera%26aufirst%3DI.-G.%26aulast%3DTrueba%26aufirst%3DM.%26aulast%3DOrdo%25C3%25B1ez%26aufirst%3DM.%26atitle%3DControl%2520of%2520inflammatory%2520responses%2520by%2520ceramide%252C%2520sphingosine%25201-phosphate%2520and%2520ceramide%25201-phosphate%26jtitle%3DProg.%2520Lipid%2520Res.%26date%3D2016%26volume%3D61%26spage%3D51%26epage%3D62%26doi%3D10.1016%2Fj.plipres.2015.09.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hannun, Y. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Obeid, L. M.</span></span> <span> </span><span class="NLM_article-title">Sphingolipids and their metabolism in physiology and disease</span>. <i>Nat. Rev. Mol. Cell Biol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">175</span>– <span class="NLM_lpage">191</span>, <span class="refDoi"> DOI: 10.1038/nrm.2017.107</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01561&amp;key=10.1038%2Fnrm.2017.107" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01561&amp;key=29165427" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01561&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhvVKqt7fE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2018&pages=175-191&author=Y.+A.+Hannunauthor=L.+M.+Obeid&title=Sphingolipids+and+their+metabolism+in+physiology+and+disease&doi=10.1038%2Fnrm.2017.107"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Sphingolipids and their metabolism in physiology and disease</span></div><div class="casAuthors">Hannun, Yusuf A.; Obeid, Lina M.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Molecular Cell Biology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">175-191</span>CODEN:
                <span class="NLM_cas:coden">NRMCBP</span>;
        ISSN:<span class="NLM_cas:issn">1471-0072</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">A review.  Studies of bioactive lipids in general and sphingolipids in particular have intensified over the past several years, revealing an unprecedented and unanticipated complexity of the lipidome and its many functions, which rivals, if not exceeds, that of the genome or proteome.  These results highlight crit. roles for bioactive sphingolipids in most, if not all, major cell biol. responses, including all major cell signalling pathways, and they link sphingolipid metab. to key human diseases.  Nevertheless, the fairly nascent field of bioactive sphingolipids still faces challenges in its biochem. and mol. underpinnings, including defining the mol. mechanisms of pathway and enzyme regulation, the study of lipid-protein interactions and the development of cellular probes, suitable biomarkers and therapeutic approaches.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrl9A-uh9uFPrVg90H21EOLACvtfcHk0ljR7oKG0wf9kA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhvVKqt7fE&md5=81409d71ab1c29c9dea5f060105032be</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1038%2Fnrm.2017.107&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrm.2017.107%26sid%3Dliteratum%253Aachs%26aulast%3DHannun%26aufirst%3DY.%2BA.%26aulast%3DObeid%26aufirst%3DL.%2BM.%26atitle%3DSphingolipids%2520and%2520their%2520metabolism%2520in%2520physiology%2520and%2520disease%26jtitle%3DNat.%2520Rev.%2520Mol.%2520Cell%2520Biol.%26date%3D2018%26volume%3D19%26spage%3D175%26epage%3D191%26doi%3D10.1038%2Fnrm.2017.107" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kurz, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parnham, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Geisslinger, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schiffmann, S.</span></span> <span> </span><span class="NLM_article-title">Ceramides as novel disease biomarkers</span>. <i>Trends Mol. Med.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">20</span>– <span class="NLM_lpage">32</span>, <span class="refDoi"> DOI: 10.1016/j.molmed.2018.10.009</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01561&amp;key=10.1016%2Fj.molmed.2018.10.009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01561&amp;key=30477968" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01561&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitFyhtLbP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2019&pages=20-32&author=J.+Kurzauthor=M.+J.+Parnhamauthor=G.+Geisslingerauthor=S.+Schiffmann&title=Ceramides+as+novel+disease+biomarkers&doi=10.1016%2Fj.molmed.2018.10.009"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Ceramides as Novel Disease Biomarkers</span></div><div class="casAuthors">Kurz, Jennifer; Parnham, Michael J.; Geisslinger, Gerd; Schiffmann, Susanne</div><div class="citationInfo"><span class="NLM_cas:title">Trends in Molecular Medicine</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">20-32</span>CODEN:
                <span class="NLM_cas:coden">TMMRCY</span>;
        ISSN:<span class="NLM_cas:issn">1471-4914</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Ceramides are sphingolipids and integral components of the eukaryotic cell membrane.  Apart from providing structural integrity, ceramides have also been shown to act as second messengers in cell signaling processes.  In recent publications, ceramide modulation has been reported in pathol. conditions such as cancer, diabetes, Alzheimer's disease (AD), coronary artery disease (CAD), multiple sclerosis (MS), as well as depression.  Ceramides or ceramide panel combinations have been proposed as specific disease biomarkers that could be detected in diseased tissue, synovial fluid, cerebrospinal fluid (CSF), and blood.  This article reviews ceramide modulation in a selection of different diseases and the potential use of ceramides as biomarkers in diagnostics, detn. of disease stage and personalized medicine.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqOKsisq3HF1LVg90H21EOLACvtfcHk0ljR7oKG0wf9kA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitFyhtLbP&md5=f3079e8ebc71c2ab23cc1afa621e273a</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1016%2Fj.molmed.2018.10.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.molmed.2018.10.009%26sid%3Dliteratum%253Aachs%26aulast%3DKurz%26aufirst%3DJ.%26aulast%3DParnham%26aufirst%3DM.%2BJ.%26aulast%3DGeisslinger%26aufirst%3DG.%26aulast%3DSchiffmann%26aufirst%3DS.%26atitle%3DCeramides%2520as%2520novel%2520disease%2520biomarkers%26jtitle%3DTrends%2520Mol.%2520Med.%26date%3D2019%26volume%3D25%26spage%3D20%26epage%3D32%26doi%3D10.1016%2Fj.molmed.2018.10.009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">van
Eijk, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferraz, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boot, R. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aerts, J. M. F. G.</span></span> <span> </span><span class="NLM_article-title">Lyso-glycosphingolipids: presence and consequences</span>. <i>Essays Biochem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>64</i></span>,  <span class="NLM_fpage">565</span>, <span class="refDoi"> DOI: 10.1042/EBC20190090</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01561&amp;key=10.1042%2FEBC20190090" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01561&amp;key=32808655" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01561&amp;key=1%3ACAS%3A528%3ADC%252BB3cXitFaqtbjL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=64&publication_year=2020&pages=565&author=M.+van%0AEijkauthor=M.+J.+Ferrazauthor=R.+G.+Bootauthor=J.+M.+F.+G.+Aerts&title=Lyso-glycosphingolipids%3A+presence+and+consequences&doi=10.1042%2FEBC20190090"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Lyso-glycosphingolipids: presence and consequences</span></div><div class="casAuthors">van Eijk, Marco; Ferraz, Maria J.; Boot, Rolf G.; Aerts, Johannes M. F. G.</div><div class="citationInfo"><span class="NLM_cas:title">Essays in Biochemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">64</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">565-578</span>CODEN:
                <span class="NLM_cas:coden">ESBIAV</span>;
        ISSN:<span class="NLM_cas:issn">1744-1358</span>.
    
            (<span class="NLM_cas:orgname">Portland Press Ltd.</span>)
        </div><div class="casAbstract">Lyso-glycosphingolipids are generated in excess in glycosphingolipid storage disorders.  In the course of these pathologies glycosylated sphingolipid species accumulate within lysosomes due to flaws in the resp. lipid degrading machinery.  Deacylation of accumulating glycosphingolipids drives the formation of lyso-glycosphingolipids.  In lysosomal storage diseases such as Gaucher Disease, Fabry Disease, Krabbe disease, GM1- and GM2 gangliosidosis, Niemann Pick type C and Metachromatic leukodystrophy massive intra-lysosomal glycosphingolipid accumulation occurs.  The lysosomal enzyme acid ceramidase generates the deacylated lyso-glycosphingolipid species.  This review discusses how the various lyso-glycosphingolipids are synthesized, how they may contribute to abnormal immunity in glycosphingolipid storing lysosomal diseases and what therapeutic opportunities exist.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrw9yRedbOINbVg90H21EOLACvtfcHk0ljR7oKG0wf9kA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXitFaqtbjL&md5=18a11c134a2ed76adc52c4a0c5a27418</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1042%2FEBC20190090&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1042%252FEBC20190090%26sid%3Dliteratum%253Aachs%26aulast%3Dvan%2BEijk%26aufirst%3DM.%26aulast%3DFerraz%26aufirst%3DM.%2BJ.%26aulast%3DBoot%26aufirst%3DR.%2BG.%26aulast%3DAerts%26aufirst%3DJ.%2BM.%2BF.%2BG.%26atitle%3DLyso-glycosphingolipids%253A%2520presence%2520and%2520consequences%26jtitle%3DEssays%2520Biochem.%26date%3D2020%26volume%3D64%26spage%3D565%26doi%3D10.1042%2FEBC20190090" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sahu, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hannun, Y. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yao, N.</span></span> <span> </span><span class="NLM_article-title">Emergence of membrane sphingolipids as a potential therapeutic target</span>. <i>Biochimie</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>158</i></span>,  <span class="NLM_fpage">257</span>– <span class="NLM_lpage">264</span>, <span class="refDoi"> DOI: 10.1016/j.biochi.2019.01.018</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01561&amp;key=10.1016%2Fj.biochi.2019.01.018" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01561&amp;key=30703477" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01561&amp;key=1%3ACAS%3A528%3ADC%252BC1MXisFWmt7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=158&publication_year=2019&pages=257-264&author=S.+K.+Sahuauthor=Y.+A.+Hannunauthor=N.+Yao&title=Emergence+of+membrane+sphingolipids+as+a+potential+therapeutic+target&doi=10.1016%2Fj.biochi.2019.01.018"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Emergence of membrane sphingolipids as a potential therapeutic target</span></div><div class="casAuthors">Sahu, Sunil Kumar; Hannun, Yusuf A.; Yao, Nan</div><div class="citationInfo"><span class="NLM_cas:title">Biochimie</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">158</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">257-264</span>CODEN:
                <span class="NLM_cas:coden">BICMBE</span>;
        ISSN:<span class="NLM_cas:issn">0300-9084</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Though sphingolipids are ubiquitously present in eukaryotic cells, but until the last decade, they were merely considered as a structural component of the plasma membrane with limited function.  However, over the last decade, numerous functions have been ascribed to sphingolipids after the seminal discoveries on the bioactivities of several sphingolipids.  Sphingolipids are now well-recognized signals for fundamental cellular processes.  Here we discussed about the advent of several sphingolipids components as potential therapeutic target for both human and plants.  Sphingolipid contents and/or sphingolipid-metabolizing enzyme expression/activity often get impaired during pathophysiol. conditions, and hence manipulation of this signaling pathway may be beneficial in disease diagnosis, and the plasma concns. can serve as an important prognostic and diagnostic marker for the disease.  Sphingolipids are emerging as a goldmine for new therapeutic drug targets with promising new applications (cosmeceutical and nutraceutical), thereby opening new avenues for pharmaceuticals and nutraceutical industries.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqmUxzI4fnNurVg90H21EOLACvtfcHk0ljZQgl2R0kKlQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXisFWmt7w%253D&md5=6855bfbe3633b819a87f27b6b6f70898</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1016%2Fj.biochi.2019.01.018&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.biochi.2019.01.018%26sid%3Dliteratum%253Aachs%26aulast%3DSahu%26aufirst%3DS.%2BK.%26aulast%3DHannun%26aufirst%3DY.%2BA.%26aulast%3DYao%26aufirst%3DN.%26atitle%3DEmergence%2520of%2520membrane%2520sphingolipids%2520as%2520a%2520potential%2520therapeutic%2520target%26jtitle%3DBiochimie%26date%3D2019%26volume%3D158%26spage%3D257%26epage%3D264%26doi%3D10.1016%2Fj.biochi.2019.01.018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Coant, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sakamoto, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mao, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hannun, Y. A.</span></span> <span> </span><span class="NLM_article-title">Ceramidases, roles in sphingolipid metabolism and in health and disease</span>. <i>Adv. Biol. Regul.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>63</i></span>,  <span class="NLM_fpage">122</span>– <span class="NLM_lpage">131</span>, <span class="refDoi"> DOI: 10.1016/j.jbior.2016.10.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01561&amp;key=10.1016%2Fj.jbior.2016.10.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01561&amp;key=27771292" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01561&amp;key=1%3ACAS%3A528%3ADC%252BC28XhslSqsbvK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2017&pages=122-131&author=N.+Coantauthor=W.+Sakamotoauthor=C.+Maoauthor=Y.+A.+Hannun&title=Ceramidases%2C+roles+in+sphingolipid+metabolism+and+in+health+and+disease&doi=10.1016%2Fj.jbior.2016.10.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Ceramidases, roles in sphingolipid metabolism and in health and disease</span></div><div class="casAuthors">Coant, Nicolas; Sakamoto, Wataru; Mao, Cungui; Hannun, Yusuf A.</div><div class="citationInfo"><span class="NLM_cas:title">Advances in Biological Regulation</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">122-131</span>CODEN:
                <span class="NLM_cas:coden">ABRDE5</span>;
        ISSN:<span class="NLM_cas:issn">2212-4934</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Over the past three decades, extensive research has been able to det. the biol. functions for the main bioactive sphingolipids, namely ceramide, sphingosine, and sphingosine 1-phosphate (S1P) (Hannun, 1996; Hannun et al., 1986; Okazaki et al., 1989).  These studies have managed to define the metab., regulation, and function of these bioactive sphingolipids.  This emerging body of literature has also implicated bioactive sphingolipids, particularly S1P and ceramide, as key regulators of cellular homeostasis.  Ceramidases have the important role of cleaving fatty acid from ceramide and producing sphingosine, thereby controlling the interconversion of these two lipids.  Thus far, five human ceramidases encoded by five different genes have been identified: acid ceramidase (AC), neutral ceramidase (NC), alk. ceramidase 1 (ACER1), alk. ceramidase 2 (ACER2), and alk. ceramidase 3 (ACER3).  These ceramidases are classified according to their optimal pH for catalytic activity.  AC, which is localized to the lysosomal compartment, has been assocd. with Farber's disease and is involved in the regulation of cell viability.  Neutral ceramidase, which is localized to the plasma membrane and primarily expressed in the small intestine and colon, is involved in digestion, and has been implicated in colon carcinogenesis.  ACER1 which can be found in the endoplasmic reticulum and is highly expressed in the skin, plays an important role in keratinocyte differentiation.  ACER2, localized to the Golgi complex and highly expressed in the placenta, is involved in programed cell death in response to DNA damage.  ACER3, also localized to the endoplasmic reticulum and the Golgi complex, is ubiquitously expressed, and is involved in motor coordination-assocd. Purkinje cell degeneration.  This review seeks to consolidate the current knowledge regarding these key cellular players.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGowWeoXuPUgXrVg90H21EOLACvtfcHk0ljZQgl2R0kKlQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhslSqsbvK&md5=84e937e947b7a38256761a6ab60a7353</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1016%2Fj.jbior.2016.10.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jbior.2016.10.002%26sid%3Dliteratum%253Aachs%26aulast%3DCoant%26aufirst%3DN.%26aulast%3DSakamoto%26aufirst%3DW.%26aulast%3DMao%26aufirst%3DC.%26aulast%3DHannun%26aufirst%3DY.%2BA.%26atitle%3DCeramidases%252C%2520roles%2520in%2520sphingolipid%2520metabolism%2520and%2520in%2520health%2520and%2520disease%26jtitle%3DAdv.%2520Biol.%2520Regul.%26date%3D2017%26volume%3D63%26spage%3D122%26epage%3D131%26doi%3D10.1016%2Fj.jbior.2016.10.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Parveen, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bender, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Law, S.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mishra, V. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, C.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ke, L.-Y.</span></span> <span> </span><span class="NLM_article-title">Role of ceramidases in sphingolipid metabolism and human diseases</span>. <i>Cells</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">1573</span>– <span class="NLM_lpage">1592</span>, <span class="refDoi"> DOI: 10.3390/cells8121573</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01561&amp;key=10.3390%2Fcells8121573" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01561&amp;key=1%3ACAS%3A528%3ADC%252BB3cXptVSqtL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2019&pages=1573-1592&author=F.+Parveenauthor=D.+Benderauthor=S.-H.+Lawauthor=V.+K.+Mishraauthor=C.-C.+Chenauthor=L.-Y.+Ke&title=Role+of+ceramidases+in+sphingolipid+metabolism+and+human+diseases&doi=10.3390%2Fcells8121573"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Role of ceramidases in sphingolipid metabolism and human diseases</span></div><div class="casAuthors">Parveen, Farzana; Bender, Daniel; Law, Shi-Hui; Mishra, Vineet Kumar; Chen, Chih-Chieh; Ke, Liang-Yin</div><div class="citationInfo"><span class="NLM_cas:title">Cells</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1573</span>CODEN:
                <span class="NLM_cas:coden">CELLC6</span>;
        ISSN:<span class="NLM_cas:issn">2073-4409</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">Human pathologies such as Alzheimer's disease, type 2 diabetes-induced insulin resistance, cancer, and cardiovascular diseases have altered lipid homeostasis.  Among these imbalanced lipids, the bioactive sphingolipids ceramide and sphingosine-1 phosphate (S1P) are pivotal in the pathophysiol. of these diseases.  Several enzymes within the sphingolipid pathway contribute to the homeostasis of ceramide and S1P.  Ceramidase is key in the degrdn. of ceramide into sphingosine and free fatty acids.  In humans, five different ceramidases are known-acid ceramidase, neutral ceramidase, and alk. ceramidase 1, 2, and 3-which are encoded by five different genes (ASAH1, ASAH2, ACER1, ACER2, and ACER3, resp.).  Notably, the neutral ceramidase N-acylsphingosine amidohydrolase 2 (ASAH2) shows considerable differences between humans and animals in terms of tissue expression levels.  Besides, the subcellular localization of ASAH2 remains controversial.  In this review, we sum up the results obtained for identifying gene divergence, structure, subcellular localization, and manipulating factors and address the role of ASAH2 along with other ceramidases in human diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGol2bCWkWONUbVg90H21EOLACvtfcHk0ljZQgl2R0kKlQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXptVSqtL4%253D&md5=4ff578971ab07c327e0291add9c311e4</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.3390%2Fcells8121573&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fcells8121573%26sid%3Dliteratum%253Aachs%26aulast%3DParveen%26aufirst%3DF.%26aulast%3DBender%26aufirst%3DD.%26aulast%3DLaw%26aufirst%3DS.-H.%26aulast%3DMishra%26aufirst%3DV.%2BK.%26aulast%3DChen%26aufirst%3DC.-C.%26aulast%3DKe%26aufirst%3DL.-Y.%26atitle%3DRole%2520of%2520ceramidases%2520in%2520sphingolipid%2520metabolism%2520and%2520human%2520diseases%26jtitle%3DCells%26date%3D2019%26volume%3D8%26spage%3D1573%26epage%3D1592%26doi%3D10.3390%2Fcells8121573" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">García-Barros, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coant, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kawamori, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wada, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Snider, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Truman, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, B. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Furuya, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clarke, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bialkowska, A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghaleb, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, V. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Obeid, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hannun, Y. A.</span></span> <span> </span><span class="NLM_article-title">Role of neutral ceramidase in colon cancer</span>. <i>FASEB J.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>30</i></span>,  <span class="NLM_fpage">4159</span>– <span class="NLM_lpage">4171</span>, <span class="refDoi"> DOI: 10.1096/fj.201600611R</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01561&amp;key=10.1096%2Ffj.201600611R" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01561&amp;key=27609772" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01561&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsFKrs7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2016&pages=4159-4171&author=M.+Garc%C3%ADa-Barrosauthor=N.+Coantauthor=T.+Kawamoriauthor=M.+Wadaauthor=A.+J.+Sniderauthor=J.+P.+Trumanauthor=B.+X.+Wuauthor=H.+Furuyaauthor=C.+J.+Clarkeauthor=A.+B.+Bialkowskaauthor=A.+Ghalebauthor=V.+W.+Yangauthor=L.+M.+Obeidauthor=Y.+A.+Hannun&title=Role+of+neutral+ceramidase+in+colon+cancer&doi=10.1096%2Ffj.201600611R"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Role of neutral ceramidase in colon cancer</span></div><div class="casAuthors">Garcia-Barros, Monica; Coant, Nicolas; Kawamori, Toshihiko; Wada, Masayuki; Snider, Ashley J.; Truman, Jean-Philip; Wu, Bill X.; Furuya, Hideki; Clarke, Christopher J.; Bialkowska, Agnieszka B.; Ghaleb, Amr; Yang, Vincent W.; Obeid, Lina M.; Hannun, Yusuf A.</div><div class="citationInfo"><span class="NLM_cas:title">FASEB Journal</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">4159-4171</span>CODEN:
                <span class="NLM_cas:coden">FAJOEC</span>;
        ISSN:<span class="NLM_cas:issn">0892-6638</span>.
    
            (<span class="NLM_cas:orgname">Federation of American Societies for Experimental Biology</span>)
        </div><div class="casAbstract">Alterations in sphingolipid metab., esp. ceramide and sphingosine 1-phosphate, have been linked to colon cancer, suggesting that enzymes of sphingolipid metab. may emerge as novel regulators and targets in colon cancer.  Neutral ceramidase (nCDase), a key enzyme in sphingolipid metab. that hydrolyzes ceramide into sphingosine, is highly expressed in the intestine; however, its role in colon cancer has not been defined.  Here we show that mol. and pharmacol. inhibition of nCDase in colon cancer cells increases ceramide, and this is accompanied by decreased cell survival and increased apoptosis and autophagy, with minimal effects on noncancerous cells.  Inhibition of nCDase resultedinloss of β-catenin and inhibition of ERK, components of pathways relevant for colon cancer development.  Furthermore, inhibition of nCDase in a xenograft model delayed tumor growth and increased ceramide while decreasing proliferation.  It is noteworthy that mice lacking nCDase treated with azoxymethane were protected fromtumor formation.  Taken together, these studies show that nCDase is pivotal for regulating initiation and development of colon cancer, and these data suggest that this enzyme is a suitable and novel target for colon cancer therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrjFMZMfHdb-bVg90H21EOLACvtfcHk0li28R1pjjZ3Hw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsFKrs7Y%253D&md5=408b6c905c1a504d00ca89f2ec955d9e</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1096%2Ffj.201600611R&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1096%252Ffj.201600611R%26sid%3Dliteratum%253Aachs%26aulast%3DGarc%25C3%25ADa-Barros%26aufirst%3DM.%26aulast%3DCoant%26aufirst%3DN.%26aulast%3DKawamori%26aufirst%3DT.%26aulast%3DWada%26aufirst%3DM.%26aulast%3DSnider%26aufirst%3DA.%2BJ.%26aulast%3DTruman%26aufirst%3DJ.%2BP.%26aulast%3DWu%26aufirst%3DB.%2BX.%26aulast%3DFuruya%26aufirst%3DH.%26aulast%3DClarke%26aufirst%3DC.%2BJ.%26aulast%3DBialkowska%26aufirst%3DA.%2BB.%26aulast%3DGhaleb%26aufirst%3DA.%26aulast%3DYang%26aufirst%3DV.%2BW.%26aulast%3DObeid%26aufirst%3DL.%2BM.%26aulast%3DHannun%26aufirst%3DY.%2BA.%26atitle%3DRole%2520of%2520neutral%2520ceramidase%2520in%2520colon%2520cancer%26jtitle%3DFASEB%2520J.%26date%3D2016%26volume%3D30%26spage%3D4159%26epage%3D4171%26doi%3D10.1096%2Ffj.201600611R" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Coant, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hannun, Y. A.</span></span> <span> </span><span class="NLM_article-title">Neutral ceramidase: advances in mechanisms, cell regulation, and roles in cancer</span>. <i>Adv. Biol. Regul.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>71</i></span>,  <span class="NLM_fpage">141</span>– <span class="NLM_lpage">146</span>, <span class="refDoi"> DOI: 10.1016/j.jbior.2018.10.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01561&amp;key=10.1016%2Fj.jbior.2018.10.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01561&amp;key=30389354" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01561&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitVCktr%252FN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=71&publication_year=2019&pages=141-146&author=N.+Coantauthor=Y.+A.+Hannun&title=Neutral+ceramidase%3A+advances+in+mechanisms%2C+cell+regulation%2C+and+roles+in+cancer&doi=10.1016%2Fj.jbior.2018.10.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Neutral ceramidase: Advances in mechanisms, cell regulation, and roles in cancer</span></div><div class="casAuthors">Coant, Nicolas; Hannun, Yusuf A.</div><div class="citationInfo"><span class="NLM_cas:title">Advances in Biological Regulation</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">71</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">141-146</span>CODEN:
                <span class="NLM_cas:coden">ABRDE5</span>;
        ISSN:<span class="NLM_cas:issn">2212-4934</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Extensive research conducted in the last three decades has identified the roles for the main bioactive sphingolipids, namely ceramide, sphingosine, and sphingosine 1-phosphate (S1P) as key regulators of cellular homeostasis, growth and death.  One of the major groups of enzymes in the ceramide pathway, ceramidases, converts ceramide into sphingosine and fatty acids, with sphingosine being further metabolized to S1P.  Thus, these enzymes play important roles in the network controlling the functions assocd. with these bioactive sphingolipids.  Among the family of ceramidases, neutral ceramidase (nCDase), which is named according to its optimal pH for catalytic activity, has received increased attention in the last decade.  The goal of this review is to provide a brief background on bioactive sphingolipids and the ceramidases.  We then describe more recent advances on nCDase, specifically the resoln. of its crystal structure and understanding its roles in cell biol. and physiol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoHkDx4Pq8957Vg90H21EOLACvtfcHk0li28R1pjjZ3Hw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitVCktr%252FN&md5=89677c27d48978f5f7821a0920541e7e</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1016%2Fj.jbior.2018.10.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jbior.2018.10.005%26sid%3Dliteratum%253Aachs%26aulast%3DCoant%26aufirst%3DN.%26aulast%3DHannun%26aufirst%3DY.%2BA.%26atitle%3DNeutral%2520ceramidase%253A%2520advances%2520in%2520mechanisms%252C%2520cell%2520regulation%252C%2520and%2520roles%2520in%2520cancer%26jtitle%3DAdv.%2520Biol.%2520Regul.%26date%3D2019%26volume%3D71%26spage%3D141%26epage%3D146%26doi%3D10.1016%2Fj.jbior.2018.10.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liakath-Ali, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vancollie, V. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lelliott, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Speak, A. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lafont, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Protheroe, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ingvorsen, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galli, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Green, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gleeson, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ryder, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Glover, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vizcay-Barrena, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karp, N. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arends, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brenn, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spiegel, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adams, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watt, F. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van der Weyden, L.</span></span> <span> </span><span class="NLM_article-title">Alkaline ceramidase 1 is essential for mammalian skin homeostasis and regulating whole-body energy expenditure</span>. <i>J. Pathol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>239</i></span>,  <span class="NLM_fpage">374</span>– <span class="NLM_lpage">383</span>, <span class="refDoi"> DOI: 10.1002/path.4737</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01561&amp;key=10.1002%2Fpath.4737" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01561&amp;key=27126290" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01561&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtVWmu7vF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=239&publication_year=2016&pages=374-383&author=K.+Liakath-Aliauthor=V.+E.+Vancollieauthor=C.+J.+Lelliottauthor=A.+O.+Speakauthor=D.+Lafontauthor=H.+J.+Protheroeauthor=C.+Ingvorsenauthor=A.+Galliauthor=A.+Greenauthor=D.+Gleesonauthor=E.+Ryderauthor=L.+Gloverauthor=G.+Vizcay-Barrenaauthor=N.+A.+Karpauthor=M.+J.+Arendsauthor=T.+Brennauthor=S.+Spiegelauthor=D.+J.+Adamsauthor=F.+M.+Wattauthor=L.+van+der+Weyden&title=Alkaline+ceramidase+1+is+essential+for+mammalian+skin+homeostasis+and+regulating+whole-body+energy+expenditure&doi=10.1002%2Fpath.4737"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Alkaline ceramidase 1 is essential for mammalian skin homeostasis and regulating whole-body energy expenditure</span></div><div class="casAuthors">Liakath-Ali, Kifayathullah; Vancollie, Valerie E.; Lelliott, Christopher J.; Speak, Anneliese O.; Lafont, David; Protheroe, Hayley J.; Ingvorsen, Camilla; Galli, Antonella; Green, Angela; Gleeson, Diane; Ryder, Ed; Glover, Leanne; Vizcay-Barrena, Gema; Karp, Natasha A.; Arends, Mark J.; Brenn, Thomas; Spiegel, Sarah; Adams, David J.; Watt, Fiona M.; van der Weyden, Louise</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pathology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">239</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">374-383</span>CODEN:
                <span class="NLM_cas:coden">JPTLAS</span>;
        ISSN:<span class="NLM_cas:issn">1096-9896</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons Ltd.</span>)
        </div><div class="casAbstract">The epidermis is the outermost layer of skin that acts as a barrier to protect the body from the external environment and to control water and heat loss.  This barrier function is established through the multistage differentiation of keratinocytes and the presence of bioactive sphingolipids such as ceramides, the levels of which are tightly regulated by a balance of ceramide synthase and ceramidase activities.  Here we reveal the essential role of alk. ceramidase 1 (Acer1) in the skin.  Acer1-deficient (Acer1-/-) mice showed elevated levels of ceramide in the skin, aberrant hair shaft cuticle formation and cyclic alopecia.  We demonstrate that Acer1 is specifically expressed in differentiated interfollicular epidermis, infundibulum and sebaceous glands and consequently Acer1-/- mice have significant alterations in infundibulum and sebaceous gland architecture.  Acer1-/- skin also shows perturbed hair follicle stem cell compartments.  These alterations result in Acer1-/- mice showing increased transepidermal water loss and a hypermetabolism phenotype with assocd. redn. of fat content with age.  We conclude that Acer1 is indispensable for mammalian skin homeostasis and whole-body energy homeostasis. © 2016 The Authors.  The Journal of Pathol. published by John Wiley & Sons Ltd on behalf of Pathol. Society of Great Britain and Ireland.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpGes66APLUrLVg90H21EOLACvtfcHk0li28R1pjjZ3Hw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtVWmu7vF&md5=c297e027f36783fec5de3a86a3e98983</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1002%2Fpath.4737&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fpath.4737%26sid%3Dliteratum%253Aachs%26aulast%3DLiakath-Ali%26aufirst%3DK.%26aulast%3DVancollie%26aufirst%3DV.%2BE.%26aulast%3DLelliott%26aufirst%3DC.%2BJ.%26aulast%3DSpeak%26aufirst%3DA.%2BO.%26aulast%3DLafont%26aufirst%3DD.%26aulast%3DProtheroe%26aufirst%3DH.%2BJ.%26aulast%3DIngvorsen%26aufirst%3DC.%26aulast%3DGalli%26aufirst%3DA.%26aulast%3DGreen%26aufirst%3DA.%26aulast%3DGleeson%26aufirst%3DD.%26aulast%3DRyder%26aufirst%3DE.%26aulast%3DGlover%26aufirst%3DL.%26aulast%3DVizcay-Barrena%26aufirst%3DG.%26aulast%3DKarp%26aufirst%3DN.%2BA.%26aulast%3DArends%26aufirst%3DM.%2BJ.%26aulast%3DBrenn%26aufirst%3DT.%26aulast%3DSpiegel%26aufirst%3DS.%26aulast%3DAdams%26aufirst%3DD.%2BJ.%26aulast%3DWatt%26aufirst%3DF.%2BM.%26aulast%3Dvan%2Bder%2BWeyden%26aufirst%3DL.%26atitle%3DAlkaline%2520ceramidase%25201%2520is%2520essential%2520for%2520mammalian%2520skin%2520homeostasis%2520and%2520regulating%2520whole-body%2520energy%2520expenditure%26jtitle%3DJ.%2520Pathol.%26date%3D2016%26volume%3D239%26spage%3D374%26epage%3D383%26doi%3D10.1002%2Fpath.4737" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sun, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crellin, H. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bielawski, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Szulc, Z. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thiers, B. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Obeid, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mao, C.</span></span> <span> </span><span class="NLM_article-title">Upregulation of the human alkaline ceramidase 1 and acid ceramidase mediates calcium-induced differentiation of epidermal keratinocytes</span>. <i>J. Invest. Dermatol.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>128</i></span>,  <span class="NLM_fpage">389</span>– <span class="NLM_lpage">397</span>, <span class="refDoi"> DOI: 10.1038/sj.jid.5701025</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01561&amp;key=10.1038%2Fsj.jid.5701025" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01561&amp;key=17713573" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01561&amp;key=1%3ACAS%3A528%3ADC%252BD1cXmsV2ltg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=128&publication_year=2008&pages=389-397&author=W.+Sunauthor=R.+Xuauthor=W.+Huauthor=J.+Jinauthor=H.+A.+Crellinauthor=J.+Bielawskiauthor=Z.+M.+Szulcauthor=B.+H.+Thiersauthor=L.+M.+Obeidauthor=C.+Mao&title=Upregulation+of+the+human+alkaline+ceramidase+1+and+acid+ceramidase+mediates+calcium-induced+differentiation+of+epidermal+keratinocytes&doi=10.1038%2Fsj.jid.5701025"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Upregulation of the Human Alkaline Ceramidase 1 and Acid Ceramidase Mediates Calcium-Induced Differentiation of Epidermal Keratinocytes</span></div><div class="casAuthors">Sun, Wei; Xu, Ruijuan; Hu, Wei; Jin, Junfei; Crellin, Heather A.; Bielawski, Jacek; Szulc, Zdzislaw M.; Thiers, Bruce H.; Obeid, Lina M.; Mao, Cungui</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Investigative Dermatology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">128</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">389-397</span>CODEN:
                <span class="NLM_cas:coden">JIDEAE</span>;
        ISSN:<span class="NLM_cas:issn">0022-202X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Extracellular calcium (Ca2+o) potently induces the growth arrest and differentiation of human epidermal keratinocytes (HEKs).  We report that Ca2+o markedly upregulates the human alk. ceramidase 1 (haCER1) in HEKs; and its upregulation mediates the Ca2+o-induced growth arrest and differentiation of HEKs.  HaCER1 is the human ortholog of mouse alk. ceramidase 1 that we previously identified.  HaCER1 catalyzed the hydrolysis of very long-chain ceramides to generate sphingosine (SPH).  This in vitro activity required Ca2+.  Ectopic expression of haCER1 in HEKs decreased the levels of D-e-C24:1-ceramide and D-e-C24:0-ceramide but elevated the levels of both SPH and its phosphate (S1P), whereas RNA interference-mediated knockdown of haCER1 caused the opposite effects on the levels of these sphingolipids in HEKs.  Similar to haCER1 overexpression, Ca2+o increased the levels of SPH and S1P, and this was attenuated by haCER1 knockdown. haCER1 knockdown also inhibited the Ca2+o-induced growth arrest of HEKs and the Ca2+o-induced expression of keratin 1 and involucrin in HEKs.  In addn., the acid ceramidase (AC) was also upregulated by Ca2+o; and its knockdown attenuated the Ca2+o-induced expression of keratin 1 and involucrin in HEKs.  These results strongly suggest that upregulation of haCER1 and AC mediates the Ca2+o-induced growth arrest and differentiation of HEKs by generating SPH and S1P.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqVoiEV5ww6obVg90H21EOLACvtfcHk0lhFDRzT5Lw3xQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXmsV2ltg%253D%253D&md5=8b2831c9327084efd1a3260a2c942fa8</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1038%2Fsj.jid.5701025&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.jid.5701025%26sid%3Dliteratum%253Aachs%26aulast%3DSun%26aufirst%3DW.%26aulast%3DXu%26aufirst%3DR.%26aulast%3DHu%26aufirst%3DW.%26aulast%3DJin%26aufirst%3DJ.%26aulast%3DCrellin%26aufirst%3DH.%2BA.%26aulast%3DBielawski%26aufirst%3DJ.%26aulast%3DSzulc%26aufirst%3DZ.%2BM.%26aulast%3DThiers%26aufirst%3DB.%2BH.%26aulast%3DObeid%26aufirst%3DL.%2BM.%26aulast%3DMao%26aufirst%3DC.%26atitle%3DUpregulation%2520of%2520the%2520human%2520alkaline%2520ceramidase%25201%2520and%2520acid%2520ceramidase%2520mediates%2520calcium-induced%2520differentiation%2520of%2520epidermal%2520keratinocytes%26jtitle%3DJ.%2520Invest.%2520Dermatol.%26date%3D2008%26volume%3D128%26spage%3D389%26epage%3D397%26doi%3D10.1038%2Fsj.jid.5701025" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xu, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mileva, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hannun, Y. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Obeid, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mao, C.</span></span> <span> </span><span class="NLM_article-title">Alkaline ceramidase 2 and its bioactive product sphingosine are novel regulators of the DNA damage response</span>. <i>Oncotarget</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">18440</span>– <span class="NLM_lpage">18457</span>, <span class="refDoi"> DOI: 10.18632/oncotarget.7825</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01561&amp;key=10.18632%2Foncotarget.7825" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01561&amp;key=26943039" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01561&amp;key=1%3ACAS%3A280%3ADC%252BC28jmvV2lsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2016&pages=18440-18457&author=R.+Xuauthor=K.+Wangauthor=I.+Milevaauthor=Y.+A.+Hannunauthor=L.+M.+Obeidauthor=C.+Mao&title=Alkaline+ceramidase+2+and+its+bioactive+product+sphingosine+are+novel+regulators+of+the+DNA+damage+response&doi=10.18632%2Foncotarget.7825"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Alkaline ceramidase 2 and its bioactive product sphingosine are novel regulators of the DNA damage response</span></div><div class="casAuthors">Xu Ruijuan; Wang Kai; Hannun Yusuf A; Obeid Lina M; Mao Cungui; Xu Ruijuan; Wang Kai; Hannun Yusuf A; Obeid Lina M; Mao Cungui; Mileva Izolda; Obeid Lina M</div><div class="citationInfo"><span class="NLM_cas:title">Oncotarget</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">18440-57</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Human cells respond to DNA damage by elevating sphingosine, a bioactive sphingolipid that induces programmed cell death (PCD) in response to various forms of stress, but its regulation and role in the DNA damage response remain obscure.  Herein we demonstrate that DNA damage increases sphingosine levels in tumor cells by upregulating alkaline ceramidase 2 (ACER2) and that the upregulation of the ACER2/sphingosine pathway induces PCD in response to DNA damage by increasing the production of reactive oxygen species (ROS).  Treatment with the DNA damaging agent doxorubicin increased both ACER2 expression and sphingosine levels in HCT116 cells in a dose-dependent manner.  ACER2 overexpression increased sphingosine in HeLa cells whereas knocking down ACER2 inhibited the doxorubicin-induced increase in sphingosine in HCT116 cells, suggesting that DNA damage elevates sphingosine by upregulating ACER2.  Knocking down ACER2 inhibited an increase in the apoptotic and necrotic cell population and the cleavage of poly ADP ribose polymerase (PARP) in HCT116 cells in response to doxorubicin as well as doxorubicin-induced release of lactate dehydrogenase (LDH) from these cells.  Similar to treatment with doxorubicin, ACER2 overexpression induced an increase in the apoptotic and necrotic cell population and PARP cleavage in HeLa cells and LDH release from cells, suggesting that ACER2 upregulation mediates PCD in response to DNA damage through sphingosine.  Mechanistic studies demonstrated that the upregulation of the ACER2/sphingosine pathway induces PCD by increasing ROS levels.  Taken together, these results suggest that the ACER2/sphingosine pathway mediates PCD in response to DNA damage through ROS production.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRCO-JaxZbqSpdYoSR9eyvsfW6udTcc2ebQ2RBOnz8libntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC28jmvV2lsw%253D%253D&md5=baf9847bfe0128f958d8de5ed003ebd4</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.18632%2Foncotarget.7825&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18632%252Foncotarget.7825%26sid%3Dliteratum%253Aachs%26aulast%3DXu%26aufirst%3DR.%26aulast%3DWang%26aufirst%3DK.%26aulast%3DMileva%26aufirst%3DI.%26aulast%3DHannun%26aufirst%3DY.%2BA.%26aulast%3DObeid%26aufirst%3DL.%2BM.%26aulast%3DMao%26aufirst%3DC.%26atitle%3DAlkaline%2520ceramidase%25202%2520and%2520its%2520bioactive%2520product%2520sphingosine%2520are%2520novel%2520regulators%2520of%2520the%2520DNA%2520damage%2520response%26jtitle%3DOncotarget%26date%3D2016%26volume%3D7%26spage%3D18440%26epage%3D18457%26doi%3D10.18632%2Foncotarget.7825" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Szulc, Z. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bielawski, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Obeid, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mao, C.</span></span> <span> </span><span class="NLM_article-title">Alkaline ceramidase 3 (ACER3) hydrolyzes unsaturated long-chain ceramides, and its down-regulation inhibits both cell proliferation and apoptosis</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>285</i></span>,  <span class="NLM_fpage">7964</span>– <span class="NLM_lpage">7976</span>, <span class="refDoi"> DOI: 10.1074/jbc.m109.063586</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01561&amp;key=10.1074%2Fjbc.M109.063586" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01561&amp;key=20068046" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01561&amp;key=1%3ACAS%3A528%3ADC%252BC3cXislyqtLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=285&publication_year=2010&pages=7964-7976&author=W.+Huauthor=R.+Xuauthor=W.+Sunauthor=Z.+M.+Szulcauthor=J.+Bielawskiauthor=L.+M.+Obeidauthor=C.+Mao&title=Alkaline+ceramidase+3+%28ACER3%29+hydrolyzes+unsaturated+long-chain+ceramides%2C+and+its+down-regulation+inhibits+both+cell+proliferation+and+apoptosis&doi=10.1074%2Fjbc.m109.063586"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Alkaline Ceramidase 3 (ACER3) Hydrolyzes Unsaturated Long-chain Ceramides, and Its Down-regulation Inhibits Both Cell Proliferation and Apoptosis</span></div><div class="casAuthors">Hu, Wei; Xu, Ruijuan; Sun, Wei; Szulc, Zdzislaw M.; Bielawski, Jacek; Obeid, Lina M.; Mao, Cungui</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">285</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">7964-7976</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">Ceramides with different fatty acyl chains may vary in their physiol. or pathol. roles; however, it remains unclear how cellular levels of individual ceramide species are regulated.  Here, we demonstrate that our previously cloned human alk. ceramidase 3 (ACER3) specifically controls the hydrolysis of ceramides carrying unsatd. long acyl chains, unsatd. long-chain (ULC) ceramides.  In vitro, ACER3 only hydrolyzed C18:1-, C20:1-, C20:4-ceramides, dihydroceramides, and phytoceramides.  In cells, ACER3 overexpression decreased C18:1- and C20:1-ceramides and dihydroceramides, whereas ACER3 knockdown by RNA interference had the opposite effect, suggesting that ACER3 controls the catabolism of ULC ceramides and dihydroceramides.  ACER3 knockdown inhibited cell proliferation and up-regulated the cyclin-dependent kinase inhibitor p21CIP1/WAF1.  Blocking p21CIP1/WAF1 up-regulation attenuated the inhibitory effect of ACER3 knockdown on cell proliferation, suggesting that ACER3 knockdown inhibits cell proliferation because of p21CIP1/WAF1 up-regulation.  ACER3 knockdown inhibited cell apoptosis in response to serum deprivation.  ACER3 knockdown up-regulated the expression of the alk. ceramidase 2 (ACER2), and the ACER2 up-regulation decreased non-ULC ceramide species while increasing both sphingosine and its phosphate.  Collectively, these data suggest that ACER3 catalyzes the hydrolysis of ULC ceramides and dihydroceramides and that ACER3 coordinates with ACER2 to regulate cell proliferation and survival.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpCiCEwa7GRxLVg90H21EOLACvtfcHk0lhFDRzT5Lw3xQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXislyqtLk%253D&md5=24778e515470e14507c49f98f8fae8c8</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M109.063586&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M109.063586%26sid%3Dliteratum%253Aachs%26aulast%3DHu%26aufirst%3DW.%26aulast%3DXu%26aufirst%3DR.%26aulast%3DSun%26aufirst%3DW.%26aulast%3DSzulc%26aufirst%3DZ.%2BM.%26aulast%3DBielawski%26aufirst%3DJ.%26aulast%3DObeid%26aufirst%3DL.%2BM.%26aulast%3DMao%26aufirst%3DC.%26atitle%3DAlkaline%2520ceramidase%25203%2520%2528ACER3%2529%2520hydrolyzes%2520unsaturated%2520long-chain%2520ceramides%252C%2520and%2520its%2520down-regulation%2520inhibits%2520both%2520cell%2520proliferation%2520and%2520apoptosis%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2010%26volume%3D285%26spage%3D7964%26epage%3D7976%26doi%3D10.1074%2Fjbc.m109.063586" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schrandt, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shah, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gong, Y. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Preston, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yi, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, C.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spyropoulos, D. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rhee, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ge, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Snider, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hannun, Y. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Obeid, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mao, C.</span></span> <span> </span><span class="NLM_article-title">Alkaline ceramidase 3 deficiency results in purkinje cell degeneration and cerebellar ataxia due to dyshomeostasis of sphingolipids in the brain</span>. <i>PLoS Genet.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">e1005591</span>– <span class="NLM_lpage">e1005622</span>, <span class="refDoi"> DOI: 10.1371/journal.pgen.1005591</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01561&amp;key=10.1371%2Fjournal.pgen.1005591" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01561&amp;key=26474409" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01561&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtFelsrfN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2015&pages=e1005591-e1005622&author=K.+Wangauthor=R.+Xuauthor=J.+Schrandtauthor=P.+Shahauthor=Y.+Z.+Gongauthor=C.+Prestonauthor=L.+Wangauthor=J.+K.+Yiauthor=C.-L.+Linauthor=W.+Sunauthor=D.+D.+Spyropoulosauthor=S.+Rheeauthor=M.+Liauthor=J.+Zhouauthor=S.+Geauthor=G.+Zhangauthor=A.+J.+Sniderauthor=Y.+A.+Hannunauthor=L.+M.+Obeidauthor=C.+Mao&title=Alkaline+ceramidase+3+deficiency+results+in+purkinje+cell+degeneration+and+cerebellar+ataxia+due+to+dyshomeostasis+of+sphingolipids+in+the+brain&doi=10.1371%2Fjournal.pgen.1005591"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Alkaline ceramidase 3 deficiency results in Purkinje cell degeneration and cerebellar ataxia due to dyshomeostasis of sphingolipids in the brain</span></div><div class="casAuthors">Wang, Kai; Xu, Ruijuan; Schrandt, Jennifer; Shah, Prithvi; Gong, Yong Z.; Preston, Chet; Wang, Louis; Yi, Jae Kyo; Lin, Chih-Li; Sun, Wei; Spyropoulos, Demetri D.; Rhee, Soyoung; Li, Mingsong; Zhou, Jie; Ge, Shaoyu; Zhang, Guofeng; Snider, Ashley J.; Hannun, Yusuf A.; Obeid, Lina M.; Mao, Cungui</div><div class="citationInfo"><span class="NLM_cas:title">PLoS Genetics</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">e1005591/1-e1005591/31</span>CODEN:
                <span class="NLM_cas:coden">PGLEB5</span>;
        ISSN:<span class="NLM_cas:issn">1553-7404</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">Dyshomeostasis of both ceramides and sphingosine-1-phosphate (S1P) in the brain has been implicated in aging-assocd. neurodegenerative disorders in humans.  However, mechanisms that maintain the homeostasis of these bioactive sphingolipids in the brain remain unclear.  Mouse alk. ceramidase 3 (Acer3), which preferentially catalyzes the hydrolysis of C18:1-ceramide, a major unsatd. long-chain ceramide species in the brain, is upregulated with age in the mouse brain.  Acer3 knockout causes an age-dependent accumulation of various ceramides and C18:1-monohexosylceramide and abolishes the age-related increase in the levels of sphingosine and S1P in the brain; thereby resulting in Purkinje cell degeneration in the cerebellum and deficits in motor coordination and balance.  Our results indicate that Acer3 plays critically protective roles in controlling the homeostasis of various sphingolipids, including ceramides, sphingosine, S1P, and certain complex sphingolipids in the brain and protects Purkinje cells from premature degeneration.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGquK9k-H7uHI7Vg90H21EOLACvtfcHk0liX4QhZ0ZmQUA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtFelsrfN&md5=d4df63930a9c02e142dc5761a1908ee3</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pgen.1005591&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pgen.1005591%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DK.%26aulast%3DXu%26aufirst%3DR.%26aulast%3DSchrandt%26aufirst%3DJ.%26aulast%3DShah%26aufirst%3DP.%26aulast%3DGong%26aufirst%3DY.%2BZ.%26aulast%3DPreston%26aufirst%3DC.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DYi%26aufirst%3DJ.%2BK.%26aulast%3DLin%26aufirst%3DC.-L.%26aulast%3DSun%26aufirst%3DW.%26aulast%3DSpyropoulos%26aufirst%3DD.%2BD.%26aulast%3DRhee%26aufirst%3DS.%26aulast%3DLi%26aufirst%3DM.%26aulast%3DZhou%26aufirst%3DJ.%26aulast%3DGe%26aufirst%3DS.%26aulast%3DZhang%26aufirst%3DG.%26aulast%3DSnider%26aufirst%3DA.%2BJ.%26aulast%3DHannun%26aufirst%3DY.%2BA.%26aulast%3DObeid%26aufirst%3DL.%2BM.%26aulast%3DMao%26aufirst%3DC.%26atitle%3DAlkaline%2520ceramidase%25203%2520deficiency%2520results%2520in%2520purkinje%2520cell%2520degeneration%2520and%2520cerebellar%2520ataxia%2520due%2520to%2520dyshomeostasis%2520of%2520sphingolipids%2520in%2520the%2520brain%26jtitle%3DPLoS%2520Genet.%26date%3D2015%26volume%3D11%26spage%3De1005591%26epage%3De1005622%26doi%3D10.1371%2Fjournal.pgen.1005591" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Edvardson, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yi, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jalas, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Webb, B. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Snider, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fedick, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kleinman, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Treff, N. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mao, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elpeleg, O.</span></span> <span> </span><span class="NLM_article-title">Deficiency of the alkaline ceramidase ACER3 manifests in early childhood by progressive leukodystrophy</span>. <i>J. Med. Genet.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>53</i></span>,  <span class="NLM_fpage">389</span>– <span class="NLM_lpage">396</span>, <span class="refDoi"> DOI: 10.1136/jmedgenet-2015-103457</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01561&amp;key=10.1136%2Fjmedgenet-2015-103457" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01561&amp;key=26792856" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01561&amp;key=1%3ACAS%3A528%3ADC%252BC1cXkvFKjsLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2016&pages=389-396&author=S.+Edvardsonauthor=J.+K.+Yiauthor=C.+Jalasauthor=R.+Xuauthor=B.+D.+Webbauthor=J.+Sniderauthor=A.+Fedickauthor=E.+Kleinmanauthor=N.+R.+Treffauthor=C.+Maoauthor=O.+Elpeleg&title=Deficiency+of+the+alkaline+ceramidase+ACER3+manifests+in+early+childhood+by+progressive+leukodystrophy&doi=10.1136%2Fjmedgenet-2015-103457"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Deficiency of the alkaline ceramidase ACER3 manifests in early childhood by progressive leukodystrophy</span></div><div class="casAuthors">Edvardson, Simon; Yi, Jae Kyo; Jalas, Chaim; Xu, Ruijuan; Webb, Bryn D.; Snider, Justin; Fedick, Anastasia; Kleinman, Elisheva; Treff, Nathan R.; Mao, Cungui; Elpeleg, Orly</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medical Genetics</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">389-396</span>CODEN:
                <span class="NLM_cas:coden">JMDGAE</span>;
        ISSN:<span class="NLM_cas:issn">0022-2593</span>.
    
            (<span class="NLM_cas:orgname">BMJ Publishing Group</span>)
        </div><div class="casAbstract">Background/aims Leukodystrophies due to abnormal prodn. of myelin cause extensive morbidity in early life; their genetic background is still largely unknown.  We aimed at reaching a mol. diagnosis in Ashkenazi-Jewish patients who suffered from developmental regression at 6-13 mo, leukodystrophy and peripheral neuropathy.  Methods Exome anal., detn. of alk. ceramidase activity catalyzing the conversion of C18:1- ceramide to sphingosine and D-ribo-C12-N-(7-nitrobenz-2- oxa-1,3-diazol-4-yl) (NBD)-phytoceramide to NBD-C12- fatty acid using liq. chromatog.-tandem mass spectrometry (LC-MS/MS) and thin layer chromatog., resp., and sphingolipid anal. in patients' blood by LC-MS/MS.  Results The patients were homozygous for p.E33G in the ACER3, which encodes a C18:1-alk. ceramidase and C20:1-alk. ceramidase.  The mutation abolished ACER3 catalytic activity in the patients' cells and failed to restore alk. ceramidase activity in yeast mutant strain.  The levels of ACER3 substrates, C18:1-ceramides and dihydroceramides and C20:1-ceramides and dihydroceramides and other long-chain ceramides and dihydroceramides were markedly increased in the patients' plasma, along with that of complex sphingolipids, including monohexosylceramides and lactosylceramides.  Conclusions Homozygosity for the p.E33G mutation in the ACER3 gene results in inactivation of ACER3, leading to the accumulation of various sphingolipids in blood and probably in brain, likely accounting for this new form of childhood leukodystroph.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrehSzH5J9uSrVg90H21EOLACvtfcHk0liX4QhZ0ZmQUA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXkvFKjsLY%253D&md5=cada68b70a98e6b78509e9935b58d5db</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1136%2Fjmedgenet-2015-103457&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1136%252Fjmedgenet-2015-103457%26sid%3Dliteratum%253Aachs%26aulast%3DEdvardson%26aufirst%3DS.%26aulast%3DYi%26aufirst%3DJ.%2BK.%26aulast%3DJalas%26aufirst%3DC.%26aulast%3DXu%26aufirst%3DR.%26aulast%3DWebb%26aufirst%3DB.%2BD.%26aulast%3DSnider%26aufirst%3DJ.%26aulast%3DFedick%26aufirst%3DA.%26aulast%3DKleinman%26aufirst%3DE.%26aulast%3DTreff%26aufirst%3DN.%2BR.%26aulast%3DMao%26aufirst%3DC.%26aulast%3DElpeleg%26aufirst%3DO.%26atitle%3DDeficiency%2520of%2520the%2520alkaline%2520ceramidase%2520ACER3%2520manifests%2520in%2520early%2520childhood%2520by%2520progressive%2520leukodystrophy%26jtitle%3DJ.%2520Med.%2520Genet.%26date%3D2016%26volume%3D53%26spage%3D389%26epage%3D396%26doi%3D10.1136%2Fjmedgenet-2015-103457" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bernardo, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hurwitz, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zenk, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Desnick, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferlinz, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schuchman, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sandhoff, K.</span></span> <span> </span><span class="NLM_article-title">Purification, characterization, and biosynthesis of human acid ceramidase</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1995</span>,  <span class="NLM_volume"><i>270</i></span>,  <span class="NLM_fpage">11098</span>– <span class="NLM_lpage">11102</span>, <span class="refDoi"> DOI: 10.1074/jbc.270.19.11098</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01561&amp;key=10.1074%2Fjbc.270.19.11098" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01561&amp;key=7744740" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01561&amp;key=1%3ACAS%3A528%3ADyaK2MXls1ejtb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=270&publication_year=1995&pages=11098-11102&author=K.+Bernardoauthor=R.+Hurwitzauthor=T.+Zenkauthor=R.+Desnickauthor=K.+Ferlinzauthor=E.+Schuchmanauthor=K.+Sandhoff&title=Purification%2C+characterization%2C+and+biosynthesis+of+human+acid+ceramidase&doi=10.1074%2Fjbc.270.19.11098"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Purification, characterization, and biosynthesis of human acid ceramidase</span></div><div class="casAuthors">Bernardo, Katussevani; Hurwitz, Robert; Zenk, Thomas; Desnick, Robert J.; Ferlinz, Klaus; Schuchman, Edward H.; Sandhoff, Konrad</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">1995</span>),
    <span class="NLM_cas:volume">270</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">11098-102</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">Acid ceramidase (N-acylsphingosine deacylase, EC 3.5.1.23) (I) is the lysosomal enzyme catalyzing the hydrolysis of ceramide to sphingosine and free fatty acid.  Its inherited deficiency causes ceramide accumulation in inherited deficiency causes ceramide accumulation in Faber's disease.  I was purified to apparent homogeneity from human urine by sequential chromatog. on octyl-Sepharose, Con A-Sepharose, Blue-Sepharose, and DEAE-cellulose.  The final prepn., which was enriched ∼4450-fold over the starting material, resulted in a polypeptide of ∼50 kDa and could be reduced into 2 subunits of ∼13 (α) and ∼40 (β) kDa.  Treatment of purified I with endoglycosidase H or peptide N-glycanase F reduced the mol. wt. of the β subunit to ∼30-35 and ∼27 kDa, resp.  In contrast, the mol. wt. of the α subunit was unchanged.  Purified I had an apparent Km of 149 μM and a Vmax of 136 nmol/mg/h using N-lauroylsphingosine as substrate.  Polyclonal antibodies were raised against the purified urinary enzyme and used to investigate the biosynthesis of I.  Immunopptn. studies on metabolically labeled skin fibroblasts indicated that both subunits arise from a single precursor of ∼55 kDa.  A minor protein of newly synthesized I was secreted into the medium as a monomeric 47-kDa protein, indicating that generation of the mature heterodimeric enzyme occurs in endosomal and/or lysosomal compartments.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpm-1pFxhqHCLVg90H21EOLACvtfcHk0ljPkM9eZNnPPQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2MXls1ejtb4%253D&md5=d8f667c773db8a01ca5d22e49dd36123</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1074%2Fjbc.270.19.11098&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.270.19.11098%26sid%3Dliteratum%253Aachs%26aulast%3DBernardo%26aufirst%3DK.%26aulast%3DHurwitz%26aufirst%3DR.%26aulast%3DZenk%26aufirst%3DT.%26aulast%3DDesnick%26aufirst%3DR.%26aulast%3DFerlinz%26aufirst%3DK.%26aulast%3DSchuchman%26aufirst%3DE.%26aulast%3DSandhoff%26aufirst%3DK.%26atitle%3DPurification%252C%2520characterization%252C%2520and%2520biosynthesis%2520of%2520human%2520acid%2520ceramidase%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D1995%26volume%3D270%26spage%3D11098%26epage%3D11102%26doi%3D10.1074%2Fjbc.270.19.11098" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ferlinz, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kopal, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bernardo, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Linke, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bär, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Breiden, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neumann, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lang, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schuchman, E. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sandhoff, K.</span></span> <span> </span><span class="NLM_article-title">Human acid ceramidase. Processing, glycosylation, and lysosomal targeting</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>276</i></span>,  <span class="NLM_fpage">35352</span>– <span class="NLM_lpage">35360</span>, <span class="refDoi"> DOI: 10.1074/jbc.m103066200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01561&amp;key=10.1074%2Fjbc.M103066200" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01561&amp;key=11451951" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01561&amp;key=1%3ACAS%3A528%3ADC%252BD3MXntFaiu74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=276&publication_year=2001&pages=35352-35360&author=K.+Ferlinzauthor=G.+Kopalauthor=K.+Bernardoauthor=T.+Linkeauthor=J.+B%C3%A4rauthor=B.+Breidenauthor=U.+Neumannauthor=F.+Langauthor=E.+H.+Schuchmanauthor=K.+Sandhoff&title=Human+acid+ceramidase.+Processing%2C+glycosylation%2C+and+lysosomal+targeting&doi=10.1074%2Fjbc.m103066200"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Human acid ceramidase. Processing, glycosylation, and lysosomal targeting</span></div><div class="casAuthors">Ferlinz, Klaus; Kopal, Guido; Bernardo, Katussevani; Linke, Thomas; Bar, Julia; Breiden, Bernadette; Neumann, Ulrich; Lang, Florian; Schuchman, Edward H.; Sandhoff, Konrad</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">276</span>
        (<span class="NLM_cas:issue">38</span>),
    <span class="NLM_cas:pages">35352-35360</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">The biosynthesis of human acid ceramidase (hAC) starts with the expression of a single precursor polypeptide of ∼53-55 kDa, which is subsequently processed to the mature, heterodimeric enzyme (40 + 13 kDa) in the endosomes/lysosomes.  Secretion of hAC by either fibroblasts or acid ceramidase cDNA-transfected COS cells is extraordinarily low.  Both lysosomal targeting and endocytosis critically depend on a functional mannose 6-phosphate receptor as judged by the following criteria: (i) hAC-precursor secretion by NH4Cl-treated fibroblasts and I-cell disease fibroblasts, (ii) inhibition of the formation of mature heterodimeric hAC in NH4Cl-treated fibroblasts or in I-cell disease fibroblasts, and (iii) blocked endocytosis of hAC precursor by mannose 6-phosphate receptor-deficient fibroblasts or the addn. of mannose 6-phosphate.  The influence of the six individual potential N-glycosylation sites of human acid ceramidase on targeting, processing, and catalytic activity was detd. by site-directed mutagenesis.  Five glycosylation sites (sites 1-5 from the N terminus) are used.  The elimination of sites 2, 4, and 6 has no influence on lysosomal processing or enzymic activity of recombinant ceramidase.  The removal of sites 1, 3, and 5 inhibits the formation of the heterodimeric enzyme form.  None of the mutant ceramidases gave rise to an increased rate of secretion, suggesting that lysosomal targeting does not depend on one single carbohydrate chain.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGphqd4zG5xUarVg90H21EOLACvtfcHk0ljPkM9eZNnPPQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXntFaiu74%253D&md5=ed5f3b1df1fde010beeba41678f61fcc</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M103066200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M103066200%26sid%3Dliteratum%253Aachs%26aulast%3DFerlinz%26aufirst%3DK.%26aulast%3DKopal%26aufirst%3DG.%26aulast%3DBernardo%26aufirst%3DK.%26aulast%3DLinke%26aufirst%3DT.%26aulast%3DB%25C3%25A4r%26aufirst%3DJ.%26aulast%3DBreiden%26aufirst%3DB.%26aulast%3DNeumann%26aufirst%3DU.%26aulast%3DLang%26aufirst%3DF.%26aulast%3DSchuchman%26aufirst%3DE.%2BH.%26aulast%3DSandhoff%26aufirst%3DK.%26atitle%3DHuman%2520acid%2520ceramidase.%2520Processing%252C%2520glycosylation%252C%2520and%2520lysosomal%2520targeting%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2001%26volume%3D276%26spage%3D35352%26epage%3D35360%26doi%3D10.1074%2Fjbc.m103066200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Newton, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lima, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maceyka, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spiegel, S.</span></span> <span> </span><span class="NLM_article-title">Revisiting the sphingolipid rheostat: Evolving concepts in cancer therapy</span>. <i>Exp. Cell Res.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>333</i></span>,  <span class="NLM_fpage">195</span>– <span class="NLM_lpage">200</span>, <span class="refDoi"> DOI: 10.1016/j.yexcr.2015.02.025</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01561&amp;key=10.1016%2Fj.yexcr.2015.02.025" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01561&amp;key=25770011" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01561&amp;key=1%3ACAS%3A528%3ADC%252BC2MXksFWis7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=333&publication_year=2015&pages=195-200&author=J.+Newtonauthor=S.+Limaauthor=M.+Maceykaauthor=S.+Spiegel&title=Revisiting+the+sphingolipid+rheostat%3A+Evolving+concepts+in+cancer+therapy&doi=10.1016%2Fj.yexcr.2015.02.025"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Revisiting the sphingolipid rheostat- evolving concepts in cancer therapy</span></div><div class="casAuthors">Newton, Jason; Lima, Santiago; Maceyka, Michael; Spiegel, Sarah</div><div class="citationInfo"><span class="NLM_cas:title">Experimental Cell Research</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">333</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">195-200</span>CODEN:
                <span class="NLM_cas:coden">ECREAL</span>;
        ISSN:<span class="NLM_cas:issn">0014-4827</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  This article discusses about role of sphingolipid metabolites such as ceramide and sphingosine-1-phosphate in cell fate along with effects of targeting sphingosine-1-phosphate metabolic enzymes in modulation of progression and drug resistance of cancer in human.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrGeaW9kxBn-LVg90H21EOLACvtfcHk0ljPkM9eZNnPPQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXksFWis7s%253D&md5=0c70739b9f3c002817f82203d832500a</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1016%2Fj.yexcr.2015.02.025&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.yexcr.2015.02.025%26sid%3Dliteratum%253Aachs%26aulast%3DNewton%26aufirst%3DJ.%26aulast%3DLima%26aufirst%3DS.%26aulast%3DMaceyka%26aufirst%3DM.%26aulast%3DSpiegel%26aufirst%3DS.%26atitle%3DRevisiting%2520the%2520sphingolipid%2520rheostat%253A%2520Evolving%2520concepts%2520in%2520cancer%2520therapy%26jtitle%3DExp.%2520Cell%2520Res.%26date%3D2015%26volume%3D333%26spage%3D195%26epage%3D200%26doi%3D10.1016%2Fj.yexcr.2015.02.025" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Huang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Withers, B. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dickson, R. C.</span></span> <span> </span><span class="NLM_article-title">Sphingolipids and lifespan regulation</span>. <i>Biochim. Biophys. Acta, Mol. Cell Biol. Lipids</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>1841</i></span>,  <span class="NLM_fpage">657</span>– <span class="NLM_lpage">664</span>, <span class="refDoi"> DOI: 10.1016/j.bbalip.2013.08.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01561&amp;key=10.1016%2Fj.bbalip.2013.08.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01561&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtlGqs7vN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1841&publication_year=2014&pages=657-664&author=X.+Huangauthor=B.+R.+Withersauthor=R.+C.+Dickson&title=Sphingolipids+and+lifespan+regulation&doi=10.1016%2Fj.bbalip.2013.08.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Sphingolipids and lifespan regulation</span></div><div class="casAuthors">Huang, Xinhe; Withers, Bradley R.; Dickson, Robert C.</div><div class="citationInfo"><span class="NLM_cas:title">Biochimica et Biophysica Acta, Molecular and Cell Biology of Lipids</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">1841</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">657-664</span>CODEN:
                <span class="NLM_cas:coden">BBMLFG</span>;
        ISSN:<span class="NLM_cas:issn">1388-1981</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B. V.</span>)
        </div><div class="casAbstract">A review.  Diseases including cancer, type 2 diabetes, cardiovascular and immune dysfunction and neurodegeneration become more prevalent as we age, and combined with the increase in av. human lifespan, place an ever increasing burden on the health care system.  In this chapter we focus on finding ways of modulating sphingolipids to prevent the development of age-assocd. diseases or delay their onset, both of which could improve health in elderly, fragile people.  Reducing the incidence of or delaying the onset of diseases of aging has blossomed in the past decade because of advances in understanding signal transduction pathways and cellular processes, esp. in model organisms, that are largely conserved in most eukaryotes and that can be modulated to reduce signs of aging and increase health span.  In model organisms such interventions must also increase lifespan to be considered significant, but this is not a requirement for use in humans.  The most encouraging interventions in model organisms involve lowering the concn. of one or more sphingolipids so as to reduce the activity of key signaling pathways, one of the most promising being the Target of Rapamycin Complex 1 (TORC1) protein kinase pathway.  Other potential ways in which modulating sphingolipids may contribute to improving the health profile of the elderly is by reducing oxidative stresses, inflammatory responses and growth factor signaling.  Lastly, perhaps the most interesting way to modulate sphingolipids and promote longevity is by lowering the activity of serine palmitoyltransferase, the first enzyme in the de novo sphingolipid biosynthesis pathway.  Available data in yeasts and rodents are encouraging and as we gain insights into mol. mechanisms the strategies for improving human health by modulating sphingolipids will become more apparent.  This article is part of a Special Issue entitled New Frontiers in Sphingolipid Biol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr-1RgynOoylLVg90H21EOLACvtfcHk0lhYmMiVOSru6w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtlGqs7vN&md5=43c74eeb2e56fcd45233c75fde965851</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1016%2Fj.bbalip.2013.08.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bbalip.2013.08.006%26sid%3Dliteratum%253Aachs%26aulast%3DHuang%26aufirst%3DX.%26aulast%3DWithers%26aufirst%3DB.%2BR.%26aulast%3DDickson%26aufirst%3DR.%2BC.%26atitle%3DSphingolipids%2520and%2520lifespan%2520regulation%26jtitle%3DBiochim.%2520Biophys.%2520Acta%252C%2520Mol.%2520Cell%2520Biol.%2520Lipids%26date%3D2014%26volume%3D1841%26spage%3D657%26epage%3D664%26doi%3D10.1016%2Fj.bbalip.2013.08.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pettus, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chalfant, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hannun, Y. A.</span></span> <span> </span><span class="NLM_article-title">Ceramide in apoptosis: an overview and current perspectives</span>. <i>Biochim. Biophys. Acta, Mol. Cell Biol. Lipids</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>1585</i></span>,  <span class="NLM_fpage">114</span>– <span class="NLM_lpage">125</span>, <span class="refDoi"> DOI: 10.1016/s1388-1981(02)00331-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01561&amp;key=10.1016%2FS1388-1981%2802%2900331-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01561&amp;key=12531544" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01561&amp;key=1%3ACAS%3A528%3ADC%252BD3sXivVOqtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1585&publication_year=2002&pages=114-125&author=B.+J.+Pettusauthor=C.+E.+Chalfantauthor=Y.+A.+Hannun&title=Ceramide+in+apoptosis%3A+an+overview+and+current+perspectives&doi=10.1016%2Fs1388-1981%2802%2900331-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Ceramide in apoptosis: an overview and current perspectives</span></div><div class="casAuthors">Pettus, Benjamin J.; Chalfant, Charles E.; Hannun, Yusuf A.</div><div class="citationInfo"><span class="NLM_cas:title">Biochimica et Biophysica Acta, Molecular and Cell Biology of Lipids</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">1585</span>
        (<span class="NLM_cas:issue">2-3</span>),
    <span class="NLM_cas:pages">114-125</span>CODEN:
                <span class="NLM_cas:coden">BBMLFG</span>;
        ISSN:<span class="NLM_cas:issn">1388-1981</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Recent years have witnessed significant advances in the understanding of the role of ceramide in apoptosis.  This review summarizes these recent findings and discusses insights from studies of ceramide metab., topol., and effector actions.  The recent identification of several genes for enzymes of ceramide metab., the development of mass spectrometric methods for ceramide anal., and the increasing mol. and pharmacol. tools to probe ceramide metab. and function promise an accelerated phase in defining the mol. and biochem. details of the role of ceramide in apoptosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoXIUeERO-epbVg90H21EOLACvtfcHk0lhYmMiVOSru6w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXivVOqtg%253D%253D&md5=e1cc8bcdf206d5417e085bdd0d6f0096</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1016%2FS1388-1981%2802%2900331-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1388-1981%252802%252900331-1%26sid%3Dliteratum%253Aachs%26aulast%3DPettus%26aufirst%3DB.%2BJ.%26aulast%3DChalfant%26aufirst%3DC.%2BE.%26aulast%3DHannun%26aufirst%3DY.%2BA.%26atitle%3DCeramide%2520in%2520apoptosis%253A%2520an%2520overview%2520and%2520current%2520perspectives%26jtitle%3DBiochim.%2520Biophys.%2520Acta%252C%2520Mol.%2520Cell%2520Biol.%2520Lipids%26date%3D2002%26volume%3D1585%26spage%3D114%26epage%3D125%26doi%3D10.1016%2Fs1388-1981%2802%2900331-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Morales, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goñi, F. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kolesnick, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fernandez-Checa, J. C.</span></span> <span> </span><span class="NLM_article-title">Sphingolipids and cell death</span>. <i>Apoptosis</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">923</span>– <span class="NLM_lpage">939</span>, <span class="refDoi"> DOI: 10.1007/s10495-007-0721-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01561&amp;key=10.1007%2Fs10495-007-0721-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01561&amp;key=17294080" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01561&amp;key=1%3ACAS%3A528%3ADC%252BD2sXksFamtr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2007&pages=923-939&author=A.+Moralesauthor=H.+Leeauthor=F.+M.+Go%C3%B1iauthor=R.+Kolesnickauthor=J.+C.+Fernandez-Checa&title=Sphingolipids+and+cell+death&doi=10.1007%2Fs10495-007-0721-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Sphingolipids and cell death</span></div><div class="casAuthors">Morales, Albert; Lee, Hyunmi; Goni, Felix M.; Kolesnick, Richard; Fernandez-Checa, Jose C.</div><div class="citationInfo"><span class="NLM_cas:title">Apoptosis</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">923-939</span>CODEN:
                <span class="NLM_cas:coden">APOPFN</span>;
        ISSN:<span class="NLM_cas:issn">1360-8185</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">A review.  Sphingolipids (SLs) have been considered for many years as predominant building blocks of biol. membranes with key structural functions and little relevance in cellular signaling.  However, this view has changed dramatically in recent years with the recognition that certain SLs such as ceramide, sphingosine 1-phosphate and gangliosides, participate actively in signal transduction pathways, regulating many different cell functions such as proliferation, differentiation, adhesion and cell death.  In particular, ceramide has attracted considerable attention in cell biol. and biophysics due to its key role in the modulation of membrane phys. properties, signaling and cell death regulation.  This latter function is largely exerted by the ability of ceramide to activate the major pathways governing cell death such as the endoplasmic reticulum and mitochondria.  Overall, the evidence so far indicates a key function of SLs in disease pathogenesis and hence their regulation may be of potential therapeutic relevance in different pathologies including liver diseases, neurodegeneration and cancer biol. and therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoO8HgnKrzkeLVg90H21EOLACvtfcHk0lhYmMiVOSru6w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXksFamtr4%253D&md5=5f7e22e3f90eaab152197336d1f0a37b</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1007%2Fs10495-007-0721-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10495-007-0721-0%26sid%3Dliteratum%253Aachs%26aulast%3DMorales%26aufirst%3DA.%26aulast%3DLee%26aufirst%3DH.%26aulast%3DGo%25C3%25B1i%26aufirst%3DF.%2BM.%26aulast%3DKolesnick%26aufirst%3DR.%26aulast%3DFernandez-Checa%26aufirst%3DJ.%2BC.%26atitle%3DSphingolipids%2520and%2520cell%2520death%26jtitle%3DApoptosis%26date%3D2007%26volume%3D12%26spage%3D923%26epage%3D939%26doi%3D10.1007%2Fs10495-007-0721-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Desai, N. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olivera, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seki, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brooker, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spiegel, S.</span></span> <span> </span><span class="NLM_article-title">Sphingosine-1-phosphate, a novel lipid, involved in cellular proliferation</span>. <i>J. Cell Biol.</i> <span class="NLM_year" style="font-weight: bold;">1991</span>,  <span class="NLM_volume"><i>114</i></span>,  <span class="NLM_fpage">155</span>– <span class="NLM_lpage">167</span>, <span class="refDoi"> DOI: 10.1083/jcb.114.1.155</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01561&amp;key=10.1083%2Fjcb.114.1.155" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01561&amp;key=2050740" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01561&amp;key=1%3ACAS%3A528%3ADyaK3MXksVKku7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=114&publication_year=1991&pages=155-167&author=H.+Zhangauthor=N.+N.+Desaiauthor=A.+Oliveraauthor=T.+Sekiauthor=G.+Brookerauthor=S.+Spiegel&title=Sphingosine-1-phosphate%2C+a+novel+lipid%2C+involved+in+cellular+proliferation&doi=10.1083%2Fjcb.114.1.155"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Sphingosine-1-phosphate, a novel lipid, involved in cellular proliferation</span></div><div class="casAuthors">Zhang, Hong; Desai, Naishadh N.; Olivera, Ana; Seki, Takashi; Brooker, Gary; Spiegel, Sarah</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Cell Biology</span>
        (<span class="NLM_cas:date">1991</span>),
    <span class="NLM_cas:volume">114</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">155-67</span>CODEN:
                <span class="NLM_cas:coden">JCLBA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9525</span>.
    </div><div class="casAbstract">The rapid increase in 32P-labeled sphingosine-1-phosphate levels induced by sphingosine was concn. dependent and correlated with its effect on DNA synthesis.  Similar to the mitogenic effects of sphingosine, low concns. of sphingosine-1-phosphate stimulated DNA synthesis and induced pronounced morphol. alterations.  Both sphingosine and sphingosine-1-phosphate stimulated DNA synthesis in cells made protein kinase C deficient by prolonged treatment with phorbol ester and sphingosine still elicited similar increases in sphingosine-1-phosphate levels in these cells.  Although both sphingosine and sphingosine-1-phosphate acted synergistically with a wide variety of growth factors, there was no additive or synergistic effect in response to a combination of sphingosine and sphingosine-1-phosphate.  Using a digital imaging system for measurement of Ca changes, it was obsd. that both sphingosine and sphingosine-1-phosphate are potent Ca-mobilizing agonists in viable 3T3 fibroblasts.  The rapid rise in cytosolic free Ca was independent of the presence of Ca in the external medium, indicating that the response is due to the mobilization of Ca from internal stores.  Sphingosine-1-phosphate may be a component of the intracellular 2nd messenger system that is involved in Ca release and the regulation of cell growth induced by sphingosine.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoNmAVbQBZTs7Vg90H21EOLACvtfcHk0lhYmMiVOSru6w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3MXksVKku7c%253D&md5=f5991020e4dd2971ef810f20022b8f23</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1083%2Fjcb.114.1.155&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1083%252Fjcb.114.1.155%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DDesai%26aufirst%3DN.%2BN.%26aulast%3DOlivera%26aufirst%3DA.%26aulast%3DSeki%26aufirst%3DT.%26aulast%3DBrooker%26aufirst%3DG.%26aulast%3DSpiegel%26aufirst%3DS.%26atitle%3DSphingosine-1-phosphate%252C%2520a%2520novel%2520lipid%252C%2520involved%2520in%2520cellular%2520proliferation%26jtitle%3DJ.%2520Cell%2520Biol.%26date%3D1991%26volume%3D114%26spage%3D155%26epage%3D167%26doi%3D10.1083%2Fjcb.114.1.155" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Payne, S. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Milstien, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spiegel, S.</span></span> <span> </span><span class="NLM_article-title">Sphingosine-1-phosphate: dual messenger functions</span>. <i>FEBS Lett.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>531</i></span>,  <span class="NLM_fpage">54</span>– <span class="NLM_lpage">57</span>, <span class="refDoi"> DOI: 10.1016/s0014-5793(02)03480-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01561&amp;key=10.1016%2Fs0014-5793%2802%2903480-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01561&amp;key=12401202" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01561&amp;key=1%3ACAS%3A528%3ADC%252BD38XotVOjtLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=531&publication_year=2002&pages=54-57&author=S.+G.+Payneauthor=S.+Milstienauthor=S.+Spiegel&title=Sphingosine-1-phosphate%3A+dual+messenger+functions&doi=10.1016%2Fs0014-5793%2802%2903480-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Sphingosine-1-phosphate: dual messenger functions</span></div><div class="casAuthors">Payne, Shawn G.; Milstien, Sheldon; Spiegel, Sarah</div><div class="citationInfo"><span class="NLM_cas:title">FEBS Letters</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">531</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">54-57</span>CODEN:
                <span class="NLM_cas:coden">FEBLAL</span>;
        ISSN:<span class="NLM_cas:issn">0014-5793</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science B.V.</span>)
        </div><div class="casAbstract">A review.  The sphingolipid metabolite, sphingosine-1-phosphate (S1P), is a serum-borne lipid that regulates many vital cellular processes.  S1P is the ligand of a family of 5 specific G protein-coupled receptors that are differentially expressed in different tissues and regulate diverse cellular actions.  Much less is known of the intracellular actions of S1P.  It has been suggested that S1P may also function as an intracellular 2nd messenger to regulate Ca2+ mobilization, cell growth, and suppression of apoptosis in response to a variety of extracellular stimuli.  Dissecting the dual actions and identification of intracellular targets of S1P has been challenging, but there is ample evidence to suggest that the balance between S1P and ceramide and/or sphingosine levels in cells is an important determinant of cell fate.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo76yT7OtSBfLVg90H21EOLACvtfcHk0lhQVV_8hUc4Pw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XotVOjtLg%253D&md5=ba8373675f89dc1cdea56cd3a3ad9cd3</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1016%2Fs0014-5793%2802%2903480-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fs0014-5793%252802%252903480-4%26sid%3Dliteratum%253Aachs%26aulast%3DPayne%26aufirst%3DS.%2BG.%26aulast%3DMilstien%26aufirst%3DS.%26aulast%3DSpiegel%26aufirst%3DS.%26atitle%3DSphingosine-1-phosphate%253A%2520dual%2520messenger%2520functions%26jtitle%3DFEBS%2520Lett.%26date%3D2002%26volume%3D531%26spage%3D54%26epage%3D57%26doi%3D10.1016%2Fs0014-5793%2802%2903480-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Spiegel, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Milstien, S.</span></span> <span> </span><span class="NLM_article-title">Sphingosine-1-phosphate: an enigmatic signalling lipid</span>. <i>Nat. Rev. Mol. Cell Biol.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">397</span>– <span class="NLM_lpage">407</span>, <span class="refDoi"> DOI: 10.1038/nrm1103</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01561&amp;key=10.1038%2Fnrm1103" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01561&amp;key=12728273" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01561&amp;key=1%3ACAS%3A528%3ADC%252BD3sXjtlalt7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2003&pages=397-407&author=S.+Spiegelauthor=S.+Milstien&title=Sphingosine-1-phosphate%3A+an+enigmatic+signalling+lipid&doi=10.1038%2Fnrm1103"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Sphingosine-1-phosphate: an enigmatic signalling lipid</span></div><div class="casAuthors">Spiegel, Sarah; Milstien, Sheldon</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Molecular Cell Biology</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">397-407</span>CODEN:
                <span class="NLM_cas:coden">NRMCBP</span>;
        ISSN:<span class="NLM_cas:issn">1471-0072</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The evolutionarily conserved actions of the sphingolipid metabolite, sphingosine-1-phosphate (S1P), in yeast, plants, and mammals have shown that it has important functions.  In higher eukaryotes, S1P is the ligand for a family of 5 G protein-coupled receptors.  These S1P receptors are differentially expressed, coupled to various G proteins, and regulate angiogenesis, vascular maturation, cardiac development, and immunity, and are important for directed cell movement.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGos0XUAxYZwqLVg90H21EOLACvtfcHk0lhQVV_8hUc4Pw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXjtlalt7o%253D&md5=689a33cfeb4bae72637b64cd90e6c910</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1038%2Fnrm1103&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrm1103%26sid%3Dliteratum%253Aachs%26aulast%3DSpiegel%26aufirst%3DS.%26aulast%3DMilstien%26aufirst%3DS.%26atitle%3DSphingosine-1-phosphate%253A%2520an%2520enigmatic%2520signalling%2520lipid%26jtitle%3DNat.%2520Rev.%2520Mol.%2520Cell%2520Biol.%26date%3D2003%26volume%3D4%26spage%3D397%26epage%3D407%26doi%3D10.1038%2Fnrm1103" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Takabe, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spiegel, S.</span></span> <span> </span><span class="NLM_article-title">Export of sphingosine-1-phosphate and cancer progression</span>. <i>J. Lipid Res.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">1839</span>– <span class="NLM_lpage">1846</span>, <span class="refDoi"> DOI: 10.1194/jlr.r046656</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01561&amp;key=10.1194%2Fjlr.R046656" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01561&amp;key=24474820" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01561&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsVGjurnN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2014&pages=1839-1846&author=K.+Takabeauthor=S.+Spiegel&title=Export+of+sphingosine-1-phosphate+and+cancer+progression&doi=10.1194%2Fjlr.r046656"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Export of sphingosine-1-phosphate and cancer progression</span></div><div class="casAuthors">Takabe, Kazuaki; Spiegel, Sarah</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Lipid Research</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1839-1846</span>CODEN:
                <span class="NLM_cas:coden">JLPRAW</span>;
        ISSN:<span class="NLM_cas:issn">0022-2275</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology, Inc.</span>)
        </div><div class="casAbstract">A review.  Sphingosine-1-phosphate (S1P) is a bioactive lipid mediator that promotes cell survival, proliferation, migration, angiogenesis, lymphangiogenesis, and immune response; all are crit. processes of cancer progression.  Although some important roles of intracellular S1P have recently been uncovered, the majority of its biol. effects are known to be mediated via activation of five specific G protein-coupled receptors [S1P receptor (S1PR)1-S1PR5] located on the cell surface.  Secretion of S1P produced inside cells by sphingosine kinases can then signal through these receptors in autocrine, paracrine, and/or endocrine manners, coined "inside-out" signaling of S1P.  Numerous studies suggest that secreted S1P plays important roles in cancer progression; thus, understanding the mechanism by which S1P is exported out of cells, particularly cancer cells, is both interesting and important.  Here we will review the current understanding of the transport of S1P out of cancer cells and its potential roles in the tumor microenvironment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrpbPqJSPEIt7Vg90H21EOLACvtfcHk0lhQVV_8hUc4Pw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsVGjurnN&md5=2371f977febf54b94ccfc91cd00cb0c2</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1194%2Fjlr.R046656&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1194%252Fjlr.R046656%26sid%3Dliteratum%253Aachs%26aulast%3DTakabe%26aufirst%3DK.%26aulast%3DSpiegel%26aufirst%3DS.%26atitle%3DExport%2520of%2520sphingosine-1-phosphate%2520and%2520cancer%2520progression%26jtitle%3DJ.%2520Lipid%2520Res.%26date%3D2014%26volume%3D55%26spage%3D1839%26epage%3D1846%26doi%3D10.1194%2Fjlr.r046656" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schuchman, E. H.</span></span> <span> </span><span class="NLM_article-title">Acid ceramidase and the treatment of ceramide diseases: the expanding role of enzyme replacement therapy</span>. <i>Biochim. Biophys. Acta, Mol. Basis Dis.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>1862</i></span>,  <span class="NLM_fpage">1459</span>– <span class="NLM_lpage">1471</span>, <span class="refDoi"> DOI: 10.1016/j.bbadis.2016.05.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01561&amp;key=10.1016%2Fj.bbadis.2016.05.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01561&amp;key=27155573" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01561&amp;key=1%3ACAS%3A528%3ADC%252BC28XnsV2gsL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1862&publication_year=2016&pages=1459-1471&author=E.+H.+Schuchman&title=Acid+ceramidase+and+the+treatment+of+ceramide+diseases%3A+the+expanding+role+of+enzyme+replacement+therapy&doi=10.1016%2Fj.bbadis.2016.05.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Acid ceramidase and the treatment of ceramide diseases: The expanding role of enzyme replacement therapy</span></div><div class="casAuthors">Schuchman, Edward H.</div><div class="citationInfo"><span class="NLM_cas:title">Biochimica et Biophysica Acta, Molecular Basis of Disease</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">1862</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1459-1471</span>CODEN:
                <span class="NLM_cas:coden">BBADEX</span>;
        ISSN:<span class="NLM_cas:issn">0925-4439</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B. V.</span>)
        </div><div class="casAbstract">Ceramides are a diverse group of sphingolipids that play important roles in many biol. processes.  Acid ceramidase (AC) is one key enzyme that regulates ceramide metab.  Early research on AC focused on the fact that it is the enzyme deficient in the rare genetic disorder, Farber Lipogranulomatosis.  Recent research has revealed that deficiency of the same enzyme is responsible for a rare form of spinal muscular atrophy assocd. with myoclonic epilepsy (SMA-PME).  Due to their diverse role in biol., accumulation of ceramides also has been implicated in the pathobiol. of many other common diseases, including infectious lung diseases, diabetes, cancers and others.  This has revealed the potential of AC as a therapy for many of these diseases.  This review will focus on the biol. of AC and the potential role of this enzyme in the treatment of human disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqxHxbePZKk7rVg90H21EOLACvtfcHk0lhs55eBVLLIPA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XnsV2gsL0%253D&md5=b44a07178d44b3de2ef72da888931fbe</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1016%2Fj.bbadis.2016.05.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bbadis.2016.05.001%26sid%3Dliteratum%253Aachs%26aulast%3DSchuchman%26aufirst%3DE.%2BH.%26atitle%3DAcid%2520ceramidase%2520and%2520the%2520treatment%2520of%2520ceramide%2520diseases%253A%2520the%2520expanding%2520role%2520of%2520enzyme%2520replacement%2520therapy%26jtitle%3DBiochim.%2520Biophys.%2520Acta%252C%2520Mol.%2520Basis%2520Dis.%26date%3D2016%26volume%3D1862%26spage%3D1459%26epage%3D1471%26doi%3D10.1016%2Fj.bbadis.2016.05.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yu, F. P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Medin, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amintas, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levade, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levade, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Medin, J. A.</span></span> <span> </span><span class="NLM_article-title">Acid ceramidase deficiency: Farber disease and SMA-PME</span>. <i>Orphanet J. Rare Dis.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">121</span>– <span class="NLM_lpage">140</span>, <span class="refDoi"> DOI: 10.1186/s13023-018-0845-z</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01561&amp;key=10.1186%2Fs13023-018-0845-z" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01561&amp;key=30029679" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01561&amp;key=1%3ACAS%3A280%3ADC%252BB3c7gtleiug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2018&pages=121-140&author=F.+P.+S.+Yuauthor=J.+A.+Medinauthor=S.+Amintasauthor=T.+Levadeauthor=T.+Levadeauthor=J.+A.+Medin&title=Acid+ceramidase+deficiency%3A+Farber+disease+and+SMA-PME&doi=10.1186%2Fs13023-018-0845-z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Acid ceramidase deficiency: Farber disease and SMA-PME</span></div><div class="casAuthors">Yu Fabian P S; Medin Jeffrey A; Amintas Samuel; Levade Thierry; Levade Thierry; Medin Jeffrey A</div><div class="citationInfo"><span class="NLM_cas:title">Orphanet journal of rare diseases</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">121</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Acid ceramidase (ACDase) deficiency is a spectrum of disorders that includes a rare lysosomal storage disorder called Farber disease (FD) and a rare epileptic disorder called spinal muscular atrophy with progressive myoclonic epilepsy (SMA-PME).  Both disorders are caused by mutations in the ASAH1 gene that encodes the lysosomal hydrolase that breaks down the bioactive lipid ceramide.  To date, there have been fewer than 200 reported cases of FD and SMA-PME in the literature.  Typical textbook manifestations of classical FD include the formation of subcutaneous nodules, accumulation of joint contractures, and development of a hoarse voice.  In reality, however, the clinical presentation is much broader.  Patients may develop severe pathologies leading to death in infancy or may develop attenuated forms of the disorder wherein they are often misdiagnosed or not diagnosed until adulthood.  A clinical variability also exists for SMA-PME, in which patients develop progressive muscle weakness and seizures.  Currently, there is no known cure for FD or for SMA-PME.  The main treatment is symptom management.  In rare cases, treatment may include surgery or hematopoietic stem cell transplantation.  Research using disease models has provided insights into the pathology as well as the role of ACDase in the development of these conditions.  Recent studies have highlighted possible biomarkers for an effective diagnosis of ACDase deficiency.  Ongoing work is being conducted to evaluate the use of recombinant human ACDase (rhACDase) for the treatment of FD.  Finally, gene therapy strategies for the treatment of ACDase deficiency are actively being pursued.  This review highlights the broad clinical definition and outlines key studies that have improved our understanding of inherited ACDase deficiency-related conditions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSjSNsollUD2zMsgLhIoICsfW6udTcc2eYTAL5DaaGMCbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3c7gtleiug%253D%253D&md5=c24c1f6d0a92e846fd3e36620b160e4e</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1186%2Fs13023-018-0845-z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs13023-018-0845-z%26sid%3Dliteratum%253Aachs%26aulast%3DYu%26aufirst%3DF.%2BP.%2BS.%26aulast%3DMedin%26aufirst%3DJ.%2BA.%26aulast%3DAmintas%26aufirst%3DS.%26aulast%3DLevade%26aufirst%3DT.%26aulast%3DLevade%26aufirst%3DT.%26aulast%3DMedin%26aufirst%3DJ.%2BA.%26atitle%3DAcid%2520ceramidase%2520deficiency%253A%2520Farber%2520disease%2520and%2520SMA-PME%26jtitle%3DOrphanet%2520J.%2520Rare%2520Dis.%26date%3D2018%26volume%3D13%26spage%3D121%26epage%3D140%26doi%3D10.1186%2Fs13023-018-0845-z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Seelan, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qian, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yokomizo, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bostwick, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, D. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, W.</span></span> <span> </span><span class="NLM_article-title">Human acid ceramidase is overexpressed but not mutated in prostate cancer</span>. <i>Genes, Chromosomes Cancer</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>29</i></span>,  <span class="NLM_fpage">137</span>– <span class="NLM_lpage">146</span>, <span class="refDoi"> DOI: 10.1002/1098-2264(2000)9999:9999<::aid-gcc1018>3.0.co;2-e</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01561&amp;key=10.1002%2F1098-2264%282000%299999%3A9999%3C%3A%3AAID-GCC1018%3E3.0.CO%3B2-E" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01561&amp;key=10959093" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01561&amp;key=1%3ACAS%3A528%3ADC%252BD3cXntVWiurg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2000&pages=137-146&author=R.+S.+Seelanauthor=C.+Qianauthor=A.+Yokomizoauthor=D.+G.+Bostwickauthor=D.+I.+Smithauthor=W.+Liu&title=Human+acid+ceramidase+is+overexpressed+but+not+mutated+in+prostate+cancer&doi=10.1002%2F1098-2264%282000%299999%3A9999%3C%3A%3Aaid-gcc1018%3E3.0.co%3B2-e"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Human acid ceramidase is overexpressed but not mutated in prostate cancer</span></div><div class="casAuthors">Seelan, Ratnam S.; Qian, Chiping; Yokomizo, Akira; Bostwick, David G.; Smith, David I.; Liu, Wanguo</div><div class="citationInfo"><span class="NLM_cas:title">Genes, Chromosomes & Cancer</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">137-146</span>CODEN:
                <span class="NLM_cas:coden">GCCAES</span>;
        ISSN:<span class="NLM_cas:issn">1045-2257</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Liss, Inc.</span>)
        </div><div class="casAbstract">The human acid ceramidase gene, that causes Farber disease, is located in 8p22, a region frequently altered in several cancers, including prostate cancer.  Acid ceramidase catalyzes the hydrolysis of ceramide, a potent lipid second messenger mol. that promotes apoptosis and inhibits cellular proliferation.  It is not known whether this gene, or its expression, is altered in prostate cancer.  Here, the authors report the structural organization of the human gene, its expression in human tissues, and the identification of several single nucleotide polymorphisms.  No cancer-related mutations were found in the gene in a panel of prostate tumor DNAs analyzed, but increased expression was obsd. in prostate tumor tissues when compared with matched normals.  This increase was obsd. in all three prostate tumor cell lines tested (DU145, LnCAP, and PC3) when compared to a BPH (benign prostatic hyperplasia) cell line and 15/36 prostate tumors.  These results suggest that acid ceramidase may play an important role in prostate carcinogenesis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo2Y-_n5vjRdbVg90H21EOLACvtfcHk0lhs55eBVLLIPA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXntVWiurg%253D&md5=9c690947f4f44a446d83608ffda02c54</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1002%2F1098-2264%282000%299999%3A9999%3C%3A%3AAID-GCC1018%3E3.0.CO%3B2-E&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252F1098-2264%25282000%25299999%253A9999%253C%253A%253AAID-GCC1018%253E3.0.CO%253B2-E%26sid%3Dliteratum%253Aachs%26aulast%3DSeelan%26aufirst%3DR.%2BS.%26aulast%3DQian%26aufirst%3DC.%26aulast%3DYokomizo%26aufirst%3DA.%26aulast%3DBostwick%26aufirst%3DD.%2BG.%26aulast%3DSmith%26aufirst%3DD.%2BI.%26aulast%3DLiu%26aufirst%3DW.%26atitle%3DHuman%2520acid%2520ceramidase%2520is%2520overexpressed%2520but%2520not%2520mutated%2520in%2520prostate%2520cancer%26jtitle%3DGenes%252C%2520Chromosomes%2520Cancer%26date%3D2000%26volume%3D29%26spage%3D137%26epage%3D146%26doi%3D10.1002%2F1098-2264%282000%299999%3A9999%3C%3A%3Aaid-gcc1018%3E3.0.co%3B2-e" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Realini, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palese, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pizzirani, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pontis, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Basit, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bach, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ganesan, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Piomelli, D.</span></span> <span> </span><span class="NLM_article-title">Acid ceramidase in melanoma: expression, localization, and effects of pharmacological inhibition</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>291</i></span>,  <span class="NLM_fpage">2422</span>– <span class="NLM_lpage">2434</span>, <span class="refDoi"> DOI: 10.1074/jbc.m115.666909</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01561&amp;key=10.1074%2Fjbc.M115.666909" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01561&amp;key=26553872" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01561&amp;key=1%3ACAS%3A528%3ADC%252BC28Xhs1Cqsbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=291&publication_year=2016&pages=2422-2434&author=N.+Realiniauthor=F.+Paleseauthor=D.+Pizziraniauthor=S.+Pontisauthor=A.+Basitauthor=A.+Bachauthor=A.+Ganesanauthor=D.+Piomelli&title=Acid+ceramidase+in+melanoma%3A+expression%2C+localization%2C+and+effects+of+pharmacological+inhibition&doi=10.1074%2Fjbc.m115.666909"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Acid Ceramidase in Melanoma. Expression, location, and effects of pharmacological inhibitors</span></div><div class="casAuthors">Realini, Natalia; Palese, Francesca; Pizzirani, Daniela; Pontis, Silvia; Basit, Abdul; Bach, Anders; Ganesan, Anand; Piomelli, Daniele</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">291</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">2422-2434</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">Acid ceramidase (AC) is a lysosomal cysteine amidase that controls sphingolipid signaling by lowering the levels of ceramides and concomitantly increasing those of sphingosine and its bioactive metabolite, sphingosine 1-phosphate.  In the present study, we evaluated the role of AC-regulated sphingolipid signaling in melanoma.  We found that AC expression is markedly elevated in normal human melanocytes and proliferative melanoma cell lines, compared with other skin cells (keratinocytes and fibroblasts) and non-melanoma cancer cells.  High AC expression was also obsd. in biopsies from human subjects with Stage II melanoma.  Immunofluorescence studies revealed that the subcellular localization of AC differs between melanocytes (where it is found in both cytosol and nucleus) and melanoma cells (where it is primarily localized to cytosol).  In addn. to having high AC levels, melanoma cells generate lower amts. of ceramides than normal melanocytes do.  This down-regulation in ceramide prodn. appears to result from suppression of the de novo biosynthesis pathway.  To test whether AC might contribute to melanoma cell proliferation, we blocked AC activity using a new potent (IC50 = 12 nm) and stable inhibitor.  AC inhibition increased cellular ceramide levels, decreased sphingosine 1-phosphate levels, and acted synergistically with several, albeit not all, antitumoral agents.  The results suggest that AC-controlled sphingolipid metab. may play an important role in the control of melanoma proliferation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpQ1pGRTPNfObVg90H21EOLACvtfcHk0lg04jPrnbl_zg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xhs1Cqsbo%253D&md5=40dd33dee5301d0b79ee77c54b3b3fe3</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M115.666909&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M115.666909%26sid%3Dliteratum%253Aachs%26aulast%3DRealini%26aufirst%3DN.%26aulast%3DPalese%26aufirst%3DF.%26aulast%3DPizzirani%26aufirst%3DD.%26aulast%3DPontis%26aufirst%3DS.%26aulast%3DBasit%26aufirst%3DA.%26aulast%3DBach%26aufirst%3DA.%26aulast%3DGanesan%26aufirst%3DA.%26aulast%3DPiomelli%26aufirst%3DD.%26atitle%3DAcid%2520ceramidase%2520in%2520melanoma%253A%2520expression%252C%2520localization%252C%2520and%2520effects%2520of%2520pharmacological%2520inhibition%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2016%26volume%3D291%26spage%3D2422%26epage%3D2434%26doi%3D10.1074%2Fjbc.m115.666909" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Roh, J.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, J. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, E. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jang, H. J.</span></span> <span> </span><span class="NLM_article-title">Targeting acid ceramidase sensitises head and neck cancer to cisplatin</span>. <i>Eur. J. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>52</i></span>,  <span class="NLM_fpage">163</span>– <span class="NLM_lpage">172</span>, <span class="refDoi"> DOI: 10.1016/j.ejca.2015.10.056</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01561&amp;key=10.1016%2Fj.ejca.2015.10.056" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01561&amp;key=26687835" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01561&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvFems7zF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2016&pages=163-172&author=J.-L.+Rohauthor=J.+Y.+Parkauthor=E.+H.+Kimauthor=H.+J.+Jang&title=Targeting+acid+ceramidase+sensitises+head+and+neck+cancer+to+cisplatin&doi=10.1016%2Fj.ejca.2015.10.056"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting acid ceramidase sensitises head and neck cancer to cisplatin</span></div><div class="casAuthors">Roh, Jong-Lyel; Park, Jin Young; Kim, Eun Hye; Jang, Hye Jin</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Cancer</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">163-172</span>CODEN:
                <span class="NLM_cas:coden">EJCAEL</span>;
        ISSN:<span class="NLM_cas:issn">0959-8049</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Acid ceramidase (AC), a key enzyme in ceramide metab., plays a role in cancer progression and resistance to therapy.  However, the role of AC in head and neck cancer (HNC) has not been addressed.  Here, we investigate the effect of AC inhibition on the response to cisplatin-based chemotherapy for HNC.AC protein and mRNA (mRNA) expression were examd. in primary tumors and paired normal tissues, and in HNC cell lines.  The effects of genetic and pharmacol. AC inhibition using small hairpin RNA (shRNA) and N-oleoyl-ethanolamine (NOE), alone and in combination with cisplatin, were assessed in human HNC cells by measuring cell viability, cell cycle progression, apoptosis, mRNA, and protein expression, and in preclin. tumor xenograft mouse models.AC overexpression was obsd. in four of six primary tumor tissues and six of nine HNC cell lines.  Cisplatin sensitivity was significantly decreased by AC overexpression and significantly increased by AC downregulation in HNC cells (P < 0.01).  NOE or AC shRNA-mediated AC inhibition enhanced cisplatin-induced HNC cell death by increasing ceramide prodn. and activating pro-apoptotic proteins, and these effects were abrogated by PUMA small interfering RNA transfection.  AC inhibition promoted cisplatin-induced apoptosis of HNC cells in vitro and in vivo.AC overexpression is assocd. with cisplatin sensitivity, suggesting its potential role as a chemotherapeutic target for HNC.  Genetic or pharmacol. AC inhibition promotes cisplatin cytotoxicity in HNC cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGomDQBsoYn4e7Vg90H21EOLACvtfcHk0lg04jPrnbl_zg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvFems7zF&md5=21cc9a783fabe8e2147577e80841a660</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1016%2Fj.ejca.2015.10.056&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejca.2015.10.056%26sid%3Dliteratum%253Aachs%26aulast%3DRoh%26aufirst%3DJ.-L.%26aulast%3DPark%26aufirst%3DJ.%2BY.%26aulast%3DKim%26aufirst%3DE.%2BH.%26aulast%3DJang%26aufirst%3DH.%2BJ.%26atitle%3DTargeting%2520acid%2520ceramidase%2520sensitises%2520head%2520and%2520neck%2520cancer%2520to%2520cisplatin%26jtitle%3DEur.%2520J.%2520Cancer%26date%3D2016%26volume%3D52%26spage%3D163%26epage%3D172%26doi%3D10.1016%2Fj.ejca.2015.10.056" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Klobučar, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grbčić, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pavelić, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jonjić, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Visentin, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sedić, M.</span></span> <span> </span><span class="NLM_article-title">Acid ceramidase inhibition sensitizes human colon cancer cells to oxaliplatin through downregulation of transglutaminase 2 and beta1 integrin/FAK-mediated signalling</span>. <i>Biochem. Biophys. Res. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>503</i></span>,  <span class="NLM_fpage">843</span>– <span class="NLM_lpage">848</span>, <span class="refDoi"> DOI: 10.1016/j.bbrc.2018.06.085</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01561&amp;key=10.1016%2Fj.bbrc.2018.06.085" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01561&amp;key=29920241" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01561&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtFymsr%252FE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=503&publication_year=2018&pages=843-848&author=M.+Klobu%C4%8Darauthor=P.+Grb%C4%8Di%C4%87author=S.+K.+Paveli%C4%87author=N.+Jonji%C4%87author=S.+Visentinauthor=M.+Sedi%C4%87&title=Acid+ceramidase+inhibition+sensitizes+human+colon+cancer+cells+to+oxaliplatin+through+downregulation+of+transglutaminase+2+and+beta1+integrin%2FFAK-mediated+signalling&doi=10.1016%2Fj.bbrc.2018.06.085"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Acid ceramidase inhibition sensitizes human colon cancer cells to oxaliplatin through downregulation of transglutaminase 2 and β1 integrin/FAK-mediated signalling</span></div><div class="casAuthors">Klobucar, Marko; Grbcic, Petra; Pavelic, Sandra Kraljevic; Jonjic, Nives; Visentin, Sarah; Sedic, Mirela</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical and Biophysical Research Communications</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">503</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">843-848</span>CODEN:
                <span class="NLM_cas:coden">BBRCA9</span>;
        ISSN:<span class="NLM_cas:issn">0006-291X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Acid ceramidase (ASAH1) has been implicated in the progression and chemoresistance in different cancers.  Its role in colon cancer biol. and response to std. chemotherapy has been poorly addressed so far.  Here, we have investigated ASAH1 expression at the protein level in human colon cancer cell lines and tissues from colon cancer patients, and have examd. in vitro the possible link between ASAH1 expression and functional activity of p53 protein whose inactivation is assocd. with the progression from adenoma to malignant tumor in colon cancer.  Finally, we have explored the role of ASAH1 in response and resistance mechanisms to oxaliplatin (OXA) in HCT 116 colon cancer cells.  We have demonstrated that human colon cancer cells and colorectal adenocarcinoma tissues constitutively express ASAH1, and that its expression is higher in tumor tissues than in normal colonic mucosa.  Furthermore, we found an inverse correlation between ASAH1 expression and p53 functional activity.  Obtained data revealed that ASAH1 was involved in HCT 116 cell response to OXA and that anti-proliferative, pro-apoptotic, anti-migratory and anti-clonogenic effects of OXA could be significantly increased by combination treatment with ASAH1 inhibitor carmofur.  Increased OXA sensitivity was assocd. with downregulation of signalling involved in acquired resistance to OXA in colon cancer, in particular transglutaminase 2 and β1 integrin/FAK, which resulted in the suppression of NF-κB and Akt.  Thus, combination of OXA with ASAH1 inhibitors could be a promising strategy to counter chemoresistance and improve treatment outcome in advanced colon cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoUqtsO2v4hpLVg90H21EOLACvtfcHk0lg04jPrnbl_zg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtFymsr%252FE&md5=dd13faabb73a822e616fef8e37a769bd</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1016%2Fj.bbrc.2018.06.085&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bbrc.2018.06.085%26sid%3Dliteratum%253Aachs%26aulast%3DKlobu%25C4%258Dar%26aufirst%3DM.%26aulast%3DGrb%25C4%258Di%25C4%2587%26aufirst%3DP.%26aulast%3DPaveli%25C4%2587%26aufirst%3DS.%2BK.%26aulast%3DJonji%25C4%2587%26aufirst%3DN.%26aulast%3DVisentin%26aufirst%3DS.%26aulast%3DSedi%25C4%2587%26aufirst%3DM.%26atitle%3DAcid%2520ceramidase%2520inhibition%2520sensitizes%2520human%2520colon%2520cancer%2520cells%2520to%2520oxaliplatin%2520through%2520downregulation%2520of%2520transglutaminase%25202%2520and%2520beta1%2520integrin%252FFAK-mediated%2520signalling%26jtitle%3DBiochem.%2520Biophys.%2520Res.%2520Commun.%26date%3D2018%26volume%3D503%26spage%3D843%26epage%3D848%26doi%3D10.1016%2Fj.bbrc.2018.06.085" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Doan, N. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alhajala, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Al-Gizawiy, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mueller, W. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rand, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Connelly, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cochran, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chitambar, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clark, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmainda, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mirza, S. P.</span></span> <span> </span><span class="NLM_article-title">Acid ceramidase and its inhibitors: a de novo drug target and a new class of drugs for killing glioblastoma cancer stem cells with high efficiency</span>. <i>Oncotarget</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">112662</span>– <span class="NLM_lpage">112674</span>, <span class="refDoi"> DOI: 10.18632/oncotarget.22637</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01561&amp;key=10.18632%2Foncotarget.22637" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01561&amp;key=29348854" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01561&amp;key=1%3ACAS%3A280%3ADC%252BC1Mvit1SrtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=112662-112674&author=N.+B.+Doanauthor=H.+Alhajalaauthor=M.+M.+Al-Gizawiyauthor=W.+M.+Muellerauthor=S.+D.+Randauthor=J.+M.+Connellyauthor=E.+J.+Cochranauthor=C.+R.+Chitambarauthor=P.+Clarkauthor=J.+Kuoauthor=K.+M.+Schmaindaauthor=S.+P.+Mirza&title=Acid+ceramidase+and+its+inhibitors%3A+a+de+novo+drug+target+and+a+new+class+of+drugs+for+killing+glioblastoma+cancer+stem+cells+with+high+efficiency&doi=10.18632%2Foncotarget.22637"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Acid ceramidase and its inhibitors: a de novo drug target and a new class of drugs for killing glioblastoma cancer stem cells with high efficiency</span></div><div class="casAuthors">Doan Ninh B; Mirza Shama P; Doan Ninh B; Mueller Wade M; Alhajala Hisham; Chitambar Christopher R; Schmainda Kathleen M; Al-Gizawiy Mona M; Rand Scott D; Connelly Jennifer M; Cochran Elizabeth J; Clark Paul; Kuo John; Schmainda Kathleen M; Mirza Shama P; Mirza Shama P</div><div class="citationInfo"><span class="NLM_cas:title">Oncotarget</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">68</span>),
    <span class="NLM_cas:pages">112662-112674</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Glioblastoma remains the most common, malignant primary cancer of the central nervous system with a low life expectancy and an overall survival of less than 1.5 years.  The treatment options are limited and there is no cure.  Moreover, almost all patients develop recurrent tumors, which typically are more aggressive.  Therapeutically resistant glioblastoma or glioblastoma stem-like cells (GSCs) are hypothesized to cause this inevitable recurrence.  Identifying prognostic biomarkers of glioblastoma will potentially advance knowledge about glioblastoma tumorigenesis and enable discovery of more effective therapies.  Proteomic analysis of more than 600 glioblastoma-specific proteins revealed, for the first time, that expression of acid ceramidase (ASAH1) is associated with poor glioblastoma survival.  CD133+ GSCs express significantly higher ASAH1 compared to CD133- GSCs and serum-cultured glioblastoma cell lines, such as U87MG.  These findings implicate ASAH1 as a plausible independent prognostic marker, providing a target for a therapy tailored toward GSCs.  We further demonstrate that ASAH1 inhibition increases cellular ceramide level and induces apoptosis.  Strikingly, U87MG cells, and three different patient-derived glioblastoma stem-like cancer cell lines were efficiently killed, through apoptosis, by three different known ASAH1 inhibitors with IC50's ranging from 11-104 μM.  In comparison, the standard glioblastoma chemotherapy agent, temozolomide, had minimal GSC-targeted effects at comparable or even higher concentrations (IC50 > 750 μM against GSCs).  ASAH1 is identified as a de novo glioblastoma drug target, and ASAH1 inhibitors, such as carmofur, are shown to be highly effective and to specifically target glioblastoma GSCs.  Carmofur is an ASAH1 inhibitor that crosses the blood-brain barrier, a major bottleneck in glioblastoma treatment.  It has been approved in Japan since 1981 for colorectal cancer therapy.  Therefore, it is poised for repurposing and translation to glioblastoma clinical trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTkPFERLjQD2MrRqEXsZufAfW6udTcc2eYKddOBtzKqKbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1Mvit1SrtQ%253D%253D&md5=cf2b957e6c9b8664b919941d4a1eeddb</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.18632%2Foncotarget.22637&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18632%252Foncotarget.22637%26sid%3Dliteratum%253Aachs%26aulast%3DDoan%26aufirst%3DN.%2BB.%26aulast%3DAlhajala%26aufirst%3DH.%26aulast%3DAl-Gizawiy%26aufirst%3DM.%2BM.%26aulast%3DMueller%26aufirst%3DW.%2BM.%26aulast%3DRand%26aufirst%3DS.%2BD.%26aulast%3DConnelly%26aufirst%3DJ.%2BM.%26aulast%3DCochran%26aufirst%3DE.%2BJ.%26aulast%3DChitambar%26aufirst%3DC.%2BR.%26aulast%3DClark%26aufirst%3DP.%26aulast%3DKuo%26aufirst%3DJ.%26aulast%3DSchmainda%26aufirst%3DK.%2BM.%26aulast%3DMirza%26aufirst%3DS.%2BP.%26atitle%3DAcid%2520ceramidase%2520and%2520its%2520inhibitors%253A%2520a%2520de%2520novo%2520drug%2520target%2520and%2520a%2520new%2520class%2520of%2520drugs%2520for%2520killing%2520glioblastoma%2520cancer%2520stem%2520cells%2520with%2520high%2520efficiency%26jtitle%3DOncotarget%26date%3D2017%26volume%3D8%26spage%3D112662%26epage%3D112674%26doi%3D10.18632%2Foncotarget.22637" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mahdy, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elojeimy, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meacham, W. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Turner, L. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bai, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gault, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McPherson, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garcia, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beckham, T. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saad, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bielawska, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bielawski, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hannun, Y. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keane, T. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taha, M. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hammouda, H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Norris, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, X.</span></span> <span> </span><span class="NLM_article-title">Acid ceramidase upregulation in prostate cancer cells confers resistance to radiation: AC inhibition, a potential radiosensitizer</span>. <i>Mol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">430</span>– <span class="NLM_lpage">438</span>, <span class="refDoi"> DOI: 10.1038/mt.2008.281</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01561&amp;key=10.1038%2Fmt.2008.281" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01561&amp;key=19107118" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01561&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhsFart7fF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2009&pages=430-438&author=A.+E.+Mahdyauthor=J.+C.+Chengauthor=J.+Liauthor=S.+Elojeimyauthor=W.+D.+Meachamauthor=L.+S.+Turnerauthor=A.+Baiauthor=C.+R.+Gaultauthor=A.+S.+McPhersonauthor=N.+Garciaauthor=T.+H.+Beckhamauthor=A.+Saadauthor=A.+Bielawskaauthor=J.+Bielawskiauthor=Y.+A.+Hannunauthor=T.+E.+Keaneauthor=M.+I.+Tahaauthor=H.+M.+Hammoudaauthor=J.+S.+Norrisauthor=X.+Liu&title=Acid+ceramidase+upregulation+in+prostate+cancer+cells+confers+resistance+to+radiation%3A+AC+inhibition%2C+a+potential+radiosensitizer&doi=10.1038%2Fmt.2008.281"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Acid Ceramidase Upregulation in Prostate Cancer Cells Confers Resistance to Radiation: AC Inhibition, a Potential Radiosensitizer</span></div><div class="casAuthors">Mahdy, Ayman E. M.; Cheng, Joseph C.; Li, Jun; Elojeimy, Saeed; Meacham, William D.; Turner, Lorianne S.; Bai, Aiping; Gault, Christopher R.; McPherson, Alex S.; Garcia, Nicole; Beckham, Thomas H.; Saad, Antonio; Bielawska, Alicja; Bielawski, Jacek; Hannun, Yusuf A.; Keane, Thomas E.; Taha, Mohhammed I.; Hammouda, Hisham M.; Norris, James S.; Liu, Xiang</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Therapy</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">430-438</span>CODEN:
                <span class="NLM_cas:coden">MTOHCK</span>;
        ISSN:<span class="NLM_cas:issn">1525-0016</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Radiation resistance in a subset of prostate tumors remains a challenge to prostate cancer radiotherapy.  The current study on the effects of radiation on prostate cancer cells reveals that radiation programs an unpredicted resistance mechanism by upregulating acid ceramidase (AC).  Irradiated cells demonstrated limited changes of ceramide levels while elevating levels of sphingosine and sphingosine-1-phosphate.  By genetically downregulating AC with small interfering RNA (siRNA), we obsd. radiosensitization of cells using clonogenic and cytotoxicity assays.  Conversely, AC overexpression further decreased sensitivity to radiation.  We also obsd. that radiation-induced AC upregulation was sufficient to create cross-resistance to chemotherapy as demonstrated by decreased sensitivity to Taxol and C6 ceramide compared to controls.  Lower levels of caspase 3/7 activity were detected in cells pretreated with radiation, also indicating increased resistance.  Finally, utilization of the small mol. AC inhibitor, LCL385, sensitized PPC-1 cells to radiation and significantly decreased tumor xenograft growth.  These data suggest a new mechanism of cancer cell resistance to radiation, through upregulation of AC i.e., in part, mediated by application of the therapy itself.  An improved understanding of radiotherapy and the application of combination therapy achieved in this study offer new opportunities for the modulation of radiation effects in the treatment of cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqcfZKQJLJrLbVg90H21EOLACvtfcHk0ljuuLwMd-JWlA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhsFart7fF&md5=96aa1d9b77ef926f93655a78e610e20a</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1038%2Fmt.2008.281&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fmt.2008.281%26sid%3Dliteratum%253Aachs%26aulast%3DMahdy%26aufirst%3DA.%2BE.%26aulast%3DCheng%26aufirst%3DJ.%2BC.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DElojeimy%26aufirst%3DS.%26aulast%3DMeacham%26aufirst%3DW.%2BD.%26aulast%3DTurner%26aufirst%3DL.%2BS.%26aulast%3DBai%26aufirst%3DA.%26aulast%3DGault%26aufirst%3DC.%2BR.%26aulast%3DMcPherson%26aufirst%3DA.%2BS.%26aulast%3DGarcia%26aufirst%3DN.%26aulast%3DBeckham%26aufirst%3DT.%2BH.%26aulast%3DSaad%26aufirst%3DA.%26aulast%3DBielawska%26aufirst%3DA.%26aulast%3DBielawski%26aufirst%3DJ.%26aulast%3DHannun%26aufirst%3DY.%2BA.%26aulast%3DKeane%26aufirst%3DT.%2BE.%26aulast%3DTaha%26aufirst%3DM.%2BI.%26aulast%3DHammouda%26aufirst%3DH.%2BM.%26aulast%3DNorris%26aufirst%3DJ.%2BS.%26aulast%3DLiu%26aufirst%3DX.%26atitle%3DAcid%2520ceramidase%2520upregulation%2520in%2520prostate%2520cancer%2520cells%2520confers%2520resistance%2520to%2520radiation%253A%2520AC%2520inhibition%252C%2520a%2520potential%2520radiosensitizer%26jtitle%3DMol.%2520Ther.%26date%3D2009%26volume%3D17%26spage%3D430%26epage%3D438%26doi%3D10.1038%2Fmt.2008.281" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Saad, A. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meacham, W. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bai, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anelli, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elojeimy, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mahdy, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Turner, L. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bielawska, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bielawski, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keane, T. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Obeid, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hannun, Y. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Norris, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, X.</span></span> <span> </span><span class="NLM_article-title">The functional effects of acid ceramidase overexpression in prostate cancer progression and resistance to chemotherapy</span>. <i>Cancer Biol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">1455</span>– <span class="NLM_lpage">1460</span>, <span class="refDoi"> DOI: 10.4161/cbt.6.9.4623</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01561&amp;key=10.4161%2Fcbt.6.9.4623" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01561&amp;key=17881906" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01561&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtlCitb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2007&pages=1455-1460&author=A.+F.+Saadauthor=W.+D.+Meachamauthor=A.+Baiauthor=V.+Anelliauthor=S.+Elojeimyauthor=A.+E.+Mahdyauthor=L.+S.+Turnerauthor=J.+Chengauthor=A.+Bielawskaauthor=J.+Bielawskiauthor=T.+E.+Keaneauthor=L.+M.+Obeidauthor=Y.+A.+Hannunauthor=J.+S.+Norrisauthor=X.+Liu&title=The+functional+effects+of+acid+ceramidase+overexpression+in+prostate+cancer+progression+and+resistance+to+chemotherapy&doi=10.4161%2Fcbt.6.9.4623"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">The functional effects of acid ceramidase overexpression in prostate cancer progression and resistance to chemotherapy</span></div><div class="casAuthors">Saad, Antonio F.; Meacham, William D.; Bai, Aiping; Anelli, Viviane; Elojeimy, Saeed; Mahdy, Ayman E. M.; Turner, Lorianne S.; Cheng, Joe; Bielawska, Alicja; Bielawski, Jacek; Keane, Thomas E.; Obeid, Lina M.; Hannun, Yusuf A.; Norris, James S.; Liu, Xiang</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Biology & Therapy</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1455-1460</span>CODEN:
                <span class="NLM_cas:coden">CBTAAO</span>;
        ISSN:<span class="NLM_cas:issn">1538-4047</span>.
    
            (<span class="NLM_cas:orgname">Landes Bioscience</span>)
        </div><div class="casAbstract">Among the many processes regulating cell death, ceramide signaling is a vital component.  We previously detd. that acid ceramidase (AC) is upregulated in 60% of primary prostate cancer (PCa) tissues, suggesting that AC may play a role in tumor development.  In order to det. the significance of AC elevation, stable clones of DU145 cells with AC overexpression (AC-EGFP) were generated.  Compared to controls (EGFP), AC-EGFP cells exhibited enhanced cell proliferation and migration.  S.c. injection of AC-EGFP cells into Nu/Nu mice resulted in larger tumor vols. compared to EGFP controls.  Moreover, using the MTS viability assay, AC-EGFP cells were more resistant to cell death induced by doxorubicin, cisplatin, etoposide, gemcitabine or C6-ceramide.  Conversely, knock down of AC using siRNA, sensitized AC-EGFP cells to these drugs.  In addn., mass spectroscopic anal. of sphingolipids indicated that long chain ceramide levels were decreased in AC-EGFP cells treated with either doxorubicin or etoposide.  In conclusion, this study implicates AC as a crit. regulator of PCa progression by affecting not only tumor cell proliferation and migration but also responses to drug therapy, suggesting AC as a potential therapeutic target in advanced PCa.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGraaHP0ax4FC7Vg90H21EOLACvtfcHk0ljuuLwMd-JWlA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtlCitb8%253D&md5=6825c755b1ccad4ec808f1f6d64f5e6e</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.4161%2Fcbt.6.9.4623&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4161%252Fcbt.6.9.4623%26sid%3Dliteratum%253Aachs%26aulast%3DSaad%26aufirst%3DA.%2BF.%26aulast%3DMeacham%26aufirst%3DW.%2BD.%26aulast%3DBai%26aufirst%3DA.%26aulast%3DAnelli%26aufirst%3DV.%26aulast%3DElojeimy%26aufirst%3DS.%26aulast%3DMahdy%26aufirst%3DA.%2BE.%26aulast%3DTurner%26aufirst%3DL.%2BS.%26aulast%3DCheng%26aufirst%3DJ.%26aulast%3DBielawska%26aufirst%3DA.%26aulast%3DBielawski%26aufirst%3DJ.%26aulast%3DKeane%26aufirst%3DT.%2BE.%26aulast%3DObeid%26aufirst%3DL.%2BM.%26aulast%3DHannun%26aufirst%3DY.%2BA.%26aulast%3DNorris%26aufirst%3DJ.%2BS.%26aulast%3DLiu%26aufirst%3DX.%26atitle%3DThe%2520functional%2520effects%2520of%2520acid%2520ceramidase%2520overexpression%2520in%2520prostate%2520cancer%2520progression%2520and%2520resistance%2520to%2520chemotherapy%26jtitle%3DCancer%2520Biol.%2520Ther.%26date%3D2007%26volume%3D6%26spage%3D1455%26epage%3D1460%26doi%3D10.4161%2Fcbt.6.9.4623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tanimukai, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iqbal, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grundke-Iqbal, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gong, C.-X.</span></span> <span> </span><span class="NLM_article-title">Elevation of the level and activity of acid ceramidase in Alzheimer’s disease brain</span>. <i>Eur. J. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">3489</span>– <span class="NLM_lpage">3497</span>, <span class="refDoi"> DOI: 10.1111/j.1460-9568.2004.03852.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01561&amp;key=10.1111%2Fj.1460-9568.2004.03852.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01561&amp;key=15610181" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01561&amp;key=1%3ACAS%3A280%3ADC%252BD2cnjsVymsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2004&pages=3489-3497&author=Y.+Huangauthor=H.+Tanimukaiauthor=F.+Liuauthor=K.+Iqbalauthor=I.+Grundke-Iqbalauthor=C.-X.+Gong&title=Elevation+of+the+level+and+activity+of+acid+ceramidase+in+Alzheimer%E2%80%99s+disease+brain&doi=10.1111%2Fj.1460-9568.2004.03852.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Elevation of the level and activity of acid ceramidase in Alzheimer's disease brain</span></div><div class="casAuthors">Huang Yu; Tanimukai Hitoshi; Liu Fei; Iqbal Khalid; Grundke-Iqbal Inge; Gong Cheng-Xin</div><div class="citationInfo"><span class="NLM_cas:title">The European journal of neuroscience</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">3489-97</span>
        ISSN:<span class="NLM_cas:issn">0953-816X</span>.
    </div><div class="casAbstract">Protein glycosylation modifies the processing of several key proteins involved in the molecular pathogenesis of Alzheimer's disease (AD).  Aberrant glycosylation of tau and down-regulation of sialyltransferase in AD brain suggest a possible dysregulation of protein glycosylation that may play a role in AD.  We therefore isolated major glycoproteins from AD brain by using lectin-affinity chromatographies and ion-exchange chromatography and further separated them using SDS-polyacylamide gel electrophoresis.  Mass spectrometry analysis of 11 isolated glycoproteins led to their identification as: neuronal cell adhesion molecule, beta-globin, IgM heavy chain VH1 region precursor, contactin precursor, dipeptidylpeptidase VI, CD81 partner 3, prenylcysteine lyase, adipocyte plasma-associated protein, acid ceramidase and two novel proteins.  We found that the level and activity of acid ceramidase (AC), one of the major identified human brain glycoproteins, were significantly elevated in AD brain.  Immunohistochemical staining indicated that AC was located mainly in the cell bodies of neurons and colocalized with neurofibrillary tangles.  Our findings suggest that AC might play a role in controlling neuronal apoptosis and that AC-mediated signalling pathways might be involved in the molecular mechanism of AD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQSqqlZmYRDfrGbPKh4T9eAfW6udTcc2eZPG4I_Egx82rntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2cnjsVymsA%253D%253D&md5=80dbc51128110c4deeb4d8cf44bf133e</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1111%2Fj.1460-9568.2004.03852.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1460-9568.2004.03852.x%26sid%3Dliteratum%253Aachs%26aulast%3DHuang%26aufirst%3DY.%26aulast%3DTanimukai%26aufirst%3DH.%26aulast%3DLiu%26aufirst%3DF.%26aulast%3DIqbal%26aufirst%3DK.%26aulast%3DGrundke-Iqbal%26aufirst%3DI.%26aulast%3DGong%26aufirst%3DC.-X.%26atitle%3DElevation%2520of%2520the%2520level%2520and%2520activity%2520of%2520acid%2520ceramidase%2520in%2520Alzheimer%25E2%2580%2599s%2520disease%2520brain%26jtitle%3DEur.%2520J.%2520Neurosci.%26date%3D2004%26volume%3D20%26spage%3D3489%26epage%3D3497%26doi%3D10.1111%2Fj.1460-9568.2004.03852.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gieselmann, V.</span></span> <span> </span><span class="NLM_article-title">Lysosomal storage diseases</span>. <i>Biochim. Biophys. Acta, Mol. Basis Dis.</i> <span class="NLM_year" style="font-weight: bold;">1995</span>,  <span class="NLM_volume"><i>1270</i></span>,  <span class="NLM_fpage">103</span>– <span class="NLM_lpage">136</span>, <span class="refDoi"> DOI: 10.1016/0925-4439(94)00075-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01561&amp;key=10.1016%2F0925-4439%2894%2900075-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01561&amp;key=7727535" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01561&amp;key=1%3ACAS%3A528%3ADyaK2MXkvFGms7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1270&publication_year=1995&pages=103-136&author=V.+Gieselmann&title=Lysosomal+storage+diseases&doi=10.1016%2F0925-4439%2894%2900075-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Lysosomal storage diseases</span></div><div class="casAuthors">Gieselmann, Volkmar</div><div class="citationInfo"><span class="NLM_cas:title">Biochimica et Biophysica Acta, Molecular Basis of Disease</span>
        (<span class="NLM_cas:date">1995</span>),
    <span class="NLM_cas:volume">1270</span>
        (<span class="NLM_cas:issue">2-3</span>),
    <span class="NLM_cas:pages">103-36</span>CODEN:
                <span class="NLM_cas:coden">BBADEX</span>;
        ISSN:<span class="NLM_cas:issn">0925-4439</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review with 410 refs. on lipidoses, disorders of glycoprotein degrdn., and mucopolysaccharidoses.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrM-4LaaOM1orVg90H21EOLACvtfcHk0lia0Y0P5ltYMA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2MXkvFGms7o%253D&md5=533266b4fdac47258d9a924b0dd4a3b4</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1016%2F0925-4439%2894%2900075-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0925-4439%252894%252900075-2%26sid%3Dliteratum%253Aachs%26aulast%3DGieselmann%26aufirst%3DV.%26atitle%3DLysosomal%2520storage%2520diseases%26jtitle%3DBiochim.%2520Biophys.%2520Acta%252C%2520Mol.%2520Basis%2520Dis.%26date%3D1995%26volume%3D1270%26spage%3D103%26epage%3D136%26doi%3D10.1016%2F0925-4439%2894%2900075-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ballabio, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gieselmann, V.</span></span> <span> </span><span class="NLM_article-title">Lysosomal disorders: From storage to cellular damage</span>. <i>Biochim. Biophys. Acta, Mol. Cell Res.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>1793</i></span>,  <span class="NLM_fpage">684</span>– <span class="NLM_lpage">696</span>, <span class="refDoi"> DOI: 10.1016/j.bbamcr.2008.12.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01561&amp;key=10.1016%2Fj.bbamcr.2008.12.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01561&amp;key=19111581" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01561&amp;key=1%3ACAS%3A528%3ADC%252BD1MXjslOlsbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1793&publication_year=2009&pages=684-696&author=A.+Ballabioauthor=V.+Gieselmann&title=Lysosomal+disorders%3A+From+storage+to+cellular+damage&doi=10.1016%2Fj.bbamcr.2008.12.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Lysosomal disorders: From storage to cellular damage</span></div><div class="casAuthors">Ballabio, Andrea; Gieselmann, Volkmar</div><div class="citationInfo"><span class="NLM_cas:title">Biochimica et Biophysica Acta, Molecular Cell Research</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">1793</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">684-696</span>CODEN:
                <span class="NLM_cas:coden">BBAMCO</span>;
        ISSN:<span class="NLM_cas:issn">0167-4889</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Lysosomal storage diseases represent a group of about 50 genetic disorders caused by deficiencies of lysosomal and non-lysosomal proteins.  Patients accumulate compds. which are normally degraded in the lysosome.  In many diseases this accumulation affects various organs leading to severe symptoms and premature death.  The revelation of the mechanism by which stored compds. affect cellular function is the basis for understanding pathophysiol. underlying lysosomal storage diseases.  In the past years it has become clear that storage compds. interfere with various processes on the cellular level.  The spectrum covers e.g. receptor activation by non-physiol. ligands, modulation of receptor response and intracellular effectors of signal transduction cascades, impairment of autophagy, and others.  Importantly, many of these processes are assocd. with accumulation of storage material in non-lysosomal compartments.  Here we summarize current knowledge on the effects that storage material can elicit on the cellular level.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGphT4XBgFcs3rVg90H21EOLACvtfcHk0lia0Y0P5ltYMA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXjslOlsbk%253D&md5=618ababe4f0b39bd914c25d235c30693</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1016%2Fj.bbamcr.2008.12.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bbamcr.2008.12.001%26sid%3Dliteratum%253Aachs%26aulast%3DBallabio%26aufirst%3DA.%26aulast%3DGieselmann%26aufirst%3DV.%26atitle%3DLysosomal%2520disorders%253A%2520From%2520storage%2520to%2520cellular%2520damage%26jtitle%3DBiochim.%2520Biophys.%2520Acta%252C%2520Mol.%2520Cell%2520Res.%26date%3D2009%26volume%3D1793%26spage%3D684%26epage%3D696%26doi%3D10.1016%2Fj.bbamcr.2008.12.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">39</a></strong><div class="NLM_citation" id="rightTab-cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cox, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cachón-González, M. B.</span></span> <span> </span><span class="NLM_article-title">The cellular pathology of lysosomal diseases</span>. <i>J. Pathol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>226</i></span>,  <span class="NLM_fpage">241</span>– <span class="NLM_lpage">254</span>, <span class="refDoi"> DOI: 10.1002/path.3021</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01561&amp;key=10.1002%2Fpath.3021" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01561&amp;key=21990005" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01561&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhsFCqsbvO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=226&publication_year=2012&pages=241-254&author=T.+M.+Coxauthor=M.+B.+Cach%C3%B3n-Gonz%C3%A1lez&title=The+cellular+pathology+of+lysosomal+diseases&doi=10.1002%2Fpath.3021"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">The cellular pathology of lysosomal diseases</span></div><div class="casAuthors">Cox, Timothy M.; Cachon-Gonzalez, M. Begona</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pathology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">226</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">241-254</span>CODEN:
                <span class="NLM_cas:coden">JPTLAS</span>;
        ISSN:<span class="NLM_cas:issn">0022-3417</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons Ltd.</span>)
        </div><div class="casAbstract">A review.  With a constitutive recycling function and the capacity to digest exogenous material as well as endogenous organelles in the process of autophagy, lysosomes are at the heart of the living cell.  Dynamic interactions with other cellular components ensure that the lysosomal compartment is a central point of convergence in countless diverse diseases.  Inborn lysosomal (storage) diseases represent about 70 genetically distinct conditions, with a combined birth frequency of about 1 in 7500.  Many are assocd. with macromol. storage, causing phys. disruption of the organelle and cognate structures; in neurons, ectopic dendritogenesis and axonal swelling due to distension with membraneous tubules and autophagic vacuoles are obsd.  Disordered autophagy is almost universal in lysosomal diseases but biochem. injury due to toxic metabolites such as lysosphingolipid mols., abnormal calcium homeostasis and endoplasmic reticulum stress responses and immune-inflammatory processes occur.  However, in no case have the mechanistic links between individual clinico-pathol. manifestations and the underlying mol. defect been precisely defined.  With access to the external fluid-phase and intracellular trafficking pathways, the lysosome and its diseases are a focus of pioneering investment in biotechnol.; this has generated innovative orphan drugs and, in the case of Gaucher's disease, effective treatment for the haematol. and visceral manifestations.  Given that two-thirds of lysosomal diseases have potentially devastating consequences in the nervous system, future therapeutic research will require an integrative understanding of the unitary steps in their neuro pathogenesis.  Informative genetic variants illustrated by patients with primary defects in this organelle offer unique insights into the central role of lysosomes in human health and disease.  We provide a conspectus of inborn lysosomal diseases and their pathobiol.; the cryptic evolution of events leading to irreversible changes may be dissocd. from the cellular storage phenotype, as revealed by the outcome of therapeutic gene transfer undertaken at different stages of disease.  Copyright © 2011 Pathol. Society of Great Britain and Ireland.  Published by John Wiley & Sons, Ltd.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqL5CDde9M4OLVg90H21EOLACvtfcHk0lgGkW7YaRfx_Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhsFCqsbvO&md5=d0675527595829b6e888182d8d0f9a76</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1002%2Fpath.3021&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fpath.3021%26sid%3Dliteratum%253Aachs%26aulast%3DCox%26aufirst%3DT.%2BM.%26aulast%3DCach%25C3%25B3n-Gonz%25C3%25A1lez%26aufirst%3DM.%2BB.%26atitle%3DThe%2520cellular%2520pathology%2520of%2520lysosomal%2520diseases%26jtitle%3DJ.%2520Pathol.%26date%3D2012%26volume%3D226%26spage%3D241%26epage%3D254%26doi%3D10.1002%2Fpath.3021" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref40"><div class="reference"><strong class="refLabel"><a href="#ref40" class="rightTabRefNumLink">40</a></strong><div class="NLM_citation" id="rightTab-cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Stirnemann, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Belmatoug, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Camou, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Serratrice, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Froissart, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caillaud, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levade, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Astudillo, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Serratrice, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brassier, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rose, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Billette
de Villemeur, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berger, M.</span></span> <span> </span><span class="NLM_article-title">A review of gaucher disease pathophysiology, clinical presentation and treatments</span>. <i>Int. J. Mol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">441</span>– <span class="NLM_lpage">471</span>, <span class="refDoi"> DOI: 10.3390/ijms18020441</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01561&amp;key=10.3390%2Fijms18020441" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01561&amp;key=1%3ACAS%3A528%3ADC%252BC1cXkvVSju70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2017&pages=441-471&author=J.+Stirnemannauthor=N.+Belmatougauthor=F.+Camouauthor=C.+Serratriceauthor=R.+Froissartauthor=C.+Caillaudauthor=T.+Levadeauthor=L.+Astudilloauthor=J.+Serratriceauthor=A.+Brassierauthor=C.+Roseauthor=T.+Billette%0Ade+Villemeurauthor=M.+Berger&title=A+review+of+gaucher+disease+pathophysiology%2C+clinical+presentation+and+treatments&doi=10.3390%2Fijms18020441"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">A review of gaucher disease pathophysiology, clinical presentation and treatments</span></div><div class="casAuthors">Stirnemann, Jerome; Belmatoug, Nadia; Camou, Fabrice; Serratrice, Christine; Froissart, Roseline; Caillaud, Catherine; Levade, Thierry; Astudillo, Leonardo; Serratrice, Jacques; Brassier, Anais; Rose, Christian; Billette de Villemeur, Thierry; Berger, Marc G.</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Molecular Sciences</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">441/1-441/30</span>CODEN:
                <span class="NLM_cas:coden">IJMCFK</span>;
        ISSN:<span class="NLM_cas:issn">1422-0067</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">A review.  Gaucher disease (GD, ORPHA355) is a rare, autosomal recessive genetic disorder.  It is caused by a deficiency of the lysosomal enzyme, glucocerebrosidase, which leads to an accumulation of its substrate, glucosylceramide, in macrophages.  In the general population, its incidence is approx. 1/40,000 to 1/60,000 births, rising to 1/800 in Ashkenazi Jews.  The main cause of the cytopenia, splenomegaly, hepatomegaly, and bone lesions assocd. with the disease is considered to be the infiltration of the bone marrow, spleen, and liver by Gaucher cells.  Type-1 Gaucher disease, which affects the majority of patients (90% in Europe and USA, but less in other regions), is characterized by effects on the viscera, whereas types 2 and 3 are also assocd. with neurol. impairment, either severe in type 2 or variable in type 3.  A diagnosis of GD can be confirmed by demonstrating the deficiency of acid glucocerebrosidase activity in leukocytes.  Mutations in the GBA1 gene should be identified as they may be of prognostic value in some cases.  Patients with type-1 GD-but also carriers of GBA1 mutation-have been found to be predisposed to developing Parkinson's disease, and the risk of neoplasia assocd. with the disease is still subject to discussion.  Disease-specific treatment consists of i.v. enzyme replacement therapy (ERT) using one of the currently available mols. (imiglucerase, velaglucerase, or taliglucerase).  Orally administered inhibitors of glucosylceramide biosynthesis can also be used (miglustat or eliglustat).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqpeVOOYHDqyLVg90H21EOLACvtfcHk0lgGkW7YaRfx_Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXkvVSju70%253D&md5=38a4c125a4007d25177135c8996f7abe</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.3390%2Fijms18020441&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fijms18020441%26sid%3Dliteratum%253Aachs%26aulast%3DStirnemann%26aufirst%3DJ.%26aulast%3DBelmatoug%26aufirst%3DN.%26aulast%3DCamou%26aufirst%3DF.%26aulast%3DSerratrice%26aufirst%3DC.%26aulast%3DFroissart%26aufirst%3DR.%26aulast%3DCaillaud%26aufirst%3DC.%26aulast%3DLevade%26aufirst%3DT.%26aulast%3DAstudillo%26aufirst%3DL.%26aulast%3DSerratrice%26aufirst%3DJ.%26aulast%3DBrassier%26aufirst%3DA.%26aulast%3DRose%26aufirst%3DC.%26aulast%3DBillette%2Bde%2BVillemeur%26aufirst%3DT.%26aulast%3DBerger%26aufirst%3DM.%26atitle%3DA%2520review%2520of%2520gaucher%2520disease%2520pathophysiology%252C%2520clinical%2520presentation%2520and%2520treatments%26jtitle%3DInt.%2520J.%2520Mol.%2520Sci.%26date%3D2017%26volume%3D18%26spage%3D441%26epage%3D471%26doi%3D10.3390%2Fijms18020441" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref41"><div class="reference"><strong class="refLabel"><a href="#ref41" class="rightTabRefNumLink">41</a></strong><div class="NLM_citation" id="rightTab-cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Won, J.-S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, I.</span></span> <span> </span><span class="NLM_article-title">Biochemical, cell biological, pathological, and therapeutic aspects of Krabbe’s disease</span>. <i>J. Neurosci. Res.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>94</i></span>,  <span class="NLM_fpage">990</span>– <span class="NLM_lpage">1006</span>, <span class="refDoi"> DOI: 10.1002/jnr.23873</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01561&amp;key=10.1002%2Fjnr.23873" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01561&amp;key=27638584" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01561&amp;key=1%3ACAS%3A528%3ADC%252BC28XhsFWltr3I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=94&publication_year=2016&pages=990-1006&author=J.-S.+Wonauthor=A.+K.+Singhauthor=I.+Singh&title=Biochemical%2C+cell+biological%2C+pathological%2C+and+therapeutic+aspects+of+Krabbe%E2%80%99s+disease&doi=10.1002%2Fjnr.23873"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Biochemical, cell biological, pathological, and therapeutic aspects of Krabbe's disease</span></div><div class="casAuthors">Won, Je-Seong; Singh, Avtar K.; Singh, Inderjit</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Neuroscience Research</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">94</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">990-1006</span>CODEN:
                <span class="NLM_cas:coden">JNREDK</span>;
        ISSN:<span class="NLM_cas:issn">0360-4012</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">A review.  Krabbe's disease (KD; also called globoid cell leukodystrophy) is a genetic disorder involving demyelination of the central (CNS) and peripheral (PNS) nervous systems.  The disease may be subdivided into three types, an infantile form, which is the most common and severe; a juvenile form; and a rare adult form.  KD is an autosomal recessive disorder caused by a deficiency of galactocerebrosidase activity in lysosomes, leading to accumulation of galactoceramide and neurotoxic galactosylsphingosine (psychosine [PSY]) in macrophages (globoid cells) as well as neural cells, esp. in oligodendrocytes and Schwann cells.  This ultimately results in damage to myelin in both CNS and PNS with assocd. morbidity and mortality.  Accumulation of PSY, a lysolipid with detergent-like properties, over a threshold level could trigger membrane destabilization, leading to cell lysis.  Moreover, subthreshold concns. of PSY trigger cell signaling pathways that induce oxidative stress, mitochondrial dysfunction, apoptosis, inflammation, endothelial/vascular dysfunctions, and neuronal and axonal damage.  From the time the "psychosine hypothesis" was proposed, considerable efforts have been made in search of an effective therapy for lowering PSY load with pharmacol., gene, and stem cell approaches to attenuate PSY-induced neurotoxicity.  This Review focuses on the recent advances and prospective research for understanding disease mechanisms and therapeutic approaches for KD. © 2016 Wiley Periodicals, Inc.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoyiXLjIgjfi7Vg90H21EOLACvtfcHk0lgGkW7YaRfx_Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhsFWltr3I&md5=4f5306516d90cf3abf8a9023172ac8dc</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1002%2Fjnr.23873&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjnr.23873%26sid%3Dliteratum%253Aachs%26aulast%3DWon%26aufirst%3DJ.-S.%26aulast%3DSingh%26aufirst%3DA.%2BK.%26aulast%3DSingh%26aufirst%3DI.%26atitle%3DBiochemical%252C%2520cell%2520biological%252C%2520pathological%252C%2520and%2520therapeutic%2520aspects%2520of%2520Krabbe%25E2%2580%2599s%2520disease%26jtitle%3DJ.%2520Neurosci.%2520Res.%26date%3D2016%26volume%3D94%26spage%3D990%26epage%3D1006%26doi%3D10.1002%2Fjnr.23873" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref42"><div class="reference"><strong class="refLabel"><a href="#ref42" class="rightTabRefNumLink">42</a></strong><div class="NLM_citation" id="rightTab-cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ferraz, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marques, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verhoek, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strijland, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mirzaian, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scheij, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ouairy, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lahav, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wisse, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Overkleeft, H. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boot, R. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aerts, J. M.</span></span> <span> </span><span class="NLM_article-title">Lysosomal glycosphingolipid catabolism by acid ceramidase: formation of glycosphingoid bases during deficiency of glycosidases</span>. <i>FEBS Lett.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>590</i></span>,  <span class="NLM_fpage">716</span>– <span class="NLM_lpage">725</span>, <span class="refDoi"> DOI: 10.1002/1873-3468.12104</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01561&amp;key=10.1002%2F1873-3468.12104" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01561&amp;key=26898341" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01561&amp;key=1%3ACAS%3A528%3ADC%252BC28Xht1Krur7N" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=590&publication_year=2016&pages=716-725&author=M.+J.+Ferrazauthor=M.+D.+Marquesauthor=M.+Verhoekauthor=A.+Strijlandauthor=M.+Mirzaianauthor=S.+Scheijauthor=C.+M.+Ouairyauthor=D.+Lahavauthor=P.+Wisseauthor=H.+S.+Overkleeftauthor=R.+G.+Bootauthor=J.+M.+Aerts&title=Lysosomal+glycosphingolipid+catabolism+by+acid+ceramidase%3A+formation+of+glycosphingoid+bases+during+deficiency+of+glycosidases&doi=10.1002%2F1873-3468.12104"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Lysosomal glycosphingolipid catabolism by acid ceramidase: formation of glycosphingoid bases during deficiency of glycosidases</span></div><div class="casAuthors">Ferraz, Maria J.; Marques, Andre R. A.; Appelman, Monique D.; Verhoek, Marri; Strijland, Anneke; Mirzaian, Mina; Scheij, Saskia; Ouairy, Cecile M.; Lahav, Daniel; Wisse, Patrick; Overkleeft, Herman S.; Boot, Rolf G.; Aerts, Johannes M.</div><div class="citationInfo"><span class="NLM_cas:title">FEBS Letters</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">590</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">716-725</span>CODEN:
                <span class="NLM_cas:coden">FEBLAL</span>;
        ISSN:<span class="NLM_cas:issn">0014-5793</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Glycosphingoid bases are elevated in inherited lysosomal storage disorders with deficient activity of glycosphingolipid catabolizing glycosidases.  We investigated the mol. basis of the formation of glucosyl sphingosine and globotriaosyl sphingosine during deficiency of glucocerebrosidase (Gaucher disease) and α-galactosidase A (Fabry disease).  Independent genetic and pharmacol. evidence is presented pointing to an active role of acid ceramidase in both processes through deacylation of lysosomal glycosphingolipids.  The potential pathophysiol. relevance of elevated glycosphingoid bases generated through this alternative metab. in patients suffering from lysosomal glycosidase defects is discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqD3HCj2x7-AbVg90H21EOLACvtfcHk0lhxGxoWHf8q2g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xht1Krur7N&md5=ecfbbdaaf640b5e567ea771241262e09</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1002%2F1873-3468.12104&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252F1873-3468.12104%26sid%3Dliteratum%253Aachs%26aulast%3DFerraz%26aufirst%3DM.%2BJ.%26aulast%3DMarques%26aufirst%3DM.%2BD.%26aulast%3DVerhoek%26aufirst%3DM.%26aulast%3DStrijland%26aufirst%3DA.%26aulast%3DMirzaian%26aufirst%3DM.%26aulast%3DScheij%26aufirst%3DS.%26aulast%3DOuairy%26aufirst%3DC.%2BM.%26aulast%3DLahav%26aufirst%3DD.%26aulast%3DWisse%26aufirst%3DP.%26aulast%3DOverkleeft%26aufirst%3DH.%2BS.%26aulast%3DBoot%26aufirst%3DR.%2BG.%26aulast%3DAerts%26aufirst%3DJ.%2BM.%26atitle%3DLysosomal%2520glycosphingolipid%2520catabolism%2520by%2520acid%2520ceramidase%253A%2520formation%2520of%2520glycosphingoid%2520bases%2520during%2520deficiency%2520of%2520glycosidases%26jtitle%3DFEBS%2520Lett.%26date%3D2016%26volume%3D590%26spage%3D716%26epage%3D725%26doi%3D10.1002%2F1873-3468.12104" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref43"><div class="reference"><strong class="refLabel"><a href="#ref43" class="rightTabRefNumLink">43</a></strong><div class="NLM_citation" id="rightTab-cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benitez, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagree, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dearborn, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guzman, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woloszynek, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giaramita, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yip, B. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elsbernd, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Babcock, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fowler, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wozniak, D. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vogler, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Medin, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crawford, B. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sands, M. S.</span></span> <span> </span><span class="NLM_article-title">Genetic ablation of acid ceramidase in Krabbe disease confirms the psychosine hypothesis and identifies a new therapeutic target</span>. <i>Proc. Natl. Acad. Sci. U.S.A.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>116</i></span>,  <span class="NLM_fpage">20097</span>– <span class="NLM_lpage">20103</span>, <span class="refDoi"> DOI: 10.1073/pnas.1912108116</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01561&amp;key=10.1073%2Fpnas.1912108116" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01561&amp;key=31527255" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01561&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhvFSitrfE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=116&publication_year=2019&pages=20097-20103&author=Y.+Liauthor=Y.+Xuauthor=B.+A.+Benitezauthor=M.+S.+Nagreeauthor=J.+T.+Dearbornauthor=X.+Jiangauthor=M.+A.+Guzmanauthor=J.+C.+Woloszynekauthor=A.+Giaramitaauthor=B.+K.+Yipauthor=J.+Elsberndauthor=M.+C.+Babcockauthor=M.+Loauthor=S.+C.+Fowlerauthor=D.+F.+Wozniakauthor=C.+A.+Voglerauthor=J.+A.+Medinauthor=B.+E.+Crawfordauthor=M.+S.+Sands&title=Genetic+ablation+of+acid+ceramidase+in+Krabbe+disease+confirms+the+psychosine+hypothesis+and+identifies+a+new+therapeutic+target&doi=10.1073%2Fpnas.1912108116"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">Genetic ablation of acid ceramidase in Krabbe disease confirms the psychosine hypothesis and identifies a new therapeutic target</span></div><div class="casAuthors">Li, Yedda; Xu, Yue; Benitez, Bruno A.; Nagree, Murtaza S.; Dearborn, Joshua T.; Jiang, Xuntian; Guzman, Miguel A.; Woloszynek, Josh C.; Giaramita, Alex; Yip, Bryan K.; Elsbernd, Joseph; Babcock, Michael C.; Lo, Melanie; Fowler, Stephen C.; Wozniak, David F.; Vogler, Carole A.; Medin, Jeffrey A.; Crawford, Brett E.; Sands, Mark S.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">116</span>
        (<span class="NLM_cas:issue">40</span>),
    <span class="NLM_cas:pages">20097-20103</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Infantile globoid cell leukodystrophy (GLD, Krabbe disease) is a fatal demyelinating disorder caused by a deficiency in the lysosomal enzyme galactosylceramidase (GALC).  GALC deficiency leads to the accumulation of the cytotoxic glycolipid, galactosylsphingosine (psychosine).  Complementary evidence suggested that psychosine is synthesized via an anabolic pathway.  Here, we show instead that psychosine is generated catabolically through the deacylation of galactosylceramide by acid ceramidase (ACDase).  This reaction uncouples GALC deficiency from psychosine accumulation, allowing us to test the long-standing "psychosine hypothesis".  We demonstrate that genetic loss of ACDase activity (Farber disease) in the GALC-deficient mouse model of human GLD (twitcher) eliminates psychosine accumulation and cures GLD.  These data suggest that ACDase could be a target for substrate redn. therapy (SRT) in Krabbe patients.  We show that pharmacol. inhibition of ACDase activity with carmofur significantly decreases psychosine accumulation in cells from a Krabbe patient and prolongs the life span of the twitcher (Twi) mouse.  Previous SRT expts. in the Twi mouse utilized L-cycloserine, which inhibits an enzyme several steps upstream of psychosine synthesis, thus altering the balance of other important lipids.  Drugs that directly inhibit ACDase may have a more acceptable safety profile due to their mechanistic proximity to psychosine biogenesis.  In total, these data clarify our understanding of psychosine synthesis, confirm the long-held psychosine hypothesis, and provide the impetus to discover safe and effective inhibitors of ACDase to treat Krabbe disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoMIjeCuiB29bVg90H21EOLACvtfcHk0lhxGxoWHf8q2g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhvFSitrfE&md5=921bc583ee05d71e2d55dd98a235fd1b</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1912108116&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1912108116%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DY.%26aulast%3DXu%26aufirst%3DY.%26aulast%3DBenitez%26aufirst%3DB.%2BA.%26aulast%3DNagree%26aufirst%3DM.%2BS.%26aulast%3DDearborn%26aufirst%3DJ.%2BT.%26aulast%3DJiang%26aufirst%3DX.%26aulast%3DGuzman%26aufirst%3DM.%2BA.%26aulast%3DWoloszynek%26aufirst%3DJ.%2BC.%26aulast%3DGiaramita%26aufirst%3DA.%26aulast%3DYip%26aufirst%3DB.%2BK.%26aulast%3DElsbernd%26aufirst%3DJ.%26aulast%3DBabcock%26aufirst%3DM.%2BC.%26aulast%3DLo%26aufirst%3DM.%26aulast%3DFowler%26aufirst%3DS.%2BC.%26aulast%3DWozniak%26aufirst%3DD.%2BF.%26aulast%3DVogler%26aufirst%3DC.%2BA.%26aulast%3DMedin%26aufirst%3DJ.%2BA.%26aulast%3DCrawford%26aufirst%3DB.%2BE.%26aulast%3DSands%26aufirst%3DM.%2BS.%26atitle%3DGenetic%2520ablation%2520of%2520acid%2520ceramidase%2520in%2520Krabbe%2520disease%2520confirms%2520the%2520psychosine%2520hypothesis%2520and%2520identifies%2520a%2520new%2520therapeutic%2520target%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2019%26volume%3D116%26spage%3D20097%26epage%3D20103%26doi%3D10.1073%2Fpnas.1912108116" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref44"><div class="reference"><strong class="refLabel"><a href="#ref44" class="rightTabRefNumLink">44</a></strong><div class="NLM_citation" id="rightTab-cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gebai, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gorelik, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Illes, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagar, B.</span></span> <span> </span><span class="NLM_article-title">Structural basis for the activation of acid ceramidase</span>. <i>Nat. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">1621</span>, <span class="refDoi"> DOI: 10.1038/s41467-018-03844-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01561&amp;key=10.1038%2Fs41467-018-03844-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01561&amp;key=29692406" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01561&amp;key=1%3ACAS%3A280%3ADC%252BC1Mjmtl2rtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2018&pages=1621&author=A.+Gebaiauthor=A.+Gorelikauthor=Z.+Liauthor=K.+Illesauthor=B.+Nagar&title=Structural+basis+for+the+activation+of+acid+ceramidase&doi=10.1038%2Fs41467-018-03844-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">Structural basis for the activation of acid ceramidase</span></div><div class="casAuthors">Gebai Ahmad; Gorelik Alexei; Li Zixian; Illes Katalin; Nagar Bhushan</div><div class="citationInfo"><span class="NLM_cas:title">Nature communications</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">1621</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Acid ceramidase (aCDase, ASAH1) hydrolyzes lysosomal membrane ceramide into sphingosine, the backbone of all sphingolipids, to regulate many cellular processes.  Abnormal function of aCDase leads to Farber disease, spinal muscular atrophy with progressive myoclonic epilepsy, and is associated with Alzheimer's, diabetes, and cancer.  Here, we present crystal structures of mammalian aCDases in both proenzyme and autocleaved forms.  In the proenzyme, the catalytic center is buried and protected from solvent.  Autocleavage triggers a conformational change exposing a hydrophobic channel leading to the active site.  Substrate modeling suggests distinct catalytic mechanisms for substrate hydrolysis versus autocleavage.  A hydrophobic surface surrounding the substrate binding channel appears to be a site of membrane attachment where the enzyme accepts substrates facilitated by the accessory protein, saposin-D.  Structural mapping of disease mutations reveals that most would destabilize the protein fold.  These results will inform the rational design of aCDase inhibitors and recombinant aCDase for disease therapeutics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcT6RpR0JSKnbwHqQV89nF-2fW6udTcc2eafWEhxE5UnCLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1Mjmtl2rtg%253D%253D&md5=a7fb6f187dc50d25c9a14597053718c1</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1038%2Fs41467-018-03844-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41467-018-03844-2%26sid%3Dliteratum%253Aachs%26aulast%3DGebai%26aufirst%3DA.%26aulast%3DGorelik%26aufirst%3DA.%26aulast%3DLi%26aufirst%3DZ.%26aulast%3DIlles%26aufirst%3DK.%26aulast%3DNagar%26aufirst%3DB.%26atitle%3DStructural%2520basis%2520for%2520the%2520activation%2520of%2520acid%2520ceramidase%26jtitle%3DNat.%2520Commun.%26date%3D2018%26volume%3D9%26spage%3D1621%26doi%3D10.1038%2Fs41467-018-03844-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref45"><div class="reference"><strong class="refLabel"><a href="#ref45" class="rightTabRefNumLink">45</a></strong><div class="NLM_citation" id="rightTab-cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bielawska, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greenberg, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perry, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jayadev, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shayman, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McKay, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hannun, Y. A.</span></span> <span> </span><span class="NLM_article-title">(1S,2R)-D-erythro-2-(N-myristoylamino)-1-phenyl-1-propanol as an inhibitor of ceramidase</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1996</span>,  <span class="NLM_volume"><i>271</i></span>,  <span class="NLM_fpage">12646</span>– <span class="NLM_lpage">12654</span>, <span class="refDoi"> DOI: 10.1074/jbc.271.21.12646</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01561&amp;key=10.1074%2Fjbc.271.21.12646" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01561&amp;key=8647877" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01561&amp;key=1%3ACAS%3A528%3ADyaK28XjtFantLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=271&publication_year=1996&pages=12646-12654&author=A.+Bielawskaauthor=M.+S.+Greenbergauthor=D.+Perryauthor=S.+Jayadevauthor=J.+A.+Shaymanauthor=C.+McKayauthor=Y.+A.+Hannun&title=%281S%2C2R%29-D-erythro-2-%28N-myristoylamino%29-1-phenyl-1-propanol+as+an+inhibitor+of+ceramidase&doi=10.1074%2Fjbc.271.21.12646"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">(1S,2R)-D-erythro-2-(N-myristoylamino)-1-phenyl-1-propanol as an inhibitor of ceramidase</span></div><div class="casAuthors">Bielawska, Alicja; Greenberg, Mathew S.; Perry, David; Jayadev, Supriya; Shayman, James A.; McKay, Charles; Hannun, Yusuf A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">271</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">12646-12654</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">The cellular and biochem. activities of the ceramide analog, (1S,2R)-D-erythro-2-(N-myristoylamino)-1-phenyl-1-propanol (D-e-MAPP), were examd.  The addn. of 5 μM D-e-MAPP to HL-60 human promyelocytic leukemia cells resulted in a concn.- and time-dependent growth suppression accompanied by an arrest in the G0/G1 phase of the cell cycle; thus mimicking the action of exogenous ceramides.  Its enantiomer, L-e-MAPP, was without effect.  Two lines of evidence suggested that D-e-MAPP may not function as a direct analog of ceramide.  First, D-e-MAPP possesses a stereochem. configuration opposite to that of D-erythro-ceramide.  Second, D-e-MAPP failed to activate ceramide-activated phosphoprotein phosphatase in vitro.  Therefore, the authors examd. if D-e-MAPP functioned indirectly by modulating endogenous ceramide levels.  The addn. of D-e-MAPP to cells, but not L-e-MAPP, caused a time- and concn.-dependent elevation in endogenous ceramide levels reaching >3-fold over baseline following 24 h of treatment.  Both D-e-MAPP and L-e-MAPP underwent similar uptake by HL-60 cells.  D-E-MAPP was poorly metabolized, and remained intact in cells, whereas L-e-MAPP underwent a time- and concn.-dependent metab., primarily through N-deacylation.  In vitro, L-e-MAPP was metabolized by alk. ceramidase to an extent similar to that seen with C16-ceramide.  D-E-MAPP was not metabolized.  Instead, D-e-MAPP inhibited alk. ceramidase activity in vitro with an IC50 of 1-5 μM.  D-E-MAPP did not modulate the activity of other ceramide-metabolizing enzymes in vitro or in cells, and it was a poor inhibitor of acid ceramidase (IC50 > 500 μM).  Finally, D-e-MAPP inhibited the metab. of L-e-MAPP in cells.  These studies demonstrate that D-e-MAPP functions as an inhibitor of alk. ceramidase in vitro and in cells resulting in elevation in endogenous levels of ceramide with the consequent biol. effects of growth suppression and cell cycle arrest.  These studies point to an important role for ceramidases in the regulation of endogenous levels of ceramide.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr7PyYHPPP3ebVg90H21EOLACvtfcHk0lhCyhE8kcFcqw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK28XjtFantLg%253D&md5=1ed01f1936e1d2a9dcbd9b4b137ebbaa</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1074%2Fjbc.271.21.12646&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.271.21.12646%26sid%3Dliteratum%253Aachs%26aulast%3DBielawska%26aufirst%3DA.%26aulast%3DGreenberg%26aufirst%3DM.%2BS.%26aulast%3DPerry%26aufirst%3DD.%26aulast%3DJayadev%26aufirst%3DS.%26aulast%3DShayman%26aufirst%3DJ.%2BA.%26aulast%3DMcKay%26aufirst%3DC.%26aulast%3DHannun%26aufirst%3DY.%2BA.%26atitle%3D%25281S%252C2R%2529-D-erythro-2-%2528N-myristoylamino%2529-1-phenyl-1-propanol%2520as%2520an%2520inhibitor%2520of%2520ceramidase%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D1996%26volume%3D271%26spage%3D12646%26epage%3D12654%26doi%3D10.1074%2Fjbc.271.21.12646" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref46"><div class="reference"><strong class="refLabel"><a href="#ref46" class="rightTabRefNumLink">46</a></strong><div class="NLM_citation" id="rightTab-cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sugita, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moser, H. W.</span></span> <span> </span><span class="NLM_article-title">Ceramidase and ceramide synthesis in human kidney and cerebellum: description of a new alkaline ceramidase</span>. <i>Biochim. Biophys. Acta, Lipids Lipid Metab.</i> <span class="NLM_year" style="font-weight: bold;">1975</span>,  <span class="NLM_volume"><i>398</i></span>,  <span class="NLM_fpage">125</span>– <span class="NLM_lpage">131</span>, <span class="refDoi"> DOI: 10.1016/0005-2760(75)90176-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01561&amp;key=10.1016%2F0005-2760%2875%2990176-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01561&amp;key=238641" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01561&amp;key=1%3ACAS%3A528%3ADyaE2MXkvFChtb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=398&publication_year=1975&pages=125-131&author=M.+Sugitaauthor=J.+T.+Williamsauthor=H.+W.+Moser&title=Ceramidase+and+ceramide+synthesis+in+human+kidney+and+cerebellum%3A+description+of+a+new+alkaline+ceramidase&doi=10.1016%2F0005-2760%2875%2990176-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">Ceramidase and ceramide synthesis in human kidney and cerebellum.  Description of a new alkaline ceramidase</span></div><div class="casAuthors">Sugita, Mutsumi; Williams, Marcia; Dulaney, John T.; Moser, Hugo W.</div><div class="citationInfo"><span class="NLM_cas:title">Biochimica et Biophysica Acta, Lipids and Lipid Metabolism</span>
        (<span class="NLM_cas:date">1975</span>),
    <span class="NLM_cas:volume">398</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">125-31</span>CODEN:
                <span class="NLM_cas:coden">BBLLA6</span>;
        ISSN:<span class="NLM_cas:issn">0005-2760</span>.
    </div><div class="casAbstract">In normal cerebellum ceramide cleavage and the reverse reaction, free fatty acid-dependent ceramide synthesis, both occur not only at pH 4.0 but also at pH 9.0, although normal kidney exhibits these activities only at pH 4.0.  Both tissues are capable of synthesizing ceramide via an acyl-CoA-dependent pathway at neutral pH.  The synthetic analog of ceramide, N-oleoyl-ethanolamine, is a potent inhibitor of ceramidase.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp3dnZmqqVFYrVg90H21EOLACvtfcHk0lhCyhE8kcFcqw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaE2MXkvFChtb4%253D&md5=a59f9b1a82754943c2da77f5c9deaf19</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1016%2F0005-2760%2875%2990176-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0005-2760%252875%252990176-9%26sid%3Dliteratum%253Aachs%26aulast%3DSugita%26aufirst%3DM.%26aulast%3DWilliams%26aufirst%3DJ.%2BT.%26aulast%3DMoser%26aufirst%3DH.%2BW.%26atitle%3DCeramidase%2520and%2520ceramide%2520synthesis%2520in%2520human%2520kidney%2520and%2520cerebellum%253A%2520description%2520of%2520a%2520new%2520alkaline%2520ceramidase%26jtitle%3DBiochim.%2520Biophys.%2520Acta%252C%2520Lipids%2520Lipid%2520Metab.%26date%3D1975%26volume%3D398%26spage%3D125%26epage%3D131%26doi%3D10.1016%2F0005-2760%2875%2990176-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref47"><div class="reference"><strong class="refLabel"><a href="#ref47" class="rightTabRefNumLink">47</a></strong><div class="NLM_citation" id="rightTab-cit47"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Grijalvo, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bedia, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Triola, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Casas, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Llebaria, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Teixidó, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rabal, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levade, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Delgado, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fabriàs, G.</span></span> <span> </span><span class="NLM_article-title">Design, synthesis and activity as acid ceramidase inhibitors of 2-oxooctanoyl and N-oleoylethanolamine analogues</span>. <i>Chem. Phys. Lipids</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>144</i></span>,  <span class="NLM_fpage">69</span>– <span class="NLM_lpage">84</span>, <span class="refDoi"> DOI: 10.1016/j.chemphyslip.2006.07.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01561&amp;key=10.1016%2Fj.chemphyslip.2006.07.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01561&amp;key=16942762" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01561&amp;key=1%3ACAS%3A528%3ADC%252BD28XhtVygsLbE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=144&publication_year=2006&pages=69-84&author=S.+Grijalvoauthor=C.+Bediaauthor=G.+Triolaauthor=J.+Casasauthor=A.+Llebariaauthor=J.+Teixid%C3%B3author=O.+Rabalauthor=T.+Levadeauthor=A.+Delgadoauthor=G.+Fabri%C3%A0s&title=Design%2C+synthesis+and+activity+as+acid+ceramidase+inhibitors+of+2-oxooctanoyl+and+N-oleoylethanolamine+analogues&doi=10.1016%2Fj.chemphyslip.2006.07.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">Design, synthesis and activity as acid ceramidase inhibitors of 2-oxooctanoyl and N-oleoylethanolamine analogues</span></div><div class="casAuthors">Grijalvo, Santiago; Bedia, Carmen; Triola, Gemma; Casas, Josefina; Llebaria, Amadeu; Teixido, Jordi; Rabal, Obdulia; Levade, Thierry; Delgado, Antonio; Fabrias, Gemma</div><div class="citationInfo"><span class="NLM_cas:title">Chemistry and Physics of Lipids</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">144</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">69-84</span>CODEN:
                <span class="NLM_cas:coden">CPLIA4</span>;
        ISSN:<span class="NLM_cas:issn">0009-3084</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">The synthesis of novel N-acylethanolamines and their use as inhibitors of the aCDase is reported here.  The compds. are either 2-oxooctanamides or oleamides of sphingosine analogs featuring a 3-hydroxy-4,5-hexadecenyl tail replaced by ether or thioether moieties.  It appears that, within the 2-oxooctanamide family, the C3-OH group of the sphingosine mol. is required for inhibition both in vitro and in cultured cells.  Furthermore, although the (E)-4 double bond is not essential for inhibitory activity, the (E) configuration is required, since the analog with a (Z)-4 unsatn. was not inhibitory.  None of the oleamides inhibited the aCDase in vitro.  Conversely, with the exception of N-oleoylethanolamine and its analogs with S-decyl and S-hexadecyl substituents, all the synthesized oleamides inhibited the aCDase in cultured cells, although with a relatively low potency.  We conclude that novel aCDase inhibitors can evolve from N-acylation of sphingoid bases with electron deficient-acyl groups.  In contrast, chem. modification of the N-oleoylsphingosine backbone does not seem to offer an appropriate strategy to obtain aCDase inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpVLIJyKt70kbVg90H21EOLACvtfcHk0liNX8lf1BvaDg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhtVygsLbE&md5=2a5303057207a7f0aa16e56801ad0c47</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1016%2Fj.chemphyslip.2006.07.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.chemphyslip.2006.07.001%26sid%3Dliteratum%253Aachs%26aulast%3DGrijalvo%26aufirst%3DS.%26aulast%3DBedia%26aufirst%3DC.%26aulast%3DTriola%26aufirst%3DG.%26aulast%3DCasas%26aufirst%3DJ.%26aulast%3DLlebaria%26aufirst%3DA.%26aulast%3DTeixid%25C3%25B3%26aufirst%3DJ.%26aulast%3DRabal%26aufirst%3DO.%26aulast%3DLevade%26aufirst%3DT.%26aulast%3DDelgado%26aufirst%3DA.%26aulast%3DFabri%25C3%25A0s%26aufirst%3DG.%26atitle%3DDesign%252C%2520synthesis%2520and%2520activity%2520as%2520acid%2520ceramidase%2520inhibitors%2520of%25202-oxooctanoyl%2520and%2520N-oleoylethanolamine%2520analogues%26jtitle%3DChem.%2520Phys.%2520Lipids%26date%3D2006%26volume%3D144%26spage%3D69%26epage%3D84%26doi%3D10.1016%2Fj.chemphyslip.2006.07.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref48"><div class="reference"><strong class="refLabel"><a href="#ref48" class="rightTabRefNumLink">48</a></strong><div class="NLM_citation" id="rightTab-cit48"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Raisova, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goltz, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bektas, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bielawska, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riebeling, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hossini, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eberle, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hannun, Y. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Orfanos, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Geilen, C. C.</span></span> <span> </span><span class="NLM_article-title">Bcl-2 overexpression prevents apoptosis induced by ceramidase inhibitors in malignant melanoma and HaCaT keratinocytes</span>. <i>FEBS Lett.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>516</i></span>,  <span class="NLM_fpage">47</span>– <span class="NLM_lpage">52</span>, <span class="refDoi"> DOI: 10.1016/s0014-5793(02)02472-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01561&amp;key=10.1016%2FS0014-5793%2802%2902472-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01561&amp;key=11959101" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01561&amp;key=1%3ACAS%3A528%3ADC%252BD38XivVaisbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=516&publication_year=2002&pages=47-52&author=M.+Raisovaauthor=G.+Goltzauthor=M.+Bektasauthor=A.+Bielawskaauthor=C.+Riebelingauthor=A.+M.+Hossiniauthor=J.+Eberleauthor=Y.+A.+Hannunauthor=C.+E.+Orfanosauthor=C.+C.+Geilen&title=Bcl-2+overexpression+prevents+apoptosis+induced+by+ceramidase+inhibitors+in+malignant+melanoma+and+HaCaT+keratinocytes&doi=10.1016%2Fs0014-5793%2802%2902472-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">Bcl-2 overexpression prevents apoptosis induced by ceramidase inhibitors in malignant melanoma and HaCaT keratinocytes</span></div><div class="casAuthors">Raisova, Monika; Goltz, Gerit; Bektas, Meryem; Bielawska, Alicja; Riebeling, Christian; Hossini, Amir M.; Eberle, Jurgen; Hannun, Yusuf A.; Orfanos, Constantin E.; Geilen, Christoph C.</div><div class="citationInfo"><span class="NLM_cas:title">FEBS Letters</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">516</span>
        (<span class="NLM_cas:issue">1-3</span>),
    <span class="NLM_cas:pages">47-52</span>CODEN:
                <span class="NLM_cas:coden">FEBLAL</span>;
        ISSN:<span class="NLM_cas:issn">0014-5793</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science B.V.</span>)
        </div><div class="casAbstract">The authors examd. the biol. effects of the ceramide analogs (1S,2R)-2-N-myristoylamino-1-phenyl-1-propanol (D-e-MAPP) and (1R,2R)-2-N-myristoylamino-1-(4-nitrophenyl)-1,3-propandiol (D-NMAPPD) on human HaCaT keratinocytes and human melanoma cells.  The authors could demonstrate that D-e-MAPP and D-NMAPPD are able to suppress acid ceramidase activity.  The elevation of the endogenous level of ceramide is followed by induction of apoptosis and suppression of proliferation in HaCaT keratinocytes.  Moreover, the authors recently identified a group of human melanoma cell populations which are heterogeneously susceptible to C2-ceramide-mediated apoptosis.  Studies with these melanoma cells revealed correlation between ceramide-mediated apoptosis and D-NMAPPD-induced apoptosis, confirming the effect of this inhibitor on ceramide signaling in human melanoma cells.  These findings suggest ceramidase inhibitors as a potential new therapeutical class of antiproliferative and cytostatic drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqHkVJsCkB4OLVg90H21EOLACvtfcHk0liNX8lf1BvaDg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XivVaisbk%253D&md5=b4fac80e2573fe62b6e90b5a518eff44</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1016%2FS0014-5793%2802%2902472-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0014-5793%252802%252902472-9%26sid%3Dliteratum%253Aachs%26aulast%3DRaisova%26aufirst%3DM.%26aulast%3DGoltz%26aufirst%3DG.%26aulast%3DBektas%26aufirst%3DM.%26aulast%3DBielawska%26aufirst%3DA.%26aulast%3DRiebeling%26aufirst%3DC.%26aulast%3DHossini%26aufirst%3DA.%2BM.%26aulast%3DEberle%26aufirst%3DJ.%26aulast%3DHannun%26aufirst%3DY.%2BA.%26aulast%3DOrfanos%26aufirst%3DC.%2BE.%26aulast%3DGeilen%26aufirst%3DC.%2BC.%26atitle%3DBcl-2%2520overexpression%2520prevents%2520apoptosis%2520induced%2520by%2520ceramidase%2520inhibitors%2520in%2520malignant%2520melanoma%2520and%2520HaCaT%2520keratinocytes%26jtitle%3DFEBS%2520Lett.%26date%3D2002%26volume%3D516%26spage%3D47%26epage%3D52%26doi%3D10.1016%2Fs0014-5793%2802%2902472-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref49"><div class="reference"><strong class="refLabel"><a href="#ref49" class="rightTabRefNumLink">49</a></strong><div class="NLM_citation" id="rightTab-cit49"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Proksch, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klein, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arenz, C.</span></span> <span> </span><span class="NLM_article-title">Potent inhibition of acid ceramidase by novel B-13 analogues</span>. <i>J. Lipids</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>2011</i></span>,  <span class="NLM_fpage">971618</span>, <span class="refDoi"> DOI: 10.1155/2011/971618</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01561&amp;key=10.1155%2F2011%2F971618" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01561&amp;key=21490813" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01561&amp;key=1%3ACAS%3A280%3ADC%252BC3MvjsVKmsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2011&publication_year=2011&pages=971618&author=D.+Prokschauthor=J.+J.+Kleinauthor=C.+Arenz&title=Potent+inhibition+of+acid+ceramidase+by+novel+B-13+analogues&doi=10.1155%2F2011%2F971618"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">Potent inhibition of Acid ceramidase by novel B-13 analogues</span></div><div class="casAuthors">Proksch Denny; Klein Jan Jasper; Arenz Christoph</div><div class="citationInfo"><span class="NLM_cas:title">Journal of lipids</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">2011</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">971618</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The lipid-signalling molecule ceramide is known to induce apoptosis in a variety of cell types.  Inhibition of the lysosomal acid ceramidase can increase cellular ceramide levels and thus induce apoptosis.  Indeed, inhibitors of acid ceramidase have been reported to induce cell death and to display potentiating effects to classical radio- or chemo therapy in a number of in vitro and in vivo cancer models.  The most potent in vitro inhibitor of acid ceramidase, B-13, recently revealed to be virtually inactive towards lysosomal acid ceramidase in living cells.  In contrast, a number of weakly basic B-13 analogues have been shown to accumulate in the acidic compartments of living cells and to efficiently inhibit lysosomal acid ceramidase.  However, introduction of weakly basic groups at the ω-position of the fatty acid moiety of B-13 led to a significant reduction of potency towards acid ceramidase from cellular extracts.  Herein, we report a novel B-13-derived scaffold for more effective inhibitors of acid ceramidase.  Furthermore, we provide hints for an introduction of basic functional groups at an alternative site of the B-13 scaffold that do not interfere with acid ceramidase inhibition in vitro.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSBEW1u4DksqVVwdslNBF-tfW6udTcc2ebcPr261_p79bntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3MvjsVKmsg%253D%253D&md5=c1160708d814d43c68b3ba460b49874a</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1155%2F2011%2F971618&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1155%252F2011%252F971618%26sid%3Dliteratum%253Aachs%26aulast%3DProksch%26aufirst%3DD.%26aulast%3DKlein%26aufirst%3DJ.%2BJ.%26aulast%3DArenz%26aufirst%3DC.%26atitle%3DPotent%2520inhibition%2520of%2520acid%2520ceramidase%2520by%2520novel%2520B-13%2520analogues%26jtitle%3DJ.%2520Lipids%26date%3D2011%26volume%3D2011%26spage%3D971618%26doi%3D10.1155%2F2011%2F971618" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref50"><div class="reference"><strong class="refLabel"><a href="#ref50" class="rightTabRefNumLink">50</a></strong><div class="NLM_citation" id="rightTab-cit50"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Camacho, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meca-Cortés, Ó.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abad, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">García, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rubio, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Díaz, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Celià-Terrassa, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cingolani, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bermudo, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fernández, P. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blanco, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Delgado, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Casas, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fabriàs, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomson, T. M.</span></span> <span> </span><span class="NLM_article-title">Acid ceramidase as a therapeutic target in metastatic prostate cancer</span>. <i>J. Lipid Res.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>54</i></span>,  <span class="NLM_fpage">1207</span>– <span class="NLM_lpage">1220</span>, <span class="refDoi"> DOI: 10.1194/jlr.m032375</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01561&amp;key=10.1194%2Fjlr.M032375" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01561&amp;key=23423838" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01561&amp;key=1%3ACAS%3A528%3ADC%252BC3sXlsFaruro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2013&pages=1207-1220&author=L.+Camachoauthor=%C3%93.+Meca-Cort%C3%A9sauthor=J.+L.+Abadauthor=S.+Garc%C3%ADaauthor=N.+Rubioauthor=A.+D%C3%ADazauthor=T.+Celi%C3%A0-Terrassaauthor=F.+Cingolaniauthor=R.+Bermudoauthor=P.+L.+Fern%C3%A1ndezauthor=J.+Blancoauthor=A.+Delgadoauthor=J.+Casasauthor=G.+Fabri%C3%A0sauthor=T.+M.+Thomson&title=Acid+ceramidase+as+a+therapeutic+target+in+metastatic+prostate+cancer&doi=10.1194%2Fjlr.m032375"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">Acid ceramidase as a therapeutic target in metastatic prostate cancer</span></div><div class="casAuthors">Camacho, Luz; Meca-Cortes, Oscar; Abad, Jose Luis; Garcia, Simon; Rubio, Nuria; Diaz, Alba; Celia-Terrassa, Toni; Cingolani, Francesca; Bermudo, Raquel; Fernandez, Pedro L.; Blanco, Jeronimo; Delgado, Antonio; Casas, Josefina; Fabrias, Gemma; Thomson, Timothy M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Lipid Research</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1207-1220</span>CODEN:
                <span class="NLM_cas:coden">JLPRAW</span>;
        ISSN:<span class="NLM_cas:issn">0022-2275</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology, Inc.</span>)
        </div><div class="casAbstract">Acid ceramidase (AC) catalyzes the hydrolysis of ceramide into sphingosine, in turn a substrate of sphingosine kinases that catalyze its conversion into the mitogenic sphingosine-1-phosphate.  AC is expressed at high levels in several tumor types and has been proposed as a cancer therapeutic target.  Using a model derived from PC-3 prostate cancer cells, the highly tumorigenic, metastatic, and chemoresistant clone PC-3/Mc expressed higher levels of the AC ASAH1 than the nonmetastatic clone PC-3/S.  Stable knockdown of ASAH1 in PC-3/Mc cells caused an accumulation of ceramides, inhibition of clonogenic potential, increased requirement for growth factors, and inhibition of tumorigenesis and lung metastases.  We developed de novo ASAH1 inhibitors, which also caused a dose-dependent accumulation of ceramides in PC-3/Mc cells and inhibited their growth and clonogenicity.  Finally, immunohistochem. anal. of primary prostate cancer samples showed that higher levels of ASAH1 were assocd. with more advanced stages of this neoplasia.  These observations confirm ASAH1 as a therapeutic target in advanced and chemoresistant forms of prostate cancer and suggest that our new potent and specific AC inhibitors could act by counteracting crit. growth properties of these highly aggressive tumor cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGprkd7ioZLP4bVg90H21EOLACvtfcHk0lgdOjoZseeGoA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXlsFaruro%253D&md5=581be45e3daf85648de6a281b7fcf3be</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1194%2Fjlr.M032375&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1194%252Fjlr.M032375%26sid%3Dliteratum%253Aachs%26aulast%3DCamacho%26aufirst%3DL.%26aulast%3DMeca-Cort%25C3%25A9s%26aufirst%3D%25C3%2593.%26aulast%3DAbad%26aufirst%3DJ.%2BL.%26aulast%3DGarc%25C3%25ADa%26aufirst%3DS.%26aulast%3DRubio%26aufirst%3DN.%26aulast%3DD%25C3%25ADaz%26aufirst%3DA.%26aulast%3DCeli%25C3%25A0-Terrassa%26aufirst%3DT.%26aulast%3DCingolani%26aufirst%3DF.%26aulast%3DBermudo%26aufirst%3DR.%26aulast%3DFern%25C3%25A1ndez%26aufirst%3DP.%2BL.%26aulast%3DBlanco%26aufirst%3DJ.%26aulast%3DDelgado%26aufirst%3DA.%26aulast%3DCasas%26aufirst%3DJ.%26aulast%3DFabri%25C3%25A0s%26aufirst%3DG.%26aulast%3DThomson%26aufirst%3DT.%2BM.%26atitle%3DAcid%2520ceramidase%2520as%2520a%2520therapeutic%2520target%2520in%2520metastatic%2520prostate%2520cancer%26jtitle%3DJ.%2520Lipid%2520Res.%26date%3D2013%26volume%3D54%26spage%3D1207%26epage%3D1220%26doi%3D10.1194%2Fjlr.m032375" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref51"><div class="reference"><strong class="refLabel"><a href="#ref51" class="rightTabRefNumLink">51</a></strong><div class="NLM_citation" id="rightTab-cit51"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ordóñez, Y. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abad, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aseeri, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Casas, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garcia, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Casasampere, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schuchman, E. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levade, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Delgado, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Triola, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fabrias, G.</span></span> <span> </span><span class="NLM_article-title">Activity-based imaging of acid ceramidase in living cells</span>. <i>J. Am. Chem. Soc.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>141</i></span>,  <span class="NLM_fpage">7736</span>– <span class="NLM_lpage">7742</span>, <span class="refDoi"> DOI: 10.1021/jacs.8b11687</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jacs.8b11687" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01561&amp;key=1%3ACAS%3A528%3ADC%252BC1MXosVOhsb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=141&publication_year=2019&pages=7736-7742&author=Y.+F.+Ord%C3%B3%C3%B1ezauthor=J.+L.+Abadauthor=M.+Aseeriauthor=J.+Casasauthor=V.+Garciaauthor=M.+Casasampereauthor=E.+H.+Schuchmanauthor=T.+Levadeauthor=A.+Delgadoauthor=G.+Triolaauthor=G.+Fabrias&title=Activity-based+imaging+of+acid+ceramidase+in+living+cells&doi=10.1021%2Fjacs.8b11687"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit51R"><div class="casContent"><span class="casTitleNuber">51</span><div class="casTitle"><span class="NLM_cas:atitle">Activity-Based Imaging of Acid Ceramidase in Living Cells</span></div><div class="casAuthors">Ordonez, Yadira F.; Abad, Jose Luis; Aseeri, Mazen; Casas, Josefina; Garcia, Virginie; Casasampere, Mireia; Schuchman, Edward H.; Levade, Thierry; Delgado, Antonio; Triola, Gemma; Fabrias, Gemma</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">141</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">7736-7742</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Acid ceramidase (AC) hydrolyzes ceramides into sphingoid bases and fatty acids.  The enzyme is overexpressed in several types of cancer and Alzheimer's disease, and its genetic defect causes different incurable disorders.  The availability of a method for the specific visualization of catalytically active AC in intracellular compartments is crucial for diagnosis and follow-up of therapeutic strategies in diseases linked to altered AC activity.  This work was undertaken to develop activity-based probes for the detection of AC.  Several analogs of the AC inhibitor SABRAC were synthesized and found to act as very potent (two-digit nM range) irreversible AC inhibitors by reaction with the active site Cys143.  Detection of active AC in cell-free systems was achieved either by using fluorescent SABRAC analogs or by click chem. with an azide-substituted analog.  The compd. affording the best features allowed the unprecedented labeling of active AC in living cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqx2rO1y9xv5LVg90H21EOLACvtfcHk0lgdOjoZseeGoA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXosVOhsb8%253D&md5=5c1fe4e82ef6c2268c69a3bd7f733227</span></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1021%2Fjacs.8b11687&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjacs.8b11687%26sid%3Dliteratum%253Aachs%26aulast%3DOrd%25C3%25B3%25C3%25B1ez%26aufirst%3DY.%2BF.%26aulast%3DAbad%26aufirst%3DJ.%2BL.%26aulast%3DAseeri%26aufirst%3DM.%26aulast%3DCasas%26aufirst%3DJ.%26aulast%3DGarcia%26aufirst%3DV.%26aulast%3DCasasampere%26aufirst%3DM.%26aulast%3DSchuchman%26aufirst%3DE.%2BH.%26aulast%3DLevade%26aufirst%3DT.%26aulast%3DDelgado%26aufirst%3DA.%26aulast%3DTriola%26aufirst%3DG.%26aulast%3DFabrias%26aufirst%3DG.%26atitle%3DActivity-based%2520imaging%2520of%2520acid%2520ceramidase%2520in%2520living%2520cells%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D2019%26volume%3D141%26spage%3D7736%26epage%3D7742%26doi%3D10.1021%2Fjacs.8b11687" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref52"><div class="reference"><strong class="refLabel"><a href="#ref52" class="rightTabRefNumLink">52</a></strong><div class="NLM_citation" id="rightTab-cit52"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Draper, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xia, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhuang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, C. D.</span></span> <span> </span><span class="NLM_article-title">Discovery and evaluation of inhibitors of human ceramidase</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">2052</span>– <span class="NLM_lpage">2061</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.mct-11-0365</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01561&amp;key=10.1158%2F1535-7163.MCT-11-0365" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01561&amp;key=21885864" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01561&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhsVeltLbL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2011&pages=2052-2061&author=J.+M.+Draperauthor=Z.+Xiaauthor=R.+A.+Smithauthor=Y.+Zhuangauthor=W.+Wangauthor=C.+D.+Smith&title=Discovery+and+evaluation+of+inhibitors+of+human+ceramidase&doi=10.1158%2F1535-7163.mct-11-0365"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit52R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery and Evaluation of Inhibitors of Human Ceramidase</span></div><div class="casAuthors">Draper, Jeremiah M.; Xia, Zuping; Smith, Ryan A.; Zhuang, Yan; Wang, Wenxue; Smith, Charles D.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2052-2061</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The ceramide/sphingosine-1-phosphate (S1P) rheostat has been hypothesized to play a crit. role in regulating tumor cell fate, with elevated levels of ceramide inducing death and elevated levels of S1P leading to survival and proliferation.  Ceramidases are key enzymes that control this rheostat by hydrolyzing ceramide to produce sphingosine and may also confer resistance to drugs and radiation.  Therefore, ceramidase inhibitors have excellent potential for development as new anticancer drugs.  In this study, we identify a novel ceramidase inhibitor (Ceranib-1) by screening a small mol. library and describe the synthesis of a more potent analog (Ceranib-2).  In a cell-based assay, both compds. were found to inhibit cellular ceramidase activity toward an exogenous ceramide analog, induce the accumulation of multiple ceramide species, decrease levels of sphingosine and S1P, inhibit the proliferation of cells alone and in combination with paclitaxel, and induce cell-cycle arrest and cell death.  In vivo, Ceranib-2 was found to delay tumor growth in a syngeneic tumor model without hematol. suppression or overt signs of toxicity.  These data support the selection of ceramidases as suitable targets for anticancer drug development and provide the first nonlipid inhibitors of human ceramidase activity.  Mol Cancer Ther; 10(11); 2052-61.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpB2jpM4jQkMrVg90H21EOLACvtfcHk0lgdOjoZseeGoA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhsVeltLbL&md5=0adf607e83b91dff2ed50d989cdeb34e</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-11-0365&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-11-0365%26sid%3Dliteratum%253Aachs%26aulast%3DDraper%26aufirst%3DJ.%2BM.%26aulast%3DXia%26aufirst%3DZ.%26aulast%3DSmith%26aufirst%3DR.%2BA.%26aulast%3DZhuang%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DW.%26aulast%3DSmith%26aufirst%3DC.%2BD.%26atitle%3DDiscovery%2520and%2520evaluation%2520of%2520inhibitors%2520of%2520human%2520ceramidase%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2011%26volume%3D10%26spage%3D2052%26epage%3D2061%26doi%3D10.1158%2F1535-7163.mct-11-0365" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref53"><div class="reference"><strong class="refLabel"><a href="#ref53" class="rightTabRefNumLink">53</a></strong><div class="NLM_citation" id="rightTab-cit53"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yildiz-Ozer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oztopcu-Vatan, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kus, G.</span></span> <span> </span><span class="NLM_article-title">The investigation of ceranib-2 on apoptosis and drug interaction with carboplatin in human non small cell lung cancer cells in vitro</span>. <i>Cytotechnology</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>70</i></span>,  <span class="NLM_fpage">387</span>– <span class="NLM_lpage">396</span>, <span class="refDoi"> DOI: 10.1007/s10616-017-0154-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01561&amp;key=10.1007%2Fs10616-017-0154-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01561&amp;key=29230631" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01561&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhvFOmtLrM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=70&publication_year=2018&pages=387-396&author=M.+Yildiz-Ozerauthor=P.+Oztopcu-Vatanauthor=G.+Kus&title=The+investigation+of+ceranib-2+on+apoptosis+and+drug+interaction+with+carboplatin+in+human+non+small+cell+lung+cancer+cells+in+vitro&doi=10.1007%2Fs10616-017-0154-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit53R"><div class="casContent"><span class="casTitleNuber">53</span><div class="casTitle"><span class="NLM_cas:atitle">The investigation of ceranib-2 on apoptosis and drug interaction with carboplatin in human non small cell lung cancer cells in vitro</span></div><div class="casAuthors">Yildiz-Ozer, Merve; Oztopcu-Vatan, Pinar; Kus, Gokhan</div><div class="citationInfo"><span class="NLM_cas:title">Cytotechnology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">70</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">387-396</span>CODEN:
                <span class="NLM_cas:coden">CYTOER</span>;
        ISSN:<span class="NLM_cas:issn">0920-9069</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Ceramide is found to be involved in inhibition of cell division and induction of apoptosis in certain tumor cells.  Ceranib-2 is an agent that increases ceramide levels by inhibiting ceramidase in cancer cells.  Therefore, we aimed to investigate the effects of ceranib-2 on cell survival, apoptosis and interaction with carboplatin in human non-small cell lung cancer cells.  The cytotoxic effect of ceranib-2 (1-100μM) was detd. by MTT assay in human lung adenocarcinoma (A549) and large cell lung carcinoma (H460) cells.  Carboplatin (1-100μM) and lung bronchial epithelial cells (BEAS-2B) were used as pos. controls.  Morphol. and ultrastructural changes were analyzed by light microscope and TEM.  Apoptotic/necrotic cell death and acid ceramidase activity were analyzed by ELISA.  Combination effects of ceranib-2 and carboplatin were investigated by MTT.  The expression levels of CASP3, CASP9, BAX and BCL-2 were examd. by qRT-PCR.  The IC50 of ceranib-2 was detd. as 22μM in A549 cells and 8μM in H460 cells for 24 h.  Morphol. changes and induction of DNA fragmentation have revealed apoptotic effects of ceranib-2 in both cell lines.  Ceranib-2 and carboplatin has shown synergism in combined treatment at 10 and 25μM doses in H460 cells for 24 h.  Ceranib-2 inhibited acid ceramidase activity by 44% at 25μM in H460 cells.  Finally, CASP3, CASP9 and BAX expressions were increased while BCL-2 expression was reduced in both cells.  Our results obtained some preliminary results about the cytotoxic and apoptotic effects of ceranib-2 for the first time in NSCLC cell lines.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqDjZ_ufhN1cbVg90H21EOLACvtfcHk0lhadRi4Lqll-A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhvFOmtLrM&md5=7f3de4445930da4a914fae8878a81965</span></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.1007%2Fs10616-017-0154-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10616-017-0154-8%26sid%3Dliteratum%253Aachs%26aulast%3DYildiz-Ozer%26aufirst%3DM.%26aulast%3DOztopcu-Vatan%26aufirst%3DP.%26aulast%3DKus%26aufirst%3DG.%26atitle%3DThe%2520investigation%2520of%2520ceranib-2%2520on%2520apoptosis%2520and%2520drug%2520interaction%2520with%2520carboplatin%2520in%2520human%2520non%2520small%2520cell%2520lung%2520cancer%2520cells%2520in%2520vitro%26jtitle%3DCytotechnology%26date%3D2018%26volume%3D70%26spage%3D387%26epage%3D396%26doi%3D10.1007%2Fs10616-017-0154-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref54"><div class="reference"><strong class="refLabel"><a href="#ref54" class="rightTabRefNumLink">54</a></strong><div class="NLM_citation" id="rightTab-cit54"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cho, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, H. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, M.-W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kwon, H. J.</span></span> <span> </span><span class="NLM_article-title">A guanidine-based synthetic compound suppresses angiogenesis via inhibition of acid ceramidase</span>. <i>ACS Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">11</span>– <span class="NLM_lpage">19</span>, <span class="refDoi"> DOI: 10.1021/acschembio.8b00558</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acschembio.8b00558" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01561&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitlKmsbfI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2019&pages=11-19&author=S.+M.+Choauthor=H.+K.+Leeauthor=Q.+Liuauthor=M.-W.+Wangauthor=H.+J.+Kwon&title=A+guanidine-based+synthetic+compound+suppresses+angiogenesis+via+inhibition+of+acid+ceramidase&doi=10.1021%2Facschembio.8b00558"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit54R"><div class="casContent"><span class="casTitleNuber">54</span><div class="casTitle"><span class="NLM_cas:atitle">A Guanidine-Based Synthetic Compound Suppresses Angiogenesis via Inhibition of Acid Ceramidase</span></div><div class="casAuthors">Cho, Sung Min; Lee, Hyung Keun; Liu, Qing; Wang, Ming-Wei; Kwon, Ho Jeong</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Biology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">11-19</span>CODEN:
                <span class="NLM_cas:coden">ACBCCT</span>;
        ISSN:<span class="NLM_cas:issn">1554-8929</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Angiogenesis generates new blood vessels from pre-existing vessels.  Tumors induce the formation of new blood vessels to ensure sufficient oxygen and nutrients for their growth.  Normally, angiogenesis is induced by various pro-angiogenesis factors, including vascular endothelial growth factor (VEGF).  Inhibition of VEGF is a promising approach to cancer treatment.  A guanidine-based synthetic compd., E2, was identified as a potent hit from 68 guanidine-based derivs. by screening for angiogenesis inhibitors showing antiproliferative activity in human umbilical vein endothelial cells (HUVECs).  To explore the mode of action of E2(I), target proteins were investigated using phage display biopanning, and acid ceramidase 1 (ASAH1) was identified as an E2-binding protein.  Drug affinity responsive target stability (DARTS) and ASAH1 activity assays revealed the direct binding of E2 to ASAH1.  Moreover, siRNA knockdown of ASAH1 demonstrated its role as an angiogenesis factor.  Consequently, E2 inhibited chemoinvasion and tube formation of HUVECs in a dose-dependent manner.  E2 also potently suppressed neo-vascularization of chorioallantoic membranes in vivo.  Collectively, these data suggest that E2 is a novel angiogenesis inhibitor and ASAH1 is proposed to be a new antiangiogenesis target.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoNp2VCUdl057Vg90H21EOLACvtfcHk0lhadRi4Lqll-A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitlKmsbfI&md5=8fe37e555f70ebc4cdd41431d10f48b5</span></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.1021%2Facschembio.8b00558&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facschembio.8b00558%26sid%3Dliteratum%253Aachs%26aulast%3DCho%26aufirst%3DS.%2BM.%26aulast%3DLee%26aufirst%3DH.%2BK.%26aulast%3DLiu%26aufirst%3DQ.%26aulast%3DWang%26aufirst%3DM.-W.%26aulast%3DKwon%26aufirst%3DH.%2BJ.%26atitle%3DA%2520guanidine-based%2520synthetic%2520compound%2520suppresses%2520angiogenesis%2520via%2520inhibition%2520of%2520acid%2520ceramidase%26jtitle%3DACS%2520Chem.%2520Biol.%26date%3D2019%26volume%3D14%26spage%3D11%26epage%3D19%26doi%3D10.1021%2Facschembio.8b00558" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref55"><div class="reference"><strong class="refLabel"><a href="#ref55" class="rightTabRefNumLink">55</a></strong><div class="NLM_citation" id="rightTab-cit55"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Realini, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Solorzano, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pagliuca, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pizzirani, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Armirotti, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luciani, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Costi, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bandiera, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Piomelli, D.</span></span> <span> </span><span class="NLM_article-title">Discovery of highly potent acid ceramidase inhibitors with in vitro tumor chemosensitizing activity</span>. <i>Sci. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">1035</span>, <span class="refDoi"> DOI: 10.1038/srep01035</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01561&amp;key=10.1038%2Fsrep01035" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01561&amp;key=23301156" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01561&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtFaqt7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2013&pages=1035&author=N.+Realiniauthor=C.+Solorzanoauthor=C.+Pagliucaauthor=D.+Pizziraniauthor=A.+Armirottiauthor=R.+Lucianiauthor=M.+P.+Costiauthor=T.+Bandieraauthor=D.+Piomelli&title=Discovery+of+highly+potent+acid+ceramidase+inhibitors+with+in+vitro+tumor+chemosensitizing+activity&doi=10.1038%2Fsrep01035"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit55R"><div class="casContent"><span class="casTitleNuber">55</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of highly potent acid ceramidase inhibitors with in vitro tumor chemosensitizing activity</span></div><div class="casAuthors">Realini, Natalia; Solorzano, Carlos; Pagliuca, Chiara; Pizzirani, Daniela; Armirotti, Andrea; Luciani, Rosaria; Costi, Maria Paola; Bandiera, Tiziano; Piomelli, Daniele</div><div class="citationInfo"><span class="NLM_cas:title">Scientific Reports</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">srep01035, 7 pp.</span>CODEN:
                <span class="NLM_cas:coden">SRCEC3</span>;
        ISSN:<span class="NLM_cas:issn">2045-2322</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The expression of acid ceramidase (AC) - a cysteine amidase that hydrolyzes the proapoptotic lipid ceramide - is abnormally high in several human tumors, which is suggestive of a role in chemoresistance.  Available AC inhibitors lack, however, the potency and drug-likeness necessary to test this idea.  Here we show that the antineoplastic drug carmofur, which is used in the clinic to treat colorectal cancers, is a potent AC inhibitor and that this property is essential to its anti-proliferative effects.  Modifications in the chem. scaffold of carmofur yield new AC inhibitors that act synergistically with std. antitumoral drugs to prevent cancer cell proliferation.  These findings identify AC as an unexpected target for carmofur, and suggest that this mol. can be used as starting point for the design of novel chemosensitizing agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoknWbdLSLhRbVg90H21EOLACvtfcHk0lhadRi4Lqll-A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtFaqt7w%253D&md5=7ff74388fc2bea42c0e97fa8cbcfe61f</span></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.1038%2Fsrep01035&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsrep01035%26sid%3Dliteratum%253Aachs%26aulast%3DRealini%26aufirst%3DN.%26aulast%3DSolorzano%26aufirst%3DC.%26aulast%3DPagliuca%26aufirst%3DC.%26aulast%3DPizzirani%26aufirst%3DD.%26aulast%3DArmirotti%26aufirst%3DA.%26aulast%3DLuciani%26aufirst%3DR.%26aulast%3DCosti%26aufirst%3DM.%2BP.%26aulast%3DBandiera%26aufirst%3DT.%26aulast%3DPiomelli%26aufirst%3DD.%26atitle%3DDiscovery%2520of%2520highly%2520potent%2520acid%2520ceramidase%2520inhibitors%2520with%2520in%2520vitro%2520tumor%2520chemosensitizing%2520activity%26jtitle%3DSci.%2520Rep.%26date%3D2013%26volume%3D3%26spage%3D1035%26doi%3D10.1038%2Fsrep01035" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref56"><div class="reference"><strong class="refLabel"><a href="#ref56" class="rightTabRefNumLink">56</a></strong><div class="NLM_citation" id="rightTab-cit56"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pizzirani, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pagliuca, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Realini, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Branduardi, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bottegoni, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mor, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bertozzi, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scarpelli, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Piomelli, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bandiera, T.</span></span> <span> </span><span class="NLM_article-title">Discovery of a new class of highly potent inhibitors of acid ceramidase: synthesis and structure–activity relationship (SAR)</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">3518</span>– <span class="NLM_lpage">3530</span>, <span class="refDoi"> DOI: 10.1021/jm301879g</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm301879g" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01561&amp;key=1%3ACAS%3A528%3ADC%252BC3sXms1Wjtbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=3518-3530&author=D.+Pizziraniauthor=C.+Pagliucaauthor=N.+Realiniauthor=D.+Branduardiauthor=G.+Bottegoniauthor=M.+Morauthor=F.+Bertozziauthor=R.+Scarpelliauthor=D.+Piomelliauthor=T.+Bandiera&title=Discovery+of+a+new+class+of+highly+potent+inhibitors+of+acid+ceramidase%3A+synthesis+and+structure%E2%80%93activity+relationship+%28SAR%29&doi=10.1021%2Fjm301879g"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit56R"><div class="casContent"><span class="casTitleNuber">56</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of a New Class of Highly Potent Inhibitors of Acid Ceramidase: Synthesis and Structure-Activity Relationship (SAR)</span></div><div class="casAuthors">Pizzirani, Daniela; Pagliuca, Chiara; Realini, Natalia; Branduardi, Davide; Bottegoni, Giovanni; Mor, Marco; Bertozzi, Fabio; Scarpelli, Rita; Piomelli, Daniele; Bandiera, Tiziano</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">3518-3530</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">1-(Alkylamino)-2,4-pyrimidinediones such as I [R = H, F, MeO, F3C, Ph; R1 = Me(CH2)nNH; R2 = H, Me, MeO2C; n = 5, 7] were prepd. as inhibitors of acid ceramidase for potential use as antitumor agents.  Uracils bearing an electron-withdrawing substituent at position 5, a substituent such as Me at position 3, and an alkylaminocarbonyl moiety with a six- to eight-carbon alkyl group at position 1 were the most effective inhibitors of acid ceramidase of the compds. tested.  The acid ceramidase inhibition and stability of an alkylaminopyrimidinedione was correlated with the stabilization of the antibonding orbital of its N1-carbonyl bond.  I (R = H, F, Ph; R2 = H, Me; n = 5, 7) inhibited a human cancer cell line (SW403) with IC50 values of 20-24 μM.  I (R = F, F3C, MeO; R2 = H, MeO2C; n = 5, 7) inhibited acid ceramidase with single digit-nanomolar IC50 values (IC50 = 4-7 nM).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrSG4lPgE1b1bVg90H21EOLACvtfcHk0ljgym__CruOoQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXms1Wjtbo%253D&md5=e8b1cb63aa40e8654de70985febc56dd</span></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=10.1021%2Fjm301879g&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm301879g%26sid%3Dliteratum%253Aachs%26aulast%3DPizzirani%26aufirst%3DD.%26aulast%3DPagliuca%26aufirst%3DC.%26aulast%3DRealini%26aufirst%3DN.%26aulast%3DBranduardi%26aufirst%3DD.%26aulast%3DBottegoni%26aufirst%3DG.%26aulast%3DMor%26aufirst%3DM.%26aulast%3DBertozzi%26aufirst%3DF.%26aulast%3DScarpelli%26aufirst%3DR.%26aulast%3DPiomelli%26aufirst%3DD.%26aulast%3DBandiera%26aufirst%3DT.%26atitle%3DDiscovery%2520of%2520a%2520new%2520class%2520of%2520highly%2520potent%2520inhibitors%2520of%2520acid%2520ceramidase%253A%2520synthesis%2520and%2520structure%25E2%2580%2593activity%2520relationship%2520%2528SAR%2529%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D3518%26epage%3D3530%26doi%3D10.1021%2Fjm301879g" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref57"><div class="reference"><strong class="refLabel"><a href="#ref57" class="rightTabRefNumLink">57</a></strong><div class="NLM_citation" id="rightTab-cit57"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Diamanti, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bottegoni, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldoni, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Realini, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pagliuca, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bertozzi, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Piomelli, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pizzirani, D.</span></span> <span> </span><span class="NLM_article-title">Pyrazole-based acid ceramidase inhibitors: design, synthesis, and structure–activity relationships</span>. <i>Synthesis</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>48</i></span>,  <span class="NLM_fpage">2739</span>– <span class="NLM_lpage">2756</span>, <span class="refDoi"> DOI: 10.1055/s-0035-1561456</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01561&amp;key=10.1055%2Fs-0035-1561456" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01561&amp;key=1%3ACAS%3A528%3ADC%252BC28Xps1ahur0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2016&pages=2739-2756&author=E.+Diamantiauthor=G.+Bottegoniauthor=L.+Goldoniauthor=N.+Realiniauthor=C.+Pagliucaauthor=F.+Bertozziauthor=D.+Piomelliauthor=D.+Pizzirani&title=Pyrazole-based+acid+ceramidase+inhibitors%3A+design%2C+synthesis%2C+and+structure%E2%80%93activity+relationships&doi=10.1055%2Fs-0035-1561456"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit57R"><div class="casContent"><span class="casTitleNuber">57</span><div class="casTitle"><span class="NLM_cas:atitle">Pyrazole-Based Acid Ceramidase Inhibitors: Design, Synthesis, and Structure-Activity Relationships</span></div><div class="casAuthors">Diamanti, Eleonora; Bottegoni, Giovanni; Goldoni, Luca; Realini, Natalia; Pagliuca, Chiara; Bertozzi, Fabio; Piomelli, Daniele; Pizzirani, Daniela</div><div class="citationInfo"><span class="NLM_cas:title">Synthesis</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">48</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">2739-2756</span>CODEN:
                <span class="NLM_cas:coden">SYNTBF</span>;
        ISSN:<span class="NLM_cas:issn">1437-210X</span>.
    
            (<span class="NLM_cas:orgname">Georg Thieme Verlag</span>)
        </div><div class="casAbstract">Acid ceramidase (a.c.) is a lysosomal cysteine amidase responsible for the cleavage of ceramide into sphingosine, which is then phosphorylated to sphingosine 1-phosphate.  AC regulates the intracellular levels of ceramide and sphingosine, and a.c. inhibition may be useful in the treatment of disorders, such as cancer, in which ceramide-mediated signaling may be dysfunctional.  Despite their potential exptl. and therapeutic value, the no. of available small-mol. inhibitors of a.c. activity remains limited.  In the present study is described the discovery of a class of potent pyrazole carboxamide-based a.c. inhibitors, which were identified using the at. property field (APF) approach and developed through systematic SAR studies and in vitro pharmacol. characterization.  The best compd. of this series inhibits a.c. with nanomolar potency and causes ceramide accumulation and sphingosine depletion in intact G361 proliferative melanoma cells.  By expanding the current armamentarium of a.c. inhibitors, these results should facilitate future efforts to unravel the biol. of a.c. and the therapeutic potential of its inhibition.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpZ0V1BSSYCl7Vg90H21EOLACvtfcHk0ljgym__CruOoQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xps1ahur0%253D&md5=3308bc4d0f16df0692358e6cc75235de</span></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=10.1055%2Fs-0035-1561456&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1055%252Fs-0035-1561456%26sid%3Dliteratum%253Aachs%26aulast%3DDiamanti%26aufirst%3DE.%26aulast%3DBottegoni%26aufirst%3DG.%26aulast%3DGoldoni%26aufirst%3DL.%26aulast%3DRealini%26aufirst%3DN.%26aulast%3DPagliuca%26aufirst%3DC.%26aulast%3DBertozzi%26aufirst%3DF.%26aulast%3DPiomelli%26aufirst%3DD.%26aulast%3DPizzirani%26aufirst%3DD.%26atitle%3DPyrazole-based%2520acid%2520ceramidase%2520inhibitors%253A%2520design%252C%2520synthesis%252C%2520and%2520structure%25E2%2580%2593activity%2520relationships%26jtitle%3DSynthesis%26date%3D2016%26volume%3D48%26spage%3D2739%26epage%3D2756%26doi%3D10.1055%2Fs-0035-1561456" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref58"><div class="reference"><strong class="refLabel"><a href="#ref58" class="rightTabRefNumLink">58</a></strong><div class="NLM_citation" id="rightTab-cit58"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ortega, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arencibia, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">La Sala, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borgogno, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bauer, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bono, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Braccia, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Armirotti, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Girotto, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ganesan, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Vivo, M.</span></span> <span> </span><span class="NLM_article-title">Pharmacophore identification and scaffold exploration to discover novel, potent, and chemically stable inhibitors of acid ceramidase in melanoma cells</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">5800</span>– <span class="NLM_lpage">5815</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b00472</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b00472" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01561&amp;key=1%3ACAS%3A528%3ADC%252BC2sXpslSrsr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=5800-5815&author=J.+A.+Ortegaauthor=J.+M.+Arencibiaauthor=G.+La+Salaauthor=M.+Borgognoauthor=I.+Bauerauthor=L.+Bonoauthor=C.+Bracciaauthor=A.+Armirottiauthor=S.+Girottoauthor=A.+Ganesanauthor=M.+De+Vivo&title=Pharmacophore+identification+and+scaffold+exploration+to+discover+novel%2C+potent%2C+and+chemically+stable+inhibitors+of+acid+ceramidase+in+melanoma+cells&doi=10.1021%2Facs.jmedchem.7b00472"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit58R"><div class="casContent"><span class="casTitleNuber">58</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacophore Identification and Scaffold Exploration to Discover Novel, Potent, and Chemically Stable Inhibitors of Acid Ceramidase in Melanoma Cells</span></div><div class="casAuthors">Ortega, Jose Antonio; Arencibia, Jose M.; La Sala, Giuseppina; Borgogno, Marco; Bauer, Inga; Bono, Luca; Braccia, Clarissa; Armirotti, Andrea; Girotto, Stefania; Ganesan, Anand; De Vivo, Marco</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">5800-5815</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Acid ceramidase (AC) hydrolyzes ceramides, which are central lipid messengers for metab. and signaling of sphingolipids.  A growing body of evidence links deregulation of sphingolipids to several diseases, including cancer.  Indeed, AC expression is abnormally high in melanoma cells.  AC inhibition may thus be key to treating malignant melanoma.  Here, the authors have used a systematic scaffold exploration to design a general pharmacophore for AC inhibition.  This pharmacophore comprises a 6+5 fused ring heterocycle linked to an aliph. substituent via a urea moiety.  The authors have thus identified the novel benzimidazole derivs., which are highly potent AC inhibitors.  Their chem. and metabolic stability is comparable or superior to that of previously reported AC inhibitors.  Moreover, they are potent against endogenous AC in intact melanoma cells.  These novel inhibitors merit further characterization and can serve as a promising starting point for the discovery of new antimelanoma therapeutics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqsJbGrbc7g0bVg90H21EOLACvtfcHk0ljgym__CruOoQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXpslSrsr4%253D&md5=9ad5f49ead19498e6080e7dbed47c5be</span></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b00472&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b00472%26sid%3Dliteratum%253Aachs%26aulast%3DOrtega%26aufirst%3DJ.%2BA.%26aulast%3DArencibia%26aufirst%3DJ.%2BM.%26aulast%3DLa%2BSala%26aufirst%3DG.%26aulast%3DBorgogno%26aufirst%3DM.%26aulast%3DBauer%26aufirst%3DI.%26aulast%3DBono%26aufirst%3DL.%26aulast%3DBraccia%26aufirst%3DC.%26aulast%3DArmirotti%26aufirst%3DA.%26aulast%3DGirotto%26aufirst%3DS.%26aulast%3DGanesan%26aufirst%3DA.%26aulast%3DDe%2BVivo%26aufirst%3DM.%26atitle%3DPharmacophore%2520identification%2520and%2520scaffold%2520exploration%2520to%2520discover%2520novel%252C%2520potent%252C%2520and%2520chemically%2520stable%2520inhibitors%2520of%2520acid%2520ceramidase%2520in%2520melanoma%2520cells%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26spage%3D5800%26epage%3D5815%26doi%3D10.1021%2Facs.jmedchem.7b00472" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref59"><div class="reference"><strong class="refLabel"><a href="#ref59" class="rightTabRefNumLink">59</a></strong><div class="NLM_citation" id="rightTab-cit59"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pizzirani, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bach, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Realini, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Armirotti, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mengatto, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bauer, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Girotto, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pagliuca, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Vivo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Summa, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ribeiro, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Piomelli, D.</span></span> <span> </span><span class="NLM_article-title">Benzoxazolone carboxamides: potent and systemically active inhibitors of intracellular acid ceramidase</span>. <i>Angew. Chem., Int. Ed.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>127</i></span>,  <span class="NLM_fpage">495</span>– <span class="NLM_lpage">499</span>, <span class="refDoi"> DOI: 10.1002/ange.201409042</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01561&amp;key=10.1002%2Fange.201409042" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=127&publication_year=2015&pages=495-499&author=D.+Pizziraniauthor=A.+Bachauthor=N.+Realiniauthor=A.+Armirottiauthor=L.+Mengattoauthor=I.+Bauerauthor=S.+Girottoauthor=C.+Pagliucaauthor=M.+De+Vivoauthor=M.+Summaauthor=A.+Ribeiroauthor=D.+Piomelli&title=Benzoxazolone+carboxamides%3A+potent+and+systemically+active+inhibitors+of+intracellular+acid+ceramidase&doi=10.1002%2Fange.201409042"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=10.1002%2Fange.201409042&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fange.201409042%26sid%3Dliteratum%253Aachs%26aulast%3DPizzirani%26aufirst%3DD.%26aulast%3DBach%26aufirst%3DA.%26aulast%3DRealini%26aufirst%3DN.%26aulast%3DArmirotti%26aufirst%3DA.%26aulast%3DMengatto%26aufirst%3DL.%26aulast%3DBauer%26aufirst%3DI.%26aulast%3DGirotto%26aufirst%3DS.%26aulast%3DPagliuca%26aufirst%3DC.%26aulast%3DDe%2BVivo%26aufirst%3DM.%26aulast%3DSumma%26aufirst%3DM.%26aulast%3DRibeiro%26aufirst%3DA.%26aulast%3DPiomelli%26aufirst%3DD.%26atitle%3DBenzoxazolone%2520carboxamides%253A%2520potent%2520and%2520systemically%2520active%2520inhibitors%2520of%2520intracellular%2520acid%2520ceramidase%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2015%26volume%3D127%26spage%3D495%26epage%3D499%26doi%3D10.1002%2Fange.201409042" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref60"><div class="reference"><strong class="refLabel"><a href="#ref60" class="rightTabRefNumLink">60</a></strong><div class="NLM_citation" id="rightTab-cit60"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bach, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pizzirani, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Realini, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vozella, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Russo, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Penna, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Melzig, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scarpelli, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Piomelli, D.</span></span> <span> </span><span class="NLM_article-title">Benzoxazolone carboxamides as potent acid ceramidase inhibitors: synthesis and structure–activity relationship (SAR) Studies</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">9258</span>– <span class="NLM_lpage">9272</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b01188</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b01188" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01561&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvVWnsbvI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=9258-9272&author=A.+Bachauthor=D.+Pizziraniauthor=N.+Realiniauthor=V.+Vozellaauthor=D.+Russoauthor=I.+Pennaauthor=L.+Melzigauthor=R.+Scarpelliauthor=D.+Piomelli&title=Benzoxazolone+carboxamides+as+potent+acid+ceramidase+inhibitors%3A+synthesis+and+structure%E2%80%93activity+relationship+%28SAR%29+Studies&doi=10.1021%2Facs.jmedchem.5b01188"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit60R"><div class="casContent"><span class="casTitleNuber">60</span><div class="casTitle"><span class="NLM_cas:atitle">Benzoxazolone Carboxamides as Potent Acid Ceramidase Inhibitors: Synthesis and Structure-Activity Relationship (SAR) Studies</span></div><div class="casAuthors">Bach, Anders; Pizzirani, Daniela; Realini, Natalia; Vozella, Valentina; Russo, Debora; Penna, Ilaria; Melzig, Laurin; Scarpelli, Rita; Piomelli, Daniele</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">9258-9272</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Ceramides are lipid-derived intracellular messengers involved in the control of senescence, inflammation, and apoptosis.  The cysteine amidase, acid ceramidase (AC), hydrolyzes these substances into sphingosine and fatty acid and, by doing so, regulates their signaling activity.  AC inhibitors may be useful in the treatment of pathol. conditions, such as cancer, in which ceramide levels are abnormally reduced.  Here, we present a systematic SAR investigation of the benzoxazolone carboxamides, a recently described class of AC inhibitors that display high potency and systemic activity in mice.  We examd. a diverse series of substitutions on both benzoxazolone ring and carboxamide side chain.  Several modifications enhanced potency and stability, and one key compd. with a balanced activity-stability profile I was found to inhibit AC activity in mouse lungs and cerebral cortex after systemic administration.  The results expand our arsenal of AC inhibitors, thereby facilitating the use of these compds. as pharmacol. tools and their potential development as drug leads.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoXKrFwyTWVt7Vg90H21EOLACvtfcHk0ljIiGmABLiqQQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvVWnsbvI&md5=1b8de2b433b0e1b42299cf224d53e33a</span></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b01188&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b01188%26sid%3Dliteratum%253Aachs%26aulast%3DBach%26aufirst%3DA.%26aulast%3DPizzirani%26aufirst%3DD.%26aulast%3DRealini%26aufirst%3DN.%26aulast%3DVozella%26aufirst%3DV.%26aulast%3DRusso%26aufirst%3DD.%26aulast%3DPenna%26aufirst%3DI.%26aulast%3DMelzig%26aufirst%3DL.%26aulast%3DScarpelli%26aufirst%3DR.%26aulast%3DPiomelli%26aufirst%3DD.%26atitle%3DBenzoxazolone%2520carboxamides%2520as%2520potent%2520acid%2520ceramidase%2520inhibitors%253A%2520synthesis%2520and%2520structure%25E2%2580%2593activity%2520relationship%2520%2528SAR%2529%2520Studies%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D9258%26epage%3D9272%26doi%3D10.1021%2Facs.jmedchem.5b01188" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref61"><div class="reference"><strong class="refLabel"><a href="#ref61" class="rightTabRefNumLink">61</a></strong><div class="NLM_citation" id="rightTab-cit61"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Di
Martino, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tardia, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cilibrasi, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caputo, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mazzonna, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Russo, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Penna, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Realini, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Margaroli, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Migliore, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pizzirani, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ottonello, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bertozzi, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Armirotti, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nguyen, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bongarzone, E. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lansbury, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Skerlj, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scarpelli, R.</span></span> <span> </span><span class="NLM_article-title">Lead optimization of benzoxazolone carboxamides as orally bioavailable and CNS penetrant acid ceramidase inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>63</i></span>,  <span class="NLM_fpage">3634</span>– <span class="NLM_lpage">3664</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.9b02004</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b02004" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01561&amp;key=1%3ACAS%3A528%3ADC%252BB3cXkvFyiur0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2020&pages=3634-3664&author=S.+Di%0AMartinoauthor=P.+Tardiaauthor=V.+Cilibrasiauthor=S.+Caputoauthor=M.+Mazzonnaauthor=D.+Russoauthor=I.+Pennaauthor=N.+Realiniauthor=N.+Margaroliauthor=M.+Miglioreauthor=D.+Pizziraniauthor=G.+Ottonelloauthor=S.+M.+Bertozziauthor=A.+Armirottiauthor=D.+Nguyenauthor=Y.+Sunauthor=E.+R.+Bongarzoneauthor=P.+Lansburyauthor=M.+Liuauthor=R.+Skerljauthor=R.+Scarpelli&title=Lead+optimization+of+benzoxazolone+carboxamides+as+orally+bioavailable+and+CNS+penetrant+acid+ceramidase+inhibitors&doi=10.1021%2Facs.jmedchem.9b02004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit61R"><div class="casContent"><span class="casTitleNuber">61</span><div class="casTitle"><span class="NLM_cas:atitle">Lead Optimization of Benzoxazolone Carboxamides as Orally Bioavailable and CNS Penetrant Acid Ceramidase Inhibitors</span></div><div class="casAuthors">Di Martino, Simona; Tardia, Piero; Cilibrasi, Vincenzo; Caputo, Samantha; Mazzonna, Marco; Russo, Debora; Penna, Ilaria; Realini, Natalia; Margaroli, Natasha; Migliore, Marco; Pizzirani, Daniela; Ottonello, Giuliana; Bertozzi, Sine Mandrup; Armirotti, Andrea; Nguyen, Duc; Sun, Ying; Bongarzone, Ernesto R.; Lansbury, Peter; Liu, Min; Skerlj, Renato; Scarpelli, Rita</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">3634-3664</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Sphingolipids (SphLs) are a diverse class of mols. that are regulated by a complex network of enzymic pathways.  A disturbance in these pathways leads to lipid accumulation and initiation of several SphL-related disorders.  Acid ceramidase is one of the key enzymes that regulate the metab. of ceramides and glycosphingolipids, which are important members of the SphL family.  Herein, we describe the lead optimization studies of benzoxazolone carboxamides resulting in piperidine 22m(), where we demonstrated target engagement in two animal models of neuropathic lysosomal storage diseases (LSDs), Gaucher's and Krabbe's diseases.  After daily i.p. administration at 90 mg kg-1, 22m significantly reduced the brain levels of the toxic lipids glucosylsphingosine (GluSph) in 4L;C* mice and galactosylsphingosine (GalSph) in Twitcher mice.  We believe that 22m is a lead mol. that can be further developed for the correction of severe neurol. LSDs where GluSph or GalSph play a significant role in disease pathogenesis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGocXf_shVZ0drVg90H21EOLACvtfcHk0lh6J_cAJbMMWg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXkvFyiur0%253D&md5=ef0b0dbe54b610f1c28634d5337d5ce3</span></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b02004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b02004%26sid%3Dliteratum%253Aachs%26aulast%3DDi%2BMartino%26aufirst%3DS.%26aulast%3DTardia%26aufirst%3DP.%26aulast%3DCilibrasi%26aufirst%3DV.%26aulast%3DCaputo%26aufirst%3DS.%26aulast%3DMazzonna%26aufirst%3DM.%26aulast%3DRusso%26aufirst%3DD.%26aulast%3DPenna%26aufirst%3DI.%26aulast%3DRealini%26aufirst%3DN.%26aulast%3DMargaroli%26aufirst%3DN.%26aulast%3DMigliore%26aufirst%3DM.%26aulast%3DPizzirani%26aufirst%3DD.%26aulast%3DOttonello%26aufirst%3DG.%26aulast%3DBertozzi%26aufirst%3DS.%2BM.%26aulast%3DArmirotti%26aufirst%3DA.%26aulast%3DNguyen%26aufirst%3DD.%26aulast%3DSun%26aufirst%3DY.%26aulast%3DBongarzone%26aufirst%3DE.%2BR.%26aulast%3DLansbury%26aufirst%3DP.%26aulast%3DLiu%26aufirst%3DM.%26aulast%3DSkerlj%26aufirst%3DR.%26aulast%3DScarpelli%26aufirst%3DR.%26atitle%3DLead%2520optimization%2520of%2520benzoxazolone%2520carboxamides%2520as%2520orally%2520bioavailable%2520and%2520CNS%2520penetrant%2520acid%2520ceramidase%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2020%26volume%3D63%26spage%3D3634%26epage%3D3664%26doi%3D10.1021%2Facs.jmedchem.9b02004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref62"><div class="reference"><strong class="refLabel"><a href="#ref62" class="rightTabRefNumLink">62</a></strong><div class="NLM_citation" id="rightTab-cit62"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dong, X.-Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X.</span></span> <span> </span><span class="NLM_article-title">New synthetic strategy for chiral 2-oxazolidinones derivatives via rhodium-catalyzed asymmetric hydrogenation</span>. <i>Tetrahedron Lett.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">658</span>– <span class="NLM_lpage">662</span>, <span class="refDoi"> DOI: 10.1016/j.tetlet.2015.12.105</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01561&amp;key=10.1016%2Fj.tetlet.2015.12.105" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01561&amp;key=1%3ACAS%3A528%3ADC%252BC28XnsF2gsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2016&pages=658-662&author=Q.+Wangauthor=X.+Tanauthor=Z.+Zhuauthor=X.-Q.+Dongauthor=X.+Zhang&title=New+synthetic+strategy+for+chiral+2-oxazolidinones+derivatives+via+rhodium-catalyzed+asymmetric+hydrogenation&doi=10.1016%2Fj.tetlet.2015.12.105"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit62R"><div class="casContent"><span class="casTitleNuber">62</span><div class="casTitle"><span class="NLM_cas:atitle">New synthetic strategy for chiral 2-oxazolidinones derivatives via rhodium-catalyzed asymmetric hydrogenation</span></div><div class="casAuthors">Wang, Qingli; Tan, Xuefeng; Zhu, Ziyue; Dong, Xiu-Qin; Zhang, Xumu</div><div class="citationInfo"><span class="NLM_cas:title">Tetrahedron Letters</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">658-662</span>CODEN:
                <span class="NLM_cas:coden">TELEAY</span>;
        ISSN:<span class="NLM_cas:issn">0040-4039</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Asym. hydrogenation of 4-substituted cyclic enamido esters catalyzed by a rhodium-TangPhos complex provides an efficient method for the synthesis of chiral 4-substituted oxazolinones with excellent yields and good enantioselectivities.  The products are valuable chiral building blocks and the applications as chiral auxiliaries and pharmaceuticals are well-known.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoqPTQAbbn24LVg90H21EOLACvtfcHk0lh6J_cAJbMMWg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XnsF2gsg%253D%253D&md5=0ae31b529dbadfcb4202127e4d90a417</span></div><a href="/servlet/linkout?suffix=cit62&amp;dbid=16384&amp;doi=10.1016%2Fj.tetlet.2015.12.105&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tetlet.2015.12.105%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DQ.%26aulast%3DTan%26aufirst%3DX.%26aulast%3DZhu%26aufirst%3DZ.%26aulast%3DDong%26aufirst%3DX.-Q.%26aulast%3DZhang%26aufirst%3DX.%26atitle%3DNew%2520synthetic%2520strategy%2520for%2520chiral%25202-oxazolidinones%2520derivatives%2520via%2520rhodium-catalyzed%2520asymmetric%2520hydrogenation%26jtitle%3DTetrahedron%2520Lett.%26date%3D2016%26volume%3D57%26spage%3D658%26epage%3D662%26doi%3D10.1016%2Fj.tetlet.2015.12.105" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref63"><div class="reference"><strong class="refLabel"><a href="#ref63" class="rightTabRefNumLink">63</a></strong><div class="NLM_citation" id="rightTab-cit63"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Brown, M. L.</span>; <span class="NLM_string-name">Cheung, M.</span>; <span class="NLM_string-name">Dickerson, S. H.</span>; <span class="NLM_string-name">Gauthier, C.</span>; <span class="NLM_string-name">Harris, P. A.</span>; <span class="NLM_string-name">Hunter, R. N.</span>; <span class="NLM_string-name">Pacofsky, G.</span>; <span class="NLM_string-name">Peel, M. R.</span>; <span class="NLM_string-name">Stafford, J. A.</span></span> <span> </span><span class="NLM_article-title">Chemical compounds</span>. <span class="NLM_patent">WO 2004032882 A2</span>, <span class="NLM_year">2004</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2004&author=M.+L.+Brown&author=M.+Cheung&author=S.+H.+Dickerson&author=C.+Gauthier&author=P.+A.+Harris&author=R.+N.+Hunter&author=G.+Pacofsky&author=M.+R.+Peel&author=J.+A.+Stafford&title=Chemical+compounds"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit63&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DBrown%26aufirst%3DM.%2BL.%26atitle%3DChemical%2520compounds%26date%3D2004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref64"><div class="reference"><strong class="refLabel"><a href="#ref64" class="rightTabRefNumLink">64</a></strong><div class="NLM_citation" id="rightTab-cit64"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Knölker, H.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Braxmeier, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schlechtingen, G.</span></span> <span> </span><span class="NLM_article-title">A Novel method for the synthesis of isocyanates under mild conditions</span>. <i>Angew. Chem., Int. Ed.</i> <span class="NLM_year" style="font-weight: bold;">1995</span>,  <span class="NLM_volume"><i>34</i></span>,  <span class="NLM_fpage">2497</span>– <span class="NLM_lpage">2500</span>, <span class="refDoi"> DOI: 10.1002/anie.199524971</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01561&amp;key=10.1002%2Fanie.199524971" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=1995&pages=2497-2500&author=H.-J.+Kn%C3%B6lkerauthor=T.+Braxmeierauthor=G.+Schlechtingen&title=A+Novel+method+for+the+synthesis+of+isocyanates+under+mild+conditions&doi=10.1002%2Fanie.199524971"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit64&amp;dbid=16384&amp;doi=10.1002%2Fanie.199524971&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.199524971%26sid%3Dliteratum%253Aachs%26aulast%3DKn%25C3%25B6lker%26aufirst%3DH.-J.%26aulast%3DBraxmeier%26aufirst%3DT.%26aulast%3DSchlechtingen%26aufirst%3DG.%26atitle%3DA%2520Novel%2520method%2520for%2520the%2520synthesis%2520of%2520isocyanates%2520under%2520mild%2520conditions%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D1995%26volume%3D34%26spage%3D2497%26epage%3D2500%26doi%3D10.1002%2Fanie.199524971" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref65"><div class="reference"><strong class="refLabel"><a href="#ref65" class="rightTabRefNumLink">65</a></strong><div class="NLM_citation" id="rightTab-cit65"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Eckert, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Forster, B.</span></span> <span> </span><span class="NLM_article-title">Triphosgene, a crystalline phosgene substitute</span>. <i>Angew. Chem., Int. Ed.</i> <span class="NLM_year" style="font-weight: bold;">1987</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">894</span>– <span class="NLM_lpage">895</span>, <span class="refDoi"> DOI: 10.1002/anie.198708941</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01561&amp;key=10.1002%2Fanie.198708941" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=1987&pages=894-895&author=H.+Eckertauthor=B.+Forster&title=Triphosgene%2C+a+crystalline+phosgene+substitute&doi=10.1002%2Fanie.198708941"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit65&amp;dbid=16384&amp;doi=10.1002%2Fanie.198708941&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.198708941%26sid%3Dliteratum%253Aachs%26aulast%3DEckert%26aufirst%3DH.%26aulast%3DForster%26aufirst%3DB.%26atitle%3DTriphosgene%252C%2520a%2520crystalline%2520phosgene%2520substitute%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D1987%26volume%3D26%26spage%3D894%26epage%3D895%26doi%3D10.1002%2Fanie.198708941" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref66"><div class="reference"><strong class="refLabel"><a href="#ref66" class="rightTabRefNumLink">66</a></strong><div class="NLM_citation" id="rightTab-cit66"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Guha, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baik, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koo, S.</span></span> <span> </span><span class="NLM_article-title">TMS·OTf-catalyzed α-bromination of carbonyl compounds by N-bromosuccinimide</span>. <i>Tetrahedron Lett.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>47</i></span>,  <span class="NLM_fpage">291</span>– <span class="NLM_lpage">293</span>, <span class="refDoi"> DOI: 10.1016/j.tetlet.2005.11.023</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01561&amp;key=10.1016%2Fj.tetlet.2005.11.023" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01561&amp;key=1%3ACAS%3A528%3ADC%252BD2MXht12qsbrL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2006&pages=291-293&author=S.+K.+Guhaauthor=B.+Wuauthor=B.+S.+Kimauthor=W.+Baikauthor=S.+Koo&title=TMS%C2%B7OTf-catalyzed+%CE%B1-bromination+of+carbonyl+compounds+by+N-bromosuccinimide&doi=10.1016%2Fj.tetlet.2005.11.023"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit66R"><div class="casContent"><span class="casTitleNuber">66</span><div class="casTitle"><span class="NLM_cas:atitle">TMS·OTf-catalyzed α-bromination of carbonyl compounds by N-bromosuccinimide</span></div><div class="casAuthors">Guha, Samar Kumar; Wu, Bo; Kim, Beom Soo; Baik, Woonphil; Koo, Sangho</div><div class="citationInfo"><span class="NLM_cas:title">Tetrahedron Letters</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">47</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">291-293</span>CODEN:
                <span class="NLM_cas:coden">TELEAY</span>;
        ISSN:<span class="NLM_cas:issn">0040-4039</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Various carbonyl compds. undergo α-bromination reaction under a mild and practical condition utilizing N-bromosuccinimide (NBS), catalyzed by trimethylsilyl trifluoromethanesulfonate (TMS.OTf).  This method is also effective for the side-chain bromination of heteroarom. carbonyl compds. without the ring brominations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrU1RgBMEwTt7Vg90H21EOLACvtfcHk0ljvcVl050NAWQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXht12qsbrL&md5=53bcb50f555bd780cde04e6d513564dd</span></div><a href="/servlet/linkout?suffix=cit66&amp;dbid=16384&amp;doi=10.1016%2Fj.tetlet.2005.11.023&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tetlet.2005.11.023%26sid%3Dliteratum%253Aachs%26aulast%3DGuha%26aufirst%3DS.%2BK.%26aulast%3DWu%26aufirst%3DB.%26aulast%3DKim%26aufirst%3DB.%2BS.%26aulast%3DBaik%26aufirst%3DW.%26aulast%3DKoo%26aufirst%3DS.%26atitle%3DTMS%25C2%25B7OTf-catalyzed%2520%25CE%25B1-bromination%2520of%2520carbonyl%2520compounds%2520by%2520N-bromosuccinimide%26jtitle%3DTetrahedron%2520Lett.%26date%3D2006%26volume%3D47%26spage%3D291%26epage%3D293%26doi%3D10.1016%2Fj.tetlet.2005.11.023" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref67"><div class="reference"><strong class="refLabel"><a href="#ref67" class="rightTabRefNumLink">67</a></strong><div class="NLM_citation" id="rightTab-cit67"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dementiev, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joachimiak, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nguyen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gorelik, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Illes, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shabani, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gelsomino, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahn, E.-Y. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagar, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doan, N.</span></span> <span> </span><span class="NLM_article-title">Molecular mechanism of inhibition of acid ceramidase by carmofur</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">987</span>– <span class="NLM_lpage">992</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b01723</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b01723" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01561&amp;key=1%3ACAS%3A528%3ADC%252BC1cXisVGnsLrE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=987-992&author=A.+Dementievauthor=A.+Joachimiakauthor=H.+Nguyenauthor=A.+Gorelikauthor=K.+Illesauthor=S.+Shabaniauthor=M.+Gelsominoauthor=E.-Y.+E.+Ahnauthor=B.+Nagarauthor=N.+Doan&title=Molecular+mechanism+of+inhibition+of+acid+ceramidase+by+carmofur&doi=10.1021%2Facs.jmedchem.8b01723"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit67R"><div class="casContent"><span class="casTitleNuber">67</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular mechanism of inhibition of acid ceramidase by carmofur</span></div><div class="casAuthors">Dementiev, Alexey; Joachimiak, Andrzej; Nguyen, Ha; Gorelik, Alexei; Illes, Katalin; Shabani, Saman; Gelsomino, Michael; Ahn, Eun-Young Erin; Nagar, Bhushan; Doan, Ninh</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">987-992</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Human acid ceramidase (AC) is a lysosomal cysteine amidase, which has received a great deal of interest in recent years as a potential target for the development of new therapeutics against melanoma and glioblastoma tumors.  Despite the strong interest in obtaining structural information, only the structures of the apo-AC enzyme in its zymogen and activated conformations are available.  In this work, the crystal structure of AC in complex with the covalent carmofur inhibitor is presented.  Carmofur (1-hexylcarbamoyl-5-fluorouracil) is an antineoplastic drug contg. an electrophilic carbonyl reactive group that targets the catalytic cysteine.  This novel structural data explains the basis of the AC inhibition, provides insights into the enzymic properties of the protein, and is a great aid toward the structure-based drug design of potent inhibitors for AC, providing the detailed mechanism, which has eluded the scientific community for more than 30 years, of carmofur's mysterious 5-fluorouracil-independent antitumor activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqLv97-NENYSbVg90H21EOLACvtfcHk0ljvcVl050NAWQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXisVGnsLrE&md5=b88fa5e1014bc879d160e210dd1c2dfa</span></div><a href="/servlet/linkout?suffix=cit67&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b01723&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b01723%26sid%3Dliteratum%253Aachs%26aulast%3DDementiev%26aufirst%3DA.%26aulast%3DJoachimiak%26aufirst%3DA.%26aulast%3DNguyen%26aufirst%3DH.%26aulast%3DGorelik%26aufirst%3DA.%26aulast%3DIlles%26aufirst%3DK.%26aulast%3DShabani%26aufirst%3DS.%26aulast%3DGelsomino%26aufirst%3DM.%26aulast%3DAhn%26aufirst%3DE.-Y.%2BE.%26aulast%3DNagar%26aufirst%3DB.%26aulast%3DDoan%26aufirst%3DN.%26atitle%3DMolecular%2520mechanism%2520of%2520inhibition%2520of%2520acid%2520ceramidase%2520by%2520carmofur%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26spage%3D987%26epage%3D992%26doi%3D10.1021%2Facs.jmedchem.8b01723" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref68"><div class="reference"><strong class="refLabel"><a href="#ref68" class="rightTabRefNumLink">68</a></strong><div class="NLM_citation" id="rightTab-cit68"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ishikawa, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hashimoto, Y.</span></span> <span> </span><span class="NLM_article-title">Improvement in aqueous solubility in small molecule drug discovery programs by disruption of molecular planarity and symmetry</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>54</i></span>,  <span class="NLM_fpage">1539</span>– <span class="NLM_lpage">1554</span>, <span class="refDoi"> DOI: 10.1021/jm101356p</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm101356p" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01561&amp;key=1%3ACAS%3A528%3ADC%252BC3MXisVWltLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=1539-1554&author=M.+Ishikawaauthor=Y.+Hashimoto&title=Improvement+in+aqueous+solubility+in+small+molecule+drug+discovery+programs+by+disruption+of+molecular+planarity+and+symmetry&doi=10.1021%2Fjm101356p"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit68R"><div class="casContent"><span class="casTitleNuber">68</span><div class="casTitle"><span class="NLM_cas:atitle">Improvement in Aqueous Solubility in Small Molecule Drug Discovery Programs by Disruption of Molecular Planarity and Symmetry</span></div><div class="casAuthors">Ishikawa, Minoru; Hashimoto, Yuichi</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1539-1554</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpKbtbfvqKZjrVg90H21EOLACvtfcHk0ljvcVl050NAWQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXisVWltLw%253D&md5=a88804b3850625ef9c3f7424366acb91</span></div><a href="/servlet/linkout?suffix=cit68&amp;dbid=16384&amp;doi=10.1021%2Fjm101356p&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm101356p%26sid%3Dliteratum%253Aachs%26aulast%3DIshikawa%26aufirst%3DM.%26aulast%3DHashimoto%26aufirst%3DY.%26atitle%3DImprovement%2520in%2520aqueous%2520solubility%2520in%2520small%2520molecule%2520drug%2520discovery%2520programs%2520by%2520disruption%2520of%2520molecular%2520planarity%2520and%2520symmetry%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D1539%26epage%3D1554%26doi%3D10.1021%2Fjm101356p" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref69"><div class="reference"><strong class="refLabel"><a href="#ref69" class="rightTabRefNumLink">69</a></strong><div class="NLM_citation" id="rightTab-cit69"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gorelik, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gebai, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Illes, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Piomelli, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagar, B.</span></span> <span> </span><span class="NLM_article-title">Molecular mechanism of activation of the immunoregulatory amidase NAAA</span>. <i>Proc. Natl. Acad. Sci. U.S.A.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>115</i></span>,  <span class="NLM_fpage">E10032</span>– <span class="NLM_lpage">E10040</span>, <span class="refDoi"> DOI: 10.1073/pnas.1811759115</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01561&amp;key=10.1073%2Fpnas.1811759115" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01561&amp;key=30301806" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01561&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitVyhsLvP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=115&publication_year=2018&pages=E10032-E10040&author=A.+Gorelikauthor=A.+Gebaiauthor=K.+Illesauthor=D.+Piomelliauthor=B.+Nagar&title=Molecular+mechanism+of+activation+of+the+immunoregulatory+amidase+NAAA&doi=10.1073%2Fpnas.1811759115"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit69R"><div class="casContent"><span class="casTitleNuber">69</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular mechanism of activation of the immunoregulatory amidase NAAA</span></div><div class="casAuthors">Gorelik, Alexei; Gebai, Ahmad; Illes, Katalin; Piomelli, Daniele; Nagar, Bhushan</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">115</span>
        (<span class="NLM_cas:issue">43</span>),
    <span class="NLM_cas:pages">E10032-E10040</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Palmitoylethanolamide is a bioactive lipid that strongly alleviates pain and inflammation in animal models and in humans.  Its signaling activity is terminated through degrdn. by N-acylethanolamine acid amidase (NAAA), a cysteine hydrolase expressed at high levels in immune cells.  Pharmacol. inhibitors of NAAA activity exert profound analgesic and antiinflammatory effects in rodent models, pointing to this protein as a potential target for therapeutic drug discovery.  To facilitate these efforts and to better understand the mol. mechanism of action of NAAA, we detd. crystal structures of this enzyme in various activation states and in complex with several ligands, including both a covalent and a reversible inhibitor.  Self-proteolysis exposes the otherwise buried active site of NAAA to allow catalysis.  Formation of a stable substrate- or inhibitor-binding site appears to be conformationally coupled to the interaction of a pair of hydrophobic helixes in the enzyme with lipid membranes, resulting in the creation of a linear hydrophobic cavity near the active site that accommodates the liganda's acyl chain.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpe4SyudaY7MrVg90H21EOLACvtfcHk0lj3O8pVf2UsPw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitVyhsLvP&md5=9debd68d3239a82bd60849c9cf98e8ae</span></div><a href="/servlet/linkout?suffix=cit69&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1811759115&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1811759115%26sid%3Dliteratum%253Aachs%26aulast%3DGorelik%26aufirst%3DA.%26aulast%3DGebai%26aufirst%3DA.%26aulast%3DIlles%26aufirst%3DK.%26aulast%3DPiomelli%26aufirst%3DD.%26aulast%3DNagar%26aufirst%3DB.%26atitle%3DMolecular%2520mechanism%2520of%2520activation%2520of%2520the%2520immunoregulatory%2520amidase%2520NAAA%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2018%26volume%3D115%26spage%3DE10032%26epage%3DE10040%26doi%3D10.1073%2Fpnas.1811759115" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref70"><div class="reference"><strong class="refLabel"><a href="#ref70" class="rightTabRefNumLink">70</a></strong><div class="NLM_citation" id="rightTab-cit70"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kovalevich, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Langford, D.</span></span> <span> </span><span class="NLM_article-title">Considerations for the use of SH-SY5Y neuroblastoma cells in neurobiology</span>. <i>Methods Mol. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>1078</i></span>,  <span class="NLM_fpage">9</span>– <span class="NLM_lpage">21</span>, <span class="refDoi"> DOI: 10.1007/978-1-62703-640-5_2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01561&amp;key=10.1007%2F978-1-62703-640-5_2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01561&amp;key=23975817" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01561&amp;key=1%3ACAS%3A528%3ADC%252BC2MXjsFOhsb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1078&publication_year=2013&pages=9-21&author=J.+Kovalevichauthor=D.+Langford&title=Considerations+for+the+use+of+SH-SY5Y+neuroblastoma+cells+in+neurobiology&doi=10.1007%2F978-1-62703-640-5_2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit70R"><div class="casContent"><span class="casTitleNuber">70</span><div class="casTitle"><span class="NLM_cas:atitle">Considerations for the Use of SH - SY5Y Neuroblastoma Cells in Neurobiology</span></div><div class="casAuthors">Kovalevich, Jane; Langford, Dianne</div><div class="citationInfo"><span class="NLM_cas:title">Methods in Molecular Biology (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">1078</span>
        (<span class="NLM_cas:issue">Neuronal Cell Culture</span>),
    <span class="NLM_cas:pages">9-21</span>CODEN:
                <span class="NLM_cas:coden">MMBIED</span>;
        ISSN:<span class="NLM_cas:issn">1064-3745</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">The use of primary mammalian neurons derived from embryonic central nervous system tissue is limited by the fact that once terminally differentiated into mature neurons, the cells can no longer be propagated.  Transformed neuronal-like cell lines can be used in vitro to overcome this limitation.  However, several caveats exist when utilizing cells derived from malignant tumors.  In this context, the popular SH - SY5Y neuroblastoma cell line and its use in in vitro systems is described.  Originally derived from a metastatic bone tumor biopsy, SH - SY5Y (ATCC CRL-2266) cells are a subline of the parental line SK - N - SH (ATCC HTB-11).  SK-N-SH were subcloned three times; first to SH - SY , then to SH - SY5 , and finally to SH - SY5Y .  SH - SY5Y were deposited to the ATCC in 1970 by June L.  Biedler.Three important characteristics of SH - SY5Y cells should be considered when using these cells in in vitro studies.  First, cultures include both adherent and floating cells, both types of which are viable.  Few studies address the biol. significance of the adherent vs. floating phenotypes, but most reported studies utilize adherent populations and discard the floating cells during media changes.  Second, early studies by Biedler's group indicated that the parental differentiated SK - N - SH cells contained two morphol. distinct phenotypes: neuroblast-like cells and epithelial-like cells (Ross et al., J Nat Cancer Inst 71:741-747, 1983).  These two phenotypes may correspond to the "N" and "S" types described in later studies in SH - SY5Y by Encinas et al. (J Neurochem 75:991-1003, 2000).  Cells with neuroblast-like morphol. are pos. for tyrosine hydroxylase (TH) and dopamine-β-hydroxylase characteristic of catecholaminergic neurons, whereas the epithelial-like counterpart cells lacked these enzymic activities (Ross et al., J Nat Cancer Inst 71:741-747, 1983).  Third, SH - SY5Y cells can be differentiated to a more mature neuron-like phenotype that is characterized by neuronal markers.  There are several methods to differentiate SH - SY5Y cells and are mentioned below.  Retinoic acid is the most commonly used means for differentiation and will be addressed in detail.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrCVTav2R1Mr7Vg90H21EOLACvtfcHk0lj3O8pVf2UsPw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXjsFOhsb8%253D&md5=c4b1a3d107c070810b83efd461a2d0ec</span></div><a href="/servlet/linkout?suffix=cit70&amp;dbid=16384&amp;doi=10.1007%2F978-1-62703-640-5_2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252F978-1-62703-640-5_2%26sid%3Dliteratum%253Aachs%26aulast%3DKovalevich%26aufirst%3DJ.%26aulast%3DLangford%26aufirst%3DD.%26atitle%3DConsiderations%2520for%2520the%2520use%2520of%2520SH-SY5Y%2520neuroblastoma%2520cells%2520in%2520neurobiology%26jtitle%3DMethods%2520Mol.%2520Biol.%26date%3D2013%26volume%3D1078%26spage%3D9%26epage%3D21%26doi%3D10.1007%2F978-1-62703-640-5_2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref71"><div class="reference"><strong class="refLabel"><a href="#ref71" class="rightTabRefNumLink">71</a></strong><div class="NLM_citation" id="rightTab-cit71"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xicoy, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wieringa, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martens, G. J.</span></span> <span> </span><span class="NLM_article-title">The SH-SY5Y cell line in Parkinson’s disease research: a systematic review</span>. <i>Mol. Neurodegener.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">10</span>– <span class="NLM_lpage">20</span>, <span class="refDoi"> DOI: 10.1186/s13024-017-0149-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01561&amp;key=10.1186%2Fs13024-017-0149-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01561&amp;key=28118852" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01561&amp;key=1%3ACAS%3A528%3ADC%252BC1cXjsFGitLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2017&pages=10-20&author=H.+Xicoyauthor=B.+Wieringaauthor=G.+J.+Martens&title=The+SH-SY5Y+cell+line+in+Parkinson%E2%80%99s+disease+research%3A+a+systematic+review&doi=10.1186%2Fs13024-017-0149-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit71R"><div class="casContent"><span class="casTitleNuber">71</span><div class="casTitle"><span class="NLM_cas:atitle">The SH-SY5Y cell line in Parkinson's disease research: a systematic review</span></div><div class="casAuthors">Xicoy, Helena; Wieringa, Be; Martens, Gerard J. M.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Neurodegeneration</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">10/1-10/11</span>CODEN:
                <span class="NLM_cas:coden">MNOEAZ</span>;
        ISSN:<span class="NLM_cas:issn">1750-1326</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">Parkinson's disease (PD) is a devastating and highly prevalent neurodegenerative disease for which only symptomatic treatment is available.  In order to develop a truly effective disease-modifying therapy, improvement of our current understanding of the mol. and cellular mechanisms underlying PD pathogenesis and progression is crucial.  For this purpose, standardization of research protocols and disease models is necessary.  As human dopaminergic neurons, the cells mainly affected in PD, are difficult to obtain and maintain as primary cells, current PD research is mostly performed with permanently established neuronal cell models, in particular the neuroblastoma SH-SY5Y lineage.  This cell line is frequently chosen because of its human origin, catecholaminergic (though not strictly dopaminergic) neuronal properties, and ease of maintenance.  However, there is no consensus on many fundamental aspects that are assocd. with its use, such as the effects of culture media compn. and of variations in differentiation protocols.  Here we present the outcome of a systematic review of scientific articles that have used SH-SY5Y cells to explore PD.  We describe the cell source, culture conditions, differentiation protocols, methods/approaches used to mimic PD and the preclin. validation of the SH-SY5Y findings by employing alternative cellular and animal models.  Thus, this overview may help to standardize the use of the SH-SY5Y cell line in PD research and serve as a future user's guide.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrZVJyPwUVS5LVg90H21EOLACvtfcHk0lj3O8pVf2UsPw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXjsFGitLs%253D&md5=829cd2918af329627c201c6c0fc859d4</span></div><a href="/servlet/linkout?suffix=cit71&amp;dbid=16384&amp;doi=10.1186%2Fs13024-017-0149-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs13024-017-0149-0%26sid%3Dliteratum%253Aachs%26aulast%3DXicoy%26aufirst%3DH.%26aulast%3DWieringa%26aufirst%3DB.%26aulast%3DMartens%26aufirst%3DG.%2BJ.%26atitle%3DThe%2520SH-SY5Y%2520cell%2520line%2520in%2520Parkinson%25E2%2580%2599s%2520disease%2520research%253A%2520a%2520systematic%2520review%26jtitle%3DMol.%2520Neurodegener.%26date%3D2017%26volume%3D12%26spage%3D10%26epage%3D20%26doi%3D10.1186%2Fs13024-017-0149-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref72"><div class="reference"><strong class="refLabel"><a href="#ref72" class="rightTabRefNumLink">72</a></strong><div class="NLM_citation" id="rightTab-cit72"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kyriakou, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lederer, C. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kleanthous, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drousiotou, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Malekkou, A.</span></span> <span> </span><span class="NLM_article-title">Acid ceramidase depletion impairs neuronal survival and induces morphological defects in neurites associated with altered gene transcription and sphingolipid content</span>. <i>Int. J. Mol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">1607</span>– <span class="NLM_lpage">1631</span>, <span class="refDoi"> DOI: 10.3390/ijms21051607</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01561&amp;key=10.3390%2Fijms21051607" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01561&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhvVaqtLzP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2020&pages=1607-1631&author=K.+Kyriakouauthor=C.+W.+Ledererauthor=M.+Kleanthousauthor=A.+Drousiotouauthor=A.+Malekkou&title=Acid+ceramidase+depletion+impairs+neuronal+survival+and+induces+morphological+defects+in+neurites+associated+with+altered+gene+transcription+and+sphingolipid+content&doi=10.3390%2Fijms21051607"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit72R"><div class="casContent"><span class="casTitleNuber">72</span><div class="casTitle"><span class="NLM_cas:atitle">Acid ceramidase depletion impairs neuronal survival and induces morphological defects in neurites associated with altered gene transcription and sphingolipid content</span></div><div class="casAuthors">Kyriakou, Kalia; Lederer, Carsten W.; Kleanthous, Marina; Drousiotou, Anthi; Malekkou, Anna</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Molecular Sciences</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1607</span>CODEN:
                <span class="NLM_cas:coden">IJMCFK</span>;
        ISSN:<span class="NLM_cas:issn">1422-0067</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">The ASAH1 gene encodes acid ceramidase (AC), an enzyme that is implicated in the metab. of ceramide (Cer).  Mutations in the ASAH1 gene cause two different disorders, Farber disease (FD), a rare lysosomal storage disorder, and a rare form of spinal muscular atrophy combined with progressive myoclonic epilepsy (SMA-PME).  In the absence of human in vitro neuronal disease models and to gain mechanistic insights into pathol. effects of ASAH1 deficiency, we established and characterized a stable ASAH1 knockdown (ASAH1KD) SH-SY5Y cell line.  ASAH1KD cells displayed reduced proliferation due to elevated apoptosis and G1/S cell cycle arrest.  Distribution of LAMP1-pos. lysosomes towards the cell periphery and significantly shortened and less branched neurites upon differentiation, implicate AC for lysosome positioning and neuronal development, resp.  Lipidomic anal. revealed changes in the intracellular levels of distinct sphingolipid species, importantly without Cer accumulation, in line with altered gene transcription within the sphingolipid pathway.  Addnl., the transcript levels for Rho GTPases (RhoA, Rac1, and Cdc42), which are key regulators of axonal orientation, neurite branching and lysosome positioning were found to be dysregulated.  This study shows the crit. role of AC in neurons and suggests how AC depletion leads to defects seen in neuropathol. of SMA-PME and FD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrdFcJ08olUeLVg90H21EOLACvtfcHk0lhgg6w0hyKH5Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhvVaqtLzP&md5=6eca7dad3eb3a0b15aaacc3589042f05</span></div><a href="/servlet/linkout?suffix=cit72&amp;dbid=16384&amp;doi=10.3390%2Fijms21051607&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fijms21051607%26sid%3Dliteratum%253Aachs%26aulast%3DKyriakou%26aufirst%3DK.%26aulast%3DLederer%26aufirst%3DC.%2BW.%26aulast%3DKleanthous%26aufirst%3DM.%26aulast%3DDrousiotou%26aufirst%3DA.%26aulast%3DMalekkou%26aufirst%3DA.%26atitle%3DAcid%2520ceramidase%2520depletion%2520impairs%2520neuronal%2520survival%2520and%2520induces%2520morphological%2520defects%2520in%2520neurites%2520associated%2520with%2520altered%2520gene%2520transcription%2520and%2520sphingolipid%2520content%26jtitle%3DInt.%2520J.%2520Mol.%2520Sci.%26date%3D2020%26volume%3D21%26spage%3D1607%26epage%3D1631%26doi%3D10.3390%2Fijms21051607" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref73"><div class="reference"><strong class="refLabel"><a href="#ref73" class="rightTabRefNumLink">73</a></strong><div class="NLM_citation" id="rightTab-cit73"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yamanaka, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kondoh, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Terada, M.</span></span> <span> </span><span class="NLM_article-title">Kinetic resolution of racemic amino alcohols through intermolecular acetalization catalyzed by a chiral Bronsted acid</span>. <i>J. Am. Chem. Soc.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>137</i></span>,  <span class="NLM_fpage">1048</span>– <span class="NLM_lpage">1051</span>, <span class="refDoi"> DOI: 10.1021/ja512238n</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ja512238n" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01561&amp;key=1%3ACAS%3A528%3ADC%252BC2MXns12guw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=137&publication_year=2015&pages=1048-1051&author=T.+Yamanakaauthor=A.+Kondohauthor=M.+Terada&title=Kinetic+resolution+of+racemic+amino+alcohols+through+intermolecular+acetalization+catalyzed+by+a+chiral+Bronsted+acid&doi=10.1021%2Fja512238n"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit73R"><div class="casContent"><span class="casTitleNuber">73</span><div class="casTitle"><span class="NLM_cas:atitle">Kinetic Resolution of Racemic Amino Alcohols through Intermolecular Acetalization Catalyzed by a Chiral Bronsted Acid</span></div><div class="casAuthors">Yamanaka, Takuto; Kondoh, Azusa; Terada, Masahiro</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">137</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1048-1051</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">In the presence of nonracemic bis(triisopropylphenyl) binaphthylphosphoric or octahydrobinaphthylphosphoric acids, racemic (phenoxycarbonyl)amino alcs. such as RCH(OH)CH2NHCO2Ph [R = Ph, 2-naphthyl, 1,3-benzodioxol-5-yl, 2-thienyl, (E)-PhCH:CMe, i-Pr, cyclohexyl, t-Bu, TBSOCMe2, 2-hexyl-1,3-dithiane-2-yl] underwent enantioselective acetalization and kinetic resoln. with 2,3-dihydrofuran to yield nonracemic amino alcs. (R)-RCH(OH)CH2NHCO2Ph [R = Ph, 2-naphthyl, 1,3-benzodioxol-5-yl, 2-thienyl, (E)-PhCH:CMe, i-Pr, cyclohexyl, t-Bu, TBSOCMe2, 2-hexyl-1,3-dithiane-2-yl; TBS = tert-butyldimethylsilyl] and (S)-O-2-tetrahydrofuranylated amino alcs.; the alcs. were isolated in 32-50% recoveries and in 94-99% ee.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrvpCoP5D-airVg90H21EOLACvtfcHk0lhgg6w0hyKH5Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXns12guw%253D%253D&md5=0131909d83e98eaf38ff64504b7e52dd</span></div><a href="/servlet/linkout?suffix=cit73&amp;dbid=16384&amp;doi=10.1021%2Fja512238n&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja512238n%26sid%3Dliteratum%253Aachs%26aulast%3DYamanaka%26aufirst%3DT.%26aulast%3DKondoh%26aufirst%3DA.%26aulast%3DTerada%26aufirst%3DM.%26atitle%3DKinetic%2520resolution%2520of%2520racemic%2520amino%2520alcohols%2520through%2520intermolecular%2520acetalization%2520catalyzed%2520by%2520a%2520chiral%2520Bronsted%2520acid%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D2015%26volume%3D137%26spage%3D1048%26epage%3D1051%26doi%3D10.1021%2Fja512238n" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref74"><div class="reference"><strong class="refLabel"><a href="#ref74" class="rightTabRefNumLink">74</a></strong><div class="NLM_citation" id="rightTab-cit74"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dinsmore, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mercer, S. P.</span></span> <span> </span><span class="NLM_article-title">Carboxylation and Mitsunobu reaction of amines to give carbamates: retention vs inversion of configuration is substituent-dependent</span>. <i>Org. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">2885</span>– <span class="NLM_lpage">2888</span>, <span class="refDoi"> DOI: 10.1021/ol0491080</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ol0491080" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01561&amp;key=1%3ACAS%3A528%3ADC%252BD2cXlvFamsrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2004&pages=2885-2888&author=C.+J.+Dinsmoreauthor=S.+P.+Mercer&title=Carboxylation+and+Mitsunobu+reaction+of+amines+to+give+carbamates%3A+retention+vs+inversion+of+configuration+is+substituent-dependent&doi=10.1021%2Fol0491080"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit74R"><div class="casContent"><span class="casTitleNuber">74</span><div class="casTitle"><span class="NLM_cas:atitle">Carboxylation and Mitsunobu reaction of amines to give carbamates: Retention vs inversion of configuration is substituent-dependent</span></div><div class="casAuthors">Dinsmore, Christopher J.; Mercer, Swati P.</div><div class="citationInfo"><span class="NLM_cas:title">Organic Letters</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">2885-2888</span>CODEN:
                <span class="NLM_cas:coden">ORLEF7</span>;
        ISSN:<span class="NLM_cas:issn">1523-7060</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A mild method for the synthesis of carbamates from amino alcs. involved sequential carboxylation with carbon dioxide, followed by a Mitsunobu reaction.  Unexpectedly, the stereochem. course of the Mitsunobu reaction was dependent on whether the carbamic acid intermediate was N-substituted with hydrogen (retention) or carbon (inversion).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrAw4KyvNDZgbVg90H21EOLACvtfcHk0lhgg6w0hyKH5Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXlvFamsrc%253D&md5=62ee852830c0b7f21dacbdc39529663e</span></div><a href="/servlet/linkout?suffix=cit74&amp;dbid=16384&amp;doi=10.1021%2Fol0491080&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fol0491080%26sid%3Dliteratum%253Aachs%26aulast%3DDinsmore%26aufirst%3DC.%2BJ.%26aulast%3DMercer%26aufirst%3DS.%2BP.%26atitle%3DCarboxylation%2520and%2520Mitsunobu%2520reaction%2520of%2520amines%2520to%2520give%2520carbamates%253A%2520retention%2520vs%2520inversion%2520of%2520configuration%2520is%2520substituent-dependent%26jtitle%3DOrg.%2520Lett.%26date%3D2004%26volume%3D6%26spage%3D2885%26epage%3D2888%26doi%3D10.1021%2Fol0491080" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref75"><div class="reference"><strong class="refLabel"><a href="#ref75" class="rightTabRefNumLink">75</a></strong><div class="NLM_citation" id="rightTab-cit75"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Basit, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Piomelli, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Armirotti, A.</span></span> <span> </span><span class="NLM_article-title">Rapid evaluation of 25 key sphingolipids and phosphosphingolipids in human plasma by LC-MS/MS</span>. <i>Anal. Bioanal. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>407</i></span>,  <span class="NLM_fpage">5189</span>– <span class="NLM_lpage">5198</span>, <span class="refDoi"> DOI: 10.1007/s00216-015-8585-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01561&amp;key=10.1007%2Fs00216-015-8585-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01561&amp;key=25749796" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01561&amp;key=1%3ACAS%3A528%3ADC%252BC2MXktVKjtbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=407&publication_year=2015&pages=5189-5198&author=A.+Basitauthor=D.+Piomelliauthor=A.+Armirotti&title=Rapid+evaluation+of+25+key+sphingolipids+and+phosphosphingolipids+in+human+plasma+by+LC-MS%2FMS&doi=10.1007%2Fs00216-015-8585-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit75R"><div class="casContent"><span class="casTitleNuber">75</span><div class="casTitle"><span class="NLM_cas:atitle">Rapid evaluation of 25 key sphingolipids and phosphosphingolipids in human plasma by LC-MS/MS</span></div><div class="casAuthors">Basit, Abdul; Piomelli, Daniele; Armirotti, Andrea</div><div class="citationInfo"><span class="NLM_cas:title">Analytical and Bioanalytical Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">407</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">5189-5198</span>CODEN:
                <span class="NLM_cas:coden">ABCNBP</span>;
        ISSN:<span class="NLM_cas:issn">1618-2642</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">We report on a new, sensitive, and fast LC-MS/MS method for the simultaneous detn. of 25 key sphingolipid components in human plasma, including phosphorylated sphinganine and sphingosine, in a single 9-min run.  This method enables an effective and high-throughput coverage of the metabolic changes involving the sphingolipidome during physiol. or pathol. states.  The method is based on liq.-liq. extn. followed by reversed-phase LC-MS/MS.  Exogenous odd-chain lipids are used as cost-effective but reliable internal stds.  The method was fully validated in surrogate matrix and naive human plasma following FDA guidelines.  Sample stability and diln. integrity were also tested and verified.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqMk_mtifaXnLVg90H21EOLACvtfcHk0lgyQ3XB1hu6Ng"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXktVKjtbo%253D&md5=57a06856ca08eea60fe0cd4a1ac3d2b8</span></div><a href="/servlet/linkout?suffix=cit75&amp;dbid=16384&amp;doi=10.1007%2Fs00216-015-8585-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00216-015-8585-6%26sid%3Dliteratum%253Aachs%26aulast%3DBasit%26aufirst%3DA.%26aulast%3DPiomelli%26aufirst%3DD.%26aulast%3DArmirotti%26aufirst%3DA.%26atitle%3DRapid%2520evaluation%2520of%252025%2520key%2520sphingolipids%2520and%2520phosphosphingolipids%2520in%2520human%2520plasma%2520by%2520LC-MS%252FMS%26jtitle%3DAnal.%2520Bioanal.%2520Chem.%26date%3D2015%26volume%3D407%26spage%3D5189%26epage%3D5198%26doi%3D10.1007%2Fs00216-015-8585-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><div class="accessionCode mb-5"><div class="toolbar-section accession-codes"><ul><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5U7Z" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5U7Z','PDB','5U7Z'); return false;">PDB: 5U7Z</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6MHM" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6MHM','PDB','6MHM'); return false;">PDB: 6MHM</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6DXX" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6DXX','PDB','6DXX'); return false;">PDB: 6DXX</a></li></ul></div></div><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i153"><a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01561">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_80518"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acs.jmedchem.0c01561?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c01561</a>.<ul id="rightTab-silist" class="NLM_list-list_type-label"><li><p class="inline">AC inhibitory activity data and assay methods for selected literature compounds; <i>V</i><sub>max</sub> and <i>K</i><sub>M</sub> determinations; <sup>1</sup>H NMR and <sup>13</sup>C NMR spectra of the final compounds; retention times and UPLC analytical methods of the final compounds; and UPLC traces of the final compounds (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01561/suppl_file/jm0c01561_si_001.pdf">PDF</a>)</p></li><li><p class="inline">Molecular formula strings (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01561/suppl_file/jm0c01561_si_002.csv">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c01561/suppl_file/jm0c01561_si_001.pdf">jm0c01561_si_001.pdf (9.72 MB)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c01561/suppl_file/jm0c01561_si_002.csv">jm0c01561_si_002.csv (2.86 kb)</a></li></ul></div></div><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.0c01561&amp;pbContext=%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.0c01561%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2020.63.issue-24%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.0c01561" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                4MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"6799da8538423d5a","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
